FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Fryer, SL Brandel, M Ford, JM Turner, JA Van Erp, TG Voyvodic, J Belger, A Bustillo, J O'Leary, D Mueller, B Calhoun, VD Wible, C Potkin, SG Mathalon, DH AF Fryer, Susanna L. Brandel, Michael Ford, Judith M. Turner, Jessica A. Van Erp, Theodorus G. Voyvodic, James Belger, Aysenil Bustillo, Juan O'Leary, Daniel Mueller, Bryon Calhoun, Vince D. Wible, Cindy Potkin, Steven G. Mathalon, Daniel H. CA FBIRN TI Amplitude of Low Frequency Fluctuation Reductions in Schizophrenia Relate to Neurocognitive Performance: An Fbirn Study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE attention; executive functioning; psychosis; resting-state fMRI; cognitive biomarker C1 [Fryer, Susanna L.; Brandel, Michael; Ford, Judith M.; Mathalon, Daniel H.] UCSF Sch Med, San Francisco, CA USA. [Fryer, Susanna L.; Brandel, Michael; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Turner, Jessica A.; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA. [Van Erp, Theodorus G.; Potkin, Steven G.] Univ Calif Irvine, Irvine, CA USA. [Voyvodic, James] Duke Univ, Raleigh, NC USA. [Belger, Aysenil] Univ N Carolina, Chapel Hill, NC USA. [Bustillo, Juan] Univ New Mexico, Albuquerque, NM 87131 USA. [O'Leary, Daniel] Univ Iowa, Iowa City, IA USA. [Mueller, Bryon] Univ Minnesota, Minneapolis, MN USA. [Wible, Cindy] Harvard Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 715 BP 205S EP 205S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101801215 ER PT J AU Jahshan, C Wynn, JK Lee, J Horan, WP Mathis, KI Green, MF AF Jahshan, Carol Wynn, Jonathan K. Lee, Junghee Horan, William P. Mathis, Kristopher I. Green, Michael F. TI The Neurophysiology of Biological Motion Perception in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE biological motion; motion perception; EEG; mu suppression; schizophrenia C1 [Jahshan, Carol; Wynn, Jonathan K.; Lee, Junghee; Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Jahshan, Carol; Wynn, Jonathan K.; Lee, Junghee; Horan, William P.; Mathis, Kristopher I.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 714 BP 205S EP 205S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101801214 ER PT J AU Light, GA Rissling, AJ Miyakoshi, M Sugar, CA Braff, DL Makeig, S AF Light, Gregory A. Rissling, Anthony J. Miyakoshi, Makoto Sugar, Catherine A. Braff, David L. Makeig, Scott TI Deconstructing the Neural Substrates and Functional Correlates of Sensory Processing Impairments in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE schizophrenia; cognition; biomarker; EEG; function C1 [Light, Gregory A.; Rissling, Anthony J.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Light, Gregory A.; Braff, David L.] VA San Diego Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC VISN 22, San Diego, CA USA. [Miyakoshi, Makoto; Makeig, Scott] Univ Calif San Diego, Inst Neural Computat, Swartz Ctr Computat Neurosci, La Jolla, CA 92093 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA. [Sugar, Catherine A.] Greater Los Angeles VA Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC VISN 22, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 716 BP 205S EP 206S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101801216 ER PT J AU Shvil, E Sullivan, GM Schafer, S Markowitz, JC Papini, S Wager, TD Milad, MR Neria, Y AF Shvil, Erel Sullivan, Gregory M. Schafer, Scott Markowitz, John C. Papini, Santiago Wager, Tor D. Milad, Mohammed R. Neria, Yuval TI Bias Toward Threat in an Ambiguous Context in PTSD: An fMRI Study of Context Modulation in Trauma SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE PTSD; Context; Fear; dACC; fMRI C1 [Shvil, Erel; Sullivan, Gregory M.; Markowitz, John C.; Neria, Yuval] Columbia Univ, NYSPI, New York, NY USA. [Schafer, Scott] Univ Colorado, Boulder, CO 80309 USA. [Papini, Santiago] CUNY, NYSPI, New York, NY 10021 USA. [Wager, Tor D.] Univ Colorado, Boulder, NY USA. [Milad, Mohammed R.] Harvard Univ, Sch Med, Charlestown, MA USA. [Milad, Mohammed R.] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 774 BP 224S EP 225S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101801274 ER PT J AU Hove, MJ Biederman, J Valera, EM AF Hove, Michael J. Biederman, Joseph Valera, Eve M. TI Postural Sway in Adult ADHD Correlates with Diagnostic Measures SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE ADHD; Postural Sway; Structural MRI; ASRS C1 [Hove, Michael J.; Biederman, Joseph; Valera, Eve M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 786 BP 228S EP 229S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101801286 ER PT J AU Koenigsberg, HW Denny, B Fan, J Liu, X Rimsky, L McMaster, A New, AS Siever, LJ AF Koenigsberg, Harold W. Denny, Bryan Fan, Jin Liu, Xun Rimsky, Liza McMaster, Antonia New, Antonia S. Siever, Larry J. TI Affective Instability in Personality Disorder Patients is Inversely Correlated with Anterior Cingulate Activity during Habituation to Negative Stimuli SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Affective Instability; Borderline Personality Disorder; Avoidant Personality Disorder; Emotion Regulation; Habituation C1 [Koenigsberg, Harold W.; Denny, Bryan; Fan, Jin; Liu, Xun; Rimsky, Liza; McMaster, Antonia; New, Antonia S.; Siever, Larry J.] Icahn Sch Med Mt Sinai, New York, NY USA. [Koenigsberg, Harold W.] James J Peters VA Med Ctr, Mental Hlth Patinet Care Ctr, Bronx, NY USA. [Fan, Jin] Queens Coll, Queens, NY USA. [Liu, Xun] Chinese Acad Sci, Inst Psychol, Beijing, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 828 BP 242S EP 242S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101801328 ER PT J AU Moran, LV Stoeckel, LE Wang, K Hong, LE Ongur, D Pizzagalli, DA Evins, AE AF Moran, Lauren V. Stoeckel, Luke E. Wang, Kristina Hong, L. Elliot Ongur, Dost Pizzagalli, Diego A. Evins, A. Eden TI Insular Functional Connectivity with Reward Network Regions and Reward Sensitivity in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE schizophrenia; insula; reward; ventral striatum; ventromedial prefrontal cortex C1 [Moran, Lauren V.; Wang, Kristina; Ongur, Dost; Pizzagalli, Diego A.] McLean Hosp, Belmont, MA 02178 USA. [Stoeckel, Luke E.; Evins, A. Eden] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hong, L. Elliot] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 836 BP 245S EP 245S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101801336 ER PT J AU Sullivan, GM Schafer, S Shvil, E Papini, S Joyner, E Markowitz, JC Milad, M Wager, TD Neria, Y AF Sullivan, Gregory M. Schafer, Scott Shvil, Erel Papini, Santiago Joyner, Emily Markowitz, John C. Milad, Mohamed Wager, Tor D. Neria, Yuval TI Behavioral and Neural Correlates of Overgeneralization in PTSD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE posttraumatic stress disorder; generalization; conditioning; anterior cingulate cortex; ventromedial prefrontal cortex C1 [Sullivan, Gregory M.; Shvil, Erel; Papini, Santiago; Joyner, Emily; Markowitz, John C.; Neria, Yuval] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. [Schafer, Scott; Wager, Tor D.] Univ Colorado, Boulder, CO 80309 USA. [Milad, Mohamed] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Milad, Mohamed] Harvard Univ, Sch Med, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 904 BP 267S EP 267S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101801404 ER PT J AU Mathalon, DH Perkins, D Walker, E Addington, J Bearden, C Cadenhead, K Cornblatt, B McGlashan, T Seidman, L Tsuang, M Woods, S Cannon, TD AF Mathalon, Daniel H. Perkins, Diana Walker, Elaine Addington, Jean Bearden, Carrie Cadenhead, Kristin Cornblatt, Barbara McGlashan, Thomas Seidman, Larry Tsuang, Ming Woods, Scott Cannon, Tyrone D. CA NAPLS Consortium TI Impaired Synaptic Plasticity, Synaptic Over-pruning, Inflammation, and Stress: A Pathogenic Model of the Transition to Psychosis in Clinical High Risk Youth SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Prodrome; Psychosis; Gray Matter; Mismatch Negativity; Inflamamtion C1 [Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Perkins, Diana] Univ N Carolina, Raleigh Durham, NC USA. [Walker, Elaine] Emory Univ, Atlanta, GA 30322 USA. [Addington, Jean] Univ Calgary, Calgary, AB, Canada. [Bearden, Carrie] Univ Calif Los Angeles, Los Angeles, CA USA. [Cadenhead, Kristin; Tsuang, Ming] Univ Calif San Diego, San Diego, CA 92103 USA. [Cornblatt, Barbara] Hillside Hosp, New York, NY USA. [McGlashan, Thomas; Woods, Scott] Yale Univ, New Haven, CT USA. [Seidman, Larry] Harvard Univ, Boston, MA 02115 USA. [Cannon, Tyrone D.] Yale Univ, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1009 BP 277S EP 278S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802010 ER PT J AU Petryshen, T AF Petryshen, Tracey TI Animal Models of Bipolar Disorder: Genetic and Epigenetic Effects SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE bipolar disorder; ankyrin 3; epigenetic; behavior; mouse C1 [Petryshen, Tracey] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Petryshen, Tracey] Broad Inst MIT & Harvard, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1040 BP 288S EP 288S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802041 ER PT J AU Doyle, AE AF Doyle, Alysa E. TI Polygenic Risk for Schizophrenia Predicts Cognition and Psychosis in Clinically-referred Youth: A Neurobehavioral High Risk Study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE cognition; schizophrenia; polygenic; RDoC; risk C1 [Doyle, Alysa E.] Massachusets Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1104 BP 306S EP 307S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802097 ER PT J AU Leussis, M Gjeluci, K Dinieri, JA Garza, JC Petryshen, TL AF Leussis, Melanie Gjeluci, Klaudio Dinieri, Jennifer A. Garza, Jacob C. Petryshen, Tracey L. TI Significance of the Bipolar Gene Ankyrin 3 in the Neural Circuitry of Impulsive-like Behaviors SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Ankyrin 3; impulsive behavior; bipolar; TALEs C1 [Leussis, Melanie; Gjeluci, Klaudio; Dinieri, Jennifer A.; Garza, Jacob C.; Petryshen, Tracey L.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Leussis, Melanie] Univ Cambridge Emmanuel Coll, Boston, MA USA. [Leussis, Melanie; Gjeluci, Klaudio; Dinieri, Jennifer A.; Garza, Jacob C.; Petryshen, Tracey L.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Gjeluci, Klaudio] Univ Massachusetts, Boston, MA 02125 USA. [Dinieri, Jennifer A.; Garza, Jacob C.; Petryshen, Tracey L.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1115 BP 310S EP 311S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802108 ER PT J AU Brunet, A Saumier, D Tremblay, J Orr, SP Pitman, RK AF Brunet, Alain Saumier, Daniel Tremblay, Jacques Orr, Scott P. Pitman, Roger K. TI Randomized Placebo-Controlled Trial of Propranolol plus Traumatic Memory Reactivation for PTSD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE stress disorders; post-traumatic; propranolol; memory retrieval; reconsolidation; treatment C1 [Brunet, Alain; Saumier, Daniel; Tremblay, Jacques] Douglas Inst Res Ctr, Montreal, PQ, Canada. [Brunet, Alain; Tremblay, Jacques] McGill Univ, Montreal, PQ, Canada. [Orr, Scott P.; Pitman, Roger K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 4 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1156 BP 323S EP 324S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802149 ER PT J AU Davis, MC Green, MF Lee, J Horan, WP Wynn, JK Marder, SR AF Davis, Michael C. Green, Michael F. Lee, Junghee Horan, William P. Wynn, Jonathan K. Marder, Stephen R. TI Can Oxytocin Enhance Learning During Social Cognitive Skills Training in Schizophrenia? SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE oxytocin; schizophrenia; social cognition; social cognitive skills training; empathy C1 [Davis, Michael C.; Green, Michael F.; Lee, Junghee; Horan, William P.; Wynn, Jonathan K.; Marder, Stephen R.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Davis, Michael C.; Green, Michael F.; Lee, Junghee; Horan, William P.; Wynn, Jonathan K.; Marder, Stephen R.] VA Greater Los Angeles, VISN Mental Illness Res Educ & Clin Ctr 22, Los Angeles, CA USA. RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 0 TC 0 Z9 0 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1163 BP 326S EP 326S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802156 ER PT J AU Hall, C Begley, A Butters, M Corey-Bloom, J Lebowitz, B Reynolds, CF Shear, MK Simon, N Zisook, S AF Hall, Charles Begley, Amy Butters, Meryl Corey-Bloom, Jody Lebowitz, Barry Reynolds, Charles F. Shear, M. Katherine Simon, Naomi Zisook, Sidney TI Cognitive Function in Complicated Grief SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Grief; Cognition C1 [Hall, Charles; Begley, Amy; Butters, Meryl; Reynolds, Charles F.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Corey-Bloom, Jody; Lebowitz, Barry; Zisook, Sidney] Univ Calif San Diego, San Diego, CA 92103 USA. [Shear, M. Katherine] Columbia Univ, Med Ctr, New York, NY USA. [Simon, Naomi] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Simon, Naomi] Harvard Univ, Sch Med, Boston, MA USA. [Zisook, Sidney] VA Healthcare Syst, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1188 BP 333S EP 334S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802181 ER PT J AU Mears, RP Spencer, KM AF Mears, Ryan P. Spencer, Kevin M. TI Oscillatory and Evoked Measures of Visual Stimulus Specific Plasticity in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Plasticity; Oscillations; Gamma; ERP; Visual C1 [Mears, Ryan P.; Spencer, Kevin M.] VA Boston Healthcare Syst, Psychiat, Boston, MA USA. [Mears, Ryan P.; Spencer, Kevin M.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1206 BP 339S EP 339S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802199 ER PT J AU Doyle, AE Faraone, SV McGrath, L Thermenos, H Juelich, R Chaponis, J Ferreira, M Biederman, J Seidman, LJ AF Doyle, Alysa E. Faraone, Stephen V. McGrath, Lauren Thermenos, Heidi Juelich, Richard Chaponis, Jon Ferreira, Manuel Biederman, Joseph Seidman, Larry J. TI Multivariate Association of CDH13 Variants and Cortical Thickness in ADHD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE CDH13; ADHD; CORTICAL THICKNESS; NEUROIMAGING; GENETICS C1 [Doyle, Alysa E.] Mass General Harvard Med Sch, Ctr Human Genet Res Psychiat, Boston, MA USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [McGrath, Lauren] Amer Univ, Sch Educ Teaching & Hlth, Washington, DC 20016 USA. [Thermenos, Heidi; Seidman, Larry J.] Beth Israel Deaconess Harvard Med Sch, Boston, MA USA. [Juelich, Richard] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Chaponis, Jon] Mass Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA USA. [Ferreira, Manuel] Queensland Inst Med Res, Boston, MA USA. [Biederman, Joseph] Mass General Harvard Med Sch, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1231 BP 347S EP 347S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802224 ER PT J AU Perez-Rodriguez, MM Rothstein, E Rimsky, L Hoque, N Lichtman, T McMaster, A Chowdhury, S Mascitelli, K Bevilacqua, L Ungar, A Ripoll, L Goldman, D Hodgkinson, C Goodman, M New, AS Siever, LJ AF Perez-Rodriguez, M. Mercedes Rothstein, Ethan Rimsky, Liza Hoque, Nabila Lichtman, Tamar McMaster, Antonia Chowdhury, Salwa Mascitelli, Katie Bevilacqua, Laura Ungar, Allison Ripoll, Luis Goldman, David Hodgkinson, Colin Goodman, Marianne New, Antonia S. Siever, Larry J. TI Arginine Vasopressin Receptor Gene Variants Associated with Aggression, Borderline and Schizotypal Personality Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Vasopressin; Borderline personality disorder; Schizotypal personality disorder; SNP; Aggression C1 [Perez-Rodriguez, M. Mercedes; Rothstein, Ethan; Rimsky, Liza; Hoque, Nabila; Lichtman, Tamar; McMaster, Antonia; Chowdhury, Salwa; Mascitelli, Katie; Ungar, Allison; Ripoll, Luis; Goodman, Marianne; New, Antonia S.; Siever, Larry J.] Icahn Sch Med Mt Sinai, New York, NY USA. [Perez-Rodriguez, M. Mercedes; Rothstein, Ethan; Rimsky, Liza; Hoque, Nabila; Lichtman, Tamar; McMaster, Antonia; Chowdhury, Salwa; Mascitelli, Katie; Goodman, Marianne; New, Antonia S.; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bevilacqua, Laura; Goldman, David; Hodgkinson, Colin] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA. RI Perez Rodriguez, Maria/B-9410-2013 OI Perez Rodriguez, Maria/0000-0001-5137-1993 NR 0 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1239 BP 349S EP 349S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802232 ER PT J AU Kling, MA Goodenowe, DB Appleby, DH Xie, SX Arnold, SE Bennett, DA AF Kling, Mitchel A. Goodenowe, Dayan B. Appleby, Dina H. Xie, Sharon X. Arnold, Steven E. Bennett, David A. TI Mixed-effects Model Analysis of Serum Phospholipids in Alzheimer-type Dementia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Lipidomics; Plasmalogens; Alzheimer's Disease; Biomarkers; Mass spectrometry C1 [Kling, Mitchel A.; Appleby, Dina H.; Arnold, Steven E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kling, Mitchel A.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. [Goodenowe, Dayan B.] Phenomenome Discoveries Inc, Off CEO, Saskatoon, SK, Canada. [Xie, Sharon X.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Arnold, Steven E.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Bennett, David A.] Rush Med Coll, Dept Neurol Sci, Chicago, IL 60612 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1253 BP 354S EP 354S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802246 ER PT J AU Albaugh, MD Ducharme, S Karama, S Watts, R Nguyen, TV McKinstry, RC Botteron, KN Evans, AC Hudziak, JJ AF Albaugh, Matthew D. Ducharme, Simon Karama, Sherif Watts, Richard Tuong-Vi Nguyen McKinstry, Robert C. Botteron, Kelly N. Evans, Alan C. Hudziak, James J. CA Brain Dev Cooperative Grp TI Increased Fiber Tract Organization is Associated with Anxious/Depressed Symptoms in Typically Developing Youths SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE DTI; anxiety; depression; development C1 [Albaugh, Matthew D.; Hudziak, James J.] Univ Vermont, Coll Med, Vermont Ctr Children Youth & Families, Burlington, VT USA. [Ducharme, Simon] Harvard Univ, Dept Psychiat & Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Ducharme, Simon] Harvard Univ, McLean Hosp, Boston, MA 02115 USA. [Karama, Sherif; Tuong-Vi Nguyen; Evans, Alan C.] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada. [Karama, Sherif] McGill Univ, Douglas Mental Hlth Univ Inst, Dept Psychiat & Neurol, Montreal, PQ, Canada. [Watts, Richard] Univ Vermont, Coll Med, Dept Radiol, Burlington, VT USA. [McKinstry, Robert C.; Botteron, Kelly N.] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1258 BP 356S EP 356S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802251 ER PT J AU Levitt, J Rathi, Y Raviv, TR McCarley, RW Shenton, ME AF Levitt, James Rathi, Yogesh Raviv, Tammy R. McCarley, Robert W. Shenton, Martha E. TI DTI Connectivity-Based Parcellation of the Striatum in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Diffusion Tensor Imaging; MRI; Schizophrenia; Striatum; Tractography C1 [Levitt, James; McCarley, Robert W.; Shenton, Martha E.] Harvard Univ, VA Boston Healthcare Syst, Brockton, MA 02401 USA. [Levitt, James; Rathi, Yogesh; Raviv, Tammy R.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. RI Riklin Raviv, Tammy/A-3462-2013 NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1319 BP 375S EP 375S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802312 ER PT J AU Gilman, JM Lee, S Kuster, JK Lee, MJ Kim, B Wighton, P van der Kouwe, A Blood, AJ Breiter, HC AF Gilman, Jodi M. Lee, Sang Kuster, John K. Lee, Myung Joo Kim, Byoungwoo Wighton, Paul van der Kouwe, Andre Blood, Anne J. Breiter, Hans C. TI Neural Mechanisms of Social Influence in Young Adult Cannabis Users SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Cannabis; Social Influence; Reward; Nucleus Accumbens; Decision Making C1 [Gilman, Jodi M.; Breiter, Hans C.] Harvard Univ, Sch Med, Dept Psychiat, Lab Neuroimaging & Genet, Charlestown, MA USA. [Lee, Sang; Lee, Myung Joo; Kim, Byoungwoo; Breiter, Hans C.] Northwestern Univ, Feinberg Sch Med, Warren Wright Adolescent Ctr, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Kuster, John K.] Massachusetts Gen Hosp, Dept Psychiat, Lab Neuroimaging & Genet, Mood & Motor Control Lab, Charlestown, MA USA. [Wighton, Paul; van der Kouwe, Andre] Harvard Univ, Sch Med, Dept Radiol, Athinoula A Martinos Control Lab, Charlestown, MA USA. [Blood, Anne J.] Harvard Univ, Sch Med, Dept Psychiat, Mood & Motor Control Lab,Lab Neuroimaging & Genet, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1332 BP 379S EP 379S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802325 ER PT J AU Gilman, JM Kim, B Lee, S Kuster, JK Mao, JR Blood, AJ Breiter, HC AF Gilman, Jodi M. Kim, Byoungwoo Lee, Sang Kuster, John K. Mao, Jianren Blood, Anne J. Breiter, Hans C. TI The Insula Mediates the Interaction of Craving and Pain in Addiction SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Pain; Craving; Addiction; Cocaine; Insula C1 [Gilman, Jodi M.] Harvard Univ, Sch Med, Dept Psychiat, Lab Neuroimaging & Genet, Charlestown, MA USA. [Kim, Byoungwoo; Lee, Sang; Breiter, Hans C.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Warren Wright Adolescent Ctr, Chicago, IL 60611 USA. [Kuster, John K.] Massachusetts Gen Hosp, Dept Psychiat, Lab Neuroimaging & Genet, Mood & Motor Control Lab, Charlestown, MA USA. [Mao, Jianren] Harvard Univ, MGH Ctr Translat Res Prescript Drug Abuse, Dept Anesthesiol, Sch Med, Charlestown, MA USA. [Blood, Anne J.] Harvard Univ, Mood & Motor Control Lab, Lab Neuroimaging & Genet, Dept Psychiat,Med Sch, Charlestown, MA USA. [Breiter, Hans C.] Harvard Univ, Lab Neuroimaging & Genet, Dept Psychiat, Sch Med, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1340 BP 382S EP 382S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802333 ER PT J AU Walsh-Messinger, J Ramirez, PM Wong, P McMahon, K Malone, T Opler, LA Malaspina, D AF Walsh-Messinger, Julie Ramirez, Paul Michael Wong, Philip McMahon, Kevin Malone, Tara Opler, Lewis A. Malaspina, Dolores TI Associations between Olfactory Hedonics and Smell Identification Vary by Sex in Schizophrenia Cases and Healthy Controls SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY 2014 CL New York, NY SP Soc Biol Psychiat DE Olfaction; Schizophrenia; Sex Differences C1 [Walsh-Messinger, Julie] Icahn Sch Med Mt Sinai, New York, NY USA. [Walsh-Messinger, Julie] James J Peters VA Med Ctr, MIRECC, Bronx, NY USA. [Ramirez, Paul Michael; Wong, Philip] Long Isl Univ, Brooklyn, NY USA. [McMahon, Kevin; Malone, Tara] NYU, Sch Med, InSPIRES, New York, NY USA. [Opler, Lewis A.] Columbia Univ, New York, NY USA. [Malaspina, Dolores] NYU, Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2014 VL 75 IS 9 SU S MA 1382 BP 395S EP 396S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE6KS UT WOS:000334101802375 ER PT J AU Lim, M Elkind, J Xiong, GX Rodin, J Galante, R Zhu, JX Zhang, L Lian, J Kuzma, N Pack, A Cohen, A AF Lim, Miranda Elkind, Jaclynn Xiong, Guoxing Rodin, Julianna Galante, Ray Zhu, Jingxu Zhang, Lin Lian, Jie Kuzma, Nicholas Pack, Allan Cohen, Akiva TI Mild TBI causes sleep disturbances which are mitigated by dietary therapy SO BRAIN INJURY LA English DT Meeting Abstract C1 [Lim, Miranda] Portland VA Med Ctr, Portland, OR USA. [Elkind, Jaclynn; Xiong, Guoxing; Cohen, Akiva] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Rodin, Julianna; Galante, Ray; Zhu, Jingxu; Zhang, Lin; Lian, Jie; Kuzma, Nicholas; Pack, Allan] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0005 BP 517 EP 518 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000003 ER PT J AU Isokuortti, H Luoto, TM Kataja, A Siironen, J Liimatainen, S Iverson, GL Ylinen, A Ohman, J AF Isokuortti, Harri Luoto, Teemu M. Kataja, Anneli Siironen, Jari Liimatainen, Suvi Iverson, Grant L. Ylinen, Aarne Oehman, Juha TI Necessity of monitoring after negative head CT in patients with an acute head injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Isokuortti, Harri; Ylinen, Aarne] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland. [Isokuortti, Harri; Ylinen, Aarne] Univ Helsinki, Helsinki, Finland. [Luoto, Teemu M.; Liimatainen, Suvi; Oehman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland. [Kataja, Anneli] Tampere Univ Hosp, Dept Radiol, Med Imaging Ctr, Tampere, Finland. [Siironen, Jari] Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland. [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0069 BP 537 EP 538 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000057 ER PT J AU Luoto, TM Iverson, GL Silverberg, ND Kataja, A Brander, A Tenovuo, O Ohman, J AF Luoto, Teemu M. Iverson, Grant L. Silverberg, Noah D. Kataja, Anneli Brander, Antti Tenovuo, Olli Ohman, Juha TI A head-to-head comparison of the Sport Concussion Assessment Tool 2 (SCAT2) and the Military Assessment of Concussion Evaluation (MACE) SO BRAIN INJURY LA English DT Meeting Abstract C1 [Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland. [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Harvard, MA USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Charlestown, MA USA. [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada. [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada. [Kataja, Anneli; Brander, Antti] Tampere Univ Hosp, Dept Radiol, Med Imaging Ctr, Tampere, Finland. [Tenovuo, Olli] Univ Turku, Dept Neurol, FIN-20520 Turku, Finland. [Tenovuo, Olli] Turku Univ, Cent Hosp, Turku, Finland. NR 0 TC 0 Z9 0 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0072 BP 538 EP 539 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000060 ER PT J AU Hanninen, T Tuominen, M Vartiainen, M Parkkari, J Ohman, J Iverson, GL Luoto, TM AF Hanninen, Timo Tuominen, Markku Vartiainen, Matti Parkkari, Jari Ohman, Juha Iverson, Grant L. Luoto, Teemu M. TI The Sport Concussion Assessment Tool 3 (SCAT3)-Baseline values for professional ice hockey players SO BRAIN INJURY LA English DT Meeting Abstract C1 [Hanninen, Timo; Parkkari, Jari] UKK Inst Hlth Promot Res, Tampere Res Ctr Sports Med, Tampere, Finland. [Tuominen, Markku] Medisport Inc, Tampere, Finland. [Vartiainen, Matti] Univ Helsinki, Inst Behav Sci, Helsinki, Finland. [Ohman, Juha; Luoto, Teemu M.] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland. [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0111 BP 553 EP 554 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000097 ER PT J AU Villien, M Edlow, B McIntosh, E Purohit, M Van der Kouwe, A Sherman, J Greer, D Zafonte, R Wu, O AF Villien, Marjorie Edlow, Brian McIntosh, Elissa Purohit, Maulik Van der Kouwe, Andre Sherman, Janet Greer, David Zafonte, Ross Wu, Ona TI Brain network dysfunction in young athletes with persistent post-concussion syndrome SO BRAIN INJURY LA English DT Meeting Abstract C1 [Villien, Marjorie; Edlow, Brian; McIntosh, Elissa; Van der Kouwe, Andre; Sherman, Janet; Wu, Ona] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Purohit, Maulik; Zafonte, Ross] Spaulding Rehabil Hosp, Boston, MA USA. [Greer, David] Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0117 BP 556 EP 557 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000103 ER PT J AU Pasternak, O Bouix, S Rathi, Y Branch, C Westin, CF Shenton, M Lipton, M AF Pasternak, Ofer Bouix, Sylvain Rathi, Yogesh Branch, Craig Westin, Carl-Fredrik Shenton, Martha Lipton, Michael TI Characterization of acute diffusion MRI abnormalities following concussion using a joint distribution free-water imaging normative atlas SO BRAIN INJURY LA English DT Meeting Abstract C1 [Pasternak, Ofer; Bouix, Sylvain; Rathi, Yogesh; Westin, Carl-Fredrik; Shenton, Martha] Harvard Univ, Sch Med, Boston, MA USA. [Branch, Craig; Lipton, Michael] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Shenton, Martha] VA Boston Healthcare Syst, Brockton, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0143 BP 565 EP 565 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000125 ER PT J AU Pape, T Rosenow, J Steiner, M Parrish, T Guernon, A Harton, B McNamee, S Patil, V Walker, M Froelich, K Burress, C Odle, C Wang, X Herrold, A Zhao, WH Reda, D Coneely, M Nemeth, A AF Pape, Theresa Rosenow, Joshua Steiner, Monica Parrish, Todd Guernon, Ann Harton, Brett McNamee, Shane Patil, Vijaya Walker, Matthew Froelich, Kathleen Burress, Catherine Odle, Cheryl Wang, Xue Herrold, Amy Zhao, Weihan Reda, Domenic Coneely, Mark Nemeth, Alexander TI Therapeutic effect of familiar auditory sensory training for acute severe traumatic brain injury from a placebo-controlled trial SO BRAIN INJURY LA English DT Meeting Abstract C1 [Pape, Theresa; Steiner, Monica; Harton, Brett; Patil, Vijaya; Odle, Cheryl; Herrold, Amy; Reda, Domenic] US Dept Vet Affairs, Hines, VA USA. [Pape, Theresa; Steiner, Monica; Harton, Brett; Patil, Vijaya; Odle, Cheryl; Herrold, Amy; Reda, Domenic] US Dept Vet Affairs, Hines, IL USA. [Rosenow, Joshua; Parrish, Todd; Wang, Xue] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA. [McNamee, Shane] US Dept Vet Affairs, Hunter Holmes McGuire VAMC, Richmond, VA USA. [Walker, Matthew] Northshore Univ Hlth Syst, Evanston, IL USA. [Froelich, Kathleen; Burress, Catherine] Rehabil Inst Chicago, Chicago, IL 60611 USA. [Zhao, Weihan] Univ IL Chicago, Chicago, IL USA. [Coneely, Mark] Captain James A Lovell VAMC, N Chicago, IL USA. [Nemeth, Alexander] NW Mem Hosp, Chicago, IL 60611 USA. Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0144 BP 566 EP 566 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000126 ER PT J AU Silverberg, ND Luoto, TM Ohman, J Iverson, GL AF Silverberg, Noah D. Luoto, Teemu M. Ohman, Juha Iverson, Grant L. TI Acute assessment of mild traumatic brain injury with the King-Devick test in an emergency department sample SO BRAIN INJURY LA English DT Meeting Abstract C1 [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada. [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada. [Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland. [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0195 BP 584 EP 584 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000170 ER PT J AU Krych, D Biester, R Parrott, D Schmidt, MJ Murphy, MP AF Krych, David Biester, Rosette Parrott, Devan Schmidt, M. J. Murphy, Mary Pat TI Individuals with TBI and their significant others' perceptions of information given about the nature and possible consequences of brain injury: Analysis of a national survey SO BRAIN INJURY LA English DT Meeting Abstract C1 [Krych, David; Schmidt, M. J.; Murphy, Mary Pat] ReMed Recovery Care Ctr, Paoli, PA USA. [Biester, Rosette] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Parrott, Devan] Rehabil Hosp Indiana, Indianapolis, IN USA. [Biester, Rosette] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0219 BP 592 EP 592 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000189 ER PT J AU McGlinchey, R Rosenblatt, A Mercado, R Esterman, M DeGutis, J AF McGlinchey, Regina Rosenblatt, Andrew Mercado, Roger Esterman, Michael DeGutis, Joseph TI Internet-based cognitive training enhances attention and functional outcomes in OEF/OIF/OND veterans SO BRAIN INJURY LA English DT Meeting Abstract C1 [McGlinchey, Regina; Esterman, Michael; DeGutis, Joseph] VA Boston Healthcare Syst, Boston, MA USA. [Rosenblatt, Andrew] Univ Houston, Houston, TX USA. [Mercado, Roger] Temple Univ, Philadelphia, PA 19122 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0305 BP 624 EP 625 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000266 ER PT J AU Valera, E Francis, A Makris, N Li, Z Wegbreit, E O'Connor, M AF Valera, Eve Francis, Alan Makris, Nikos Li, Zhi Wegbreit, Ezra O'Connor, Margaret TI Brain injury in battered women and its relationship to microstructural white matter alterations: A diffusion tensor imaging study SO BRAIN INJURY LA English DT Meeting Abstract C1 [Valera, Eve; Francis, Alan; Makris, Nikos; Li, Zhi] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Wegbreit, Ezra] Brown Univ, Sch Med, Dept Psychiat, Bradley Hosp, Providence, RI 02912 USA. [O'Connor, Margaret] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0339 BP 637 EP 638 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000297 ER PT J AU Bouix, S Cai, P Pasternak, O Zafonte, R Shenton, M AF Bouix, Sylvain Cai, Phoebe Pasternak, Ofer Zafonte, Ross Shenton, Martha TI Subject-specific evaluation of mTBI with diffusion MRI: Statistical considerations SO BRAIN INJURY LA English DT Meeting Abstract C1 [Bouix, Sylvain; Cai, Phoebe; Pasternak, Ofer; Shenton, Martha] Brigham & Womens Hosp, Boston, MA 02115 USA. [Zafonte, Ross] Spaulding Rehabil Hosp, Boston, MA USA. [Zafonte, Ross] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shenton, Martha] Vet Affairs Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0352 BP 643 EP 643 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000309 ER PT J AU Katz, J Daniel, T Goodman, A Denney, T Deshpande, G Traynham, S Iverson, G Dretsch, M AF Katz, Jeffery Daniel, Thomas Goodman, Alex Denney, Thomas Deshpande, Gopikrishna Traynham, Stephanie Iverson, Grant Dretsch, Michael TI fMRI correlates of emotional dysregulation in US soldiers with post-concussion syndrome SO BRAIN INJURY LA English DT Meeting Abstract C1 [Katz, Jeffery; Daniel, Thomas; Goodman, Alex; Denney, Thomas; Deshpande, Gopikrishna] Auburn Univ, MRI Res Ctr, Auburn, AL 36849 USA. [Traynham, Stephanie] US Army Aeromed Res Lab, Ft Rucker, AL USA. [Iverson, Grant] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Iverson, Grant] Red Sox Fdn, Boston, MA USA. [Iverson, Grant] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. [Dretsch, Michael] HDQA, Arlington, VA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0403 BP 661 EP 662 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000355 ER PT J AU Luoto, TM Iverson, GL Losoi, H Lehtimaki, T Ohman, J AF Luoto, Teemu M. Iverson, Grant L. Losoi, Heidi Lehtimaki, Terho Ohman, Juha TI A prospective study of the ApoE gene as a predictor of mild traumatic brain injury outcome SO BRAIN INJURY LA English DT Meeting Abstract C1 [Luoto, Teemu M.; Losoi, Heidi; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland. [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Charlestown, MA USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. [Iverson, Grant L.] Def & Vet, Boston, MA USA. [Iverson, Grant L.] Def & Vet, Bethesda, MD USA. [Lehtimaki, Terho] Pirkanmaa Hosp Dist, Dept Clin Chem, Fimlab Labs, Tampere, Finland. [Lehtimaki, Terho] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland. NR 0 TC 0 Z9 0 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0446 BP 678 EP 678 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000395 ER PT J AU Jaramillo, C Eapen, B Robinson, J Amuan, M McGeary, C McGeary, D Pugh, MJ AF Jaramillo, Carlos Eapen, Blessen Robinson, Jedediah Amuan, Megan McGeary, Cindy McGeary, Don Pugh, Mary Jo TI Traumatic brain injury and common comorbidities associated with prevalence and persistence post-deployment headaches among US veterans of Afghanistan and Iraq wars SO BRAIN INJURY LA English DT Meeting Abstract C1 [Jaramillo, Carlos; Eapen, Blessen; Amuan, Megan; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Robinson, Jedediah] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Medicien, San Antonio, TX 78229 USA. [McGeary, Cindy; McGeary, Don] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Amuan, Megan] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0498 BP 700 EP 700 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000446 ER PT J AU Jaramillo, C Eapen, B Tate, D York, G Amuan, M Wang, CP Pugh, MJ AF Jaramillo, Carlos Eapen, Blessen Tate, David York, Gerry Amuan, Megan Wang, Chen-Pin Pugh, Mary Jo TI Post-deployment symptom clusters and associations with traumatic brain injury in US veterans of the Afghanistan and Iraq wars SO BRAIN INJURY LA English DT Meeting Abstract C1 [Jaramillo, Carlos; Eapen, Blessen; Wang, Chen-Pin; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Tate, David; York, Gerry] Def & Vet Brain Injury Ctr, San Antonio, TX USA. [Amuan, Megan] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. RI Tate, David/I-3963-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0500 BP 701 EP 701 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000448 ER PT J AU Pape, T Rosenow, J Patil, V Steiner, M Harton, B Wang, X Parrish, T Bhaumik, D Conneely, M Nemeth, A Guernon, A Zhao, WH Herrold, A Kletzel, S AF Pape, Theresa Rosenow, Joshua Patil, Vijaya Steiner, Monica Harton, Brett Wang, Xue Parrish, Todd Bhaumik, Dulal Conneely, Mark Nemeth, Alexander Guernon, Ann Zhao, Weihan Herrold, Amy Kletzel, Sandra TI TMS related changes in functional connectivity of default mode network and associated neurobehavioural gains for subjects in vegetative state after traumatic brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Pape, Theresa; Patil, Vijaya; Steiner, Monica; Harton, Brett; Herrold, Amy; Kletzel, Sandra] US Dept Vet Affairs, Hines, IL USA. [Rosenow, Joshua; Wang, Xue; Parrish, Todd; Nemeth, Alexander] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Bhaumik, Dulal; Zhao, Weihan] Univ Illinois, Chicago, IL USA. [Conneely, Mark] Fed Hlth Care Ctr, N Chicago, IL USA. [Guernon, Ann] Marianjoy Rehabiitat Hosp, Wheaton, IL USA. NR 0 TC 0 Z9 0 U1 3 U2 9 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0517 BP 708 EP 708 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000463 ER PT J AU McGlinchey, R Lippa, S Fonda, J Fortier, C Amick, M Kenna, A Milberg, W AF McGlinchey, Regina Lippa, Sara Fonda, Jennifer Fortier, Catherine Amick, Melissa Kenna, Alexandra Milberg, William TI Mild traumatic brain injury in veterans modifies risk for associated co-morbidities: Defining the deployment trauma cluster SO BRAIN INJURY LA English DT Meeting Abstract C1 [McGlinchey, Regina; Lippa, Sara; Fonda, Jennifer; Fortier, Catherine; Amick, Melissa; Kenna, Alexandra; Milberg, William] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0673 BP 765 EP 765 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000603 ER PT J AU McGlinchey, R Fonda, J Milberg, W Rudolph, J Hunt, P Reynolds, M Yonan, C AF McGlinchey, Regina Fonda, Jennifer Milberg, William Rudolph, James Hunt, Phillip Reynolds, Matthew Yonan, Charles TI Study of pseudobulbar affect symptoms in veterans with mild traumatic brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [McGlinchey, Regina; Fonda, Jennifer; Milberg, William; Rudolph, James] VA Boston Healthcare Syst, Boston, MA USA. [Hunt, Phillip; Reynolds, Matthew] Evidera, Lexington, MA USA. [Yonan, Charles] Avanir Pharmaceut Inc, Aliso Viejo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0742 BP 792 EP 793 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000670 ER PT J AU Dams-O'Connor, K Crane, P Diaz-Arrastia, R Gordon, W Keene, D Perl, D Sonnen, J Edlow, B AF Dams-O'Connor, Kristen Crane, Paul Diaz-Arrastia, Ramon Gordon, Wayne Keene, Dirk Perl, Daniel Sonnen, Joshua Edlow, Brian TI Late effects of TBI (LE-TBI) consortium: A multidisciplinary study to advance understanding of TBI outcomes SO BRAIN INJURY LA English DT Meeting Abstract C1 [Dams-O'Connor, Kristen; Gordon, Wayne] Icahn Sch Med Mt Sinai, New York, NY USA. [Crane, Paul; Keene, Dirk; Sonnen, Joshua] Univ Washington, Seattle, WA 98195 USA. [Diaz-Arrastia, Ramon; Perl, Daniel] Uniformed Serv Univ Hlth Sci, Rockville, MD USA. [Edlow, Brian] Massachusetts Gen Hosp, Martinos Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0762 BP 800 EP 801 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000689 ER PT J AU Pugh, MJ Orman, J Jaramillo, C Salinsky, M McNamee, S Eapen, B Towne, A Grafman, J AF Pugh, Mary Jo Orman, Jean Jaramillo, Carlos Salinsky, Martin McNamee, Shane Eapen, Blessen Towne, Alan Grafman, Jordan TI The prevalence of epilepsy and association with traumatic brain injury in veterans of the Afghanistan and Iraq wars SO BRAIN INJURY LA English DT Meeting Abstract C1 [Pugh, Mary Jo; Jaramillo, Carlos; Eapen, Blessen] South Texas Vet Healthcare Syst, San Antonio, TX USA. [Orman, Jean] US Army, Inst Surg Res, San Antonio, TX USA. [Salinsky, Martin] Portland VA Med Ctr, Portland, OR USA. [McNamee, Shane; Towne, Alan] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Grafman, Jordan] Rehabil Inst Chicago, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0781 BP 807 EP 807 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000706 ER PT J AU Smart, O Kuzma, N Lim, MM AF Smart, Otis Kuzma, Nicholas Lim, Miranda M. TI EEG cross-frequency coupling in mild traumatic brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Smart, Otis] Emory Univ, Atlanta, GA 30322 USA. [Kuzma, Nicholas] Portland State Univ, Portland, OR 97207 USA. [Lim, Miranda M.] Portland VA Med Ctr, Portland, OR USA. [Lim, Miranda M.] Oregon Hlth & Sci Univ, Div Sleep Med, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0783 BP 808 EP 808 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000708 ER PT J AU Carlson, K O'Neil, M McAndrew, L Storzbach, D Cifu, D Sayer, N AF Carlson, Kathleen O'Neil, Maya McAndrew, Lisa Storzbach, Daniel Cifu, David Sayer, Nina TI Risk of hospitalization due to motor vehicle crashes among Iraq and Afghanistan war veterans diagnosed with traumatic brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Carlson, Kathleen; O'Neil, Maya; Storzbach, Daniel] Portland VA Med Ctr, Portland, OR USA. [McAndrew, Lisa] VA New Jersey Hlth Care Syst, E Orange, NJ USA. [Cifu, David] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Sayer, Nina] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. RI Sayer, Nina/E-3249-2016 NR 0 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0836 BP 830 EP 830 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000758 ER PT J AU Norman, R Jaramillo, C Eapen, B Amuan, M Pugh, MJ AF Norman, Rocio Jaramillo, Carlos Eapen, Blessen Amuan, Megan Pugh, Mary Jo TI Stuttering (fluency disorders) and traumatic brain injury in US veterans of Iraq and Afghanistan SO BRAIN INJURY LA English DT Meeting Abstract C1 [Norman, Rocio; Jaramillo, Carlos; Eapen, Blessen; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Amuan, Megan] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0862 BP 840 EP 840 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000782 ER PT J AU Fisher, L Pedrelli, P Giacino, J Cardoos, A Hammond, F Bogner, J Bombardier, C Hart, T Bergquist, T Ketchum, J Zafonte, R AF Fisher, Lauren Pedrelli, Paola Giacino, Joseph Cardoos, Amber Hammond, Flora Bogner, Jennifer Bombardier, Charles Hart, Tessa Bergquist, Thomas Ketchum, Jessica Zafonte, Ross TI Rates of suicidal behaviour following traumatic brain injury (TBI): Five year follow-up data from the traumatic brain injury model systems (TBIMS) SO BRAIN INJURY LA English DT Meeting Abstract C1 [Fisher, Lauren; Pedrelli, Paola; Cardoos, Amber] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Giacino, Joseph; Zafonte, Ross] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA. [Hammond, Flora] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Bogner, Jennifer] Ohio State Univ, Columbus, OH 43210 USA. [Bombardier, Charles] Univ Washington, Seattle, WA 98195 USA. [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA. [Bergquist, Thomas] Mayo Clin, Rochester, MN USA. [Ketchum, Jessica] Virginia Commonwealth Univ, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0868 BP 842 EP 842 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000787 ER PT J AU Koerte, IK Mayinger, M Green, K Giwerc, M Dahlben, B Fredman, E Eckbo, R Baugh, CM Stamm, J Makris, N Lin, A Pasternak, O Rathi, Y Stern, RA Shenton, ME AF Koerte, Inga K. Mayinger, Michael Green, Katie Giwerc, Michelle Dahlben, Brian Fredman, Eli Eckbo, Ryan Baugh, Christine M. Stamm, Julie Makris, Nikos Lin, Alexander Pasternak, Ofer Rathi, Yogesh Stern, Robert A. Shenton, Martha E. TI White matter microstructure and cortical thickness in former NFL players SO BRAIN INJURY LA English DT Meeting Abstract C1 [Koerte, Inga K.; Mayinger, Michael; Green, Katie; Giwerc, Michelle; Dahlben, Brian; Fredman, Eli; Eckbo, Ryan; Baugh, Christine M.; Makris, Nikos; Pasternak, Ofer; Rathi, Yogesh] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02115 USA. [Stamm, Julie; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA. [Stamm, Julie; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA. [Lin, Alexander] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Shenton, Martha E.] VA Boston Healthcare Syst, Neurosci Lab, Clin Neurosci Div, Brockton, MA USA. Univ Munich, Inst Clin Radiol, Munich, Germany. NR 0 TC 0 Z9 0 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0874 BP 844 EP 844 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000792 ER PT J AU Rodriguez, N Loya, F Binder, D Buchanan, B Novakovic-Agopian, T Murphy, M Bruhns, M Chen, A AF Rodriguez, Nicholas Loya, Fred Binder, Deborah Buchanan, Bruce Novakovic-Agopian, Tatjana Murphy, Michelle Bruhns, Maya Chen, Anthony TI 'Working your way up' from simple to complex situations in game-assisted training of attention regulation for individuals with brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Rodriguez, Nicholas; Loya, Fred; Binder, Deborah; Bruhns, Maya] VA Northern Calif Hlth Care Syst, Martinez, CA USA. [Buchanan, Bruce] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Novakovic-Agopian, Tatjana; Murphy, Michelle] San Francisco VA Med Ctr, San Francisco, CA USA. [Chen, Anthony] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0883 BP 848 EP 848 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000801 ER PT J AU Tishler, RB AF Tishler, Roy B. TI Increased clarity on the use of radiotherapy in the management of desmoplastic melanoma SO CANCER LA English DT Editorial Material ID LYMPH-NODE BIOPSY; MALIGNANT-MELANOMA; ADJUVANT RADIOTHERAPY; PROGNOSTIC-FACTORS; CLINICAL-BEHAVIOR; LOCAL-CONTROL; RADIATION; PURE AB Desmoplastic melanoma is a rare type of cutaneous melanoma with a distinct clinical behavior characterized by a propensity for local recurrence. The 2 articles in this issue of Cancer present significant information clarifying the role of adjuvant radiotherapy in the treatment of patients with desmoplastic melanoma. C1 [Tishler, Roy B.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Tishler, RB (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM roy_tishler@dfci.harvard.edu NR 19 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 1 PY 2014 VL 120 IS 9 BP 1315 EP 1318 DI 10.1002/cncr.28613 PG 4 WC Oncology SC Oncology GA AF4BT UT WOS:000334657100006 PM 24877163 ER PT J AU Lubitz, CC Kong, CY McMahon, PM Daniels, GH Chen, YF Economopoulos, KP Gazelle, GS Weinstein, MC AF Lubitz, Carrie C. Kong, Chung Y. McMahon, Pamela M. Daniels, Gilbert H. Chen, Yufei Economopoulos, Konstantinos P. Gazelle, G. Scott Weinstein, Milton C. TI Annual financial impact of well-differentiated thyroid cancer care in the United States SO CANCER LA English DT Article DE thyroid cancer; cost of cancer care; economic analysis; cost analysis ID IODINE REMNANT ABLATION; RADIOACTIVE IODINE; INCREASING INCIDENCE; COLORECTAL-CANCER; INITIAL THERAPY; BETHESDA SYSTEM; RISK; CARCINOMA; OUTCOMES; SURGERY AB BACKGROUND Well-differentiated thyroid cancer (WDTC) is a prevalent disease, which is increasing in incidence faster than any other cancer. Substantial direct medical care costs are related to the diagnosis and treatment of newly diagnosed patients as well as the ongoing surveillance of patients who have a long life expectancy. Prior analyses of the aggregate health care costs attributable to WDTC in the United States have not been reported. METHODS A stacked cohort cost analysis was performed on the US population from 1985 to 2013 to estimate the number of WDTC survivors in 2013. Incidence rates, and cancer-specific and overall survival were based on Surveillance, Epidemiology, and End Results (SEER) data. Current and projected direct medical care costs attributable to the care of patients with WDTC were then estimated. Health care-related costs and event probabilities were based on Medicare reimbursement schedules and the literature. RESULTS Estimated overall societal cost of WDTC care in 2013 for all US patients diagnosed after 1985 is $1.6 billion. Diagnosis, surgery, and adjuvant therapy for newly diagnosed patients (41%) constitutes the greatest proportion of costs, followed by surveillance of survivors (37%), and nonoperative death costs attributable to thyroid cancer care (22%). Projected 2030 costs (in 2013 US dollars) based on current incidence trends exceed $3.5 billion. CONCLUSIONS Health care costs of WDTC are substantial. Unlike other cancers, the majority of the cost is incurred in the initial and continuing phases of care. With the projected increasing incidence, population, and survival trends, costs will continue to escalate. Cancer 2014;120:1345-1352. (c) 2014 American Cancer Society. C1 [Lubitz, Carrie C.; Kong, Chung Y.; McMahon, Pamela M.; Daniels, Gilbert H.; Chen, Yufei; Economopoulos, Konstantinos P.; Gazelle, G. Scott] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Lubitz, Carrie C.; Chen, Yufei; Economopoulos, Konstantinos P.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Lubitz, Carrie C.; Kong, Chung Y.; McMahon, Pamela M.; Economopoulos, Konstantinos P.; Gazelle, G. Scott] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Kong, Chung Y.; McMahon, Pamela M.; Gazelle, G. Scott] Harvard Univ, Dept Radiol, Sch Med, Boston, MA 02114 USA. [Daniels, Gilbert H.] Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA. [Daniels, Gilbert H.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Gazelle, G. Scott; Weinstein, Milton C.] Harvard Univ, Dept Hlth Policy & Management, Sch Publ Hlth, Boston, MA 02114 USA. RP Lubitz, CC (reprint author), Harvard Univ, Sch Med, Div Gen Surg, Massachusetts Gen Hosp, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA. EM clubitz@partners.org OI Economopoulos, Konstantinos/0000-0003-4856-0405 FU Program in Cancer Outcomes Research Training Grant [NCI R25CA092203]; Massachusetts General Hospital Department of Surgery; Massachusetts General Hospital American Cancer Society Institutional Research Grant FX Funding is provided by a Program in Cancer Outcomes Research Training Grant (NCI R25CA092203), Massachusetts General Hospital Department of Surgery, and Massachusetts General Hospital American Cancer Society Institutional Research Grant. NR 50 TC 27 Z9 27 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 1 PY 2014 VL 120 IS 9 BP 1345 EP 1352 DI 10.1002/cncr.28562 PG 8 WC Oncology SC Oncology GA AF4BT UT WOS:000334657100010 PM 24481684 ER PT J AU Odejide, OO Jacobson, JO Abel, GA AF Odejide, Oreofe O. Jacobson, Joseph O. Abel, Gregory A. TI Reply to quality control of bone marrow aspirates: Additional steps toward a safer and more efficient procedure SO CANCER LA English DT Letter ID CHECKLIST; INTERVENTION; POPULATION; MORTALITY C1 [Odejide, Oreofe O.] Dana Farber Canc Inst, Div Populat Sci, Dept Med Oncol, Boston, MA 02115 USA. [Jacobson, Joseph O.] Dana Farber Canc Inst, Div Qual & Safety, Dept Med Oncol, Boston, MA 02115 USA. [Abel, Gregory A.] Dana Farber Canc Inst, Div Populat Sci, Dept Med Oncol, Ctr Leukemia, Boston, MA 02115 USA. RP Odejide, OO (reprint author), Dana Farber Canc Inst, Div Populat Sci, Dept Med Oncol, Boston, MA 02115 USA. NR 5 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 1 PY 2014 VL 120 IS 9 BP 1442 EP 1442 DI 10.1002/cncr.28603 PG 1 WC Oncology SC Oncology GA AF4BT UT WOS:000334657100023 PM 24481832 ER PT J AU Yu, GQ Gail, MH Shi, JX Klepac-Ceraj, V Paster, BJ Dye, BA Wang, GQ Wei, WQ Fan, JH Qiao, YL Dawsey, SM Freedman, ND Abnet, CC AF Yu, Guoqin Gail, Mitchell H. Shi, Jianxin Klepac-Ceraj, Vanja Paster, Bruce J. Dye, Bruce A. Wang, Guo-Qing Wei, Wen-Qiang Fan, Jin-Hu Qiao, You-Lin Dawsey, Sanford M. Freedman, Neal D. Abnet, Christian C. TI Association between Upper Digestive Tract Microbiota and Cancer-Predisposing States in the Esophagus and Stomach SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID SQUAMOUS-CELL CARCINOMA; HELICOBACTER-PYLORI INFECTION; INFLAMMATORY BOWEL DISEASES; SERUM PEPSINOGENS; GUT MICROBIOME; GASTRIC-CANCER; PERNICIOUS-ANEMIA; HIGH-RISK; POPULATION; CHINA AB Background: The human upper digestive tract microbial community (microbiota) is not well characterized and few studies have explored how it relates to human health. We examined the relationship between upper digestive tract microbiota and two cancer-predisposing states, serum pepsinogen I/pepsinogen II ratio (PGI/II; predictor of gastric cancer risk) and esophageal squamous dysplasia (ESD; the precursor lesion of esophageal squamous cell carcinoma; ESCC) in a cross-sectional design. Methods: The Human Oral Microbe Identification Microarray was used to test for the presence of 272 bacterial species in 333 upper digestive tract samples from a Chinese cancer screening cohort. Serum PGI and PGII were determined by ELISA. ESD was determined by chromoendoscopy with biopsy. Results: Lower microbial richness (number of bacterial genera per sample) was significantly associated with lower PGI/II ratio (P = 0.034) and the presence of ESD (P = 0.018). We conducted principal component (PC) analysis on a beta-diversity matrix (pairwise difference in microbiota), and observed significant correlations between PC1, PC3, and PGI/II (P = 0.004 and 0.009, respectively), and between PC1 and ESD (P = 0.003). Conclusions: Lower microbial richness in upper digestive tract was independently associated with both cancer-predisposing states in the esophagus and stomach (presence of ESD and lower PGI/II). Impact: These novel findings suggest that the upper digestive tract microbiota may play a role in the etiology of chronic atrophic gastritis and ESD, and therefore in the development of gastric and esophageal cancers. (C) 2014 AACR. C1 [Yu, Guoqin; Gail, Mitchell H.; Shi, Jianxin; Dawsey, Sanford M.; Freedman, Neal D.; Abnet, Christian C.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Dye, Bruce A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Klepac-Ceraj, Vanja; Paster, Bruce J.] Forsyth Inst, Cambridge, MA USA. [Klepac-Ceraj, Vanja] Wellesley Coll, Wellesley, MA 02181 USA. [Paster, Bruce J.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. [Wang, Guo-Qing; Wei, Wen-Qiang; Fan, Jin-Hu; Qiao, You-Lin] Chinese Acad Med Sci, Inst Canc, Beijing 100021, Peoples R China. RP Yu, GQ (reprint author), NCI, Div Canc Epidemiol & Genet, Genet Epidemiol Branch, 9609 Med Ctr Dr,Room 6E518,MSC 9704, Bethesda, MD 20892 USA. EM yug3@mail.nih.gov RI Qiao, You-Lin/B-4139-2012; Abnet, Christian/C-4111-2015; Freedman, Neal/B-9741-2015; OI Qiao, You-Lin/0000-0001-6380-0871; Abnet, Christian/0000-0002-3008-7843; Freedman, Neal/0000-0003-0074-1098; Klepac-Ceraj, Vanja/0000-0001-5387-5706 FU Intramural Research Program of the NIH, National Cancer Institute FX This study was supported by the Intramural Research Program of the NIH, National Cancer Institute. NR 33 TC 14 Z9 15 U1 0 U2 25 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2014 VL 23 IS 5 BP 735 EP 741 DI 10.1158/1055-9965.EPI-13-0855 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AG0ZU UT WOS:000335145300005 PM 24700175 ER PT J AU Frantz, S Nahrendorf, M AF Frantz, Stefan Nahrendorf, Matthias TI Cardiac macrophages and their role in ischaemic heart disease SO CARDIOVASCULAR RESEARCH LA English DT Review DE Macrophage; Myocardial infarction; Heart failure; Bone marrow; Spleen ID ACUTE MYOCARDIAL-INFARCTION; STEM-CELL NICHE; BONE-MARROW; MAGNETIC-RESONANCE; MONOCYTE EMIGRATION; SPLENIC RESERVOIR; MESENCHYMAL STEM; PROGENITOR CELLS; MOUSE HEART; IRON-OXIDE AB Cardiac macrophages are abundant in the healthy heart and after myocardial infarction (MI). Different macrophage phenotypes likely promote myocardial health vs. disease. Infarct macrophages are inflammatory and derive from circulating monocytes produced by the haematopoietic system. These cells are centrally involved in inflammatory tissue remodelling, resolution of inflammation during post-MI healing, and left ventricular remodelling. Presumably, macrophages interact with myocytes, endothelial cells, and fibroblasts. Although macrophages are primarily recruited to the ischaemic myocardium, the remote non-ischaemic myocardium macrophage population changes dynamically after MI. Macrophages known roles in defending the steady state and their pathological actions in other disease contexts provide a road map for exploring cardiac macrophages and their phenotypes, functions, and therapeutic potential. In our review, we summarize recent insights into the role of cardiac macrophages, focus on their actions after ischaemia, and highlight emerging research topics. C1 [Frantz, Stefan] Univ Hosp Wurzburg, Dept Internal Med 1, D-97080 Wurzburg, Germany. [Frantz, Stefan] Univ Hosp Wurzburg, Comprehens Heart Failure Ctr, D-97080 Wurzburg, Germany. [Nahrendorf, Matthias] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02138 USA. RP Nahrendorf, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Simches Res Bldg,185 Cambridge St, Boston, MA 02138 USA. EM mnahrendorf@mgh.harvard.edu RI Frantz, Stefan/G-1723-2012 FU National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services [HHSN268201000044C, R01-HL095629, R01-HL114477, R01-HL117829]; Bundesministerium fur Bildung und Forschung [BMBF01 EO1004]; Deutsche Forschungsgemeinschaft [SFB688 TP A10] FX This project has been funded in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN268201000044C, and grants R01-HL095629, R01-HL114477, R01-HL117829 (M.N.), as well as grants from the Bundesministerium fur Bildung und Forschung (BMBF01 EO1004) and Deutsche Forschungsgemeinschaft (SFB688 TP A10) (S.F.). NR 77 TC 50 Z9 58 U1 7 U2 14 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0008-6363 EI 1755-3245 J9 CARDIOVASC RES JI Cardiovasc. Res. PD MAY 1 PY 2014 VL 102 IS 2 BP 240 EP 248 DI 10.1093/cvr/cvu025 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF9AA UT WOS:000335005900007 PM 24501331 ER PT J AU Gaggin, HK Dang, PV Do, LD defilippi, CR Christenson, RH Lewandrowski, EL Lewandrowski, KB Truong, BQ Pham, VQ Vu, VH Vu, TV Nguyen, TB Belcher, AM Femia, A Kelley, C Januzzi, JL AF Gaggin, Hanna K. Dang, Phuoc V. Do, Loi D. defilippi, Christopher R. Christenson, Robert H. Lewandrowski, Elizabeth L. Lewandrowski, Kent B. Truong, Binh Q. Pham, Vinh Q. Vu, Vu H. Vu, Truong V. Nguyen, Toan B. Belcher, Arianna M. Femia, Alexandra Kelley, Cynthia Januzzi, James L. TI Reference Interval Evaluation of High-Sensitivity Troponin T and N-Terminal B-Type Natriuretic Peptide in Vietnam and the US: The North South East West Trial SO CLINICAL CHEMISTRY LA English DT Article ID CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; FAILURE; ASSAY; DIAGNOSIS; MORTALITY; RISK AB BACKGROUND: Reference intervals of high-sensitivity troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been determined from Western populations. No data are available regarding expected values in Asian populations. METHODS: A total of 1157 age-and sex-matched healthy individuals (mean age, 41.2 years; 48.0% male) were prospectively enrolled from the US (n = 565) and Vietnam (n = 592). Blood samples were analyzed for hs-cTnT and NT-proBNP. Median values were determined for each country and compared in unadjusted analyses and in analyses adjusted for age, sex, body mass index, study site, race, and vital signs. RESULTS: Median hs-cTnT concentrations were slightly higher for individuals from the US than for those from Vietnam, but both were below the limit of detection (3.7 vs 3.0 ng/L, respectively; P = 0.03). More US participants had an hs-cTnT concentration above the limit of detection (57.2% vs 47.3%; P = 0.001), but the 99th percentile concentration was slightly higher for Asians (US 15.1 vs Vietnam 19.0 ng/L). Concentrations for > 98% of both populations were below the standard hs-cTnT 99th percentile of 14.0 ng/L (P = 0.54). Median NT-proBNP concentrations were slightly higher for US participants compared with Vietnamese participants (28 vs 16 ng/L, respectively; P < 0.001). Following adjustment, differences in concentrations of NT-proBNP between healthy US and Vietnamese populations remained significant, whereas for hs-cTnT the differences were no longer significant. Inclusion of hs-cTnT values down to the limit of blank did not change the result. CONCLUSIONS: The differences in hs-cTnT and NT-proBNP between healthy individuals from the US and Vietnam are small. Previously derived reference intervals for both analytes may be applied in Asian populations. (C) 2014 American Association for Clinical Chemistry C1 [Gaggin, Hanna K.; Lewandrowski, Elizabeth L.; Lewandrowski, Kent B.; Belcher, Arianna M.; Femia, Alexandra; Januzzi, James L.] Massachusetts Gen Hosp, Boston, MA USA. [Dang, Phuoc V.; Truong, Binh Q.; Vu, Vu H.] Univ Med Ctr, Ctr Heart, Ho Chi Minh City, Vietnam. [Do, Loi D.; Pham, Vinh Q.; Vu, Truong V.] Bach Mai Hosp, Hanoi, Vietnam. [defilippi, Christopher R.; Christenson, Robert H.; Kelley, Cynthia] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Nguyen, Toan B.] Medic Med Ctr, Ho Chi Minh City, Vietnam. RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, Div Cardiol, Yawkey 5984,55 Fruit St, Boston, MA 02114 USA. EM jjanuzzi@partners.org FU Ruth and James Clark Fund for Cardiac Research Innovation FX Roche Diagnostics ( Indianapolis, IN), Siemens, and Singulex; H.K. Gaggin, the Ruth and James Clark Fund for Cardiac Research Innovation; P.V. Dang, Roche Diagnostics; L.D. Do, Roche Diagnostics; C.R. deFilippi, Roche Diagnostics; R.H. Christenson, Roche Diagnostics; J.L. Januzzi, the Roman W. DeSanctis Clinical Scholar Endowment, Roche Diagnostics, Siemens Diagnostics, Critical Diagnostics, and BRAHMS. NR 16 TC 9 Z9 9 U1 0 U2 2 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD MAY PY 2014 VL 60 IS 5 BP 758 EP 764 DI 10.1373/clinchem.2013.216275 PG 7 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AG1AR UT WOS:000335147700012 PM 24568795 ER PT J AU Hedgire, SS Elmi, A Kambadakone, AR Yoon, S Blake, M Harisinghani, MG AF Hedgire, Sandeep S. Elmi, Azadeh Kambadakone, Avinash R. Yoon, Sam Blake, Michael Harisinghani, Mukesh G. TI MDCT imaging of Alloderm biologic mesh spacers in the abdomen and pelvis - preliminary experience SO CLINICAL IMAGING LA English DT Article DE Biologic mesh spacers; Alloderm; Soft tissue attenuation; MDCT; Oncosurgery; External beam radiation ID ALLOGRAFT DERMAL IMPLANT; MATRIX ALLODERM; REPAIR; SITE AB The purpose of this study was to assess the attenuation characteristics of the Alloderm Biologic Mesh Spacer (ABMS) in the abdomen and pelvis. Of nine patients with ABMS, five underwent multidetector computed tomographic scans at 1, 4, and 7 months postsurgery. Two patients underwent positron emission tomography-computed tomography (PET-CT). The pre- and postcontrast images were evaluated for attenuation characteristics of ABMS. The PET-CT scans were reviewed for [18F]-fluorodeoxyglucose (FDG) uptake. We observed increase in the attenuation characteristics of the spacers on follow-up imaging (P<.05). No FOG uptake was noted on PET-CF. To conclude, ABMS demonstrates soft tissue attenuation on noncontrast CT and shows increase attenuation on serial CT scans. (C) 2014 Elsevier Inc. All rights reserved. C1 [Hedgire, Sandeep S.; Elmi, Azadeh; Kambadakone, Avinash R.; Blake, Michael; Harisinghani, Mukesh G.] Massachusetts Gen Hosp, Dept Abdominal Imaging & Intervent, Boston, MA 02114 USA. [Yoon, Sam] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA. RP Hedgire, SS (reprint author), Massachusetts Gen Hosp, Dept Abdominal Imaging & Intervent, 55 Fruit St, Boston, MA 02114 USA. EM Hedgire.Sandeep@mgh.harvard.edu NR 10 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-7071 EI 1873-4499 J9 CLIN IMAG JI Clin. Imaging PD MAY-JUN PY 2014 VL 38 IS 3 BP 279 EP 282 DI 10.1016/j.clinimag.2013.12.020 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AG2VY UT WOS:000335276400012 PM 24556330 ER PT J AU Abtahi, SM Elmi, A Hedgire, SS Ho, YC Pourjabbar, S Singh, S Kalra, M Harisinghani, M AF Abtahi, Seyed Mandi Elmi, Azadeh Hedgire, Sandeep S. Ho, Yuen Chi Pourjabbar, Sarvenaz Singh, Sarabjeet Kalra, Mannudeep Harisinghani, Mukesh TI Depiction of celiac ganglia on positron emission tomography and computed tomography in patients with lung cancer SO CLINICAL IMAGING LA English DT Article DE Celiac ganglia; PET-CT; CT; Postmortem MDCT; Lung cancer AB Objective: To differentiate imaging characteristics of celiac ganglia from metastatic lesion on positron emission tomography-computed tomography (PET-CT) in patients with lung cancer and correlate these findings to postmortem multidetector row computed tomography (MDCT). Methods: One hundred twenty-nine patients were included. Imaging characteristics and fluorodeoxyglucose (FDG) avidity of the celiac ganglia were recorded. Postmortem MDCT of 20 subjects were reviewed. Results: Celiac ganglia were identified unilaterally in 127 and bilaterally in 108 patients without abnormal FDG uptake. Postmortem images showed celiac ganglia in all cases with no significant difference compared to our patients. Conclusions: Familiarity with CI' characteristics and FDG-avidity of celiac ganglia enable us to distinguish them from metastatic lesions in their vicinity. (C) 2014 Elsevier Inc. All rights reserved. C1 [Abtahi, Seyed Mandi; Elmi, Azadeh; Hedgire, Sandeep S.; Ho, Yuen Chi; Pourjabbar, Sarvenaz; Singh, Sarabjeet; Kalra, Mannudeep; Harisinghani, Mukesh] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. RP Abtahi, SM (reprint author), Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, 55 Fruit St,White 270, Boston, MA 02114 USA. EM Abtahi.Seyed@mgh.harvard.edu NR 8 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-7071 EI 1873-4499 J9 CLIN IMAG JI Clin. Imaging PD MAY-JUN PY 2014 VL 38 IS 3 BP 292 EP 295 DI 10.1016/j.clinimag.2013.12.017 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AG2VY UT WOS:000335276400015 PM 24560748 ER PT J AU Ginat, DT Walcott, BP Mordes, D Schaefer, PW Nahed, B AF Ginat, Daniel Thomas Walcott, Brian P. Mordes, Daniel Schaefer, Pamela W. Nahed, Brian TI Intracranial organizing hematoma with papillary endothelial hyperplasia features after resection and involved field radiotherapy for cerebellar juvenile pilocytic astrocytoma SO CLINICAL IMAGING LA English DT Article DE Organizing hematoma; Intravascular papillary endothelial hyperplasia; CT; MRI; Radiotherapy; Neurosurgery ID CEREBRAL ARTERIOVENOUS-MALFORMATION; ENCAPSULATED EXPANDING HEMATOMA; KNIFE STEREOTACTIC RADIOSURGERY; OF-THE-LITERATURE; MASSON TUMOR; REGION AB This article describes a case of organizing hematoma with features of papillary endothelial hyperplasia arising at the site of a right cerebellar juvenile pilocytic astrocytoma previously treated with surgery and involved-field radiation therapy. CTA demonstrated a mass with abnormal vascularity in the treatment bed. MRI demonstrated the evolution of the lesion from a cystic mass with a heterogeneously enhancing nodule with blood products into a nearly solid-enhancing mass with abundant areas of susceptibility effect and surrounding vasogenic edema. These imaging features warrant considering papillary endothelial hyperplasia in the differential diagnosis for a mass that develops after radiotherapy. (c) 2014 Elsevier Inc. All rights reserved. C1 [Ginat, Daniel Thomas] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA. [Walcott, Brian P.; Nahed, Brian] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Mordes, Daniel] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Schaefer, Pamela W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Ginat, DT (reprint author), Univ Chicago, 5841 S Maryland Ave, Chicago, IL 60637 USA. EM dtg1@uchicago.edu NR 19 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-7071 EI 1873-4499 J9 CLIN IMAG JI Clin. Imaging PD MAY-JUN PY 2014 VL 38 IS 3 BP 322 EP 325 DI 10.1016/j.clinimag.2013.12.003 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AG2VY UT WOS:000335276400021 PM 24456989 ER PT J AU Nachega, JB Parienti, JJ Uthman, OA Gross, R Dowdy, DW Sax, PE Gallant, JE Mugavero, MJ Mills, EJ Giordano, TP AF Nachega, Jean B. Parienti, Jean-Jacques Uthman, Olalekan A. Gross, Robert Dowdy, David W. Sax, Paul E. Gallant, Joel E. Mugavero, Michael J. Mills, Edward J. Giordano, Thomas P. TI Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE randomized controlled trials; ART; fixed-dose combination; once-daily; twice-daily ID TWICE-DAILY LOPINAVIR/RITONAVIR; FIXED-DOSE COMBINATION; QUALITY-OF-LIFE; VIROLOGICALLY SUPPRESSED PATIENTS; REVERSE-TRANSCRIPTASE INHIBITORS; NON-INFERIORITY TRIAL; HIV-1-INFECTED PATIENTS; MEDICATION ADHERENCE; VIRAL SUPPRESSION; TREATMENT-NAIVE AB Background. Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the impact of pill burden and once-daily vs twice-daily dosing on ART adherence and virological outcomes. Methods. A literature search of 4 electronic databases through 31 March 2013 was used. RCTs comparing once-daily vs twice-daily ART regimens that also reported on adherence and virological suppression were included. Study design, study population characteristics, intervention, outcome measures, and study quality were extracted. Study quality was rated using the Cochrane risk-of-bias tool. Results. Nineteen studies met our inclusion criteria (N = 6312 adult patients). Higher pill burden was associated with both lower adherence rates (P = .004) and worse virological suppression (P < .0001) in both once-daily and twice-daily subgroups, although the association with adherence in the once-daily subgroup was not statistically significant. The average adherence was modestly higher in once-daily regimens than twice-daily regimens (weighted mean difference = 2.55%; 95% confidence interval [CI], 1.23 to 3.87; P = .0002). Patients on once-daily regimens did not achieve virological suppression more frequently than patients on twice-daily regimens (relative risk [RR] = 1.01; 95% CI, 0.99 to 1.03; P = .50). Both adherence and viral load suppression decreased over time, but adherence decreased less with once-daily dosing than with twice-daily dosing. Conclusions. Lower pill burden was associated with both better adherence and virological suppression. Adherence, but not virological suppression, was slightly better with once- vs twice-daily regimens. C1 [Nachega, Jean B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Nachega, Jean B.; Dowdy, David W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Nachega, Jean B.; Dowdy, David W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Nachega, Jean B.] Univ Stellenbosch, Dept Med, Cape Town, South Africa. [Nachega, Jean B.] Univ Stellenbosch, Fac Med & Hlth Sci, Ctr Infect Dis, Cape Town, South Africa. [Parienti, Jean-Jacques] Cote de Nacre Univ, Cote de Nacre Teaching Hosp, Dept Biostat & Clin Res, Caen, France. [Parienti, Jean-Jacques] Univ Caen Basse Normandie, Fac Med, EA Risque Microbien 4655, Caen, France. [Uthman, Olalekan A.] Univ Warwick, Warwick Med Sch, Warwick Ctr Appl Hlth Res & Delivery WCARHD, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England. [Uthman, Olalekan A.] Univ Liverpool Liverpool Sch Trop Med, Int Hlth Grp, Liverpool, Merseyside, England. [Uthman, Olalekan A.] Univ Stellenbosch, Fac Hlth Sci, Ctr Evidence Based Hlth Care, Cape Town, South Africa. [Gross, Robert] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gross, Robert] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Sax, Paul E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Gallant, Joel E.] Southwest CARE Ctr, Santa Fe, NM USA. [Mugavero, Michael J.] Univ Alabama Birmingham, Birmingham, AL USA. [Mills, Edward J.] Univ Ottawa, Fac Hlth Sci, Ottawa, ON K1N 6N5, Canada. [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. RP Nachega, JB (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Infect Dis Epidemiol Program, 130 DeSoto St,503 Parran Hall, Pittsburgh, PA 15261 USA. EM jbn16@pitt.edu OI Uthman, Olalekan/0000-0002-8567-3081 FU US National Institutes for Allergy and Infectious Disease-National Institutes of Health (NIAID-NIH), AIDS Clinical Trial Group (ACTG), Stellenbosch University (SU)-Clinical Trial Unit (CTU) Award [2UM1AI069521-08]; US NIH-Fogarty International Center (FIC)/Health Resources and Services Administration (HRSA)/US President Emergency Plan for AIDS Relief (PEPFAR) Grant Award [T84HA21652-01-00]; European Developing Countries Clinical Trial Partnership (EDCTP) Senior Fellowship Award [TA-08-40200-021]; Wellcome Trust Southern Africa Consortium for Research Excellence (SACORE) [WT087537MA]; National Institutes of Mental Health NIMH-NIH [R34 MH083592-01A1]; Penn Center for AIDS Research (CFAR), an NIH [P30 AI 045008]; Department of Veteran Affairs Health Services Research and Development Center [CIN 13-413]; Agence Nationale de Recherche contre le SIDA (ANRS)/Institut National de la Sante et de la Recherche Medicale (INSERM) ATIP Avenir Post-Doc program [2012-YY1137]; NIH; NIAID-NIH [UM1AI069412] FX The US National Institutes for Allergy and Infectious Disease-National Institutes of Health (NIAID-NIH), AIDS Clinical Trial Group (ACTG), Stellenbosch University (SU)-Clinical Trial Unit (CTU) Award: 2UM1AI069521-08 (J. B. N.); the US NIH-Fogarty International Center (FIC)/Health Resources and Services Administration (HRSA)/US President Emergency Plan for AIDS Relief (PEPFAR) Grant Award, T84HA21652-01-00 for Medical Education Partnership Initiative (MEPI) (J. B. N.); the European Developing Countries Clinical Trial Partnership (EDCTP) Senior Fellowship Award: TA-08-40200-021 (J. B. N.); the Wellcome Trust Southern Africa Consortium for Research Excellence (SACORE): WT087537MA (J. B. N.); the National Institutes of Mental Health NIMH-NIH R34 MH083592-01A1 (E. J. M.). FAS Marie Curie International Post Doc: 2012-0064 (O. A. U.); the Penn Center for AIDS Research (CFAR), an NIH-funded program (P30 AI 045008) (R. G.). The Department of Veteran Affairs Health Services Research and Development Center Grant Award CIN 13-413 (T. P. G.). Agence Nationale de Recherche contre le SIDA (ANRS)/Institut National de la Sante et de la Recherche Medicale (INSERM) ATIP Avenir Post-Doc program: 2012-YY1137 (J. J. P.); NIH Grant; NIAID-NIH Grant Award: UM1AI069412 (P. S.). NR 88 TC 72 Z9 74 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2014 VL 58 IS 9 BP 1297 EP 1307 DI 10.1093/cid/ciu046 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AF9AJ UT WOS:000335006900016 PM 24457345 ER PT J AU Shaver, K AF Shaver, Kristi TI Diabetes Education at Work: Helping Employees Adopt and Maintain a Healthy Lifestyle SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Shaver, Kristi] SUNY Upstate Med Univ, Joslin Diabet Ctr, La Fayette, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 EI 1538-9782 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAY-JUN PY 2014 VL 28 IS 3 BP 174 EP 174 PG 1 WC Nursing SC Nursing GA AF7XW UT WOS:000334929800015 ER PT J AU Smith, A Doutrich, D Goudreau, K Guido, G Eddy, L AF Smith, Alexandra Doutrich, Dawn Goudreau, Kelly Guido, Ginny Eddy, Linda TI Exemplar Describing the Clinical Nurse Specialist's Three Spheres of Influence in the Development of a Programmatic Intervention for Chronic Persistent Pain SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Smith, Alexandra] Portland VA Med Ctr, Bend, OR USA. [Doutrich, Dawn; Guido, Ginny; Eddy, Linda] Washington State Univ, Vancouver, WA USA. [Goudreau, Kelly] Southern Oregon Rehabil Ctr & Clin, White City, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 EI 1538-9782 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAY-JUN PY 2014 VL 28 IS 3 BP 174 EP 175 PG 2 WC Nursing SC Nursing GA AF7XW UT WOS:000334929800016 ER PT J AU Archer, M AF Archer, Molly TI Implantable Cardioverter Defibrillators ( ICD): Effects of Enhanced Education on Self-efficacy and Device Acceptance SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Archer, Molly] Portland VA Med Ctr, Scappoose, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 EI 1538-9782 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAY-JUN PY 2014 VL 28 IS 3 BP 176 EP 177 PG 2 WC Nursing SC Nursing GA AF7XW UT WOS:000334929800021 ER PT J AU Jakobiec, FA Rai, R Yoon, MK AF Jakobiec, Frederick A. Rai, Ruju Yoon, Michael K. TI Fibrous Histiocytoma of the Tarsus: Clinical and Immunohistochemical Observations With a Differential Diagnosis SO CORNEA LA English DT Article DE eyelid; androgen receptor; CD34; solitary fibrous tumor; tarsus; fibrous histiocytoma; CD68 ID PALPEBRAL CONJUNCTIVA; KERATINOUS CYST; TUMOR AB Purpose: To describe the diagnostic clinical findings and immunopathology of a fibrous histiocytoma of the upper eyelid tarsus of a 42-year-old man. Methods: Analysis of clinical features and results of histopathologic and immunohistochemical evaluations using antibodies against the biomarkers smooth muscle actin, S100, CD1a, CD3, CD20, CD31, CD34, CD68, CD163, factor XIIIa, adipophilin, androgen receptor, and Ki-67. Results: The skin moved over a firm lesion that was situated in the tarsus and protruded from the palpebral conjunctiva as a whitish flat-domed noninflamed mass that had caused an irritating corneal epitheliopathy. Histopathologically, there was a storiform or spiral nebular growth pattern, a moderate amount of intercellular collagen, and no nuclear atypia or mitotic activity. The main immunohistochemical findings were CD34 and smooth muscle actin negativity among the tumor cells and a scarcity of CD68/163 histiocytes. Androgen receptors were identified in the tumor cells. Conclusions: CD34(-) histiocytoma of the tarsus is a rare, benign, and separate entity from a CD34(+) solitary fibrous tumor. Conservative tarsectomy is curative. C1 [Jakobiec, Frederick A.; Rai, Ruju] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Dept Ophthalmol, Boston, MA 02114 USA. [Jakobiec, Frederick A.; Rai, Ruju; Yoon, Michael K.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Yoon, Michael K.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Ophthalm Plast Surg Serv, Boston, MA 02114 USA. RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St,Suite 328, Boston, MA 02114 USA. EM fred_jakobiec@meei.harvard.edu NR 19 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-3740 EI 1536-4798 J9 CORNEA JI Cornea PD MAY PY 2014 VL 33 IS 5 BP 536 EP 539 DI 10.1097/ICO.0000000000000095 PG 4 WC Ophthalmology SC Ophthalmology GA AE7FO UT WOS:000334162500020 PM 24608257 ER PT J AU Quan, JH Yusufzai, T AF Quan, Jinhua Yusufzai, Timur TI HARP preferentially co-purifies with RPA bound to DNA-PK and blocks RPA phosphorylation SO EPIGENETICS LA English DT Article DE annealing helicase; HARP; SMARCAL1; RPA; DNA-PK ID REPLICATION PROTEIN-A; KINASE; SMARCAL1; COMPLEXES; DOMAIN; DAMAGE AB The HepA-related protein (HARP/SMARCAL1) is an ATP-dependent annealing helicase that is capable of rewinding DNA structures that are stably unwound due to binding of the single-stranded DNA (ssDNA)-binding protein Replication Protein A (RPA). HARP has been implicated in maintaining genome integrity through its role in DNA replication and repair, two processes that generate RPA-coated ssDNA. In addition, mutations in HARP cause a rare disease known as Schimke immuno-osseous dysplasia. In this study, we purified HARP containing complexes with the goal of identifying the predominant factors that stably associate with HARP. We found that HARP preferentially interacts with RPA molecules that are bound to the DNA-dependent protein kinase (DNA-PK). We also found that RPA is phosphorylated by DNA-PK in vitro, while the RPA-HARP complexes are not. Our results suggest that, in addition to its annealing helicase activity, which eliminates the natural binding substrate for RPA, HARP blocks the phosphorylation of RPA by DNA-PK. C1 [Quan, Jinhua; Yusufzai, Timur] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Yusufzai, T (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM timur_yusufzai@dfci.harvard.edu FU Dana-Farber Cancer Institute; Ellison Medical Foundation; NIH [RO1GM058272] FX We thank James T Kadonaga and Patricia Szajner for critical reading of this manuscript. This work was supported by the Dana-Farber Cancer Institute and the Ellison Medical Foundation. Initial studies were also supported with the NIH grant RO1GM058272 to James T Kadonaga. NR 24 TC 1 Z9 1 U1 0 U2 3 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1559-2294 EI 1559-2308 J9 EPIGENETICS-US JI Epigenetics PD MAY 1 PY 2014 VL 9 IS 5 BP 693 EP 697 DI 10.4161/epi.28310 PG 5 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA AG4NN UT WOS:000335397000006 PM 24565939 ER PT J AU Slane, JD Klump, KL McGue, M Iacono, G AF Slane, Jennifer D. Klump, Kelly L. McGue, Matthew Iacono, G. TI Genetic and Environmental Factors Underlying Comorbid Bulimic Behaviours and Alcohol Use Disorders: A Moderating Role for the Dysregulated Personality Cluster? SO EUROPEAN EATING DISORDERS REVIEW LA English DT Article DE bulimia nervosa; alcohol use disorders; personality ID SUBSTANCE USE DISORDERS; POPULATION-BASED TWIN; EATING-DISORDERS; PSYCHIATRIC-DISORDERS; NERVOSA; WOMEN; DEPENDENCE; ABUSE; HERITABILITY; SAMPLE AB Women with bulimia nervosa (BN) frequently have co-occurring alcohol use disorders (AUDs). Studies of shared genetic transmission of these disorders have been mixed. Personality heterogeneity among individuals with BN may explain discrepant findings. Cluster analysis has characterized women with BN in groups on the basis of personality profiles. One group, the Dysregulated cluster, characterized largely by behavioural disinhibition and emotional dysregulation may be more closely linked etiologically to AUDs. This study examined whether genetic associations between BN and AUDs are the strongest among the Dysregulated cluster. Symptoms of BN and AUDs were assessed in female twins at ages 17 and 25years from the Minnesota Twin Family Study. Personality clusters were defined using the Multidimensional Personality Questionnaire. Twin moderation models suggested small-to-moderate common genetic transmission between BN and AUDs. However, shared genetic effects did not differ by personality cluster. Findings suggest that personality clusters are unlikely to account for inconsistent findings regarding their shared aetiology. Copyright (c) 2014 John Wiley & Sons, Ltd and Eating Disorders Association. C1 [Slane, Jennifer D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res 4, Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Slane, Jennifer D.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. [Klump, Kelly L.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. [McGue, Matthew; Iacono, G.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. RP Slane, JD (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA. EM slane@msu.edu FU NIAAA NIH HHS [R01 AA009367] NR 52 TC 3 Z9 3 U1 5 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1072-4133 EI 1099-0968 J9 EUR EAT DISORD REV JI Eur. Eat. Disord. Rev. PD MAY PY 2014 VL 22 IS 3 BP 159 EP 169 DI 10.1002/erv.2284 PG 11 WC Psychology, Clinical SC Psychology GA AE7IT UT WOS:000334171700059 PM 24616026 ER PT J AU Wang, P Qu, X Wang, X Zhu, X Zeng, H Chen, H Zhu, H AF Wang, P. Qu, X. Wang, X. Zhu, X. Zeng, H. Chen, H. Zhu, H. TI Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5 '-LTR promoter SO GENE THERAPY LA English DT Article ID NF-KAPPA-B; GENE-EXPRESSION; T-CELLS; REPLICATION; CURE; TAT; DNA; INHIBITION; MATURATION; REPRESSION AB HIV-1 latency remains the primary obstacle to the eradication of this virus. The current latency-reversing agents cannot effectively and specifically eliminate latent HIV-1 reservoirs. Therefore, better approaches are urgently needed. In this study, we describe a novel strategy to reactivate latent HIV-1 using zinc-finger transcription factors composed of designer zinc-finger proteins and the transcriptional activation domain VP64. For the first time, we demonstrate that ZF-VP64 with HIV-1 long terminal repeat (LTR) promoter-specific affinity could significantly reactivate HIV-1 expression from latently infected cells without altering cell proliferation or cell cycle progression. We also provide evidence that the reactivation of HIV-1 by ZF-VP64 occurs through specific binding to the 5'-LTR promoter. Our results demonstrate the potential of this novel approach for anti-HIV-1 latency therapy. C1 [Wang, P.; Qu, X.; Wang, X.; Zhu, X.; Zeng, H.; Zhu, H.] Fudan Univ, Inst Genet, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China. [Chen, H.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA. RP Zhu, H (reprint author), Fudan Univ, Inst Genet, Sch Life Sci, State Key Lab Genet Engn, 220 Handan Rd, Shanghai 200433, Peoples R China. EM hzzhu@fudan.edu.cn FU National Grand Program on Key Infectious Disease [2014ZX10001003]; National Natural Science Foundation of China [31271418] FX We thank the NIH AIDS Research and Reference Reagent Program for providing the J-Lat clone A10.6 cells. We also thank Prof Jianqing Xu (Shanghai Medical College of Fudan University) for providing the pNL4-3-EGFP plasmid. This work was supported by the National Grand Program on Key Infectious Disease (2014ZX10001003) and National Natural Science Foundation of China (31271418 to H Zhu). NR 39 TC 8 Z9 9 U1 1 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0969-7128 EI 1476-5462 J9 GENE THER JI Gene Ther. PD MAY PY 2014 VL 21 IS 5 BP 490 EP 495 DI 10.1038/gt.2014.21 PG 6 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA AG7TE UT WOS:000335620800005 PM 24622733 ER PT J AU Babadi, B Brown, EN AF Babadi, Behtash Brown, Emery N. TI A Review of Multitaper Spectral Analysis SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE Electroencephalogram (EEG) analysis; multitaper; spectral estimation ID SLEEP; BRAIN AB Nonparametric spectral estimation is a widely used technique in many applications ranging from radar and seismic data analysis to electroencephalography (EEG) and speech processing. Among the techniques that are used to estimate the spectral representation of a system based on finite observations, multitaper spectral estimation has many important optimality properties, but is not aswidely used as it possibly could be. We give a brief overview of the standard nonparametric spectral estimation theory and the multitaper spectral estimation, and give two examples from EEG analyses of anesthesia and sleep. C1 [Babadi, Behtash] Univ Maryland, Dept Elect & Comp Engn, College Pk, MD 20742 USA. [Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Brown, Emery N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Brown, Emery N.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Brown, Emery N.] Inst Med Engn & Sci, Cambridge, MA 02139 USA. RP Babadi, B (reprint author), Univ Maryland, Dept Elect & Comp Engn, College Pk, MD 20742 USA. EM behtash@umd.edu; enb@neurostat.mit.edu FU NIH [R01GM10498] FX This work was supported by: NIH Award R01GM10498 (ENB). Asterisk indicates corresponding author. NR 29 TC 23 Z9 23 U1 1 U2 17 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0018-9294 EI 1558-2531 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD MAY PY 2014 VL 61 IS 5 SI SI BP 1555 EP 1564 DI 10.1109/TBME.2014.2311996 PG 10 WC Engineering, Biomedical SC Engineering GA AG1BP UT WOS:000335150300018 PM 24759284 ER PT J AU Lee, LC Genet, M Dang, AB Ge, L Guccione, JM Ratcliffe, MB AF Lee, Lik Chuan Genet, Martin Dang, Alan B. Ge, Liang Guccione, Julius M. Ratcliffe, Mark B. TI Applications of Computational Modeling in Cardiac Surgery SO JOURNAL OF CARDIAC SURGERY LA English DT Article ID FINITE-ELEMENT MODEL; ISCHEMIC MITRAL REGURGITATION; LEFT-VENTRICULAR MECHANICS; CHRONIC HEART-FAILURE; IN-VIVO; WALL STRESS; SUPPORT DEVICE; BORDER ZONE; OVINE MODEL; ANNULOPLASTY AB Although computational modeling is common in many areas of science and engineering, only recently have advances in experimental techniques and medical imaging allowed this tool to be applied in cardiac surgery. Despite its infancy in cardiac surgery, computational modeling has been useful in calculating the effects of clinical devices and surgical procedures. In this review, we present several examples that demonstrate the capabilities of computational cardiac modeling in cardiac surgery. Specifically, we demonstrate its ability to simulate surgery, predict myofiber stress and pump function, and quantify changes to regional myocardial material properties. In addition, issues that would need to be resolved in order for computational modeling to play a greater role in cardiac surgery are discussed. doi: 10.1111/jocs.12332 (J Card Surg 2014;29:293-302) C1 [Lee, Lik Chuan; Genet, Martin; Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Lee, Lik Chuan; Genet, Martin; Dang, Alan B.; Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. [Lee, Lik Chuan; Genet, Martin; Dang, Alan B.; Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Dang, Alan B.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Div Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@va.gov RI Genet, Martin/H-4247-2015 OI Genet, Martin/0000-0003-2204-201X FU NIH [R01-HL-084431, R01-HL-077921, R01-HL-118627, R01-HL-63348] FX Grant sponsor: NIH; Grant numbers: R01-HL-084431; R01-HL-077921; R01-HL-118627; R01-HL-63348 NR 48 TC 9 Z9 9 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0886-0440 EI 1540-8191 J9 J CARDIAC SURG JI J. Card. Surg. PD MAY PY 2014 VL 29 IS 3 BP 293 EP 302 DI 10.1111/jocs.12332 PG 10 WC Cardiac & Cardiovascular Systems; Surgery SC Cardiovascular System & Cardiology; Surgery GA AG1IQ UT WOS:000335168900001 PM 24708036 ER PT J AU Bose, A Kandala, J Upadhyay, GA Riedl, L Ahmado, I Padmanabhan, R Gewirtz, H Mulligan, LJ Singh, JP AF Bose, Abhishek Kandala, Jagdesh Upadhyay, Gaurav A. Riedl, Lindsay Ahmado, Imad Padmanabhan, Ram Gewirtz, Henry Mulligan, Lawrence J. Singh, Jagmeet P. TI Impact of Myocardial Viability and Left Ventricular Lead Location on Clinical Outcome in Cardiac Resynchronization Therapy Recipients with Ischemic Cardiomyopathy SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE myocardial scar; implantable cardioverter defibrillator; ischemia; cardiac resynchronization therapy; heart failure ID CHRONIC HEART-FAILURE; CONDUCTION DELAY; SCAR BURDEN; POSITION; TC-99M-SESTAMIBI; TOMOGRAPHY; TISSUE; CARE AB Role of Ischemia and Scar in CRT Patients with CAD Introduction Cardiac resynchronization therapy (CRT) recipients with ischemic cardiomyopathy (ICM) have scar segments that may limit ventricular resynchronization and clinical response. The impact of myocardial viability at the left ventricular (LV) pacing site on CRT response is poorly elucidated. Methods and Results A retrospective cohort of 160 ICM patients with single photon emission computed tomography-myocardial perfusion imaging before device implantation were included. Coronary venous angiography and chest radiographs helped classify segmental location of LV lead (LVL). The primary outcome was a composite of heart failure (HF) hospitalization and mortality at 3 years, and secondary outcome was change in systolic function at 6 months. The patients were divided into groups based on the myocardial substrate at the site of LVL: LVL on or adjacent to (1) normal myocardium (LVL-N, n = 64), (2) segmental scar (LVL-S, n = 62), and (3) scar and ischemia (LVL-SI, n = 34). Upon follow-up, 75 (47%) patients reached primary endpoint with a higher incidence noted in LVL-S (60%), and LVL-SI (53%), compared to 31% in LVL-N (P = 0.004). Kaplan Meier method demonstrated poor event free survival for primary outcome in LVL-S (P = 0.002), and LVL-SI (P = 0.03). In Cox proportional hazard model, LVL-S (HR: 2.26, P = 0.004), and LVL-SI (1.9, P = 0.047) were independent predictors of primary outcome. Conclusion In CRT recipients with ICM, scar and reversible ischemia in or adjacent to LV pacing site were independent predictors of HF hospitalization and death. C1 [Bose, Abhishek; Kandala, Jagdesh; Upadhyay, Gaurav A.; Riedl, Lindsay] Massachusetts Gen Hosp, Div Cardiol, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Ahmado, Imad; Padmanabhan, Ram; Gewirtz, Henry] Massachusetts Gen Hosp, Div Cardiol, Nucl Cardiol Serv, Boston, MA 02114 USA. [Mulligan, Lawrence J.] Medtronic, Therapy Delivery Res, Minneapolis, MN USA. RP Singh, JP (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv,Heart Ctr, Boston, MA 02114 USA. EM jsingh@partners.org FU Medtronic Inc.; Max Schaldach Fellowship Award of the Heart Rhythm Society; Wild Family Foundation; FluoroPharma, Inc.; Biotronik; Boston Scientific; Medtronic; St. Jude Medical FX This study was supported by a research grant from Medtronic Inc. The results are the responsibility of the authors and do not represent the views of Medtronic Inc.; Dr. Upadhyay reports receiving salary support from the Max Schaldach Fellowship Award of the Heart Rhythm Society. Dr. Gewirtz has received financial support from the Wild Family Foundation and FluoroPharma, Inc. Dr. Singh reports serving as an advisor or consultant for Biotronik, Boston Scientific, Medtronic, Sorin, St. Jude Medical, Respicardia, and CardioInsight; serving as a speaker or a member of a speakers bureau for Biotronik, Boston Scientific, Sorin, and St. Jude Medical; and receiving grants for clinical research from Biotronik, Boston Scientific, Medtronic, and St. Jude Medical. NR 27 TC 12 Z9 12 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 EI 1540-8167 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD MAY PY 2014 VL 25 IS 5 BP 507 EP 513 DI 10.1111/jce.12348 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF8ZC UT WOS:000335003500011 PM 24350650 ER PT J AU Schaefer, JH Leung, WD Wu, LM Van Cott, EM Lok, J Whalen, M van Leyen, K Lauer, A van Ryn, J Lo, EH Foerch, C AF Schaefer, Jan Hendrik Leung, Wendy Wu, Limin Van Cott, Elizabeth M. Lok, Josephine Whalen, Michael van Leyen, Klaus Lauer, Arne van Ryn, Joanne Lo, Eng H. Foerch, Christian TI Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE anticoagulation; dabigatran; intracerebral hemorrhage; novel oral anticoagulants; traumatic brain injury; warfarin ID THROMBIN INHIBITOR DABIGATRAN; RE-LY TRIAL; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; FACTOR-XA INHIBITORS; ATRIAL-FIBRILLATION; INTRACRANIAL HEMORRHAGE; ORAL THROMBIN; MICE; COMPLICATIONS; MANAGEMENT AB To date, only limited data are available on the effects of pretreatment with novel oral anticoagulants in the event of traumatic brain injury (TBI). We determined intracerebral hemorrhage volume and functional outcome in a standardized TBI model in mice treated with warfarin or dabigatran. Additionally, we investigated whether excess concentrations of dabigatran could increase bleeding and whether this was preventable by using prothrombin complex concentrate (PCC). C57 mice were treated orally with warfarin or dabigatran; sham-treated mice served as controls. Effective anticoagulation was verified by measurement of international normalized ratio and diluted thrombin time, and TBI was induced by controlled cortical impact (CCI). Twenty-four hours after CCI, intracerebral hemorrhage volume was larger in warfarin-pretreated mice than in controls (10.1 +/- 4.9 vs 4.1 +/- 1.7 mu L; analysis of variance post hoc P=0.001), but no difference was found between controls and dabigatran-pretreated mice (5.3 +/- 1.5 mu L). PCC applied 30 minutes after CCI did not reliably reduce intracerebral hemorrhage induced by excess dabigatran concentration compared with saline (10.4 +/- 11.2 vs 8.7 +/- 7.1 mu L). Our data suggest pathophysiological differences in TBI occurring during warfarin and dabigatran anticoagulation. The reduced hemorrhage formation under dabigatran therapy could present a safety advantage compared with warfarin. An excess dabigatran concentration, however, can increase hemorrhage. C1 [Schaefer, Jan Hendrik; Lauer, Arne; Foerch, Christian] Goethe Univ Frankfurt, Dept Neurol, D-60528 Frankfurt, Germany. [Schaefer, Jan Hendrik; Leung, Wendy; Wu, Limin; Lok, Josephine; van Leyen, Klaus; Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Res Lab, Boston, MA USA. [Wu, Limin] Jilin Univ, Bethune Hosp 1, Dept Neurol, Changchun 130023, Peoples R China. [Van Cott, Elizabeth M.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Lok, Josephine; Whalen, Michael] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Whalen, Michael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Boston, MA USA. [van Ryn, Joanne] Boehringer Ingelheim GmbH & Co KG, CardioMetab Dis Res, Biberach, Germany. RP Schaefer, JH (reprint author), Goethe Univ Frankfurt, Dept Neurol, Schleusenweg 2-16, D-60528 Frankfurt, Germany. EM jhs@stud.uni-frankfurt.de FU Boehringer Ingelheim FX This study was supported by Boehringer Ingelheim with a restricted grant. NR 25 TC 6 Z9 6 U1 0 U2 24 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD MAY PY 2014 VL 34 IS 5 BP 870 EP 875 DI 10.1038/jcbfm.2014.31 PG 6 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA AG5AE UT WOS:000335430700018 PM 24549187 ER PT J AU Rusjan, PM Wilson, AA Miler, L Fan, I Mizrahi, R Houle, S Vasdev, N Meyer, JH AF Rusjan, Pablo M. Wilson, Alan A. Miler, Laura Fan, Ian Mizrahi, Romina Houle, Sylvain Vasdev, Neil Meyer, Jeffrey H. TI Kinetic modeling of the monoamine oxidase B radioligand [C-11]SL25.1188 in human brain with high-resolution positron emission tomography SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE [C-11]SL25.1188; human; MAO-B; modeling; PET; reversible radioligand ID QUANTITATIVE ENZYME AUTORADIOGRAPHY; CEREBRAL-BLOOD-FLOW; MAO-B; PET; BINDING; DISEASE; RECONSTRUCTION; RADIOSYNTHESIS; INHIBITION; EXTRACTION AB This article describes the kinetic modeling of [C-11]SL25.1188 ([(S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)-benzo[d]isoxazol-3-yl]-oxazolidin-2-[C-11]one]) binding to monoamine oxidase B (MAO-B) in the human brain using high-resolution positron emission tomography (PET). Seven healthy subjects underwent two separate 90- minute PET scans after an intravenous injection of [C-11]SL25.1188. Complementary arterial blood sampling was acquired. Radioactivity was quickly eliminated from plasma with 80% of parent compound remaining at 90 minutes. Metabolites were more polar than the parent compound. Time-activity curves showed high brain uptake, early peak and washout rate consistent with known regional MAO-B concentration. A two-tissue compartment model (2-TCM) provided better fits to the data than a 1-TCM. Measurement of total distribution volume (V-T) showed very good identifiability (based on coefficient of variation (COV)) for all regions of interest (ROls) (COV(V-T) < 8%), low between-subject variability (similar to 20%), and quick temporal convergence (within 5% of final value at 45 minutes). Logan graphical method produces very good estimation of VT. Regional VT highly correlated with previous postmortem report of MAO-B level (r(2)= >= 0.9). Specific binding would account from 70% to 90% of V-T. Hence, V-T measurement of [C-11]SL25.1(1)88 PET is an excellent estimation of MAO-B concentration. C1 [Rusjan, Pablo M.; Wilson, Alan A.; Miler, Laura; Fan, Ian; Mizrahi, Romina; Houle, Sylvain; Meyer, Jeffrey H.] CAMH, Res Imaging Ctr, Toronto, ON M5T 1R8, Canada. [Wilson, Alan A.; Mizrahi, Romina; Houle, Sylvain; Meyer, Jeffrey H.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Vasdev, Neil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, Boston, MA USA. [Vasdev, Neil] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. RP Rusjan, PM (reprint author), CAMH, PET Ctr, 250 Coll St, Toronto, ON M5T 1R8, Canada. EM pablo.rusjan@camhpet.ca RI Wilson, Alan/A-1788-2011 FU Canadian Institutes of Health Research NR 39 TC 9 Z9 9 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD MAY PY 2014 VL 34 IS 5 BP 883 EP 889 DI 10.1038/jcbfm.2014.34 PG 7 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA AG5AE UT WOS:000335430700020 PM 24517979 ER PT J AU Linnoila, J Chitnis, T AF Linnoila, Jenny Chitnis, Tanuja TI Balo Concentric Sclerosis in Children A Case Series SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE Balo; all pediatric; multiple sclerosis ID MULTIPLE-SCLEROSIS; FEATURES AB Balo concentric sclerosis is a unique and rare phenomenon in demyelinating disease. Typically thought of as a subtype of multiple sclerosis, Balo concentric sclerosis is characterized pathologically by striking rings of demyelination alternating with areas of preserved myelination. Its exact prevalence in adult and especially pediatric populations is unknown. Although traditionally considered to be an acute and fatal disease of adults, there are a handful of reports of Balo concentric sclerosis cases in pediatric patients. Here we report Balo concentric sclerosis-like demyelinating disease in 3 female pediatric patients, representing 2.2% of a cohort of 134 pediatric patients with demyelinating diseases who have been seen in our center since 2005. The relatively high prevalence of Balo concentric sclerosis-like cases in our pediatric demyelinating diseases center, none of which have been fatal, supports the premise that the developing immune and central nervous systems may manifest and respond to demyelinating disease differently from adults. C1 [Linnoila, Jenny; Chitnis, Tanuja] Massachusetts Gen Hosp, Partners Pediat Multiple Sclerosis Ctr, Dept Child Neurol, Boston, MA 02114 USA. RP Chitnis, T (reprint author), Massachusetts Gen Hosp, Partners Pediat Multiple Sclerosis Ctr, Boston, MA 02114 USA. EM tchitnis@partners.org FU National MS Society (Regional Pediatric MS Centers of Excellence Award); NIH/NINDS [R25NS065743] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National MS Society (Regional Pediatric MS Centers of Excellence Award) awarded to T. Chitnis; and NIH/NINDS (grant R25NS065743), awarded to J Linnoila. NR 17 TC 1 Z9 1 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 EI 1708-8283 J9 J CHILD NEUROL JI J. Child Neurol. PD MAY PY 2014 VL 29 IS 5 BP 603 EP 607 DI 10.1177/0883073813517294 PG 5 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA AG0FJ UT WOS:000335090400005 PM 24423690 ER PT J AU Arnato, KR Wang, S Hastings, AK Youngblood, VM Santapuram, PR Chen, HY Cates, JM Colvin, DC Ye, F Brantley-Sieders, DM Cook, RS Tan, L Gray, NS Chen, J AF Arnato, Katherine R. Wang, Shan Hastings, Andrew K. Youngblood, Victoria M. Santapuram, Pranav R. Chen, Haiying Cates, Justin M. Colvin, Daniel C. Ye, Fei Brantley-Sieders, Dana M. Cook, Rebecca S. Tan, Li Gray, Nathanael S. Chen, Jin TI Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID RECEPTOR TYROSINE KINASE; CELL LUNG-CANCER; METASTATIC PROGRESSION; TUMOR ANGIOGENESIS; SURVIVAL; ACTIVATION; ADENOCARCINOMA; EXPRESSION; MICE; MIGRATION AB Genome-wide analyses determined previously that the receptor tyrosine kinase (RTK) EPHA2 is commonly overexpressed in non-small cell lung cancers (NSCLCs). EPHA2 overexpression is associated with poor clinical outcomes; therefore, EPHA2 may represent a promising therapeutic target for patients with NSCLC. In support of this hypothesis, here we have shown that targeted disruption of EphA2 in a murine model of aggressive Kras-mutant NSCLC impairs tumor growth. Knockdown of EPH42 in human NSCLC cell lines reduced cell growth and viability, confirming the epithelial cell autonomous requirements for EPHA2 in NSCLCs. Targeting EPHA2 in NSCLCs decreased S6K1-mediated phosphorylation of cell death agonist BAD and induced apoptosis. Induction of EPHA2 knockdown within established NSCLC tumors in a subcutaneous murine model reduced tumor volume and induced tumor cell death. Furthermore, an ATP-competitive EPHA2 RTK inhibitor, ALW-II-41-27, reduced the number of viable NSCLC cells in a time-dependent and. dose-dependent manner in vitro and induced tumor regression in human NSCLC xenografts in vivo. Collectively, these data demonstrate a role for EPHA2 in the maintenance and progression of NSCLCs and provide evidence that ALW-II-41-27 effectively,inhibits EPHA2-mediated tumor growth in preclinical models of NSCLC. C1 [Arnato, Katherine R.; Youngblood, Victoria M.; Santapuram, Pranav R.; Cook, Rebecca S.; Chen, Jin] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA. [Wang, Shan; Brantley-Sieders, Dana M.; Chen, Jin] Vanderbilt Univ, Div Rheumatol & Immunol, Nashville, TN 37232 USA. [Hastings, Andrew K.; Cates, Justin M.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Chen, Haiying] Univ Melbourne, Melbourne, Vic, Australia. [Cates, Justin M.; Brantley-Sieders, Dana M.; Cook, Rebecca S.; Chen, Jin] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA. [Colvin, Daniel C.] Vanderbilt Univ, Inst Imaging Sci, Nashville, TN 37232 USA. [Ye, Fei] Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA. [Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol, Boston, MA USA. [Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, Jin] Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA. [Chen, Jin] Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Nashville, TN USA. RP Chen, J (reprint author), Vanderbilt Univ, Med Ctr N, 1161 21st Ave South, Nashville, TN 37232 USA. EM jin.chen@vanderbilt.edu RI Cates, Justin/D-5927-2014 OI Cates, Justin/0000-0002-7336-5196 FU Department of Veterans Affairs through a VA Merit Award; NIH [R01 CA95004, R01 CA173469, F-31 CA167878]; SPORE program [P50CA090949]; VICC thoracic program; Vanderbilt International Scholar Program; NCI Cancer Center [P30 CA068485] FX We would like to thank David Carbone, William Pao, and Pierre Massion for advice and helpful discussion. We would also like to acknowledge Matthew Patricelli and Tyzoon Nomanbhoy (ActivX Bios.ciences) for analysis of drug-target interaction in situ in xenograft tumors using the proteomics platform KiNativ. This work was supported by Department of Veterans Affairs through a VA Merit Award (to J. Chen), NIH grants R01 CA95004 (to J. Chen) and R01 CA173469 (to N. Gray), NIH grant F-31 CA167878 (to K. Amato), pilot projects from the SPORE program P50CA090949 and VICC thoracic program (to J. Chen), and the Vanderbilt International Scholar Program (to H. Chen). This work was also supported in part by the NCI Cancer Center Support Grant P30 CA068485, utilizing the Translational Pathology, Flow Cytometry, and Small Animal Imaging Shared Resources. NR 30 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD MAY PY 2014 VL 124 IS 5 BP 2037 EP 2049 DI 10.1172/JCI72522 PG 13 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AG4XU UT WOS:000335424500019 ER PT J AU Bird, GH Boyapalle, S Wong, T Opoku-Nsiah, K Bedi, R Crannell, WC Perry, AF Nguyen, H Sampayo, V Devareddy, A Mohapatra, S Mohapatra, SS Walensky, LD AF Bird, Gregory H. Boyapalle, Sandhya Wong, Terianne Opoku-Nsiah, Kwadwo Bedi, Raminder Crannell, W. Christian Perry, Alisa F. Huy Nguyen Sampayo, Viviana Devareddy, Ankita Mohapatra, Subhra Mohapatra, Shyam S. Walensky, Loren D. TI Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; BRONCHIAL EPITHELIAL-CELLS; PROTECTS BALB/C MICE; FUSION PROTEIN; ANTIVIRAL ACTIVITY; GENE-TRANSFER; VIRAL LOAD; IN-VIVO; INHIBITOR; INFLUENZA AB Respiratory syncytial virus (RSV) infection accounts for approximately 64 million cases of respiratory disease and 200,000 deaths worldwide each year, yet no broadly effective prophylactic or treatment regimen is available. RSV deploys paired, self-associating, heptad repeat domains of its fusion protein, RSV-F, to form a fusogenic 6-helix bundle that enables the virus to penetrate the host cell membrane. Here, we developed hydrocarbon double-stapled RSV fusion peptides that exhibit stabilized a-helical structure and striking proteolytic resistance. Pretreatment with double-stapled RSV peptides that specifically bound to the RSV fusion bundle inhibited infection by both laboratory and clinical RSV isolates in cells and murine infection models. Intranasal delivery of a lead double-stapled RSV peptide effectively prevented viral infection of the flares. A chitosan-based nanopartide preparation markedly enhanced pulmonary delivery, further preventing progression of RSV infection to the lung. Thus, our results provide a strategy for inhibiting RSV infection by mucosal and endotracheal delivery of double-stapled RSV fusion peptides. C1 [Bird, Gregory H.; Opoku-Nsiah, Kwadwo; Crannell, W. Christian; Perry, Alisa F.; Walensky, Loren D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Bird, Gregory H.; Opoku-Nsiah, Kwadwo; Crannell, W. Christian; Perry, Alisa F.; Walensky, Loren D.] Dana Farber Canc Inst, Linde Program Canc Chem Biol, Boston, MA 02215 USA. [Bird, Gregory H.; Walensky, Loren D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Pediat, Boston, MA USA. [Boyapalle, Sandhya; Wong, Terianne; Huy Nguyen; Sampayo, Viviana; Devareddy, Ankita; Mohapatra, Subhra; Mohapatra, Shyam S.] James A Haley Vet Adm Med Ctr, Tampa, FL USA. [Boyapalle, Sandhya; Wong, Terianne; Bedi, Raminder; Mohapatra, Subhra; Mohapatra, Shyam S.] Univ S Florida, Nanomed Res Ctr, Tampa, FL USA. [Boyapalle, Sandhya; Wong, Terianne; Bedi, Raminder; Mohapatra, Subhra; Mohapatra, Shyam S.] Univ S Florida, Div Translat Med, Dept Internal Med, Tampa, FL USA. [Wong, Terianne; Mohapatra, Subhra] Univ S Florida, Dept Mol Med, Tampa, FL USA. RP Walensky, LD (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Mayer 664, Boston, MA 02215 USA. EM shyam.mohapatra@va.gov; loren_walensky@dfci.harvard.edu RI Mohapatra, Shyam/C-2500-2012 FU NIH [5R01AI084102, 1P3OHL101265-01]; Burroughs Wellcome Fund Career Award; Research Career Scientist Award [5101BX000954-02]; Department of Veteran Affairs; University of South Florida Signature Research Program Fellowship; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX We thank E. Smith for assistance with figure preparation and M. Moore for providing the engineered RSV strains and clinical isolate 2-20. This work was supported in part by NIH grant 5R01AI084102 and a Burroughs Wellcome Fund Career Award in the Biomedical Sciences to L.D. Walensky, a Research Career Scientist Award and VA Merit Review Award 5101BX000954-02 by the Department of Veteran Affairs and NIH grant 1P3OHL101265-01 to S.S. Mohapatra, and a University of South Florida Signature Research Program Fellowship to T. Wong. This study is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; the contents of this report do not represent the views of the Department States Government. of Veterans Affairs or the United NR 46 TC 19 Z9 19 U1 4 U2 20 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD MAY PY 2014 VL 124 IS 5 BP 2113 EP 2124 DI 10.1172/JCI71856 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AG4XU UT WOS:000335424500026 PM 24743147 ER PT J AU Brooks, YS Ostano, P Jo, SH Dai, J Getsios, S Dziunycz, P Hofbauer, GFL Cerveny, K Chiorino, G Lefort, K Dotto, GP AF Brooks, Yang Sui Ostano, Paola Jo, Seung-Hee Dai, Jun Getsios, Spiro Dziunycz, Piotr Hofbauer, Gunther F. L. Cerveny, Kara Chiorino, Giovanna Lefort, Karine Dotto, G. Paolo TI Multifactorial ER beta and NOTCH1 control of squamous differentiation and cancer SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID ESTROGEN-RECEPTOR-ALPHA; CELL LUNG-CANCER; GENE-EXPRESSION; BREAST-CANCER; SKIN-CANCER; EPIDERMAL DIFFERENTIATION; SIGNALING PATHWAY; TUMOR SUPPRESSION; TRANSCRIPTION; CARCINOMA AB Downxnodulation or loss-of-function mutations of the gene encoding NOTCH1 are associated with dysfunctional squamous cell differentiation and development of squamous cell carcinoma (SCC) in skin and internal organs. While NOTCH1 receptor activation has been well characterized, little is known about how NOTCH1 gene transcription is regulated. Using bioinformatics and functional screening approaches, we identified several regulators of the NOTCH1 gene in keratinocytes, with the transcription factors DLX5 and EGR3 and estrogen receptor beta (ER beta) directly controlling its expression in differentiation. DLX5 and ERG3 are required for RNA polymerase II (PolII) recruitment to the NOTCH1 locus, while ER beta controls NOTCH1 transcription through RNA Poll pause release. Expression of several identified NOTCH1 regulators, including ER beta is frequently compromised in skin, head and neck, and lung SCCs and SCC-derived cell lines. Furthermore, a keratinocyte ER beta-dependent program of gene expression is subverted in SCCs from various body sites, and there are consistent differences in mutation and gene-expression signatures of head and neck and lung SCCs in female versus male patients. Experimentally increased ER beta expression or treatment with ER beta agonists inhibited proliferation of SCC cells and promoted NOTCH1 expression and squamous differentiation both in vitro and in mouse xenotransplants. Our data identify a link between transcriptional control of NOTCH1 expression and the estrogen response in keratinocytes, with implications for differentiation therapy of squamous cancer. C1 [Brooks, Yang Sui; Jo, Seung-Hee; Dai, Jun; Dotto, G. Paolo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA. [Brooks, Yang Sui; Jo, Seung-Hee; Dai, Jun] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Ostano, Paola; Chiorino, Giovanna] Edo & Elvo Tempia Valenta Fdn, Canc Genome Lab, Biella, Italy. [Getsios, Spiro] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA. [Dziunycz, Piotr; Hofbauer, Gunther F. L.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland. [Cerveny, Kara] Reed Coll, Dept Biol, Portland, OR 97202 USA. [Lefort, Karine; Dotto, G. Paolo] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland. [Lefort, Karine] Univ Hosp CHUV, Dept Dermatol, Lausanne, Switzerland. RP Dotto, GP (reprint author), Univ Lausanne, Inst Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland. EM Paolo.Dotto@unil.ch RI Dai, Jun/J-9718-2015; Hofbauer, Gunther/B-2671-2010; Chiorino, Giovanna/K-5037-2016 OI Hofbauer, Gunther/0000-0003-0542-7989; Chiorino, Giovanna/0000-0002-9502-6400 FU Swiss National Science Foundation [310030B/138653/1]; NIH [AR39190, AR054856]; Oncosuisse [OCS-2922-02-2012]; Ruth L. Kirschstein National Research Service Award (NIH/NIAMS) [F32 AR059471]; Lauretana S.P.A. FX We thank A.L. Brass and R.J. Ryan for advice on the siRNA screen and ChIP assays, respectively; G. Tolstonog, J.R. Testa, W. Tourtelotte, S. Inoue, and U. Just for expression vectors; B.C. Nguyen for help with animal surgery; and the Northwestern University Skin Disease Research Center Keratinocytes Core Facility and Paul Hoover for the 3D organotypic reconstitution assays. This work was supported by the Swiss National Science Foundation (grant 310030B/138653/1), the NIH (grants AR39190 and AR054856), Oncosuisse (grant OCS-2922-02-2012), and a Ruth L. Kirschstein National Research Service Award (NIH/NIAMS F32 AR059471 to Y. Brooks). P. Ostano was supported by a grant from Lauretana S.P.A. NR 66 TC 11 Z9 11 U1 0 U2 8 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD MAY PY 2014 VL 124 IS 5 BP 2260 EP 2276 DI 10.1172/JCI72718 PG 17 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AG4XU UT WOS:000335424500039 PM 24743148 ER PT J AU Liu, JF Cannistra, SA AF Liu, Joyce F. Cannistra, Stephen A. TI Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID RECURRENT EPITHELIAL OVARIAN; PEGYLATED LIPOSOMAL DOXORUBICIN; GYNECOLOGIC-ONCOLOGY-GROUP; RANDOMIZED PHASE-III; PRIMARY PERITONEAL; TRIAL; OUTCOMES C1 [Liu, Joyce F.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cannistra, Stephen A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Liu, JF (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 19 TC 6 Z9 6 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 1 PY 2014 VL 32 IS 13 BP 1287 EP 1289 DI 10.1200/JCO.2013.54.7299 PG 3 WC Oncology SC Oncology GA AF7SP UT WOS:000334915300002 PM 24637996 ER PT J AU Gray, SW Hicks-Courant, K Cronin, A Rollins, BJ Weeks, JC AF Gray, Stacy W. Hicks-Courant, Katherine Cronin, Angel Rollins, Barrett J. Weeks, Jane C. TI Physicians' Attitudes About Multiplex Tumor Genomic Testing SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CANCER RECURRENCE RISK; GENETIC RESEARCH; NATIONAL-SURVEY; SUSCEPTIBILITY; MEDICINE; RETURN; LUNG; CARE AB Purpose Although predictive multiplex somatic genomic tests hold the potential to transform care by identifying targetable alterations in multiple cancer genes, little is known about how physicians will use such tests in practice. Participants and Methods Before the initiation of enterprise-wide multiplex testing at a major cancer center, we surveyed all clinically active adult cancer physicians to assess their current use of somatic testing, their attitudes about multiplex testing, and their genomic confidence. Results A total of 160 physicians participated (response rate, 61%): 57% were medical oncologists; 29%, surgeons; 14% radiation oncologists; 37%, women; and 83%, research principal investigators. Twenty-two percent of physicians reported low confidence in their genomic knowledge. Eighteen percent of physicians anticipated testing patients infrequently (<= 10%), whereas 25% anticipate testing most patients (>= 90%). Higher genomic confidence was associated with wanting to test a majority of patients (adjusted odds ratio [OR], 6.09; 95% CI, 2.1 to 17.5) and anticipating using actionable (adjusted OR, 2.46; 95% CI, 1.2 to 5.2) or potentially actionable (adjusted OR, 2.89; 95% CI, 1.1 to 7.9) test results to inform treatment recommendations. Forty-two percent of physicians endorsed disclosure of uncertain genomic findings to patients. Conclusion Physicians at a tertiary-care National Cancer Institute-designated comprehensive cancer center varied considerably in how they planned to incorporate predictive multiplex somatic genomic tests into practice and in their attitudes about the disclosure of genomic information of uncertain significance. Given that many physicians reported low genomic confidence, evidence-based guidelines and enhanced physician genomic education efforts may be needed to ensure that genomically guided cancer care is adequately delivered. C1 [Gray, Stacy W.; Cronin, Angel; Rollins, Barrett J.; Weeks, Jane C.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Gray, Stacy W.; Rollins, Barrett J.; Weeks, Jane C.] Harvard Univ, Sch Med, Boston, MA USA. [Gray, Stacy W.; Rollins, Barrett J.; Weeks, Jane C.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hicks-Courant, Katherine] Univ Massachusetts, Sch Med, Worcester, MA USA. RP Gray, SW (reprint author), Dana Farber Canc Inst, Ctr Populat Sci, Dept Med Oncol, 450 Brookline Ave,Dana 1123-A, Boston, MA 02215 USA. EM stacyw_gray@dfci.harvard.edu FU NHGRI NIH HHS [U01 HG006492] NR 28 TC 47 Z9 47 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 1 PY 2014 VL 32 IS 13 BP 1317 EP + DI 10.1200/JCO.2013.52.4298 PG 12 WC Oncology SC Oncology GA AF7SP UT WOS:000334915300009 PM 24663044 ER PT J AU Potosky, AL Haque, R Cassidy-Bushrow, AE Yood, MU Jiang, M Tsai, HT Luta, G Keating, NL Smith, MR Van Den Eeden, SK AF Potosky, Arnold L. Haque, Reina Cassidy-Bushrow, Andrea E. Yood, Marianne Ulcickas Jiang, Miao Tsai, Huei-Ting Luta, George Keating, Nancy L. Smith, Matthew R. Van Den Eeden, Stephen K. TI Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CARDIOVASCULAR-DISEASE; MEDICARE POPULATION; REDUCING BIAS; MEN; RISK; REIMBURSEMENT; RADIOTHERAPY; GUIDELINE; PATTERNS; SURVIVAL AB Purpose Primary androgen-deprivation therapy (PADT) is often used to treat clinically localized prostate cancer, but its effects on cause-specific and overall mortality have not been established. Given the widespread use of PADT and the potential risks of serious adverse effects, accurate mortality data are needed to inform treatment decisions. Methods We conducted a retrospective cohort study using comprehensive utilization and cancer registry data from three integrated health plans. All men were newly diagnosed with clinically localized prostate cancer. Men who were diagnosed between 1995 and 2008, were not treated with curative intent therapy, and received follow-up through December 2010 were included in the study (n = 15,170). We examined all-cause and prostate cancer-specific mortality as our main outcomes. We used Cox proportional hazards models with and without propensity score analysis. Results Overall, PADT was associated with neither a risk of all-cause mortality (hazard ratio [HR], 1.04; 95% CI, 0.97 to 1.11) nor prostate-cancer-specific mortality (HR, 1.03; 95% CI, 0.89 to 1.19) after adjusting for all sociodemographic and clinical characteristics. PADT was associated with decreased risk of all-cause mortality but not prostate-cancer-specific mortality. PADT was associated with decreased risk of all-cause mortality only among the subgroup of men with a high risk of cancer progression (HR, 0.88; 95% CI, 0.78 to 0.97). Conclusion We found no mortality benefit from PADT compared with no PADT for most men with clinically localized prostate cancer who did not receive curative intent therapy. Men with higher-risk disease may derive a small clinical benefit from PADT. Our study provides the best available contemporary evidence on the lack of survival benefit from PADT for most men with clinically localized prostate cancer. C1 [Potosky, Arnold L.; Tsai, Huei-Ting; Luta, George] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Haque, Reina] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Van Den Eeden, Stephen K.] Kaiser Permanente No Calif, Oakland, CA USA. [Cassidy-Bushrow, Andrea E.] Henry Ford Hosp, Detroit, MI 48202 USA. [Yood, Marianne Ulcickas] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Keating, Nancy L.] Harvard Univ, Sch Med, Boston, MA USA. [Smith, Matthew R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jiang, Miao] Harvey L Neiman Hlth Policy Inst, Reston, VA USA. RP Potosky, AL (reprint author), Georgetown Univ, Med Ctr, Harris Bldg,Suite 4100,3300 Whitehaven St NW, Washington, DC 20007 USA. EM alp49@georgetown.edu OI Luta, George/0000-0001-9013-2207; Luta, George/0000-0002-4035-7632 FU NCI NIH HHS [RC1 CA146238, K24 CA121990, P30 CA051008, P30CA051008, R01 CA142934, R01CA142934, RC1CA146238] NR 36 TC 22 Z9 22 U1 1 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 1 PY 2014 VL 32 IS 13 BP 1324 EP + DI 10.1200/JCO.2013.52.5782 PG 9 WC Oncology SC Oncology GA AF7SP UT WOS:000334915300010 PM 24638009 ER PT J AU Lyman, GH Temin, S Edge, SB Newman, LA Turner, RR Weaver, DL Benson, A Bosserman, LD Burstein, HJ Cody, H Hayman, J Perkins, CL Podoloff, DA Giuliano, AE AF Lyman, Gary H. Temin, Sarah Edge, Stephen B. Newman, Lisa A. Turner, Roderick R. Weaver, Donald L. Benson, Al B., III Bosserman, Linda D. Burstein, Harold J. Cody, Hiram, III Hayman, James Perkins, Cheryl L. Podoloff, Donald A. Giuliano, Armando E. TI Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID STANDARD AXILLARY TREATMENT; RANDOMIZED CONTROLLED-TRIAL; SURGICAL ADJUVANT BREAST; CARCINOMA IN-SITU; NSABP B-32 TRIAL; RACS SNAC TRIAL; NEOADJUVANT CHEMOTHERAPY; DISSECTION; MORBIDITY; OUTCOMES AB Purpose To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer. Methods The American Society of Clinical Oncology convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy. A systematic review of the literature was conducted from February 2004 to January 2013 in Medline. Guideline recommendations were based on the review of the evidence by Update Committee. Results This guideline update reflects changes in practice since the 2005 guideline. Nine randomized clinical trials (RCTs) met systematic review criteria for clinical questions 1 and 2; 13 cohort studies informed clinical question 3. Recommendations Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissection (ALND). Women with one to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases). Women with SLN metastases who will undergo mastectomy should be offered ALND. These three recommendation are based on RCTs. Women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB. Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB. These recommendations are based on cohort studies and/or informal consensus. In some cases, updated evidence was insufficient to update previous recommendations. C1 [Lyman, Gary H.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Temin, Sarah] Amer Soc Clin Oncol, Alexandria, VA 22314 USA. [Edge, Stephen B.] Baptist Canc Ctr, Memphis, TN USA. [Newman, Lisa A.; Hayman, James] Univ Michigan, Ann Arbor, MI 48109 USA. [Turner, Roderick R.] John Wayne Canc Inst, Santa Monica, CA USA. [Bosserman, Linda D.] Wilshire Oncol Med Grp, Rancho Cordova, CA USA. [Giuliano, Armando E.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Podoloff, Donald A.] Univ Vermont, Coll Med, Burlington, VT USA. [Podoloff, Donald A.] Vermont Canc Ctr, Burlington, VT USA. [Benson, Al B., III] Northwestern Univ, Chicago, IL 60611 USA. [Burstein, Harold J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cody, Hiram, III] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Podoloff, Donald A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Lyman, GH (reprint author), Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA. EM guidelines@asco.org NR 51 TC 208 Z9 228 U1 5 U2 22 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 1 PY 2014 VL 32 IS 13 BP 1365 EP + DI 10.1200/JCO.2013.54.1177 PG 22 WC Oncology SC Oncology GA AF7SP UT WOS:000334915300015 PM 24663048 ER PT J AU Kelstrup, AM Juillerat, P Korzenik, J AF Kelstrup, Anne Mette Juillerat, Pascal Korzenik, Joshua TI The accuracy of self-reported medical history: A preliminary analysis of the promise of internet-based research in Inflammatory Bowel Diseases SO JOURNAL OF CROHNS & COLITIS LA English DT Article DE Self-report; Accuracy; Online questionnaire; Inflammatory Bowel Disease; Web-based; Internet ID ULCERATIVE-COLITIS; COLORECTAL-CANCER; PATIENT KNOWLEDGE; AGREEMENT; INFORMATION; RECORDS; CROHNS; RISK AB Background and aims: Internet-based surveys provide a potentially important tool for Inflammatory Bowel Disease (IBD) research. The advantages include low cost, large numbers of participants, rapid study completion and less extensive infrastructure than traditional methods. The aim was to determine the accuracy of patient self-reporting in internet-based IBD research and identify predictors of greater reliability. Methods: 197 patients from a tertiary care center answered an online survey concerning personal medical history and an evaluation of disease specific knowledge. Self-reported medical details were compared with data abstracted from medical records. Agreement was assessed by kappa (kappa) statistics. Results: Participants responded correctly with excellent agreement (kappa = 0.96-0.97) on subtype of IBD and history of surgery. The agreement was also excellent for colectomy (kappa = 0.88) and small bowel resection (kappa = 0.91), moderate for abscesses and fistulas (kappa = 0.60 and 0.63), but poor regarding partial colectomy (kappa = 0.39). Time since last colonoscopy was self-reported with better agreement (kappa = 0.84) than disease activity. For disease location/extent, moderate agreements at kappa = 69% and 64% were observed for patients with Crohn's disease and ulcerative colitis, respectively. Subjects who scored higher than the average in the IBD knowledge assessment were significantly more accurate about disease location than their complementary group (74% vs. 59%, p = 0.02). Conclusion: This study demonstrates that IBD patients accurately report their medical history regarding type of disease and surgical procedures. More detailed medical information is less reliably reported. Disease knowledge assessment may help in identifying the most accurate individuals and could therefore serve as validity criteria. Internet-based surveys are feasiblewith high reliability about basic disease features only. However, the participants in this study were engaged at a tertiary center, which potentially leads to a bias and compromises generalization to an unfiltered patient group. (C) 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved. C1 [Kelstrup, Anne Mette; Juillerat, Pascal; Korzenik, Joshua] Massachusetts Gen Hosp, Crohns & Colitis Ctr, Boston, MA 02114 USA. [Kelstrup, Anne Mette] Koge Hosp, Dept Med, Koge, Denmark. [Juillerat, Pascal] Univ Hosp Bern, Inselspital, Clin Visceral Surg & Med, CH-3010 Bern, Switzerland. RP Kelstrup, AM (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM anne_mette_kelstrup@hotmail.com FU Pout Riis and Vibeke Binders foundation; Swiss National Science Foundation (SNF) [PBLAP3-124341] FX We thank the research staff, M. Cohen, E. Cole and C. Bader, at the Crohn's and Colitis Center, Massachusetts General Hospital, who helped in collecting the data. Prof. P. Bytzer, MD, and T. W. Dahl for reviewing, and for the inspiration in the writing process. This study was supported by the Pout Riis and Vibeke Binders foundation (AMK) and The Swiss National Science Foundation (SNF): Grant No PBLAP3-124341 (PJ). NR 24 TC 4 Z9 4 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1873-9946 EI 1876-4479 J9 J CROHNS COLITIS JI J. Crohns Colitis PD MAY 1 PY 2014 VL 8 IS 5 BP 349 EP 356 DI 10.1016/j.crohns.2013.09.012 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AG2XP UT WOS:000335280700002 PM 24183653 ER PT J AU Rivlin, M Blazar, PE Kachooei, AR AF Rivlin, Michael Blazar, Philip E. Kachooei, Amir Reza TI Letter Regarding "Corticosteroid Injection With or Without Thumb Spica Cast for de Quervain Tenosynovitis" SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Letter C1 [Rivlin, Michael; Kachooei, Amir Reza] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Blazar, Philip E.] Harvard Univ, Brigham & Womens Hosp, Dept Orthoped, Boston, MA 02115 USA. [Kachooei, Amir Reza] Mashhad Univ Med Sci, Mashhad, Iran. RP Rivlin, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 4 TC 1 Z9 1 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD MAY PY 2014 VL 39 IS 5 BP 1023 EP 1023 DI 10.1016/j.jhsa.2014.02.026 PG 1 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AG4WX UT WOS:000335422200035 PM 24766837 ER PT J AU Hayes, D Naguib, A Kirkby, S Galantowicz, M McConnell, PI Baker, PB Kopp, BT Lloyd, EA Astor, TL AF Hayes, Don, Jr. Naguib, Aymen Kirkby, Stephen Galantowicz, Mark McConnell, Patrick I. Baker, Peter B. Kopp, Benjamin T. Lloyd, Eric A. Astor, Todd L. TI Comprehensive evaluation of lung allograft function in infants after lung and heart-lung transplantation SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article DE allograft; bronchoscopy; CT scan; evaluation; fiberoptic; flexible; infant; heart-lung; lung; outpatient; pulmonary function; sedation; surveillance; transplantation ID SURVEILLANCE TRANSBRONCHIAL BIOPSIES; WORKING FORMULATION; PULMONARY-FUNCTION; PEDIATRIC LUNG; FUNCTION TESTS; RECIPIENTS; BRONCHOSCOPY; REJECTION; MANAGEMENT; DIAGNOSIS AB BACKGROUND: Limited data exist on methods to evaluate allograft function in infant recipients of lung and heart-lung transplants. At our institution, we developed a procedural protocol in coordination with pediatric anesthesia where infants were sedated to perform infant pulmonary function testing, computed tomography imaging of the chest, and flexible fiberoptic bronchoscopy with transbronchial biopsies. METHODS: A retrospective review was performed of children aged younger than 1 year who underwent lung or heart-lung transplantation at our institution to assess the effect of this procedural protocol in the evaluation of infant lung allografts. RESULTS: Since 2005, 5 infants have undergone thoracic transplantation (3 heart-lung, 2 lung). At time of transplant, the mean +/- standard deviation age was 7.2 +/- 2.8 months (range, 3-11 months). Of 24 procedural sessions performed to evaluate lung allografts, 83% (20 of 24) were considered surveillance where the patients were completely asymptomatic. Of the surveillance procedures, 80% were performed as an outpatient, whereas 20% were done as inpatients during the lung or heart-lung transplant post-operative period before discharge home. Sedation was performed with propofol alone (23 of 24) or in addition to ketamine (1 of 24) infusion; mean sedation time was 141 +/- 39 minutes (range, 70-214) minutes. Of the 16 outpatient procedures, patients were discharged after 14 (88%) on the same day, and after 2 (12%) were admitted for observation, with 1 being due to transportation issues and the other due to fever during the observation period. CONCLUSIONS: A comprehensive procedural protocol to evaluate allograft function in infant lung and heart-lung transplant recipients was performed safely as an outpatient. (C) 2014 International Society for Heart and Lung Transplantation. All rights reserved. C1 [Hayes, Don, Jr.; Kirkby, Stephen; Kopp, Benjamin T.] Ohio State Univ, Nationwide Childrens Hosp, Sect Pulm Med, Dept Pediat, Columbus, OH 43205 USA. [Naguib, Aymen] Ohio State Univ, Nationwide Childrens Hosp, Div Pediat Cardiac Anesthesia, Dept Anesthesiol & Pain Med, Columbus, OH 43205 USA. [Galantowicz, Mark; McConnell, Patrick I.] Ohio State Univ, Nationwide Childrens Hosp, Dept Cardiothorac Surg, Columbus, OH 43205 USA. [Baker, Peter B.] Ohio State Univ, Nationwide Childrens Hosp, Dept Pathol, Sect Surg Pathol, Columbus, OH 43205 USA. [Lloyd, Eric A.] Ohio State Univ, Nationwide Childrens Hosp, Dept Pediat, Sect Crit Care Med, Columbus, OH 43205 USA. [Astor, Todd L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA USA. RP Hayes, D (reprint author), Ohio State Univ, Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA. EM hayes.705@osu.edu RI Yates, Andrew/E-4344-2011; Lloyd, Eric/E-3530-2011; OI kopp, Benjamin/0000-0002-2021-7990 NR 27 TC 4 Z9 4 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 EI 1557-3117 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD MAY PY 2014 VL 33 IS 5 BP 507 EP 513 DI 10.1016/j.healun.2014.01.867 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA AG0RK UT WOS:000335123100008 PM 24650857 ER PT J AU Brennan, CW Olds, DM Dolansky, M Estrada, CA Patrician, PA AF Brennan, Caitlin W. Olds, Danielle M. Dolansky, Mary Estrada, Carlos A. Patrician, Patricia A. TI Learning by doing: observing an interprofessional process as an interprofessional team SO JOURNAL OF INTERPROFESSIONAL CARE LA English DT Article DE Interprofessional collaboration; interprofessional education; interprofessional evaluation; teams ID EDUCATION; PROGRAM; QUALITY AB New competencies exist for interprofessional education, which are centered on the goal of improving quality of care and patient safety through improved interprofessional collaboration. Interprofessional education and effective interprofessional collaboration are cornerstones of the Veterans Affairs Quality Scholars fellowship program. The purpose of this project was to evaluate an innovative interprofessional education strategy in which teams of physicians and nurses were "learning by doing'' as they observed and analyzed the functioning of an interprofessional process, specifically, inpatient discharge. Fellows completed voluntary, anonymous surveys seeking their perspectives about the project. Fellows' feedback revealed several themes, with both positive and negative characteristics related to team functioning, interprofessional understanding, microsystem knowledge, pooled knowledge and assignment challenges. The strength of this strategy is exemplified by the fact that fellows not only learned from each other's separate professional observations, but also observed the emergence of a shared interprofessional perspective through working together. C1 [Brennan, Caitlin W.] NIH, Ctr Clin, Dept Nursing Res & Practice Dev, Bethesda, MD 20892 USA. [Olds, Danielle M.] Univ Kansas, Med Ctr, NDNQI, Kansas City, KS 66103 USA. [Dolansky, Mary] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. [Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. [Patrician, Patricia A.] Univ Alabama Birmingham, Birmingham, AL USA. RP Brennan, CW (reprint author), NIH, Ctr Clin, Dept Nursing, 10 Ctr Dr,Room 2B08, Bethesda, MD 20892 USA. EM caitlin.brennan@nih.gov FU Intramural NIH HHS [Z99 CL999999] NR 6 TC 5 Z9 5 U1 0 U2 7 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1356-1820 EI 1469-9567 J9 J INTERPROF CARE JI J. Interprofessional Care PD MAY PY 2014 VL 28 IS 3 BP 249 EP 251 DI 10.3109/13561820.2013.838750 PG 3 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AG2DI UT WOS:000335225800012 PM 24070019 ER PT J AU Nelson, B Zhou, XQ White, M Hartshorn, K Takahashi, K Kinane, TB Anandaiah, A Koziel, H AF Nelson, Benjamin Zhou, Xiuqin White, Mitchell Hartshorn, Kevan Takahashi, Kazue Kinane, T. Bernard Anandaiah, Asha Koziel, Henry TI Recombinant human mannose-binding lectin dampens human alveolar macrophage inflammatory responses to influenza A virus in vitro SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE apoptosis; respiratory burst; C-type lecin; TNF; innate immunity; biological response modifier ID PATTERN-RECOGNITION MOLECULE; DEFICIENT MICE; HOST-DEFENSE; CELL-LINE; INFECTION; RECEPTOR; DISEASE; IDENTIFICATION; PHAGOCYTOSIS; RESOLUTION AB IAV pneumonia remains a serious global health problem, and preventative and therapeutic strategies remain limited. AM are critical effector cells in the control of influenza, impairing IAV replication, promoting IAV clearance, and promoting efferocytosis and resolution of lung inflammation. MBL, an innate immune pattern recognition molecule, present in the lungs, binds IAV, and plasma MBL deficiency is associated with increased susceptibility to IAV, although the mechanism remains incompletely understood, and the influence of MBL on the IAV-AM interaction has not been established. In the current study, focusing on human macrophages (U937 cell line and clinically relevant human AM), data demonstrated that unopsonized IAV is readily internalized, induced release of TNF and ROS, and promoted macrophage apoptosis. In contrast, IAV, opsonized with rhMBL, reduced IAV uptake and macrophage apoptosis and dramatically reduced TNF release and ROS. Macrophage host-defense responses were reduced further in the presence of MASPs. Taken together, these data support the concept that rhMBL may serve a protective innate host response and a critical biological response modifier function by limiting AM inflammation, oxidative injury, and AM apoptosis, which may allow effective IAV clearance while limiting collateral damage to vital organs, such as the lungs. RhMBL may significantly down modulate human alveolar macrophage inflammatory responses to rhMBL-opsonized IAV, which may limit lung damage. C1 [Nelson, Benjamin; Zhou, Xiuqin; Anandaiah, Asha; Koziel, Henry] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Dept Med, Boston, MA 02215 USA. [Nelson, Benjamin; Kinane, T. Bernard; Anandaiah, Asha; Koziel, Henry] Harvard Univ, Sch Med, Boston, MA USA. [Nelson, Benjamin; Kinane, T. Bernard] Massachusetts Gen Hosp Children, Dept Pediat, Div Pulm Med, Boston, MA USA. [White, Mitchell; Hartshorn, Kevan] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [White, Mitchell; Hartshorn, Kevan] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA. [White, Mitchell; Hartshorn, Kevan] Boston City Hosp, Dept Med, Boston, MA 02118 USA. [Takahashi, Kazue; Kinane, T. Bernard] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. RP Koziel, H (reprint author), Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Kirstein Hall,Room E KSB-23, Boston, MA 02215 USA. EM hkoziel@bidmc.harvard.edu FU Cystic Fibrosis Foundation [HL 063655, AI 074503] FX Grant Support for this paper was from the Cystic Fibrosis Foundation (HL 063655 and AI 074503). We are grateful to all persons who volunteered for research bronchoscopy. We thank Elizabeth Vassar-Sternburg, Kristin Linnell, Ann Hougland, Xiomarra Guerra, Johanna Leary, Cynthia Peguero, Jose Munguia, and the entire Beth Israel Deaconess Medical Center West Procedure Center staff for excellent technical assistance with research bronchoscopy. These data were presented, in part, at the American Thoracic Society 2011 International Conference in Denver, CO, USA. NR 46 TC 3 Z9 3 U1 0 U2 4 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 EI 1938-3673 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD MAY PY 2014 VL 95 IS 5 BP 715 EP 722 DI 10.1189/jlb.0313161 PG 8 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA AG3SV UT WOS:000335340900004 PM 24399838 ER PT J AU Bit-Ivan, EN Suh, E Shim, HS Weintraub, S Hyman, BT Arnold, SE McCarty-Wood, E Van Deerlin, VM Schneider, JA Trojanowski, JQ Frosch, MP Baker, MC Rademakers, R Mesulam, M Bigio, EH AF Bit-Ivan, Esther N. Suh, Eunran Shim, Hyung-Sub Weintraub, Sandra Hyman, Bradley T. Arnold, Steven E. McCarty-Wood, Elisabeth Van Deerlin, Viviana M. Schneider, Julie A. Trojanowski, John Q. Frosch, Matthew P. Baker, Matt C. Rademakers, Rosa Mesulam, Marsel Bigio, Eileen H. TI A Novel GRN Mutation ( GRN c. 708+6_+9delTGAG) in Frontotemporal Lobar Degeneration With TDP-43YPositive Inclusions: Clinicopathologic Report of 6 Cases SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Dementia; Familial FTD; FTLD-TDP; GRN; Mutation; Progranulin ID PROGRANULIN; DEMENTIA AB Understanding of frontotemporal lobar degeneration, the underlying pathology most often linked to the clinical diagnosis of frontotemporal dementia, is rapidly increasing. Mutations in 7 known genes (MAPT, GRN, C9orf72, VCP, CHMP2B, and, rarely, TARDBP and FUS) are associated with frontotemporal dementia, and the pathologic classification of frontotemporal lobar degeneration has recently been modified to reflect these discoveries. Mutations in one of these genes (GRN), which encodes progranulin, have been implicated in up to a quarter of cases of frontotemporal lobar degeneration with TDP-43 (TAR DNA-binding protein 43)-positive inclusions; currently, there are more than 60 known pathogenic mutations of the gene. We present the clinical, pathologic, and genetic findings on 6 cases from 4 families, 5 of which were shown to have a novel GRN c.708+6_+9delTGAG mutation. C1 [Bit-Ivan, Esther N.; Bigio, Eileen H.] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA. [Weintraub, Sandra] Northwestern Univ, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Mesulam, Marsel] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. [Weintraub, Sandra; Mesulam, Marsel; Bigio, Eileen H.] Northwestern Cognit Neurol & Alzheimer Dis Ctr, Chicago, IL USA. [Schneider, Julie A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Suh, Eunran; Arnold, Steven E.; McCarty-Wood, Elisabeth; Van Deerlin, Viviana M.; Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA. [Shim, Hyung-Sub] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA. [Hyman, Bradley T.; Frosch, Matthew P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Baker, Matt C.; Rademakers, Rosa] Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA. RP Bigio, EH (reprint author), Northwestern Univ, Feinberg Sch Med, 710 N Fairbanks Ct,Olson 2-458, Chicago, IL 60611 USA. EM e-bigio@northwestern.edu FU National Institutes of Health [P30 AG13854, AG017586, AG010124, AG005134, R01 NS065782] FX This study was supported, in part, by National Institutes of Health Grants P30 AG13854 (Eileen H. Bigio), AG017586 (Eunran Suh, John Q. Trojanowski, Elisabeth McCarty-Wood, and Viviana M. Van Deerlin), AG010124 (John Q. Trojanowski, Steven E. Arnold, and Viviana M. Van Deerlin), AG005134 (Matthew P. Frosch and Bradley T. Hyman), and R01 NS065782 (Rosa Rademakers). NR 16 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 EI 1554-6578 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD MAY PY 2014 VL 73 IS 5 BP 467 EP 473 DI 10.1097/NEN.0000000000000070 PG 7 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA AF9BY UT WOS:000335011300008 PM 24709683 ER PT J AU Castillo, J Goparaju, B Bianchi, MT AF Castillo, Jelina Goparaju, Balaji Bianchi, Matt T. TI Sleep-wake misperception in sleep apnea patients undergoing diagnostic versus titration polysomnography SO JOURNAL OF PSYCHOSOMATIC RESEARCH LA English DT Article DE Paradoxical insomnia; Subjective; Self-report ID COMORBID INSOMNIA; BREATHING DISORDERS; SUBJECTIVE SLEEP; TIME-ESTIMATION; PERCEPTION; DURATION; ADULTS; SUFFERERS; PATTERN; ONSET AB Objective: Insomnia is commonly co-morbid with obstructive sleep apnea. Among patients reporting insomnia symptoms, sleep misperception occurs when self-reported sleep duration under-estimates objective measures. Misperception represents a clinical challenge since insomnia management is based entirely on patient self-report. We tested the hypothesis that misperception occurring in sleep apnea patients would improve with subsequent treatment. Methods: We compared subjective sleep-wake reports with objective sleep in adults with obstructive sleep apnea (n = 405) in two nights of polysomnography (diagnostic and treatment) within a median interval of 92 days. Results: Sleep latency was generally over-estimated, while wake after sleep onset and number of awakenings were under-estimated. None of these estimations differed between diagnostic and treatment polysomnograms. We observed a large spectrum of total sleep time misperception values during the diagnostic polysomnogram, with one third of the cohort under-estimating their total sleep time by at least 60 min. Of those with >60 minute misperception, we observed improved total sleep time perception during treatment polysomnography. Improved perception correlated with improvements in self-reported sleep quality and response confidence. We found no polysomnogram or demographic predictors of total sleep time misperception for the diagnostic polysomnogram, nor did we find objective correlates of improved perception during titration. Conclusion: Our results suggest that misperception may improve with treatment of obstructive sleep apnea in patients who also exhibit misperception. Within subject changes in misperception are consistent with misperception being, at least to some extent, a state characteristic, which has implications for management of patients with comorbid insomnia and sleep apnea. (C) 2014 Elsevier Inc. All rights reserved. C1 [Castillo, Jelina; Goparaju, Balaji; Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Sleep Div, Boston, MA 02114 USA. [Bianchi, Matt T.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA. RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM mtbianchi@partners.org FU Department of Neurology, Massachusetts General Hospital; Young Clinician Award from the Center for Integration of Medicine and Innovative Technology [2011A051243]; Harvard Catalyst KL2 Medical Research Investigator Fellowship [5KL2RR025757-04] FX Dr Bianchi received support from the Department of Neurology, Massachusetts General Hospital, the Young Clinician Award from the Center for Integration of Medicine and Innovative Technology (2011A051243), and the Harvard Catalyst KL2 Medical Research Investigator Fellowship (5KL2RR025757-04). NR 44 TC 5 Z9 6 U1 1 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3999 EI 1879-1360 J9 J PSYCHOSOM RES JI J. Psychosomat. Res. PD MAY PY 2014 VL 76 IS 5 BP 361 EP 367 DI 10.1016/j.jpsychores.2014.03.001 PG 7 WC Psychiatry SC Psychiatry GA AG0RL UT WOS:000335123200003 PM 24745776 ER PT J AU Delgado, C Ward, P Chertow, GM Storer, L Dalrymple, L Block, T Kaysen, GA Kornak, J Grimes, B Kutner, NG Johansen, KL AF Delgado, Cynthia Ward, Patricia Chertow, Glenn M. Storer, Lindsey Dalrymple, Lorien Block, Torin Kaysen, George A. Kornak, John Grimes, Barbara Kutner, Nancy G. Johansen, Kirsten L. TI Calibration of the Brief Food Frequency Questionnaire Among Patients on Dialysis SO JOURNAL OF RENAL NUTRITION LA English DT Article ID NATIONAL-CANCER-INSTITUTE; DIETARY ASSESSMENT; HEMODIALYSIS-PATIENTS; HISTORY QUESTIONNAIRE; NUTRITIONAL EPIDEMIOLOGY; RECORDS; VALIDITY; RECALL; HEMO; ASSOCIATION AB Objective: Estimating dietary intake is challenging in patients with chronic diseases. The aim of this study was to calibrate the Block Brief 2000 food frequency questionnaire (BFFQ) using 3-day food diary records among patients on dialysis. Methods: Data from 3-day food diary records from 146 patients new to dialysis were reviewed and entered into National Cancer Institute self-administered 24-hour dietary recall (ASA24), a web-based dietary interview system. The information was then re-entered omitting foods reported in the diaries that were not in the BFFQ to generate a "BFFQ-restricted'' set of intakes. We modeled each major dietary component (i.e., energy [total calories], protein, carbohydrate, fat) separately using linear regression. The main independent variables were BFFQ-restricted food diary estimates computed as the average of the 3 days of diaries, restricted to items included in the BFFQ, with the unrestricted 3-day food diary averages as dependent variables. Results: The BFFQ-restricted diary energy estimate of 1,325 +/- 545 kcal was 87% of the energy intake in the full food diary (1,510.3 +/- 510.4, P < .0001). The BFFQ-restricted diary carbohydrate intake was 83% of the full food diary (156.7 +/- 78.7 g vs. 190.4 +/- 72.7, P < .0001). The BFFQ-restricted fat intake was 90% of the full-diary-reported fat intake (50.1 +/- 24.1 g vs. 56.4 +/- 21.6 g, P < . 0001). Daily protein intake assessments were not statistically different by BFFQ-restricted diary and full diary assessment (63.1 +/- 28.5 vs. 64.1 +/- 21.4 g, P = .60). The associations between BFFQ-restricted diary intake and unrestricted intake were linear. Three-day diary-reported intake could be estimated from BFFQ-restricted intake with r(2) ranging from 0.36 to 0.56 (P < .0001 for energy [total calories], protein, carbohydrate, and fat). Final equations did not include adjustments for age, sex, or race because the patterns of associations were not significantly different. Conclusion: Energy and macronutrient estimates by BFFQ are lower than estimates from 3-day food diaries, but simple calibration equations can be used to approximate total intake from BFFQ responses. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. C1 [Delgado, Cynthia; Storer, Lindsey; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Delgado, Cynthia; Storer, Lindsey; Johansen, Kirsten L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ward, Patricia] Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. [Chertow, Glenn M.; Kaysen, George A.; Kornak, John; Grimes, Barbara; Johansen, Kirsten L.] US Renal Data Syst Nutr Special Studies, San Francisco, CA USA. [Dalrymple, Lorien; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. [Block, Torin] NutritionQuest, Berkeley, CA USA. [Kornak, John; Grimes, Barbara] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Delgado, C (reprint author), San Francisco Dept Vet Affairs, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA. EM cynthia.delgado@ucsf.edu FU USRDS Nutrition Special Studies Center [N01-DK-7-0005] FX This project is sponsored by the USRDS Nutrition Special Studies Center (N01-DK-7-0005). The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. NR 29 TC 1 Z9 1 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 EI 1532-8503 J9 J RENAL NUTR JI J. Renal Nutr. PD MAY PY 2014 VL 24 IS 3 BP 151 EP U30 DI 10.1053/j.jrn.2013.12.004 PG 7 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA AG3JZ UT WOS:000335313500004 PM 24613023 ER PT J AU Stephenson, K Meston, C AF Stephenson, Kyle Meston, Cindy TI WHY IS IMPAIRED SEXUAL FUNCTION DISTRESSING TO WOMEN? THE PRIMACY OF PLEASURE IN FEMALE SEXUAL DYSFUNCTION SO JOURNAL OF SEXUAL MEDICINE LA English DT Meeting Abstract C1 [Stephenson, Kyle] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Meston, Cindy] Univ Texas Austin, Austin, TX 78712 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD MAY PY 2014 VL 11 SU 4 MA 2 BP 225 EP 225 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AG0FM UT WOS:000335091300036 ER PT J AU Economos, CD Moore, CE Hyatt, RR Kuder, J Chen, T Meydani, SN Meydani, M Klein, E Biancuzzo, RM Holick, MF AF Economos, Christina D. Moore, Carolyn E. Hyatt, Raymond R. Kuder, Julia Chen, Tai Meydani, Simin Nikbin Meydani, Mohsen Klein, Ellen Biancuzzo, Rachael M. Holick, Michael F. TI Multinutrient-Fortified Juices Improve Vitamin D and Vitamin E Status in Children: A Randomized Controlled Trial SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Vitamin D; Vitamin E; Multinutrient juice ID NUTRITION EXAMINATION SURVEY; D DEFICIENCY; ALPHA-TOCOPHEROL; NATIONAL-HEALTH; US POPULATION; UNITED-STATES; ADOLESCENTS; RICKETS; RETINOL; WOMEN AB Background Provision of fortified juices. may provide a convenient method.to maintain and increase blood fat-soluble vitamins. Objective To determine whether children consuming orange juice fortified with calcium and combinations of vitamins D, E, and A could increase serum 25-hydroxyvitamin D [25(OH)D], alpha-tocopherol, and retinol levels. Design A 12-week randomized, double-blind, controlled trial. Participants/setting One hundred eighty participants (aged 8.04 +/- 1.42 years) were recruited at Tufts (n=70) and Boston University (n=110) during 2005-2006. Of those recruited, 176 children were randomized into three groups: CaD (700 mg calcium+200 IU vitamin D), CaDEA (700 mg calcium+200 IU vitamin D+12 IU vitamin E+2,000 IU vitamin A as beta carotene), or Ca (700 mg calcium). Children consumed two 240-mL glasses of CaD, CaDEA, or Ca fortified orange juice daily for 12 weeks. Main outcome measures Serum 25(OH)D, alpha-tocopherol, and retinol concentrations. Statistical analyses Changes in 25(OH)D, alpha-tocopherol, retinol, and parathyroid hormone concentrations were examined. Covariates included sex, age, race/ethnicity, body mass index, and baseline 25(OH)D, alpha-tocopherol, retinol, or parathyroid hormone levels. Multivariate models and repeated measures analysis of variance tested for group differences with pre-post measures (n=141). Results Baseline 25(OH)D was 68.4 +/- 27.7 nmol/L (27.4 +/- 11.10 ng/mL), with 21.7% of participants having inadequate 25(OH)D (< 50 nmol/L [20.03 ng/mL]). The CaD group's 25(OH)D increase was greater than that of the Ca group (12.7 nmol/L [5.09 ng/mL], 95% CI 1.3 to 24.1; P=0.029). The CaDEA group's increase in a-tocopherol concentration was greater than that in the Ca or CaD groups (3.79,mu mol/L 10.16 mu g/mL), 95% CI 2.5 to 5.1 and 3.09 mu mol/L ([0.13 mu g/mL], 95% Cl 1.8 to 4.3), respectively (P < 0.0001). Retinol levels did not change, and body weight remained as expected for growth. Conclusions Daily consumption of orange juice providing 200 IU vitamin D and 12 IU vitamin E increased 25(OH)D and alpha-tocopherol concentrations in young children within 12 weeks. C1 [Economos, Christina D.; Meydani, Simin Nikbin] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. [Moore, Carolyn E.] Texas Womans Univ, Houston, TX USA. [Hyatt, Raymond R.] Tufts Univ, Boston, MA 02111 USA. [Kuder, Julia] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. [Chen, Tai; Klein, Ellen; Biancuzzo, Rachael M.; Holick, Michael F.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Meydani, Simin Nikbin; Meydani, Mohsen] Tufts Univ, Jean Mayer USDA HNRCA, Boston, MA 02111 USA. [Meydani, Simin Nikbin] Tufts Univ, Friedman Sch Nutr Sci & Policy, Nutr Immunol Lab, Boston, MA 02111 USA. [Meydani, Simin Nikbin] Tufts Univ, Sackler Grad Sch, Boston, MA 02111 USA. RP Economos, CD (reprint author), Tufts Univ, Friedman Sch Nutr Sci & Policy, 150 Harrison Ave, Boston, MA 02111 USA. EM christina.economos@tufts.edu FU Beverage Institute for Health Wellness; Coca Cola Company, Atlanta, GA FX This research was sponsored by The Beverage Institute for Health & Wellness, The Coca Cola Company, Atlanta, GA. The sponsor had no role in study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the report for publication. Also, no honorarium, grant, or other form of payment was given to anyone to produce the manuscript. NR 35 TC 7 Z9 8 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD MAY PY 2014 VL 114 IS 5 BP 709 EP 717 DI 10.1016/j.jand.2013.07.027 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AG4XR UT WOS:000335424200008 PM 24139824 ER PT J AU Westen, D DeFife, JA Malone, JC DiLallo, J AF Westen, Drew DeFife, Jared A. Malone, Johanna C. DiLallo, John TI An Empirically Derived Classification of Adolescent Personality Disorders SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE adolescent personality disorders; internalizing; externalizing; emotional dysregulation; adolescent personality pathology ID WESTEN ASSESSMENT PROCEDURE; CALLOUS-UNEMOTIONAL TRAITS; ASSESSMENT PROCEDURE SWAP; AXIS-II DISORDERS; DEVELOPMENTAL HISTORY; INTERNAL CONSISTENCY; MENTAL-DISORDERS; CLINICIAN REPORT; CONDUCT PROBLEMS; DSM-III AB Objective: This study describes an empirically derived approach to diagnosing adolescent personality pathology that is clinically relevant and empirically grounded. Method: A random national sample of psychiatrists and clinical psychologists (N = 950) described a randomly selected adolescent patient (aged 13-18 years, stratified by age and gender) in their care using the Shedler-Westen Assessment Procedure-II-A for Adolescents (SWAP-II-A) and several additional questionnaires. Results: We applied a form of factor analysis to identify naturally occurring personality groupings within the patient sample. The analysis yielded 10 clinically coherent adolescent personality descriptions organized into 3 higher-order clusters (internalizing, externalizing, and borderline-dysregulated). We also obtained a higher-order personality strengths factor. These factors and clusters strongly resembled but were not identical to factors similarly identified in adult patients. In a second, independent sample from an intensive day treatment facility, 2 clinicians (the patients' treating clinician and the medical director) independently completed the SWAP-II-A, the Child Behavior Checklist (CBCL), and a measure of adaptive functioning. Two additional clinicians, blinded to the data from the first 2 clinicians, independently rated patients' ward behavior using a validated measure of interpersonal behavior. Clinicians diagnosed the personality syndromes with high agreement and minimal comorbidity among diagnoses, and SWAP-II-A descriptions strongly correlated in expected ways with the CBCL, adaptive functioning, and ward ratings. Conclusion: The results support the importance of personality diagnosis in adolescents and provide an approach to diagnosing adolescent personality that is empirically based and clinically useful. C1 [Westen, Drew; DeFife, Jared A.] Emory Univ, Atlanta, GA 30322 USA. [Malone, Johanna C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Malone, Johanna C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [DiLallo, John] NYU, Sch Med, New York, NY 10003 USA. [DiLallo, John] New York City Adm Childrens Serv, New York, NY USA. RP Westen, D (reprint author), Emory Univ, Dept Psychiat & Psychol, 36 Eagle Row, Atlanta, GA 30322 USA. EM dwesten@emory.edu FU National Institute of Mental Health (NIMH) [R01-MH62378, R01-MH78100] FX This research was supported by National Institute of Mental Health (NIMH) grants R01-MH62378 and R01-MH78100. NR 81 TC 4 Z9 4 U1 6 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 EI 1527-5418 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD MAY PY 2014 VL 53 IS 5 BP 528 EP 549 DI 10.1016/j.jaac.2013.12.030 PG 22 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA AG0HJ UT WOS:000335096200007 PM 24745953 ER PT J AU Wrzosek, MI AF Wrzosek, Marika Inga TI How Children Succeed: Grit, Curiosity, and the Hidden Power of Character. SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Book Review C1 [Wrzosek, Marika Inga] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Wrzosek, MI (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM marika.wrzosek@gmail.com NR 1 TC 0 Z9 0 U1 2 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 EI 1527-5418 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD MAY PY 2014 VL 53 IS 5 BP 593 EP 595 DI 10.1016/j.jaac.2014.01.008 PG 3 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA AG0HJ UT WOS:000335096200015 ER PT J AU Lo, RC Lu, B Fokkema, MTM Conrad, M Patel, VI Fillinger, M Matyal, R Schermerhorn, ML AF Lo, Ruby C. Lu, Bing Fokkema, Margriet T. M. Conrad, Mark Patel, Virendra I. Fillinger, Mark Matyal, Robina Schermerhorn, Marc L. CA Vasc Study Grp New England TI Relative importance of aneurysm diameter and body size for predicting abdominal aortic aneurysm rupture in men and women SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID SURFACE-AREA; ENDOVASCULAR REPAIR; PRACTICE GUIDELINES; GENDER-DIFFERENCES; VASCULAR-SURGERY; UNITED-STATES; WALL STRESS; SURVEILLANCE; RISK; ASSOCIATION AB Objective: Women have been shown to have up to a fourfold higher risk of abdominal aortic aneurysm (AAA) rupture at any given aneurysm diameter compared with men, leading to recommendations to offer repair to women at lower diameter thresholds. Although this higher risk of rupture may simply reflect greater relative aortic dilatation in women who have smaller aortas to begin with, this has never been quantified. Our objective was therefore to quantify the relationship between rupture and aneurysm diameter relative to body size and determine whether a differential association between aneurysm diameter, body size, and rupture risk exists for men and women. Methods: We performed a retrospective review of all patients in the Vascular Study Group of New England (VSGNE) database who underwent endovascular or open AAA repair. Height and weight were used to calculate each patient's body mass index and body surface area (BSA). Next, indices of each measure of body size (height, weight, body mass index, BSA) relative to aneurysm diameter were calculated for each patient. To generate these indices, we divided aneurysm diameter (in cm) by the measure of body size; for example, aortic size index (ASI) = aneurysm diameter (cm)/BSA (m(2)). Along with other relevant clinical variables, we used these indices to construct different age-adjusted and multivariable-adjusted logistic regression models to determine predictors of ruptured repair vs elective repair. Models for men and women were developed separately, and different models were compared using the area under the curve. Results: We identified 4045 patients (78% male) who underwent AAA repair (53% endovascular aortic aneurysm repairs). Women had significantly smaller diameter aneurysms, lower BSA, and higher BSA indices than men. For men, the variable that increased the odds of rupture the most was aneurysm diameter (area under the curve = 0.82). Men exhibited an increased rupture risk with increasing aneurysm diameter (<5.5 cm: odds ratio [OR], 1.0; 5.5-6.4 cm: OR, 0.9; 95% confidence interval [CI], 0.5-1.7; P = .771; 6.5-7.4 cm: OR, 3.9; 95% CI, 1.9-1.0; P < .001; >= 7.5 cm: OR, 11.3; 95% CI, 4.9-25.8; P < .001). In contrast, the variable most predictive of rupture in women was ASI (area under the curve = 0.81), with higher odds of rupture at a higher ASI (ASI>3.5-3.9: OR, 6.4; 95% CI, 1.7-24.1; P = .006; ASI >= 4.0: OR, 9.5; 95% CI, 2.3-39.4; P = .002). For women, aneurysm diameter was not a significant predictor of rupture after adjusting for ASI. Conclusions: Aneurysm diameter indexed to body size is the most important determinant of rupture for women, whereas aneurysm diameter alone is most predictive of rupture for men. Women with the largest diameter aneurysms and the smallest body sizes are at the greatest risk of rupture. C1 [Lo, Ruby C.; Fokkema, Margriet T. M.; Matyal, Robina; Schermerhorn, Marc L.] Beth Israel Deaconess Med Ctr, Div Vasc & Endovasc Surg, Boston, MA 02215 USA. [Lu, Bing] Brigham & Womens Hosp, Dept Rheumatol Immunol & Allergy, Boston, MA 02115 USA. [Conrad, Mark; Patel, Virendra I.] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. [Fillinger, Mark] Dartmouth Hitchcock Med Ctr, Vasc Surg Sect, Lebanon, NH 03766 USA. RP Schermerhorn, ML (reprint author), 110 Francis St,Ste 5B, Boston, MA 02215 USA. EM mscherme@bidmc.harvard.edu FU National Institutes of Health [HL00774] FX This work was supported by the National Institutes of Health T32 Harvard-Longwood Research Training in Vascular Surgery Grant HL00774. NR 40 TC 24 Z9 24 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAY PY 2014 VL 59 IS 5 BP 1209 EP 1216 DI 10.1016/j.jvs.2013.10.104 PG 8 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AG3GQ UT WOS:000335304400006 PM 24388278 ER PT J AU Heinzen, EL Arzimanoglou, A Brashear, A Clapcote, SJ Gurrieri, F Goldstein, DB Johannesson, SH Mikati, MA Neville, B Nicole, S Ozelius, LJ Poulsen, H Schyns, T Sweadner, KJ van den Maagdenberg, A Vilsen, B AF Heinzen, Erin L. Arzimanoglou, Alexis Brashear, Allison Clapcote, Steven J. Gurrieri, Fiorella Goldstein, David B. Johannesson, Sigurdur H. Mikati, Mohamad A. Neville, Brian Nicole, Sophie Ozelius, Laurie J. Poulsen, Hanne Schyns, Tsveta Sweadner, Kathleen J. van den Maagdenberg, Am Vilsen, Bente CA ATP1A3 Working Grp TI Distinct neurological disorders with ATP1A3 mutations SO LANCET NEUROLOGY LA English DT Review ID RAPID-ONSET DYSTONIA; NA+-K+-ATPASE; NOCTURNAL ALTERNATING HEMIPLEGIA; DE-NOVO MUTATIONS; CLINICAL-MANIFESTATIONS; NA,K-ATPASE ISOZYMES; HETEROZYGOUS MICE; CHROMOSOME 19Q13; PARKINSONISM RDP; ALPHA-3 ISOFORM AB Genetic research has shown that mutations that modify the protein-coding sequence of ATP1A3, the gene encoding the alpha(3) subunit of Na+/K+-ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood. These discoveries link two clinically distinct neurological diseases to the same gene, however, ATP143 mutations are, with one exception, disease-specific. Although the exact mechanism of how these mutations lead to disease is still unknown, much knowledge has been gained about functional consequences of ATP1A3 mutations using a range of in-vitro and animal model systems, and the role of Na+/K+-ATPases in the brain. Researchers and dinidans are attempting to further characterise neurological manifestations associated with mutations in ATP1A3, and to build on the existing molecular knowledge to understand how specific mutations can lead to different diseases. C1 [Heinzen, Erin L.; Goldstein, David B.] Duke Univ, Sch Med, Ctr Human Genome Variat, Durham, NC 27008 USA. [Heinzen, Erin L.] Duke Univ, Sch Med, Dept Med, Med Genet Sect, Durham, NC 27008 USA. [Goldstein, David B.] Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC 27008 USA. [Mikati, Mohamad A.] Duke Univ, Sch Med, Div Pediat Neurol, Durham, NC 27008 USA. [Mikati, Mohamad A.] Duke Univ, Sch Med, Dept Neurobiol, Durham, NC 27008 USA. [Arzimanoglou, Alexis] Univ Hosp Lyon, HFME, Epilepsy Sleep & Pediat Neurophysiol Dept, Lyon, France. [Arzimanoglou, Alexis] Ctr Rech Neurosci Lyon, CNRS, UMR 5292, INSERM U1028, Lyon, France. [Brashear, Allison] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC USA. [Clapcote, Steven J.] Univ Leeds, Sch Biomed Sci, Leeds, W Yorkshire, England. [Gurrieri, Fiorella] Univ Cattolica S Cuore, Ist Genet Med, Rome, Italy. [Johannesson, Sigurdur H.] AHC Federat Europe, Reykjavik, Iceland. [Johannesson, Sigurdur H.] AHC Assoc Iceland, Reykjavik, Iceland. [Neville, Brian] UCL, Inst Child Hlth, London, England. [Nicole, Sophie] Inst Cerveau & Moelle, Ctr Rech, INSERM, U975, Paris, France. [Nicole, Sophie] CNRS, UMR7225, Paris, France. [Nicole, Sophie] Univ Paris 06, UMRS975, Paris, France. [Ozelius, Laurie J.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA. [Ozelius, Laurie J.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA. [Poulsen, Hanne] Aarhus Univ, Dept Mol Biol & Genet, Danish Res Inst Translat Neurosci, Nord EMBL Partnership Mol Med, Aarhus, Denmark. [Poulsen, Hanne] Danish Natl Res Fdn, Ctr Membrane Pumps Cells & Dis PUMPKIN, Aarhus, Denmark. [Schyns, Tsveta] European Network Res Alternating Hemiplegia, Brussels, Belgium. [Sweadner, Kathleen J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [van den Maagdenberg, Am] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands. [van den Maagdenberg, Am] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands. [Vilsen, Bente] Aarhus Univ, Dept Biomed, Aarhus, Denmark. RP Heinzen, EL (reprint author), Duke Univ, Sch Med, Levine Sci Res Bldg, Durham, NC 27008 USA. EM e.heinzen@duke.edu RI Brashear, Allison/G-3853-2015; Koenderink, Jan/N-3578-2014; Roder, John/G-6468-2013; Gurrieri, Fiorella/K-3214-2016; Nicole, Sophie/E-5955-2017; OI Gurrieri, Fiorella/0000-0002-6775-5972; Lykke-Hartmann, Karin/0000-0002-6702-183X FU European Network for Research; Duke University; Ontario Mental Health Foundation Research Studentship; Canadian Institutes of Health Research; Amalgamated Transit Union FX We acknowledge the support of the European Network for Research on Alternating Hemiplegia, and Duke University for organising the first meeting of the ATP1A3 Working Group in Brussels, Belgium, in December, 2012. This Review arose from the discussions and presentations at that meeting. Other financial contributors to this meeting include RTD Services, Austria, French Association for Alternating Hemiplegia (AFHA), Icelandic Association for Alternating Hemiplegia (AHCAI), Italian Association for Alternating Hemiplegia (A.I.S.E.A Onlus), Spanish Association for Alternating Hemiplegia (AESHA), Dutch Association for Alternating Hemiplegia (AHC Vereniging Nederland), German Association for Alternating Hemiplegia (AHC-Deutschland eV), and the US Foundation for Alternating Hemiplegia (AHCF). We also thank individuals who contributed to and supported the efforts of the ATP1A3 Working Group: Sharon Ciccodicola (AHCF), Thierry Billette de Villemeur, Lynn Egan (AHCF), NardoNardocci, Anne Roubergue, Francesca Ragona, Shoji Tsuji, Rosaria Vavassori, and Federico Vigevano. Additionally, some of the work presented in this Review was supported by the Ontario Mental Health Foundation Research Studentship, MOP 94856 from the Canadian Institutes of Health Research, and a grant from the Amalgamated Transit Union. Artwork shown in figure 5 was produced by Samantha Sliwa. NR 89 TC 53 Z9 54 U1 2 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD MAY PY 2014 VL 13 IS 5 BP 503 EP 514 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA AG0LX UT WOS:000335108100016 PM 24739246 ER PT J AU Blum, K Oscar-Berman, M Badgaiyan, RD Palomo, T Gold, MS AF Blum, Kenneth Oscar-Berman, Marlene Badgaiyan, Rajendra D. Palomo, Tomas Gold, Mark S. TI Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior SO MEDICAL HYPOTHESES LA English DT Article ID D2 RECEPTOR GENE; REWARD DEFICIENCY SYNDROME; GAMMA-TYPE ENDORPHINS; WHOLE HEMISPHERE AUTORADIOGRAPHY; ALCOHOL-USE DISORDERS; NUCLEUS-ACCUMBENS; A1 ALLELE; DRD2 GENE; TOURETTE SYNDROME; PREFRONTAL CORTEX AB The dopamine system has been implicated in both substance use disorder (SUD) and schizophrenia. A recent meta-analysis suggests that A1 allele of the DRD2 gene imposes genetic risk for SUD, especially alcoholism and has been implicated in Reward Deficiency Syndrome (RDS). We hypothesize that dopamine D2 receptor (DRD2) gene Taq1 A2 allele is associated with a subtype of non-SUD schizophrenics and as such may act as a putative protective agent against the development of addiction to alcohol or other drugs of abuse. Schizophrenics with SUD may be carriers of the DRD2 Taq1 A1 allele, and/or other RDS reward polymorphisms and have hypodopaminergic reward function. One plausible mechanism for alcohol seeking in schizophrenics with SUD, based on previous research, may be a deficiency of gamma type endorphins that has been linked to schizophrenic type psychosis. We also propose that alcohol seeking behavior in schizophrenics, may serve as a physiological self-healing process linked to the increased function of the gamma endorphins, thereby reducing abnormal dopaminergic activity at the nucleus accumbens (NAc). These hypotheses warrant further investigation and cautious interpretation. We, therefore, encourage research involving neuroimaging, genome wide association studies (GWAS), and epigenetic investigation into the relationship between neurogenetics and systems biology to unravel the role of dopamine in psychiatric illness and SUD. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Blum, Kenneth; Gold, Mark S.] Univ Florida, Coll Med, Dept Psychiat, Gainesville, FL 32611 USA. [Blum, Kenneth; Gold, Mark S.] Univ Florida, Coll Med, McKnight Brain Inst, Gainesville, FL USA. [Oscar-Berman, Marlene] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Oscar-Berman, Marlene] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA. [Oscar-Berman, Marlene] Boston VA Healthcare Syst, Boston, MA USA. [Badgaiyan, Rajendra D.] SUNY Buffalo, Dept Psychiat & Neuroimaging Lab, Buffalo, NY 14260 USA. [Palomo, Tomas] Hosp Univ 12 Octubre, Serv Psiquiat, Unidad Alcoholismo & Patol Dual, E-28041 Madrid, Spain. [Blum, Kenneth] Path Res Fdn, Dept Clin Neurol, New York, NY USA. [Blum, Kenneth] IGENE LLC, Dept Genom, Austin, TX USA. [Blum, Kenneth] Univ Vermont, Coll Med, Dept Psychiat, Human Integrated Serv Unit,Ctr Clin & Translat Sc, Burlington, VT USA. [Blum, Kenneth] Domin Diagnost LLC, North Kingstown, RI USA. [Blum, Kenneth] Malibu Beach Recovery Ctr, Dept Addict Res & Therapy, Malibu Beach, CA USA. [Blum, Kenneth] RD Solut LLC, Res Ctr, Austin, TX USA. [Blum, Kenneth] RD Solut LLC, Dept Nutrigen, La Jolla, CA USA. RP Blum, K (reprint author), Univ Florida, Coll Med, Dept Psychiat, Gainesville, FL 32611 USA. EM drd2gene@gmail.com FU National Institutes of Health [NIAAA RO1-AA07112, K05-AA00219, 1R01NS073884, 1R21MH073624]; Medical Research Service of the US Department of Veterans Affairs; VA Merit Review [CX000479, CX000780] FX Marlene Oscar-Berman is the recipient of grants from the National Institutes of Health, NIAAA RO1-AA07112 and K05-AA00219 and the Medical Research Service of the US Department of Veterans Affairs. Dr. Kenneth Blum is a recipients of a grant awarded to PATH Foundation NY from the Life Extension Foundation, Ft Lauderdale, Florida. The work of Dr Badgaiyan was partially supported by the National Institutes of Health grants 1R01NS073884 and 1R21MH073624 and the VA Merit Review Grants CX000479 and CX000780. We appreciate the expert editorial assistance of Margaret A. Madigan. NR 219 TC 5 Z9 5 U1 5 U2 20 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 EI 1532-2777 J9 MED HYPOTHESES JI Med. Hypotheses PD MAY PY 2014 VL 82 IS 5 BP 606 EP 614 DI 10.1016/j.mehy.2014.02.019 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AG0KT UT WOS:000335105100018 PM 24636783 ER PT J AU Karagozian, R Derdak, Z Baffy, G AF Karagozian, Raffi Derdak, Zoltan Baffy, Gyoergy TI Obesity-associated mechanisms of hepatocarcinogenesis SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Review DE Nonalcoholic fatty liver disease; Hepatocellular carcinoma; Adipose tissue remodeling; Insulin resistance; Lipotoxicity ID NONALCOHOLIC FATTY LIVER; BODY-MASS INDEX; TERM-FOLLOW-UP; HUMAN HEPATOCELLULAR-CARCINOMA; UNFOLDED PROTEIN RESPONSE; INDEPENDENT RISK-FACTOR; DE-NOVO LIPOGENESIS; CHRONIC HEPATITIS-C; INSULIN-RESISTANCE; METABOLIC SYNDROME AB Obesity has been recognized as a key component of the metabolic syndrome, a cluster of risk factors associated with diabetes and cardiovascular morbidity. In addition, obesity has been linked to higher frequency of cancers in a variety of tissues including the liver. Liver cancer most often occurs as hepatocellular carcinoma (HCC) complicating cirrhosis due to chronic viral infection or toxic injury and remains the third leading cause of cancer death in the world. However, HCC is increasingly diagnosed among individuals with obesity and related disorders. As these metabolic conditions have become globally prevalent, they coexist with well-established risk factors of HCC and create a unique challenge for the liver as a chronically diseased organ. Obesity-associated HCC has recently been attributed to molecular mechanisms such as chronic inflammation due to adipose tissue remodeling and pro-inflammatory adipokine secretion, ectopic lipid accumulation and lipotoxicity, altered gut microbiota, and disrupted senescence in stellate cells, as well as insulin resistance leading to increased levels of insulin and insulin-like growth factors. These mechanisms synergize with those occurring in chronic liver disease resulting from other etiologies and accelerate the development of HCC before or after the onset of cirrhosis. Increasingly common interactions between oncogenic pathways linked to obesity and chronic liver disease may explain why HCC is one of the few malignancies with rising incidence in developed countries. Better understanding of this complex process will improve our strategies of cancer prevention, prediction, and surveillance. Published by Elsevier Inc. C1 [Karagozian, Raffi] Columbia Univ Coll Phys & Surg, Dept Med, Div Gastroenterol, New York, NY 10032 USA. [Derdak, Zoltan] Brown Univ, Rhode Isl Hosp, Liver Res Ctr, Providence, RI 02903 USA. [Derdak, Zoltan] Brown Univ, Alpert Sch Med, Providence, RI 02912 USA. [Baffy, Gyoergy] VA Boston Healthcare Syst, Dept Med, Boston, MA 02130 USA. [Baffy, Gyoergy] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. RP Baffy, G (reprint author), VA Boston Healthcare Syst, Gastroenterol Sect, 150 S Huntington Ave,Room 6A-46, Boston, MA 02130 USA. EM gbaffy@partners.org NR 151 TC 37 Z9 41 U1 1 U2 17 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 EI 1532-8600 J9 METABOLISM JI Metab.-Clin. Exp. PD MAY PY 2014 VL 63 IS 5 BP 607 EP 617 DI 10.1016/j.metabol.2014.01.011 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AG1UC UT WOS:000335200700002 PM 24629562 ER PT J AU Lee, CH Hoang, LN Yip, S Reyes, C Marino-Enriquez, A Eilers, G Tao, D Chiang, S Fletcher, JA Soslow, RA Nucci, MR Oliva, E AF Lee, Cheng-Han Hoang, Lien N. Yip, Stephen Reyes, Carolina Marino-Enriquez, Adrian Eilers, Grant Tao, Derrick Chiang, Sarah Fletcher, Jonathan A. Soslow, Robert A. Nucci, Marisa R. Oliva, Esther TI Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement SO MODERN PATHOLOGY LA English DT Article DE ANO1; endometrial stromal sarcoma; KIT; NUTM2A; NUTM2B; YWHAE ID OF-THE-LITERATURE; TUMOR 1 DOG1; C-KIT; HIGH-GRADE; IMMUNOHISTOCHEMICAL DIAGNOSIS; MONOCLONAL-ANTIBODY; IMATINIB MESYLATE; UTERINE SARCOMAS; SOFT-TISSUE; CD117 AB Endometrial stromal sarcomas with the YWHAE-NUTM2A/B genetic fusion characteristically contain high-grade round to epithelioid cell component that is strongly and diffusely cyclin D1-positive and it may or may not show an associated low-grade fibroblastic/myxoid cell component. They are clinically more aggressive than endometrial stromal sarcomas with the JAZF1-SUZ12 genetic fusion and frequently demonstrate extrauterine extension at initial clinical presentation. In this setting, the tumor may be misdiagnosed as gastrointestinal stromal tumor. This study examines the expression of KIT and ANO1 in 14 YWHAE-NUTM2A/B tumors by immunohistochemistry. Staining localization was determined as membranous and/or cytoplasmic, and the staining intensity was assessed (negative, weak, moderate and strong). Of the 14 tumors, 6 contained only a high-grade round cell component, 2 only a low-grade fibroblastic component and 6 had both components in the slides evaluated. The high-grade round cell component displayed moderate to strong membranous/cytoplasmic KIT staining in all tumors (12 of 12). The low-grade fibroblastic cell component showed only weak cytoplasmic KIT staining in 3 of 8 tumors. In contrast, ANO1 was negative in all 14 neoplasms, irrespective of the component evaluated. Sanger sequencing analysis (exons 9, 11, 13 and 17) and Ampliseq Cancer Panel mutation screen (Ion Torrent) demonstrated no KIT mutations in three KIT-positive YWHAE-NUTM2A/B tumors. This study shows that the high-grade round cell component of YWHAE-NUTM2A/B endometrial stromal sarcoma consistently expresses KIT but lacks KIT hotspot mutations. KIT expression may represent a potential diagnostic pitfall in the evaluation of YWHAE-NUTM2A/B endometrial stromal sarcoma presenting with pelvic/abdominal mass, particularly in situations where its uterine origin is not definitive, and thus a panel of antibodies that includes ANO1 and cyclin D1 is necessary. C1 [Lee, Cheng-Han] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada. [Lee, Cheng-Han] Royal Alexandra Hosp, Edmonton, AB, Canada. [Hoang, Lien N.; Yip, Stephen] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada. [Reyes, Carolina; Chiang, Sarah; Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Marino-Enriquez, Adrian; Eilers, Grant; Tao, Derrick; Fletcher, Jonathan A.; Nucci, Marisa R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Oliva, E (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 2, Boston, MA 02114 USA. EM eoliva@partners.org OI Soslow, Robert/0000-0002-7269-5898 NR 34 TC 15 Z9 17 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD MAY PY 2014 VL 27 IS 5 BP 751 EP 757 DI 10.1038/modpathol.2013.199 PG 7 WC Pathology SC Pathology GA AG4ZJ UT WOS:000335428600013 PM 24186140 ER PT J AU Milwid, JM Elman, JS Li, M Shen, KY Manrai, A Gabow, A Yarmush, J Jiao, YX Fletcher, A Lee, J Cima, MJ Yarmush, ML Parekkadan, B AF Milwid, Jack M. Elman, Jessica S. Li, Matthew Shen, Keyue Manrai, Arjun Gabow, Aaron Yarmush, Joshua Jiao, Yunxin Fletcher, Anne Lee, Jungwoo Cima, Michael J. Yarmush, Martin L. Parekkadan, Biju TI Enriched Protein Screening of Human Bone Marrow Mesenchymal Stromal Cell Secretions Reveals MFAPS and PENK as Novel IL-10 Modulators SO MOLECULAR THERAPY LA English DT Article ID HEPATOCYTE GROWTH-FACTOR; GENOME-WIDE ASSOCIATION; MOLECULAR-CLONING; STEM-CELLS; RHEUMATOID-ARTHRITIS; BEHCETS-DISEASE; IN-VITRO; IL10; INTERLEUKIN-10; CYTOKINE AB The secreted proteins from a cell constitute a natural biologic library that can offer significant insight into human health and disease. Discovering new secreted proteins from cells is bounded by the limitations of traditional separation and detection tools to physically fractionate and analyze samples. Here, we present a new method to systematically identify bioactive cell-secreted proteins that circumvent traditional proteomic methods by first enriching for protein candidates by differential gene expression profiling. The bone marrow stromal cell secretome was analyzed using enriched gene expression datasets in combination with potency assay testing. Four proteins expressed by stromal cells with previously unknown anti-inflammatory properties were identified, two of which provided a significant survival benefit to mice challenged with lethal endotoxic shock. Greater than 85% of secreted factors were recaptured that were otherwise undetected by proteomic methods, and remarkable hit rates of 1 8% in vitro and 9% in vivo were achieved. C1 [Milwid, Jack M.; Elman, Jessica S.; Li, Matthew; Shen, Keyue; Jiao, Yunxin; Lee, Jungwoo; Yarmush, Martin L.; Parekkadan, Biju] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv,Dept Surg, Boston, MA 02114 USA. [Milwid, Jack M.; Li, Matthew; Manrai, Arjun] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Li, Matthew] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Gabow, Aaron] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA. [Fletcher, Anne] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Yarmush, Joshua; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA. [Parekkadan, Biju] Harvard Stem Cell Inst, Cambridge, MA USA. RP Parekkadan, B (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv,Dept Surg, Boston, MA 02114 USA. EM biju_parekkadan@hms.harvard.edu FU National Institutes of Health [K01DK087770, R01EB012521, R01DK43371]; National Human Genome Research Institute [T32 HG002295]; Shriners Hospitals for Children FX We would like to acknowledge John Asara for assistance with the mass spectrometry, Mick Correll for assistance with the gene expression analysis, and Patricia Della Pelle and Ryan Murray for assistance with histology and image acquisition. We would also like to acknowledge David Yarmush and Michael Cima for helpful discussions and insight. The research was funded in part by grants from the National Institutes of Health: K01DK087770 (B.P.), R01EB012521 (B.R), R01DK43371 (M.L.Y.), the Shriners Hospitals for Children (B.R). J.M.M. was partially supported by a training grant from the National Human Genome Research Institute (T32 HG002295). J.M.M. conceived the ideas, designed and executed the experiments, interpreted data, and wrote the manuscript. M.L. designed and executed the experiments. A.G. analyzed the gene expression data. M.F. performed the western blots. Y.J. assisted in the recombinant protein screen. J.L. assisted in the animal experiments. M.L.Y. interpreted data and provided funding. B.P. conceived the ideas, designed and executed the experiments, interpreted data, wrote the manuscript, and provided funding. J.M.M., M.L., M.L.Y., and B.P. are listed as inventors on a patent application that pertains to the presented results. NR 52 TC 8 Z9 9 U1 1 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1525-0016 EI 1525-0024 J9 MOL THER JI Mol. Ther. PD MAY PY 2014 VL 22 IS 5 BP 999 EP 1007 DI 10.1038/mt.2014.17 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA AG4WQ UT WOS:000335421500013 PM 24496384 ER PT J AU Mancias, JD Wang, XX Gygi, SP Harper, JW Kimmelman, AC AF Mancias, Joseph D. Wang, Xiaoxu Gygi, Steven P. Harper, J. Wade Kimmelman, Alec C. TI Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy SO NATURE LA English DT Article ID ANDROGEN RECEPTOR; RAT-LIVER; AUTOPHAGY; IRON; CANCER; COACTIVATOR; MECHANISMS; EXPRESSION; CELLS AB Autophagy, the process by which proteins and organelles are sequestered in double-membrane structures called autophagosomes and delivered to lysosomes for degradation, is critical in diseases such as cancer and neurodegeneration(1,2). Much of our understanding of this process has emerged from analysis of bulk cytoplasmic autophagy, but our understanding of how specific cargo, including organelles, proteins or intracellular pathogens, are targeted for selective autophagy is limited(3). Here we use quantitative proteomics to identify a cohort of novel and known autophagosome-enriched proteins in human cells, including cargo receptors. Like known cargo receptors, nuclear receptor coactivator 4 (NCOA4) was highly enriched in autophagosomes, and associated with ATG8 proteins that recruit cargo-receptor complexes into autophagosomes. Unbiased identification of NCOA4-associated proteins revealed ferritin heavy and light chains, components of an iron-filled cage structure that protects cells from reactive iron species(4) but is degraded via autophagy to release iron(5,6) through an unknown mechanism. We found that delivery of ferritin to lysosomes required NCOA4, and an inability of NCOA4-deficient cells to degrade ferritin led to decreased bioavailable intracellular iron. This work identifies NCOA4 as a selective cargo receptor for autophagic turnover of ferritin (ferritinophagy), which is critical for iron homeostasis, and provides a resource for further dissection of autophagosomal cargo-receptor connectivity. C1 [Mancias, Joseph D.; Wang, Xiaoxu; Kimmelman, Alec C.] Dana Farber Canc Inst, Div Genom Stabil & DNA Repair, Dept Radiat Oncol, Boston, MA 02215 USA. [Mancias, Joseph D.; Gygi, Steven P.; Harper, J. Wade] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Mancias, Joseph D.] Harvard Radiat Oncol Program, Boston, MA 02115 USA. [Mancias, Joseph D.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. RP Kimmelman, AC (reprint author), Dana Farber Canc Inst, Div Genom Stabil & DNA Repair, Dept Radiat Oncol, Boston, MA 02215 USA. EM wade_harper@hms.harvard.edu; alec_kimmelman@dfci.harvard.edu FU National Institutes of Health [GM070565, GM095567]; National Cancer Institute [R01CA157490]; American Cancer Society [RSG-13-298-01-TBG]; Lustgarten Foundation; American Board of Radiology Holman Research Pathway Post-doctoral Fellowship; American Society of Radiation Oncology Junior Faculty Career Research Training Award [JF2013-2] FX We thank R. Everley and E. Huttlin for assistance with LC-MS/MS, A. Cuervo for assistance with autophagosome purification protocol development, Y. Liu for technical support with cell culture, A. White, J. Lydeard and S. Hayes for interaction proteomics support, M. Haigis for access to nitrogen cavitation equipment, and the Nikon Imaging and Electron Microscopy Centers (Harvard Medical School) for imaging support. We thank Millennium Pharmaceuticals for the GABARAPL2 antibody. We acknowledge support from National Institutes of Health grants GM070565 and GM095567 to J. W. H., and National Cancer Institute grant R01CA157490, American Cancer Society Research Scholar grant RSG-13-298-01-TBG and the Lustgarten Foundation to A. C. K. J. D. M. was supported by an American Board of Radiology Holman Research Pathway Post-doctoral Fellowship and an American Society of Radiation Oncology Junior Faculty Career Research Training Award (JF2013-2). J. W. H. is a consultant for Millennium: The Takeda Oncology Company and Biogen Idec. A. C. K. is a consultant for Forma Therapeutics. NR 30 TC 99 Z9 101 U1 13 U2 62 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD MAY 1 PY 2014 VL 509 IS 7498 BP 105 EP + DI 10.1038/nature13148 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG1TM UT WOS:000335199100048 PM 24695223 ER PT J AU Peisley, A Wu, B Xu, H Chen, ZJJ Hur, S AF Peisley, Alys Wu, Bin Xu, Hui Chen, Zhijian J. Hur, Sun TI Structural basis for ubiquitin-mediated antiviral signal activation by RIG-I SO NATURE LA English DT Article ID INNATE IMMUNE-RESPONSE; RNA RECOGNITION; PROTEIN; COMPLEX; OLIGOMERIZATION; INTERFERON; SEQUENCE; REVEALS; SENSORS; MAVS AB Ubiquitin (Ub) has important roles in a wide range of intracellular signalling pathways. In the conventional view, ubiquitin alters the signalling activity of the target protein through covalent modification, but accumulating evidence points to the emerging role of noncovalent interaction between ubiquitin and the target. In the innate immune signalling pathway of a viral RNA sensor, RIG-I, both covalent and non-covalent interactions with K63-linked ubiquitin chains (K63-Ub(n)) were shown to occur in its signalling domain, a tandem caspase activation and recruitment domain (hereafter referred to as 2CARD)(1,2). Non-covalent binding of K63-Ub(n) to 2CARD induces its tetramer formation, a requirement for downstream signal activation(3). Here we report the crystal structure of the tetramer of human RIG-I 2CARD bound by three chains of K63-Ub(2). 2CARD assembles into a helical tetramer resembling a 'lock-washer', in which the tetrameric surface serves as a signalling platform for recruitment and activation of the downstream signalling molecule, MAVS. Ubiquitin chains are bound along the outer rim of the helical trajectory, bridging adjacent subunits of 2CARD and stabilizing the 2CARD tetramer. The combination of structural and functional analyses reveals that binding avidity dictates the K63-linkage and chain-length specificity of 2CARD, and that covalent ubiquitin conjugation of 2CARD further stabilizes the Ub-2CARD interaction and thus the 2CARD tetramer. Our work provides unique insights into the novel types of ubiquitin-mediated signal-activation mechanism, and previously unexpected synergism between the covalent and non-covalent ubiquitin interaction modes. C1 [Peisley, Alys; Wu, Bin; Hur, Sun] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Peisley, Alys; Wu, Bin; Hur, Sun] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Xu, Hui; Chen, Zhijian J.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA. [Chen, Zhijian J.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP Hur, S (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. EM Sun.Hur@childrens.harvard.edu RI Wu, Bin/C-4715-2015 FU GSK; Welch Foundation [I-1389]; NIH [R01-GM63692]; Pew Scholarship; BCH FX We thank G. Meigs at ALS BL 8.3.1 for data collection, and H. Wu and M. Eck for comments on the manuscript. This work was supported by GSK fellowship (B. W.), The Welch Foundation (I-1389; Z.J.C.), NIH (R01-GM63692; Z.J.C), Pew Scholarship (S. H.) and Career Development Award from BCH (S. H.). NR 30 TC 80 Z9 80 U1 3 U2 38 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD MAY 1 PY 2014 VL 509 IS 7498 BP 110 EP + DI 10.1038/nature13140 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG1TM UT WOS:000335199100049 PM 24590070 ER PT J AU Yealy, DM Kellum, JA Huang, DT Barnato, AE Weissfeld, LA Pike, F Terndrup, T Wang, HE Hou, PC LoVecchio, F Filbin, MR Shapiro, NI Angus, DC AF Yealy, Donald M. Kellum, John A. Huang, David T. Barnato, Amber E. Weissfeld, Lisa A. Pike, Francis Terndrup, Thomas Wang, Henry E. Hou, Peter C. LoVecchio, Frank Filbin, Michael R. Shapiro, Nathan I. Angus, Derek C. CA ProCESS Investigators TI A Randomized Trial of Protocol-Based Care for Early Septic Shock SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID GOAL-DIRECTED THERAPY; SEVERE SEPSIS; CLINICAL-TRIAL; UNITED-STATES AB BackgroundIn a single-center study published more than a decade ago involving patients presenting to the emergency department with severe sepsis and septic shock, mortality was markedly lower among those who were treated according to a 6-hour protocol of early goal-directed therapy (EGDT), in which intravenous fluids, vasopressors, inotropes, and blood transfusions were adjusted to reach central hemodynamic targets, than among those receiving usual care. We conducted a trial to determine whether these findings were generalizable and whether all aspects of the protocol were necessary. MethodsIn 31 emergency departments in the United States, we randomly assigned patients with septic shock to one of three groups for 6 hours of resuscitation: protocol-based EGDT; protocol-based standard therapy that did not require the placement of a central venous catheter, administration of inotropes, or blood transfusions; or usual care. The primary end point was 60-day in-hospital mortality. We tested sequentially whether protocol-based care (EGDT and standard-therapy groups combined) was superior to usual care and whether protocol-based EGDT was superior to protocol-based standard therapy. Secondary outcomes included longer-term mortality and the need for organ support. ResultsWe enrolled 1341 patients, of whom 439 were randomly assigned to protocol-based EGDT, 446 to protocol-based standard therapy, and 456 to usual care. Resuscitation strategies differed significantly with respect to the monitoring of central venous pressure and oxygen and the use of intravenous fluids, vasopressors, inotropes, and blood transfusions. By 60 days, there were 92 deaths in the protocol-based EGDT group (21.0%), 81 in the protocol-based standard-therapy group (18.2%), and 86 in the usual-care group (18.9%) (relative risk with protocol-based therapy vs. usual care, 1.04; 95% confidence interval [CI], 0.82 to 1.31; P=0.83; relative risk with protocol-based EGDT vs. protocol-based standard therapy, 1.15; 95% CI, 0.88 to 1.51; P=0.31). There were no significant differences in 90-day mortality, 1-year mortality, or the need for organ support. ConclusionsIn a multicenter trial conducted in the tertiary care setting, protocol-based resuscitation of patients in whom septic shock was diagnosed in the emergency department did not improve outcomes. (Funded by the National Institute of General Medical Sciences; ProCESS ClinicalTrials.gov number, NCT00510835.) C1 [Yealy, Donald M.; Kellum, John A.; Huang, David T.; Barnato, Amber E.; Weissfeld, Lisa A.; Pike, Francis; Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA 15261 USA. [Terndrup, Thomas] Ohio State Univ, Columbus, OH 43210 USA. [Wang, Henry E.] Univ Alabama Birmingham, Birmingham, AL USA. [Hou, Peter C.] Brigham & Womens Hosp, Boston, MA 02115 USA. [LoVecchio, Frank] Maricopa Cty Gen Hosp, Phoenix, AZ USA. [Filbin, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shapiro, Nathan I.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Angus, DC (reprint author), Univ Pittsburgh, Dept Crit Care Med, 3550 Terrace St,614 Scaife Hall, Pittsburgh, PA 15261 USA. EM angusdc@upmc.edu RI Conrad, Steven/F-3257-2015; Angus, Derek/E-9671-2012; Shapiro, Nathan/F-1718-2016 OI Conrad, Steven/0000-0002-4014-969X; FU National Institute of General Medical Sciences, National Institutes of Health [P50 GM076659]; Thermo Fisher Scientific; Cumberland Pharmaceuticals; Rapid Pathogen Screening; Cheetah Medical; Astute Medical; MedImmune; Ferring Pharmaceuticals; Roche Diagnostics; Pfizer; Eli Lilly; Eisai FX Supported by a grant (P50 GM076659) from the National Institute of General Medical Sciences, National Institutes of Health.; Dr. Shapiro reports receiving consulting fees from Thermo Fisher Scientific, fees for serving on a data and safety monitoring board from Cumberland Pharmaceuticals, and grant support from Thermo Fisher Scientific, Rapid Pathogen Screening, Cheetah Medical, and Astute Medical. Dr. Angus reports receiving consulting fees from MedImmune, Ferring Pharmaceuticals, and Roche Diagnostics, lecture fees from Pfizer, fees for serving on a data and safety monitoring board from Eli Lilly, and grant support through his institution from Eisai. No other potential conflict of interest relevant to this article was reported. NR 21 TC 494 Z9 523 U1 13 U2 56 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 1 PY 2014 VL 370 IS 18 BP 1683 EP 1693 DI 10.1056/NEJMoa1401602 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA AG4QM UT WOS:000335405200006 ER PT J AU Motzer, RJ Hutson, TE McCann, L Deen, K Choueiri, TK AF Motzer, Robert J. Hutson, Thomas E. McCann, Lauren Deen, Keith Choueiri, Toni K. TI Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter AB Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma. Median survival was 42.5 months with pazopanib and 43.6 months with sunitinib, a difference that wasnot significant.To the Editor: In the August 22 issue,(1) we reported on a phase 3 trial showing the noninferiority, with respect to progression-free survival, of pazopanib versus sunitinib as first-line treatment for clear-cell, metastatic renal-cell carcinoma, as assessed by independent review. We now report the results of the final analysis of overall survival. Overall survival, a secondary end point, was defined as the time from randomization to death from any cause. The final analysis of overall survival in the intention-to-treat population was to be performed when 650 patients had died or 2 years after the last patient was enrolled. Overall survival ... C1 [Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hutson, Thomas E.] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA. [McCann, Lauren; Deen, Keith] GlaxoSmithKline, Collegeville, PA USA. [Choueiri, Toni K.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Motzer, RJ (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. EM motzerr@mskcc.org NR 2 TC 70 Z9 72 U1 0 U2 8 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 1 PY 2014 VL 370 IS 18 BP 1769 EP 1770 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AG4QM UT WOS:000335405200032 PM 24785224 ER PT J AU Zou, Z Huang, B Wu, X Zhang, H Qi, J Bradner, J Nair, S Chen, LF AF Zou, Z. Huang, B. Wu, X. Zhang, H. Qi, J. Bradner, J. Nair, S. Chen, L-F TI Brd4 maintains constitutively active NF-kappa B in cancer cells by binding to acetylated RelA SO ONCOGENE LA English DT Article DE Brd4; cancer; degradation; JQ; NF-kappa B; ubiquitination ID POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL REGULATION; DOWN-REGULATION; PROGRESSION; PROTEINS; INFLAMMATION; TARGET; DEACETYLASE; INHIBITION; ACTIVATION AB Acetylation of the RelA subunit of NF-kappa B at lysine-310 regulates the transcriptional activation of NF-kappa B target genes and contributes to maintaining constitutively active NF-kappa B in tumors. Bromodomain-containing factor Brd4 has been shown to bind to acetylated lysine-310 (AcLys310) and to regulate the transcriptional activity of NF-kappa B, but the role of this binding in maintaining constitutively active NF-kappa B in tumors remains elusive. In this study, we demonstrate the structural basis for the binding of bromodomains (BDs) of bromodomain-containing protein 4 ( Brd4) to AcLys310 and identify the BD inhibitor JQ1 as an effective small molecule to block this interaction. JQ1 suppresses TNF-alpha-mediated NF-kappa B activation and NF-kappa B-dependent target gene expression. In addition, JQ1 inhibits the proliferation and transformation potential of A549 lung cancer cells and suppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice. Furthermore, we demonstrate that depletion of Brd4 or treatment of cells with JQ1 induces the ubiquitination and degradation of the constitutively active nuclear form of RelA. Our results identify a novel function of Brd4 in maintaining the persistently active form of NF-kappa B found in tumors, and they suggest that interference with the interaction between acetylated RelA and Brd4 could be a potential therapeutic approach for the treatment of NF-kappa B-driven cancer. C1 [Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Nair, S.; Chen, L-F] Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA. [Qi, J.; Bradner, J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Chen, L-F] Univ Illinois, Coll Med, Urbana, IL 61801 USA. RP Chen, LF (reprint author), Univ Illinois, Coll Med, Dept Biochem, MC-714, Urbana, IL 61801 USA. EM lfchen@life.illinois.edu FU UIUC; NIH [DK-085158] FX We thank members in the Chen lab for discussion and A Lamb for assistance in the preparation of the manuscript. This work is supported in part by funds provided by UIUC (to LFC) and NIH grants DK-085158 (to LFC). NR 51 TC 43 Z9 44 U1 1 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 EI 1476-5594 J9 ONCOGENE JI Oncogene PD MAY 1 PY 2014 VL 33 IS 18 BP 2395 EP 2404 DI 10.1038/onc.2013.179 PG 10 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA AG5ID UT WOS:000335451800012 PM 23686307 ER PT J AU Cespedes, EM Horan, CM Gillman, MW Gortmaker, SL Price, S Rifas-Shiman, SL Mitchell, K Taveras, EM AF Cespedes, Elizabeth M. Horan, Christine M. Gillman, Matthew W. Gortmaker, Steven L. Price, Sarah Rifas-Shiman, Sheryl L. Mitchell, Kathleen Taveras, Elsie M. TI Participant characteristics and intervention processes associated with reductions in television viewing in the High Five for Kids study SO PREVENTIVE MEDICINE LA English DT Article DE Television; Behavior; Child; Obesity; Intervention studies ID RANDOMIZED CONTROLLED-TRIAL; CHILDHOOD OBESITY; PRESCHOOL-CHILDREN; PHYSICAL-ACTIVITY; YOUNG-CHILDREN; PRIMARY-CARE; SCREEN TIME; AGED CHILDREN; TREAT OBESITY; HIP-HOP AB Objective. To evaluate the High Five for Kids intervention effect on television within subgroups, examine participant characteristics associated with process measures and assess perceived helpfulness of television intervention components. Method. High Five (randomized controlled trial of 445 overweight/obese 2-7 year-olds in Massachusetts [2006-2008]) reduced television by 0.36 h/day. 1-year effects on television viewing, stratified by subgroup, were assessed using linear regression. Among intervention participants (n = 253), associations of intervention component helpfulness with television reduction were examined using linear regression and associations of participant characteristics with processes linked to television reduction (choosing television and completing intervention visits) were examined using logistic regression. Results. High Five reduced television across subgroups. Parents of Latino (versus white) children had lower odds of completing 2 study visits (Odds Ratio: 0.39[95% Confidence Interval: 0.18, 0.84]). Parents of black (versus white) children had higher odds of choosing television (Odds Ratio: 2.23 [95% Confidence Interval: 1.08, 4.59]), as did parents of obese (versus overweight) children and children watching >= 2 h/day (versus <2) at baseline. Greater perceived helpfulness was associated with greater television reduction. Conclusion. Clinic-based motivational interviewing reduces television viewing in children. Low cost education approaches (e.g., printed materials) may be well-received. Parents of children at higher obesity risk could be more motivated to reduce television. (C) 2014 Elsevier Inc. All rights reserved. C1 [Cespedes, Elizabeth M.; Horan, Christine M.; Gillman, Matthew W.; Price, Sarah; Rifas-Shiman, Sheryl L.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA 02215 USA. [Cespedes, Elizabeth M.; Horan, Christine M.; Gillman, Matthew W.; Price, Sarah; Rifas-Shiman, Sheryl L.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Cespedes, Elizabeth M.; Gortmaker, Steven L.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02215 USA. [Cespedes, Elizabeth M.; Gillman, Matthew W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02215 USA. [Mitchell, Kathleen] Harvard Vanguard Med Associates, Boston, MA USA. [Taveras, Elsie M.] MassGen Hosp Children, Div Gen Pediat, Boston, MA USA. RP Cespedes, EM (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM emc611@mail.harvard.edu OI Cespedes Feliciano, Elizabeth/0000-0003-1192-4017 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01 HD 050966] FX This study was supported by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD 050966). NR 41 TC 2 Z9 2 U1 2 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD MAY PY 2014 VL 62 BP 64 EP 70 DI 10.1016/j.ypmed.2014.02.005 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AF7MS UT WOS:000334899800013 PM 24518002 ER PT J AU Blaine, K Rogers, J Winickoff, JP Oppenheimer, SC Timm, A Ozonoff, A Geller, AC AF Blaine, Kevin Rogers, Jayne Winickoff, Jonathan P. Oppenheimer, Sarah C. Timm, Alison Ozonoff, Al Geller, Alan C. TI Engaging in secondhand smoke reduction discussions with parents of hospitalized pediatric patients: A national survey of pediatric nurses in the United States SO PREVENTIVE MEDICINE LA English DT Article DE Tobacco smoke exposure; Hospitalized child; Nursing education; Nursing pediatric; Pediatric hospitals ID CHILD HOSPITALIZATION; CESSATION INTERVENTION; RESPIRATORY ILLNESS; TOBACCO CESSATION; CONTROLLED-TRIAL; KNOWLEDGE; ATTITUDES AB Objective: To identify individual- and system-level predictors and barriers associated with US pediatric nurses' routine counseling about child secondhand smoke exposure for parents of hospitalized children. Methods: In 2008, members of the Society of Pediatric Nurses completed a questionnaire assessing demographic, hospital systems, and work attitudes related to the following outcomes: asking about child secondhand smoke exposure, informing about sources of secondhand smoke exposure, counseling about the dangers of secondhand smoke exposure, and advising a smoke-free home policy. Results: Of 1475 eligible nurses, 888 completed the survey. We found that 39% asked, 43% informed, 29% counseled, and 25% advised parents. Nurses working in hospitals with mandatory prompts in the medical record to assess child secondhand smoke exposure, the availability of written materials for parent smokers, and regular secondhand smoke counseling training for nurses had increased odds of routinely engaging parents in secondhand smoke reduction best practices. Nurses reported parents' resistance to discussions about smoking, short hospital stays, and non-standardized care as the most common barriers to counseling parents. Conclusion: System supports in hospitals significantly increases the odds of nurses engaging in child secondhand smoke reduction practices. Strengthening existing systems and introducing new policies are critical for nurses' engagement of parents in discussions about reducing child secondhand smoke exposure. (C) 2014 Elsevier Inc. All rights reserved. C1 [Blaine, Kevin; Oppenheimer, Sarah C.; Geller, Alan C.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. [Rogers, Jayne; Ozonoff, Al] Boston Childrens Hosp, Boston, MA 02115 USA. [Winickoff, Jonathan P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Timm, Alison] Boston Univ, Boston, MA 02215 USA. RP Blaine, K (reprint author), Boston Childrens Hosp, Div Gen Pediat, 21 Autumn St,2 FL,222, Boston, MA 02115 USA. EM kevin.blaine@childrens.harvard.edu FU Flight Attendant's Medical Research Institute FX This study was supported by the Flight Attendant's Medical Research Institute. NR 26 TC 4 Z9 4 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD MAY PY 2014 VL 62 BP 83 EP 88 DI 10.1016/j.ypmed.2014.01.021 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AF7MS UT WOS:000334899800016 PM 24502846 ER PT J AU Ivkovic, A Stern, TA AF Ivkovic, Ana Stern, Theodore A. TI Lithium-Induced Neurotoxicity: Clinical Presentations, Pathophysiology, and Treatment SO PSYCHOSOMATICS LA English DT Article ID BIPOLAR DISORDER; RESONANCE SPECTROSCOPY; INTOXICATION; TOXICITY; PHARMACOKINETICS; BRAIN; CARBONATE C1 [Ivkovic, Ana; Stern, Theodore A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Ivkovic, A (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St Warren 605, Boston, MA 02114 USA. EM aivkovic@partners.org NR 27 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD MAY-JUN PY 2014 VL 55 IS 3 BP 296 EP 302 PG 7 WC Psychiatry; Psychology SC Psychiatry; Psychology GA AG2ZR UT WOS:000335286100010 PM 24388123 ER PT J AU Falls, BA Gurrera, RJ AF Falls, Brian A. Gurrera, Ronald J. TI Serotonin Syndrome in a Patient on Tramadol, Bupropion, Trazodone, and Oxycodone SO PSYCHOSOMATICS LA English DT Article ID ALCOHOL-WITHDRAWAL SYNDROME; LOW-DOSE TRAZODONE; CASE SERIES; ANTIDEPRESSANTS; OVERDOSE C1 [Falls, Brian A.; Gurrera, Ronald J.] VA Boston Healthcare Syst, Psychiat, Brockton, MA USA. RP Falls, BA (reprint author), Univ Calif Davis, Div Psychiat & Law, Med Ctr, 2230 Stockton Blvd, Sacramento, CA 95817 USA. EM brian.falls@ucdmc.ucdavis.edu NR 20 TC 1 Z9 2 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD MAY-JUN PY 2014 VL 55 IS 3 BP 305 EP 309 PG 5 WC Psychiatry; Psychology SC Psychiatry; Psychology GA AG2ZR UT WOS:000335286100012 PM 24360532 ER PT J AU Brink, JA AF Brink, James A. TI Radiation Dose Reduction in Renal Colic Protocol CT: Are We Doing Enough to Ensure Adoption of Best Practices? SO RADIOLOGY LA English DT Editorial Material C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Brink, JA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND 216, Boston, MA 02114 USA. EM jabrink@partners.org NR 7 TC 4 Z9 5 U1 0 U2 4 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD MAY PY 2014 VL 271 IS 2 BP 323 EP 325 DI 10.1148/radiol.14140455 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AG1CQ UT WOS:000335153000003 PM 24761953 ER PT J AU Sattui, SE Singh, JA Gaffo, AL AF Sattui, Sebastian E. Singh, Jasvinder A. Gaffo, Angelo L. TI Comorbidities in Patients with Crystal Diseases and Hyperuricemia SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Crystal arthropathies; Comorbidities; Gout; Hyperuricemia; Cardiovascular disease; Metabolic syndrome; Renal disease; Calcium pyrophosphate arthropathy ID SERUM URIC-ACID; CHRONIC-KIDNEY-DISEASE; PERIPHERAL ARTERIAL-DISEASE; INDUCED METABOLIC SYNDROME; DIHYDRATE DEPOSITION DISEASE; CARDIOMETABOLIC RISK-FACTORS; NUTRITION EXAMINATION SURVEY; XANTHINE-OXIDASE INHIBITION; MULTIPLE-SCLEROSIS PATIENTS; CALCIUM-PHOSPHATE CRYSTALS AB Crystal arthropathies are among the most common causes of painful inflammatory arthritis. Gout, the most common example, has been associated with cardiovascular and renal disease. In recent years, evidence for these associations and those involving other comorbidities, such as the metabolic syndrome, have emerged, and the importance of asymptomatic hyperuricemia has been established. In this review, an update on evidence, both experimental and clinical, is presented, and associations between hyperuricemia, gout, and several comorbidities are described.. Causality regarding calcium pyrophosphate arthropathy and associated comorbidities is also reviewed. C1 [Sattui, Sebastian E.] Univ Alabama Birmingham, Sch Med, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama, Sch Med, Dept Med, Div Clin Immunol & Rheumatol, Rochester, MN 55905 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Gaffo, Angelo L.] Vet Affairs Med Ctr, Rheumatol Sect, Birmingham, AL 35233 USA. [Gaffo, Angelo L.] Univ Alabama Birmingham, Sch Med, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. RP Gaffo, AL (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, 1720 2nd Ave Suth,FOT 1203, Birmingham, AL 35294 USA. EM agaffo@uab.edu FU Savient; Takeda; Regeneron; Allergan; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National-Institute of Aging (NIA); National Cancer Institute (NCI); Birmingham VA Medical Center FX S.E. Sattui and A.L. Gaffo have no conflict of interest. J.A. Singh has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Allergan, and Regeneron. J.A. Singh is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National-Institute of Aging (NIA), and National Cancer Institute (NCI) and the resources and use of facilities at the Birmingham VA Medical Center, AL. NR 214 TC 12 Z9 13 U1 1 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X EI 1558-3163 J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD MAY PY 2014 VL 40 IS 2 BP 251 EP + DI 10.1016/j.rdc.2014.01.005 PG 29 WC Rheumatology SC Rheumatology GA AG4WO UT WOS:000335421300008 PM 24703346 ER PT J AU Lawson, EH Hall, BL Louie, R Zingmond, DS Ko, CY AF Lawson, Elise H. Hall, Bruce Lee Louie, Rachel Zingmond, David S. Ko, Clifford Y. TI Identification of modifiable factors for reducing readmission after colectomy: A national analysis SO SURGERY LA English DT Article ID LENGTH-OF-STAY; COLORECTAL SURGERY; HOSPITAL READMISSIONS; QUALITY-IMPROVEMENT; CLAIMS DATA; MORTALITY; REGISTRY AB Background. Rates of hospital readmission are currently used for public reporting and pay for performance. Colectomy procedures account for a large number of readmissions among operative procedures. Our objective was to compare the importance of 3 groups of clinical variables (demographics, preoperative risk factors, and postoperative complications) in predicting readmission after colectomy procedures. Methods. Patient records (2005-2008) from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) were linked to Medicare inpatient claims. Patient demographics (n = 2), preoperative risk factors (n = 23), and 30-day postoperative complications (n = 17) were identified from ACS-NSQIP, whereas 30-day postoperative readmissions and costs were determined from Medicare. Multivariable logistic regression models were used to examine risk-adjusted predictors of colectomy readmission. Results. Among 12,981 colectomy patients, the 30-day postoperative readmission rate was 13.5%. Readmitted patients had slightly greater rates of comorbidities and indicators of clinical severity and substantially greater rates of complications than non-readmitted patients. After risk adjustment, patients with a complication were 3.3 times as likely to be readmitted as patients without a complication. Among individual complications, progressive renal failure and organ-space surgical site infection had the highest risk-adjusted relative risks of readmission (4.6 and 4.0, respectively). Demographic, preoperative risk factor, and postoperative complication variables increased the dbility to discriminate readmissions (reflected by the c-statistic) by 5.3%, 23.3%, and 35.4%, respectively. Conclusion. Postoperative complications after colectomy are more predictive of readmiSsion than traditional risk factors. Focusing quality improvement efforts on preventing and managing postoperative complications may be the most important step toward reducing readmission rates. C1 [Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Hall, Bruce Lee; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Lawson, Elise H.; Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Louie, Rachel; Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU Centers for Medicare & Medicaid Services (CMS); American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program; VA Health Services Research and Development program [RWJ 65-020] FX E.H.L. and C.Y.K. are Former RWJF Clinical Scholars. This study was partially funded by a contract from the Centers for Medicare & Medicaid Services (CMS). EHL's time was supported by the VA Health Services Research and Development program (RWJ 65-020) and the American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program. For the remaining authors, none were declared. NR 18 TC 16 Z9 16 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAY PY 2014 VL 155 IS 5 BP 754 EP 766 DI 10.1016/j.surg.2013.12.016 PG 13 WC Surgery SC Surgery GA AG3BP UT WOS:000335291100005 PM 24787101 ER PT J AU Scales, CD Saigal, CS Hanley, JM Dick, AW Setodji, CM Litwin, MS AF Scales, Charles D., Jr. Saigal, Christopher S. Hanley, Janet M. Dick, Andrew W. Setodji, Claude M. Litwin, Mark S. CA NIDDK Urologic Dis Amer Project TI The impact of unplanned postprocedure visits in the management of patients with urinary stones SO SURGERY LA English DT Article ID UNITED-STATES; URETERAL CALCULI; KIDNEY-STONES; READMISSIONS; SURGERY; VOLUME; UROLITHIASIS; PREVALENCE; CYSTECTOMY; HOSPITALS AB Background. Unplanned follow-up care is the focus of intense health policy interest, as evidenced by recent financial penalties imposed under the Affordable Care Act. To date, however, unplanned postoperative care remains poorly characterized, particularly for patients with kidney stones. Our objective was to describe the frequency, variation, and financial impact of unplanned, high-acuity, follow-up visits in the treatment of patients with urinary stone disease. Methods. We identified privately insured patients undergoing percutaneous nephrostolithotomy,,ureteroscopy, or shock-wave lithotripsy for stone disease. The primary outcome was occurrence of an emergency department visit or hospital admission within 30 days of the procedure. Multivariable models estimated the odds of an unplanned visit and the incremental cost of those visits, controlling for important covariates. Results. We identified 93,523 initial procedures to fragment or remove stones. Overall, 1 in 7 patients had an unplanned postprocedural visit. Unplanned visits were least common after shock-wave lithotripsy (12%) and occurred with similar frequency after ureteroscopy and percutaneous nephrostolithotomy (15%). Procedures at high-volume facilities were substantially less likely to result in an unplanned visit (odds ratio 0.80, 95% confidence interval [95% CI] 0.74-0.87, P <.001). When an unplanned visit occurred, adjusted incremental expenditures per episode were greater after shockwave lithotripsy ($32,156 [95% CI $30,453-33,859]) than after ureteroscopy ($23,436 [95% CI $22,281-24,590]). Conclusion. Patients not infrequently experience an unplanned, high-acuity visit after low-risk procedures to remove urinary stones, and the cost of these encounters is substantial. Interventions are indicated to identify and reduce preventable unplanned visits. C1 [Scales, Charles D., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA 90095 USA. [Scales, Charles D., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, US Dept Vet Affairs, Los Angeles, CA 90095 USA. [Scales, Charles D., Jr.; Saigal, Christopher S.; Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Scales, Charles D., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Hanley, Janet M.; Dick, Andrew W.; Setodji, Claude M.; Litwin, Mark S.] RAND Corp, Santa Monica, CA USA. [Litwin, Mark S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA. RP Scales, CD (reprint author), Duke Univ, Div Urol Surg, DUMC 3707, Durham, NC 27710 USA. EM chuck.scales@duke.edu FU Robert Wood Johnson Foundation Clinical Scholars program; US Department of Veterans Affairs; National Institute of Diabetes and Digestive and Kidney Diseases [HHSN276201200016C]; National Library of Medicine FX Drs. Scales was supported by the Robert Wood Johnson Foundation Clinical Scholars program and the US Department of Veterans Affairs. The Urologic Diseases in America Project is supported by grant HHSN276201200016C from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Library of Medicine. NR 24 TC 13 Z9 13 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAY PY 2014 VL 155 IS 5 BP 769 EP 775 DI 10.1016/j.surg.2013.12.013 PG 7 WC Surgery SC Surgery GA AG3BP UT WOS:000335291100007 PM 24787103 ER PT J AU Santry, HP Pringle, PL Collins, CE Kiefe, CI AF Santry, Heena P. Pringle, Patricia L. Collins, Courtney E. Kiefe, Catarina I. TI A qualitative analysis of acute care surgery in the United States: It's more than just "a competent surgeon with a sharp knife and a willing attitude" SO SURGERY LA English DT Article ID EMERGENCY GENERAL-SURGERY; ACADEMIC TRAUMA CENTER; SURGICAL EMERGENCIES; ACUTE CHOLECYSTITIS; MEDICAL LITERATURE; INJURED PATIENTS; USERS GUIDES; HEALTH-CARE; MODEL; SERVICE AB Background. Since acute care surgery (ACS) was conceptualized a. decade ago, the specialty has been adopted widely; however, little is known about the structure and function of ACS teams. Methods. We conducted 18 open-ended interviews with ACS leaders (representing geographic [New England, Northeast, Mid-Atlantic, South, West, Midwest] and practice [Public/Charity, Community, University] diversity)., Two independent reviewers analyzed transcribed interviews using an inductive approach (NVivo qualitative analysis software). Results. All respondents described ACS as a specialty treating "time-sensitive surgical disease" including trauma, emergency general surgery (EGS), and surgical critical care (SCC); 11 of 18 combined trauma and EGS into a single clinical team; 9 of 18 included elective general surgery. Emergency orthopedics, emergency neurosurgery, and surgical subspecialty triage were rare (1/18 each). Eight of 18 ACS teams had scheduled EGS operating room time. All had a core group of trauma and SCC surgeons; 13 of 18 shared EGS due to volume, human resources, or competition for revenue. Only 12 of 18 had formal signout rounds; only 2 of 18 had prospective EGS data registries. Streamlined access to EGS, evidence-based protocols, and improved education were considered strengths of ACS. ACS was described as the "last great surgical service" reinvigorated to provide "timely," cost-effective EGS by experts in "resuscitation and critical care" and to attract "young, talented, eager surgeons" to trauma/SCC; however, there was concern that ACS might become the "wastebasket for everything that happens at inconvenient times." Conclusion. Despite rapid adoption of ACS, its implementation varies widely. Standardization of scope of practice, continuity of care, and registry development may improve EGS outcomes and allow the specialty to thrive. C1 [Santry, Heena P.; Collins, Courtney E.] Univ Massachusetts, Sch Med, Dept Surg, Boston, MA 02125 USA. [Pringle, Patricia L.] Univ Massachusetts, Dept Med, Massachusetts Gen Hosp, Sch Med, Boston, MA 02125 USA. [Santry, Heena P.; Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Boston, MA 02125 USA. RP Santry, HP (reprint author), Dept Surg, Room S3-727,55 Lake Ave North, Worcester, MA 01655 USA. EM heena.santry@umassmemorial.org FU University of Massachusetts Clinical Scholar Award through the National Center for Advancing Translational Sciences of the National Institutes of Health [UL1RR031982, 1KL2RR031981-01, UL1TR000161] FX The research reported in this publication was in part supported by the University of Massachusetts Clinical Scholar Award (H.P.S.) through the National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers UL1RR031982, 1KL2RR031981-01, and UL1TR000161. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 61 TC 8 Z9 8 U1 3 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAY PY 2014 VL 155 IS 5 BP 809 EP 825 DI 10.1016/j.surg.2013.12.012 PG 17 WC Surgery SC Surgery GA AG3BP UT WOS:000335291100012 PM 24787108 ER PT J AU Asbun, HJ Conlon, K Fernandez-Cruz, L Riess, H Shrikhande, SV Adham, M Bassi, C Bockhorn, M Buchler, M Charnley, RM Dervenis, C Fingerhutt, A Gouma, DJ Hartwig, W Imrie, C Izbicki, JR Lillemoe, KD Milicevic, M Montorsi, M Neoptolemos, JP Sandberg, AA Sarr, M Vollmer, C Yeo, CJ Traverso, LW AF Asbun, Horacio J. Conlon, Kevin Fernandez-Cruz, Laureano Riess, Helmut Shrikhande, Shailesh V. Adham, Mustapha Bassi, Claudio Bockhorn, Maximilian Buechler, Markus Charnley, Richard M. Dervenis, Chrisios Fingerhutt, Abe Gouma, Dirk J. Hartwig, Werner Imrie, Clem Izbicki, Jakob R. Lillemoe, Keith D. Milicevic, Miroslav Montorsi, Marco Neoptolemos, John P. Sandberg, Aken A. Sarr, Michael Vollmer, Charles Yeo, Charles J. Traverso, L. William CA Int Study Grp Pancreatic Surg TI When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery SO SURGERY LA English DT Article ID FINE-NEEDLE-ASPIRATION; DIGESTIVE NEUROENDOCRINE NEOPLASMS; AUTOIMMUNE PANCREATITIS; ENDOSCOPIC ULTRASOUND; DIAGNOSTIC-ACCURACY; BENIGN DISEASE; CANCER; TUMORS; MALIGNANCY; GUIDELINES AB Background. Pancreatoduodenectomy (PD) provides the best chance for cure in the treatment of patients with localized pancreatic head cancer. In patients with a suspected, clinically resectable pancreatic head malignancy, the need for histologic confirmation before proceeding with PD has not historically been required, but remains controversial. Methods. An international panel of pancreatic surgeons working in well-known, high-volume centers reviewed the literature and worked together to establish a consensus on when to perform a PD in the absence of positive histology. Results. The incidence of benign disease after PD for a presumed malignancy is 5-13%. Diagnosis by endoscopic cholangiapancreatography brushings and percutaneous fine-needle aspiration are highly specific, but poorly sensitive. Aspiration biopsy guided by enclascopic ultrasonography (EUS) has greater sensitivity, but it is highly operator dependent and increases expense. The incidence of autoimmune pancreatitis (AlP) in the benign resected specimens is 30-43%. EUS-guided Trucut biopsy, serum levels of immunoglobulin G4, and HISORt (Histology, Imaging, Serology, Other organ involvement, and Response to therapy) are used for diagnosis. If AIP is suspected but not confirmed, the response to a short course of steroids is helpful for diagnosis. Conclusion. In the presence of a solid mass suspicious formalignancy, consensus was reached that biopsy proof is not required before proceeding with resection. Confirmation of malignancy, however, is mandatory for patients with borderline. resectable disease to be treated with neoadjuvant therapy before exploration for resection. When a diagnosis of AIP is highly suspected, a biopsy is recommended, and a short course of steroid treatment should be considered if the biopsy does not reveal features suspicious for malignancy. C1 [Asbun, Horacio J.] Mayo Clin, Dept Gen Surg, Jacksonville, FL 32224 USA. [Conlon, Kevin] Univ Dublin Trinity Coll, Professorial Surg Unit, Dublin 2, Ireland. [Fernandez-Cruz, Laureano] Univ Barcelona, Dept Surg, Hosp Clin Barcelona, Barcelona, Spain. [Riess, Helmut] Tech Univ Munich, Klinikum Rechts Isar, Dept Surg, D-80290 Munich, Germany. [Shrikhande, Shailesh V.] Tata Mem Hosp, Dept Surg Oncol, Bombay, Maharashtra, India. [Adham, Mustapha] Hop Edouard Herriot, Dept HPB Surg, Lyon, France. [Bassi, Claudio] Univ Verona, Pancreas Inst, Dept Surg & Oncol, I-37100 Verona, Italy. [Bockhorn, Maximilian; Izbicki, Jakob R.] Univ Hosp Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Hamburg, Germany. [Buechler, Markus; Hartwig, Werner] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany. [Charnley, Richard M.] Freeman Rd Hosp, Dept HPB & Transplant Surg, Newcastle Upon Tyne, Tyne & Wear, England. [Dervenis, Chrisios] Agia Olga Hosp, Dept Surg 1, Athens, Greece. [Fingerhutt, Abe] Ctr Hosp Intercommunal, Dept Digest Surg, Poissy, France. [Gouma, Dirk J.] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands. [Imrie, Clem] Univ Glasgow, Acacdem Unit Surg, Glasgow, Lanark, Scotland. [Lillemoe, Keith D.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Milicevic, Miroslav] Univ Belgrade, Clin Ctr Serbia, Surg Clin 1, Belgrade, Serbia. [Montorsi, Marco] Univ Milan, IRCCS, Inst Clin Humanitas, Dept Gen Surg, Milan, Italy. [Neoptolemos, John P.] Univ Liverpool, Liverpool Canc Res UK Ctr, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England. [Sandberg, Aken A.] Karolinska Univ Hosp, Karolinska Inst, Dept Surg, Huddinge, Sweden. [Sarr, Michael] Mayo Clin, Dept Gastroenterol & Gen Surg, Rochester, MN USA. [Vollmer, Charles] Hosp Univ Penn, Dept Gastrointestinal Surg, Philadelphia, PA 19104 USA. [Yeo, Charles J.] Thomas Jefferson Univ, Dept Surg, Jefferson Pancreas Biliary & Related Canc Ctr, Philadelphia, PA 19107 USA. [Traverso, L. William] St Lukes Clin, Ctr Pancreat & Liver Dis, Boise, ID USA. RP Asbun, HJ (reprint author), Mayo Clin Florida, Div Gen Surg, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. EM Asbun.Horacio@mayo.edu RI Adham, Mustapha/A-1270-2017; OI Imrie, Clem/0000-0002-1190-7084 NR 31 TC 20 Z9 28 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAY PY 2014 VL 155 IS 5 BP 887 EP 892 DI 10.1016/j.surg.2013.12.032 PG 6 WC Surgery SC Surgery GA AG3BP UT WOS:000335291100020 PM 24661765 ER PT J AU Lee, J Quraishi, SA Bhatnagar, S Zafonte, RP Masiakos, PT AF Lee, Jarone Quraishi, Sadeq A. Bhatnagar, Saurabha Zafonte, Ross P. Masiakos, Peter T. TI The economic cost of firearm-related injuries in the United States from 2006 to 2010 SO SURGERY LA English DT Article AB Background. Estimates of the number of firearm-related injuries widely vary. Although focus has been primarily on deaths, the societal cost of caring for victims of these-injuries is largely unknown. Our goal was to estimate the economic impact of nonfatal, firearm-related injuries in the United States based on recent, publically available data. Methods. We queried several national registries for hospital and emergency department (ED) discharges from 2006 to 2010 to estimate the annual incidence of firearm-related injuries. The cost of direct medical services and lost productivity from firearm-related injuries were extrapolated from recently published estimates. To identify potentially important trends, we compared the economic impact and payer mix for firearm-related injuries in 2006 with those in 2010. Results. During the 5-year analytic period, we identified 385,769 (SE=29,328) firearm-related ED visits resulting in 141,914 (SE=14,243) hospital admissions, costing more than $88 billion (SE=$8.0 billion). Between 2006 and 2010, there was a decrease in the rate of hospital visits from 6.65 per 10,000 visits in 2006 to 5.76 per 10,000 visits in 2010 (P<.001). Similarly, the rate of hospital admissions and ED visits without admission decreased from 2.58 per 10,000 to 1.96 per 10,000 (P<.001) and 4.08 per 10,000 to 3.79 per 10,000 (P<.001). Regression of the economic costs from 2006 to 2010, adjusted for Consumer Price Index, showed no change (P=.15). There was a decrease in the proportion of Uninsured between 2006 and 2010 from 51.6% to 46.78% (P<.001). Conclusion. Firearm-related injuries are a major economic burden to not only the American health care system but also to American society. The incidence of these injuries has decreased slightly from 2006 to 2010, with no change in the economic burden. Research aimed at understanding the associated financial, social, health, and disability-related issues related to firearm injuries is necessary and would likely enhance our knowledge of the causes of these events, and may accelerate development of interventions and policies to decrease the staggering medical and societal cost of gun violence. C1 [Lee, Jarone] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Quraishi, Sadeq A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Masiakos, Peter T.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA. [Masiakos, Peter T.] Harvard Univ, Sch Med, Boston, MA USA. [Bhatnagar, Saurabha; Zafonte, Ross P.] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Bhatnagar, Saurabha; Zafonte, Ross P.] Spaulding Rehabil Hosp, Boston, MA USA. RP Masiakos, PT (reprint author), Massachusetts Gen, Dept Pediat Surg, 55 Fruit St, Boston, MA 02114 USA. EM pmasiakos@partners.org NR 8 TC 17 Z9 17 U1 1 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAY PY 2014 VL 155 IS 5 BP 894 EP 898 DI 10.1016/j.surg.2014.02.011 PG 5 WC Surgery SC Surgery GA AG3BP UT WOS:000335291100022 PM 24684950 ER PT J AU Jacobs, LM Warshaw, AL AF Jacobs, Lenworth M. Warshaw, Andrew L. TI Commentary on: The economic cost of firearm-related injuries in the United States from 2006 to 2010 SO SURGERY LA English DT Editorial Material C1 [Jacobs, Lenworth M.] Hartford Hosp, Hartford, CT 06102 USA. [Warshaw, Andrew L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jacobs, LM (reprint author), Hartford Hosp, 80 Seymour St, Hartford, CT 06102 USA. EM Lenworth.jacobs@hhchealth.org NR 7 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAY PY 2014 VL 155 IS 5 BP 899 EP 900 DI 10.1016/j.surg.2014.02.012 PG 2 WC Surgery SC Surgery GA AG3BP UT WOS:000335291100023 PM 24684951 ER PT J AU Thanos, A Jakobiec, FA Mendoza, PR Hatton, MP AF Thanos, Aristomenis Jakobiec, Frederick A. Mendoza, Pia R. Hatton, Mark P. TI Ectopic (choristomatous) orbital respiratory cyst: Histopathology and immunohistochemistry SO SURVEY OF OPHTHALMOLOGY LA English DT Review DE respiratory cyst; orbit; choristoma; cilia; immunohistochemistry ID EPITHELIUM; DACRYOPS; LESIONS AB A 24-year-old woman underwent excision of a slowly growing mass located in the right superomedial orbit that had histopathologic and immunohistochemical findings consistent with a choristomatous respiratory cyst. This rare condition may either arise primarily from embryologic respiratory epithelium rests in the orbit or develop secondarily. as the result of trauma or chronic sinus disease complicated by mucocele formation. (C) 2014 Elsevier Inc. All rights reserved. C1 [Thanos, Aristomenis; Jakobiec, Frederick A.; Mendoza, Pia R.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Thanos, Aristomenis; Jakobiec, Frederick A.; Mendoza, Pia R.; Hatton, Mark P.] Harvard Univ, Sch Med, Boston, MA USA. [Jakobiec, Frederick A.; Mendoza, Pia R.] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Boston, MA 02114 USA. [Hatton, Mark P.] Ophthalm Consultants Boston, Boston, MA USA. RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St,Suite 328, Boston, MA 02114 USA. EM Fred_jakobiec@meei.harvard.edu NR 19 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6257 EI 1879-3304 J9 SURV OPHTHALMOL JI Surv. Ophthalmol. PD MAY-JUN PY 2014 VL 59 IS 3 BP 328 EP 333 DI 10.1016/j.survophthal.2013.07.001 PG 6 WC Ophthalmology SC Ophthalmology GA AG1TW UT WOS:000335200100005 PM 24359804 ER PT J AU Miller, JW AF Miller, Joan W. TI The Harvard angiogenesis story SO SURVEY OF OPHTHALMOLOGY LA English DT Review DE age-related macular degeneration (AMD); angiogenesis; choroidal neovascularization (CNV); Factor X; Harvard; Macula Society; Paul Henkind Memorial Lecture retinopathy; vascular endothelial growth factor (VEGF) ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; DIABETIC MACULAR EDEMA; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; OCCLUSION 12-MONTH OUTCOMES; RANIBIZUMAB PLUS PROMPT; FACTOR VEGF; IRIS NEOVASCULARIZATION; SUSTAINED BENEFITS; HYPOXIC INDUCTION AB I shall discuss the work of researchers at Harvard Medical School who came together in the early 1990s. Scattered across various Harvard-affiliated hospitals and research centers, these individuals were unified by their interest in ocular neovascularization. Together and separately, they investigated models of ocular neovascularization, exploring tumor angiogenesis in eye development and disease. (C) 2014 The Author. Published by Elsevier Inc. All rights reserved. C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. RP Miller, JW (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM joan_miller@meei.harvard.edu NR 38 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6257 EI 1879-3304 J9 SURV OPHTHALMOL JI Surv. Ophthalmol. PD MAY-JUN PY 2014 VL 59 IS 3 BP 361 EP 364 DI 10.1016/j.survophthal.2013.07.003 PG 4 WC Ophthalmology SC Ophthalmology GA AG1TW UT WOS:000335200100011 PM 24138892 ER PT J AU Pond, GR Di Lorenzo, G Necchi, A Eigl, BJ Kolinsky, MP Chacko, RT Dorff, TB Harshman, LC Milowsky, MI Lee, RJ Galsky, MD Federico, P Bolger, G DeShazo, M Mehta, A Goyal, J Sonpavde, G AF Pond, Gregory R. Di Lorenzo, Giuseppe Necchi, Andrea Eigl, Bernhard J. Kolinsky, Michael P. Chacko, Raju T. Dorff, Tanya B. Harshman, Lauren C. Milowsky, Matthew I. Lee, Richard J. Galsky, Matthew D. Federico, Piera Bolger, Graerne DeShazo, Mollie Mehta, Amitkumar Goyal, Jatinder Sonpavde, Guru TI Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article DE Penile squamous cell carcinoma; Advanced; Systemic therapy; Prognosis ID SOUTHWEST-ONCOLOGY-GROUP; PHASE-II; COMBINATION CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; CISPLATIN; CANCER; METHOTREXATE; BLEOMYCIN; 5-FLUOROURACIL; AMPUTATION AB Background: Prognostic factors in men with penile squamous cell carcinoma (PSCC) receiving systemic therapy are unknown. A prognostic classification system in this disease may facilitate interpretation of outcomes and guide rational drug development. We performed a retrospective analysis to identify prognostic factors in men with PSCC receiving first-line systemic therapy for advanced disease. Patients and methods: Individual patient level data were obtained from 13 institutions to study prognostic factors in the context of first-line systemic therapy for advanced PSCC. Cox proportional hazards regression analysis was conducted to examine the prognostic effect of these candidate factors on progression-free survival (PFS) and overall survival (OS): age, stage, hemoglobin, neutrophil count, lymphocyte count, albumin, site of metastasis (visceral or nonvisceral), smoking, circumcision, regimen, ECOG performance status (PS), lymphovascular invasion, precancerous lesion, and surgery following chemotherapy. The effect of different treatments was then evaluated adjusting for factors in the prognostic model. Results: The study included 140 eligible men. Mean age across all men was 57.0 years. Among them, 8.6%, 21.4%, and 70.0% of patients had stage 2, 3, and 4 diseases, respectively; 40.7% had ECOG PS >= 1, 47.4% had visceral metastases, and 73.6% received cisplatin-based chemotherapy. The multivariate model of poor prognostic factors included visceral metastases (P < 0.001) and ECOG PS >= 1 (P < 0.001) for both PFS and OS. A risk stratification model constructed with 0, 1, and both poor prognostic factors was internally validated and demonstrated moderate discriminatory ability (c-statistic of 0.657 and 0.677 for OS and PFS, respectively). The median OS for the entire population was 9 months. Median OS was not reached, 8, and 7 months for those with 0, 1, and both risk factors, respectively. Cisplatin-based regimens were associated with better OS (P = 0.017) but not PFS (P = 0.37) compared with noncisplatin-based regimens after adjusting for the 2 prognostic factors. Conclusions: In men with advanced PSCC receiving first-line systemic therapy, visceral metastases and ECOG PS >= 1 were poor prognostic factors. A prognostic model including these factors exhibited moderate discriminatory ability for outcomes and warrants external validation. Patients receiving cisplatin-based regimens exhibited better outcomes compared with noncisplatin-based regimens after adjusting for prognostic factors. (C) 2014 Elsevier Inc. All rights reserved. C1 [Pond, Gregory R.] McMaster Univ, Hamilton, ON, Canada. [Di Lorenzo, Giuseppe; Federico, Piera] Univ Naples Federico II, Naples, Italy. [Necchi, Andrea] Fdn IRCCS Ist Nazl Tumori, Milan, Italy. [Eigl, Bernhard J.] BC Canc Agcy, Vancouver, BC, Canada. [Kolinsky, Michael P.] Univ Alberta, Edmonton, AB, Canada. [Chacko, Raju T.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Dorff, Tanya B.] Univ So Calif, Los Angeles, CA USA. [Harshman, Lauren C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Milowsky, Matthew I.] Univ N Carolina, Chapel Hill, NC USA. [Lee, Richard J.] Masachussetts Gen Hosp, Ctr Canc, Boston, MA USA. [Galsky, Matthew D.] Mt Sinai Tisch Canc Inst, New York, NY USA. [Bolger, Graerne; DeShazo, Mollie; Mehta, Amitkumar; Sonpavde, Guru] UAB, Ctr Comprehens Canc, Birmingham, AL 35233 USA. [Goyal, Jatinder] UAB, Med Ctr, Dept Med, Birmingham, AL USA. RP Sonpavde, G (reprint author), UAB, Ctr Comprehens Canc, Birmingham, AL 35233 USA. EM gsonpavde@uabmc.edu OI Necchi, Andrea/0000-0002-3007-2756 FU UAB Urologic oncology research grant FX Funding source: UAB Urologic oncology research grant. NR 32 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 EI 1873-2496 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD MAY PY 2014 VL 32 IS 4 BP 501 EP 508 DI 10.1016/j.urolonc.2013.10.007 PG 8 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA AG4WY UT WOS:000335422300019 PM 24332646 ER PT J AU Hayano, K Lee, SH Yoshida, H Zhu, AX Sahani, DV AF Hayano, Koichi Lee, Sang Ho Yoshida, Hiroyuki Zhu, Andrew X. Sahani, Dushyant V. TI Fractal Analysis of CT Perfusion Images for Evaluation of Antiangiogenic Treatment and Survival in Hepatocellular Carcinoma SO ACADEMIC RADIOLOGY LA English DT Article DE CT perfusion; hepatocellular carcinoma; angiogenesis; heterogeneity; antiangiogenic treatment ID ENDOTHELIAL GROWTH-FACTOR; MRI PARAMETER MAPS; PROGNOSTIC-SIGNIFICANCE; TUMOR VASCULATURE; RECTAL-CANCER; THERAPY; BEVACIZUMAB; BIOMARKERS; NORMALIZATION; HETEROGENEITY AB Rationale and Objectives: Tumor vascular heterogeneity is a recognized biomarker for cancer progression. Our purpose was to assess the tumor perfusion heterogeneity during antiangiogenic therapy in hepatocellular carcinoma (HCC) by means of fractal analysis on computed tomography perfusion (CTP) images. Materials and Methods: Twenty-two patients (15 men and 7 women; mean age: 61.5 years) with.advanced HCC underwent CTP at baseline and 2 weeks after administration of bevacizumab. Perfusion maps of blood flow (BF) were generated by the adiabatic approximation to the tissue homogeneity model with a motion registration, and fractal analyses were applied to gray-scale perfusion maps using a plug in tool on ImageJ software (NIH, Bethesda, MD). A differential box-counting method was applied, and the fractal dimension (FD) was calculated as a heterogeneity parameter. Results: Patients were grouped into favorable progression-free survival (PFS) group (PFS>6 months, 11 patients) and unfavorable PFS group (PFS <= 6, 11 patients). After 2 weeks of antiangiogenic therapy, the BF decreased significantly (P <.0001), whereas the FD showed no significant change (P =.69). The percent change of the FD in tumor BF was significantly different between patients with favorable PFS and those without (-2.52% vs. 3.72%, P =.01), whereas the change of tumor BF showed no significant difference between them (-28.93% vs. -25.47%, P=.64). In Kaplan-Meier analysis, patients with greater reduction in the percent change of FD and lower baseline FD in tumor BF showed significantly longer overall survival (P =.009, P =.005). Conclusions: Fractal analysis of tumor BF can be a biomarker for antiangiogenic therapy. C1 [Hayano, Koichi; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA. [Lee, Sang Ho; Yoshida, Hiroyuki] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Zhu, Andrew X.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. RP Hayano, K (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, 55 Fruit St,White 270, Boston, MA 02114 USA. EM khayano@partners.org RI Lee, Sang Ho/B-9149-2017 OI Lee, Sang Ho/0000-0002-4634-4904 NR 41 TC 9 Z9 13 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 EI 1878-4046 J9 ACAD RADIOL JI Acad. Radiol. PD MAY PY 2014 VL 21 IS 5 BP 654 EP 660 DI 10.1016/j.acra.2014.01.020 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AF2RH UT WOS:000334559200014 PM 24703479 ER PT J AU Moulton, EA Elman, I Becerra, LR Goldstein, RZ Borsook, D AF Moulton, Eric A. Elman, Igor Becerra, Lino R. Goldstein, Rita Z. Borsook, David TI The cerebellum and addiction: insights gained from neuroimaging research SO ADDICTION BIOLOGY LA English DT Review DE opioids; PET.; craving; cocaine; MRI; Alcohol; marijuana ID POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; GRAY-MATTER VOLUME; INTRINSIC FUNCTIONAL CONNECTIVITY; COGNITIVE-AFFECTIVE SYNDROME; BRAIN GLUCOSE-METABOLISM; HEAVY CANNABIS USERS; PREFRONTAL CORTEX; MARIJUANA USERS; DRUG-ADDICTION AB Although cerebellar alterations have been consistently noted in the addiction literature, the pathophysiology of this link remains unclear. The cerebellum is commonly classified as a motor structure, but human functional neuroimaging along with clinical observations in cerebellar stroke patients and anatomical tract tracing in non-human primates suggests its involvement in cognitive and affective processing. A comprehensive literature search on the role of the cerebellum in addiction was performed. This review article (1) considers the potential role of the cerebellum in addiction; (2) summarizes the cerebellar structural alterations linked to addiction; (3) presents the functional neuroimaging evidence linking the cerebellum with addiction; and (4) proposes a model for addiction that underscores the role of the cerebellum. The data implicate the cerebellum as an intermediary between motor and reward, motivation and cognitive control systems, as all are relevant etiologic factors in addiction. Furthermore, consideration of these findings could contribute to deeper and more sophisticated insights into normal reward and motivational function. The goal of this review is to spread awareness of cerebellar involvement in addictive processes, and to suggest a preliminary model for its potential role. C1 [Moulton, Eric A.; Becerra, Lino R.; Borsook, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, PAIN Grp,Ctr Pain & Brain,Boston Childrens Hosp,M, Boston, MA USA. [Elman, Igor] Providence Vet Adm Med Ctr, Providence, RI USA. [Elman, Igor] Harvard Univ, Sch Med, Dept Psychiat, Cambridge Hlth Alliance, Cambridge, MA 02138 USA. [Goldstein, Rita Z.] Brookhaven Natl Lab, Upton, NY 11973 USA. RP Moulton, EA (reprint author), Boston Childrens Hosp, PAIN Grp, 9 Hope Ave, Waltham, MA 02453 USA. EM eric.moulton@childrens.harvard.edu FU National Institutes of Health (National Institute on Drug Abuse) [K01DA024289, R01DA023579, R21DA034954]; National Institutes of Health (National Institute of Neurological Disorders and Stroke) [K24NS064050] FX This work was supported by the National Institutes of Health (National Institute on Drug Abuse Grant K01DA024289 to E. A. M.; National Institute of Neurological Disorders and Stroke Grant K24NS064050 to D. B.; National Institute on Drug Abuse Grants R01DA023579 and R21DA034954 to R.Z.G.). NR 109 TC 18 Z9 18 U1 3 U2 25 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 EI 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD MAY PY 2014 VL 19 IS 3 BP 317 EP 331 DI 10.1111/adb.12101 PG 15 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA AF3FS UT WOS:000334597500001 PM 24851284 ER PT J AU Taylor, SW Mayer, KH Elsesser, SM Mimiaga, MJ O'Cleirigh, C Safren, SA AF Taylor, S. Wade Mayer, Kenneth H. Elsesser, Steven M. Mimiaga, Matthew J. O'Cleirigh, Conall Safren, Steven A. TI Optimizing Content for Pre-exposure Prophylaxis (PrEP) Counseling for Men Who Have Sex with Men: Perspectives of PrEP Users and High-Risk PrEP Na < ve Men SO AIDS AND BEHAVIOR LA English DT Article DE Pre-exposure prophylaxis (PrEP); Antiretroviral therapy for prevention; ART; HIV prevention; MSM; Adherence ID HIV PREVENTION; ANTIRETROVIRAL PROPHYLAXIS; QUALITATIVE DESCRIPTION; DECISION-MAKING; INFECTION; ADHERENCE; BARRIERS; TRIAL; MEDICATION; THERAPY AB Existing trials of antiretroviral (ARV) medication as chemoprophylaxis against HIV reveal that the degree of protection is primarily dependent on product adherence. However, there is a lack of data on targets for behavioral interventions to improve adherence to ARV as prevention. Information from individuals who have used ARV as pre-exposure prophylaxis (PrEP) can inform behavioral intervention development. Thirty-nine HIV-uninfected MSM at high risk for HIV acquisition participated in one of four semi-structured focus groups. Two of the focus groups consisted of MSM who had been prescribed and used PrEP in the context of a clinical trial; the other two consisted of high-risk MSM who had not previously used PrEP. An in-depth, within-case/across-case content analysis resulted in six descriptive themes potentially salient for a PrEP adherence behavioral intervention: (1) motivations to use PrEP, (2) barriers to PrEP use, (3) facilitators to PrEP use, (4) sexual decision-making in the context of PrEP, (5) prospective PrEP education content, and, (6) perceived effective characteristics of PrEP delivery personnel. Addressing these themes in behavioral interventions in the context of prescribing PrEP may result in the optimal "packaging" public health programs that implement PrEP for high-risk MSM. C1 [Taylor, S. Wade; Mayer, Kenneth H.; Elsesser, Steven M.; Mimiaga, Matthew J.; O'Cleirigh, Conall; Safren, Steven A.] Fenway Hlth, Fenway Inst, Boston, MA 02215 USA. [Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis,Dept Med, Boston, MA 02215 USA. [Mimiaga, Matthew J.; O'Cleirigh, Conall; Safren, Steven A.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Mimiaga, Matthew J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Taylor, SW (reprint author), Fenway Hlth, Fenway Inst, Boston, MA 02215 USA. EM wtaylor@fenwayhealth.org NR 42 TC 11 Z9 11 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD MAY PY 2014 VL 18 IS 5 BP 871 EP 879 DI 10.1007/s10461-013-0617-7 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AF1TT UT WOS:000334497500009 ER PT J AU du Plessis, L Jacobson, JL Jacobson, SW Hess, AT van der Kouwe, A Avison, MJ Molteno, CD Stanton, ME Stanley, JA Peterson, BS Meintjes, EM AF du Plessis, Lindie Jacobson, Joseph L. Jacobson, Sandra W. Hess, Aaron T. van der Kouwe, Andre Avison, Malcolm J. Molteno, Christopher D. Stanton, Mark E. Stanley, Jeffrey A. Peterson, Bradley S. Meintjes, Ernesta M. TI An In Vivo 1 HMagnetic Resonance Spectroscopy Study of the Deep Cerebellar Nuclei in Children with Fetal Alcohol Spectrum Disorders SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Fetal Alcohol Spectrum Disorders; Prenatal Alcohol Exposure; Magnetic Resonance Spectroscopy; N-Acetylaspartate; Choline; Glutamate ID PRENATAL ALCOHOL; MAGNETIC-RESONANCE; HUMAN BRAIN; YOUNG-ADULTS; EXPOSURE; WATER; AGE; INDIVIDUALS; METABOLITES; INFANCY AB BackgroundPrenatal alcohol exposure has been linked to impairment in cerebellar structure and function, including eyeblink conditioning. The deep cerebellar nuclei, which play a critical role in cerebellar-mediated learning, receive extensive inputs from brain stem and cerebellar cortex and provide the point of origin for most of the output fibers to other regions of the brain. We used in vivo H-1 magnetic resonance spectroscopy (MRS) to examine effects of prenatal alcohol exposure on neurochemistry in this important cerebellar region. MethodsMRS data from the deep cerebellar nuclei were acquired from 37 children with heavy prenatal alcohol exposure and 17 non- or minimally exposed controls from the Cape Coloured (mixed ancestry) community in Cape Town, South Africa. ResultsIncreased maternal alcohol consumption around time of conception was associated with lower N-Acetylaspartate (NAA) levels in the deep nuclei (r=-0.33, p<0.05). Higher levels of alcohol consumption during pregnancy were related to lower levels of the choline-containing metabolites (r=-0.37, p<0.01), glycerophosphocholine plus phosphocholine (Cho). Alcohol consumption levels both at conception (r=0.35, p<0.01) and during pregnancy (r=0.38, p<0.01) were related to higher levels of glutamate plus glutamine (Glx). All these effects continued to be significant after controlling for potential confounders. ConclusionsThe lower NAA levels seen in relation to prenatal alcohol exposure may reflect impaired neuronal integrity in the deep cerebellar nuclei. Our finding of lower Cho points to disrupted Cho metabolism of membrane phospholipids, reflecting altered neuropil development with potentially reduced content of dendrites and synapses. The alcohol-related alterations in Glx may suggest a disruption of the glutamate-glutamine cycling involved in glutamatergic excitatory neurotransmission. C1 [du Plessis, Lindie; Hess, Aaron T.; Meintjes, Ernesta M.] Univ Cape Town, MRC UCT Med Imaging Res Unit, ZA-7925 Cape Town, South Africa. [du Plessis, Lindie; Jacobson, Joseph L.; Jacobson, Sandra W.; Hess, Aaron T.; Meintjes, Ernesta M.] Univ Cape Town, Dept Human Biol, ZA-7925 Cape Town, South Africa. [Jacobson, Joseph L.; Jacobson, Sandra W.; Molteno, Christopher D.] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa. [Jacobson, Joseph L.; Jacobson, Sandra W.; Stanley, Jeffrey A.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. [van der Kouwe, Andre] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [van der Kouwe, Andre] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Avison, Malcolm J.] Vanderbilt Univ, Inst Imaging Sci, Nashville, TN 37235 USA. [Stanton, Mark E.] Univ Delaware, Dept Psychol, Newark, DE USA. [Peterson, Bradley S.] Columbia Coll Phys & Surg, Div Child Psychiat, New York, NY USA. RP Meintjes, EM (reprint author), Univ Cape Town, Fac Hlth Sci, Dept Human Biol, ZA-7925 Observatory, South Africa. EM ernesta.meintjes@gmail.com OI Hess, Aaron/0000-0002-9289-5619 FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [R01 AA016781, R01 AA09524, U01 AA014790, R21AA017410, U24 AA014815]; NIAAA Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD); NIH Office of Research on Minority Health; South African Research Chairs Initiative of the Department of Science and Technology; National Research Foundation of South Africa; Focus Area Grant from the South African National Research Foundation [FA2005040800024]; University of Cape Town; Wayne State University; State of Michigan FX This research was funded by grants from the National Institute on Alcohol Abuse and Alcoholism (NIAAA): R01 AA016781 and an administrative supplement to R01 AA09524 (S. Jacobson, PI); U01 AA014790 (S. Jacobson, PI); R21AA017410 (E. Meintjes and A. van der Kouwe, PIs); and U24 AA014815 (K. Jones, PI) in conjunction with the NIAAA Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). This research was also supported by a grant from the NIH Office of Research on Minority Health, the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation of South Africa, Focus Area Grant FA2005040800024 from the South African National Research Foundation (E. Meintjes, PI), and seed money grants from the University of Cape Town, the President of Wayne State University, and the Joseph Young, Sr., Fund from the State of Michigan. We thank Bruce Spottiswoode, PhD, the CUBIC radiographers, Marie-Louise de Villiers and Nailah Maroof, and our UCT and WSU research staff, Maggie September, Mariska Pienaar, Nicolette Hamman, and Neil Dodge. We also thank the dysmorphologists, H. Eugene Hoyme, Luther K. Robinson, and Nathanial Khaole, who conducted the dysmorphology examinations of the children for the FASD diagnosis. We greatly appreciate the participation of the mothers and children in the longitudinal study. The authors declare no competing financial interests. NR 41 TC 10 Z9 10 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2014 VL 38 IS 5 BP 1330 EP 1338 DI 10.1111/acer.12380 PG 9 WC Substance Abuse SC Substance Abuse GA AF4BU UT WOS:000334657200018 PM 24655149 ER PT J AU Ananthakrishnan, AN Cagan, A Gainer, VS Cheng, SC Cai, T Szolovits, P Shaw, SY Churchill, S Karlson, EW Murphy, SN Kohane, I Liao, KP AF Ananthakrishnan, A. N. Cagan, A. Gainer, V. S. Cheng, S-C. Cai, T. Szolovits, P. Shaw, S. Y. Churchill, S. Karlson, E. W. Murphy, S. N. Kohane, I. Liao, K. P. TI Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ULCERATIVE-COLITIS; CROHNS-DISEASE; D LEVEL; CATHELICIDIN; DIARRHEA; OUTCOMES; PEPTIDE; HEALTH; IMPACT; HOSPITALIZATION AB Background Patients with inflammatory bowel diseases (IBD) have an increased risk of clostridium difficile infection (CDI). Cathelicidins are anti-microbial peptides that attenuate colitis and inhibit the effect of clostridial toxins. Plasma calcifediol [25(OH)D] stimulates production of cathelicidins. Aim To examine the association between plasma 25(OH)D and CDI in patients with IBD. Methods From a multi-institutional IBD cohort, we identified patients with at least one measured plasma 25(OH)D. Our primary outcome was development of CDI. Multivariate logistic regression models adjusting for potential confounders were used to identify independent effect of plasma 25(OH)D on risk of CDI. Results We studied 3188 IBD patients of whom 35 patients developed CDI. Patients with CDI-IBD were older and had greater co-morbidity. The mean plasma 25(OH)D level was significantly lower in patients who developed CDI (20.4ng/mL) compared to non-CDI-IBD patients (27.1ng/mL) (P=0.002). On multivariate analysis, each 1ng/mL increase in plasma 25(OH)D was associated with a 4% reduction in risk of CDI (OR 0.96, 95% CI 0.93-0.99, P=0.046). Compared to individuals with vitamin D >20ng/mL, patients with levels <20ng/mL were more likely to develop CDI (OR 2.27, 95% CI 1.16-4.44). The mean plasma 25(OH)D in patients with CDI who subsequently died was significantly lower (12.8 +/- 8.1ng/mL) compared to those who were alive at the end of follow-up (24.3 +/- 13.2ng/mL) (P=0.01). Conclusions Higher plasma calcifediol [25(OH)D] is associated with reduced risk of C. difficile infection in patients with IBD. Further studies of therapeutic supplementation of vitamin D in patients with inflammatory bowel disease and C. difficile infection may be warranted. C1 [Ananthakrishnan, A. N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ananthakrishnan, A. N.; Shaw, S. Y.; Karlson, E. W.; Murphy, S. N.; Kohane, I.; Liao, K. P.] Harvard Univ, Sch Med, Boston, MA USA. [Cagan, A.; Gainer, V. S.] Partners HealthCare, Res IS & Comp, Charlestown, MA USA. [Cheng, S-C.; Cai, T.; Murphy, S. N.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Szolovits, P.] MIT, Cambridge, MA 02139 USA. [Shaw, S. Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Churchill, S.; Kohane, I.] Brigham & Womens Hosp, Natl Ctr Biomed Comp I2b2, Boston, MA 02115 USA. [Karlson, E. W.; Liao, K. P.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Murphy, S. N.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Kohane, I.] Childrens Hosp, Boston, MA 02115 USA. RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM aananthakrishnan@partners.org OI Szolovits, Peter/0000-0001-8411-6403 FU NIH [U54-LM008748, K08 AR060257, K24 AR052403, P60 AR047782, R01 AR049880]; American Gastroenterological Association; US National Institutes of Health [K23 DK097142]; Harold and Duval Bowen Fund FX The study was supported by NIH U54-LM008748. A.N.A is supported by funding from the American Gastroenterological Association and from the US National Institutes of Health (K23 DK097142). K. P. L. is supported by NIH K08 AR060257 and the Harold and Duval Bowen Fund. E. W. K is supported by grants from the NIH (K24 AR052403, P60 AR047782, R01 AR049880). NR 46 TC 18 Z9 19 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD MAY PY 2014 VL 39 IS 10 BP 1136 EP 1142 DI 10.1111/apt.12706 PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA AE9DH UT WOS:000334304200011 PM 24641590 ER PT J AU Cicardi, M Aberer, W Banerji, A Bas, M Bernstein, JA Bork, K Caballero, T Farkas, H Grumach, A Kaplan, AP Riedl, MA Triggiani, M Zanichelli, A Zuraw, B AF Cicardi, M. Aberer, W. Banerji, A. Bas, M. Bernstein, J. A. Bork, K. Caballero, T. Farkas, H. Grumach, A. Kaplan, A. P. Riedl, M. A. Triggiani, M. Zanichelli, A. Zuraw, B. CA HAWK EAACI TI Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group SO ALLERGY LA English DT Review DE urticaria; dermatology; education; clinical immunology; angioedema ID C1 INHIBITOR DEFICIENCY; ACQUIRED C1-INHIBITOR DEFICIENCY; CONVERTING-ENZYME-INHIBITORS; IDIOPATHIC NONHISTAMINERGIC ANGIOEDEMA; BRADYKININ-MEDIATED ANGIOEDEMA; ANGIONEUROTIC-EDEMA; FACTOR-XII; ESTERASE INHIBITOR; ACUTE ATTACKS; TRANEXAMIC ACID AB Angioedema is defined as localized and self-limiting edema of the subcutaneous and submucosal tissue, due to a temporary increase in vascular permeability caused by the release of vasoactive mediator(s). When angioedema recurs without significant wheals, the patient should be diagnosed to have angioedema as a distinct disease. In the absence of accepted classification, different types of angioedema are not uniquely identified. For this reason, the European Academy of Allergy and Clinical Immunology gave its patronage to a consensus conference aimed at classifying angioedema. Four types of acquired and three types of hereditary angioedema were identified as separate forms from the analysis of the literature and were presented in detail at the meeting. Here, we summarize the analysis of the data and the resulting classification of angioedema. C1 [Cicardi, M.; Zanichelli, A.] Univ Milan, Luigi Sacco Hosp Milan, Dept Biomed & Clin Sci Luigi Sacco, I-20122 Milan, Italy. [Aberer, W.] Med Univ Graz, Dept Dermatol, Graz, Austria. [Banerji, A.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Bas, M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Otorhinolaryngol, D-80290 Munich, Germany. [Bernstein, J. A.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol,Allergy Sect, Cincinnati, OH USA. [Bork, K.] Johannes Gutenberg Univ Mainz, Dept Dermatol, D-55122 Mainz, Germany. [Caballero, T.] Hosp La Paz Inst Hlth Res IdiPaz, Biomed Res Network Rare Dis CIBERER U754, Dept Allergy, Madrid, Spain. [Farkas, H.] Semmelweis Univ, Natl Angioedema Ctr, Dept Internal Med 3, H-1085 Budapest, Hungary. [Grumach, A.] Fac Med ABC, Dept Clin Med, Sao Paulo, Brazil. [Kaplan, A. P.] Med Univ S Carolina, Charleston, SC 29425 USA. [Riedl, M. A.; Zuraw, B.] Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA. [Triggiani, M.] Univ Salerno, Dept Med, I-84100 Salerno, Italy. RP Cicardi, M (reprint author), Univ Milan, Luigi Sacco Hosp Milan, Dept Biomed & Clin Sci Luigi Sacco, I-20122 Milan, Italy. EM marco.cicardi@unimi.it RI Caballero, Teresa/H-6454-2014; Martin, Ludovic/K-2674-2015; IBIS, ALERGICAS/C-1733-2016; cicardi, marco/K-9219-2016; OI Caballero, Teresa/0000-0003-3005-9858; cicardi, marco/0000-0003-1251-225X; Guilarte, Mar/0000-0001-7242-9584; Grumach, Anete/0000-0002-9803-0309 FU Shire, CSL Behring; CSL Behring; Pharming; Shire; ViroPharma; Dyax; CSL; Santarus; Advisory Board; Shire HGT, Inc.Santarus; Isis FX fMC: Consultant for CSL Behring, Viropharma, Dyax, SOBI, Pharming, BioCryst, Sigma Tau; Research/educational grant from Shire, CSL Behring. WA: Advisor and speaker for CSL Behring, Shire, and ViroPharma; funding to attend conferences and other educational events from CSL Behring, Pharming, Shire, and ViroPharma; donations to his departmental fund and participated in clinical trials for Shire. AB: Clinical Research funding from Dyax, Shire, CSL, Viropharma, Santarus; Advisory Board: Dyax, Santarus, Shire. MB: Consultant for Shire. JAB: Principal Investigator, Consultant, and Speaker for: Viropharma, CSL Behring, Dyax, and Shire; Principal Investigator and Consultant for: Pharming; Editorial Board: Journal of Angioedema; Medical Advisory Board: HAEA organization. KB: Consultant for CSL Behring, Shire, and Viropharma. TC: Speaker fees from Shire HGT, Inc./Jerini AG, and ViroPharma; Consultancy fees from Shire HGT, Inc./Jerini AG, ViroPharma, and CSL Behring; Funding for travel and meeting attendance from CSL Behring and Shire HGT, Inc.; Has participated in clinical trials for Dyax, Pharming, CSL Behring, and Shire HGT, Inc./Jerini AG. AG: has served on Advisory Boards and as speaker for Shire. HF: Speaker Shire and Swedish Orphan Biovitrium; Consultant for CSL Behring, Pharming, Shire, Swedish Orphan Biovitrium, and Viropharma; Travel expenses from CSL Behring, Pharming, Shire, Swedish Orphan Biovitrium, and Viropharma. APK: Grant support from Dyax, Shire, CSL Behring, Viro Pharma; Consultant for Dyax, Genentech, BioCryst; Lecture Series: Robert Michael Educational Institute, Dyax. MAR: Research funding: CSL Behring, Dyax, Pharming, Shire, ViroPharma; Consultant: BioCryst, CSL Behring, Dyax, Isis, Santarus, Shire, ViroPharma; Speaker: CSL Behring, Dyax, Shire, ViroPharma. MT: research grant from CSL Behring, consultant for Shire, Viropharma, and SOBI. BZ: Research funding: Shire; Consultant: CSL Behring, Dyax, Isis, BioCryst; Speaker: Dyax, RMEI. NR 152 TC 124 Z9 127 U1 1 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-4538 EI 1398-9995 J9 ALLERGY JI Allergy PD MAY PY 2014 VL 69 IS 5 BP 602 EP 616 DI 10.1111/all.12380 PG 15 WC Allergy; Immunology SC Allergy; Immunology GA AE2QB UT WOS:000333816900007 PM 24673465 ER PT J AU Eisenberg, JD Gilmore, ME Kalra, MK Kong, CY Pandharipande, PV AF Eisenberg, Jonathan D. Gilmore, Michael E. Kalra, Mannudeep K. Kong, Chung Yin Pandharipande, Pari V. TI Prioritizing Examination-Centered Over Patient-Centered Dose Reduction: A Hazard of Institutional "Benchmarking" SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE benchmarking; dose reduction; patient centered; radiation ID RADIATION-INDUCED CANCER; ITERATIVE RECONSTRUCTION; COMPUTED-TOMOGRAPHY; QUALITY-ASSURANCE; PEDIATRIC CT; ABDOMINAL CT; EXPOSURE; RISK; ADULTS; SCANS AB OBJECTIVE. The purpose of this article is to evaluate whether examination-specific radiation dose metrics reliably measure an institution's success in reducing cancer risks. MATERIALS AND METHODS. We projected health benefits from dose-reduction programs in a hypothetical institution that sought to decrease exposures from abdominopelvic CT. Using modeling techniques to project radiation-induced cancer risks and tertiary center data to inform the institution's abdominopelvic CT age distribution, we compared a program in which effective doses were reduced equally (from 10 to 7 mSv) across all scans with programs in which dose reduction was age dependent. For each program, we projected lethal cancers averted, life expectancy gained, and average institutional dose achieved. Markov Chain Monte Carlo methods were used to estimate uncertainty in projections. RESULTS. The analysis's age distribution drew from 20,979 CT scans; 39% were from patients 65 years old and older. To illustrate trends yielded, if all patients in the hypothetical institution underwent 7-mSv (instead of 10-mSv) scans, we projected the maximum number of lethal cancers averted to be seven per 100,000 patients, and maximum life expectancy gained to be 0.26 days per patient, when averaged over the institution's population. When restricting dose reduction (from 10 to 7 mSv) to patients younger than 65 years, benefits were slightly lower (five lethal cancers averted per 100,000 patients and 0.22 days per patient gained); however, the average institutional dose was substantially higher (8.2 mSv). Although dose reduction in patients 65 years old and older accounted for only 16% of possible institutional life expectancy gains, this patient group contributed disproportionately (39%) to the institution's average dose. CONCLUSION. Institutional examination-specific dose metrics can be misleading, because the least-benefited patients may contribute disproportionately toward "improved" averages. C1 [Eisenberg, Jonathan D.; Gilmore, Michael E.; Kong, Chung Yin; Pandharipande, Pari V.] Massachusetts Gen Hosp, Inst Technol Assessment, Dept Radiol, Boston, MA 02114 USA. [Eisenberg, Jonathan D.; Gilmore, Michael E.; Kalra, Mannudeep K.; Kong, Chung Yin; Pandharipande, Pari V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Eisenberg, Jonathan D.] Univ Massachusetts, Sch Med, Boston, MA 02125 USA. [Kalra, Mannudeep K.; Kong, Chung Yin; Pandharipande, Pari V.] Harvard Univ, Sch Med, Boston, MA USA. RP Pandharipande, PV (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, Dept Radiol, 101 Merrimac St,10th Fl, Boston, MA 02114 USA. EM pari@mgh-ita.org FU Radiological Society of North America; National Cancer Institute [K07CA133097, K25CA133141]; Medical Imaging and Technology Alliance; GE FX This work was supported in part by a Radiological Society of North America medical student research grant (to J. D. Eisenberg) and by the National Cancer Institute (award numbers K07CA133097 to P. V. Pandharipande and K25CA133141 to C. Y. Kong). The research content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. P. V. Pandharipande receives research funding from the Medical Imaging and Technology Alliance for research that pertains to the use of CT but is otherwise unrelated. M. K. Kalra receives payment as a speaker in the GE Master Course on Radiation Dose (CME accredited). NR 53 TC 1 Z9 1 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2014 VL 202 IS 5 BP 1062 EP 1068 DI 10.2214/AJR.13.11235 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AF7VE UT WOS:000334922200032 PM 24758661 ER PT J AU Carter, BW Lichtenberger, JP Wu, CC AF Carter, Brett W. Lichtenberger, John P., III Wu, Carol C. TI Acquired Abnormalities of the Pulmonary Arteries SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE acquired abnormalities; CT; MDCT; pulmonary arteries ID ARTERIOVENOUS-MALFORMATIONS; RADIOGRAPHIC FINDINGS; CT; EMBOLISM; HYPERTENSION; ANGIOGRAPHY; DIAGNOSIS; ANEURYSMS; FEATURES; DISEASE C1 [Carter, Brett W.] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA. [Lichtenberger, John P., III] David Grant Med Ctr, Dept Radiol, Travis Afb, CA USA. [Wu, Carol C.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. RP Carter, BW (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, 1515 Holcombe Blvd,Unit 1478, Houston, TX 77030 USA. EM bcarter2@mdanderson.org NR 21 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2014 VL 202 IS 5 BP W415 EP W421 DI 10.2214/AJR.13.11760 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AF7VE UT WOS:000334922200001 PM 24758676 ER PT J AU Juan, YH Saboo, SS Tirumani, SH Khandelwal, A Shinagare, AB Ramaiya, N Krajewski, KM AF Juan, Yu-Hsiang Saboo, Sachin S. Tirumani, Sree Harsha Khandelwal, Ashish Shinagare, Atul B. Ramaiya, Nikhil Krajewski, Katherine M. TI Malignant Skin and Subcutaneous Neoplasms in Adults: Multimodality Imaging With CT, MRI, and F-18-FDG PET/CT SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE CT; cutaneous and subcutaneous malignancies; FDG PET/CT; MRI; skin ID T-CELL LYMPHOMA; POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE FINDINGS; PRIMARY CUTANEOUS LYMPHOMAS; WHO-EORTC CLASSIFICATION; DERMATOFIBROSARCOMA PROTUBERANS; SOFT-TISSUE; FDG-PET/CT; COMPUTED-TOMOGRAPHY; PATHOLOGICAL CORRELATION AB OBJECTIVE. The purpose of this article is to enlighten radiologists with the clinical presentation, multimodality imaging features, local recurrence, distant spread, differential diagnosis, and prognosis of skin and subcutaneous malignancies. CONCLUSION. Cutaneous and subcutaneous malignancies represent the most common type of cancer and frequently present with overlapping imaging appearances. CT, MRI, and F-18-FDG PET/CT are commonly used for staging, preoperative planning, and posttreatment assessment. Knowledge of the multimodality imaging features can narrow down the differential diagnosis and elucidate their metastatic pattern. C1 [Juan, Yu-Hsiang; Saboo, Sachin S.; Tirumani, Sree Harsha; Khandelwal, Ashish; Shinagare, Atul B.; Ramaiya, Nikhil; Krajewski, Katherine M.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Juan, Yu-Hsiang; Saboo, Sachin S.; Tirumani, Sree Harsha; Khandelwal, Ashish; Shinagare, Atul B.; Ramaiya, Nikhil; Krajewski, Katherine M.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Juan, Yu-Hsiang] Linkou & Chang Gung Univ, Chang Gung Mem Hosp, Dept Med Imaging & Intervent, Taoyuan, Taiwan. [Tirumani, Sree Harsha; Krajewski, Katherine M.] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA. RP Saboo, SS (reprint author), Brigham & Womens Hosp, Dept Radiol, L1,ASB 1,75 Francis St, Boston, MA 02115 USA. EM ssaboo@partners.org NR 102 TC 1 Z9 1 U1 0 U2 5 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2014 VL 202 IS 5 BP W422 EP W438 DI 10.2214/AJR.13.11424 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AF7VE UT WOS:000334922200002 PM 24758677 ER PT J AU Staats, PN McCluggage, WG Clement, PB Young, RH AF Staats, Paul N. McCluggage, W. Glenn Clement, Philip B. Young, Robert H. TI Primary Intestinal-type Glandular Lesions of the Vagina Clinical, Pathologic, and Immunohistochemical Features of 14 Cases Ranging From Benign Polyp to Adenoma to Adenocarcinoma SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE adenoma; adenocarcinoma; intestinal; vagina; polyp ID OF-THE-LITERATURE; PRIMARY MUCINOUS ADENOCARCINOMA; TUBULOVILLOUS ADENOMA; VILLOGLANDULAR ADENOCARCINOMA; CLOACOGENIC ORIGIN; VILLOUS-ADENOMA; VULVA; EPITHELIUM AB Primary intestinal-type glandular lesions of the vagina are rare. We report a series of 14 lesions, including 1 intestinal-type polyp without neoplastic features, 3 adenomas (2 with high-grade dysplasia), and 10 adenocarcinomas. Patients ranged in age from 20 to 86 years (mean 60 y) and presented with vaginal bleeding or a mass. No history of diethylstilbestrol exposure, adenosis, or endometriosis was elicited in any patient. The lesions were mostly polypoid, small (0.8 to 2.0 cm), and located in the posterior (6 cases) and lower (7 cases) vagina. One carcinoma metastasized to a para-aortic lymph node; the others were confined to the vagina. The neoplasms exhibited histologic features identical to those seen in primary large intestinal tumors, including variable numbers of goblet cells and in 1 case neuroendocrine cells. Five of the adenocarcinomas contained areas consistent with a precursor adenoma. In 3 cases, a benign urothelium-lined duct was adjacent to the lesion, and in 2 patients benign intestinal-type epithelium was present; no other potential benign precursor lesions were seen. Immunohistochemical analysis was performed on 6 cases; the tumors were positive for CDX-2 (6/6), CK20 (5/6), CEA (5/5), CK7 (4/6), and CA-125 (2/4) and were negative for ER (0/6) and p16 (0/2). Clinical outcome data were available in 3 patients with adenocarcinomas; 1 died of disease in < 1 year, and 2 were alive with no evidence of disease at 2 and 7 years. The pertinent literature is reviewed, and the potential origin and differential diagnosis of these lesions are discussed. C1 [Staats, Paul N.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA. [Young, Robert H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA USA. [McCluggage, W. Glenn] Royal Grp Hosp Trust, Dept Pathol, Belfast, Antrim, North Ireland. [Clement, Philip B.] Univ British Columbia, Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada. RP Staats, PN (reprint author), Univ Maryland, Sch Med, Dept Pathol, 22 South Greene St, Baltimore, MD 21201 USA. EM pstaats@umm.edu NR 36 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD MAY PY 2014 VL 38 IS 5 BP 593 EP 603 DI 10.1097/PAS.0000000000000157 PG 11 WC Pathology; Surgery SC Pathology; Surgery GA AF7ZG UT WOS:000334933700002 PM 24722061 ER PT J AU Kao, CS Ulbright, TM Young, RH Idrees, MT AF Kao, Chia-Sui Ulbright, Thomas M. Young, Robert H. Idrees, Muhammad T. TI Testicular Embryonal Carcinoma A Morphologic Study of 180 Cases Highlighting Unusual and Unemphasized Aspects SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE patterns; differential diagnosis; testis; embryonal carcinoma; morphology ID GERM-CELL TUMORS; YOLK-SAC TUMOR; PROGNOSTIC RISK-FACTORS; CLINICAL STAGE; TUNICA VAGINALIS; SURVEILLANCE PROTOCOL; PATHOLOGICAL STAGE; IDENTIFY PATIENTS; DIFFUSE EMBRYOMA; FOLLOW-UP AB A total of 180 consecutive testicular cancers containing a component of embryonal carcinoma (EC) were reviewed to assess the morphologic features of the EC component. EC mostly (84%) occurred as a component of a mixed germ cell tumor, but 16% were pure. Solid (55%), glandular (17%), and papillary (11%) were the most common primary patterns (predominant architectural pattern occupying at least 50%), whereas other less common primary patterns included nested (3%), micropapillary (2%), anastomosing glandular (1%), sieve-like glandular (< 1%), pseudopapillary (< 1%), and blastocyst-like (< 1%). Occasionally, EC developed predominantly in the context of polyembryoma-like (6%) and diffuse embryoma-like ("necklace" pattern) (3%) proliferations. In all, 69% had secondary architectural patterns, the most frequent being glandular (31%), papillary (14%), and solid (12%). An applique appearance, in which smudged and degenerate-appearing EC cells appear "applied" to the tumor periphery, was common (67%). EC cells with clear cytoplasm and distinct cell membranes (seminoma-like) were present in 11%, and dense lymphocytic infiltration and granulomatous inflammation were seen in 7% and 3%, respectively. Features simulating yolk sac tumor and teratoma were also seen: pseudoendodermal sinuses (34%), columnar cells (20%), and secretory-type subnuclear cytoplasmic vacuoles (6%). Syncytiotrophoblast cells were frequent (46%). Intratubular EC, typically partly necrotic and calcified, occurred in 24%. The associated stroma was more often non-neoplastic (53%) than neoplastic (29%). The rarity of some poorly characterized patterns of EC (micropapillary, blastocyst-like, anastomosing glandular, and sieve-like glandular) and some that overlap with those of other germ cell tumors, as well as some uncommon cytologic features, may result in misinterpretation, potentially impacting management. The association with other more common patterns and typical cytologic features, together with simple awareness of these variant morphologies, are helpful in establishing an accurate diagnosis of EC. C1 [Kao, Chia-Sui; Ulbright, Thomas M.; Idrees, Muhammad T.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46020 USA. [Young, Robert H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Lab, Boston, MA USA. RP Idrees, MT (reprint author), Indiana Univ Sch Med, Dept Pathol, 350 West 11th St, Indianapolis, IN 46020 USA. EM midrees@iupui.edu NR 65 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD MAY PY 2014 VL 38 IS 5 BP 689 EP 697 DI 10.1097/PAS.0000000000000171 PG 9 WC Pathology; Surgery SC Pathology; Surgery GA AF7ZG UT WOS:000334933700013 PM 24503753 ER PT J AU Misdraji, J Lauwers, GY Irving, JA Batts, KP Young, RH AF Misdraji, Joseph Lauwers, Gregory Y. Irving, Julie A. Batts, Kenneth P. Young, Robert H. TI Appendiceal or Cecal Endometriosis With Intestinal Metaplasia A Potential Mimic of Appendiceal Mucinous Neoplasms SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE mucinous adenocarcinoma; low-grade appendiceal mucinous neoplasm; endometriosis; cecum; appendix; intestinal metaplasia ID INTUSSUSCEPTION; COLONIZATION; MUCOCELE; TRACT; PERFORATION; CARCINOMA; PREGNANCY; SECONDARY; DISEASE; MUCOSA AB Appendiceal or cecal endometriosis uncommonly presents diagnostic challenges, but rare cases with intestinal metaplasia can mimic mucinous tumors of the appendix. We describe 6 cases of appendiceal or cecal endometriosis with intestinal metaplasia that grossly and microscopically mimicked appendiceal mucinous tumors. The cases were characterized by marked mural hypertrophy and elastosis, with distortion of the appendix, and virtual obliteration of the lumen of the appendix. All cases had conventional endometriosis, together with varying amounts of endometriosis with intestinal-type epithelium. In 2 cases, scant or virtually no stroma around some mucin-filled glands made their recognition as endometriosis more difficult. None of the cases had dysplasia of the mucinous epithelium. All patients had benign follow-up (mean 3.6 y). Endometriosis with intestinal metaplasia is a rare phenomenon that, when it occurs in the appendix or cecum, may lead to misdiagnosis as a low-grade appendiceal mucinous neoplasm or mucinous carcinoma. C1 [Misdraji, Joseph; Lauwers, Gregory Y.; Young, Robert H.] Harvard Univ, Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Sch Med, Boston, MA USA. [Batts, Kenneth P.] Virginia Piper Canc Inst, Hosp Pathol Associates, Minneapolis, MN USA. [Irving, Julie A.] Univ British Columbia, Dept Pathol, Vancouver, BC V5Z 1M9, Canada. RP Misdraji, J (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren Bldg, Boston, MA 02114 USA. EM jmisdraji@partners.org NR 34 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD MAY PY 2014 VL 38 IS 5 BP 698 EP 705 DI 10.1097/PAS.0000000000000167 PG 8 WC Pathology; Surgery SC Pathology; Surgery GA AF7ZG UT WOS:000334933700014 PM 24451279 ER PT J AU Kuhlen, J Guyer, A Morphew, T Tachdjian, R Banerji, A AF Kuhlen, James Guyer, Autumn Morphew, Tricia Tachdjian, Raffi Banerji, Aleena TI Assessment of home infusion program for treating nonlaryngeal hereditary angioedema attacks SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Letter C1 [Kuhlen, James; Banerji, Aleena] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Guyer, Autumn] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Morphew, Tricia] Childrens Hosp Orange Cty, Orange Cove, FL USA. [Tachdjian, Raffi] Ronald Reagan UCLA Med Ctr, Santa Monica, CA USA. RP Kuhlen, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM jkuhlen@partners.org NR 8 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 EI 1534-4436 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD MAY PY 2014 VL 112 IS 5 BP 471 EP 472 DI 10.1016/j.anai.2014.02.004 PG 2 WC Allergy; Immunology SC Allergy; Immunology GA AF5PC UT WOS:000334764400013 PM 24630437 ER PT J AU Egede, LE Gebregziabher, M Echols, C Lynch, CP AF Egede, Leonard E. Gebregziabher, Mulugeta Echols, Carrae Lynch, Cheryl P. TI Longitudinal Effects of Medication Nonadherence on Glycemic Control SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE databases; type 2 diabetes; epidemiology; outcomes research/analysis ID OF-VETERANS-AFFAIRS; DIABETES-MELLITUS; CLAIMS DATA; ADHERENCE; OUTCOMES; CARE; HOSPITALIZATION; INTERVENTIONS; MANAGEMENT; PROGRAM AB Background: Medication nonadherence is known to worsen glycemic control. Few studies have examined this relationship over several years. Objective: The aim of this study was to examine the longitudinal effect of medication nonadherence on glycennic control among a large cohort of veterans. Methods: Analysis was performed on a cohort of II 272 veterans with type 2 diabetes followed from April 1994 to May 2006. The primary outcome measures were mean glycosylated hemoglobin A 1 c (A 1 C) and proportion in poor control (A 1 C > 8%) over time. The main predictor was medication nonadherence based on medication possession ratio (MPR). Other covariates included sociodemographics and ICD-9 coded medical and psychiatric comorbidities. Generalized linear mixed models (GLMMs) were used to assess the relationship between MPR and A 1 C after adjusting for covariates. Results: Mean follow-up was 5.4 years. In the linear mixed model, after adjusting for baseline A 1 C and other confounding variables, mean A 1 C decreased by 0.24 (P < 0.001) for each 10% increase in MPR (95% Cl = -0.27, -0.21). In the fully adjusted GLMM, each percentage increase in MPR was associated with a 48% lower likelihood of having poor glycemic control (odds ratio = 0.52; 95% Cl = 0.4, 0.6). In both continuous and dichotomized A 1 C analyses, average A 1 C showed a decreasing trend over the study period (P < 0.001). Conclusions: In patients with type 2 diabetes, glycemic control worsens over time in the presence of medication nonadherence. Future studies need to take into account the complexity of patient-and system-level factors affecting long-term medication adherence to improve diabetes-related outcomes. C1 [Egede, Leonard E.; Lynch, Cheryl P.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Egede, Leonard E.; Gebregziabher, Mulugeta; Lynch, Cheryl P.] Med Univ S Carolina, Charleston, SC 29425 USA. [Echols, Carrae] US Dept Labor, Washington, DC 20210 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU Center for Disease Prevention and Health Interventions for Diverse Populations [REA 08-261]; Veterans Health Affairs Health Services Research and Development FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Grant No. REA 08-261, Center for Disease Prevention and Health Interventions for Diverse Populations funded by Veterans Health Affairs Health Services Research and Development (PI: Leonard E. Egede). NR 30 TC 10 Z9 11 U1 0 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD MAY PY 2014 VL 48 IS 5 BP 562 EP 570 DI 10.1177/1060028014526362 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AF1NF UT WOS:000334479900001 PM 24586059 ER PT J AU Zeidler, KR Berkowitz, RL Chun, YS Alizadeh, K Castle, J Colwell, AS Desai, AR Evans, G Hollenbeck, S Johnson, DJ Morris, D Ascherman, JA AF Zeidler, Kamakshi R. Berkowitz, R. Laurence Chun, Yoon S. Alizadeh, Kaveh Castle, John Colwell, Amy S. Desai, Ankit R. Evans, Gregory Hollenbeck, Scott Johnson, Debra J. Morris, Donald Ascherman, Jeffrey A. TI AeroForm Patient Controlled Tissue Expansion and Saline Tissue Expansion for Breast Reconstruction A Randomized Controlled Trial SO ANNALS OF PLASTIC SURGERY LA English DT Article DE breast reconstruction; carbon dioxide tissue expander; saline tissue expander; breast tissue expansion; BRCA2; breast cancer; mastectomy; BRCA1 ID CANCER AB Background Prosthetic reconstruction of the breast, as a 2-staged procedure using tissue expanders followed by placement of permanent implants, offers favorable aesthetic results with minimal additional surgical intervention. However, the current outpatient process to fill saline expanders can be lengthy and onerous, involving months of office visits and discomfort from the bolus saline expansions. We present a new technology (AeroForm Tissue Expansion System), which has the potential to improve the process of breast tissue expansion by providing a method for low-volume incremental filling, eliminating the need for injections and directly involving the patient by allowing her some control over the expansion process. Methods The described study is a 2:1 randomized controlled trial of the investigational CO2 expansion system and saline expanders. Of the 82 women receiving expanders, 58 (39 bilateral and 19 unilateral; bilateral rate, 67%) were implanted with CO2 tissue expanders and 24 subjects (15 bilateral and 9 unilateral; bilateral rate, 63%) were implanted with saline expanders. Results Preliminary validated expansion results were available for 55 women. Available mean time for active expansion in the CO2 group was 18.2 (9.2) days (median, 14.0; range, 5-39; number of expanders, 53), which was less than the mean time for active expansion in the saline group: 57.4 (33.6) days (median, 55; range, 5-137; number of expanders, 33). Available mean time from implant placement to exchange for a permanent prosthesis in the CO2 group was shorter [106.3 (42.9) days; median, 99; range, 42-237; number of expanders, 53] than for the women in the control group [151.7 (62.6) days; median, 140; range, 69-433; number of expanders, 33]. After 2 events-underexpansion (n = 1) and erosion (n = 1)-in the CO2 group, the internal membrane was redesigned and the expander bulk was decreased to minimize the risk of underexpansion and erosion in subsequent patients. Conclusions Preliminary evidence indicates that the CO2-based tissue expansion system performs the same function as saline expansion devices without significantly altering the risk to the patient and that the device has the potential to make the expansion process faster and more convenient for both the patient and the physician. C1 [Zeidler, Kamakshi R.; Berkowitz, R. Laurence] Aesthet & Plast & Reconstruct Surg, Campbell, CA 95008 USA. [Chun, Yoon S.] Harvard Univ, Sch Med, Brigham & Womens Faulkner Hosp, Boston, MA USA. [Alizadeh, Kaveh] Long Isl Plast Surg Grp, Garden City, NY USA. [Castle, John] Univ Massachusetts, Div Plast Surg, Mem Med Ctr, Worcester, MA 01605 USA. [Colwell, Amy S.] Massachusetts Gen Hosp, Div Plast Surg, Boston, MA 02114 USA. [Desai, Ankit R.] Desai Ctr Plast & Reconstruct Surg, Jacksonville, FL USA. [Evans, Gregory] Univ Calif Irvine Med Ctr, Aesthet & Plast Surg Inst, Orange, CA USA. [Hollenbeck, Scott] Duke Univ, Med Ctr, Div Plast & Reconstruct Surg, Durham, NC USA. [Johnson, Debra J.] Sutter Community Hosp, Plast Surg Ctr, Sacramento, CA USA. [Morris, Donald] Beth Israel Deaconess Med Ctr, Brookline, MA USA. [Ascherman, Jeffrey A.] Columbia Univ, Dept Surg, Div Plast Surg, Presbyterian Med Ctr, New York, NY USA. RP Zeidler, KR (reprint author), Aesthet & Plast & Reconstruct Surg, 3803 S Bascom Ave,Suite 100, Campbell, CA 95008 USA. EM Kamakshi.zeidler@gmail.com FU AirXpanders, Inc, Palo Alto, CA FX Supported by AirXpanders, Inc, Palo Alto, CA, in terms of associated materials, data collection, monitoring, administrative costs and research, writing, and editorial support. NR 10 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-7043 EI 1536-3708 J9 ANN PLAS SURG JI Ann. Plast. Surg. PD MAY PY 2014 VL 72 SU 1 BP S51 EP S55 DI 10.1097/SAP.0000000000000175 PG 5 WC Surgery SC Surgery GA AF7XR UT WOS:000334929300013 PM 24740025 ER PT J AU Jacobson, CA Sun, LX Kim, HT McDonough, SM Reynolds, CG Schowalter, M Koreth, J Cutler, CS Ho, VT Alyea, EP Armand, P Blazar, BR Soiffer, RJ Antin, JH Ritz, J Sarantopoulos, S AF Jacobson, Caron A. Sun, Lixian Kim, Haesook T. McDonough, Sean M. Reynolds, Carol G. Schowalter, Michael Koreth, John Cutler, Corey S. Ho, Vincent T. Alyea, Edwin P. Armand, Philippe Blazar, Bruce R. Soiffer, Robert J. Antin, Joseph H. Ritz, Jerome Sarantopoulos, Stefanie TI Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Chronic graft-versus-host disease; B cell activating factor; B cell ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; UMBILICAL-CORD BLOOD; LYMPHOCYTE STIMULATOR; BONE-MARROW; MYELOID CELLS; CHRONIC GVHD; EXCESS BAFF; TRANSPLANTATION; INTENSITY; HOMEOSTASIS AB Excessive levels of B cell activating factor (BAFF) are found in patients with active chronic graft-versus-host disease (cGVHD). In mice, BAFF has been shown to be essential for B cell recovery after myeloablation. To assess how BAFF levels relate to transplantation factors and subsequent development of cGVHD, we prospectively monitored 412 patients in the first year after allogeneic peripheral blood or bone marrow hematopoietic stem cell transplantation (HSCT) and censored data at time of cGVHD onset. In patients who did not develop cGVHD, we affirmed a temporal pattern of gradually decreasing BAFF levels as B cell numbers increase after myeloablative conditioning. In contrast, after reduced-intensity conditioning, BAFF levels remained high throughout the first post-HSCT year, suggesting that the degree of myeloablation resulted in delayed B cell recovery associated with persistence of higher BAFF levels. Given that high BAFF/B cell ratios have been associated with active cGVHD, we examined differences in early BAFF/B cell ratios and found significantly different BAFF/B cell ratios at 3 months post-HSCT only after myeloablative conditioning in patients who subsequently developed cGVHD. In addition to HSCT conditioning type, the use of sirolimus was significantly associated with higher BAFF levels after HSCT, and this also was potentially related to lower B cell numbers. Taken together, our results are important for interpreting BAFF measurements in cGVHD biomarker studies. (c) 2014 American Society for Blood and Marrow Transplantation. C1 [Jacobson, Caron A.; McDonough, Sean M.; Reynolds, Carol G.; Schowalter, Michael; Koreth, John; Cutler, Corey S.; Ho, Vincent T.; Alyea, Edwin P.; Armand, Philippe; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Sun, Lixian; Kim, Haesook T.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Blazar, Bruce R.] Univ Minnesota, Div Blood & Marrow Transplantat, Minneapolis, MN USA. [Sarantopoulos, Stefanie] Duke Univ, Med Ctr, Durham, NC 27710 USA. [Sarantopoulos, Stefanie] Duke Canc Inst, Durham, NC USA. RP Sarantopoulos, S (reprint author), Duke Univ, Med Ctr, 2400 Pratt St,Suite 9000, Durham, NC 27710 USA. EM stefanie.sarantopoulos@duke.edu OI Ritz, Jerome/0000-0001-5526-4669 FU National Institues of Health [P01 CA142106, K08 HL107756]; Dunkin' Donuts Rising Stars Program; Triad Golfers Against Cancer; Jock and Bunny Adams Research and Education Endowment; Ted and Eileen Pasquarello Research Fund FX This study was supported by National Institues of Health grants P01 CA142106 and K08 HL107756, the Dunkin' Donuts Rising Stars Program, the Triad Golfers Against Cancer, the Jock and Bunny Adams Research and Education Endowment, and the Ted and Eileen Pasquarello Research Fund. NR 42 TC 14 Z9 16 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD MAY PY 2014 VL 20 IS 5 BP 668 EP 675 DI 10.1016/j.bbmt.2014.01.021 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AF3YQ UT WOS:000334649000011 PM 24462743 ER PT J AU Yeh, AC Brunner, AM Spitzer, TR Chen, YB Coughlin, E McAfee, S Ballen, K Attar, E Caron, M Preffer, FI Yeap, BY Dey, BR AF Yeh, Albert C. Brunner, Andrew M. Spitzer, Thomas R. Chen, Yi-Bin Coughlin, Erin McAfee, Steven Ballen, Karen Attar, Eyal Caron, Martin Preffer, Frederic I. Yeap, Beow Y. Dey, Bimalangshu R. TI Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE GVHD; Urate oxidase; Allogeneic transplant ID BONE-MARROW-TRANSPLANTATION; RISK-FACTORS; LEUKEMIA; LYMPHOMA AB Graft-versus-host disease (GVHD) is a donor T cell driven response against host tissue that can complicate allogeneic hematopoietic stem cell transplantation (HSCT). During acute GVHD, endogenous adjuvants such as uric acid are released by damaged host tissue, activating alloreactive donor T cells. A phase I study was conducted at the Massachusetts General Hospital between 2007 and 2010 to test the hypothesis that reduction of uric acid levels during allogeneic HSCT can modulate the development of acute GVHD. Twenty-one patients with hematologic malignancies in complete remission undergoing myeloablative peripheral blood HSCT received recombinant urate oxidase at .20 mg/kg for 5 consecutive days during conditioning. Results were compared with all patients who underwent allogeneic HSCT at our institution during the same time period who met the same inclusion and exclusion criteria but were not enrolled in the study. The only major adverse event was a case of hemolytic anemia in a patient who had glucose-6-phosphate dehydrogenase deficiency. Primary outcome was the cumulative incidence of grades II to IV acute GVHD, which was significantly decreased in the treatment group in the intention-to-treat analysis (57% [12/21] versus 24% [5/21], P=.036) and in the per-protocol analysis (P=.017). Patients who developed acute GVHD had a higher level of serum uric acid during the pretransplantation period compared with those who did not (P<.001). There was no difference in disease-free or overall survival. Our study suggests that urate oxidase can be safely administered during myeloablative conditioning and may reduce the incidence of acute GVHD. (C) 2014 American Society for Blood and Marrow Transplantation. C1 [Yeh, Albert C.; Brunner, Andrew M.; Spitzer, Thomas R.; Chen, Yi-Bin; Coughlin, Erin; McAfee, Steven; Ballen, Karen; Attar, Eyal; Caron, Martin; Yeap, Beow Y.; Dey, Bimalangshu R.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. [Preffer, Frederic I.] Massachusetts Gen Hosp, Hematol Oncol Infus Unit, Boston, MA 02114 USA. RP Dey, BR (reprint author), Massachusetts Gen Hosp, Hematol Oncol Infus Unit, 100 Blossom St, Boston, MA 02114 USA. EM bdey@partners.org NR 14 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD MAY PY 2014 VL 20 IS 5 BP 730 EP 734 DI 10.1016/j.bbmt.2014.02.003 PG 5 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AF3YQ UT WOS:000334649000019 PM 24530972 ER PT J AU Sjostrom, M Hartman, L Grabau, D Fornander, T Malmstrom, P Nordenskjold, B Sgroi, DC Skoog, L Stal, O Leeb-Lundberg, LMF Ferno, M AF Sjostrom, Martin Hartman, Linda Grabau, Dorthe Fornander, Tommy Malmstrom, Per Nordenskjold, Bo Sgroi, Dennis C. Skoog, Lambert Stal, Olle Leeb-Lundberg, L. M. Fredrik Ferno, Marten TI Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE G protein-coupled estrogen receptor; GPR30; Breast cancer; Tamoxifen; Estrogen; Prognosis ID OVARIAN-CANCER; ADJUVANT TAMOXIFEN; STOCKHOLM TRIAL; GPR30; CELLS; SURVIVAL; GROWTH; EXPRESSION; G-PROTEIN-COUPLED-RECEPTOR-30; PROLIFERATION AB G protein-coupled estrogen receptor (GPER), or GPR30, is a membrane receptor reported to mediate non-genomic estrogen responses. Tamoxifen is a partial agonist at GPER in vitro. Here, we investigated if GPER expression is prognostic in primary breast cancer, if the receptor is treatment-predictive for adjuvant tamoxifen, and if receptor subcellular localization has any impact on the prognostic value. Total and plasma membrane (PM) GPER expression was analyzed by immunohistochemistry in breast tumors from 742 postmenopausal lymph node-negative patients subsequently randomized for tamoxifen treatment for 2-5 years versus no systemic treatment, regardless of estrogen receptor (ER) status, and with a median follow-up of 17 years for patients free of event. PM GPER expression was a strong independent prognostic factor for poor prognosis in breast cancer without treatment-predictive information for tamoxifen. In the tamoxifen-treated ER-positive and progesterone receptor (PgR)-positive patient subgroup, the absence of PM GPER (53 % of all ER-positive tumors) predicted 91 % 20-year distant disease-free survival, compared to 73 % in the presence of GPER (p = 0.001). Total GPER expression showed positive correlations with ER and PgR and negative correlation with histological grade, but the correlations were biphasic. On the other hand, PM GPER expression showed strong negative correlations with ER and PgR, and strong positive correlation with HER2 overexpression and high histological grade. GPER overexpression and PM localization are critical events in breast cancer progression, and lack of GPER in the PM is associated with excellent long-term prognosis in ER-positive and PgR-positive tamoxifen-treated primary breast cancer. C1 [Sjostrom, Martin; Hartman, Linda; Malmstrom, Per; Ferno, Marten] Lund Univ, Dept Clin Sci, Div Oncol, Lund, Sweden. [Hartman, Linda] Reg Canc Ctr South, Lund, Sweden. [Grabau, Dorthe] Lund Univ, Dept Clin Sci, Div Pathol, Lund, Sweden. [Fornander, Tommy] Karolinska Univ Hosp, Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden. [Malmstrom, Per] Skane Univ Hosp, Skane Dept Oncol, Lund, Sweden. [Nordenskjold, Bo; Stal, Olle] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Oncol, Linkoping, Sweden. [Sgroi, Dennis C.] Massachusetts Gen Hosp, Dept Pathol, Mol Pathol Res Unit, Boston, MA 02114 USA. [Skoog, Lambert] Karolinska Univ Hosp, Karolinska Inst, Dept Pathol, Stockholm, Sweden. [Leeb-Lundberg, L. M. Fredrik] Lund Univ, Dept Expt Med Sci, Lund, Sweden. RP Leeb-Lundberg, LMF (reprint author), Lund Univ, Dept Expt Med Sci, Lund, Sweden. EM fredrik.leeb-lundberg@med.lu.se OI Sjostrom, Martin/0000-0002-2629-9966 FU Swedish Cancer Foundation; Swedish Research Council; Gunnar; Arvid; Elisabeth Nilsson Foundation; Mrs. Berta Kamprad Foundation; University Hospital of Lund Research Foundation; Anna and Edwin Bergers Foundation; Skane County Council's Research and Development Foundation; Clinical Research within the National Health Service; Stockholm Cancer Society; King Gustaf V's Jubilee Foundation FX We are indebted to the participating departments of the Stockholm-Gotland Breast Cancer group. We thank Birgitta Holmlund and Kristina Lovgren for excellent technical assistance. We also thank the BioCare strategic research school for providing an excellent research environment. The study was supported by funds from the Swedish Cancer Foundation, Swedish Research Council, Gunnar, Arvid, and Elisabeth Nilsson Foundation, Mrs. Berta Kamprad Foundation, The University Hospital of Lund Research Foundation, Anna and Edwin Bergers Foundation, Skane County Council's Research and Development Foundation, and Governmental Funding of Clinical Research within the National Health Service, The Stockholm Cancer Society, and King Gustaf V's Jubilee Foundation. NR 44 TC 14 Z9 17 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD MAY PY 2014 VL 145 IS 1 BP 61 EP 71 DI 10.1007/s10549-014-2936-4 PG 11 WC Oncology SC Oncology GA AF2CE UT WOS:000334519400006 PM 24715381 ER PT J AU Hill, DA Horick, NK Isaacs, C Domchek, SM Tomlinson, GE Lowery, JT Kinney, AY Berg, JS Edwards, KL Moorman, PG Plon, SE Strong, LC Ziogas, A Griffin, CA Kasten, CH Finkelstein, DM AF Hill, Deirdre A. Horick, Nora K. Isaacs, Claudine Domchek, Susan M. Tomlinson, Gail E. Lowery, Jan T. Kinney, Anita Y. Berg, Jonathan S. Edwards, Karen L. Moorman, Patricia G. Plon, Sharon E. Strong, Louise C. Ziogas, Argyrois Griffin, Constance A. Kasten, Carol H. Finkelstein, Dianne M. TI Long-term risk of medical conditions associated with breast cancer treatment SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Breast neoplasms; Lymphedema; Osteoporosis; Heart disease; Chemotherapy; Radiotherapy ID BONE-MINERAL DENSITY; HEART-FAILURE; ADJUVANT CHEMOTHERAPY; POSTMENOPAUSAL WOMEN; PROSPECTIVE COHORT; LYMPHEDEMA; TAMOXIFEN; SURVIVORS; RADIOTHERAPY; MORTALITY AB Early and late effects of cancer treatment are of increasing concern with growing survivor populations, but relevant data are sparse. We sought to determine the prevalence and hazard ratio of such effects in breast cancer cases. Women with invasive breast cancer and women with no cancer history recruited for a cancer research cohort completed a mailed questionnaire at a median of 10 years post-diagnosis or matched reference year (for the women without cancer). Reported medical conditions including lymphedema, osteopenia, osteoporosis, and heart disease (congestive heart failure, myocardial infarction, coronary heart disease) were assessed in relation to breast cancer therapy and time since diagnosis using Cox regression. The proportion of women currently receiving treatment for these conditions was calculated. Study participants included 2,535 women with breast cancer and 2,428 women without cancer (response rates 66.0 % and 50.4 %, respectively) Women with breast cancer had an increased risk of lymphedema (Hazard ratio (HR) 8.6; 95 % confidence interval (CI) 6.3-11.6), osteopenia (HR 2.1; 95 % CI 1.8-2.4), and osteoporosis (HR 1.5; 95 % CI 1.2-1.9) but not heart disease, compared to women without cancer Hazard ratios varied by treatment and time since diagnosis. Overall, 49.3 % of breast cancer cases reported at least one medical condition, and at 10 or more years post-diagnosis, 37.7 % were currently receiving condition-related treatment. Responses from survivors a decade following cancer diagnosis demonstrate substantial treatment-related morbidity, and emphasize the need for continued medical surveillance and follow-up care into the second decade post-diagnosis. C1 [Hill, Deirdre A.; Kinney, Anita Y.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA. [Hill, Deirdre A.; Kinney, Anita Y.] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA. [Horick, Nora K.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Isaacs, Claudine] Georgetown Univ, Dept Med, Washington, DC USA. [Isaacs, Claudine] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA. [Domchek, Susan M.] Univ Penn, Basser Res Ctr, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Tomlinson, Gail E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Hematol Oncol, San Antonio, TX 78229 USA. [Tomlinson, Gail E.] Univ Texas Dallas, SW Med Ctr, Dallas, TX USA. [Lowery, Jan T.] Univ Colorado, Dept Epidemiol, Sch Publ Hlth, Denver, CO 80202 USA. [Berg, Jonathan S.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC USA. [Berg, Jonathan S.] Univ N Carolina, Sch Med, Dept Internal Med Hematol Oncol, Chapel Hill, NC USA. [Edwards, Karen L.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Washington, Sch Publ Hlth, Inst Publ Hlth Genet, Seattle, WA 98195 USA. [Moorman, Patricia G.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA. [Moorman, Patricia G.] Duke Univ, Med Ctr, Canc Prevent Detect & Control Res Program, Durham, NC 27710 USA. [Plon, Sharon E.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Plon, Sharon E.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Strong, Louise C.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA. [Ziogas, Argyrois] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. [Griffin, Constance A.] Johns Hopkins Sch Med, Dept Pathol & Oncol, Baltimore, MD USA. [Kasten, Carol H.] US FDA, USDA ARS, Silver Spring, MD USA. [Finkelstein, Dianne M.] Harvard Univ, Boston, MA 02115 USA. RP Hill, DA (reprint author), Univ New Mexico, Dept Internal Med, MSC 10-5550, Albuquerque, NM 87131 USA. EM dahill@salud.unm.edu FU National Cancer Institute [HHSN2612007440000C]; [U01CA07 8284]; [U24CA078134]; [U24CA078142]; [U24CA078146]; [U24CA078148]; [U24CA078156]; [U24CA078157]; [U24CA078164]; [U24CA078174] FX This study was supported by grants U01CA07 8284, U24CA078134, U24CA078142, U24CA078146, U24CA078148, U24CA078156, U24CA078157, U24CA078164, U24CA078174; and contract HHSN2612007440000C from the National Cancer Institute. NR 30 TC 6 Z9 6 U1 3 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD MAY PY 2014 VL 145 IS 1 BP 233 EP 243 DI 10.1007/s10549-014-2928-4 PG 11 WC Oncology SC Oncology GA AF2CE UT WOS:000334519400023 PM 24696430 ER PT J AU Farvid, MS Cho, E Chen, WY Eliassen, AH Willett, WC AF Farvid, Maryam S. Cho, Eunyoung Chen, Wendy Y. Eliassen, A. Heather Willett, Walter C. TI Premenopausal dietary fat in relation to pre- and post-menopausal breast cancer SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Fat intake; Animal fat; Breast cancer ID CORONARY-HEART-DISEASE; MODIFICATION TRIAL; MEAT CONSUMPTION; RISK; COHORT; WOMEN; HEALTH; VALIDITY; ACIDS AB We examined the association between fat intake and breast cancer incidence in the Nurses' Health Study II. We followed 88,804 women aged 26-45 years from 1991 to 2011 and documented incident breast cancers. Dietary fat, assessed by questionnaires in 1991, was examined in relation to total, premenopausal, and postmenopausal breast cancers. Multivariable-adjusted Cox proportional hazards models were used to estimate relative risk (RR) and 95 % confidence intervals (95 % CI). During 20 years of follow-up, 2,830 incident invasive breast cancer cases were diagnosed. Total fat intake was not associated with risk of breast cancer overall. After adjustment for demographic, anthropometric, lifestyle, and dietary factors, a positive association was observed between animal fat intake and breast cancer overall (RR for highest vs lowest quintile, 1.18; 95 % CI 1.04-1.33; P (trend) = 0.01). A positive association with animal fat intake was also seen among premenopausal women, but not among postmenopausal women. Higher intakes of saturated fat and monounsaturated fat were each associated with modestly higher breast cancer risk among all women, and higher cholesterol intake was associated with higher premenopausal breast cancer risk. However, the associations of saturated fat, monounsaturated fat and animal fat, were attenuated and non-significant after adjustment for red meat intake. Intakes of other types of fat including vegetable fat, dairy fat, polyunsaturated fat, and trans fat were not associated with breast cancer risk. Our finding suggests a positive association between early adult intake of animal fat and breast cancer risk. C1 [Farvid, Maryam S.; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Farvid, Maryam S.] Shahid Beheshti Univ Med Sci, Fac Nutr Sci & Food Technol, Dept Community Nutr, Tehran, Iran. [Cho, Eunyoung; Chen, Wendy Y.; Eliassen, A. Heather; Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Cho, Eunyoung; Chen, Wendy Y.; Eliassen, A. Heather; Willett, Walter C.] Harvard Univ, Sch Med, Boston, MA USA. [Cho, Eunyoung] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA. [Chen, Wendy Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Eliassen, A. Heather; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Farvid, MS (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. EM mfarvid@hsph.harvard.edu FU National Institutes of Health [R01CA050385] FX The study was supported by the National Institutes of Health Grant (R01CA050385). The study sponsors were not involved in the study design and collection, analysis and interpretation of data, or the writing of the article or the decision to submit it for publication. The authors were independent from study sponsors. We would like to thank the participants and staff of the Nurses' Health Study II, for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. In addition, this study was approved by the Connecticut Department of Public Health (DPH) Human Investigations Committee. Certain data used in this publication were obtained from the DPH. The authors' responsibility were as follows: MSF, EC, WYC, AHE, and WCW: designed the research; MSF: analyzed and wrote the manuscript; and WCW: had primary responsibility for the final content of the manuscript; and all authors: provided critical input in the writing of the manuscript and read and approved the final manuscript. The authors assume full responsibility for analyses and interpretation of these data. NR 29 TC 11 Z9 11 U1 2 U2 19 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD MAY PY 2014 VL 145 IS 1 BP 255 EP 265 DI 10.1007/s10549-014-2895-9 PG 11 WC Oncology SC Oncology GA AF2CE UT WOS:000334519400025 PM 24715379 ER PT J AU Riches, JC O'Donovan, C Kingdon, SJ McClanahan, F Clear, AJ Neuberg, DS Croce, CM Ramsay, AG Rassenti, LZ Kipps, TJ Gribben, JG AF Riches, J. C. O'Donovan, C. Kingdon, S. J. McClanahan, F. Clear, A. J. Neuberg, D. S. Croce, C. M. Ramsay, A. G. Rassenti, L. Z. Kipps, T. J. Gribben, J. G. TI Trisomy 12 chronic lymphocytic leukaemia cells exhibit functional upregulation of integrin signalling that is modulated by NOTCH1 mutations SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Meeting Abstract CT 54th Annual Scientific Meeting of the British-Society-for-Haematology CY APR 28-30, 2014 CL Birmingham, ENGLAND SP British Soc Haematol C1 [Riches, J. C.; O'Donovan, C.; Kingdon, S. J.; McClanahan, F.; Clear, A. J.; Ramsay, A. G.; Gribben, J. G.] Queen Mary Univ London, Barts Canc Inst, Dept Haematooncol, London, England. [Neuberg, D. S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Croce, C. M.] Ohio State Univ, Wexner Med Ctr, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. [Rassenti, L. Z.; Kipps, T. J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD MAY PY 2014 VL 165 SU 1 SI SI MA 38 BP 20 EP 20 PG 1 WC Hematology SC Hematology GA AF7VP UT WOS:000334923300039 ER PT J AU Coutre, SE Othus, M Powell, B Willman, CL Stock, W Paietta, E Levitan, D Wetzler, M Attar, EC Altman, JK Gore, SD Maher, T Kopecky, KJ Tallman, MS Larson, RA Appelbaum, FR AF Coutre, Steven E. Othus, Megan Powell, Bayard Willman, Cheryl L. Stock, Wendy Paietta, Elisabeth Levitan, Denise Wetzler, Meir Attar, Eyal C. Altman, Jessica K. Gore, Steven D. Maher, Tracy Kopecky, Kenneth J. Tallman, Martin S. Larson, Richard A. Appelbaum, Frederick R. TI Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE malignant haematology; leukaemia trials; acute promyelocytic leukaemia; leukaemia clinical ID TRANS-RETINOIC ACID; CHEMOTHERAPY; REMISSION; ATRA; MULTICENTER; INTERGROUP; SURVIVAL; PETHEMA; ADULTS; C9710 AB Aa total of 105 patients (age >= 18years) with newly diagnosed low or intermediate risk acute promyelocytic leukaemia (APL) were treated with a standard induction and consolidation regimen including arsenic trioxide (ATO). Sixty-eight patients who were polymerase chain reaction (PCR) negative for PML-RARA post-consolidation were randomized to either 1year of maintenance with tretinoin, mercaptopurine and methotrexate, or observation. Enrollment in this non-inferiority trial was stopped prematurely due to slow accrual. With a median follow up of 36 center dot 1months, the overall survival of the 105 patients was 93%, and there have been no relapses in the patients randomized to maintenance or observation. These results demonstrate that cures can be expected in >90% of patients with low and intermediate risk APL and suggest that maintenance therapy may not be needed if patients are treated with an intensive post-remission regimen including ATO. This trial was registered at clinicaltrials.gov as #NCT00492856. C1 [Coutre, Steven E.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Othus, Megan; Maher, Tracy; Kopecky, Kenneth J.] SWOG Stat Ctr, Seattle, WA USA. [Powell, Bayard; Levitan, Denise] Wake Forest Univ, Sch Med, Wake Forest, NC USA. [Willman, Cheryl L.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA. [Stock, Wendy; Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. [Paietta, Elisabeth] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA. [Wetzler, Meir] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Attar, Eyal C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Altman, Jessica K.] Northwestern Univ, Chicago, IL 60611 USA. [Gore, Steven D.] Johns Hopkins Univ, Baltimore, MD USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Coutre, SE (reprint author), Stanford Univ, Sch Med, 875 Blake Wilbur Dr, Stanford, CA 94305 USA. EM coutre@stanford.edu OI Larson, Richard/0000-0001-9168-3203 FU PHS by National Cancer Institute [DHHS: CA32102, CA38926, CA46282, CA11083, CA41287, CA35431, CA27057, CA45807, CA20319, CA45808, CA76132, CA86780, CA58861, CA14028 (SWOG), CA31946 (CALGB), CA21115, CA17145, CA16116(ECOG)] FX This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA46282, CA11083, CA41287, CA35431, CA27057, CA45807, CA20319, CA45808, CA76132, CA86780, CA58861, CA14028 (SWOG); CA31946 (CALGB); CA21115, CA17145 and CA16116(ECOG). NR 18 TC 10 Z9 10 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD MAY PY 2014 VL 165 IS 4 BP 497 EP 503 DI 10.1111/bjh.12775 PG 7 WC Hematology SC Hematology GA AF4MI UT WOS:000334686500007 PM 24528179 ER PT J AU Tremmel, JA Patel, RAG Bhatt, DL Cilingiroglu, M Pinto, DS Dean, LS Grines, CL AF Tremmel, Jennifer A. Patel, Rajan A. G. Bhatt, Deepak L. Cilingiroglu, Mehmet Pinto, Duane S. Dean, Larry S. Grines, Cindy L. TI Commentary on late breaking trials in interventional cardiology at ESC, VIVA, TCT, AHA (Fall 2012), and ACC 2013 SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE valvular heart disease; stents; antithrombotics; peripheral arterial disease; myocardial infarction; review ID ELEVATION MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; FRACTIONAL FLOW RESERVE; RESISTANT HYPERTENSION; BALLOON ANGIOPLASTY; ELUTING STENTS; THERAPY; PCI; DISEASE; EVENTS AB With the plethora of clinical trials, it is difficult for busy interventional cardiologists to stay up to date. Therefore, the Society for Cardiovascular Angiography and Interventions (SCAI) publications committee concisely summarized and provided editorial commentary on the most important trials from recent, large international meetings. The intent is to provide this summary every six months to allow quick assimilation of trial results into interventional practice. (c) 2013 Wiley Periodicals, Inc. C1 [Tremmel, Jennifer A.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Patel, Rajan A. G.] John Ochsner Heart & Vasc Inst, Ochsner Med Ctr, New Orleans, LA USA. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bhatt, Deepak L.; Pinto, Duane S.] Harvard Univ, Sch Med, Boston, MA USA. [Cilingiroglu, Mehmet] Univ Arkansas Med Sci, Arkansas Heart Hosp, Little Rock, AR 72205 USA. [Pinto, Duane S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Dean, Larry S.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Grines, Cindy L.] Detroit Med Ctr Cardiovasc Inst, Detroit, MI USA. RP Tremmel, JA (reprint author), 300 Pasteur Dr,Room H2103, Stanford, CA 94305 USA. EM jtremmel@stanford.edu FU Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Medtronic; Roche; Sanofi Aventis; Medicines Company; Edwards Lifesciences FX Dr. Jennifer A. Tremmel Terumo Medical (Consulting/Honoraria), St. Jude Medical (Consulting/Honoraria), Boston Scientific (Consulting/Honoraria), Volcano Corporation (Consulting/Honoraria), Recor Medical (Consulting/Honoraria). Dr. Deepak L. Bhatt: Advisory Board: Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Get With The Guidelines Steering Committee; Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology); Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), WebMD (CME steering committees); Data Monitoring Committees: Duke Clinical Research Institute; Harvard Clinical Research Institute; Mayo Clinic; Population Health Research Institute; Research Grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Roche, Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda. Dr. Larry S. Dean: Edwards Lifesciences (Research Grants). Dr. Cindy L. Grines: Abbott Vascular (Advisory Board), The Medicines Company (Advisory Board). Dr. Rajan A.G. Patel, Dr. Mehmet Cilingiroglu, and Dr. Duane S. Pinto have no conflicts of interest. NR 22 TC 0 Z9 0 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAY 1 PY 2014 VL 83 IS 6 BP 936 EP 943 DI 10.1002/ccd.25301 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF6AX UT WOS:000334797900024 PM 24273219 ER PT J AU Vardi, M Novack, V Pencina, MJ Doros, G Burke, DA Elmariah, S Cutlip, DE Mauri, L Yeh, RW AF Vardi, Moshe Novack, Victor Pencina, Michael J. Doros, Gheorghe Burke, David A. Elmariah, Sammy Cutlip, Donald E. Mauri, Laura Yeh, Robert W. TI Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: A meta-analysis and critical examination of current methodologies SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE restenosis; stent structure; peripheral vascular disease ID SUPERFICIAL FEMORAL-ARTERY; BALLOON ANGIOPLASTY; INTERMITTENT CLAUDICATION; PROXIMAL POPLITEAL; VASCULAR-MEDICINE; ELUTING STENTS; LESIONS; IMPLANTATION; TRIAL; GUIDELINES AB Background The efficacy and safety of primary stenting for superficial femoral artery (SFA) disease have been benchmarked against historically derived performance goals. However, contemporary evidence evaluating SFA stenting is accumulating. The objective of this systematic review and meta-analysis was to quantitatively assess outcomes after primary SFA stenting with nitinol stents in contemporary practice, to compare these rates with commonly used efficacy and safety goals, and to discuss the clinical and regulatory implications of these findings. Methods and Results We searched MEDLINE, the US Food and Drug Administration (FDA) website, reference lists of qualifying articles, and conference proceedings until October 2012. Studies prospectively assessing primary nitinol stenting for diseased SFA were sought. Data from 11 prospective clinical trials were included. The twelve-month primary patency (PP) rate was reported in five trials. The meta-analytic 12-month PP rate was 71.6% (95% confidence interval [CI] 66.4-76.7%). The meta-analytic rate of 30-day freedom from a composite of death, target limb amputation, and reintervention was 99.9% (95% CI 100.0-90.0%). Conclusion Contemporary nitinol-based bare-metal stents performed well in controlled settings. Occurrence of the 1-month composite safety endpoint was extremely uncommon. (c) 2013 Wiley Periodicals, Inc. C1 [Vardi, Moshe; Pencina, Michael J.; Doros, Gheorghe; Burke, David A.; Elmariah, Sammy; Cutlip, Donald E.; Mauri, Laura; Yeh, Robert W.] Harvard Clin Res Inst, Boston, MA 02215 USA. [Novack, Victor] Soroka Clin Res Ctr, Beer Sheva, Israel. [Pencina, Michael J.; Doros, Gheorghe] Boston Univ, Dept Biostat, Boston, MA 02215 USA. [Burke, David A.; Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA. [Elmariah, Sammy; Yeh, Robert W.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA USA. [Mauri, Laura] Brigham & Women Hosp, Div Cardiol, Boston, MA USA. RP Vardi, M (reprint author), Harvard Clin Res Inst, 930 Commonwealth Ave, Boston, MA 02215 USA. EM vardi.moshe@gmail.com FU Abbott; Boston Scientific; Cordis; Medtronic; Eli Lilly; Daiichi Sankyo; Bristol Myers Squibb; Sanofi-Aventis; Abbott Vascular FX Dr. Laura Mauri received grants to institution from Abbott, Boston Scientific, Cordis, Medtronic, Eli Lilly, Daiichi Sankyo, Bristol Myers Squibb, Sanofi-Aventis, and consulted to St Jude and Biotronik. Dr. Donald E Cutlip received research support from Medtronic and Abbott Vascular. Other authors have no disclosures. NR 33 TC 7 Z9 8 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAY 1 PY 2014 VL 83 IS 6 BP 975 EP 983 DI 10.1002/ccd.25179 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF6AX UT WOS:000334797900030 PM 23996913 ER PT J AU Hawkins, BM Drachman, DE AF Hawkins, Beau M. Drachman, Douglas E. TI Moving south to work north-transpedal access for critical limb ischemia SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material ID PREDICTORS C1 [Hawkins, Beau M.] Univ Oklahoma, Hlth Sci Ctr, Dept Internal Med, Cardiovasc Sect, Oklahoma City, OK USA. [Drachman, Douglas E.] Massachusetts Gen Hosp, Div Cardiol, Vasc Med Sect, Boston, MA 02114 USA. RP Drachman, DE (reprint author), Massachusetts Gen Hosp, Cardiol Fellowship Program, 55 Fruit St,Gray Bigelow 800, Boston, MA 02114 USA. EM ddrachman@partners.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAY 1 PY 2014 VL 83 IS 6 BP 1008 EP 1009 DI 10.1002/ccd.25479 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF6AX UT WOS:000334797900035 PM 24753175 ER PT J AU Rocha-Singh, KJ Zeller, T Jaff, MR AF Rocha-Singh, Krishna J. Zeller, Thomas Jaff, Michael R. TI Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implications SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE vascular calcification; atherosclerosis; peripheral artery disease ID CHRONIC KIDNEY-DISEASE; VITAMIN-D STATUS; VASCULAR CALCIFICATION; SECONDARY HYPERPARATHYROIDISM; CORONARY-ARTERIES; ATHERECTOMY; CALCIUM; HEMODIALYSIS; ANGIOPLASTY; MORTALITY AB Vascular calcification (VC), particularly medial (Monckeberg's medial sclerosis) arterial calcification, is common in patients with diabetes mellitus and chronic kidney disease and is associated with increased cardiovascular morbidity and mortality. Although, the underlying pathophysiological mechanisms and genetic pathways of VC are not fully known, hypocalcemia, hyperphosphatemia, and the suppression of parathyroid hormone activity are central to the development of vessel mineralization and, consequently, bone demineralization. In addition to preventive measures, such as the modification of atherosclerotic cardiovascular risk factors, current treatment strategies include the use of calcium-free phosphate binders, vitamin D analogs, and calcium mimetics that have shown promising results, albeit in small patient cohorts. The impact of intimal and medial VC on the safety and effectiveness of endovascular devices to treat symptomatic peripheral arterial disease (PAD) remains poorly defined. The absence of a generally accepted, validated vascular calcium grading scale hampers clinical progress in assessing the safety and utility of various endovascular devices (e.g., atherectomy) in treating calcified vessels. Accordingly, we propose the peripheral arterial calcium scoring system (PACSS) and a method for its clinical validation. A better understanding of the pathogenesis of vascular calcification and the development of optimal medical and endovascular treatment strategies are crucial as the population ages and presents with more chronic comorbidities. (c) 2014 Wiley Periodicals, Inc. C1 [Rocha-Singh, Krishna J.] St Johns Hosp, Prairie Heart Inst, Springfield, IL 62769 USA. [Zeller, Thomas] Univ Herzzentrum Freiburg, Bad Krozingen, Germany. [Jaff, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Rocha-Singh, KJ (reprint author), St Johns Hosp, Prairie Heart Inst, POB 19420, Springfield, IL 62769 USA. EM ksingh@prairieheart.com NR 51 TC 26 Z9 27 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAY 1 PY 2014 VL 83 IS 6 BP E212 EP E220 DI 10.1002/ccd.25387 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF6AX UT WOS:000334797900004 PM 24402839 ER PT J AU Savadjiev, P Whitford, TJ Hough, ME von Hohenberg, CC Bouix, S Westin, CF Shenton, ME Crow, TJ James, AC Kubicki, M AF Savadjiev, P. Whitford, T. J. Hough, M. E. von Hohenberg, C. Clemm Bouix, S. Westin, C-F Shenton, M. E. Crow, T. J. James, A. C. Kubicki, M. TI Sexually Dimorphic White Matter Geometry Abnormalities in Adolescent Onset Schizophrenia SO CEREBRAL CORTEX LA English DT Article DE brain asymmetry; psychosis; schizophrenia; sex differences; white matter geometry ID CEREBRAL ASYMMETRY; BRAIN ASYMMETRY; 1ST-EPISODE SCHIZOPHRENIA; IN-UTERO; LANGUAGE; PSYCHOSIS; GENDER; ORIGIN; LATERALIZATION; GYRIFICATION AB The normal human brain is characterized by a pattern of gross anatomical asymmetry. This pattern, known as the torque, is associated with a sexual dimorphism: The male brain tends to be more asymmetric than that of the female. This fact, along with well-known sex differences in brain development (faster in females) and onset of psychosis (earlier with worse outcome in males), has led to the theory that schizophrenia is a disorder in which sex-dependent abnormalities in the development of brain torque, the correlate of the capacity for language, cause alterations in interhemispheric connectivity, which are causally related to psychosis (Crow TJ, Paez P, Chance SE. 2007. Callosal misconnectivity and the sex difference in psychosis. Int Rev Psychiatry. 19(4):449457.). To provide evidence toward this theory, we analyze the geometry of interhemispheric white matter connections in adolescent-onset schizophrenia, with a particular focus on sex, using a recently introduced framework for white matter geometry computation in diffusion tensor imaging data (Savadjiev P, Kindlmann GL, Bouix S, Shenton ME, Westin CF. 2010. Local white geometry from diffusion tensor gradients. Neuroimage. 49(4):31753186.). Our results reveal a pattern of sex-dependent white matter geometry abnormalities that conform to the predictions of Crows torque theory and correlate with the severity of patients symptoms. To the best of our knowledge, this is the first study to associate geometrical differences in white matter connectivity with torque in schizophrenia. C1 [Savadjiev, P.; von Hohenberg, C. Clemm; Bouix, S.; Shenton, M. E.; Kubicki, M.] Harvard Univ, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Sch Med, Boston, MA 02215 USA. [Savadjiev, P.; Westin, C-F] Harvard Univ, Brigham & Womens Hosp, Lab Math Imaging, Sch Med, Boston, MA 02215 USA. [Whitford, T. J.] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia. [Hough, M. E.] Univ Calif San Francisco, Gazzaley Lab, San Francisco, CA 94143 USA. [von Hohenberg, C. Clemm] Univ Munich, Fac Med, Munich, Germany. [Shenton, M. E.] VA Boston Healthcare Syst, Brockton, MA USA. [Crow, T. J.; James, A. C.] Univ Oxford, Warneford Hosp, Dept Psychiat, SANE POWIC, Oxford OX3 7JX, England. RP Savadjiev, P (reprint author), Harvard Univ, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Sch Med, 1249 Boylston St,3rd Floor, Boston, MA 02215 USA. EM petersv@bwh.harvard.edu RI crow, timothy/M-8327-2014 OI crow, timothy/0000-0002-5482-6655 FU National Institutes of Health [R01MH082918, R01MH092862, R01MH074794, R01MH050740, P41RR013218, P41EB015902, P50MH080272, U54EB005149]; Department of Veteran Affairs Merit Award; Schizophrenia Center Grant; National Health and Medical Research Council of Australia, an overseas-based biomedical training fellowship [NHMRC] [520627]; National Alliance for Research on Schizophrenia and Depression (NARSAD) Brain and Behavior Research Fund, Barbara and John Streicker Young Investigator Award [17537]; Medical Research Council [G0500092]; Oxfordshire Health Services Research Committee FX This work was supported by the National Institutes of Health [grant numbers R01MH082918, R01MH092862, R01MH074794, R01MH050740, P41RR013218, P41EB015902, P50MH080272, and U54EB005149]; the Department of Veteran Affairs Merit Award (to M. E. S.) and Schizophrenia Center Grant (to MES); the National Health and Medical Research Council of Australia, an overseas-based biomedical training fellowship [NHMRC #520627, to TJW]; the National Alliance for Research on Schizophrenia and Depression (NARSAD) Brain and Behavior Research Fund, Barbara and John Streicker Young Investigator Award (17537, to T.J.W.); the Medical Research Council (G0500092, to A.J.); the Oxfordshire Health Services Research Committee (to A.J.). Conflict of Interest: None declared. NR 46 TC 9 Z9 9 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD MAY PY 2014 VL 24 IS 5 BP 1389 EP 1396 DI 10.1093/cercor/bhs422 PG 8 WC Neurosciences SC Neurosciences & Neurology GA AF8YS UT WOS:000335002500022 PM 23307635 ER PT J AU Mehta, SJ Asch, DA AF Mehta, Shivan J. Asch, David A. TI How to Help Gastroenterology Patients Help Themselves: Leveraging Insights From Behavioral Economics SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID VETERANS C1 [Mehta, Shivan J.] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA. [Mehta, Shivan J.; Asch, David A.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA. [Mehta, Shivan J.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Mehta, SJ (reprint author), Univ Penn, Perelman Sch Med, 1133 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shivan.mehta@uphs.upenn OI Asch, David/0000-0002-7970-286X NR 11 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAY PY 2014 VL 12 IS 5 BP 711 EP 714 DI 10.1016/j.cgh.2014.02.022 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF1ZL UT WOS:000334512300006 PM 24746170 ER PT J AU Schmidt, WN Nelson, DR Pawlotsky, JM Sherman, KE Thomas, DL Chung, RT AF Schmidt, Warren N. Nelson, David R. Pawlotsky, Jean-Michel Sherman, Kenneth E. Thomas, David L. Chung, Raymond T. TI Direct-Acting Antiviral Agents and the Path to Interferon Independence SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE DAA; NS3/4A Protease Inhibitor; Nucleoside/Nucleotide; Non-nucleoside ID HEPATITIS-C VIRUS; HCV GENOTYPE 1; SUSTAINED VIROLOGICAL RESPONSE; PROTEASE INHIBITOR; NS5A INHIBITOR; COMBINATION TREATMENT; PEGYLATED INTERFERON; INFECTED PATIENTS; RANDOMIZED-TRIAL; INTERIM ANALYSIS AB Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies. Studies of interferon-alpha-based therapies have helped define treatment parameters, and these treatment strategies have cured a substantial percentage of patients. However, interferon-alpha must be injected; there are problems with tolerability, adherence, and incomplete response in a large percentage of patients. New drug candidates designed to target the virus or the host have recently been introduced at an unprecedented pace. In phase I-III studies, these agents have exceeded expectations and achieved rates of response previously not thought possible. We are, therefore, entering a new era of therapy for HCV infection and interferon independence. C1 [Schmidt, Warren N.] Vet Affairs Med Ctr, Dept Internal Med, Iowa City, IA 52242 USA. [Schmidt, Warren N.] Vet Affairs Med Ctr, Res Serv, Iowa City, IA 52242 USA. [Schmidt, Warren N.] Univ Iowa, Roy G & Lucille A Carver Coll Med, Iowa City, IA USA. [Nelson, David R.] Univ Florida, Sect Hepatobiliary Dis, Gainesville, FL USA. [Pawlotsky, Jean-Michel] Univ Paris Est, Henri Mondor Hosp, Dept Virol, Natl Reference Ctr Viral Hepatitis B C & Delta, Creteil, France. [Pawlotsky, Jean-Michel] Hop Henri Mondor, INSERM, U955, F-94010 Creteil, France. [Sherman, Kenneth E.] Univ Cincinnati, Coll Med, Div Digest Dis, Hepatol Sect, Cincinnati, OH USA. [Thomas, David L.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, GI Div, Boston, MA USA. [Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Liver, Boston, MA USA. RP Schmidt, WN (reprint author), Univ Iowa Hosp & Clin, Dept Internal Med, 200 Hawkins Dr,4553 JCP, Iowa City, IA 52242 USA. EM warren-schmidt@uiowa.edu FU Merit Review grant from the Veterans Affairs [BX000159]; Doriann Foundation for hepatitis research, University of Iowa; NIH [DK78772, DA33541]; NIH/NCATS Clinical and Translational Science Award [UL1 R000064]; [K24 DK070528] FX Supported by Merit Review grant from the Veterans Affairs BX000159 and the Doriann Foundation for hepatitis research, University of Iowa (WNS); K24 DK070528 (KES); NIH DK78772, DA33541 (RTC); and NIH/NCATS Clinical and Translational Science Award to the University of Florida UL1 R000064 (DRN). NR 53 TC 23 Z9 23 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAY PY 2014 VL 12 IS 5 BP 728 EP 737 DI 10.1016/j.cgh.2013.06.024 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF1ZL UT WOS:000334512300008 PM 23872239 ER PT J AU Ananthakrishnan, AN Cheng, SC Cai, TX Cagan, A Gainer, VS Szolovits, P Shaw, SY Churchill, S Karlson, EW Murphy, SN Kohane, I Liao, KP AF Ananthakrishnan, Ashwin N. Cheng, Su-Chun Cai, Tianxi Cagan, Andrew Gainer, Vivian S. Szolovits, Peter Shaw, Stanley Y. Churchill, Susanne Karlson, Elizabeth W. Murphy, Shawn N. Kohane, Isaac Liao, Katherine P. TI Association Between Reduced Plasma 25-Hydroxy Vitamin D and Increased Risk of Cancer in Patients With Inflammatory Bowel Diseases SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Crohn's Disease; Ulcerative Colitis; Vitamin D; Malignancy; Colorectal Cancer ID CROHNS-DISEASE; COLORECTAL-CANCER; CLINICAL-TRIAL; D DEFICIENCY; LUNG-CANCER; BONE HEALTH; SUPPLEMENTATION; COHORT; ANTICANCER; MECHANISMS AB BACKGROUND & AIMS: Vitamin D deficiency is common among patients with inflammatory bowel diseases (IBD) (Crohn's disease or ulcerative colitis). The effects of low plasma 25-hydroxy vitamin D (25[OH]D) on outcomes other than bone health are understudied in patients with IBD. We examined the association between plasma level of 25(OH)D and risk of cancers in patients with IBD. METHODS: From a multi-institutional cohort of patients with IBD, we identified those with at least 1 measurement of plasma 25(OH)D. The primary outcome was development of any cancer. We examined the association between plasma 25(OH)D and risk of specific subtypes of cancer, adjusting for potential confounders in a multivariate regression model. RESULTS: We analyzed data from 2809 patients with IBD and a median plasma level of 25(OH)D of 26 ng/mL. Nearly one-third had deficient levels of vitamin D (<20 ng/mL). During a median follow-up period of 11 years, 196 patients (7%) developed cancer, excluding nonmelanoma skin cancer (41 cases of colorectal cancer). Patients with vitamin D deficiency had an increased risk of cancer (adjusted odds ratio, 1.82; 95% confidence interval, 1.25-2.65) compared with those with sufficient levels. Each 1-ng/mL increase in plasma 25(OH)D was associated with an 8% reduction in risk of colorectal cancer (odds ratio, 0.92; 95% confidence interval, 0.88-0.96). A weaker inverse association was also identified for lung cancer. CONCLUSIONS: In a large multi-institutional IBD cohort, a low plasma level of 25(OH)D was associated with an increased risk of cancer, especially colorectal cancer. C1 [Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Shaw, Stanley Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Murphy, Shawn N.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Ananthakrishnan, Ashwin N.; Shaw, Stanley Y.; Karlson, Elizabeth W.; Murphy, Shawn N.; Kohane, Isaac; Liao, Katherine P.] Harvard Univ, Sch Med, Boston, MA USA. [Cheng, Su-Chun; Cai, Tianxi] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Cagan, Andrew; Gainer, Vivian S.; Murphy, Shawn N.] Partners HealthCare, Charlestown, MA USA. [Kohane, Isaac] Childrens Hosp, Boston, MA 02115 USA. [Szolovits, Peter] MIT, Cambridge, MA 02139 USA. [Churchill, Susanne; Kohane, Isaac] Brigham & Womens Hosp, Natl Ctr Biomed Comp i2b2, Boston, MA 02115 USA. [Karlson, Elizabeth W.; Liao, Katherine P.] Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA. RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM aananthakrishnan@partners.org OI Szolovits, Peter/0000-0001-8411-6403 FU NIH [U54-LM008748, K08 AR060257, K24 AR052403, P60 AR047782, R01 AR049880]; American Gastroenterological Association; US National Institutes of Health [K23 DK097142]; Harold and Duval Bowen Fund FX The study was supported by NIH U54-LM008748. A.N.A is supported by funding from the American Gastroenterological Association and from the US National Institutes of Health (K23 DK097142). K. P. L. is supported by NIH K08 AR060257 and the Harold and Duval Bowen Fund. E. W. K is supported by grants from the NIH (K24 AR052403, P60 AR047782, R01 AR049880). NR 40 TC 35 Z9 37 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAY PY 2014 VL 12 IS 5 BP 821 EP 827 DI 10.1016/j.cgh.2013.10.011 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF1ZL UT WOS:000334512300021 PM 24161349 ER PT J AU Hodgson, N Gitlin, LN Winter, L Hauck, WW AF Hodgson, Nancy Gitlin, Laura N. Winter, Laraine Hauck, Walter W. TI Caregiver's Perceptions of the Relationship of Pain to Behavioral and Psychiatric Symptoms in Older Community-residing Adults With Dementia SO CLINICAL JOURNAL OF PAIN LA English DT Article DE family caregiver; pain; behavioral and psychiatric symptoms; dementia ID MENTAL-STATE-EXAMINATION; NURSING-HOME RESIDENTS; ALZHEIMERS-DISEASE; PSYCHOLOGICAL SYMPTOMS; NONPHARMACOLOGICAL INTERVENTION; NEUROPSYCHIATRIC SYMPTOMS; COGNITIVE IMPAIRMENT; SELF-REPORT; PEOPLE; INDIVIDUALS AB Objectives: Pain is underrecognized and undermanaged in older adults with dementia. Because dementia patients have a diminished capacity to communicate discomfort, untreated pain may be expressed in the form of behavioral and psychiatric symptoms. The goal of the present study was to examine the relationship between pain and behavioral and psychiatric symptoms of dementia in community-residing older adults from the perspective of the family caregiver. Materials and Methods: Dyads composed of 272 dementia patients, and their family caregivers were assessed to determine dementia patient's mental status; family caregiver's assessment of care recipient's pain, functional dependence, and number of behavioral symptoms; analgesic use; and demographic information. Results: Hierarchical multiple regression analysis controlling for age, marital status, race, functional disability, and analgesic use showed that pain explained a small but significant percent of variance in the number of behavioral symptoms (3%, P < 0.001). Pain had a stronger influence on the number of behavioral and psychiatric symptoms of dementia among those with severe cognitive impairment (F-1,F-69=11.75, P < 0.001) compared with those with low to moderate cognitive impairment (F-1,F-199=4.543, P=0.034.). Discussion: The findings indicate that pain is a risk factor for behavioral symptoms in individuals with dementia and suggest that pain is a more significant predictor of behavior for individuals with severe dementia, compared with those with mild/moderate stage dementia. These results reinforce the importance of proper pain assessment and its management as part of dementia care planning. C1 [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21205 USA. [Winter, Laraine] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Hauck, Walter W.] Sycamore Consulting LLC, Woodstock, GA USA. RP Hodgson, N (reprint author), Johns Hopkins Univ, Sch Nursing, 525N Wolfe St, Baltimore, MD 21205 USA. EM nhodgso1@jhu.edu FU National Institute on Aging; National Institute on Nursing Research [RO1 AG22254] FX Supported in part by funds from the National Institute on Aging and the National Institute on Nursing Research (RO1 AG22254). The authors declare no conflict of interest. NR 46 TC 5 Z9 5 U1 5 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0749-8047 EI 1536-5409 J9 CLIN J PAIN JI Clin. J. Pain PD MAY PY 2014 VL 30 IS 5 BP 421 EP 427 DI 10.1097/AJP.0000000000000018 PG 7 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA AF3FV UT WOS:000334597800006 PM 24281271 ER PT J AU Gu, Y Scarmeas, N Cosentino, S Brandt, J Albert, M Blacker, D Dubois, B Stern, Y AF Gu, Yian Scarmeas, Nikolaos Cosentino, Stephanie Brandt, Jason Albert, Marilyn Blacker, Deborah Dubois, Bruno Stern, Yaakov TI Change in Body Mass Index Before and After Alzheimer's Disease Onset SO CURRENT ALZHEIMER RESEARCH LA English DT Article DE Alzheimer's disease; body mass index; prospective study; weight ID MILD COGNITIVE IMPAIRMENT; ACCELERATED WEIGHT-LOSS; DWELLING OLDER-ADULTS; FOLLOW-UP; INCIDENT DEMENTIA; RISK-FACTORS; MIDLIFE; POPULATION; LIFE; COMMUNITY AB Objectives: A high body mass index (BMI) in middle-age or a decrease in BMI at late-age has been considered a predictor for the development of Alzheimer's disease (AD). However, little is known about the BMI change close to or after AD onset. Methods: BMI of participants from three cohorts, the Washington Heights and Inwood Columbia Aging Project (WHICAP; population-based) and the Predictors Study (clinic-based), and National Alzheimer's Coordinating Center (NACC; clinic-based) were analyzed longitudinally. We used generalized estimating equations to test whether there were significant changes of BMI over time, adjusting for age, sex, education, race, and research center. Stratification analyses were run to determine whether BMI changes depended on baseline BMI status. Results: BMI declined over time up to AD clinical onset, with an annual decrease of 0.21 (p= 0.02) in WHICAP and 0.18 (p= 0.04) kg/m(2) in NACC. After clinical onset of AD, there was no significant decrease of BMI. BMI even increased (b= 0.11, p= 0.004) among prevalent AD participants in NACC. During the prodromal period, BMI decreased over time in overweight (BMI >= 25 and < 30) WHICAP participants or obese (BMI >= 30) NACC participants. After AD onset, BMI tended to increase in underweight/normal weight (BMI < 25) patients and decrease in obese patients in all three cohorts, although the results were significant in NACC study only. Conclusions: Our study suggests that while BMI declines before the clinical AD onset, it levels off after clinical AD onset, and might even increase in prevalent AD. The pattern of BMI change may also depend on the initial BMI. C1 [Gu, Yian; Scarmeas, Nikolaos; Cosentino, Stephanie; Stern, Yaakov] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA. [Scarmeas, Nikolaos; Cosentino, Stephanie; Stern, Yaakov] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA. [Scarmeas, Nikolaos; Cosentino, Stephanie; Stern, Yaakov] Columbia Univ, Dept Neurol, New York, NY 10032 USA. [Scarmeas, Nikolaos] Univ Athens, Sch Med, Athens 11528, Greece. [Brandt, Jason; Albert, Marilyn] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Brandt, Jason; Albert, Marilyn] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Blacker, Deborah] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Dubois, Bruno] Hop La Pitie Salpetriere, Dept Neurol, Paris, France. RP Gu, Y (reprint author), Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, 630 W 168th St,P&S Box 16, New York, NY 10032 USA. EM yg2121@columbia.edu OI Brandt, Jason/0000-0001-7381-6244 FU NIH [K99 AG042483, R01AG007370, R01AG037212, R01AG028506]; NIA [U01 AG016976] FX This work is supported by NIH grants K99 AG042483, R01AG007370, R01AG037212, and R01AG028506. The NACC database is funded by NIA Grant U01 AG016976. NR 52 TC 11 Z9 11 U1 2 U2 12 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1567-2050 EI 1875-5828 J9 CURR ALZHEIMER RES JI Curr. Alzheimer Res. PD MAY PY 2014 VL 11 IS 4 BP 349 EP 356 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AF8ZN UT WOS:000335004600006 PM 24251397 ER PT J AU Cuijpers, P Turner, EH Koole, SL van Dijke, A Smit, F AF Cuijpers, Pim Turner, Erick H. Koole, Sander L. van Dijke, Annemiek Smit, Filip TI WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS SO DEPRESSION AND ANXIETY LA English DT Review DE depression; effect size; clinical relevance; minimal important difference ID IMPORTANT DIFFERENCE; HEALTH-STATUS; METAANALYSIS; PSYCHOTHERAPY; EFFICACY; SIZE AB BackgroundRandomized trials can show whether a treatment effect is statistically significant and can describe the size of the effect. There are, however, no validated methods available for establishing the clinical relevance of these outcomes. Recently, it was proposed that a standardized mean difference (SMD) of 0.50 be used as cutoff for clinical relevance in the treatment of depression. MethodsWe explore what the effect size means and why the size of an effect has little bearing on its clinical relevance. We will also examine how the minimally important difference, as seen from the patient perspective, may be helpful in deciding where the cutoff for clinical relevance should be placed for a given condition. ResultsEffect sizes in itself cannot give an indication of the clinical relevance of an intervention because the outcome itself determines the clinical relevance and not only the size of the effects. The minimal important difference (MID) could be used as a starting point for pinpointing the cutoff for clinical relevance. A first, rough attempt to implement this approach for depression resulted in a tentative clinical relevance cutoff of SMD = 0.24. Using this cutoff, psychotherapy, pharmacotherapy, and combined treatment have effect sizes above this cutoff. DiscussionStatistical outcomes cannot be equated with clinical relevance. The MID may be used for pinpointing the cutoff for clinical relevance, but more work in this area is needed. C1 [Cuijpers, Pim; Koole, Sander L.; Smit, Filip] Vrije Univ Amsterdam, Dept Clin Psychol, NL-1081 BT Amsterdam, Netherlands. [Cuijpers, Pim; Koole, Sander L.; Smit, Filip] Vrije Univ Amsterdam, VU Univ Med Ctr Amsterdam, EMGO Inst Hlth & Care Res, NL-1081 BT Amsterdam, Netherlands. [Cuijpers, Pim] Leuphana Univ, Lunebrug, Germany. [Turner, Erick H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA. [van Dijke, Annemiek] Delta Psychiat Ctr, Poortugaal, Netherlands. [Smit, Filip] Netherlands Inst Mental Hlth & Addict, Trimbos Inst, Utrecht, Netherlands. [Smit, Filip] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands. RP Cuijpers, P (reprint author), Vrije Univ Amsterdam, Dept Clin Psychol, Boechorststr 1, NL-1081 BT Amsterdam, Netherlands. EM p.cuijpers@vu.nl OI Cuijpers, Pim/0000-0001-5497-2743 NR 21 TC 16 Z9 16 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD MAY PY 2014 VL 31 IS 5 BP 374 EP 378 DI 10.1002/da.22249 PG 5 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AF6CX UT WOS:000334803100002 PM 24677535 ER PT J AU Jayawickreme, N Cahill, SP Riggs, DS Rauch, SAM Resick, PA Rothbaum, BO Foa, EB AF Jayawickreme, Nuwan Cahill, Shawn P. Riggs, David S. Rauch, Sheila A. M. Resick, Patricia A. Rothbaum, Barbara O. Foa, Edna B. TI PRIMUM NON NOCERE ( FIRST DO NO HARM): SYMPTOM WORSENING AND IMPROVEMENT IN FEMALE ASSAULT VICTIMS AFTER PROLONGED EXPOSURE FOR PTSD SO DEPRESSION AND ANXIETY LA English DT Article DE Anxiety; Cognitive Behavioral Therapy; Depression; Exposure Therapy; PTSD; Trauma; Treatment Outcome ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED-TRIAL; COGNITIVE THERAPY; IMAGINAL EXPOSURE; RAPE VICTIMS; INVENTORY; SCALE; WOMEN AB BackgroundProlonged Exposure (PE) therapy is an efficacious treatment for PTSD; despite this, many clinicians do not utilize it due to concerns it could cause patient decompensation. MethodData were pooled from four published well-controlled studies of female assault survivors with chronic PTSD (n = 361) who were randomly assigned to PE, waitlist (WL), or another psychotherapy, including cognitive processing therapy (CPT), Eye Movement and Desensitization Reprocessing (EMDR), or the combination of PE plus stress inoculation training (SIT) or PE plus cognitive restructuring. PTSD and depression severity scores were converted to categorical outcomes to evaluate the proportion of participants who showed reliable symptom change (both reliable worsening and reliable improvement). ResultsThe majority of participants completing one of the active treatments showed reliable improvement on both PTSD and depression compared to WL. Among treatment participants in general, as well as those who received PE, reliable PTSD worsening was nonexistent and the rate of reliable worsening of depression was low. There were no differences on any outcome measures among treatments. By comparison, participants in WL had higher rates of reliable symptom worsening for both PTSD and depression. Potential alternative explanations were also evaluated. ConclusionsPE and a number of other empirically supported therapies are efficacious and safe treatments for PTSD, reducing the frequency of which symptom worsening occurs in the absence of treatment. C1 [Jayawickreme, Nuwan] Manhattan Coll, Dept Psychol, Bronx, NY 10471 USA. [Cahill, Shawn P.] Univ Wisconsin, Dept Psychol, Milwaukee, WI 53201 USA. [Riggs, David S.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA. [Rauch, Sheila A. M.] Univ Michigan Med Sch, Dept Psychiat, Ann Arbor, MI USA. [Rauch, Sheila A. M.] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Resick, Patricia A.] Boston Univ Sch Med, Dept Psychiat, Boston, MA USA. [Rothbaum, Barbara O.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. [Foa, Edna B.] Univ Penn Sch Med, Dept Psychiat, Philadelphia, PA USA. RP Jayawickreme, N (reprint author), Manhattan Coll, Dept Psychol, Bronx, NY 10471 USA. EM nuwan.jayawickreme@manhattan.edu RI Rauch, Sheila/K-4450-2015 OI Rauch, Sheila/0000-0001-9686-4011 FU United States National Institute of Mental Health [MH42178, NIH-1 R01-MH51509, 1 R01 MH-56351-01A1] FX This study was supported by the United States National Institute of Mental Health, Grant MH42178 awarded to Edna B. Foa, Grant NIH-1 R01-MH51509 awarded to Patricia A. Resick, and Grant 1 R01 MH-56351-01A1 awarded to Barbara O. Rothbaum. The authors wish to thank Pavel Atanasov for assisting with data analysis. NR 26 TC 13 Z9 14 U1 3 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD MAY PY 2014 VL 31 IS 5 BP 412 EP 419 DI 10.1002/da.22225 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AF6CX UT WOS:000334803100006 PM 24382682 ER PT J AU Goldfine, AB Jablonski, KA Shoelson, SE Creager, MA AF Goldfine, Allison B. Jablonski, Kathleen A. Shoelson, Steven E. Creager, Mark A. CA TINSAL-FMD Targeting Inflammation TI Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow- Mediated Dilation ( TINSAL- FMD). Diabetes Care 2013; 36: 4132-4139 SO DIABETES CARE LA English DT Letter C1 [Goldfine, Allison B.; Shoelson, Steven E.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Goldfine, Allison B.; Creager, Mark A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Jablonski, Kathleen A.] George Washington Univ, Ctr Biostat, Rockville, MD USA. RP Creager, MA (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. EM mcreager@partners.org FU NIDDK NIH HHS [U01 DK074556] NR 5 TC 0 Z9 0 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2014 VL 37 IS 5 BP E112 EP E112 DI 10.2337/dc14-0222 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AF6QQ UT WOS:000334840100016 PM 24757239 ER PT J AU Lopes-Virella, MF Baker, NL Hunt, KJ Cleary, PA Klein, R Virella, G AF Lopes-Virella, Maria F. Baker, Nathaniel L. Hunt, Kelly J. Cleary, Patricia A. Klein, Richard Virella, Gabriel CA DCCT EDIC Res Grp TI Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects. Diabetes Care 2013; 36: 2317-2323 RESPONSE SO DIABETES CARE LA English DT Letter ID ENDOTHELIAL DYSFUNCTION; IMMUNE-COMPLEXES; COMPLICATIONS; NEPHROPATHY C1 [Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Baker, Nathaniel L.; Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Serv, Charleston, SC 29425 USA. [Cleary, Patricia A.] George Washington Univ, Ctr Biostat, Washington, DC USA. [Klein, Richard] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA. EM virellam@musc.edu FU NIDDK NIH HHS [R01 DK081352] NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2014 VL 37 IS 5 BP E108 EP E109 DI 10.2337/dc13-2976 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AF6QQ UT WOS:000334840100014 PM 24496801 ER PT J AU Walford, GA Ma, Y Christophi, CA Goldberg, RB Jarolim, P Horton, E Mather, KJ Barrett-Connor, E Davis, J Florez, JC Wang, TJ AF Walford, Geoffrey A. Ma, Yong Christophi, Costas A. Goldberg, Ronald B. Jarolim, Petr Horton, Edward Mather, Kieren J. Barrett-Connor, Elizabeth Davis, Jaclyn Florez, Jose C. Wang, Thomas J. CA Diabetes Prevention Program Res Gr TI Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program SO DIABETOLOGIA LA English DT Article DE Diabetes prevention; Insulin sensitivity; Natriuretic peptides; NT-proBNP; Obesity ID IMPACT; RISK AB Aims/hypothesis We aimed to study the relationship between measures of adiposity, insulin sensitivity and N-terminal proB- type natriuretic peptide (NT-proBNP) in the Diabetes Prevention Program (DPP). Methods The DPP is a completed clinical trial. Using stored samples from this resource, we measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n=692), intensive lifestyle intervention (n=832) or metformin (n=887). Results At baseline, log NT-proBNP did not differ between treatment arms and was correlated with baseline log ISI (p<0.0001) and WC (p=0.0003) but not with BMI (p=0.39). After 2 years of treatment, BMI decreased in the lifestyle and metformin groups (both p<0.0001); WC decreased in all three groups (p<0.05 for all); and log ISI increased in the lifestyle and metformin groups (both p<0.001). The change in log NT-proBNP did not differ in the lifestyle or metformin group vs the placebo group (p>0.05 for both). In regression models, the change in log NT-proBNP was positively associated with the change in log ISI (p<0.005) in all three study groups after adjusting for changes in BMI and WC, but was not associated with the change in BMI or WC after adjusting for changes in log ISI. Conclusion/interpretation Circulating NT-proBNP was associated with a measure of insulin sensitivity before and during preventive interventions for type 2 diabetes in the DPP. This relationship persisted after adjustment for measures of adiposity and was consistent regardless of whether a participant was treated with placebo, intensive lifestyle intervention or metformin. C1 [Walford, Geoffrey A.; Florez, Jose C.] Massachusetts Gen Hosp, Diabet Res Ctr, Diabet Unit, Boston, MA 02114 USA. [Walford, Geoffrey A.; Horton, Edward; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Walford, Geoffrey A.; Davis, Jaclyn; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Walford, Geoffrey A.; Ma, Yong; Christophi, Costas A.; Goldberg, Ronald B.; Horton, Edward; Mather, Kieren J.; Barrett-Connor, Elizabeth; Davis, Jaclyn; Florez, Jose C.] George Washington Univ, Ctr Biostat, Data Coordinating Ctr, Diabet Prevent Program, Rockville, MD 20852 USA. [Goldberg, Ronald B.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA. [Jarolim, Petr] Brigham & Womens Hosp, Dept Pathol, Div Clin Labs, Boston, MA 02115 USA. [Horton, Edward] Joslin Diabet Ctr, Boston, MA 02215 USA. [Mather, Kieren J.] Indiana Univ, Sch Med, Div Endocrinol, Indianapolis, IN 46204 USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA. [Wang, Thomas J.] Vanderbilt Univ, Med Ctr, Div Cardiol, Nashville, TN USA. RP Florez, JC (reprint author), George Washington Univ, Ctr Biostat, Data Coordinating Ctr, Diabet Prevent Program, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA. EM dppmail@biostat.bsc.gwu.edu RI Uwaifo, Gabriel/M-2361-2016; OI Uwaifo, Gabriel/0000-0002-6962-9304; Franks, Paul/0000-0002-0520-7604 FU NIH [DK007028]; Scholars in Clinical Science Program of Harvard Catalyst-The Harvard Clinical and Translational Science Center [UL1 RR 025758]; American Diabetes Association Merck Clinical and Translational Post-doctoral Fellowship [R01-HL-08675]; NIDDK [R01 DK072041] FX GAW received support from NIH training grant DK007028, from the Scholars in Clinical Science Program of Harvard Catalyst-The Harvard Clinical and Translational Science Center (award no. UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic healthcare centres), and the American Diabetes Association Merck Clinical and Translational Post-doctoral Fellowship. R01-HL-08675 (TJW) supported the natriuretic peptide measurements. JCF is supported by R01 DK072041 from NIDDK. NR 10 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD MAY PY 2014 VL 57 IS 5 BP 935 EP 939 DI 10.1007/s00125-014-3183-2 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AF1SV UT WOS:000334494700012 PM 24554005 ER PT J AU Kadayifci, A Savas, MC AF Kadayifci, Abdurrahman Savas, Muhammet Cemil TI Preprocessing nasal catheter for transnasal endoscopy SO DIGESTIVE ENDOSCOPY LA English DT Letter C1 [Kadayifci, Abdurrahman] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastroenterol,Dept Med, Boston, MA 02115 USA. [Kadayifci, Abdurrahman; Savas, Muhammet Cemil] Gaziantep Univ, Fac Med, Div Gastroenterol, Gaziantep, Turkey. RP Kadayifci, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastroenterol,Dept Med, Boston, MA 02115 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0915-5635 EI 1443-1661 J9 DIGEST ENDOSC JI Dig. Endosc. PD MAY PY 2014 VL 26 IS 3 BP 497 EP 497 DI 10.1111/den.12290 PG 1 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA AF7CI UT WOS:000334870700035 PM 24698292 ER PT J AU Kroeger, N Seligson, DB Signoretti, S Yu, H Magyar, CE Huang, JT Belldegrun, AS Pantuck, AJ AF Kroeger, Nils Seligson, David B. Signoretti, Sabina Yu, Hong Magyar, Clara E. Huang, Jiaoti Belldegrun, Arie S. Pantuck, Allan J. TI Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2 alpha SO EUROPEAN JOURNAL OF CANCER LA English DT Article DE Renal cell carcinoma; CA-IX; VEGF; mTOR; HIF-1; HIF-2; Tumour suppressor; Tumour promotor; Cancer specific survival ID CARBONIC-ANHYDRASE-IX; INDEPENDENT PREDICTOR; SURVIVAL; THERAPY; BIOLOGY; HIF1-ALPHA; RECEPTORS; SPREAD; CANCER; VEGF AB Background: Pre-clinical studies have implicated hypoxia inducible factor (HIF)-2 alpha as an important oncogene for clear cell renal cell carcinoma (ccRCC). Generally considered to act as a nuclear transcription factor, a recent study has also implicated HIF-2 alpha as a protein translational initiation complex function within the cytoplasm (Uniacke et al., 2012). We hypothesised that both the absolute expression as well as the sub-cellular localisation of HIF-2 alpha would predict clinicopathological features and cancer specific survival (CSS) in ccRCC. Methods: A tissue microarray (TMA) study was conducted on three hundred and eight ccRCC patients. Survival differences were investigated with the log rank test and associations with CSS with uni- and multivariate Cox regression analyses. Recursive partition tree analysis was used to identify relevant cutoff values. Results: High HIF-2 alpha nuclear (N) (cutoff > 32%) expression was associated with smaller tumour sizes (p = 0.002) and lower Fuhrman grades (p = 0.044), whereas tumours with high cytoplasmic (C) HIF-2 alpha (>0%) more often had positive lymph nodes (p = 0.004), distant metastases (p = 0.021) and higher Fuhrman grades (p < 0.0001). After adjustment for TNM stage, Eastern Cooperative Oncology Group performance status (ECOG PS), and Fuhrman grade, both continuous (p < 0.0001) and dichotomised (p < 0.0001) HIF-2 alpha C variables remained significant predictors of CSS, while neither HIF-2 alpha N variable was retained. Conclusion: Our investigation supports that HIF-2 alpha may have a unique tumour promoter role in the cytoplasm. This preliminary finding justifies further experimental and mechanistic studies that examine the biological functions of HIF-2 alpha when located in the cytoplasm. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Kroeger, Nils; Belldegrun, Arie S.; Pantuck, Allan J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Inst Urol Oncol, Los Angeles, CA 90095 USA. [Kroeger, Nils] Univ Med Greifswald, Dept Urol, Greifswald, Germany. [Seligson, David B.; Yu, Hong; Magyar, Clara E.; Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Signoretti, Sabina] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. RP Pantuck, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Inst Urol Oncol, 924 Westwood Blvd,Suite 1050, Los Angeles, CA 90095 USA. EM apantuck@mednet.ucla.edu NR 24 TC 8 Z9 8 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0959-8049 EI 1879-0852 J9 EUR J CANCER JI Eur. J. Cancer PD MAY PY 2014 VL 50 IS 8 BP 1531 EP 1540 DI 10.1016/j.ejca.2014.01.031 PG 10 WC Oncology SC Oncology GA AE9GQ UT WOS:000334314600014 PM 24565854 ER PT J AU Smeekens, SP Malireddi, RK Plantinga, TS Buffen, K Oosting, M Joosten, LAB Kullberg, BJ Perfect, JR Scott, WK van de Veerdonk, FL Xavier, RJ van de Vosse, E Kanneganti, TD Johnson, MD Netea, MG AF Smeekens, S. P. Malireddi, R. K. Plantinga, T. S. Buffen, K. Oosting, M. Joosten, L. A. B. Kullberg, B. J. Perfect, J. R. Scott, W. K. van de Veerdonk, F. L. Xavier, R. J. van de Vosse, E. Kanneganti, T. -D. Johnson, M. D. Netea, M. G. TI Autophagy is redundant for the host defense against systemic Candida albicans infections SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES LA English DT Article ID CHRONIC MUCOCUTANEOUS CANDIDIASIS; STAT1 MUTATIONS; INNATE IMMUNITY; HUMAN DECTIN-1; BETA-GLUCANS; RECEPTOR; RECOGNITION; MACROPHAGES; PATHWAY; SUSCEPTIBILITY AB Autophagy has been demonstrated to play an important role in the immunity against intracellular pathogens, but very little is known about its role in the host defense against fungal pathogens such as Candida albicans. Therefore, the role of autophagy for the host defense against C. albicans was assessed by complementary approaches using mice defective in autophagy, as well as immunological and genetic studies in humans. Although C. albicans induced LC3-II formation in macrophages, myeloid cell-specific ATG7(-/-) mice with defects in autophagy did not display an increased susceptibility to disseminated candidiasis. In in vitro experiments in human blood mononuclear cells, blocking autophagy modulated cytokine production induced by lipopolysaccharide, but not by C. albicans. Furthermore, autophagy modulation in human monocytes did not influence the phagocytosis and killing of C. albicans. Finally, 18 single-nucleotide polymorphisms in 13 autophagy genes were not associated with susceptibility to candidemia or clinical outcome of disease in a large cohort of patients, and there was no correlation between these genetic variants and cytokine production in either candidemia patients or healthy controls. Based on these complementary in vitro and in vivo studies, it can be concluded that autophagy is redundant for the host response against systemic infections with C. albicans. C1 [Smeekens, S. P.; Plantinga, T. S.; Buffen, K.; Oosting, M.; Joosten, L. A. B.; Kullberg, B. J.; van de Veerdonk, F. L.; Netea, M. G.] Radboud Univ Nijmegen, Med Ctr, Dept Med, NL-6525 GA Nijmegen, Netherlands. [Smeekens, S. P.; Plantinga, T. S.; Buffen, K.; Oosting, M.; Joosten, L. A. B.; Kullberg, B. J.; van de Veerdonk, F. L.; Netea, M. G.] Nijmegen Inst Infect Inflammat & Immun N4i, NL-6525 GA Nijmegen, Netherlands. [Malireddi, R. K.; Kanneganti, T. -D.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA. [Perfect, J. R.; Johnson, M. D.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC 27710 USA. [Johnson, M. D.] Campbell Univ, Coll Pharm & Hlth Sci, Durham, NC 27710 USA. [Scott, W. K.] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn, Dept Human Genet, Miami, FL 33136 USA. [Scott, W. K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA. [Xavier, R. J.] MIT, Broad Inst, Cambridge, MA 02142 USA. [Xavier, R. J.] Harvard Univ, Cambridge, MA 02142 USA. [Xavier, R. J.] Harvard Univ, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Xavier, R. J.] Harvard Univ, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA. [Xavier, R. J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA. [van de Vosse, E.] Leiden Univ, Med Ctr, Dept Infect Dis, NL-2333 ZA Leiden, Netherlands. RP Netea, MG (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Med, Geert Grootepl Zuid 8, NL-6525 GA Nijmegen, Netherlands. EM mihai.netea@radboudumc.nl RI Smeekens, Sanne/G-8307-2011; van de Vosse, Esther/B-7285-2009; Plantinga, Theo/A-6895-2015; Joosten, Leo/H-3138-2015; Kullberg, Bart Jan/C-8520-2013; van de Veerdonk, Frank/C-7256-2008; Netea, Mihai/N-5155-2014; Oosting, Marije/H-7437-2015; malireddi, rk subbarao/C-5804-2013 OI Johnson, Melissa/0000-0002-6606-9460; Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Smeekens, Sanne/0000-0002-7835-914X; van de Vosse, Esther/0000-0001-5199-3426; van de Veerdonk, Frank/0000-0002-1121-4894; malireddi, rk subbarao/0000-0001-8855-9447 FU ERC Consolidator Grant [310372]; VENI grant from the Dutch Organization for Scientific Research FX M.G.N. was supported by an ERC Consolidator Grant [310372]. T.S.P. was supported by a VENI grant from the Dutch Organization for Scientific Research. F.L.vdV. was supported by a VENI grant from the Dutch Organization for Scientific Research. NR 51 TC 14 Z9 15 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0934-9723 EI 1435-4373 J9 EUR J CLIN MICROBIOL JI Eur. J. Clin. Microbiol. Infect. Dis. PD MAY PY 2014 VL 33 IS 5 BP 711 EP 722 DI 10.1007/s10096-013-2002-x PG 12 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA AF8AV UT WOS:000334938300004 PM 24202731 ER PT J AU Hochberg, FH Atai, NA Gonda, D Hughes, MS Mawejje, B Balaj, L Carter, RS AF Hochberg, Fred H. Atai, Nadia A. Gonda, David Hughes, Michael S. Mawejje, Brolin Balaj, Leonora Carter, Robert S. TI Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS LA English DT Review DE exosomes; microvesicles; EGFRvIII; CNS; glioma; isocitrate dehydrogenase 1/2; biomarker; extracellular vesicles; cancer ID GROWTH-FACTOR RECEPTOR; CENTRAL-NERVOUS-SYSTEM; MGMT PROMOTER METHYLATION; STEM-LIKE CELLS; MALIGNANT GLIOMA; GLIOBLASTOMA-MULTIFORME; PILOCYTIC ASTROCYTOMAS; RECURRENT GLIOBLASTOMA; RADIATION-THERAPY; BRAIN-TUMORS AB Glioma is the most common brain tumor. For the more aggressive form, glioblastoma, standard treatment includes surgical resection, irradiation with adjuvant temozolomide and, on recurrence, experimental chemotherapy. However, the survival of patients remains poor. There is a critical need for minimally invasive biomarkers for diagnosis and as measures of response to therapeutic interventions. Glioma shed extracellular vesicles (EVs), which invade the surrounding tissue and circulate within both the cerebrospinal fluid and the systemic circulation. These tumor-derived EVs and their content serve as an attractive source of biomarkers. In this review, we discuss the current state of the art of biomarkers for glioma with emphasis on their EV derivation. C1 [Hochberg, Fred H.; Atai, Nadia A.; Hughes, Michael S.; Mawejje, Brolin; Balaj, Leonora] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Hochberg, Fred H.; Atai, Nadia A.; Hughes, Michael S.; Mawejje, Brolin; Balaj, Leonora] Massachusetts Gen Hosp, Program Neurosci, Boston, MA 02114 USA. [Hochberg, Fred H.; Atai, Nadia A.; Hughes, Michael S.; Mawejje, Brolin; Balaj, Leonora] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Atai, Nadia A.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Atai, Nadia A.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands. [Gonda, David; Carter, Robert S.] Univ Calif San Diego, Neurosurg Serv, San Diego, CA 92103 USA. RP Hochberg, FH (reprint author), Massachusetts Gen Hosp, Dept Neurol, Suite 340,175 Cambridge St, Boston, MA 02114 USA. EM fhochberg@partners.org FU Experimental Therapeutics and BioMonitoring of Brain Tumors; NIH Office of the Director, Office of Strategic Coordination, NIH/NINDS Common Fund Award [1 UH2 TR000931-01]; Richard Floor Biorepository Fund; AMC Scholarship, University of Amsterdam, The Netherlands; [NCI: 2PO1CA069246-16A] FX The authors thank CJF van Noorden for his helpful review comments, corrections and criticisms (University of Amsterdam, The Netherlands). This work was supported by NCI: 2PO1CA069246-16A, Experimental Therapeutics and BioMonitoring of Brain Tumors (FH Hochberg) and NIH Office of the Director, Office of Strategic Coordination, NIH/NINDS Common Fund Award: 1 UH2 TR000931-01 (RS Carter, FH Hochberg) and The Richard Floor Biorepository Fund. NA Atai was recipient of 2009 AMC Scholarship, University of Amsterdam, The Netherlands. NR 126 TC 17 Z9 17 U1 1 U2 22 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7159 EI 1744-8352 J9 EXPERT REV MOL DIAGN JI Expert Rev. Mol. Diagn. PD MAY PY 2014 VL 14 IS 4 BP 439 EP 452 DI 10.1586/14737159.2014.905202 PG 14 WC Pathology SC Pathology GA AF3FW UT WOS:000334597900006 PM 24746164 ER PT J AU Kostic, AD Xavier, RJ Gevers, D AF Kostic, Aleksandar D. Xavier, Ramnik J. Gevers, Dirk TI The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead SO GASTROENTEROLOGY LA English DT Article DE Microbiota; Crohn's Disease; Ulcerative Colitis; Metagenomics ID MUCOSA-ASSOCIATED MICROBIOTA; ACTIVE ULCERATIVE-COLITIS; HUMAN GUT MICROBIOTA; CROHNS-DISEASE; FECAL MICROBIOTA; ESCHERICHIA-COLI; COLONIC MUCOSA; FAECALIBACTERIUM-PRAUSNITZII; GASTROINTESTINAL MICROBIOTA; INTESTINAL MICROBIOTA AB Studies of the roles of microbial communities in the development of inflammatory bowel disease (IBD) have reached an important milestone. A decade of genome-wide association studies and other genetic analyses have linked IBD with loci that implicate an aberrant immune response to the intestinal microbiota. More recently, profiling studies of the intestinal microbiome have associated the pathogenesis of IBD with characteristic shifts in the composition of the intestinal microbiota, reinforcing the view that IBD results from altered interactions between intestinal microbes and the mucosal immune system. Enhanced technologies can increase our understanding of the interactions between the host and its resident microbiota and their respective roles in IBD from both a large-scale pathway view and at the metabolic level. We review important microbiome studies of patients with IBD and describe what we have learned about the mechanisms of intestinal microbiota dysfunction. We describe the recent progress in microbiome research from exploratory 16S-based studies, reporting associations of specific organisms with a disease, to more recent studies that have taken a more nuanced view, addressing the function of the microbiota by metagenomic and metabolomic methods. Finally, we propose study designs and methodologies for future investigations of the microbiome in patients with inflammatory gut and autoimmune diseases in general. C1 [Kostic, Aleksandar D.; Xavier, Ramnik J.; Gevers, Dirk] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, England. [Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Ctr Study Inflammatory Bowe, Boston, MA USA. [Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA. RP Xavier, RJ (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Richard B Simches Res Ctr, 185 Cambridge St, Boston, MA 02114 USA. EM xavier@molbio.mgh.harvard.edu OI Kostic, Aleksandar/0000-0002-0837-4360 FU Crohn's and Colitis Foundation of America; National Institutes of Health [U54 DE023798, R01 DK092405] FX Supported by grants from the Crohn's and Colitis Foundation of America (to R.J.X.) and National Institutes of Health grants U54 DE023798 and R01 DK092405 (to R.J.X.). NR 126 TC 225 Z9 234 U1 32 U2 209 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD MAY PY 2014 VL 146 IS 6 BP 1489 EP 1499 DI 10.1053/j.gastro.2014.02.009 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF1YJ UT WOS:000334509500007 PM 24560869 ER PT J AU Nieuwdorp, M Gilijamse, PW Pai, N Kaplan, LM AF Nieuwdorp, Max Gilijamse, Pim W. Pai, Nikhil Kaplan, Lee M. TI Role of the Microbiome in Energy Regulation and Metabolism SO GASTROENTEROLOGY LA English DT Article DE Obesity; Energy Expenditure; Bile Acids; Gut Microbiota ID DIET-INDUCED OBESITY; HUMAN GUT MICROBIOME; INSULIN-RESISTANCE; BILE-ACIDS; AKKERMANSIA-MUCINIPHILA; INTESTINAL MICROBIOTA; CARDIOVASCULAR RISK; DISEASE; MICROFLORA; BUTYRATE AB Intestinal microbes regulate metabolic function and energy balance; an altered microbial ecology is believed to contribute to the development of several metabolic diseases. Relative species abundance and metabolic characteristics of the intestinal microbiota change substantially in those who are obese or have other metabolic disorders and in response to ingested nutrients or therapeutic agents. The mechanisms through which the intestinal microbiota and its metabolites affect host homeostasis are just beginning to be understood. We review the relationships between the intestinal microbiota and host metabolism, including energy intake, use, and expenditure, in relation to glucose and lipid metabolism. These associations, along with interactions among the intestinal microbiota, mucus layer, bile acids, and mucosal immune responses, reveal potential mechanisms by which the microbiota affect metabolism. We discuss how controlled studies involving direct perturbations of microbial communities in human and animal models are required to identify effective therapeutic targets in the microbiota. C1 [Nieuwdorp, Max; Gilijamse, Pim W.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands. [Gilijamse, Pim W.] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1105 AZ Amsterdam, Netherlands. [Nieuwdorp, Max] Univ Goteborg, Wallenberg Lab, Sahlgrenska Ctr Cardiovasc & Metab Res, Gothenburg, Sweden. [Pai, Nikhil] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pediat Gastroenterol & Nutr, Boston, MA USA. [Pai, Nikhil; Kaplan, Lee M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Obes Metab & Nutr Inst, Boston, MA USA. [Pai, Nikhil; Kaplan, Lee M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA. RP Nieuwdorp, M (reprint author), AMC UvA, Dept Internal & Vasc Med, Meibergdreef 9,Room F4-159-2, NL-1091 EN Amsterdam, Netherlands. EM m.nieuwdorp@amc.uva.nl; lmkaplan@partners.org OI Pai, Nikhil/0000-0002-7537-6059 FU EU RESOLVE Consortium [FP7-EU 305707]; National Institutes of Health [DK088661]; Heart and Stroke Foundation of Canada [HSFCR5] FX Supported by the 2012 EU RESOLVE Consortium (grant FP7-EU 305707 to P. W. G.), National Institutes of Health grant DK088661 (to L. M. K.), and a Heart and Stroke Foundation of Canada Junior Personnel Grant (HSFCR5 to N.P.). NR 77 TC 62 Z9 67 U1 7 U2 135 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD MAY PY 2014 VL 146 IS 6 BP 1525 EP 1533 DI 10.1053/j.gastro.2014.02.008 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF1YJ UT WOS:000334509500010 PM 24560870 ER PT J AU Price, M Ruggiero, KJ Ferguson, PL Patel, SK Treiber, F Couillard, D Fahkry, SM AF Price, Matthew Ruggiero, Kenneth J. Ferguson, Pamela L. Patel, Sachin K. Treiber, Frank Couillard, Deborah Fahkry, Samir M. TI A feasibility pilot study on the use of text messages to track PTSD symptoms after a traumatic injury SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE PTSD; Traumatic stress; Text messages; Technology ID POSTTRAUMATIC-STRESS-DISORDER; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; RANDOMIZED CONTROLLED-TRIAL; MENTAL-HEALTH INTERVENTION; PHYSICAL INJURY; DSM-IV; CARE; DEPRESSION; EXPERIENCES; PREVENTION AB Objective: Monitoring posttraumatic stress disorder (PTSD) symptoms after a traumatic injury is beneficial for patients and providers. Text messages can be used to automatically monitor symptoms and impose minimal burden to patients and providers. The present study piloted such a strategy with traumatic injury patients. Method: An automated daily text message was piloted to evaluate PTSD symptoms after discharge from the hospital. Twenty-nine patients who experienced a traumatic injury received 15 daily texts and were then followed up at 1-month and 3-months after discharge. Results: 82.8% of the sample responded at least once and the average response rate per participant was 63.1%. Response rates were correlated with PTSD symptoms at baseline but not at any other time. Patient satisfaction with this approach was high. Conclusion: Text messages are a viable method to monitor PTSD symptoms after a traumatic injury. Such an approach should be evaluated on a larger scale as part of a more comprehensive early intervention for traumatic stress. (C) 2014 Elsevier Inc. All rights reserved. C1 [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Ruggiero, Kenneth J.; Treiber, Frank] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Ferguson, Pamela L.; Couillard, Deborah; Fahkry, Samir M.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Patel, Sachin K.; Treiber, Frank] Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Hlth Lifestyles, Charleston, SC 29425 USA. RP Price, M (reprint author), Univ Vermont, Dept Psychol, John Dewey Hall,Room 248 2 Colchester Ave, Burlington, VT 05405 USA. EM Matthew.Price@uvm.edu FU NCATS NIH HHS [UL1 TR000062]; NHLBI NIH HHS [R01 HL114957]; NIDDK NIH HHS [R01 DK098777]; NIMH NIH HHS [R01 MH081056, R34 MH096907, T32 MH018869] NR 38 TC 8 Z9 8 U1 7 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAY-JUN PY 2014 VL 36 IS 3 BP 249 EP 254 DI 10.1016/j.genhosppsych.2014.02.004 PG 6 WC Psychiatry SC Psychiatry GA AF2AS UT WOS:000334515600003 PM 24636721 ER PT J AU Ananthakrishnan, AN Khalili, H Konijeti, GG Higuchi, LM de Silva, P Fuchs, CS Willett, WC Richter, JM Chan, AT AF Ananthakrishnan, Ashwin N. Khalili, Hamed Konijeti, Gauree G. Higuchi, Leslie M. de Silva, Punyanganie Fuchs, Charles S. Willett, Walter C. Richter, James M. Chan, Andrew T. TI Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease SO GUT LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; RANDOMIZED CONTROLLED-TRIALS; EUROPEAN PROSPECTIVE COHORT; SUDDEN CARDIAC DEATH; ADIPOSE-TISSUE; LINOLEIC-ACID; SYSTEMIC INFLAMMATION; ADHESION MOLECULES; US WOMEN; FISH-OIL AB Introduction Dietary fats influence intestinal inflammation and regulate mucosal immunity. Data on the association between dietary fat and risk of Crohn's disease (CD) and ulcerative colitis (UC) are limited and conflicting. Methods We conducted a prospective study of women enrolled in the Nurses' Health Study cohorts. Diet was prospectively ascertained every 4 years using a validated semi-quantitative food frequency questionnaire. Self-reported CD and UC were confirmed through medical record review. We examined the effect of energy-adjusted cumulative average total fat intake and specific types of fat and fatty acids on the risk of CD and UC using Cox proportional hazards models adjusting for potential confounders. Results Among 170 805 women, we confirmed 269 incident cases of CD (incidence 8/100 000 person-years) and 338 incident cases of UC (incidence 10/100 000 person-years) over 26 years and 3 317 338 person-years of follow-up. Cumulative energy-adjusted intake of total fat, saturated fats, unsaturated fats, n-6 and n-3 polyunsaturated fatty acids (PUFAs) were not associated with risk of CD or UC. However, greater intake of long-chain n-3 PUFAs was associated with a trend towards lower risk of UC (HR 0.72, 95% CI 0.51 to 1.01). In contrast, high long-term intake of trans-unsaturated fatty acids was associated with a trend towards an increased incidence of UC (HR 1.34, 95% CI 0.94 to 1.92). Conclusions A high intake of dietary long-chain n-3 PUFAs may be associated with a reduced risk of UC. In contrast, high intake of trans-unsaturated fats may be associated with an increased risk of UC. C1 [Ananthakrishnan, Ashwin N.; Khalili, Hamed; Konijeti, Gauree G.; de Silva, Punyanganie; Richter, James M.; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ananthakrishnan, Ashwin N.; Khalili, Hamed; Konijeti, Gauree G.; Higuchi, Leslie M.; de Silva, Punyanganie; Fuchs, Charles S.; Willett, Walter C.; Richter, James M.; Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA USA. [Higuchi, Leslie M.] Childrens Hosp Boston, Div Gastroenterol & Nutr, Boston, MA USA. [Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Fuchs, Charles S.; Willett, Walter C.; Chan, Andrew T.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM aananthakrishnan@partners.org FU American Gastroenterological Association; Crohn's and Colitis Foundation of America; Broad Medical Research Program of the Broad Foundation; National Institutes of Health [K24 DK098311, P01 CA87969, P30 DK043351, K08 DK064256, K23 DK091742, K23 DK099681, UM1 CA176276] FX This work was supported by a Research Scholars Award of the American Gastroenterological Association, Crohn's and Colitis Foundation of America, the Broad Medical Research Program of the Broad Foundation, and the National Institutes of Health (K24 DK098311, P01 CA87969, P30 DK043351, K08 DK064256, K23 DK091742, K23 DK099681, UM1 CA176276). The research presented in this manuscript is original. NR 57 TC 59 Z9 61 U1 0 U2 17 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD MAY PY 2014 VL 63 IS 5 BP 776 EP 784 DI 10.1136/gutjnl-2013-305304 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF0GX UT WOS:000334393400013 PM 23828881 ER PT J AU Cheng, I Kocarnik, JM Dumitrescu, L Lindor, NM Chang-Claude, J Avery, CL Caberto, CP Love, SA Slattery, ML Chan, AT Baron, JA Hindorff, LA Park, SL Schumacher, FR Hoffmeister, M Kraft, P Butler, AM Duggan, DJ Hou, LF Carlson, CS Monroe, KR Lin, Y Carty, CL Mann, S Ma, J Giovannucci, EL Fuchs, CS Newcomb, PA Jenkins, MA Hopper, JL Haile, RW Conti, DV Campbell, PT Potter, JD Caan, BJ Schoen, RE Hayes, RB Chanock, SJ Berndt, SI Kuery, S Bezieau, S Ambite, JL Kumaraguruparan, G Richardson, DM Goodloe, RJ Dilks, HH Baker, P Zanke, BW Lemire, M Gallinger, S Hsu, L Jiao, S Harrison, TA Seminara, D Haiman, CA Kooperberg, C Wilkens, LR Hutter, CM White, E Crawford, DC Heiss, G Hudson, TJ Brenner, H Bush, WS Casey, G Le Marchand, L Peters, U AF Cheng, Iona Kocarnik, Jonathan M. Dumitrescu, Logan Lindor, Noralane M. Chang-Claude, Jenny Avery, Christy L. Caberto, Christian P. Love, Shelly-Ann Slattery, Martha L. Chan, Andrew T. Baron, John A. Hindorff, Lucia A. Park, Sungshim Lani Schumacher, Fredrick R. Hoffmeister, Michael Kraft, Peter Butler, Anne M. Duggan, David J. Hou, Lifang Carlson, Chris S. Monroe, Kristine R. Lin, Yi Carty, Cara L. Mann, Sue Ma, Jing Giovannucci, Edward L. Fuchs, Charles S. Newcomb, Polly A. Jenkins, Mark A. Hopper, John L. Haile, Robert W. Conti, David V. Campbell, Peter T. Potter, John D. Caan, Bette J. Schoen, Robert E. Hayes, Richard B. Chanock, Stephen J. Berndt, Sonja I. Kuery, Sebastien Bezieau, Stephane Ambite, Jose Luis Kumaraguruparan, Gowri Richardson, Danielle M. Goodloe, Robert J. Dilks, Holli H. Baker, Paxton Zanke, Brent W. Lemire, Mathieu Gallinger, Steven Hsu, Li Jiao, Shuo Harrison, Tabitha A. Seminara, Daniela Haiman, Christopher A. Kooperberg, Charles Wilkens, Lynne R. Hutter, Carolyn M. White, Emily Crawford, Dana C. Heiss, Gerardo Hudson, Thomas J. Brenner, Hermann Bush, William S. Casey, Graham Le Marchand, Loic Peters, Ulrike TI Pleiotropic effects of genetic risk variants for other cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia SO GUT LA English DT Article ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; PROSTATE-CANCER; CHROMOSOME 8Q24; MULTIPLE LOCI; COLON-CANCER; BREAST-CANCER; IDENTIFIES 5; DESIGN; METAANALYSIS AB Objective Genome-wide association studies have identified a large number of single nucleotide polymorphisms (SNPs) associated with a wide array of cancer sites. Several of these variants demonstrate associations with multiple cancers, suggesting pleiotropic effects and shared biological mechanisms across some cancers. We hypothesised that SNPs previously associated with other cancers may additionally be associated with colorectal cancer. In a large-scale study, we examined 171 SNPs previously associated with 18 different cancers for their associations with colorectal cancer. Design We examined 13 338 colorectal cancer cases and 40 967 controls from three consortia: Population Architecture using Genomics and Epidemiology (PAGE), Genetic Epidemiology of Colorectal Cancer (GECCO), and the Colon Cancer Family Registry (CCFR). Study-specific logistic regression results, adjusted for age, sex, principal components of genetic ancestry, and/or study specific factors (as relevant) were combined using fixed-effect meta-analyses to evaluate the association between each SNP and colorectal cancer risk. A Bonferroni-corrected p value of 2.92x10(-4) was used to determine statistical significance of the associations. Results Two correlated SNPs-rs10090154 and rs4242382-in Region 1 of chromosome 8q24, a prostate cancer susceptibility region, demonstrated statistically significant associations with colorectal cancer risk. The most significant association was observed with rs4242382 (meta-analysis OR=1.12; 95% CI 1.07 to 1.18; p = 1.74x10(-5)), which also demonstrated similar associations across racial/ethnic populations and anatomical sub-sites. Conclusions This is the first study to clearly demonstrate Region 1 of chromosome 8q24 as a susceptibility locus for colorectal cancer; thus, adding colorectal cancer to the list of cancer sites linked to this particular multicancer risk region at 8q24. C1 [Cheng, Iona] Canc Prevent Inst Calif, Fremont, CA 94538 USA. [Kocarnik, Jonathan M.; Carlson, Chris S.; Lin, Yi; Carty, Cara L.; Mann, Sue; Newcomb, Polly A.; Potter, John D.; Hsu, Li; Jiao, Shuo; Harrison, Tabitha A.; Kooperberg, Charles; Hutter, Carolyn M.; White, Emily; Peters, Ulrike] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Dumitrescu, Logan; Crawford, Dana C.] Vanderbilt Univ, Dept Mol Physiol, Nashville, TN 37235 USA. [Dumitrescu, Logan; Crawford, Dana C.] Vanderbilt Univ, Dept Biophys, Nashville, TN 37235 USA. [Dumitrescu, Logan; Goodloe, Robert J.; Dilks, Holli H.; Baker, Paxton; Crawford, Dana C.; Bush, William S.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37235 USA. [Lindor, Noralane M.; Richardson, Danielle M.] Mayo Clin Arizona, Dept Hlth Sci Res, Scottsdale, AZ 85260 USA. [Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [Avery, Christy L.; Love, Shelly-Ann; Butler, Anne M.; Heiss, Gerardo] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Caberto, Christian P.; Park, Sungshim Lani; Wilkens, Lynne R.; Le Marchand, Loic] Univ Hawaii, Ctr Canc, Epidemiol Program, Honolulu, HI 96822 USA. [Slattery, Martha L.] Univ Utah, Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT USA. [Chan, Andrew T.; Ma, Jing; Giovannucci, Edward L.; Fuchs, Charles S.] Brigham & Womens Hosp & Harvard, Dept Med, Channing Div Network Med, Boston, MA USA. [Chan, Andrew T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Baron, John A.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA. [Hindorff, Lucia A.] NHGRI, Off Populat Genom, NIH, Bethesda, MD 20892 USA. [Schumacher, Fredrick R.; Monroe, Kristine R.; Conti, David V.; Haiman, Christopher A.; Casey, Graham] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90033 USA. [Hoffmeister, Michael; Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Program Mol & Genet Epidemiol, Boston, MA 02115 USA. [Duggan, David J.] Translat Genom Res Inst, Div Genet Basis Human Dis, Phoenix, AZ USA. [Hou, Lifang] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Jenkins, Mark A.; Hopper, John L.] Univ Melbourne, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia. [Haile, Robert W.] Stanford Canc Inst, Palo Alto, CA USA. [Campbell, Peter T.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand. [Caan, Bette J.] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA. [Schoen, Robert E.] Univ Pittsburgh, Med Ctr, Dept Med & Epidemiol, Pittsburgh, PA 15260 USA. [Hayes, Richard B.] NYU, Sch Med, Div Epidemiol, Dept Environm Med, New York, NY USA. [Chanock, Stephen J.; Berndt, Sonja I.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Kuery, Sebastien; Bezieau, Stephane] CHU Nantes, Serv Genet Med, F-44035 Nantes 01, France. [Ambite, Jose Luis; Kumaraguruparan, Gowri] Univ So Calif, Informat Sci Inst, Marinadel Rey, CA USA. [Dilks, Holli H.] Vanderbilt Univ, Vanderbilt Technol Adv Genom, Nashville, TN 37235 USA. [Zanke, Brent W.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Lemire, Mathieu; Hudson, Thomas J.] Ontario Inst Canc Res, Toronto, ON, Canada. [Gallinger, Steven] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Gallinger, Steven] Mt Sinai Hosp, Dept Surg, Toronto, ON M5G 1X5, Canada. [Hsu, Li] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Seminara, Daniela] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Hutter, Carolyn M.; White, Emily; Peters, Ulrike] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Hudson, Thomas J.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada. [Hudson, Thomas J.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. [Brenner, Hermann] Germany German Canc Consortium DKTK, Heidelberg, Germany. [Bush, William S.] Vanderbilt Univ, Dept Biomed Informat, Nashville, TN 37235 USA. RP Cheng, I (reprint author), Canc Prevent Inst Calif, 2201 Walnut Ave,Suite 300, Fremont, CA 94538 USA. EM iona.cheng@cpic.org; jkocarni@fhcrc.org RI KURY, Sebastien/G-5971-2015; Hoffmeister, Michael/B-5745-2012; Bezieau, stephane/G-5621-2015; Jenkins, Mark/P-7803-2015; Brenner, Hermann/B-4627-2017; OI KURY, Sebastien/0000-0001-5497-0465; Hoffmeister, Michael/0000-0002-8307-3197; Bezieau, stephane/0000-0003-0095-1319; Jenkins, Mark/0000-0002-8964-6160; Brenner, Hermann/0000-0002-6129-1572; Bush, William/0000-0002-9729-6519; Potter, John/0000-0001-5439-1500; Hayes, Richard/0000-0002-0918-661X FU National Human Genome Research Institute (NHGRI); CALiCo [U01HG004803]; EAGLE [U01HG004798]; MEC [U01HG004802]; WHI [U01HG004790]; Coordinating Center [U01HG004801]; NHGRI ARRA supplements; NHGRI PAGE program [U01HG004803, U01HG004802, U01HG004790, U01HG004798-01]; NHGRI ARRA supplement; Vanderbilt CTSA from NCATS/NIH [UL1 TR000445]; NHGRI PAGE program (NHGRI ARRA supplement); National Cancer Institute [R37CA54281, R01 CA63464, P01CA33619, U01CA136792, U01CA98758]; National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; Atherosclerosis Risk in Communities (ARIC); National Heart, Lung, and Blood Institute contracts [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]; National Human Genome Research Institute [U01HG004402]; National Institutes of Health [HHSN268200625226C]; National Institutes of Health; NIH Roadmap for Medical Research; National Institutes of Mental Health; [R01HL087641]; [R01HL59367]; [R01HL086694]; [UL1RR025005] FX PAGE: (a) The Population Architecture Using Genomics and Epidemiology (PAGE) program is funded by the National Human Genome Research Institute (NHGRI), supported by U01HG004803 (CALiCo), U01HG004798 (EAGLE), U01HG004802 (MEC), U01HG004790 (WHI) and U01HG004801 (Coordinating Center), and their respective NHGRI ARRA supplements. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The complete list of PAGE members can be found at http://www.pagestudy.org. (b) The data and materials included in this report result from collaboration between the following studies: The 'Epidemiologic Architecture for Genes Linked to Environment (EAGLE)' is funded through the NHGRI PAGE program (U01HG004798-01 and its NHGRI ARRA supplement). The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU which is supported by institutional funding and by the Vanderbilt CTSA grant UL1 TR000445 from NCATS/NIH. The Vanderbilt University Center for Human Genetics Research, Computational Genomics Core provided computational and/or analytical support for this work. The Multiethnic Cohort study (MEC) characterisation of epidemiological architecture is funded through the NHGRI PAGE program (U01HG004802 and its NHGRI ARRA supplement). The MEC study is funded through the National Cancer Institute (R37CA54281, R01 CA63464, P01CA33619, U01CA136792 and U01CA98758). Funding support for the 'Epidemiology of putative genetic variants: The Women's Health Initiative' study is provided through the NHGRI PAGE program (U01HG004790 and its NHGRI ARRA supplement). The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whiscience.org/publications/WHI_investigators_shortlist.pdf. Funding support for the Genetic Epidemiology of Causal Variants Across the Life Course (CALiCo) program was provided through the NHGRI PAGE program (U01HG004803 and its NHGRI ARRA supplement). The following study contributed to this manuscript and is funded by the following agencies: The Atherosclerosis Risk in Communities (ARIC) Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. Assistance with phenotype harmonisation, SNP selection and annotation, data cleaning, data management, integration and dissemination, and general study coordination was provided by the PAGE Coordinating Center (U01HG004801-01 and its NHGRI ARRA supplement). The National Institutes of Mental Health also contributes to the support for the Coordinating Center.; The PAGE consortium thanks the staff and participants of all PAGE studies for their important contributions. NR 70 TC 14 Z9 14 U1 2 U2 13 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD MAY PY 2014 VL 63 IS 5 BP 800 EP 807 DI 10.1136/gutjnl-2013-305189 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF0GX UT WOS:000334393400016 PM 23935004 ER PT J AU Mise, Y Satou, S Shindoh, J Conrad, C Aoki, T Hasegawa, K Sugawara, Y Kokudo, N AF Mise, Yoshihiro Satou, Shouichi Shindoh, Junichi Conrad, Claudius Aoki, Taku Hasegawa, Kiyoshi Sugawara, Yasuhiko Kokudo, Norihiro TI Three-dimensional volumetry in 107 normal livers reveals clinically relevant inter- segment variation in size SO HPB LA English DT Article ID HEPATOCELLULAR-CARCINOMA; COMPUTED-TOMOGRAPHY; ANATOMIC RESECTION; HEPATIC RESECTION; HEPATECTOMY; SURGERY; IMPACT; CT; SUBSEGMENTECTOMY; IDENTIFICATION AB BackgroundThe anatomic resection of Couinaud's segments is one of the key techniques in liver surgery. However, the territories and volumes of the eight segments are not adequately assessed based on portal branching. MethodsThree-dimensional (3D) perfusion-based volumetry was performed in 107 normal livers. Based on Couinaud classification, the portal branches were identified and the volumes of each segment were calculated. The relationships between branching patterns of the portal veins and segmental volumes were assessed. ResultsIn descending order of volume, median volumes of segments VIII, VII, IV, V, III, VI, II and I were recorded. Segment VIII was the largest, accounting for a median of 26.1% (range: 11.1-38.0%) of total liver volume (TLV), whereas segments II and III each represented <10% of TLV. In 69.2% of subjects, the portal branches of segment V diverged from the trunk of the branches of segment VIII. No relationship was found between branching type and segment volume. ConclusionsThe territories and volumes of Couinaud's segments vary among segments, as well as among individuals. Detailed 3D volumetry is useful for preoperative evaluations of the dissection line and of future liver remnant volume in anatomic segmentectomy. C1 [Mise, Yoshihiro; Satou, Shouichi; Shindoh, Junichi; Aoki, Taku; Hasegawa, Kiyoshi; Sugawara, Yasuhiko; Kokudo, Norihiro] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo 1138655, Japan. [Conrad, Claudius] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA. RP Kokudo, N (reprint author), Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan. EM kokudo-2su@h.u-tokyo.ac.jp FU 106th Annual Congress of JSS Memorial Surgical Research Fund, Tokyo, Japan FX This work was supported by a grant-in-aid from the 106th Annual Congress of JSS Memorial Surgical Research Fund, Tokyo, Japan. NR 34 TC 11 Z9 11 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1365-182X EI 1477-2574 J9 HPB JI HPB PD MAY PY 2014 VL 16 IS 5 BP 439 EP 447 DI 10.1111/hpb.12157 PG 9 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA AF7EL UT WOS:000334876300005 PM 24033584 ER PT J AU Ishizawa, T Zuker, NB Conrad, C Lei, HJ Ciacio, O Kokudo, N Gayet, B AF Ishizawa, Takeaki Zuker, Noah B. Conrad, Claudius Lei, Hao-Jan Ciacio, Oriana Kokudo, Norihiro Gayet, Brice TI Using a `no drain' policy in 342 laparoscopic hepatectomies: which factors predict failure? SO HPB LA English DT Article ID MAJOR HEPATIC RESECTION; LIVER RESECTION; ABDOMINAL DRAINAGE; HEPATOCELLULAR-CARCINOMA; METASTASES; RISK; COMPLICATIONS; CHEMOTHERAPY; MANAGEMENT; STEATOSIS AB ObjectivesThe aim of this study was to identify factors that predict the failure of a no drain' policy in laparoscopic hepatectomy. MethodsSurgical outcomes in 342 consecutive patients undergoing laparoscopic hepatectomy were reviewed. Drains were placed only for the following predefined criteria: (i) intraoperative bile leak; (ii) bilioenteric anastomosis, and (iii) increased risk for postoperative bleeding (no drain' policy). Factors leading to need for postoperative drainage or reoperation were evaluated. ResultsDrains were placed in 44 patients (drainage group). Postoperatively, additional procedures were required in five (11.4%) patients in the drainage group and in 18 (6.0%) patients in the no-drainage group. Multivariate analysis suggested that blood loss of >400ml [odds ratio (OR) 4.50, 95% confidence interval (CI) 1.41-14.2; P = 0.010] and preoperative chemotherapy (OR = 2.24, 95% CI 0.82-6.48; P = 0.120) may increase the risk for need for postoperative procedures when intraoperative prophylactic drainage is not used. ConclusionsProphylactic drainage during liver resection should be considered not only in the presence of uncontrollable bile leak or concern for postoperative bleeding risk, but also in patients who have undergone neoadjuvant chemotherapy and those in whom intraoperative blood loss is >400ml. Otherwise, a no drain' policy is safe and would enhance the advantages of minimally invasive liver surgery. C1 [Ishizawa, Takeaki; Zuker, Noah B.; Conrad, Claudius; Lei, Hao-Jan; Ciacio, Oriana; Gayet, Brice] Univ Paris 05, Inst Mutualiste Montsouris, Dept Digest Dis, Paris, France. [Ishizawa, Takeaki; Kokudo, Norihiro] Univ Tokyo, Grad Sch Med, Dept Surg, Div Hepatobiliarypancreat Surg, Tokyo, Japan. [Zuker, Noah B.] Univ New Mexico, Dept Surg, Albuquerque, NM 87131 USA. [Conrad, Claudius] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA. [Lei, Hao-Jan] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Gen Surg, Taipei 112, Taiwan. [Lei, Hao-Jan] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan. [Ciacio, Oriana] Univ Paris South, Hepatobiliary Ctr, Paul Brousse Hosp, AP HP, Villejuif, France. RP Gayet, B (reprint author), Inst Mutualiste Montsouris, Dept Digest Dis, 42 Blvd Jourdan, F-75014 Paris, France. EM brice.gayet@imm.fr FU Takeda Science Foundation; Kanae Foundation for the Promotion of Medical Science; Phillipe Foundation; Canon Foundation in Europe; Ministry of Education, Culture, Sports, Science and Technology of Japan [23689060] FX This work was supported by grants from the Takeda Science Foundation (to TI), the Kanae Foundation for the Promotion of Medical Science (to TI), the Phillipe Foundation (to NBZ), the Canon Foundation in Europe, and the Ministry of Education, Culture, Sports, Science and Technology of Japan (to TI, no. 23689060). NR 24 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1365-182X EI 1477-2574 J9 HPB JI HPB PD MAY PY 2014 VL 16 IS 5 BP 494 EP 499 DI 10.1111/hpb.12165 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA AF7EL UT WOS:000334876300011 PM 23991910 ER PT J AU Wang, MH Fiocchi, C Zhu, XF Ripke, S Kamboh, MI Rebert, N Duerr, RH Achkar, JP AF Wang, Ming-Hsi Fiocchi, Claudio Zhu, Xiaofeng Ripke, Stephan Kamboh, M. Ilyas Rebert, Nancy Duerr, Richard H. Achkar, Jean-Paul TI Gene-gene and gene-environment interactions in ulcerative colitis SO HUMAN GENETICS LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; PRIMARY SCLEROSING CHOLANGITIS; GENOME-WIDE ASSOCIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; LOGIC REGRESSION; RISK LOCI; RHEUMATOID-ARTHRITIS; GENOTYPE IMPUTATION; SMOKING; SUSCEPTIBILITY AB Genome-wide association studies (GWAS) have identified at least 133 ulcerative colitis (UC) associated loci. The role of genetic factors in clinical practice is not clearly defined. The relevance of genetic variants to disease pathogenesis is still uncertain because of not characterized gene-gene and gene-environment interactions. We examined the predictive value of combining the 133 UC risk loci with genetic interactions in an ongoing inflammatory bowel disease (IBD) GWAS. The Wellcome Trust Case-Control Consortium (WTCCC) IBD GWAS was used as a replication cohort. We applied logic regression (LR), a novel adaptive regression methodology, to search for high-order interactions. Exploratory genotype correlations with UC sub-phenotypes [extent of disease, need of surgery, age of onset, extra-intestinal manifestations and primary sclerosing cholangitis (PSC)] were conducted. The combination of 133 UC loci yielded good UC risk predictability [area under the curve (AUC) of 0.86]. A higher cumulative allele score predicted higher UC risk. Through LR, several lines of evidence for genetic interactions were identified and successfully replicated in the WTCCC cohort. The genetic interactions combined with the gene-smoking interaction significantly improved predictability in the model (AUC, from 0.86 to 0.89, P = 3.26E-05). Explained UC variance increased from 37 to 42 % after adding the interaction terms. A within case analysis found suggested genetic association with PSC. Our study demonstrates that the LR methodology allows the identification and replication of high-order genetic interactions in UC GWAS datasets. UC risk can be predicted by a 133 loci and improved by adding gene-gene and gene-environment interactions. C1 [Wang, Ming-Hsi; Fiocchi, Claudio; Achkar, Jean-Paul] Cleveland Clin, Inst Digest Dis, Dept Gastroenterol & Hepatol, Cleveland, OH 44195 USA. [Wang, Ming-Hsi; Fiocchi, Claudio; Rebert, Nancy; Achkar, Jean-Paul] Cleveland Clin, Dept Pathobiol, Lerner Res Inst, Cleveland, OH 44195 USA. [Zhu, Xiaofeng] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. [Ripke, Stephan] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Ripke, Stephan] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Kamboh, M. Ilyas; Duerr, Richard H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Duerr, Richard H.] Univ Pittsburgh, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. RP Achkar, JP (reprint author), Cleveland Clin, Inst Digest Dis, Dept Gastroenterol & Hepatol, 9500 Euclid Ave,Desk A31, Cleveland, OH 44195 USA. EM wangm3@ccf.org; achkarj@ccf.org OI Duerr, Richard/0000-0001-6586-3905; Kamboh, M. Ilyas/0000-0002-3453-1438 FU NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [T32 DK083251, DK068112, DK062420, DK076025, AG030653]; Crohn's and Colitis Foundation of America Senior Research Award; Kenneth and Jennifer Rainin; Wesley Roj; Douglas Durham Roj Endowed Fund; Gerald and Nancy Goldberg FX T32 DK083251, NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (M-H W, CF); DK068112 (J-PA), DK062420 (RHD) and DK076025 (RHD); AG030653 (MIK); a Crohn's and Colitis Foundation of America Senior Research Award (RHD); and funds generously provided by Kenneth and Jennifer Rainin, the Wesley Roj and Douglas Durham Roj Endowed Fund, and Gerald and Nancy Goldberg. NR 55 TC 7 Z9 7 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 EI 1432-1203 J9 HUM GENET JI Hum. Genet. PD MAY PY 2014 VL 133 IS 5 BP 547 EP 558 DI 10.1007/s00439-013-1395-z PG 12 WC Genetics & Heredity SC Genetics & Heredity GA AF2CJ UT WOS:000334519900007 PM 24241240 ER PT J AU Strittmatter, L Li, Y Nakatsuka, NJ Calvo, SE Grabarek, Z Mootha, VK AF Strittmatter, Laura Li, Yang Nakatsuka, Nathan J. Calvo, Sarah E. Grabarek, Zenon Mootha, Vamsi K. TI CLYBL is a polymorphic human enzyme with malate synthase and -methylmalate synthase activity SO HUMAN MOLECULAR GENETICS LA English DT Article ID GLYOXYLATE CYCLE ENZYMES; CITRATE LYASE; PROTEIN-STRUCTURE; SWISS-MODEL; MYCOBACTERIUM-TUBERCULOSIS; RHODOBACTER-SPHAEROIDES; ALDEHYDE DEHYDROGENASE; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; CHICK LIVER AB CLYBL is a human mitochondrial enzyme of unknown function that is found in multiple eukaryotic taxa and conserved to bacteria. The protein is expressed in the mitochondria of all mammalian organs, with highest expression in brown fat and kidney. Approximately 5 of all humans harbor a premature stop polymorphism in CLYBL that has been associated with reduced levels of circulating vitamin B12. Using comparative genomics, we now show that CLYBL is strongly co-expressed with and co-evolved specifically with other components of the mitochondrial B12 pathway. We confirm that the premature stop polymorphism in CLYBL leads to a loss of protein expression. To elucidate the molecular function of CLYBL, we used comparative operon analysis, structural modeling and enzyme kinetics. We report that CLYBL encodes a malate/-methylmalate synthase, converting glyoxylate and acetyl-CoA to malate, or glyoxylate and propionyl-CoA to -methylmalate. Malate synthases are best known for their established role in the glyoxylate shunt of plants and lower organisms and are traditionally described as not occurring in humans. The broader role of a malate/-methylmalate synthase in human physiology and its mechanistic link to vitamin B12 metabolism remain unknown. C1 [Strittmatter, Laura; Li, Yang; Nakatsuka, Nathan J.; Calvo, Sarah E.; Grabarek, Zenon; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA. [Strittmatter, Laura; Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. [Nakatsuka, Nathan J.] Harvard Univ, Sch Med, Harvard Div Hlth Sci & Technol, Boston, MA 02115 USA. [Strittmatter, Laura; Calvo, Sarah E.; Grabarek, Zenon; Mootha, Vamsi K.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02141 USA. [Li, Yang] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA. RP Mootha, VK (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, 185 Cambridge St 6th Floor, Boston, MA 02114 USA. EM vamsi@hms.harvard.edu FU NSF Graduate Research Fellowship; National Institute of General Medical Sciences [T32GM007753]; National Institutes of Health [1R01GM097136] FX This work was supported by an NSF Graduate Research Fellowship (L.S.), the National Institute of General Medical Sciences (T32GM007753 to N.N.) and the National Institutes of Health (1R01GM097136 to V.K.M.). NR 62 TC 4 Z9 5 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAY 1 PY 2014 VL 23 IS 9 BP 2313 EP 2323 DI 10.1093/hmg/ddt624 PG 11 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA AE9VL UT WOS:000334359100007 PM 24334609 ER PT J AU Caron, NS Hung, CL Atwal, RS Truant, R AF Caron, Nicholas S. Hung, Claudia L. Atwal, Randy S. Truant, Ray TI Live cell imaging and biophotonic methods reveal two types of mutant huntingtin inclusions SO HUMAN MOLECULAR GENETICS LA English DT Article ID N-TERMINAL FRAGMENTS; NEURONAL INTRANUCLEAR INCLUSIONS; NEURODEGENERATIVE DISEASES; FLUORESCENT PROTEINS; TRINUCLEOTIDE REPEAT; POLYGLUTAMINE TRACT; FLANKING SEQUENCES; ALZHEIMERS-DISEASE; CASPASE CLEAVAGE; LOCALIZATION AB Huntingtons disease (HD) is an autosomal dominant, neurodegenerative disorder that can be characterized by the presence of protein inclusions containing mutant huntingtin within a subset of neurons in the brain. Since their discovery, the relevance of inclusions to disease pathology has been controversial. We show using super-resolution fluorescence imaging and Frster resonance energy transfer (FRET) in live cells, that mutant huntingtin fragments can form two morphologically and conformationally distinct inclusion types. Using fluorescence recovery after photobleaching (FRAP), we demonstrate that the two huntingtin inclusion types have unique dynamic properties. The ability to form one or the other type of inclusion can be influenced by the phosphorylation state of serine residues at amino acid positions 13 and 16 within the huntingtin protein. We can define two types of inclusions: fibrillar, which are tightly packed, do not exchange protein with the soluble phase, and result from phospho-modification at serines 13 and 16 of the N17 domain, and globular, which are loosely packed, can readily exchange with the soluble phase, and are not phosphorylated in N17. We hypothesize that the protective effect of N17 phosphorylation or phospho-mimicry seen in animal models, at the level of protein inclusions with elevated huntingtin levels, is to induce a conformation of the huntingtin amino-terminus that causes fragments to form tightly packed inclusions that do not exit the insoluble phase, and hence exert less toxicity. The identification of these sub-types of huntingtin inclusions could allow for drug discovery to promote protective inclusions of mutant huntingtin protein in HD. C1 [Caron, Nicholas S.; Hung, Claudia L.; Truant, Ray] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada. [Atwal, Randy S.] Harvard Univ, Sch Med, Massachussetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Truant, R (reprint author), HSC 4N54,1200 Main St West, Hamilton, ON L8N 3Z5, Canada. EM truantr@mcmaster.ca FU Huntington Society of Canada; Canadian Institutes of Health Research [CIHR MOP-119391]; Krembil Family foundation FX This work was supported with operating grants to R.T. from the Huntington Society of Canada, the Canadian Institutes of Health Research (CIHR MOP-119391) and the Krembil Family foundation. NR 65 TC 9 Z9 9 U1 0 U2 14 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAY 1 PY 2014 VL 23 IS 9 BP 2324 EP 2338 DI 10.1093/hmg/ddt625 PG 15 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA AE9VL UT WOS:000334359100008 PM 24334607 ER PT J AU Yoneyama, S Guo, YR Lanktree, MB Barnes, MR Elbers, CC Karczewski, KJ Padmanabhan, S Bauer, F Baumert, J Beitelshees, A Berenson, GS Boer, JMA Burke, G Cade, B Chen, W Cooper-Dehoff, RM Gaunt, TR Gieger, C Gong, Y Gorski, M Heard-Costa, N Johnson, T Lamonte, MJ Mcdonough, C Monda, KL Onland-Moret, NC Nelson, CP O'Connell, JR Ordovas, J Peter, I Peters, A Shaffer, J Shen, HQ Smith, E Speilotes, L Thomas, F Thorand, B Verschuren, WMM Anand, SS Dominiczak, A Davidson, KW Hegele, RA Heid, I Hofker, MH Huggins, GS Illig, T Johnson, JA Kirkland, S Konig, W Langaee, TY Mccaffery, J Melander, O Mitchell, BD Munroe, P Murray, SS Papanicolaou, G Redline, S Reilly, M Samani, NJ Schork, NJ Van der Schouw, YT Shimbo, D Shuldiner, AR Tobin, MD Wijmenga, C Yusuf, S Hakonarson, H Lange, LA Demerath, EW Fox, CS North, KE Reiner, AP Keating, B Taylor, KC AF Yoneyama, Sachiko Guo, Yiran Lanktree, Matthew B. Barnes, Michael R. Elbers, Clara C. Karczewski, Konrad J. Padmanabhan, Sandosh Bauer, Florianne Baumert, Jens Beitelshees, Amber Berenson, Gerald S. Boer, Jolanda M. A. Burke, Gregory Cade, Brian Chen, Wei Cooper-Dehoff, Rhonda M. Gaunt, Tom R. Gieger, Christian Gong, Yan Gorski, Mathias Heard-Costa, Nancy Johnson, Toby Lamonte, Michael J. Mcdonough, Caitrin Monda, Keri L. Onland-Moret, N. Charlotte Nelson, Christopher P. O'Connell, Jeffrey R. Ordovas, Jose Peter, Inga Peters, Annette Shaffer, Jonathan Shen, Haiqinq Smith, Erin Speilotes, Liz Thomas, Fridtjof Thorand, Barbara Verschuren, W. M. Monique Anand, Sonia S. Dominiczak, Anna Davidson, Karina W. Hegele, Robert A. Heid, Iris Hofker, Marten H. Huggins, Gordon S. Illig, Thomas Johnson, Julie A. Kirkland, Susan Koenig, Wolfgang Langaee, Taimour Y. Mccaffery, Jeanne Melander, Olle Mitchell, Braxton D. Munroe, Patricia Murray, Sarah S. Papanicolaou, George Redline, Susan Reilly, Muredach Samani, Nilesh J. Schork, Nicholas J. Van der Schouw, Yvonne T. Shimbo, Daichi Shuldiner, Alan R. Tobin, Martin D. Wijmenga, Cisca Yusuf, Salim Hakonarson, Hakon Lange, Leslie A. Demerath, Ellen W. Fox, Caroline S. North, Kari E. Reiner, Alex P. Keating, Brendan Taylor, Kira C. CA Look AHEAD Res Grp GIANT Consortium CARe IBC Consortium TI Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations SO HUMAN MOLECULAR GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE RISK; WAIST-HIP RATIO; INSULIN-RESISTANCE; METABOLIC SYNDROME; ABDOMINAL OBESITY; DRUGGABLE GENOME; BLOOD-PRESSURE; IDENTIFIES 13 AB Waist circumference (WC) and waist-to-hip ratio (WHR) are surrogate measures of central adiposity that are associated with adverse cardiovascular events, type 2 diabetes and cancer independent of body mass index (BMI). WC and WHR are highly heritable with multiple susceptibility loci identified to date. We assessed the association between SNPs and BMI-adjusted WC and WHR and unadjusted WC in up to 57 412 individuals of European descent from 22 cohorts collaborating with the NHLBIs Candidate Gene Association Resource (CARe) project. The study population consisted of women and men aged 2080 years. Study participants were genotyped using the ITMAT/Broad/CARE array, which includes 50 000 cosmopolitan tagged SNPs across 2100 cardiovascular-related genes. Each trait was modeled as a function of age, study site and principal components to control for population stratification, and we conducted a fixed-effects meta-analysis. No new loci for WC were observed. For WHR analyses, three novel loci were significantly associated (P 2.4 10(6)). Previously unreported rs2811337-G near TMCC1 was associated with increased WHR ( SE, 0.048 0.008, P 7.7 10(9)) as was rs7302703-G in HOXC10 ( 0.044 0.008, P 2.9 10(7)) and rs936108-C in PEMT ( 0.035 0.007, P 1.9 10(6)). Sex-stratified analyses revealed two additional novel signals among females only, rs12076073-A in SHC1 ( 0.10 0.02, P 1.9 10(6)) and rs1037575-A in ATBDB4 ( 0.046 0.01, P 2.2 10(6)), supporting an already established sexual dimorphism of central adiposity-related genetic variants. Functional analysis using ENCODE and eQTL databases revealed that several of these loci are in regulatory regions or regions with differential expression in adipose tissue. C1 [Yoneyama, Sachiko; Monda, Keri L.; North, Kari E.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Lange, Leslie A.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA. [Guo, Yiran; Hakonarson, Hakon; Keating, Brendan] Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr, Philadelphia, PA 19104 USA. [Guo, Yiran] BGI Shenzhen, Shenzhen 518083, Peoples R China. [Lanktree, Matthew B.] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada. [Anand, Sonia S.; Yusuf, Salim] McMaster Univ, Dept Med, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8S 4L8, Canada. [Anand, Sonia S.; Yusuf, Salim] McMaster Univ, Dept Clin Epidemiol, Populat Genom Program, Hamilton, ON L8S 4L8, Canada. [Barnes, Michael R.] Queen Mary Univ London, Natl Inst Hlth Biomed Res Unit, London EC1M 6BQ, England. [Johnson, Toby; Munroe, Patricia] Queen Mary Univ London, London EC1M 6BQ, England. [Johnson, Toby; Munroe, Patricia] Queen Mary Univ London, Genome Ctr, William Harvey Res Inst, Barts, London EC1M 6BQ, England. [Barnes, Michael R.] Queen Mary Univ London, London Sch Med, London EC1M 6BQ, England. [Johnson, Toby; Munroe, Patricia] Queen Mary Univ London, London Sch Med & Dent, London EC1M 6BQ, England. [Elbers, Clara C.; Bauer, Florianne; Onland-Moret, N. Charlotte; Van der Schouw, Yvonne T.] UMC Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands. [Karczewski, Konrad J.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Padmanabhan, Sandosh] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland. [Dominiczak, Anna] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland. [Baumert, Jens; Peters, Annette; Thorand, Barbara] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, D-85764 Neuherberg, Germany. [Gieger, Christian; Heid, Iris] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, D-85764 Neuherberg, Germany. [Illig, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, D-85764 Neuherberg, Germany. [Beitelshees, Amber; Mitchell, Braxton D.] Univ Maryland, Sch Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA. [O'Connell, Jeffrey R.; Shen, Haiqinq; Shuldiner, Alan R.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Shuldiner, Alan R.] Univ Maryland, Sch Med, Program Personalized & Genom Med, Baltimore, MD 21201 USA. [Berenson, Gerald S.; Chen, Wei] Tulane Univ, Dept Epidemiol, New Orleans, LA 70112 USA. [Boer, Jolanda M. A.; Verschuren, W. M. Monique] Natl Inst Publ Hlth & Environm, Ctr Nutr Prevent & Hlth Serv, NL-3720 BA Bilthoven, Netherlands. [Burke, Gregory] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27157 USA. [Look AHEAD Res Grp] Wake Forest Univ, Sch Med, Look AHEAD Coordinating Ctr, Winston Salem, NC 27157 USA. [Cade, Brian; Redline, Susan] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02115 USA. [Cade, Brian; Redline, Susan] Brigham & Womens Hosp, Dept Med, Div Sleep Med, Boston, MA 02115 USA. [Cooper-Dehoff, Rhonda M.; Gong, Yan; Mcdonough, Caitrin; Johnson, Julie A.; Langaee, Taimour Y.] Univ Florida, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA. [Cooper-Dehoff, Rhonda M.; Gong, Yan; Mcdonough, Caitrin; Johnson, Julie A.; Langaee, Taimour Y.] Univ Florida, Ctr Pharmacogen, Gainesville, FL 32610 USA. [Gaunt, Tom R.] MRC Integrat Epidemiol Unit, Sch Social & Community Med, Bristol BS8 2BN, Avon, England. [Gorski, Mathias; Heid, Iris] Univ Regensburg, Inst Epidemiol & Prevent Med, Dept Genet Epidemiol, D-93053 Regensburg, Germany. [Gorski, Mathias] Univ Med Ctr Regensburg, Dept Internal Med 2, D-93053 Regensburg, Germany. [Heard-Costa, Nancy] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Fox, Caroline S.] Boston Univ, Sch Med, Framingham Heart Study, Boston, MA 02118 USA. [Lamonte, Michael J.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14214 USA. [Monda, Keri L.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA. [Nelson, Christopher P.; Samani, Nilesh J.] Univ Leicester, Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England. [Nelson, Christopher P.; Samani, Nilesh J.] Glenfield Hosp, Leicester NIHR Biomed Res Unit Cardiovasc Dis, Leicester LE3 9QP, Leics, England. [Ordovas, Jose] Tufts Univ, Nutr & Genom Lab, Boston, MA 02111 USA. [Peter, Inga] Mt Sinai, Icahn Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Shaffer, Jonathan; Davidson, Karina W.; Shimbo, Daichi] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, Div Gen Med, New York, NY 10032 USA. [Smith, Erin] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA. [Smith, Erin] Univ Calif San Diego, Sch Med, Radys Childrens Hosp, La Jolla, CA 92093 USA. [Speilotes, Liz] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Speilotes, Liz] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA. [Speilotes, Liz] Univ Michigan, Ctr Computat Med & Bioinformat, Ann Arbor, MI 48109 USA. [Speilotes, Liz] Broad Inst, Cambridge, MA 02141 USA. [Thomas, Fridtjof] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN 38163 USA. [Hegele, Robert A.] Univ Western Ontario, Schulich Sch Med & Dent, Robarts Res Inst, London, ON N6A 5C1, Canada. [Hofker, Marten H.] Univ Groningen, Univ Med Ctr Groningen, Dept Mol Genet, NL-9700 AB Groningen, Netherlands. [Huggins, Gordon S.] Tufts Med Ctr, Mol Cardiol Res Inst, Ctr Translat Genom, Boston, MA 02111 USA. [Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, D-30625 Hannover, Germany. [Kirkland, Susan] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada. [Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med 2, D-89081 Ulm, Germany. [Mccaffery, Jeanne] Miriam Hosp, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA. [Mccaffery, Jeanne] Brown Univ, Warren Alpert Sch Med, Providence, RI 02906 USA. [Melander, Olle] Lund Univ, Dept Clin Sci Hypertens & Cardiovasc Dis, SE-20502 Malmo, Sweden. [Murray, Sarah S.; Schork, Nicholas J.] Scripps Hlth, Scripps Res Inst, La Jolla, CA 92037 USA. [Papanicolaou, George] NHLBI, Div Prevent & Populat Sci, NIH, Bethesda, MD 20824 USA. [Reilly, Muredach] Univ Penn, Med Ctr, Cardiovasc Inst, Philadelphia, PA 19104 USA. [Schork, Nicholas J.] Scripps Translat Sci Inst, La Jolla, CA 92037 USA. [Shuldiner, Alan R.] Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, Baltimore, MD 21201 USA. [Tobin, Martin D.] Univ Leicester, Dept Hlth Sci, Leicester LE1 7RH, Leics, England. [Tobin, Martin D.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England. [Wijmenga, Cisca] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands. [Demerath, Ellen W.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA. [North, Kari E.] Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA. [Reiner, Alex P.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Taylor, Kira C.] Univ Louisville, Sch Publ Hlth & Informat Sci, Dept Epidemiol & Populat Hlth, Louisville, KY 40202 USA. RP Taylor, KC (reprint author), Univ Louisville, Sch Publ Hlth & Informat Sci, Dept Epidemiol & Populat Hlth, Louisville, KY 40202 USA. EM kctayl04@louisville.edu RI van der Schouw, Yvonne/F-8327-2014; Gaunt, Tom/O-3918-2014; Guo, Yiran/H-4120-2011; Onland-Moret, N. Charlotte/G-9185-2011; Hegele, Robert/G-3301-2011; Thorand, Barbara/B-5349-2014; Peters, Annette/A-6117-2011; Wijmenga, Cisca/D-2173-2009; Padmanabhan, Sandosh/S-3963-2016 OI Padmanabhan, Sandosh/0000-0003-3869-5808; Gieger, Christian/0000-0001-6986-9554; Mitchell, Braxton/0000-0003-4920-4744; Lanktree, Matthew/0000-0002-5750-6286; Wijmenga, Cisca/0000-0002-5635-1614; Johnson, Toby/0000-0002-5998-3270; van der Schouw, Yvonne/0000-0002-4605-435X; Gaunt, Tom/0000-0003-0924-3247; Karczewski, Konrad/0000-0003-2878-4671; Guo, Yiran/0000-0002-6549-8589; Thorand, Barbara/0000-0002-8416-6440; FU British Heart Foundation [RG/07/005/23633, SP/08/005/25115, PG/07/131/24254]; Medical Research Council [G0902313, MC_UU_12013/8]; NCATS NIH HHS [UL1 TR000064]; NCRR NIH HHS [UL1 RR025774, UL1-RR-024156, UL1RR025005]; NHGRI NIH HHS [U01 HG007416, U01HG004402]; NHLBI NIH HHS [HL080295, K24 HL084034, N01 HC55222, N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-65226, N01-HC-95095, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, R01 HL088119, R01HL086694, R01HL087641, R01HL59367, U01 HL72515]; NIA NIH HHS [AG023629, R01 AG016592]; NICHD NIH HHS [HD-061437, HD-062783]; NIDDK NIH HHS [P30 DK017047, P30 DK072488, U01 DK057131, U01 DK057136]; NIEHS NIH HHS [R01 ES021724]; NIGMS NIH HHS [U01 GM074492, U01 GM074518] NR 68 TC 11 Z9 11 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAY 1 PY 2014 VL 23 IS 9 BP 2498 EP 2510 DI 10.1093/hmg/ddt626 PG 13 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA AE9VL UT WOS:000334359100023 PM 24345515 ER PT J AU Lee, JJ Mochel, MC Piris, A Boussahmain, C Mahalingam, M Hoang, MP AF Lee, Jonathan J. Mochel, Mark C. Piris, Adriano Boussahmain, Chakib Mahalingam, Meera Hoang, Mai P. TI p40 exhibits better specificity than p63 in distinguishing primary skin adnexal carcinomas from cutaneous metastases SO HUMAN PATHOLOGY LA English DT Article DE p40; p63; Cytokeratin 5/6; Adnexal neoplasm; Cutaneous metastasis ID SQUAMOUS-CELL CARCINOMA; IMMUNOHISTOCHEMICAL MARKERS; UROTHELIAL CARCINOMA; DIAGNOSTIC UTILITY; EXPRESSION; ADENOCARCINOMA; NEOPLASMS; BREAST; DELTA-NP63; CALRETININ AB The histopathologic distinction between primary adnexal carcinomas and metastatic adenocarcinoma to the skin from sites such as the breast, lung, and others often presents a diagnostic dilemma. Current markers of diagnostic utility include p63 and cytokeratin 5/6; however, their expression has been demonstrated in 11% to 22% and 27% of cutaneous metastases, respectively. Furthermore, the immunoreactivity of p40 and GATA3 in various cutaneous adnexal carcinomas has not been previously reported. In the present study, we compared the expression of p40, p63, cytokeratin 5/6, and GATA3 in a total of 143 cases, including 67 primary adnexal carcinomas and 76 cutaneous metastases. p40, p63, cytokeratin 5/6, and GATA3 expression was observed in 80%, 84%, 86%, and 47% of primary adnexal carcinoma, respectively, and in 8%, 17%, 26%, and 40% of cutaneous metastases, respectively. chi 2 Analysis revealed statistically significant P values (<.0001) for p40, p63, and cytokeratin 5/6 in distinguishing primary adnexal carcinoma from cutaneous metastases. In summary, while p63 and cytokeratin 5/6 have similar sensitivity (84% and 86%, respectively) in detecting primary adnexal carcinomas, p40 appeared to be the most specific marker (92%) with the best positive predictive value (90%). Since breast and lung are the most common sites of origin for cutaneous metastases, p40 is the best distinguishing marker in these settings. None of the four studied markers (p40, p63, cytokeratin 5/6, and GATA3) are helpful in distinguishing between primary adnexal carcinomas from cutaneous metastases of salivary gland or bladder malignancies. (c) 2014 Elsevier Inc. All rights reserved. C1 [Lee, Jonathan J.; Piris, Adriano; Hoang, Mai P.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Mochel, Mark C.; Piris, Adriano; Boussahmain, Chakib; Hoang, Mai P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mahalingam, Meera] Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA. RP Hoang, MP (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. EM mhoang@mgh.harvard.edu NR 31 TC 6 Z9 7 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0046-8177 EI 1532-8392 J9 HUM PATHOL JI Hum. Pathol. PD MAY PY 2014 VL 45 IS 5 BP 1078 EP 1083 DI 10.1016/j.humpath.2014.01.006 PG 6 WC Pathology SC Pathology GA AG0GL UT WOS:000335093800022 PM 24746214 ER PT J AU Zhang, Z Palmer, JN Morales, KH Howland, TJ Doghramji, LJ Adappa, ND Chiu, AG Cohen, NA Lautenbach, E AF Zhang, Zi Palmer, James N. Morales, Knashawn H. Howland, Timothy J. Doghramji, Laurel J. Adappa, Nithin D. Chiu, Alexander G. Cohen, Noam A. Lautenbach, Ebbing TI Culture-inappropriate antibiotic therapy decreases quality of life improvement after sinus surgery SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE endoscopic sinus surgery; SNOT-22; culture; chronic rhinosinusitis; antibiotic therapy; 22-item Sinonasal Outcome Test; quality of life ID CHRONIC RHINOSINUSITIS; COMPUTED-TOMOGRAPHY; CONTROLLED-TRIAL; DOUBLE-BLIND; ALLERGY; ASTHMA; OUTCOMES; IMPACT; ACID; POLYPOSIS AB Background Despite their widespread use, antibiotics have not been shown to improve chronic rhinosinusitis (CRS) outcomes. We aimed to determine whether culture-inappropriate postoperative antibiotic therapy was associated with less quality-of-life (QOL) improvement following functional endoscopic sinus surgery (FESS). Methods This retrospective cohort study recruited 376 adult CRS patients undergoing FESS between October 1, 2007 to December 31, 2011. Patient demographics, comorbidities and medications were collected at baseline. Trimethoprim-sulfamethoxazole and clindamycin were administered for 2 weeks postoperatively. The antibiotic appropriateness was determined based on bacterial resistance profile of organisms identified during intraoperative culture. The QOL outcome was defined as change of 22-item Sinonasal Outcome Test scores from preoperative visit to 1-month, 3-month, and 6-month post-FESS. Clinically significant difference was defined as at least 0.5 standard deviations (SD) of baseline QOL score in the reference group. Mixed-effects regression models were performed. Results Seven percent of patients (n = 27) had culture-inappropriate antibiotic therapy, and additional 5% (n = 19) had culture-specific antibiotic adjustment. Compared to patients with culture-appropriate antibiotics, patients with culture-inappropriate antibiotics had significantly less improvement of QOL from baseline to postoperative 1-month and 3-month follow-up where the difference became clinically significant; patients with antibiotic adjustment had more QOL improvement from baseline to 1-month follow-up, but their QOL worsened at 3-month follow-up, and these changes were not clinically significant. However, all effects washed out at 6-month follow-up with no significant differences. Conclusion Culture-inappropriate postoperative antibiotic therapy decreased short-term QOL improvement to a clinically meaningful level after FESS. Culture guided selection of antibiotics may improve short-term FESS outcome. C1 [Zhang, Zi; Morales, Knashawn H.; Lautenbach, Ebbing] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Palmer, James N.; Howland, Timothy J.; Doghramji, Laurel J.; Adappa, Nithin D.; Cohen, Noam A.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Lautenbach, Ebbing] Univ Penn, Dept Med, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. RP Zhang, Z (reprint author), 8th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM zizhang@mail.med.upenn.edu RI Chiu, Alexander/J-1230-2014; OI Chiu, Alexander/0000-0002-7592-6575; Cohen, Noam/0000-0002-9462-3932 FU National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) [K24 AI080942/AI/NIAID NIH HHS/United States] FX Funding sources for the study: National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) (K24 AI080942/AI/NIAID NIH HHS/United States to E.L.). NR 41 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD MAY PY 2014 VL 4 IS 5 BP 403 EP 410 DI 10.1002/alr.21277 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA AF7LF UT WOS:000334895900011 PM 24415647 ER PT J AU Meier, JC Remenschneider, AK D'Amico, L Holbrook, EH Gray, ST Metson, R AF Meier, Josh C. Remenschneider, Aaron K. D'Amico, Laura Holbrook, Eric H. Gray, Stacey T. Metson, Ralph TI A new model for collection of clinical outcomes data in patients with chronic rhinosinusitis SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE Quality of life; endoscopic sinus surgery; chronic rhinosinusitis; internet; outcomes measures ID ENDOSCOPIC SINUS SURGERY; QUALITY-OF-LIFE; INTERNET AB Background The need for objective assessment of patient outcomes is becoming an essential component of clinical practice for both private and academic otolaryngologists. The purpose of this study is to describe the implementation of an online model for collection of clinical outcomes data in patients with chronic rhinosinusitis (CRS). Methods Patients completed the Sinonasal Outcome Test (SNOT-22), Chronic Sinusitis Survey (CSS), and EuroQol 5-dimension assessment (EQ-5D), before and after sinus surgery. One year after initial patient enrollment, an online tool was developed to facilitate collection of postoperative data. Response rates preimplementation and postimplementation of online data collection were compared. Results A total of 520 sinus surgery patients provided outcomes data from the practices of 7 private practice (n = 308) and 4 academic otolaryngologists (n = 212). With implementation of the online collection instrument, the response rate at 3 months increased from 67% to 78.8% (p = 0.004). The overall follow-up rate at 3 months was higher in patients recruited from private as compared to academic practices (77.9% vs 69.8%, respectively, p = 0.04). Conclusion Quality of life data can be effectively collected from CRS patients in both the private and academic practice setting. The addition of an online data collection tool can significantly increase response rates, and allow a comprehensive capture of meaningful clinical outcomes. Such a model is not difficult to implement and has increasing relevance as payers begin to request outcome data from providers. C1 [Meier, Josh C.; Remenschneider, Aaron K.; D'Amico, Laura; Holbrook, Eric H.; Gray, Stacey T.; Metson, Ralph] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Meier, Josh C.; Remenschneider, Aaron K.; Holbrook, Eric H.; Gray, Stacey T.; Metson, Ralph] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Meier, JC (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM josh_meier@meei.harvard.edu FU Committee on Quality of the Massachusetts Eye and Ear Infirmary, Boston, MA FX Funding sources for the study: Committee on Quality of the Massachusetts Eye and Ear Infirmary, Boston, MA. NR 13 TC 5 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD MAY PY 2014 VL 4 IS 5 BP 411 EP 415 DI 10.1002/alr.21282 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA AF7LF UT WOS:000334895900012 PM 24431157 ER PT J AU Illidge, T Specht, L Yahalom, J Aleman, B Berthelsen, AK Constine, L Dabaja, B Dharmarajan, K Ng, A Ricardi, U Wirth, A AF Illidge, Tim Specht, Lena Yahalom, Joachim Aleman, Berthe Berthelsen, Anne Kiil Constine, Louis Dabaja, Bouthaina Dharmarajan, Kavita Andrea Ng Ricardi, Umberto Wirth, Andrew CA Int Lymphoma Radiation Oncology Gr TI Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma-Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID B-CELL LYMPHOMA; INVOLVED-FIELD RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; CANCER-PATIENTS; FDG-PET; CHEMOTHERAPY; DISEASE; TRANSPLANTATION; OUTCOMES; FAILURE AB Radiation therapy (RT) is the most effective single modality for local control of non-Hodgkin lymphoma (NHL) and is an important component of therapy for many patients. Many of the historic concepts of dose and volume have recently been challenged by the advent of modern imaging and RT planning tools. The International Lymphoma Radiation Oncology Group (ILROG) has developed these guidelines after multinational meetings and analysis of available evidence. The guidelines represent an agreed consensus view of the ILROG steering committee on the use of RT in NHL in the modern era. The roles of reduced volume and reduced doses are addressed, integrating modern imaging with 3-dimensional planning and advanced techniques of RT delivery. In the modern era, in which combined-modality treatment with systemic therapy is appropriate, the previously applied extended-field and involved-field RT techniques that targeted nodal regions have now been replaced by limiting the RT to smaller volumes based solely on detectable nodal involvement at presentation. A new concept, involved-site RT, defines the clinical target volume. For indolent NHL, often treated with RT alone, larger fields should be considered. Newer treatment techniques, including intensity modulated RT, breath holding, image guided RT, and 4-dimensional imaging, should be implemented, and their use is expected to decrease significantly the risk for normal tissue damage while still achieving the primary goal of local tumor control. (C) 2014 Elsevier Inc. C1 [Illidge, Tim] Univ Manchester, Manchester Acad Hlth Sci Ctr, Inst Canc Sci, Christie Natl Hlth Serv Fdn Trust, Manchester M20 4BX, Lancs, England. [Specht, Lena] Univ Copenhagen, Rigshosp, Dept Hematol & Oncol, DK-2100 Copenhagen, Denmark. [Yahalom, Joachim; Dharmarajan, Kavita] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA. [Aleman, Berthe] Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands. [Berthelsen, Anne Kiil] Univ Copenhagen, Rigshosp, Dept Radiat Oncol, DK-2100 Copenhagen, Denmark. [Berthelsen, Anne Kiil] Univ Copenhagen, Rigshosp, PET Ctr, DK-2100 Copenhagen, Denmark. [Constine, Louis] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA. [Constine, Louis] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Dept Pediat, Rochester, NY 14642 USA. [Dabaja, Bouthaina] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Div Radiat Oncol, Houston, TX 77030 USA. [Andrea Ng] Harvard Univ, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Andrea Ng] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ricardi, Umberto] Univ Turin, Dept Oncol, Radiat Oncol Unit, Turin, Italy. [Wirth, Andrew] Peter MacCallum Canc Inst, Div Radiat Oncol, East Melbourne, Vic, Australia. RP Illidge, T (reprint author), Univ Manchester, Christie NHS Fdn Trust, Inst Canc Sci, Manchester M20 4BX, Lancs, England. EM Tim.Illidge@ics.manchester.ac.uk RI ILLIDGE, Tim/M-3659-2015; OI ILLIDGE, Tim/0000-0003-3191-7324; Specht, Lena/0000-0002-6902-2190 FU Connecticut Sports Foundation; Global Excellence Program of the Capital Region of Denmark FX This project was supported by The Connecticut Sports Foundation and The Global Excellence Program of the Capital Region of Denmark. NR 41 TC 49 Z9 50 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2014 VL 89 IS 1 BP 49 EP 58 DI 10.1016/j.ijrobp.2014.01.006 PG 10 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AF3DA UT WOS:000334590500009 PM 24725689 ER PT J AU Niu, NN Niemierko, A Larvie, M Curtin, H Loeffler, JS McKenna, MJ Shih, HA AF Niu, Nina N. Niemierko, Andrzej Larvie, Mykol Curtin, Hugh Loeffler, Jay S. McKenna, Michael J. Shih, Helen A. TI Pretreatment Growth Rate Predicts Radiation Response in Vestibular Schwannomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID STEREOTACTIC RADIOSURGERY; NEUROFIBROMATOSIS TYPE-2; ACOUSTIC NEUROMAS; OUTCOMES; EXPANSION AB Purpose: Vestibular schwannomas (VS) are often followed without initial therapeutic intervention because many tumors do not grow and radiation therapy is associated with potential adverse effects. In an effort to determine whether maximizing initial surveillance predicts for later treatment response, the predictive value of preirradiation growth rate of VS on response to radiation therapy was assessed. Methods and Materials: Sixty-four patients with 65 VS were treated with single-fraction stereotactic radiation surgery or fractionated stereotactic radiation therapy. Pre-and postirradiation linear expansion rates were estimated using volumetric measurements on sequential magnetic resonance images (MRIs). In addition, postirradiation tumor volume change was classified as demonstrating shrinkage (ratio of volume on last follow-up MRI to MRI immediately preceding irradiation <80%), stability (ratio 80%-120%), or expansion (ratio >120%). The median pre- and postirradiation follow-up was 20.0 and 27.5 months, respectively. Seven tumors from neurofibromatosis type 2 (NF2) patients were excluded from statistical analyses. Results: In the 58 non-NF2 patients, there was a trend of correlation between pre- and postirradiation volume change rates (slope on linear regression, 0.29; P=.06). Tumors demonstrating postirradiation expansion had a median preirradiation growth rate of 89%/year, and those without postirradiation expansion had a median preirradiation growth rate of 41%/year (P=.02). As the preirradiation growth rate increased, the probability of postirradiation expansion also increased. Overall, 24.1% of tumors were stable, 53.4% experienced shrinkage, and 22.5% experienced expansion. Predictors of no postirradiation tumor expansion included no prior surgery (P=.01) and slower tumor growth rate (P=.02). The control of tumors in NF2 patients was only 43%. Conclusions: Radiation therapy is an effective treatment for VS, but tumors that grow quickly preirradiation may be more likely to increase in size. Clinicians should take into account tumor growth rate when counseling patients about treatment options. (C) 2014 Elsevier Inc. C1 [Niu, Nina N.; Larvie, Mykol; Loeffler, Jay S.; Shih, Helen A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Niu, Nina N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Larvie, Mykol] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Curtin, Hugh] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [McKenna, Michael J.] Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. RP Shih, HA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02445 USA. EM hshih@partners.org NR 17 TC 3 Z9 3 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2014 VL 89 IS 1 BP 113 EP 119 DI 10.1016/j.ijrobp.2014.01.038 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AF3DA UT WOS:000334590500017 PM 24725695 ER PT J AU Shusharina, N Cho, J Sharp, GC Choi, NC AF Shusharina, Nadya Cho, Joseph Sharp, Gregory C. Choi, Noah C. TI Correlation of F-18-FDG Avid Volumes on Pre-Radiation Therapy and Post-Radiation Therapy FDG PET Scans in Recurrent Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID RADIATION-THERAPY; TARGET VOLUME; RADIOTHERAPY; TUMOR; CT; HETEROGENEITY; DELINEATION; CHEMORADIOTHERAPY; ALGORITHM; CARCINOMA AB Purpose: To investigate the spatial correlation between high uptake regions of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography (F-18-FDG PET) before and after therapy in recurrent lung cancer. Methods and Materials: We enrolled 106 patients with inoperable lung cancer into a prospective study whose primary objectives were to determine first, the earliest time point when the maximum decrease in FDG uptake representing the maximum metabolic response (MMR) is attainable and second, the optimum cutoff value of MMR based on its predicted tumor control probability, sensitivity, and specificity. Of those patients, 61 completed the required 4 serial F-18-FDG PET examinations after therapy. Nineteen of 61 patients experienced local recurrence at the primary tumor and underwent analysis. The volumes of interest (VOI) on pretherapy FDG-PET were defined by use of an isocontour at >= 50% of maximum standard uptake value (SUVmax) (>= 50% of SUVmax) with correction for heterogeneity. The VOI on posttherapy images were defined at >= 80% of SUVmax. The VOI of pretherapy and posttherapy F-18-FDG PET images were correlated for the extent of overlap. Results: The size of VOI at pretherapy images was on average 25.7% (range, 8.8%-56.3%) of the pretherapy primary gross tumor volume (GTV), and their overlap fractions were 0.8 (95% confidence interval [CI]: 0.7-0.9), 0.63 (95% CI: 0.49-0.77), and 0.38 (95% CI: 0.19-0.57) of VOI of posttherapy FDG PET images at 10 days, 3 months, and 6 months, respectively. The residual uptake originated from the pretherapy VOI in 15 of 17 cases. Conclusions: VOI defined by the SUVmax->= 50% isocontour may be a biological target volume for escalated radiation dose. (C) 2014 Elsevier Inc. C1 [Shusharina, Nadya; Cho, Joseph; Sharp, Gregory C.; Choi, Noah C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. RP Shusharina, N (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. EM nshusharina@partners.org FU National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health [RO1 EB002907] FX Supported in part by grant RO1 EB002907 from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health. NR 22 TC 8 Z9 8 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2014 VL 89 IS 1 BP 137 EP 144 DI 10.1016/j.ijrobp.2014.01.047 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AF3DA UT WOS:000334590500020 PM 24725696 ER PT J AU Gerweck, LE Huang, PG Lu, HM Paganetti, H Zhou, YN AF Gerweck, Leo E. Huang, Peigen Lu, Hsiao-Ming Paganetti, Harald Zhou, Yenong TI Lifetime Increased Cancer Risk in Mice Following Exposure to Clinical Proton Beam-Generated Neutrons SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID ATOMIC-BOMB SURVIVORS; GAMMA-RAYS; TUMOR-INDUCTION; MULTIPLE-MYELOMA; 2ND MALIGNANCIES; FEMALE MICE; FVB/N MICE; X-RAYS; MORTALITY; RADIOTHERAPY AB Purpose: To evaluate the life span and risk of cancer following whole-body exposure of mice to neutrons generated by a passively scattered clinical spread-out Bragg peak (SOBP) proton beam. Methods and Materials: Three hundred young adult female FVB/N mice, 152 test and 148 control, were entered into the experiment. Mice were placed in an annular cassette around a cylindrical phantom, which was positioned lateral to the mid-SOBP of a 165-MeV, clinical proton beam. The average distance from the edge of the mid-SOBP to the conscious active mice was 21.5 cm. The phantom was irradiated with once-daily fractions of 25 Gy, 4 days per week, for 6 weeks. The age at death and cause of death (ie, cancer and type vs noncancer causes) were assessed over the life span of the mice. Results: Exposure of mice to a dose of 600 Gy of proton beam-generated neutrons, reduced the median life span of the mice by 4.2% (Kaplan-Meier cumulative survival, P=.053). The relative risk of death from cancer in neutron exposed versus control mice was 1.40 for cancer of all types (P=.0006) and 1.22 for solid cancers (P=.09). For a typical 60 Gy dose of clinical protons, the observed 22% increased risk of solid cancer would be expected to decrease by a factor of 10. Conclusions: Exposure of mice to neutrons generated by a proton dose that exceeds a typical course of radiation therapy by a factor of 10, resulted in a statistically significant increase in the background incidence of leukemia and a marginally significant increase in solid cancer. The results indicate that the risk of out-of-field second solid cancers from SOBP proton-generated neutrons and typical treatment schedules, is 6 to 10 times less than is suggested by current neutron risk estimates. (C) 2014 Elsevier Inc. C1 [Gerweck, Leo E.; Huang, Peigen; Lu, Hsiao-Ming; Paganetti, Harald; Zhou, Yenong] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Gerweck, LE (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM lgerweck@mgh.harvard.edu OI Paganetti, Harald/0000-0002-6257-2413 FU [NIHC06 CA059267] FX Supported by Federal Share Income: NIHC06 CA059267 (LE Gerweck). NR 34 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2014 VL 89 IS 1 BP 161 EP 166 DI 10.1016/j.ijrobp.2014.01.057 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AF3DA UT WOS:000334590500023 PM 24725699 ER PT J AU Ostergaard, SD Meyers, BS Flint, AJ Mulsant, BH Whyte, EM Ulbricht, CM Bech, P Rothschild, AJ AF Ostergaard, Soren D. Meyers, Barnett S. Flint, Alastair J. Mulsant, Benoit H. Whyte, Ellen M. Ulbricht, Christine M. Bech, Per Rothschild, Anthony J. CA STOP-PD Study Grp TI Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Affective disorders, psychotic; Antidepressive agents; Antipsychotic agents; Psychiatric status rating scales ID MAJOR DEPRESSION; DOUBLE-BLIND; HAMILTON DEPRESSION; RATING-SCALE; TRIALS; ANTIDEPRESSANTS; METAANALYSIS; COMBINATION; OLANZAPINE; FLUOXETINE AB Background: There is no established psychometric instrument dedicated to the measurement of severity in psychotic depression (PD). The aim of this study was to investigate whether a new composite rating scale, the Psychotic Depression Assessment Scale (PDAS), covering both the psychotic and the depressive domains of PD, could detect differences in effect between two psychopharmacological treatment regimens. Methods: We reanalyzed the data from the Study of Pharmacotherapy of Psychotic Depression (STOP-PD), which compared the effect of Olanzapine+Sertraline (n=129) versus Olanzapine+Placebo (n=130). The response to the two regimens was compared using both a mixed effects model and effect size statistics on the total scores of three rating scales: the 17-item Hamilton Depression Rating Scale (HAM-D-17), its 6-item melancholia subscale (HAM-D-6), and the 11-item PDAS consisting of the HAM-D6 plus five items from the Brief Psychiatric Rating Scale covering psychotic symptoms. Results: According to both statistical approaches, the PDAS, the HAM-D17 and the HAM-D6 were all able to detect significant differences in treatment effect between Olanzapine+Sertraline and Olanzapine + Placebo (Olanzapine+Sertraline being superior). Notably, 45% of the trial participants were at least "probable psychotic" at their last assessment in the trial. Limitations: The STOP-PD was not designed specifically to answer the research questions of the present study. Conclusions: The Psychotic Depression Assessment Scale (PDAS) is a sensitive measure of treatment response in PD. The fact that 45% of the patients still experienced psychotic symptoms at their last trial assessment emphasizes the need to include items pertaining to psychotic symptoms in rating scales for PD. (C) 2013 Elsevier B.V. All rights reserved. C1 [Ostergaard, Soren D.] Aalborg Univ Hosp, Aalborg Psychiat Hosp, Unit Psychiat Res, DK-9000 Aalborg, Denmark. [Ostergaard, Soren D.] Aalborg Univ Hosp, Inst Clin Med, DK-9000 Aalborg, Denmark. [Ostergaard, Soren D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA. [Meyers, Barnett S.] Cornell Univ, Dept Psychiat, Weill Med Coll, White Plains, NY USA. [Meyers, Barnett S.] New York Presbyterian Hosp, Westchester Div, White Plains, NY USA. [Flint, Alastair J.] Univ Hlth Network, Dept Psychiat, Toronto, ON, Canada. [Flint, Alastair J.; Mulsant, Benoit H.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Mulsant, Benoit H.] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Mulsant, Benoit H.; Whyte, Ellen M.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA. [Ulbricht, Christine M.; Rothschild, Anthony J.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Bech, Per] Copenhagen Univ Hosp, Psychiat Ctr North Zealand, Psychiat Res Unit, Hillerod, Denmark. [Rothschild, Anthony J.] Univ Massachusetts Mem Hlth Care, Worcester, MA USA. RP Ostergaard, SD (reprint author), Aalborg Univ Hosp, Aalborg Psychiat Hosp, Unit Psychiat Res, Mollepk Vej 10, DK-9000 Aalborg, Denmark. EM sdo@rn.dk OI Ostergaard, Soren Dinesen/0000-0002-8032-6208 FU US Public Health Service [MH 62446, MH 62518, MH 62565, MH 62624]; National Center for Research Resources [M01-RR024153, RR000056, CTSC UL1RR024996]; National Institute of Mental Health (NIMH) [MH069430, MH067710, P30 MH063363] FX The STOP-PD received funding by the US Public Health Service - MH 62446, MH 62518, MH 62565, and MH 62624; National Center for Research Resources - M01-RR024153, RR000056, CTSC UL1RR024996; the National Institute of Mental Health (NIMH) - MH069430, MH067710, and P30 MH063363; The NIMH supported the STOP-PD and participated in its implementation through the UO1 mechanism. They did not partidpate in the collection, analysis, or interpretation of study data or in the preparation, review, or approval of this manuscript. A data safety monitoring board at the NIMH provided data and safety monitoring during the STOP-PD. Eli Lilly donated olanzapine and Pfizer donated sertraline and placebo/sertraline for the STOP-PD. Neither Eli Lilly nor Pfizer participated in the design, implementation, collection, analysis, or interpretation of data in the STOP PD or in the preparation, review, or approval of this manuscript. NR 35 TC 10 Z9 10 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAY PY 2014 VL 160 BP 68 EP 73 DI 10.1016/j.jad.2013.12.020 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE9OK UT WOS:000334337000011 PM 24439830 ER PT J AU Bech, P Bille, J Moller, SB Hellstrom, LC Ostergaard, SD AF Bech, P. Bille, J. Moller, S. B. Hellstrom, L. C. Ostergaard, S. D. TI Psychometric validation of the Hopkins Symptom Checklist (SCL-90) subscales for depression, anxiety, and interpersonal sensitivity SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Psychiatric status rating scales; Affective disorders; Anxiety disorders; Personality disorders ID OUTCOME SCALES HONOS; PSYCHOTHERAPY; DISORDERS; SEVERITY; VALIDITY; HEALTH AB Background: The psychometric validity of many subscales of the 90-item Hopkins Symptom Checklist (SCL-90) remains largely unknown. Therefore, the aim of the present study was to evaluate the psychometric properties of the "Hamilton-subscales" for depression (SCL-D-16), anxiety (SCL-A(14)), their 6-item core-measures (SCL-D-6 and SCL-A(6)), the anxiety symptom scale (SCL-ASS(8)) and the interpersonal sensitivity scale (IPS5). Methods: The psychometric properties of the SCL-D-16, SCL-A(14), SCL-D-6, SCL-A(6), SCL-ASS(8), and the IPS5 were evaluated based on SCL-90 ratings from 850 clay patients from a Danish psychiatric clay hospital. The factor structure of the SCL-D-16 and the SCL-A(14) was investigated by means of principal component analysis (PCA) and the unidimensionality of all scales was estimated by Mokken analysis. Finally, the discriminant validity of the scales, i.e, their ability to distinguish between patients with various diagnoses, was tested. Results: The PCA of the SCL-D-16 and the SCE-AA separated the core depression items from the arousal items on the SCL-D-16 and the psychic anxiety items from the somatic anxiety items on the SCL-A14. According to the Mokken analyses, only the SCL-D-6, the SCL-ASS(8) and the IPS5 were unidimensional. Interestingly, the same three scales displayed discriminant validity for depression, anxiety disorders and personality disorders, respectively. Limitations: The study is based on data from Denmark. This may limit the validity of the results. Conclusions: Three unidimensional SCL-90 subscales were identified. Using these scales it is possible to perform a psychometrically valid evaluation of psychiatric patients regarding the severity of depression (HAM D-6), specific anxiety (SCL-ASS(8)) and interpersonal sensitivity (IPS5). (C) 2014 Published by Elsevier B.V. C1 [Bech, P.; Bille, J.; Moller, S. B.] Univ Copenhagen, Psychiat Ctr North Zealand, Psychiat Res Unit, Hillerod, Denmark. [Hellstrom, L. C.] Univ Copenhagen, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark. [Ostergaard, S. D.] Aalborg Univ Hosp, Aalborg Psychiat Hosp, Unit Psychiat Res, Aalborg, Denmark. [Ostergaard, S. D.] Aarhus Univ Hosp, Inst Clin Med, DK-8000 Aarhus, Denmark. [Ostergaard, S. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA. RP Bech, P (reprint author), Psychiat Ctr North Zealand, Psychiat Res Unit, Dyrehavevej 48, DK-3400 Hillerod, Denmark. EM Per.bech@regionh.dk OI Ostergaard, Soren Dinesen/0000-0002-8032-6208 FU Psychiatric Centre North Zealand FX The work performed in connection with data collection is funded by Psychiatric Centre North Zealand. NR 36 TC 15 Z9 16 U1 2 U2 26 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAY PY 2014 VL 160 BP 98 EP 103 DI 10.1016/j.jad.2013.12.005 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AE9OK UT WOS:000334337000016 PM 24445132 ER PT J AU Drosatos-Tampakaki, Z Drosatos, K Siegelin, Y Gong, S Khan, S Van Dyke, T Goldberg, IJ Schulze, PC Schulze-Spate, U AF Drosatos-Tampakaki, Zoi Drosatos, Konstantinos Siegelin, Yasemin Gong, Shan Khan, Salmiyeh Van Dyke, Thomas Goldberg, Ira J. Schulze, P. Christian Schulze-Spaete, Ulrike TI Palmitic Acid and DGAT1 Deficiency Enhance Osteoclastogenesis, while Oleic Acid- Induced Triglyceride Formation Prevents It SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE OSTEOCLASTOGENESIS; PALMITIC ACID; TNF; DGAT1; TRIGLYCERIDES ID BONE-MINERAL DENSITY; SATURATED FATTY-ACIDS; BODY-MASS INDEX; NF-KAPPA-B; POSTMENOPAUSAL WOMEN; DIABETES-MELLITUS; ADIPOSE-TISSUE; ELDERLY MEN; TNF-ALPHA; KEY ROLE AB Both obesity and diabetes mellitus are associated with alterations in lipid metabolism as well as a change in bone homeostasis and osteoclastogenesis. We hypothesized that increased fatty acid levels affect bone health by altering precursor cell differentiation and osteoclast activation. Here we show that palmitic acid (PA, 16:0) enhances receptor activator of NF-B ligand (RANKL)-stimulated osteoclastogenesis and is sufficient to induce osteoclast differentiation even in the absence of RANKL. TNF expression is crucial for PA-induced osteoclastogenesis, as shown by increased TNF mRNA levels in PA-treated cells and abrogation of PA-stimulated osteoclastogenesis by TNF neutralizing antibodies. In contrast, oleic acid (OA, 18:1) does not enhance osteoclast differentiation, leads to increased intracellular triglyceride accumulation, and inhibits PA-induced osteoclastogenesis. Adenovirus-mediated expression of diacylglycerol acyl transferase 1 (DGAT1), a gene involved in triglyceride synthesis, also inhibits PA-induced osteoclastogenesis, suggesting a protective role of DGAT1 for bone health. Accordingly, Dgat1 knockout mice have larger bone marrow-derived osteoclasts and decreased bone mass indices. In line with these findings, mice on a high-fat PA-enriched diet have a greater reduction in bone mass and structure than mice on a high-fat OA-enriched diet. Thus, we propose that TNF mediates saturated fatty acid-induced osteoclastogenesis that can be prevented by DGAT activation or supplementation with OA. (c) 2014 American Society for Bone and Mineral Research. C1 [Drosatos-Tampakaki, Zoi; Siegelin, Yasemin; Gong, Shan; Schulze-Spaete, Ulrike] Columbia Univ, Coll Dent Med, Div Periodont, New York, NY 10032 USA. [Drosatos, Konstantinos; Goldberg, Ira J.] Columbia Univ Coll Phys & Surg, Div Prevent Med & Nutr, New York, NY 10032 USA. [Khan, Salmiyeh] Barnard Coll, New York, NY USA. [Van Dyke, Thomas] Forsyth Inst, Boston, MA USA. [Schulze, P. Christian] Columbia Univ Coll Phys & Surg, Div Cardiol, New York, NY 10032 USA. RP Schulze-Spate, U (reprint author), Columbia Univ, Coll Dent Med, 630 West 168th St,PH7E-111, New York, NY 10032 USA. EM us2141@columbia.edu FU NIH T32 training grant [HL007343, K08DE018968-03, 5K23HL095742-03, P30, HL45095, 73029]; AHA Postdoctoral Fellowship [10POST4440032]; NHLBI Pathway to Independence Award [1K99HL112853] FX This study was supported by an NIH T32 training grant (HL007343) (ZDT), K08DE018968-03 (USS), 5K23HL095742-03, P30 (PCS), HL45095, and 73029 (IJG). This work was also supported by AHA Postdoctoral Fellowship 10POST4440032 and NHLBI Pathway to Independence Award 1K99HL112853 (KD). NR 84 TC 13 Z9 13 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAY PY 2014 VL 29 IS 5 BP 1183 EP 1195 DI 10.1002/jbmr.2150 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AF4CJ UT WOS:000334658700018 PM 24272998 ER PT J AU Chetty, R Bateman, AC Torlakovic, E Wang, LM Gill, P Al-Badri, A Arends, M Biddlestone, L Burroughs, S Carey, F Cowlishaw, D Crowther, S Da Costa, P Dada, MA d'Adhemar, C Dasgupta, K de Cates, C Deshpande, V Feakins, RM Foria, B Foria, V Fuller, C Green, B Greenson, JK Griffiths, P Hafezi-Bakhtiari, S Henry, J Jaynes, E Jeffers, MD Kaye, P Landers, R Lauwers, GY Loughrey, M Mapstone, N Novelli, M Odze, R Poller, D Rowsell, C Sanders, S Sarsfield, P Schofield, JB Sheahan, K Shepherd, N Sherif, A Sington, J Walsh, S Williams, N Wong, N AF Chetty, Runjan Bateman, Adrian C. Torlakovic, Emina Wang, Lai Mun Gill, Pelvender Al-Badri, Adnan Arends, Mark Biddlestone, Leigh Burroughs, Susan Carey, Frank Cowlishaw, David Crowther, Stephen Da Costa, Philip Dada, Mahomed A. d'Adhemar, Charles Dasgupta, Kaushik de Cates, Chandima Deshpande, Vikram Feakins, Roger M. Foria, Bineeta Foria, Vipul Fuller, Clare Green, Bryan Greenson, Joel K. Griffiths, Paul Hafezi-Bakhtiari, Sara Henry, James Jaynes, Eleanor Jeffers, Michael D. Kaye, Philip Landers, Robert Lauwers, Gregory Y. Loughrey, Maurice Mapstone, Nicholas Novelli, Marco Odze, Robert Poller, David Rowsell, Corwyn Sanders, Scott Sarsfield, Patrick Schofield, John B. Sheahan, Kieran Shepherd, Neil Sherif, Ali Sington, James Walsh, Shaun Williams, Namor Wong, Newton TI A pathologist's survey on the reporting of sessile serrated adenomas/polyps SO JOURNAL OF CLINICAL PATHOLOGY LA English DT Article ID DIAGNOSIS; PATHWAY; LESIONS AB Aim The purpose of this survey was to ascertain reporting habits of pathologists towards sessile serrated adenomas/polyps (SSA/P). Methods A questionnaire designed to highlight diagnostic criteria, approach and clinical implications of SSA/P was circulated electronically to 45 pathologists in the UK and North America. Results Forty-three of 45 pathologists agreed to participate. The vast majority (88%) had a special interest in gastrointestinal (GI) pathology, had great exposure to GI polyps in general with 40% diagnosing SSA/P at least once a week if not more, abnormal architecture was thought by all participants to be histologically diagnostic, and 11% would make the diagnosis if a single diagnostic histological feature was present in one crypt only, while a further 19% would diagnose SSA/P in one crypt if more than one diagnostic feature was present. The vast majority agreed that deeper sections were useful and 88% did not feel proliferation markers were useful. More than one-third did not know whether, or did not feel that, their clinicians were aware of the implications of SSA/P. Conclusions 98% of pathologists surveyed are aware that SSA/P is a precursor lesion to colorectal cancer, the majority agree on diagnostic criteria, and a significant number feel that there needs to be greater communication and awareness among pathologists and gastroenterologists about SSA/P. C1 [Chetty, Runjan; Torlakovic, Emina; Hafezi-Bakhtiari, Sara] Univ Hlth Network, Toronto, ON, Canada. [Bateman, Adrian C.; Foria, Vipul; Green, Bryan; Jaynes, Eleanor] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England. [Wang, Lai Mun; Gill, Pelvender] Oxford Univ Hosp Trust, Oxford, England. [Al-Badri, Adnan] Royal Hampshire Cty Hosp, Winchester, Hants, England. [Arends, Mark] Western Gen Infirm, Edinburgh, Midlothian, Scotland. [Biddlestone, Leigh] Royal United Hosp, Bath BA1 3NG, Avon, England. [Burroughs, Susan; Fuller, Clare] Salisbury NHS Fdn Trust, Salisbury, Wilts, England. [Carey, Frank; Walsh, Shaun] Ninewells Hosp, Dundee DD1 9SY, Scotland. [Cowlishaw, David; Poller, David] Queen Alexandra Hosp, Portsmouth, Hants, England. [Crowther, Stephen; Jeffers, Michael D.] Tallaght Hosp, Dublin, Ireland. [Da Costa, Philip] Airdale Hosp, Keighley, W Yorkshire, England. [Dada, Mahomed A.] W Suffolk Hosp, Bury St Edmunds, Suffolk, England. [d'Adhemar, Charles] Midland Reg Hosp, Tullamore, Ireland. [Dasgupta, Kaushik] Univ Hosp North Tees, Stockton On Tees, Cleveland, England. [de Cates, Chandima; Shepherd, Neil] Cheltenham Gen Hosp, Cheltenham, Glos, England. [Deshpande, Vikram; Lauwers, Gregory Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Feakins, Roger M.] Barts & London NHS Trust, London, England. [Foria, Bineeta] Royal Bournemouth Hosp, Bournemouth, Dorset, England. [Greenson, Joel K.] Univ Michigan Hosp, Ann Arbor, MI 48109 USA. [Griffiths, Paul] Swansea NHS Trust, Swansea, W Glam, Wales. [Henry, James] Queen Elizabeth Hosp, Gateshead, Tyne & Wear, England. [Kaye, Philip] Nottingham Univ Hopsitals, Nottingham, England. [Landers, Robert] Waterford Reg Hosp, Waterford, Ireland. [Loughrey, Maurice] Belfast Trust, Royal Victoria Hosp, Belfast, Antrim, North Ireland. [Mapstone, Nicholas] Royal Lancaster Infirm, Lancaster, England. [Novelli, Marco] Univ Coll London Hosp, London, England. [Odze, Robert] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rowsell, Corwyn] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Sanders, Scott] South Warwickshire Fdn Trust, Warwick, England. [Sarsfield, Patrick] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England. [Schofield, John B.] Kent Oncol Ctr, Maidstone, Kent, England. [Sheahan, Kieran] St Vincents Univ Hosp, Dublin 4, Ireland. [Sherif, Ali] Russell Hall Hosp, Dudley, England. [Sington, James] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England. [Williams, Namor] Singleton Hosp, Swansea SA2 8QA, W Glam, Wales. [Wong, Newton] Bristol Royal Infirm & Gen Hosp, Bristol, Avon, England. RP Chetty, R (reprint author), Toronto Gen Hosp, Univ Hlth Network, Dept Pathol, 11th Floor Eaton Wing,200 Elizabeth St, Toronto, ON M5G 2C4, Canada. EM runjan.chetty@gmail.com OI Bateman, Adrian/0000-0003-2222-4104 NR 16 TC 4 Z9 4 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0021-9746 EI 1472-4146 J9 J CLIN PATHOL JI J. Clin. Pathol. PD MAY PY 2014 VL 67 IS 5 BP 426 EP 430 DI 10.1136/jclinpath-2013-202128 PG 5 WC Pathology SC Pathology GA AF0II UT WOS:000334397100008 PM 24399034 ER PT J AU Kunstfeld, R Hawighorst, T Streit, M Hong, YK Nguyen, L Brown, LF Detmar, M AF Kunstfeld, Rainer Hawighorst, Thomas Streit, Michael Hong, Young-Kwon Lynh Nguyen Brown, Lawrence F. Detmar, Michael TI Thrombospondin-2 overexpression in the skin of transgenic mice reduces the susceptibility to chemically induced multistep skin carcinogenesis SO JOURNAL OF DERMATOLOGICAL SCIENCE LA English DT Article DE Angiogenesis; Skin cancer; Thrombospondin; Carcinogenesis ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; ANGIOGENESIS INHIBITOR; LYMPHATIC METASTASIS; ENDOGENOUS INHIBITOR; VEGF; GENE; LYMPHANGIOGENESIS; CARCINOMA; DENSITY AB Background: We have previously reported stromal upregulation of the endogenous angiogenesis inhibitor thrombospondin-2 (TSP-2) during multistep carcinogenesis, and we found accelerated and enhanced skin angiogenesis and carcinogenesis in TSP-2 deficient mice. Goals: To investigate whether enhanced levels of TSP-2 might protect from skin cancer development. Methods: We established transgenic mice with targeted overexpression of TSP-2 in the skin and subjected hemizygous TSP-2 transgenic mice and their wild-type littermates to a chemical skin carcinogenesis regimen. Results: TSP-2 transgenic mice showed a significantly delayed onset of tumor formation compared to wild-type mice, whereas the ratio of malignant conversion to squamous cell carcinomas was comparable in both genotypes. Computer-assisted morphometric analysis of blood vessels revealed pronounced tumor angiogenesis already in the early stages of carcinogenesis in wild type mice. TSP-2 overexpression significantly reduced tumor blood vessel density in transgenic mice but had no overt effect on LYVE-1 positive lymphatic vessels. The percentage of desmin surrounded, mature tumor-associated blood vessels and the degree of epithelial differentiation remained unaffected. The antiangiogenic effect of transgenic TSP-2 was accompanied by a significantly increased number of apoptotic tumor cells in transgenic mice. Conclusion: Our results demonstrate that enhanced levels of TSP-2 in the skin result in reduced susceptibility to chemically-induced skin carcinogenesis and identify TSP-2 as a new target for the prevention of skin cancer. (C) 2014 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved. C1 [Kunstfeld, Rainer] Med Univ Vienna, Div Gen Dermatol, Dept Dermatol, Vienna, Austria. [Kunstfeld, Rainer; Hawighorst, Thomas; Streit, Michael; Hong, Young-Kwon; Lynh Nguyen; Detmar, Michael] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. [Kunstfeld, Rainer; Hawighorst, Thomas; Streit, Michael; Hong, Young-Kwon; Lynh Nguyen; Detmar, Michael] Massachusetts Gen Hosp, Dept Dermatol, Charlestown, MA USA. [Kunstfeld, Rainer; Hawighorst, Thomas; Streit, Michael; Hong, Young-Kwon; Lynh Nguyen; Detmar, Michael] Harvard Univ, Sch Med, Charlestown, MA USA. [Hawighorst, Thomas] Univ Gottingen, Dept Gynecol & Obstet, D-37073 Gottingen, Germany. [Hong, Young-Kwon] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90033 USA. [Hong, Young-Kwon] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA. [Brown, Lawrence F.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Brown, Lawrence F.] Harvard Univ, Sch Med, Boston, MA USA. [Detmar, Michael] ETH, Swiss Fed Inst Technol, Inst Pharmaceut Sci, Zurich, Switzerland. RP Detmar, M (reprint author), ETH, Swiss Fed Inst Technol, Inst Pharmaceut Sci, Zurich, Switzerland. EM michael.detmar@pharma.ethz.ch FU National Institutes of Health [CA69184]; Swiss National Foundation [3100A0-108207, 31003A-130627]; Advanced European Research Council Grant LYVICAM; Jubilaeumsfonds of the Austrian Federal Reserve Bank [12747]; Deutsche Forschungsgemeinschaft [HA 2898 4-1, HA 2898 4-2]; Krebsliga Schweiz and Krebsliga Zurich FX This work was supported by National Institutes of Health grant CA69184, Swiss National Foundation grants 3100A0-108207 and 31003A-130627, Advanced European Research Council Grant LYVICAM, Krebsliga Schweiz and Krebsliga Zurich (to M.D.), the Jubilaeumsfonds of the Austrian Federal Reserve Bank grant 12747 (to R.K.) and Deutsche Forschungsgemeinschaft grants HA 2898 4-1 and 4-2 (to T.H.). The authors wish to thank Dr. Martin Mihm and Dr. Sam Dadras for critically evaluating H&E stained sections of skin tumors. NR 45 TC 3 Z9 4 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0923-1811 EI 1873-569X J9 J DERMATOL SCI JI J. Dermatol. Sci. PD MAY PY 2014 VL 74 IS 2 BP 106 EP 115 DI 10.1016/j.jdermsci.2014.01.002 PG 10 WC Dermatology SC Dermatology GA AF8TD UT WOS:000334987600002 PM 24507936 ER PT J AU Sun, H Buzon, MJ Shaw, A Berg, RK Yu, XG Ferrando-Martinez, S Leal, M Ruiz-Mateos, E Lichterfeld, M AF Sun, Hong Buzon, Maria J. Shaw, Amy Berg, Randi Karteebahn Yu, Xu G. Ferrando-Martinez, Sara Leal, Manuel Ruiz-Mateos, Ezequiel Lichterfeld, Mathias TI Hepatitis C Therapy With Interferon-alpha and Ribavirin Reduces CD4 T-Cell-Associated HIV-1 DNA in HIV-1/Hepatitis C Virus-Coinfected Patients SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV-1 reservoir; interferon-alpha; ribavirin; HIV-1/HCV coinfection ID REPLICATION; ERADICATION; SUPPRESSION; INTEGRATION; RESERVOIRS; PCR AB Combined treatment with interferon alpha (IFN-alpha) and ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown. Here, we show that treatment with IFN-alpha/RBV led to a moderate but significant and sustained decline of HIV-1 DNA in CD4 T cells from HIV-1/hepatitis C virus-coinfected patients receiving highly active antiretroviral therapy (n = 12). However, in vitro experiments failed to demonstrate an effect of pharmacological doses of IFN-alpha on HIV-1 reactivation. Together, these data suggest that treatment with IFN-alpha/RBV can moderately reduce the reservoir of HIV-1-infected CD4 T cells that persists despite suppressive antiretroviral therapy. C1 [Sun, Hong; Buzon, Maria J.; Shaw, Amy; Berg, Randi Karteebahn; Yu, Xu G.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA. [Sun, Hong; Buzon, Maria J.; Shaw, Amy; Berg, Randi Karteebahn; Yu, Xu G.] Harvard Univ, Boston, MA 02115 USA. [Sun, Hong] China Med Univ, Affiliated Hosp 1, Key Lab AIDS Immunol, Dept Lab Med, Shenyang, Peoples R China. [Buzon, Maria J.; Lichterfeld, Mathias] Massachusetts Gen Hosp, Infect Dis Div, Boston, MA 02114 USA. [Berg, Randi Karteebahn] Aarhus Univ Hosp Skejby, Div Infect Dis, Aarhus, Denmark. [Ferrando-Martinez, Sara; Leal, Manuel; Ruiz-Mateos, Ezequiel] Univ Seville, Virgen del Rocio Univ Hosp, Div Infect Dis Microbiol & Prevent Med, Lab Immunovirol,Biomed Inst Seville, Seville, Spain. [Ferrando-Martinez, Sara] Hosp Gen Univ Gregorio Maranon Madrid, Lab InmunoBiol Mol, Madrid, Spain. [Ferrando-Martinez, Sara] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain. [Ferrando-Martinez, Sara] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain. [Leal, Manuel; Ruiz-Mateos, Ezequiel] CSIC, Madrid, Spain. [Leal, Manuel; Ruiz-Mateos, Ezequiel] Sevicio Andaluz Salud, Seville, Spain. RP Lichterfeld, M (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA. EM mlichterfeld@partners.org RI Leal, Manuel/C-8458-2015; Ruiz-Mateos, Ezequiel/F-2937-2015; Buzon, Maria J/G-8286-2015; IBIS, INMUNOVIROLOGI/O-9246-2015 OI Ruiz-Mateos, Ezequiel/0000-0001-6747-7813; Buzon, Maria J/0000-0003-4427-9413; FU Redes Telematicas de Investigacion Cooperativa en Salud (grant RETICS) [Red de SIDA RD12/0017/0029, RD12/0017/0037]; Fondo de Investigacion Sanitaria [P08/00172, CD10/00382]; European Molecular Biology Organization; Massachusetts General Hospital; US National Institutes of Health [AI093203, AI098487, AI089339]; Doris Duke Charitable Foundation [2009034]; American Foundation for AIDS Research [108302-51-RGRL] FX Financial support. This work was supported by Redes Telematicas de Investigacion Cooperativa en Salud (grant RETICS; 2012, Red de SIDA RD12/0017/0029 and RD12/0017/0037 to M. Le.) and by Fondo de Investigacion Sanitaria (contracts P08/00172 to E. R.-M. and CD10/00382 to S. F.-M.). M. B. is supported by a fellowship award from the European Molecular Biology Organization, and by the Tosteson fellowship award from Massachusetts General Hospital. M. Li. is supported by the US National Institutes of Health (grant numbers AI093203 and AI098487), by the Clinical Scientist Development Award from the Doris Duke Charitable Foundation (grant number 2009034), and by the American Foundation for AIDS Research (grant number 108302-51-RGRL). X. G. Y. is supported by the US National Institutes of Health (grant number AI089339). NR 15 TC 16 Z9 16 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2014 VL 209 IS 9 BP 1315 EP 1320 DI 10.1093/infdis/jit628 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AF4NK UT WOS:000334689700003 PM 24277743 ER PT J AU Truong-Bolduc, QC Villet, RA Estabrooks, ZA Hooper, DC AF Truong-Bolduc, Que Chi Villet, Regis A. Estabrooks, Zoe A. Hooper, David C. TI Native Efflux Pumps Contribute Resistance to Antimicrobials of Skin and the Ability of Staphylococcus aureus to Colonize Skin SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Tet38; NorC; Fatty acid; S; aureus; Spermidine; Tetracycline ID LACTIC-ACID BACTERIA; FATTY-ACIDS; MEDIATED RESISTANCE; EXPRESSION; PROTEIN; ABSCESSES; MEMBRANE; MGRA; NORB; FLUOROQUINOLONES AB Background. Staphylococcus aureus colonizes skin in the presence of antimicrobial fatty acids and polyamines. The chromosomally encoded Tet38 efflux transporter confers resistance to tetracycline and fitness in abscesses, but its natural substrates and those of the Nor quinolone efflux pumps are unknown. Methods. Susceptibility of tet38 and other pump mutants to and pump gene induction by fatty acids and polyamines were compared. Transport of fatty acids by Tet38 was determined in membrane vesicles. Survival on skin was tested in an adapted mouse skin infection model. Results. The tet38 expression caused a 5- to 8-fold increase in resistance to palmitoleic and undecanoic acids but not polyamines. Subinhibitory concentrations of these fatty acids induced 4-fold increases in tet38 transcripts and competitively inhibited transport of Hoechst 33 342 dye in Tet38 membrane vesicles. Colonization of skin in BALB/c mice was decreased 5-fold in a delta tet38 mutant, which was complemented by plasmid-encoded tet38. Although polyamine minimum inhibitory concentrations (MICs) decreased 4-fold in a norC::cat mutant and increased 8-fold with norC overexpression, spermidine did not induce expression of norC and other pump genes, and norC::cat exhibited wild-type colonization. Conclusion. Antibacterial fatty acids may be natural substrates of Tet38, which contributes to resistance and the ability of S. aureus to colonize skin. C1 [Truong-Bolduc, Que Chi; Villet, Regis A.; Estabrooks, Zoe A.; Hooper, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA. RP Truong-Bolduc, QC (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA. EM qtruongbolduc@partners.org FU National Institutes of Health, Public Health Service grant [R37-AI23988] FX Financial support. This work was supported by the National Institutes of Health, Public Health Service grant [R37-AI23988 to D. C. H]. NR 43 TC 9 Z9 9 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2014 VL 209 IS 9 BP 1485 EP 1493 DI 10.1093/infdis/jit660 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AF4NK UT WOS:000334689700022 PM 24280365 ER PT J AU Cheney, MD Giraud, C Goldberg, SI Rosenthal, DI Hornicek, FJ Choy, E Mullen, JT Chen, YL DeLaney, TF AF Cheney, Matthew D. Giraud, Christine Goldberg, Saveli I. Rosenthal, Daniel I. Hornicek, Francis J. Choy, Edwin Mullen, John T. Chen, Yen-Lin DeLaney, Thomas F. TI MRI surveillance following treatment of extremity soft tissue sarcoma SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE neoplasm recurrence; limb salvage; magnetic resonance imaging; local; sarcoma; radiotherapy ID RADIATION-THERAPY; PROGNOSTIC-FACTORS; POSTOPERATIVE RADIOTHERAPY; LOCAL RECURRENCE; SURVIVAL; SURGERY; CHEMOTHERAPY; RESECTION; MARGINS AB Background and Objectives Local recurrence (LR) following limb-sparing surgery and radiation therapy (RT) for extremity soft tissue sarcoma (STS) is rare. The current study investigates the utility of surveillance nuclear magnetic resonance imaging (MRI) for detection of asymptomatic LRs. Methods The study cohort consisted of 168 adult patients with extremity STS treated with limb-sparing surgery and RT with curative intent between October 2001 and January 2011. Follow-up surveillance MRIs and history and physical examinations were performed per the NCCN guidelines with additional MRIs as clinically indicated. The method of LR detection and MRI number and indication were determined. Results After a median follow-up of 4.7 years (range: 0.6-10.5) 11 (6.5%; 11/168) patients developed LRs. Five hundred two MRIs were obtained, 429 (85.5%; 429/502) for surveillance and 73 (14.5%; 73/502) as clinically indicated. One hundred fourteen patients underwent >= 1 surveillance MRI. The median surveillance MRI interval was 6.4 months (range 1.4-68.9). Surveillance MRI detected an asymptomatic LR in 1 (0.9%; 1/114) patient with a complex reconstruction. Conclusions Surveillance MRI infrequently detects asymptomatic LRs following limb-sparing surgery and RT for extremity STS and should be limited to patients whose primary tumor sites are not easily assessed by history and physical examination. J. Surg. Oncol. 2014 109:???-???. (c) 2013 Wiley Periodicals, Inc. C1 [Cheney, Matthew D.] Harvard Radiat Oncol Program, Boston, MA USA. [Giraud, Christine; Goldberg, Saveli I.; Chen, Yen-Lin; DeLaney, Thomas F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Rosenthal, Daniel I.] Massachusetts Gen Hosp, Dept Diagnost Radiol, Boston, MA 02114 USA. [Hornicek, Francis J.] Massachusetts Gen Hosp, Dept Orthoped Oncol, Boston, MA 02114 USA. [Choy, Edwin] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA. [Mullen, John T.] Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA. RP Cheney, MD (reprint author), Massachusetts Gen Hosp, Harvard Radiat Oncol Program, Lunder Bldg LL2,55 Fruit St, Boston, MA 02114 USA. EM mcheney@lroc.harvard.edu OI Cheney, Matthew/0000-0001-8367-3427 FU Jennifer Hunter Yates Sarcoma Foundation; Kenneth Stanton Fund; Cassandra Moseley-Berry Fund; Moseley Family FX Grant sponsor: Jennifer Hunter Yates Sarcoma Foundation.; Grant sponsor: Kenneth Stanton Fund.; Grant sponsor: The Cassandra Moseley-Berry Fund and the Moseley Family. NR 26 TC 11 Z9 12 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4790 EI 1096-9098 J9 J SURG ONCOL JI J. Surg. Oncol. PD MAY PY 2014 VL 109 IS 6 BP 593 EP 596 DI 10.1002/jso.23541 PG 4 WC Oncology; Surgery SC Oncology; Surgery GA AE7NA UT WOS:000334183600015 PM 24374823 ER PT J AU Zhao, GF Yu, YM Shoup, TM Elmaleh, DR Bonab, AA Tompkins, RG Fischman, AJ AF Zhao, Gaofeng Yu, Yong-Ming Shoup, Timothy M. Elmaleh, David R. Bonab, Ali A. Tompkins, Ronald G. Fischman, Alan J. TI Membrane potential-dependent uptake of F-18-triphenylphosphonium-a new voltage sensor as an imaging agent for detecting burn-induced apoptosis SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE F-18-TPP; Mitochondria; Membrane potential; Apoptosis ID CYTOCHROME-C RELEASE; MITOCHONDRIAL DYSFUNCTION; CANCER CELLS; MODEL; PATHWAY; SIMVASTATIN; RESISTANCE; INDUCTION; INJURY; CATION AB Background: Mitochondrial dysfunction has been closely related to many pathologic processes, such as cellular apoptosis. Alterations in organelle membrane potential are associated with mitochondrial dysfunction. A fluorine-18 labeled phosphonium compound: F-18-triphenylphosphonium (F-18-TPP) was prepared to determine its potential use as a mitochondria-targeting radiopharmaceutical to evaluate cellular apoptosis. Methods: Studies were conducted in both ex vivo cell lines and in vivo using a burned animal model. Uptake of F-18-TPP was assessed in PC-3 cells by gamma counting under the following conditions: graded levels of extracellular potassium concentrations, incubation with carbonyl cyanide m-chlorophenylhydrazone and staurosporine. Apoptosis was studied in a burn animal model using terminal deoxynucleotidyl transferase dUTP nick end labeling staining and simultaneous assessment of F-18-TPP uptake by biodistribution. Results: We found that stepwise membrane depolarization by potassium (K) resulted in a linear decrease in F-18-TPP uptake, with a slope of 0.62 +/- 0.08 and a correlation coefficient of 0.936 +/- 0.11. Gradually increased concentrations of m-chlorophenylhydrazone lead to decreased uptake of F-18-TPP. Staurosporine significantly decreased the uptake of F-18-TPP in PC-3 cells from 14.2 +/- 3.8% to 5.6 +/- 1.3% (P < 0.001). Burn-induced significant apoptosis (sham: 4.4 +/- 1.8% versus burn: 24.6 +/- 6.7 %; P < 0.005) and a reduced uptake of tracer in the spleens of burn-injured animals as compared with sham burn controls (burn: 1.13 +/- 0.24% versus sham: 3.28 +/- 0.67%; P < 0.005). Biodistribution studies demonstrated that burn-induced significant reduction in F-18-TPP uptake in spleen, heart, lung, and liver, which were associated with significantly increased apoptosis. Conclusions: F-18-TPP is a promising new voltage sensor for detecting mitochondrial dysfunction and apoptosis in various tissues. (C) 2014 Elsevier Inc. All rights reserved. C1 [Fischman, Alan J.] Shriners Hosp Children, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Fischman, AJ (reprint author), Shriners Hosp Children, Massachusetts Gen Hosp, Dept Surg, 51 Blossom St, Boston, MA 02114 USA. EM aajjff@gmail.com FU Shriners Hospitals for Children [87100]; National Institute of Health [P50 21700] FX This study was supported by grants from Shriners Hospitals for Children (Grant 87100) and the National Institute of Health (P50 21700). NR 19 TC 2 Z9 2 U1 1 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD MAY PY 2014 VL 188 IS 2 BP 473 EP 479 DI 10.1016/j.jss.2014.01.011 PG 7 WC Surgery SC Surgery GA AF3BW UT WOS:000334587500014 PM 24582214 ER PT J AU Miller, DM Flaherty, KT Tsao, H AF Miller, David M. Flaherty, Keith T. Tsao, Hensin TI Commentary: Molecular testing in melanoma SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Editorial Material ID TERT PROMOTER MUTATIONS; BRAF V600E MUTATION; METASTATIC MELANOMA; NRAS MUTATIONS; PHASE-II; CANCER; KIT; SURVIVAL; SAFETY; VEMURAFENIB C1 [Miller, David M.] Columbia Univ, Dept Dermatol, Med Ctr, New York, NY 10027 USA. [Flaherty, Keith T.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Tsao, Hensin] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Tsao, Hensin] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Tsao, H (reprint author), Massachusetts Gen Hosp, Edwards 211,55 Fruit St, Boston, MA 02114 USA. EM htsao@partners.org NR 45 TC 3 Z9 3 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 BP 863 EP 870 DI 10.1016/j.jaad.2014.01.866 PG 8 WC Dermatology SC Dermatology GA AF6UJ UT WOS:000334849800017 PM 24534656 ER PT J AU Nanji, KC Rothschild, JM Boehne, JJ Keohane, CA Ash, JS Poon, EG AF Nanji, Karen C. Rothschild, Jeffrey M. Boehne, Jennifer J. Keohane, Carol A. Ash, Joan S. Poon, Eric G. TI Unrealized potential and residual consequences of electronic prescribing on pharmacy workflow in the outpatient pharmacy SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID PHYSICIAN ORDER ENTRY; MEDICATION INCIDENTS; UNINTENDED CONSEQUENCES; OVERCOMING BARRIERS; ERRORS; SYSTEMS; INTERVENTIONS; PERCEPTIONS; HOSPITALS AB Introduction Electronic prescribing systems have often been promoted as a tool for reducing medication errors and adverse drug events. Recent evidence has revealed that adoption of electronic prescribing systems can lead to unintended consequences such as the introduction of new errors. The purpose of this study is to identify and characterize the unrealized potential and residual consequences of electronic prescribing on pharmacy workflow in an outpatient pharmacy. Methods A multidisciplinary team conducted direct observations of workflow in an independent pharmacy and semi-structured interviews with pharmacy staff members about their perceptions of the unrealized potential and residual consequences of electronic prescribing systems. We used qualitative methods to iteratively analyze text data using a grounded theory approach, and derive a list of major themes and subthemes related to the unrealized potential and residual consequences of electronic prescribing. Results We identified the following five themes: Communication, workflow disruption, cost, technology, and opportunity for new errors. These contained 26 unique subthemes representing different facets of our observations and the pharmacy staff's perceptions of the unrealized potential and residual consequences of electronic prescribing. Discussion We offer targeted solutions to improve electronic prescribing systems by addressing the unrealized potential and residual consequences that we identified. These recommendations may be applied not only to improve staff perceptions of electronic prescribing systems but also to improve the design and/or selection of these systems in order to optimize communication and workflow within pharmacies while minimizing both cost and the potential for the introduction of new errors. C1 [Nanji, Karen C.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Nanji, Karen C.; Rothschild, Jeffrey M.; Poon, Eric G.] Harvard Univ, Sch Med, Boston, MA USA. [Nanji, Karen C.] Partners Healthcare, Boston, MA USA. [Rothschild, Jeffrey M.; Boehne, Jennifer J.; Keohane, Carol A.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA. [Ash, Joan S.] Oregon Hlth & Sci Univ, Sch Med, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Poon, Eric G.] Boston Med Ctr, Boston, MA USA. RP Nanji, KC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM knanji@partners.org FU Agency for Healthcare Research and Quality [U18HS016970] FX This project was supported by grant number U18HS016970 from the Agency for Healthcare Research and Quality (Rockville, MD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. NR 30 TC 9 Z9 9 U1 4 U2 15 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY PY 2014 VL 21 IS 3 BP 481 EP 486 DI 10.1136/amiajnl-2013-001839 PG 6 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA AF3KR UT WOS:000334611600013 PM 24154836 ER PT J AU Nanji, KC Slight, SP Seger, DL Cho, I Fiskio, JM Redden, LM Volk, LA Bates, DW AF Nanji, Karen C. Slight, Sarah P. Seger, Diane L. Cho, Insook Fiskio, Julie M. Redden, Lisa M. Volk, Lynn A. Bates, David W. TI Overrides of medication-related clinical decision support alerts in outpatients SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID PHYSICIAN ORDER ENTRY; AMBULATORY-CARE; SYSTEMS; SAFETY; ERRORS AB Background Electronic prescribing is increasingly used, in part because of government incentives for its use. Many of its benefits come from clinical decision support (CDS), but often too many alerts are displayed, resulting in alert fatigue. Objective To characterize the override rates for medication-related CDS alerts in the outpatient setting, the reasons cited for overrides at the time of prescribing, and the appropriateness of overrides. Methods We measured CDS alert override rates and the coded reasons for overrides cited by providers at the time of prescribing. Our primary outcome was the rate of CDS alert overrides; our secondary outcomes were the rate of overrides by alert type, reasons cited for overrides at the time of prescribing, and override appropriateness for a subset of 600 alert overrides. Through detailed chart reviews of alert override cases, and selective literature review, we developed appropriateness criteria for each alert type, which were modified iteratively as necessary until consensus was reached on all criteria. Results We reviewed 157 483 CDS alerts (7.9% alert rate) on 2 004 069 medication orders during the study period. 82 889 (52.6%) of alerts were overridden. The most common alerts were duplicate drug (33.1%), patient allergy (16.8%), and drug-drug interactions (15.8%). The most likely alerts to be overridden were formulary substitutions (85.0%), age-based recommendations (79.0%), renal recommendations (78.0%), and patient allergies (77.4%). An average of 53% of overrides were classified as appropriate, and rates of appropriateness varied by alert type (p<0.0001) from 12% for renal recommendations to 92% for patient allergies. Discussion About half of CDS alerts were overridden by providers and about half of the overrides were classified as appropriate, but the likelihood of overriding an alert varied widely by alert type. Refinement of these alerts has the potential to improve the relevance of alerts and reduce alert fatigue. C1 [Nanji, Karen C.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Nanji, Karen C.; Slight, Sarah P.; Cho, Insook; Bates, David W.] Univ Durham, Sch Med Pharm & Hlth, Stockton On Tees, England. [Nanji, Karen C.; Seger, Diane L.; Redden, Lisa M.; Volk, Lynn A.; Bates, David W.] Partners Healthcare Syst Inc, Wellesley, MA USA. [Slight, Sarah P.; Cho, Insook; Fiskio, Julie M.; Bates, David W.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. [Cho, Insook] Inha Univ, Sch Med, Inchon, South Korea. RP Nanji, KC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM knanji@partners.org FU Agency for Healthcare Research and Quality (AHRQ) [1U19HS021094-01] FX This work was supported by the Agency for Healthcare Research and Quality (AHRQ, Rockville, MD) grant number 1U19HS021094-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of AHRQ. NR 26 TC 39 Z9 40 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY PY 2014 VL 21 IS 3 BP 487 EP 491 DI 10.1136/amiajnl-2013-001813 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA AF3KR UT WOS:000334611600014 PM 24166725 ER PT J AU Alkhouli, M Sandhu, P Wiegers, SE Patil, P Panidis, J Pursnani, A AF Alkhouli, Mohamad Sandhu, Paul Wiegers, Susan E. Patil, Pravin Panidis, John Pursnani, Amit TI Extracardiac Findings on Routine Echocardiographic Examinations SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY LA English DT Article DE Extracardiac findings; ECG; Cardiovascular imaging; Echocardiography; Descending aortic dilatation; Pleural effusion; Ascites; Liver mass; Extracardiac mass ID EXTRA-CARDIAC FINDINGS; COMPUTED-TOMOGRAPHY; NONCARDIAC FINDINGS; ABNORMALITIES; PREVALENCE; PATHOLOGY; LUNG; CT AB Background: Incidental extracardiac findings (ECFs) have been described and studied in myocardial perfusion imaging, cardiac computed tomography, and cardiac magnetic resonance scanning. The literature is surprisingly limited with regard to ECFs in echocardiography. The aim of this study was to evaluate the prevalence and the clinical significance of ECFs in routine echocardiographic studies. Methods: The literature in other cardiovascular modalities was searched to identify and classify ECFs. ECFs in reports of transthoracic and transesophageal echocardiographic studies performed at Temple Health Network between 2009 and 2011 were sought. A sensitivity analysis was performed by reviewing the actual echocardiographic images for a subset of studies (n = 350) to determine the sensitivity and specificity of the results. The electronic medical records of patients with ECFs on echocardiography were then retrospectively reviewed, except for those with pleural effusions and descending aortic atheroma. Results: A total of 41,067 echocardiographic studies performed between September 2008 and September 2011 (39,269 transthoracic and 1,798 transesophageal studies) were screened. Of these studies, 66.5% were performed in the inpatient setting and 33.5% in the outpatient setting. The prevalence of ECFs was 4.4% (1,797 findings) and was constant during the study years. Pleural effusion was the most common ECF on transthoracic echocardiography, while descending aortic atheroma was the most common ECF on transesophageal echocardiography. Detailed chart reviews were performed in all patients with ECFs, except those with pleural effusion and descending aortic atheroma (351 cases). ECFs on echocardiography led to new diagnoses and altered management in the majority of patients with vascular or liver findings. Conclusions: In this large consecutive series, ECFs on echocardiography were relatively uncommon and had variable clinical implications. The majority or ECFs are likely low-risk findings (pleural effusion, ascites, and hiatal hernia) and can be managed conservatively. "Higher risk'' findings such as liver abnormalities, inferior vena cava filling defects, mediastinal masses, and descending aortic dilatation frequently lead to significant changes in clinical management. There is a need for uniform reporting, appropriate training, and the establishment of national guidelines for ECFs on echocardiography. C1 [Alkhouli, Mohamad; Wiegers, Susan E.; Patil, Pravin; Panidis, John] Temple Univ, Sch Med, Div Cardiol, Philadelphia, PA 19140 USA. [Sandhu, Paul] Boston Univ, Dept Internal Med, Boston, MA 02215 USA. [Pursnani, Amit] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Alkhouli, M (reprint author), Temple Univ, Sch Med, Div Cardiol, 3041 N Broad St,Suite 945,Parkinson Pavilion, Philadelphia, PA 19140 USA. EM adnanalkhouli@gmail.com NR 18 TC 4 Z9 4 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0894-7317 J9 J AM SOC ECHOCARDIOG JI J. Am. Soc. Echocardiogr. PD MAY PY 2014 VL 27 IS 5 BP 540 EP 546 DI 10.1016/j.echo.2014.01.026 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF5KD UT WOS:000334751500010 PM 24637060 ER PT J AU Phillips, D Deipolyi, AR Hesketh, RL Midia, M Oklu, R AF Phillips, Darci Deipolyi, Amy R. Hesketh, Richard L. Midia, Mehran Oklu, Rahmi TI Pelvic Congestion Syndrome: Etiology of Pain, Diagnosis, and Clinical Management SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Review ID OVARIAN VEIN EMBOLIZATION; RESOLVED MR-ANGIOGRAPHY; VARICOSE-VEINS; MEDROXYPROGESTERONE ACETATE; INTERVENTIONAL RADIOLOGY; WOMEN; INCOMPETENCE; CT; EMBOLOTHERAPY; REFLUX AB Pelvic congestion syndrome is associated with pelvic varicosities that result in chronic pelvic pain, especially in the setting of prolonged standing, coitus, menstruation, and pregnancy. Although the underlying pathophysiology of pelvic congestion syndrome is unclear, it probably results from a combination of dysfunctional venous valves, retrograde blood flow, venous hypertension, and dilatation. Asymptomatic women May also have pelvic varicosities, making pelvic congestion syndrome difficult to diagnose. This article explores the etiologies of pain, use of imaging techniques, and clinical management of pelvic congestion syndrome. Possible explanations for the spectrum of pain among women with pelvic varicosities are also discussed. C1 [Phillips, Darci; Deipolyi, Amy R.; Oklu, Rahmi] Harvard Univ, Sch Med, Boston, MA USA. [Deipolyi, Amy R.; Oklu, Rahmi] Massachusetts Gen Hosp, Dept Imaging, Div Intervent Radiol, Boston, MA 02114 USA. [Hesketh, Richard L.] Middlesex Univ Hosp, London, England. [Midia, Mehran] McMaster Univ, Div Intervent Radiol, Med Ctr, Hamilton, ON, Canada. RP Phillips, D (reprint author), Harvard Univ, Sch Med, Boston, MA USA. EM roklu@mghharvard.edu OI Deipolyi, Amy/0000-0003-3144-386X NR 52 TC 6 Z9 7 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD MAY PY 2014 VL 25 IS 5 BP 725 EP 733 DI 10.1016/j.jvir.2014.01.030 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA AF7LI UT WOS:000334896200009 PM 24745902 ER PT J AU Alley, DE Shardell, MD Peters, KW McLean, RR Dam, TTL Kenny, AM Fragala, MS Harris, TB Kiel, DP Guralnik, JM Ferrucci, L Kritchevsky, SB Studenski, SA Vassileva, MT Cawthon, PM AF Alley, Dawn E. Shardell, Michelle D. Peters, Katherine W. McLean, Robert R. Dam, Thuy-Tien L. Kenny, Anne M. Fragala, Maren S. Harris, Tamara B. Kiel, Douglas P. Guralnik, Jack M. Ferrucci, Luigi Kritchevsky, Stephen B. Studenski, Stephanie A. Vassileva, Maria T. Cawthon, Peggy M. TI Grip Strength Cutpoints for the Identification of Clinically Relevant Weakness SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Muscle; Sarcopenia; Grip strength; Physical function; Gait speed ID BONE-MINERAL DENSITY; OLDER-ADULTS; MUSCLE STRENGTH; PHYSICAL PERFORMANCE; BODY-COMPOSITION; WOMENS HEALTH; WHITE WOMEN; MOBILITY; INCHIANTI; RISK AB Weakness is common and contributes to disability, but no consensus exists regarding a strength cutpoint to identify persons at high risk. This analysis, conducted as part of the Foundation for the National Institutes of Health Sarcopenia Project, sought to identify cutpoints that distinguish weakness associated with mobility impairment, defined as gait speed less than 0.8 m/s. In pooled cross-sectional data (9,897 men and 10,950 women), Classification and Regression Tree analysis was used to derive cutpoints for grip strength associated with mobility impairment. In men, a grip strength of 2632 kg was classified as intermediate and less than 26 kg as weak; 11% of men were intermediate and 5% were weak. Compared with men with normal strength, odds ratios for mobility impairment were 3.63 (95% CI: 3.014.38) and 7.62 (95% CI 6.139.49), respectively. In women, a grip strength of 1620 kg was classified as intermediate and less than 16 kg as weak; 25% of women were intermediate and 18% were weak. Compared with women with normal strength, odds ratios for mobility impairment were 2.44 (95% CI 2.202.71) and 4.42 (95% CI 3.944.97), respectively. Weakness based on these cutpoints was associated with mobility impairment across subgroups based on age, body mass index, height, and disease status. Notably, in women, grip strength divided by body mass index provided better fit relative to grip strength alone, but fit was not sufficiently improved to merit different measures by gender and use of a more complex measure. Cutpoints for weakness derived from this large, diverse sample of older adults may be useful to identify populations who may benefit from interventions to improve muscle strength and function. C1 [Alley, Dawn E.; Shardell, Michelle D.; Guralnik, Jack M.] Univ Maryland, Dept Epidemiol & Publ Hlth, Sch Med, Baltimore, MD 21201 USA. [Peters, Katherine W.; Cawthon, Peggy M.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [McLean, Robert R.; Kiel, Douglas P.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA. [McLean, Robert R.; Kiel, Douglas P.] Harvard Univ, Sch Med, Boston, MA USA. [McLean, Robert R.; Kiel, Douglas P.] Hebrew Senior Life Inst Aging Res, Inst Aging Res, Boston, MA USA. [Dam, Thuy-Tien L.] Columbia Univ, Dept Med, New York, NY USA. [Kenny, Anne M.; Fragala, Maren S.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA. [Fragala, Maren S.] Univ Cent Florida, Orlando, FL 32816 USA. [Harris, Tamara B.] NIA, Bethesda, MD 20892 USA. [Ferrucci, Luigi] NIA, Baltimore, MD 21224 USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Sticht Ctr Aging, Winston Salem, NC 27109 USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27109 USA. [Studenski, Stephanie A.] Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA 15260 USA. [Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Vassileva, Maria T.] Fdn NIH Biomarkers Consortium, Bethesda, MD USA. RP Alley, DE (reprint author), Univ Maryland, Sch Med, 660 W Redwood St 221B, Baltimore, MD 21201 USA. EM dalley@epi.umaryland.edu OI Kiel, Douglas/0000-0001-8474-0310 FU National Institute on Aging [1U13AG041583, P30 AG024827]; Food and Drug Administration; Foundation for the NIH; Abbott Nutrition; Amgen; Eli Lilly; Merck; Novartis; Dairy Research Institute; NIH, National Institute on Aging FX Funding support for the conference and the work of the consortium was provided by the National Institute on Aging (1U13AG041583 and P30 AG024827), the Food and Drug Administration, and through grants from the Foundation for the NIH, made possible by funding from Abbott Nutrition, Amgen, Eli Lilly, Merck, Novartis, and The Dairy Research Institute. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. Additional acknowledgements for each contributing cohort and members of the FNIH Sarcopenia Project can be found in an online supplement. NR 34 TC 65 Z9 67 U1 2 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2014 VL 69 IS 5 BP 559 EP 566 DI 10.1093/gerona/glu011 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AF5EY UT WOS:000334738000008 PM 24737558 ER PT J AU Cawthon, PM Peters, KW Shardell, MD McLean, RR Dam, TTL Kenny, AM Fragala, MS Harris, TB Kiel, DP Guralnik, JM Ferrucci, L Kritchevsky, SB Vassileva, MT Studenski, SA Alley, DE AF Cawthon, Peggy M. Peters, Katherine W. Shardell, Michelle D. McLean, Robert R. Dam, Thuy-Tien L. Kenny, Anne M. Fragala, Maren S. Harris, Tamara B. Kiel, Douglas P. Guralnik, Jack M. Ferrucci, Luigi Kritchevsky, Stephen B. Vassileva, Maria T. Studenski, Stephanie A. Alley, Dawn E. TI Cutpoints for Low Appendicular Lean Mass That Identify Older Adults With Clinically Significant Weakness SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Muscle; Sarcopenia; Cutpoints ID BONE-MINERAL DENSITY; ALTERNATIVE DEFINITIONS; PHYSICAL FUNCTION; MUSCLE STRENGTH; WHITE WOMEN; MEN; SARCOPENIA; HEALTH; RISK; PERFORMANCE AB Low lean mass is potentially clinically important in older persons, but criteria have not been empirically validated. As part of the FNIH (Foundation for the National Institutes of Health) Sarcopenia Project, this analysis sought to identify cutpoints in lean mass by dual-energy x-ray absorptiometry that discriminate the presence or absence of weakness (defined in a previous report in the series as grip strength < 26kg in men and < 16kg in women). In pooled cross-sectional data stratified by sex (7,582 men and 3,688 women), classification and regression tree (CART) analysis was used to derive cutpoints for appendicular lean body mass (ALM) that best discriminated the presence or absence of weakness. Mixed-effects logistic regression was used to quantify the strength of the association between lean mass category and weakness. In primary analyses, CART models identified cutpoints for low lean mass (ALM < 19.75kg in men and < 15.02kg in women). Sensitivity analyses using ALM divided by body mass index (BMI: ALM(BMI)) identified a secondary definition (ALM(BMI) < 0.789 in men and ALM(BMI) < 0.512 in women). As expected, after accounting for study and age, low lean mass (compared with higher lean mass) was associated with weakness by both the primary (men, odds ratio [OR]: 6.9 [95% CI: 5.4, 8.9]; women, OR: 3.6 [95% CI: 2.9, 4.3]) and secondary definitions (men, OR: 4.3 [95% CI: 3.4, 5.5]; women, OR: 2.2 [95% CI: 1.8, 2.8]). ALM cutpoints derived from a large, diverse sample of older adults identified lean mass thresholds below which older adults had a higher likelihood of weakness. C1 [Cawthon, Peggy M.; Peters, Katherine W.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA. [Shardell, Michelle D.; Guralnik, Jack M.; Alley, Dawn E.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, College Pk, MD 20742 USA. [McLean, Robert R.; Kiel, Douglas P.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA. [McLean, Robert R.; Kiel, Douglas P.] Harvard Univ, Sch Med, Boston, MA USA. [Dam, Thuy-Tien L.] Columbia Univ, Dept Med, New York, NY USA. [Kenny, Anne M.; Fragala, Maren S.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA. [Fragala, Maren S.] Univ Cent Florida, Orlando, FL 32816 USA. [Harris, Tamara B.; Ferrucci, Luigi] NIA, Bethesda, MD 20892 USA. [Kiel, Douglas P.] Hebrew Senior Life Inst Aging Res, Inst Aging Res, Boston, MA USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Sticht Ctr Aging, Winston Salem, NC 27109 USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27109 USA. [Vassileva, Maria T.] Fdn NIH Biomarkers Consortium, Bethesda, MD USA. [Studenski, Stephanie A.] Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA 15260 USA. [Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Cawthon, PM (reprint author), Calif Pacific Med Ctr, Res Inst, 185 Berry St,Suite 5700, San Francisco, CA 94107 USA. EM pcawthon@sfcc-cpmc.net OI Kiel, Douglas/0000-0001-8474-0310 FU National Institute on Aging [1U13AG041583, P30 AG024827]; Food and Drug Administration; Foundation of the NIH; Abbott Nutrition; Amgen; Eli Lilly; Merck; Novartis; Dairy Research Institute FX Support for the conference and the consortium was provided by the National Institute on Aging (1U13AG041583 and P30 AG024827), the Food and Drug Administration, and through a grant from the Foundation of the NIH, supported by funds from Abbott Nutrition, Amgen, Eli Lilly, Merck, Novartis, and The Dairy Research Institute. NR 27 TC 51 Z9 51 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2014 VL 69 IS 5 BP 567 EP 575 DI 10.1093/gerona/glu023 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AF5EY UT WOS:000334738000009 PM 24737559 ER PT J AU McLean, RR Shardell, MD Alley, DE Cawthon, PM Fragala, MS Harris, TB Kenny, AM Peters, KW Ferrucci, L Guralnik, JM Kritchevsky, SB Kiel, DP Vassileva, MT Xue, QL Perera, S Studenski, SA Dam, TTL AF McLean, Robert R. Shardell, Michelle D. Alley, Dawn E. Cawthon, Peggy M. Fragala, Maren S. Harris, Tamara B. Kenny, Anne M. Peters, Katherine W. Ferrucci, Luigi Guralnik, Jack M. Kritchevsky, Stephen B. Kiel, Douglas P. Vassileva, Maria T. Xue, Qian-Li Perera, Subashan Studenski, Stephanie A. Dam, Thuy-Tien L. TI Criteria for Clinically Relevant Weakness and Low Lean Mass and Their Longitudinal Association With Incident Mobility Impairment and Mortality: The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Muscle; Sarcopenia; Mobility; Impairment ID LOWER-EXTREMITY FUNCTION; OSTEOPOROTIC FRACTURES; BODY-COMPOSITION; MUSCLE STRENGTH; OLDER PERSONS; WHITE WOMEN; MEN; EPIDEMIOLOGY; RISK; PERFORMANCE AB This analysis sought to determine the associations of the Foundation for the National Institutes of Health Sarcopenia Project criteria for weakness and low lean mass with likelihood for mobility impairment (gait speed 0.8 m/s) and mortality. Providing validity for these criteria is essential for research and clinical evaluation. Among 4,411 men and 1,869 women pooled from 6 cohort studies, 3-year likelihood for incident mobility impairment and mortality over 10 years were determined for individuals with weakness, low lean mass, and for those having both. Weakness was defined as low grip strength (< 26kg men and < 16kg women) and low grip strength-to-body mass index (BMI; kg/m(2)) ratio (< 1.00 men and < 0.56 women). Low lean mass (dual-energy x-ray absorptiometry) was categorized as low appendicular lean mass (ALM; < 19.75kg men and < 15.02kg women) and low ALM-to-BMI ratio (< 0.789 men and < 0.512 women). Low grip strength (men: odds ratio [OR] 2.31, 95% confidence interval [CI] 1.343.99; women: OR 1.99, 95% CI 1.233.21), low grip strength-to-BMI ratio (men: OR 3.28, 95% CI 1.925.59; women: OR 2.54, 95% CI 1.105.83) and low ALM-to-BMI ratio (men: OR 1.58, 95% CI 1.122.25; women: OR 1.81, 95% CI 1.142.87), but not low ALM, were associated with increased likelihood for incident mobility impairment. Weakness increased likelihood of mobility impairment regardless of low lean mass. Mortality risk patterns were inconsistent. These findings support our cut-points for low grip strength and low ALM-to-BMI ratio as candidate criteria for clinically relevant weakness and low lean mass. Further validation in other populations and for alternate relevant outcomes is needed. C1 [McLean, Robert R.; Kiel, Douglas P.] Hebrew SeniorLife Inst Aging Res, Boston, MA 02131 USA. [McLean, Robert R.; Kiel, Douglas P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Med, Sch Med, Boston, MA 02215 USA. [Shardell, Michelle D.; Alley, Dawn E.; Guralnik, Jack M.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Cawthon, Peggy M.; Peters, Katherine W.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Fragala, Maren S.; Kenny, Anne M.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA. [Fragala, Maren S.] Univ Cent Florida, Orlando, FL 32816 USA. [Harris, Tamara B.; Ferrucci, Luigi] NIA, Intramural Res Program, NIH, Bethesda, MD 20892 USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Sch Med, Sticht Ctr Aging, Winston Salem, NC 27109 USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27109 USA. [Vassileva, Maria T.] Fdn Natl Inst Hlth, Biomarkers Consortium, Bethesda, MD USA. [Xue, Qian-Li] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA. [Xue, Qian-Li] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD USA. [Perera, Subashan; Studenski, Stephanie A.] Univ Pittsburgh, Dept Internal Med, Sch Med, Pittsburgh, PA 15260 USA. [Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Dam, Thuy-Tien L.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. RP McLean, RR (reprint author), Hebrew SeniorLife Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA. EM rmclean@hsl.harvard.edu OI Kiel, Douglas/0000-0001-8474-0310 FU National Institute on Aging [1U13AG041583, P30 AG024827]; Food and Drug Administration; Foundation for the National Institutes of Health; Abbott Nutrition; Amgen; Eli Lilly; Merck; Novartis; Dairy Research Institute FX Funding support for the conference and the work of the consortium was provided by the National Institute on Aging (1U13AG041583 and P30 AG024827), the Food and Drug Administration and through grants from the Foundation for the National Institutes of Health, made possible by funding from Abbott Nutrition, Amgen, Eli Lilly, Merck, Novartis, and The Dairy Research Institute. NR 33 TC 82 Z9 83 U1 4 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2014 VL 69 IS 5 BP 576 EP 583 DI 10.1093/gerona/glu012 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AF5EY UT WOS:000334738000010 PM 24737560 ER PT J AU Al Hazzouri, AZ Vittinghoff, E Byers, A Covinsky, K Blazer, D Diem, S Ensrud, KE Yaffe, K AF Al Hazzouri, Adina Zeki Vittinghoff, Eric Byers, Amy Covinsky, Ken Blazer, Dan Diem, Susan Ensrud, Kristine E. Yaffe, Kristine TI Long-term Cumulative Depressive Symptom Burden and Risk of Cognitive Decline and Dementia Among Very Old Women SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Depression; Cognition; Alzheimers ID MINI-MENTAL-STATE; PRIMARY-CARE PATIENTS; BETA-AMYLOID LEVEL; ALZHEIMERS-DISEASE; VASCULAR-DISEASE; LATE-LIFE; IMPAIRMENT; COMMUNITY; TRAJECTORIES; ADULTS AB Depressive symptoms and cognitive outcomes are strongly interrelated. Despite that rates of depressive symptoms fluctuate during late life, little is known about the impact of long-term cumulative depressive symptom burden on cognitive decline and dementia in older adults. This study examines the association of nearly 20 years of cumulative depressive symptoms with cognitive outcomes in a cohort of older women. We assessed depressive symptoms in 7,240 women using the Geriatric Depression scale (GDS) at serial visits. We used a Poisson model with random slopes to estimate GDS trajectories for each participant from baseline to death or end of follow-up, and then characterized depressive symptom burden by quartile of the area under the curve. We assessed cognitive outcomes using repeated measures of the Mini-Mental State Examination (MMSE) and Trails B score over 20 years, Year-20 neuropsychological test battery, and adjudicated dementia and mild cognitive impairment (MCI). Adjusting for potential confounders, compared with women in the lowest quartile of cumulative depressive symptoms burden, women in the highest quartile had 21% more MMSE errors over time (95% CI 17%, 26%), 20% worse Trails B score over time (95% CI 17%, 23%), worse scores on most of the Year-20 cognitive tests, and a twofold greater likelihood of developing dementia or MCI (95% CI 1.48, 3.11). Long-term cumulative depressive symptom burden was associated with cognitive decline and risk of dementia or MCI. Older adults with a history of depression should be closely monitored for recurrent episodes or unresolved depressive symptoms as well as any cognitive deficits. C1 [Al Hazzouri, Adina Zeki; Vittinghoff, Eric; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. [Byers, Amy; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94107 USA. [Byers, Amy; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Covinsky, Ken] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94107 USA. [Blazer, Dan] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. [Diem, Susan] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Ensrud, Kristine E.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94107 USA. RP Al Hazzouri, AZ (reprint author), Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM Adina.zekialhazzouri@ucsf.edu FU National Institute of Mental Health [R01 MH086498]; National Institute on Aging [K24 AG031155, 2 R01 AG027574-22A1, R01 AG005407, R01AG027576-22, 2 R01 AG005394-22A1, AG05407, AG05394, AR35582, AR35583, AR35584, AG026720, R01 AG18037, R01 AG028144-01A1]; Alzheimer's Association [IIRG-08-88872]; American Heart Association/American Stroke Association/American Brain Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases FX This work was supported by the National Institute of Mental Health (R01 MH086498); National Institute on Aging (K24 AG031155); and Alzheimer's Association (IIRG-08-88872). Dr. Z.A.H. is supported by the American Heart Association/American Stroke Association/American Brain Foundation Lawrence M. Brass, M. D. Stroke Research Postdoctoral Fellowship. The Study of Osteoporotic Fractures was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute on Aging (Public Health Service grants: 2 R01 AG027574-22A1, R01 AG005407, R01AG027576-22, 2 R01 AG005394-22A1, AG05407, AG05394, AR35582, AR35583, AR35584, AG026720, R01 AG18037, and R01 AG028144-01A1). NR 40 TC 10 Z9 11 U1 3 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2014 VL 69 IS 5 BP 595 EP 601 DI 10.1093/gerona/glt139 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AF5EY UT WOS:000334738000013 ER PT J AU Ting, JY Wu, A Metson, R AF Ting, Jonathan Y. Wu, Arthur Metson, Ralph TI Frontal sinus drillout (modified Lothrop procedure): Long-term results in 204 patients SO LARYNGOSCOPE LA English DT Article DE Draf III procedure; frontal sinusitis; modified Lothrop procedure; Frontal drillout ID ENDOSCOPIC MODIFIED LOTHROP; FOLLOW-UP; EXPERIENCE; SURGERY AB Objectives/Hypothesis To determine the long-term results of frontal sinus drillout (also known as modified Lothrop procedure) for the treatment of advanced frontal sinus disease. Study Design Retrospective review. Methods The records of patients who underwent frontal sinus drillout by a single surgeon at an academic medical center from June 1995 through November 2011 were reviewed. Patient demographics and perioperative clinical findings were analyzed for their impact on surgical outcome. Failure was defined as restenosis of the frontal drainage pathways, necessitating additional frontal sinus surgery. Results A total of 204 patients underwent frontal drillout surgery (143 bilateral procedures) over the 16-year period. Mean follow-up was 10.2 years (range 0.9-17 years). Symptomatic re-obstruction of the frontal sinus requiring revision surgery occurred in 61 (29.9%) patients. Drillouts performed for a diagnosis of mucocele or tumor had significantly higher failure rate (38.9%, odds ratio [OR] = 2.9, P = 0.022 and 58.3%, OR = 5.3, P = 0.020, respectively). The majority of surgical failures (61%) occurred within 2 years of surgery, but delayed failures were observed up to 12 years after drillout. Clinical outcome did not correlate with a history of smoking, asthma, nasal allergy, aspirin sensitivity, prior sinus surgery, nasal polyposis, or the presence of eosinophilic mucin. Conclusion For the majority of patients who undergo frontal sinus drillout, patency of the frontal sinus outflow tract appears to be maintained for more than a decade; nevertheless, almost one-third of patients who undergo this procedure will ultimately require additional frontal sinus surgery. Level of Evidence 4. Laryngoscope, 124:1066-1070, 2014 C1 [Ting, Jonathan Y.] Indiana Univ Sch Med, Dept Otolaryngol, Indianapolis, IN 46202 USA. [Wu, Arthur] Cedars Sinai Med Ctr, Dept Otolaryngol, Los Angeles, CA 90048 USA. [Metson, Ralph] Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Metson, Ralph] Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. RP Metson, R (reprint author), Zero Emerson Pl, Boston, MA 02114 USA. EM Ralph_Metson@meei.harvard.edu NR 14 TC 11 Z9 11 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD MAY PY 2014 VL 124 IS 5 BP 1066 EP 1070 DI 10.1002/lary.24422 PG 5 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA AF4KJ UT WOS:000334680500017 PM 24114727 ER PT J AU Chambers, KJ Lin, DT Meier, J Remenschneider, A Herr, M Gray, ST AF Chambers, Kyle J. Lin, Derrick T. Meier, Josh Remenschneider, Aaron Herr, Marc Gray, Stacey T. TI Incidence and survival patterns of cranial chordoma in the United States SO LARYNGOSCOPE LA English DT Article DE Chordoma; survival; skull base ID SKULL BASE CHORDOMAS; TERM-FOLLOW-UP; CLINICAL ARTICLE; CLIVAL CHORDOMAS; MANAGEMENT; TUMORS; EXPERIENCE; RESECTION; THERAPY; SPINE AB Objectives/Hypothesis To determine trends in survival patterns for cranial chordoma in the United States. Study Design A cross-sectional analysis of a national healthcare database. Methods All cases of microscopically confirmed cranial chordoma between 1973 and 2009 from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute were examined. Age-adjusted incidence and survival rates were calculated and stratified by treatment. Additionally, in order to assess trends over time, comparisons in survival were conducted for 3 calendar year cohorts: 1975 to 1984, 1985 to 1994, and 1995 to 2004. Results A total of 594 cases of microscopically confirmed chordoma involving cranial sites were identified, which accounted for 42% of all chordomas. Age-adjusted incidence rate (IR) of all chordomas was 0.089 per 100,000. Overall median survival time with surgery plus radiation was 9.2 years. Age and treatment modality were found to influence patient survival. Specifically, age > 50 years was associated with a significant increase in mortality rate (P < .05). Five-year survival for the 1975 to 1984, 1985 to 1994, and 1995 to 2004 cohort was 48.5%, 73.0%, and 80.7%, respectively, with improved survival in the more recent cohorts (P < 0.01). Conclusion This study provides new data regarding survival patterns of cranial chordoma in the United States, with a trend toward improvement in survival in recent decades. Level of Evidence NA. Laryngoscope, 124:1097-1102, 2014 C1 Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Chambers, KJ (reprint author), Harvard Univ, Sch Med, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM kyle_chambers@meei.harvard.edu NR 36 TC 10 Z9 11 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD MAY PY 2014 VL 124 IS 5 BP 1097 EP 1102 DI 10.1002/lary.24420 PG 6 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA AF4KJ UT WOS:000334680500023 PM 24122844 ER PT J AU Gustafson, CE Higbee, D Yeckes, AR Wilson, CC De Zoeten, EF Jedlicka, P Janoff, EN AF Gustafson, C. E. Higbee, D. Yeckes, A. R. Wilson, C. C. De Zoeten, E. F. Jedlicka, P. Janoff, E. N. TI Limited expression of APRIL and its receptors prior to intestinal IgA plasma cell development during human infancy SO MUCOSAL IMMUNOLOGY LA English DT Article ID INDUCED CYTIDINE DEAMINASE; B-CELLS; LAMINA PROPRIA; IMMUNE-RESPONSES; LYMPHOID-TISSUE; IN-VITRO; GUT; TACI; MICROBIOTA; INDUCTION AB The absence of immunoglobulin A (IgA) in the intestinal tract renders young infants highly susceptible to enteric infections. However, mediators of initial IgA induction in this population are undefined. We determined the temporal acquisition of plasma cells by isotype and expression of T cell-independent (TI) and -dependent (TD) IgA class switch factors in the human intestinal tract during early infancy. We found that IgA plasma cells were largely absent in the infant intestine until after 1 month of age, approaching adult densities later in infancy than both IgM and IgG. The restricted development of IgA plasma cells in the first month was accompanied by reduced expression of the TI factor a proliferation-inducing ligand (APRIL) and its receptors TACI (transmembrane activator and calcium-modulator and cyclophilin ligand interactor) and B cell maturation antigen (BCMA) within isolated lymphoid follicles (ILFs). Moreover, both APRIL and BCMA expression strongly correlated with increasing IgA plasma cell densities over time. Conversely, TD mediators (CD40 ligand (CD40L) and CD40) were expressed within ILFs before 1 month and were not associated with IgA plasma cell generation. In addition, preterm infants had lower densities of IgA plasma cells and reduced APRIL expression compared with full-term infants. Thus, blunted TI responses may contribute to the delayed induction of intestinal IgA during early human infancy. C1 [Gustafson, C. E.; Higbee, D.; Wilson, C. C.; Janoff, E. N.] Univ Colorado, Div Infect Dis, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. [Gustafson, C. E.; Wilson, C. C.; Janoff, E. N.] Univ Colorado, Natl Jewish Hlth, Integrated Dept Immunol, Aurora, CO USA. [Gustafson, C. E.; Higbee, D.; Janoff, E. N.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Yeckes, A. R.; De Zoeten, E. F.] Univ Colorado, Dept Pediat, Aurora, CO USA. [Jedlicka, P.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA. RP Janoff, EN (reprint author), Univ Colorado, Div Infect Dis, Mucosal & Vaccine Res Program Colorado MAVRC, Anschutz Med Campus, Aurora, CO 80045 USA. EM edward.janoff@ucdenver.edu OI de Zoeten, Edwin/0000-0002-0946-9759 FU National Institutes of Health [R01HD059527, R21AI083615]; NIH/NCATS Colorado CTSI [TL1 TR000155]; Veterans Affairs Research Service FX We thank Stephanie Santorico PhD and Daniel Frank PhD for critical review of statistical analyses; Qi Wei, Dia Hani Barakat, Sara Williams, Matt Maulis, and Alison McMahon for their excellent technical support; and Eric Lee and Martin McCarter for support in specimen collection. This work has been supported by the National Institutes of Health (R01HD059527, R21AI083615), the NIH/NCATS Colorado CTSI Grant Number TL1 TR000155, and the Veterans Affairs Research Service. Contents are the authors' sole responsibility and do not necessarily represent official NIH views. This work was presented in part at the International Congress of Mucosal Immunology (ICMI 2013, Vancouver BC, Canada, 17-20 July 2013). NR 38 TC 9 Z9 9 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1933-0219 EI 1935-3456 J9 MUCOSAL IMMUNOL JI Mucosal Immunol. PD MAY PY 2014 VL 7 IS 3 BP 467 EP 477 DI 10.1038/mi.2013.64 PG 11 WC Immunology SC Immunology GA AF7VT UT WOS:000334923700003 PM 24045575 ER PT J AU Cameron, MH Fitzpatrick, M Overs, S Murchison, C Manning, J Whitham, R AF Cameron, Michelle H. Fitzpatrick, Mary Overs, Shannon Murchison, Charles Manning, Jane Whitham, Ruth TI Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE cohort studies; dalfampridine; Multiple sclerosis; cost effectiveness/economic; walking ID 6-MINUTE WALK; FUNCTIONAL COMPOSITE; EXERCISE CAPACITY; TRIAL; FAMPRIDINE; MSWS-12; MS AB Background: In short-term trials, dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS). The tolerability and effects of dalfampridine-ER in clinical practice have not been reported. Objectives: The objective of this paper is to determine the clinical tolerability and effects of dalfampridine on walking and community participation. Methods: All patients at the Portland VA Medical Center prescribed dalfampridine-ER over one year completed the Timed 25-Foot Walk (T25FW), Multiple Sclerosis Walking Scale-12 (MSWS-12), Two-Minute Timed Walk (2MTW), and Community Integration Questionnaire (CIQ) at baseline and follow-up clinic visits. Ongoing use and measures over one year were analyzed. Results: A total of 39 patients (mean age 56.5 years, mean disease duration 19.5 years, 82% male, 38% relapsing-remitting MS, 62% progressive MS) were prescribed dalfampridine-ER. Twenty-four (62%) continued to take dalfampridine-ER. At initial follow-up, all measures improved significantly from baseline (T25FW: -2.7 s, p = 0.004; 2MTW: 41 feet (ft), p = 0.002; MSWS12: -11, p < 0.001; CIQ: 1.2, p = 0.003). At one year, walking endurance and self-perceived walking were still significantly improved (2MTW: 33 ft, p = 0.03; MSWS-12: 5.9, p = 0.007). Conclusions: Dalfampridine-ER was associated with short-term improvements in walking speed and community participation, and sustained improvements in walking endurance and self-perceived impact of MS on walking for one year. Our study supports the utility of this medication in late MS. C1 [Cameron, Michelle H.; Overs, Shannon; Murchison, Charles; Whitham, Ruth] Oregon Hlth & Sci Univ, Portland, OR 97219 USA. [Cameron, Michelle H.; Overs, Shannon; Murchison, Charles; Manning, Jane; Whitham, Ruth] Portland VA Med Ctr, Portland, OR 97219 USA. RP Cameron, MH (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97219 USA. EM cameromi@ohsu.edu FU Acorda Therapeutics FX Michelle Cameron has received research funding, honoraria and fees for consulting from Acorda Therapeutics. Mary Fitzpatrick is currently employed by Biogen Idec. Shannon Overs, Charles Murchison, Jane Manning and Ruth Whitham report no conflicts of interest. NR 15 TC 2 Z9 2 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD MAY PY 2014 VL 20 IS 6 BP 733 EP 738 DI 10.1177/1352458513507356 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AF7AN UT WOS:000334865900012 PM 24099749 ER PT J AU Carruthers, RL Chitnis, T Healy, BC AF Carruthers, Robert L. Chitnis, Tanuja Healy, Brian C. TI Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE natalizumab; disease modifying therapies; progressive multifocal leukoencephalopathy; multiple sclerosis; JC Virus ID RISK AB JCV serologic status is used to determine PML risk in natalizumab-treated patients. Given two cases of natalizumab-associated PML in JCV sero-negative patients and two publications that question the false negative rate of the JCV serologic test, clinicians may question whether our understanding of PML risk is adequate. Given that there is no gold standard for diagnosing previous JCV exposure, the test characteristics of the JCV serologic test are unknowable. We propose a model of PML risk in JCV sero-negative natalizumab patients. Using the numbers of JCV sero-positive and -negative patients from a study of PML risk by JCV serologic status (sero-positive: 13,950 and sero-negative: 11,414), we apply a range of sensitivities and specificities in order calculate the number of JCV-exposed but JCV sero-negative patients (false negatives). We then apply a range of rates of developing PML in sero-negative patients to calculate the expected number of PML cases. By using the binomial function, we calculate the probability of a given number of JCV sero-negative PML cases. With this model, one has a means to establish a threshold number of JCV sero-negative natalizumab-associated PML cases at which it is improbable that our understanding of PML risk in JCV sero-negative patients is adequate. C1 [Carruthers, Robert L.; Chitnis, Tanuja; Healy, Brian C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Carruthers, Robert L.; Chitnis, Tanuja; Healy, Brian C.] Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Boston, MA 02115 USA. [Healy, Brian C.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. RP Carruthers, RL (reprint author), Partners MS Ctr, 1 Brookline Pl Suite 225, Brookline, MA 02446 USA. EM drrobertcarruthers@gmail.com FU National Multiple Sclerosis Society FX RC received a Clinical Fellowship Training Grant from the National Multiple Sclerosis Society. NR 7 TC 1 Z9 1 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD MAY PY 2014 VL 20 IS 6 BP 757 EP 760 DI 10.1177/1352458513509509 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AF7AN UT WOS:000334865900018 PM 24189572 ER PT J AU Pfreundschuh, M Martinez-Martin, D Mulvihill, E Wegmann, S Muller, DJ AF Pfreundschuh, Moritz Martinez-Martin, David Mulvihill, Estefania Wegmann, Susanne Muller, Daniel J. TI Multiparametric high-resolution imaging of native proteins by force-distance curve-based AFM SO NATURE PROTOCOLS LA English DT Article ID SINGLE-MOLECULE EXPERIMENTS; SCANNING PROBE MICROSCOPY; MEMBRANE-PROTEINS; NANOMECHANICAL PROPERTIES; SUBNANOMETER RESOLUTION; ELECTROLYTE-SOLUTIONS; AMYLOID FIBRILS; LIVING CELLS; BACTERIORHODOPSIN DEPEND; CONFORMATIONAL-CHANGES AB A current challenge in the life sciences is to understand how the properties of individual molecular machines adjust in order to meet the functional requirements of the cell. Recent developments in force-distance (FD) curve-based atomic force microscopy (FD-based AFM) enable researchers to combine sub-nanometer imaging with quantitative mapping of physical, chemical and biological properties. Here we present a protocol to apply FD-based AFM to the multiparametric imaging of native proteins under physiological conditions. We describe procedures for experimental FD-based AFM setup, high-resolution imaging of proteins in the native unperturbed state with simultaneous quantitative mapping of multiple parameters, and data interpretation and analysis. The protocol, which can be completed in 1-3 d, enables researchers to image proteins and protein complexes in the native unperturbed state and to simultaneously map their biophysical and biochemical properties at sub-nanometer resolution. C1 [Pfreundschuh, Moritz; Martinez-Martin, David; Mulvihill, Estefania; Muller, Daniel J.] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland. [Wegmann, Susanne] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. RP Muller, DJ (reprint author), Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland. EM daniel.mueller@bsse.ethz.ch RI Muller, Daniel/A-5967-2010; Martinez-Martin, David/P-3083-2016 OI Muller, Daniel/0000-0003-3075-0665; Martinez-Martin, David/0000-0002-3658-9393 FU Swiss National Science Foundation; European Union Marie Curie Actions program through the ACRITAS Initial Training Network [FP7-PEOPLE-2012-ITN]; European Molecular Biology Organization [506-2012] FX We thank D. Alsteens and I. Medalsy for stimulating discussions and advice. This work was supported by the Swiss National Science Foundation, the European Union Marie Curie Actions program through the ACRITAS Initial Training Network (FP7-PEOPLE-2012-ITN, Project 317348), and the European Molecular Biology Organization long-term fellowship 506-2012. NR 156 TC 23 Z9 24 U1 8 U2 108 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 EI 1750-2799 J9 NAT PROTOC JI Nat. Protoc. PD MAY PY 2014 VL 9 IS 5 BP 1113 EP 1130 DI 10.1038/nprot.2014.070 PG 18 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA AF9DC UT WOS:000335014500009 PM 24743419 ER PT J AU Arbustini, E Narula, N Dec, GW Reddy, KS Greenberg, B Kushwaha, S Marwick, T Pinney, S Bellazzi, R Favalli, V Kramer, C Roberts, R Zoghbi, WA Bonow, R Tavazzi, L Fuster, V Narula, J AF Arbustini, Eloisa Narula, Navneet Dec, G. William Reddy, K. Srinath Greenberg, Barry Kushwaha, Sudhir Marwick, Thomas Pinney, Sean Bellazzi, Riccardo Favalli, Valentina Kramer, Christopher Roberts, Robert Zoghbi, William A. Bonow, Robert Tavazzi, Luigi Fuster, Valentin Narula, Jagat TI MOGE(S) nosology in low-to-middle-income countries SO NATURE REVIEWS CARDIOLOGY LA English DT Letter ID ENDOMYOCARDIAL FIBROSIS; CLASSIFICATION C1 [Arbustini, Eloisa; Favalli, Valentina] Ctr Inherited Cardiovasc Dis, Pavia, Italy. [Narula, Navneet] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Pathol, New York, NY USA. [Dec, G. William] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Reddy, K. Srinath] Publ Hlth Fdn India, New Delhi, India. [Greenberg, Barry] Univ Calif San Diego, San Diego, CA 92103 USA. [Kushwaha, Sudhir] Mayo Clin, Coll Med, Rochester, MN USA. [Marwick, Thomas] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld 4072, Australia. [Pinney, Sean; Fuster, Valentin; Narula, Jagat] Mt Sinai Med Ctr, New York, NY 10029 USA. [Bellazzi, Riccardo] Univ Pavia, Dept Ind & Informat Engn, I-27100 Pavia, Italy. [Kramer, Christopher] Univ Virginia, Charlottesville, VA USA. [Roberts, Robert] Univ Ottawa, Inst Heart, John & Jennifer Ruddy Canadian Cardiovasc Res Ctr, Ottawa, ON, Canada. [Zoghbi, William A.] Methodist Hosp, Methodist DeBakey Heart & Vasc Ctr, Houston, TX 77030 USA. [Bonow, Robert] Ctr Cardiovasc Innovat, Chicago, IL USA. [Tavazzi, Luigi] Hlth Sci Fdn, Maria Cecilia Hosp, GVM Care & Res, ES, Cotignola, Italy. RP Narula, J (reprint author), Mt Sinai Med Ctr, One Gustave L Levy Pl, New York, NY 10029 USA. EM narula@mountsinai.org RI Fuster, Valentin/H-4319-2015; OI Fuster, Valentin/0000-0002-9043-9986; Arbustini, Eloisa/0000-0003-2948-7994; Favalli, Valentina/0000-0002-7058-6479 NR 14 TC 1 Z9 1 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5002 EI 1759-5010 J9 NAT REV CARDIOL JI Nat. Rev. Cardiol. PD MAY PY 2014 VL 11 IS 5 DI 10.1038/nrcardio.2013.219-c1 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF8WX UT WOS:000334997400009 PM 24663093 ER PT J AU Sham, PC Purcell, SM AF Sham, Pak C. Purcell, Shaun M. TI STUDY DESIGNS Statistical power and significance testing in large-scale genetic studies SO NATURE REVIEWS GENETICS LA English DT Review ID GENOME-WIDE ASSOCIATION; AUTISM SPECTRUM DISORDERS; SAMPLE-SIZE REQUIREMENTS; MONTE-CARLO PROCEDURES; EMPIRICAL P-VALUES; RARE VARIANTS; COMPLEX TRAITS; QUANTITATIVE TRAITS; SEQUENCE DATA; ENVIRONMENT INTERACTION AB Significance testing was developed as an objective method for summarizing statistical evidence for a hypothesis. It has been widely adopted in genetic studies, including genome-wide association studies and, more recently, exome sequencing studies. However, significance testing in both genome-wide and exome-wide studies must adopt stringent significance thresholds to allow multiple testing, and it is useful only when studies have adequate statistical power, which depends on the characteristics of the phenotype and the putative genetic variant, as well as the study design. Here, we review the principles and applications of significance testing and power calculation, including recently proposed gene-based tests for rare variants. C1 [Sham, Pak C.] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Genom Sci, Hong Kong, Hong Kong, Peoples R China. [Sham, Pak C.] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China. [Purcell, Shaun M.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China. [Purcell, Shaun M.] Icahn Sch Med Mt Sinai, Ctr Stat Genet, New York, NY 10029 USA. [Purcell, Shaun M.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Purcell, Shaun M.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Sham, PC (reprint author), Univ Hong Kong, Li Ka Shing Fac Med, Ctr Genom Sci, Jockey Club Bldg Interdisciplinary Res, Hong Kong, Hong Kong, Peoples R China. EM pcsham@hku.hk FU University of Hong Kong Strategic Research Theme on Genomics; Hong Kong Research Grants Council (HKRGC) [777511M, 776412M, 776513M]; HKRGC Theme-Based Research Scheme [T12-705/11, T12-708/12-N]; European Community Seventh Framework Programme Grant on European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI); US National Institutes of Health [R01 MH099126, R01 HG005827] FX This work was supported by The University of Hong Kong Strategic Research Theme on Genomics; Hong Kong Research Grants Council (HKRGC) General Research Funds 777511M, 776412M and 776513M; HKRGC Theme-Based Research Scheme T12-705/11 and T12-708/12-N; and the European Community Seventh Framework Programme Grant on European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI); and the US National Institutes of Health grants R01 MH099126 and R01 HG005827 (to S. M. P.). The authors thank R. Porsch and S.-W. Choi for technical assistance with the manuscript. NR 97 TC 106 Z9 108 U1 8 U2 62 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-0056 EI 1471-0064 J9 NAT REV GENET JI Nat. Rev. Genet. PD MAY PY 2014 VL 15 IS 5 BP 335 EP 346 DI 10.1038/nrg3706 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA AF3GM UT WOS:000334599700011 PM 24739678 ER PT J AU Alexander, BM Trippa, L AF Alexander, Brian M. Trippa, Lorenzo TI Progression-free survival: too much risk, not enough reward? SO NEURO-ONCOLOGY LA English DT Editorial Material C1 [Alexander, Brian M.] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Trippa, Lorenzo] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Trippa, Lorenzo] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Alexander, BM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM bmalexander@lroc.harvard.edu NR 7 TC 4 Z9 4 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD MAY PY 2014 VL 16 IS 5 BP 615 EP 616 DI 10.1093/neuonc/nou041 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AF5HU UT WOS:000334745400001 PM 24733851 ER PT J AU Han, KL Ren, M Wick, W Abrey, L Das, A Jin, J Reardon, DA AF Han, Kelong Ren, Melanie Wick, Wolfgang Abrey, Lauren Das, Asha Jin, Jin Reardon, David A. TI Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials SO NEURO-ONCOLOGY LA English DT Article DE glioblastoma; meta-analysis; overall survival; progression-free survival; regression; response rate; surrogate endpoint ID PHASE-II TRIAL; NEWLY-DIAGNOSED GLIOBLASTOMA; HIGH-GRADE GLIOMAS; BRAIN-TUMOR CONSORTIUM; RECURRENT MALIGNANT GLIOMAS; MULTIAGENT CHEMOTHERAPY PROCARBAZINE; SINGLE INSTITUTION EXPERIENCE; METASTATIC COLORECTAL-CANCER; BEVACIZUMAB PLUS IRINOTECAN; STANDARD RADIATION-THERAPY AB The aim of this study was to determine correlations between progression-free survival (PFS) and the objective response rate (ORR) with overall survival (OS) in glioblastoma and to evaluate their potential use as surrogates for OS. Published glioblastoma trials reporting OS and ORR and/or PFS with sufficient detail were included in correlative analyses using weighted linear regression. Of 274 published unique glioblastoma trials, 91 were included. PFS and OS hazard ratios were strongly correlated; R-2 0.92 (95 confidence interval [CI], 0.710.99). Linear regression determined that a 10 PFS risk reduction would yield an 8.1 0.8 OS risk reduction. R-2 between median PFS and median OS was 0.70 (95 CI, 0.590.79), with a higher value in trials using Response Assessment in Neuro-Oncology (RANO; R-2 0.96, n 8) versus Macdonald criteria (R-2 0.70; n 83). No significant differences were demonstrated between temozolomide- and bevacizumab-containing regimens (P .10) or between trials using RANO and Macdonald criteria (P .49). The regression line slope between median PFS and OS was significantly higher in newly diagnosed versus recurrent disease (0.58 vs 0.35, P .04). R-2 for 6-month PFS with 1-year OS and median OS were 0.60 (95 CI, 0.370.77) and 0.64 (95 CI, 0.420.77), respectively. Objective response rate and OS were poorly correlated (R-2 0.22). In glioblastoma, PFS and OS are strongly correlated, indicating that PFS may be an appropriate surrogate for OS. Compared with OS, PFS offers earlier assessment and higher statistical power at the time of analysis. C1 [Han, Kelong; Ren, Melanie; Das, Asha; Jin, Jin] Genentech Inc, San Francisco, CA 94080 USA. [Wick, Wolfgang] Univ Med Ctr, Heidelberg, Germany. [Wick, Wolfgang] DKFZ, Heidelberg, Germany. [Abrey, Lauren] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland. [Reardon, David A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Han, KL (reprint author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA. EM han.kelong@gene.com RI Han, Kelong/J-5233-2014 FU Genentech Inc, South San Francisco, CA, USA FX This analysis was sponsored by Genentech Inc, South San Francisco, CA, USA. NR 118 TC 24 Z9 24 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD MAY PY 2014 VL 16 IS 5 BP 696 EP 706 DI 10.1093/neuonc/not236 PG 11 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AF5HU UT WOS:000334745400010 PM 24335699 ER PT J AU Stein, MB Keshaviah, A Haddad, SA Van Ameringen, M Simon, NM Pollack, MH Smoller, JW AF Stein, Murray B. Keshaviah, Aparna Haddad, Stephen A. Van Ameringen, Michael Simon, Naomi M. Pollack, Mark H. Smoller, Jordan W. TI Influence of RGS2 on Sertraline Treatment for Social Anxiety Disorder SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE social anxiety disorder; selective serotonin reuptake inhibitor; genetics; pharmacotherapy ID SEROTONIN TRANSPORTER GENE; PHOBIA; POLYMORPHISM; PREDICTORS; EXPRESSION; DEPRESSION; BIOMARKERS; CHILDREN; LOCUS; SCALE AB Only a minority of patients with social anxiety disorder (SAD) has a robust therapeutic response to evidence-based serotonin reuptake inhibitor (SSRI) treatment. To help improve the personalized medicine approach to psychiatric care, we evaluated several candidate genetic predictors of SSRI response in SAD. At the start of a randomized controlled trial (NCT00282828), 346 patients with SAD at three sites received protocol-driven, open-label treatment with sertraline, up to 200. mg/d over 10 weeks. Efficacy was determined using a continuous measure of outcome (Liebowitz Social Anxiety Scale (LSAS)) and dichotomous indicators of response (LSAS <=,50) and remission (LSAS Predictors of efficacy were examined in multivariate regression models that included eight polymorphic variants in four candidate genes (four in RGS2, two in HTR2A, one in SLC6A2, and one in SLC6A4). Adjusting for genetic ancestral cluster and non-genetic predictors of response, all four single-nucleotide polymorphisms (SNPs) in RGS2 predicted change in LSAS over time, at study-wise significance (p = 0.00833), with the minor allele associated with less improvement over time. After adjusting for genetic ancestral cluster and non-genetic predictors of remission, two of the four RGS2 SNPs predicted likelihood of remission at or just below study-wise significance (p =0.025): rs4606 (AOR= 0.49 (95% CI = 0.27-0.90), p = 0.022) and rsI81974I (AOR= 0.50 (95% CI = 0.28-0.92), p = 0.027). Variation in RGS2, a gene previously shown to be associated with social anxiety phenotypes and serotonergic neurotransmission, may be a biomarker of the likelihood of substantially benefiting from sertraline among patients with SAD. C1 [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat & Family & Prevent Med, La Jolla, CA 92093 USA. [Keshaviah, Aparna; Haddad, Stephen A.; Simon, Naomi M.; Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Van Ameringen, Michael] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada. [Pollack, Mark H.] Rush Univ, Med Ctr, Dept Psychiat, Chicago, IL 60612 USA. RP Stein, MB (reprint author), Univ Calif San Diego, Dept Psychiat & Family & Prevent Med Anxiety & Tr, Mailcode 0855,9500 Gilman Dr, La Jolla, CA 92093 USA. EM mstein@ucsd.edu FU National Institute of Mental Health (NIMH) [MH070501, MH070919, MH094614]; Pfizer; Wyeth Pharmaceuticals; Department of Defense; Department of Veterans Affairs; Janssen-Ortho; National Institutes of Health (NIH; Speakers' Bureau for Valiant; GlaxoSmithKline; Lundbeck; Bristol Myers Squibb; Euthymics; Forest Laboratories; Eli Lilly; NCCAM; NIDA; Sepracor FX Grant support was provided by the National Institute of Mental Health (NIMH), grant numbers MH070501, MH070919, and MH094614. Support for study drug and packaging was received from Pfizer and Wyeth Pharmaceuticals. Dr Stein reports the following disclosures: Grant support from NIMH, Department of Defense, Department of Veterans Affairs. He is co-holder of a patent on the use of genetic testing to predict treatment outcomes in social anxiety disorder. He receives payment for his work as Co-Editor in Chief of upToDate in Psychiatry, and for his work as Deputy Editor of Depression and Anxiety (Wiley Press). Dr Van Ameringen reports the following disclosures: Grant/ Research Support from Janssen-Ortho, National Institutes of Health (NIH), Pfizer; Speakers' Bureau for Valiant, GlaxoSmithKline, Lundbeck, Pfizer; he has also participated in Advisory Boards for Valiant, Eli Lilly, Janssen-Ortho, Labo Pharm, Lundbeck, Pfizer, and Shire. Dr Naomi Simon reports the following disclosures: NIH, Department of Defense, American Foundation for Suicide Prevention, Forest Research, MGH Psychiarty Academy, Highland Street Foundation, American Cancer Society, Glaxo SmithKline, Sepracor, Lilly, Pfizer, and NARSAD. Dr Pollack reports the following disclosures: Advisory Boards and Consultation: Brain Cells, Eli Lilly, Johnson and Johnson, Labopharm, Medavante, Mindsite, Otsuka, Pfizer, Sepracor, Targia, Transcept; Grant Support: Bristol Myers Squibb, Euthymics, Forest Laboratories, GlaxoSmithKline, Eli Lilly, NCCAM, NIDA, NIMH, Sepracor; CME activities: Astra-Zeneca, Sepracor, Pfizer; Royalty/Patents: SIGH-A, SAFER interviews; Equity: Doyen Medical, Medavante, Mensante Corporation, Mindsite, Targia Pharmaceuticals. Dr Smoller reports the following disclosure: Scientific Advisory Board membership of Psybrain. Stephen Haddad and Aparna Keshaviah report no competing interests. NR 26 TC 9 Z9 9 U1 4 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD MAY PY 2014 VL 39 IS 6 BP 1340 EP 1346 DI 10.1038/npp.2013.301 PG 7 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AF2RV UT WOS:000334560600005 PM 24154666 ER PT J AU Petersen, KL Iyengar, S Chappell, AS Lobo, ED Reda, H Prucka, WR Verfaille, SJ AF Petersen, Karin L. Iyengar, Smriti Chappell, Amy S. Lobo, Evelyn D. Reda, Haatem Prucka, William R. Verfaille, Steven J. TI Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy volunteers SO PAIN LA English DT Article DE Hyperalgesia; Ionotropic glutamate receptor 5 receptor antagonist; Efficacy; Analgesic; Antihyperalgesic; Brief thermal stimulation model; Human experimental pain model ID HEAT-CAPSAICIN SENSITIZATION; SECONDARY HYPERALGESIA; HEAT/CAPSAICIN SENSITIZATION; MODEL; SKIN; MECHANISMS; MORPHINE; INJURY AB The objective of this study was to establish in healthy volunteers the maximally tolerated multiple dose (MTMD) of the ionotropic glutamate receptor 5 antagonist LY545694 (part A), and to investigate whether that dose had analgesic or antihyperalgesic effects in the brief thermal stimulation (BTS) pain model (Part B). Part A was a double-blind, placebo-controlled study in 3 groups of 10 healthy men. To simulate an extended-release formulation, study drug was administered orally over 6 hours (12 equally divided aliquots at 30-minute intervals). Part B was a double-blind, placebo-controlled, double-dummy, 3-way crossover study in 27 healthy men. At each of the 3 study periods, subjects received either LY545694 (MTMD; as determined during part A) as a simulated, twice daily extended-release formulation for 4 doses over 3 days, gabapentin (600 mg 8 hours apart; 6 doses over 3 days; positive control), or matching placebo. The BTS model was induced twice with a 1-hour interval on each of the 2 study days, before drug administration and at the time of expected peak analgesia of LY545694. Plasma exposure for LY545694 was approximately linear over the 25- to 75-mg dose range. The MTMD of LY545694 was 25 mg twice daily. Areas of secondary hyperalgesia were significantly smaller after administration of LY545694 and gabapentin compared with placebo (P<.0001 and P=.0004, respectively), but there was no difference between areas after administration of gabapentin and LY545694 (P=.400). Neither gabapentin nor LY545694 reduced the painfulness of skin heating during BTS model induction. The most common treatment- emergent adverse event was dizziness. The results of this study suggest that LY545694 should be explored further as a potential treatment for chronic pain involving neuronal sensitization. (C) 2014 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved. C1 [Petersen, Karin L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA. [Iyengar, Smriti; Chappell, Amy S.; Lobo, Evelyn D.; Prucka, William R.; Verfaille, Steven J.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Reda, Haatem] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Petersen, KL (reprint author), Calif Pacific Med Ctr, Res Inst, 475 Brannan St,Suite 220, San Francisco, CA 94107 USA. EM peterskp@cpmcri.org FU Eli Lilly and Company (Indianapolis, IN) FX This study was sponsored by Eli Lilly and Company (Indianapolis, IN) and/or any of its subsidiaries. Drs. Petersen and Reda were paid consultants for Eli Lilly and Company while the study was ongoing, but were not paid during the writing phase. Drs. Iyengar, Chappell, Lobo, and Prucka, and Mr. Verfaille are employees of, and minor stockholders in, Eli Lilly and Company. NR 26 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD MAY PY 2014 VL 155 IS 5 BP 929 EP 936 DI 10.1016/j.pain.2014.01.019 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA AF1YR UT WOS:000334510300016 PM 24486883 ER PT J AU Manchikanti, L Falco, F Hirsch, JA AF Manchikanti, Laxmaiah Falco, Frank Hirsch, Joshua A. TI Untitled SO PAIN LA English DT Letter ID INTERVENTIONAL TECHNIQUES; NEUROPATHIC PAIN; GUIDELINES; RECOMMENDATIONS; MANAGEMENT C1 [Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA. [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY 42003 USA. [Falco, Frank] Temple Univ Hosp & Med Sch, Pain Med Fellowship Program, Philadelphia, PA 19140 USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Endovasc Neurosurg & Neuroendovasc Program, Boston, MA 02114 USA. [Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA. RP Manchikanti, L (reprint author), Univ Louisville, Louisville, KY 40292 USA. EM drlm@thepainmd.com NR 14 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD MAY PY 2014 VL 155 IS 5 BP 1044 EP 1045 DI 10.1016/j.pain.2014.01.030 PG 3 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA AF1YR UT WOS:000334510300029 PM 24508086 ER PT J AU Ein, SH Masiakos, PT Ein, A AF Ein, Sigmund H. Masiakos, Peter T. Ein, Arlene TI The ins and outs of pyloromyotomy: what we have learned in 35 years SO PEDIATRIC SURGERY INTERNATIONAL LA English DT Article DE Infantile hypertrophic pyloric stenosis; Diagnosis; Complications ID HYPERTROPHIC PYLORIC-STENOSIS; HOSPITAL CHARACTERISTICS; RAMSTEDT PYLOROMYOTOMY; PEDIATRIC-SURGEONS; ERYTHROMYCIN; ASSOCIATION; DIAGNOSIS; INFANT; OLIVE; DETERMINANTS AB The aim of the study is to evaluate a large series of infantile hypertrophic pyloric stenosis (IHPS) patients treated by one pediatric surgeon focusing on their diagnostic difficulties and complications. From July 1969 to December 2003 (inclusive), the charts of 791 infants with IHPS were retrospectively reviewed. There were 647 (82 %) males and 144 (18 %) females; mean age was 38 days, median 51 (range 7 days-10 months). When ultrasonography (US) was routinely used (1990), the age at diagnosis decreased to < 40 days. The mean weight before and after routine US was 3.2 kg, median 3 (range 1.5-6). Twenty-five (3.1 %) were premature at diagnosis, mean age 49 days, median 56, (range 1-3 months) and mean weight 2.5 kg, median 2.3 (range 1.5-3.2). Eighty-one (10 %) had a positive family history. Forty-four (5 %) were non-Caucasians. Seventy-five (9 %) had other medical conditions, anomalies and/or associated findings. Sixty (7 %) patients had abnormal preoperative electrolytes. Ten (1.2 %) pylorics occurred after newborn operations. Of the entire total (791) who were treated, there were 13 (1.7 %) not operated on. All operations were done open initially through one of two right upper quadrant incisions, and then through an upper midline incision under general endotracheal anesthesia; 14 (1.7 %) had concomitant procedures. Prophylactic antibiotics (from 1982) decreased the wound infection rate to 3.9 %. There were a total of 87 (10 %) complications which included 9 (1.1 %) intraoperative, (including mistaken diagnoses) 78 (9 %) postoperative: 59 (2 %) early (< 1 month) and 19 (2.4 %) late (> 1 month). The 13 (1.6 %) postoperative transfers (12 from non-pediatric surgeons) had 16 (18 %) complications (including 1 death); five (33 %) requiring reoperation (4 incomplete, 1 perforation). There were two deaths. IHPS should be considered in any vomiting infant. US allows earlier diagnosis. Serious complications are uncommon and avoidable, but recognizable and easily corrected. Higher surgeon volume of pyloromyotomies (> 14 per year) is associated with fewer complications. C1 [Ein, Sigmund H.; Ein, Arlene] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Masiakos, Peter T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ein, SH (reprint author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM a_ein@istar.ca NR 76 TC 3 Z9 3 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-0358 EI 1437-9813 J9 PEDIATR SURG INT JI Pediatr. Surg. Int. PD MAY PY 2014 VL 30 IS 5 BP 467 EP 480 DI 10.1007/s00383-014-3488-8 PG 14 WC Pediatrics; Surgery SC Pediatrics; Surgery GA AF4MF UT WOS:000334686200001 PM 24626877 ER PT J AU Miller, DM Flaherty, KT AF Miller, David M. Flaherty, Keith T. TI Cyclin-dependent kinases as therapeutic targets in melanoma SO PIGMENT CELL & MELANOMA RESEARCH LA English DT Review DE melanoma; cyclin-dependent kinase; targeted therapy; cellular senescence; cell-cycle checkpoint ID CELL-CYCLE; METASTATIC MELANOMA; MALIGNANT-MELANOMA; TUMOR-SUPPRESSOR; RAF INHIBITORS; CANCER-CELLS; PHASE-II; CDK4/6 INHIBITION; BRAF INHIBITORS; GLIOMA-CELLS AB Decades of scientific insights have led to a recent expansion of the therapeutic menu for melanoma. Despite these advances, the current targeted therapies and immune checkpoint agents continue to yield suboptimal response and cure rates. Hitherto, the most effective targeted therapy strategies have centered on effectors in the mitogen-activated protein kinase (MAPK) pathway. This review focuses on the emerging evidence of combinatorial approaches targeting both MAPK signaling and dysregulations in cell-cycle checkpoints. We discuss the prospects and limitations of utilizing strategies that promote cellular senescence, such as inhibition of the interphase cyclin-dependent kinases (CDKs) and highlight the current state of CDK drug discovery in melanoma. C1 [Miller, David M.] Columbia Univ Med Ctr, Dept Dermatol, New York, NY USA. [Flaherty, Keith T.] Massachusetts Gen Hosp Canc Ctr, Div Hematol Oncol, Boston, MA 02114 USA. RP Flaherty, KT (reprint author), Massachusetts Gen Hosp Canc Ctr, Div Hematol Oncol, Boston, MA 02114 USA. EM kflaherty@partners.org NR 103 TC 7 Z9 7 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1755-1471 EI 1755-148X J9 PIGM CELL MELANOMA R JI Pigment Cell Melanoma Res. PD MAY PY 2014 VL 27 IS 3 BP 351 EP 365 DI 10.1111/pcmr.12211 PG 15 WC Oncology; Cell Biology; Dermatology SC Oncology; Cell Biology; Dermatology GA AE7IM UT WOS:000334170900007 PM 24405945 ER PT J AU Pearlson, GD Ford, JM AF Pearlson, Godfrey D. Ford, Judith M. TI Distinguishing Between Schizophrenia and Other Psychotic Disorders SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; bipolar; validity; classification ID COGNITIVE NEUROPSYCHIATRY; BIPOLAR DISORDER AB The Diagnostic and Statistical Manual of Mental Disorders (DSM) has provided diagnostic reliability across observers while neglecting biological validity. The current theme issue explores the boundaries between schizophrenia and bipolar disorder, using neuro-cognition, systems neuroscience, and genetics as points of departure to begin consideration of a biologically based reclassification of these illnesses. C1 [Pearlson, Godfrey D.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Pearlson, Godfrey D.] Yale Univ, Dept Neurobiol, New Haven, CT USA. [Pearlson, Godfrey D.] IOL, ONRC, Hartford, CT 06106 USA. [Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Pearlson, GD (reprint author), IOL, ONRC, Whitehall Bldg 207,200 Washington St, Hartford, CT 06106 USA. EM godfrey.pearlson@yale.edu FU National Institute of Mental Health [5 R37 MH43775, R01 MH07794, MH058262] FX National Institute of Mental Health grants (5 R37 MH43775, MERIT) and (R01 MH077945 to G. D. P.); National Institute of Mental Health (MH058262 and Veterans Administration to J.M.F.). NR 19 TC 5 Z9 5 U1 1 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2014 VL 40 IS 3 BP 501 EP 503 DI 10.1093/schbul/sbu055 PG 3 WC Psychiatry SC Psychiatry GA AF5JW UT WOS:000334750800007 PM 24687045 ER PT J AU Ehrlich, S Geisler, D Yendiki, A Panneck, P Roessner, V Calhoun, VD Magnotta, VA Gollub, RL White, T AF Ehrlich, Stefan Geisler, Daniel Yendiki, Anastasia Panneck, Patricia Roessner, Veit Calhoun, Vince D. Magnotta, Vincent A. Gollub, Randy L. White, Tonya TI Associations of White Matter Integrity and Cortical Thickness in Patients With Schizophrenia and Healthy Controls SO SCHIZOPHRENIA BULLETIN LA English DT Article DE cortical thickness; fractional anisotropy; structural MRI; DTI; schizophrenia ID HUMAN CEREBRAL-CORTEX; 1ST EPISODE SCHIZOPHRENIA; DIFFUSION TENSOR; ONSET SCHIZOPHRENIA; MULTIPLE-SCLEROSIS; WORKING-MEMORY; IN-VIVO; RADIAL DIFFUSIVITY; COORDINATE SYSTEM; BRAIN-DEVELOPMENT AB Typical brain development includes coordinated changes in both white matter (WM) integrity and cortical thickness (CT). These processes have been shown to be disrupted in schizophrenia, which is characterized by abnormalities in WM microstructure and by reduced CT. The aim of this study was to identify patterns of association between WM markers and cortex-wide CT in healthy controls (HCs) and patients with schizophrenia (SCZ). Using diffusion tensor imaging and structural magnetic resonance imaging data of the Mind Clinical Imaging Consortium study (130 HC and 111 SCZ), we tested for associations between (a) fractional anisotropy in selected manually labeled WM pathways (corpus callosum, anterior thalamic radiation, and superior longitudinal fasciculus) and CT, and (b) the number of lesion-like WM regions ("potholes") and CT. In HC, but not SCZ, we found highly significant negative associations between WM integrity and CT in several pathways, including frontal, temporal, and occipital brain regions. Conversely, in SCZ the number of WM potholes correlated with reduced CT in the left lateral temporal gyrus, left fusiform, and left lateral occipital brain area. Taken together, we found differential patterns of association between WM integrity and CT in HC and SCZ. Although the pattern in HC can be explained from a developmental perspective, the reduced gray matter CT in SCZ patients might be the result of focal but spatially heterogeneous disruptions of WM integrity. C1 [Ehrlich, Stefan; Yendiki, Anastasia; Panneck, Patricia; Gollub, Randy L.] Massachusetts Gen Hosp, MGH MIT HMS Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Ehrlich, Stefan; Gollub, Randy L.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Ehrlich, Stefan; Geisler, Daniel; Roessner, Veit] Tech Univ Dresden, Dept Child & Adolescent Psychiat, Univ Hosp Carl Gustav Carus, D-01307 Dresden, Germany. [Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA. [Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA. [Magnotta, Vincent A.] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA. [White, Tonya] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [White, Tonya] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN USA. [White, Tonya] Erasmus MC, Dept Child & Adolescent Psychiat, Rotterdam, Netherlands. [White, Tonya] Erasmus MC, Dept Radiol, Rotterdam, Netherlands. RP Ehrlich, S (reprint author), Tech Univ Dresden, Dept Child & Adolescent Psychiat, Translat Dev Neurosci Sect, Univ Hosp Carl Gustav Carus, Fetscherstr 74, D-01307 Dresden, Germany. EM transden.lab@uniklinikum-dresden.de OI Gollub, Randy L./0000-0002-9434-4044 FU National Institutes of Health/National Center for Research Resources [P41RR14075, MO1 RR025758-01]; Department of Energy [DE-FG02-99ER62764]; Mind Research Network, Morphometry Biomedical Informatics Research Network [1U24, RR021382A]; Function Biomedical Informatics Research Network [U24RR021992-01]; Shared Instrumentation Grants [1S10RR023401, 1S10RR019307, 1S10RR023043]; National Institutes of Health [K99/R00 EB008129]; National Institute of Mental Health [K08-MH068540]; NARSAD Young Investigator Award; Deutsche Forschungsgemeinschaft FX National Institutes of Health/National Center for Research Resources (P41RR14075); Department of Energy (DE-FG02-99ER62764); The Mind Research Network, Morphometry Biomedical Informatics Research Network (1U24, RR021382A); Function Biomedical Informatics Research Network (U24RR021992-01); National Institutes of Health/National Center for Research Resources (MO1 RR025758-01); Shared Instrumentation Grants (1S10RR023401, 1S10RR019307, and 1S10RR023043); National Institutes of Health (K99/R00 EB008129 to A.Y.); National Institute of Mental Health (K08-MH068540 to T. W.); the NARSAD Young Investigator Award (to S. E.); Deutsche Forschungsgemeinschaft (to S.E.). NR 96 TC 11 Z9 11 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2014 VL 40 IS 3 BP 665 EP 674 DI 10.1093/schbul/sbt056 PG 10 WC Psychiatry SC Psychiatry GA AF5JW UT WOS:000334750800024 PM 23661633 ER PT J AU Lee, HK Ahmed, MM King, KC Miranpuri, GS Kahle, KT Resnick, DK Sun, DD AF Lee, Hyun Kyung Ahmed, Mostafa M. King, Kevin C. Miranpuri, Gurwattan S. Kahle, Kristopher T. Resnick, Daniel K. Sun, Dandan TI Persistent phosphorylation of NKCC1 and WNK1 in the epicenter of the spinal cord following contusion injury SO SPINE JOURNAL LA English DT Article DE Contusive spinal cord injury; NKCC1; WNK1 ID NA-K-CL; SENSORY NEURONS; KINASES; COTRANSPORTER; INHIBITION; ACTIVATION; ISCHEMIA; EDEMA; DEATH; SPAK AB BACKGROUND CONTEXT: NKCC1 regulates neuronal homeostasis of chloride ions and mediates GABAergic activities in nociceptive processing. WNK1 is an upstream regulator of NKCC1 and acts via SPAK (STE20/SPS1-related proline/alanine-rich kinase) and oxidative stress-responsive kinase 1. NKCC1 activity has been shown to be important in edema formation and nociception following spinal cord injury (SCI). PURPOSE: To determine the role of NKCC1 and WNK1 in spinal cord tissues in the acute and chronic phases following contusional SCI. STUDY DESIGN: An experimental study investigating the phosphorylation profile of an important Cl-regulatory protein Na+-K+-Cl- cotransporter 1 (NKCC1) and its regulatory-kinase WNK1 (kinase with-no-lysine). METHODS: Sprague-Dawley rats underwent a contusive SCI at T9. The epicenter spinal cord tissues were harvested at Days 1, 3, and 7 for acute phase of injury or Days 35 and 42 in the chronic phase of injury. Western blot was used to compare phosphorylated levels of both NKCC1 and WNK1 in injured tissues compared with those of sham. RESULTS: A sustained increase in phosphorylation of NKCC1 and WNK1 was detected in the lesion epicenter in spinal cord during both acute and chronic phases following SCI. CONCLUSIONS: These results suggest that persistent activation of NKCC1 and WNK1 may play an important role in SCI. (C) 2014 Elsevier Inc. All rights reserved. C1 [Lee, Hyun Kyung; Ahmed, Mostafa M.; King, Kevin C.; Miranpuri, Gurwattan S.; Resnick, Daniel K.; Sun, Dandan] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosurg, Madison, WI 53792 USA. [Kahle, Kristopher T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Kahle, Kristopher T.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Sun, Dandan] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA. RP Resnick, DK (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosurg, Box 8600 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA. EM resnick@neurosurgery.wisc.edu NR 27 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 EI 1878-1632 J9 SPINE J JI Spine Journal PD MAY PY 2014 VL 14 IS 5 BP 777 EP 781 DI 10.1016/j.spinee.2013.06.100 PG 5 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA AF5RN UT WOS:000334770700009 PM 24239489 ER PT J AU Kang, JX Wan, JB He, CW AF Kang, Jing X. Wan, Jian-Bo He, Chengwei TI Concise Review: Regulation of Stem Cell Proliferation and Differentiation by Essential Fatty Acids and Their Metabolites SO STEM CELLS LA English DT Review DE Omega-6 fatty acids; Proliferation; Eicosanoids; Stem cell; Stem cell therapy; Differentiation; Omega-3 fatty acids ID DOCOSAHEXAENOIC ACID; PROSTAGLANDIN-E; LIPID RAFTS; BONE-MARROW; NEURONAL DIFFERENTIATION; ARACHIDONIC-ACID; PROGENITOR CELLS; NEUROGENESIS; EXPRESSION; PATHWAY AB Stem cell therapy holds great promise for regenerative medicine and the treatment of numerous diseases. A key issue of stem cell therapy is the control of stem cell fate, but safe and practical methods are limited. Essential fatty acids, namely omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids (PUFA), and their metabolites are critical components of cell structure and function, and could therefore influence stem cell fate. The available evidence demonstrates that n-6 and n-3 PUFA and their metabolites can act through multiple mechanisms to promote the proliferation and differentiation of various stem cell types. Therefore, elucidating the role of PUFA and their metabolites in stem cell fate regulation is both a challenge and an opportunity for stem cell biology as well as stem cell therapy. PUFA-based interventions to create a favorable environment for stem cell proliferation or differentiation may thus be a promising and practical approach to controlling stem cell fate for clinical applications. Stem Cells 2014;32:1092-1098 C1 [Kang, Jing X.; Wan, Jian-Bo; He, Chengwei] Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA. [Kang, Jing X.; Wan, Jian-Bo; He, Chengwei] Harvard Univ, Sch Med, Boston, MA USA. [Wan, Jian-Bo; He, Chengwei] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China. RP Kang, JX (reprint author), Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, 149-13th St, Charlestown, MA 02129 USA. EM kang.jing@mgh.harvard.edu OI Wan, Jian-Bo/0000-0002-6750-2617 FU San-sun Life Sciences; Fortune Education Foundation FX This study was supported by the generous funding from San-sun Life Sciences and the Fortune Education Foundation. We are also grateful to Marina Kang for her editorial assistance. NR 77 TC 10 Z9 11 U1 0 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PD MAY PY 2014 VL 32 IS 5 BP 1092 EP 1098 DI 10.1002/stem.1620 PG 7 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA AF3FP UT WOS:000334597200005 PM 24356924 ER PT J AU Telem, DA Rattner, DW Gee, DW AF Telem, Dana A. Rattner, David W. Gee, Denise W. TI Endoscopic simulator curriculum improves colonoscopy performance in novice surgical interns as demonstrated in a swine model SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article DE Education; Imaging and VR; Technical; Training; Endoscopy; Colonoscopy ID VIRTUAL-REALITY; VALIDITY; EXPERT AB The purpose of this study was to determine whether independent virtual endoscopic training accelerates the acquisition of endoscopic skill by novice surgical interns. Nine novice surgical interns participated in a prospective study comparing colonoscopy performance in a swine model before and after an independent simulator curriculum. An independent observer evaluated each intern for the ability to reach the cecum within 20 min and technical ability as determined by Global Assessment of Gastrointestinal Endoscopic Skills-Colonoscopy (GAGES-C) score and performance compared. In addition, at the conclusion of training, a post test of two basic simulated colonoscopy modules was completed and metrics evaluated. As a control, three attending physicians who routinely perform colonoscopy also completed colonoscopy in the swine model. Prior to endoscopic training, one (11 %) intern successfully intubated the cecum in 19.56 min. Following training, six (67 %) interns reached the cecum with mean time of 9.2 min (p < 0.05). Statistically significant improvement was demonstrated in four out of five GAGES-C criteria. All three experts reached the cecum, with a mean time of 4.40 min. Comparison of expert and post-curriculum intern times demonstrated the experts to be significantly faster (p < 0.05). Comparison of interns who were and were not able to reach the cecum following the simulator curriculum demonstrated significantly improved GI Mentor (TM) performance in the efficiency (79 vs. 67.1 %, p = 0.05) and time to cecum (3.37 vs. 5.59 min, p = 0.01) metrics. No other significant difference was demonstrated in GAGES-C categories or other simulator parameter. Simulator training on the GI Mentor (TM) alone significantly improved endoscopic skills in novice surgical interns as demonstrated in a swine model. This study also identified parameters on the GI Mentor (TM) that could indicate 'clinical readiness'. This study supports the role for endoscopic simulator training in surgical resident education as an adjunct to clinical experience. C1 [Telem, Dana A.] SUNY Stony Brook, Med Ctr, Div Laparoscop Bariatr & Adv GI Surg, Stony Brook, NY USA. [Rattner, David W.; Gee, Denise W.] Massachusetts Gen Hosp, Div Gastrointestinal Surg, Boston, MA 02114 USA. RP Gee, DW (reprint author), Massachusetts Gen Hosp, Div Gastrointestinal Surg, 15 Parkman St,Wang 460, Boston, MA 02114 USA. EM dtelem@gmail.com; dgee@partners.org FU Partners Health System Center of Expertise Medical Education Research Grant FX This research was supported by The Fellowship Council and a the Partners Health System Center of Expertise Medical Education Research Grant. NR 15 TC 2 Z9 2 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0930-2794 EI 1432-2218 J9 SURG ENDOSC JI Surg. Endosc. PD MAY PY 2014 VL 28 IS 5 BP 1494 EP 1499 DI 10.1007/s00464-013-3339-z PG 6 WC Surgery SC Surgery GA AF1XK UT WOS:000334507000013 PM 24337885 ER PT J AU Jones, RC Capen, DE AF Jones, Rosemary C. Capen, Diane E. TI Multiple Wall In-folds Sub-divide Single Segments During Capillary Regression in Hyperoxic Acute Lung Injury SO ULTRASTRUCTURAL PATHOLOGY LA English DT Article DE Bridging endothelial cells; capillary remodeling; inter-luminal structures ID ENDOTHELIAL GROWTH-FACTOR; INTUSSUSCEPTIVE ANGIOGENESIS; NEOVASCULARIZATION MODEL; PULMONARY-HYPERTENSION; ADULT LUNG; MOUSE LUNG; CELLS; EXPRESSION; VEGF; MORPHOGENESIS AB The present study provides further insight into the structural processes that remodel pulmonary capillaries in the injured adult lung. Early in hyperoxia acute lung injury (HALI), many sub-dividing segments are present throughout the capillary network before segment occlusion and loss predominate and capillary density decreases later in the period. A second segment sub-division triggered in regenerating capillaries after air breathing (post-HALI) demonstrates a similar mechanism of organization at a time of contrasting change in the capillary density. As we have previously reported, the process of segment sub-division includes in-folding of the endothelial-epithelial surface (alveolar-capillary membrane) to form inter-luminal structures (ILSs) and loops, with loop separation increasing segment number. Unexpectedly, the findings support remodeling of the capillary density by wall in-folding in acute lung injury, demonstrating a similar mechanism in capillary regression as well as in regeneration in the adult lung. C1 [Jones, Rosemary C.; Capen, Diane E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Jones, Rosemary C.] Harvard Univ, Sch Med, Boston, MA USA. RP Jones, RC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02163 USA. EM rcristianjones@gmail.com FU NIH [HL R01 089252] FX This work is supported by NIH HL R01 089252. NR 32 TC 0 Z9 0 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0191-3123 J9 ULTRASTRUCT PATHOL JI Ultrastruct. Pathol. PD MAY PY 2014 VL 38 IS 3 BP 178 EP 185 DI 10.3109/01913123.2014.888113 PG 8 WC Microscopy; Pathology SC Microscopy; Pathology GA AF8WY UT WOS:000334997500002 PM 24579800 ER PT J AU Harte, CB AF Harte, Christopher B. TI Nicotine Acutely Inhibits Erectile Tumescence by Altering Heart Rate Variability SO UROLOGY LA English DT Article ID PHYSIOLOGICAL SEXUAL AROUSAL; CIGARETTE-SMOKING; INTERNATIONAL INDEX; NERVOUS-SYSTEM; CESSATION; MEN; DYSFUNCTION; MEDIATION; ASSOCIATION; ACTIVATION AB OBJECTIVE To examine potential mechanisms underlying nicotine's effects on male sexual arousal by exploring the mediating role of heart rate variability (HRV). METHODS The sample comprised 22 healthy, nicotine-naive men (mean age 20.91 years; standard deviation 2.43). Data were taken from a double-blind, randomized, placebo-controlled, crossover trial previously completed and published elsewhere. During each laboratory visit, time-domain parameters of HRV (standard deviation of normal-to-normal [NN] intervals, square root of the mean squared difference of successive NN intervals, and percent of NN intervals for which successive heartbeat intervals differed by at least 50 ms [pNN50]) along with the objective (via penile plethysmography) and subjective indices of sexual arousal were assessed. RESULTS Acute nicotine ingestion (compared with placebo) was associated with dysregulated sympathovagal balance, which in turn was related to relatively reduced erectile tumescence. HRV did not mediate relations between nicotine intake and self-reported indices of sexual arousal. CONCLUSION HRV mediated the association between nicotine ingestion and erectile capacity. Findings suggest that dysfunctional cardiac autonomic tone may be an underlying mechanism by which nicotine exerts its deleterious effects on erectile health. UROLOGY 83: 1093-1098, 2014. Published by Elsevier Inc. C1 [Harte, Christopher B.] VA Boston Healthcare Syst, Res Serv, Boston, MA 02130 USA. [Harte, Christopher B.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. RP Harte, CB (reprint author), VA Boston Healthcare Syst, Res Serv, 150 S Huntington Ave,116-B4, Boston, MA 02130 USA. EM christopher.harte@va.gov FU National Institute of Child Health and Human Development [1 RO1 HD051676-01 A1] FX Portions of this work were made possible by Grant Number 1 RO1 HD051676-01 A1 to Cindy Meston from the National Institute of Child Health and Human Development. The contents are solely the responsibility of the author and do not necessarily represent the official views of the National Institute of Child Health and Human Development. NR 30 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD MAY PY 2014 VL 83 IS 5 AR 1093 DI 10.1016/j.urology.2014.01.006 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA AF5GU UT WOS:000334742800030 PM 24642073 ER PT J AU Sylvia, LG Reilly-Harrington, NA Leon, AC Kansky, CI Calabrese, JR Bowden, CL Ketter, TA Friedman, ES Iosifescu, DV Thase, ME Ostacher, MJ Keyes, M Rabideau, D Nierenberg, AA AF Sylvia, L. G. Reilly-Harrington, N. A. Leon, A. C. Kansky, C. I. Calabrese, J. R. Bowden, C. L. Ketter, T. A. Friedman, E. S. Iosifescu, D. V. Thase, M. E. Ostacher, M. J. Keyes, M. Rabideau, D. Nierenberg, A. A. TI Medication adherence in a comparative effectiveness trial for bipolar disorder SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Article DE bipolar disorder; compliance; psychopharmacology ID NEUROPSYCHIATRIC INTERVIEW MINI; MODERATE-DOSE-USE; TREATMENT NONADHERENCE; LITHIUM-TREATMENT; I-DISORDER; MAINTENANCE; PREDICTORS; DEPRESSION; MANIA; SCALE AB Objective Psychopharmacology remains the foundation of treatment for bipolar disorder, but medication adherence in this population is low (range 20-64%). We examined medication adherence in a multisite, comparative effectiveness study of lithium. Method The Lithium Moderate Dose Use Study (LiTMUS) was a 6-month, six-site, randomized effectiveness trial of adjunctive moderate dose lithium therapy compared with optimized treatment in adult out-patients with bipolar I or II disorder (N=283). Medication adherence was measured at each study visit with the Tablet Routine Questionnaire. Results We found that 4.50% of participants reported missing at least 30% of their medications in the past week at baseline and non-adherence remained low throughout the trial (<7%). Poor medication adherence was associated with more manic symptoms and side-effects as well as lower lithium serum levels at mid- and post-treatment, but not with poor quality of life, overall severity of illness, or depressive symptoms. Conclusion Participants in LiTMUS were highly adherent with taking their medications. The lack of association with possible predictors of adherence, such as depression and quality of life, could be explained by the limited variance or other factors as well as by not using an objective measure of adherence. C1 [Sylvia, L. G.; Reilly-Harrington, N. A.; Kansky, C. I.; Nierenberg, A. A.] Massachusetts Gen Hosp, Boston, MA USA. [Leon, A. C.] Weill Cornell Med Coll, New York, NY USA. [Calabrese, J. R.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Bowden, C. L.] Univ Texas Hlth Sci, San Antonio, TX USA. [Ketter, T. A.; Ostacher, M. J.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Friedman, E. S.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Iosifescu, D. V.] Mt Sinai Sch Med, New York, NY USA. [Thase, M. E.] Univ Penn, Philadelphia, PA 19104 USA. [Keyes, M.] Harvard Clin Res Inst, Boston, MA USA. [Rabideau, D.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RP Sylvia, LG (reprint author), Massachusetts Gen Hosp, 50 Staniford St,Suite 580, Boston, MA 02114 USA. EM lsylvia2@partners.org OI Ostacher, Michael/0000-0003-0353-7535 FU National Institute of Mental Health [NO1MH80001] FX This study was funded by National Institute of Mental Health (Contract # NO1MH80001). NR 36 TC 8 Z9 8 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-690X EI 1600-0447 J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PD MAY PY 2014 VL 129 IS 5 SI SI BP 359 EP 365 DI 10.1111/acps.12202 PG 7 WC Psychiatry SC Psychiatry GA AE8AP UT WOS:000334221600004 PM 24117232 ER PT J AU Post, RM Leverich, GS Kupka, R Keck, P McElroy, S Altshuler, L Frye, MA Luckenbaugh, DA Rowe, M Grunze, H Suppes, T Nolen, WA AF Post, R. M. Leverich, G. S. Kupka, R. Keck, P., Jr. McElroy, S. Altshuler, L. Frye, M. A. Luckenbaugh, D. A. Rowe, M. Grunze, H. Suppes, T. Nolen, W. A. TI Increased parental history of bipolar disorder in the United States: association with early age of onset SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Article DE assortative mating; bipolar disorder; childhood onset bipolar disorder; genetics ID ASTERISK-D-CHILD; MATERNAL DEPRESSION; MENTAL-DISORDERS; OUTPATIENTS; RISK; RATINGS AB Objective Early-onset bipolar (BP) disorder and other poor prognosis characteristics are more prevalent in patients from the United States than from the Netherlands and Germany (abbreviated as Europe). We explored the impact of parental loading for affective illness on onset and other characteristics of BP disorder. Method Parental history for unipolar (UP) and bipolar (BP) depression and course of illness characteristics were obtained from self-report in adults (average age 42) with BP disorder. Illness characteristics were examined by chi(2) and multinomial logistic regression in relationship to the degree of parental loading: i) both parents negative; ii) one UP disorder; iii) one with BP disorder; and iv) both affected. Results After controlling for many poor prognosis factors, compared with those from Europe, patients from the United States had more iii) one parent with BP disorder and iv) both parents affected. An early age of onset of BP disorder was independently associated with this increased parental loading for affective disorder. Conclusion Parental history of BP disorder and both parents with a mood disorder were more common in the United States than Europe and were associated with an early onset of bipolar disorder and other poor prognosis characteristics. These findings deserve replication and exploration of the potential mechanisms involved and their therapeutic implications. C1 [Post, R. M.; Leverich, G. S.; Rowe, M.] Bipolar Collaborat Network, Bethesda, MD 20814 USA. [Post, R. M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Kupka, R.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, Amsterdam, Netherlands. [Keck, P., Jr.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [Keck, P., Jr.; McElroy, S.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, S.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Altshuler, L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, West Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Frye, M. A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Luckenbaugh, D. A.] NIMH, NIH, Bethesda, MD 20892 USA. [Grunze, H.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Suppes, T.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, T.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, W. A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. RP Post, RM (reprint author), Bipolar Collaborat Network, 5415 W Cedar Lane 201B, Bethesda, MD 20814 USA. EM robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 FU AstraZeneca; Alkermes; Cephalon; GlaxoSmithKline; Eli Lilly; Marriott Foundation; National Institute of Mental Health; National Institute of Drug Abuse; Orexigen; Pfizer Inc.; Shire; Abbott; Bristol-Myers Squibb; Forest; Jazz; Takeda; Johnson & Johnson Pharmaceutical Research Development; Sepracor; Takeda Pharmaceuticals North America, Inc.; H. Lundbeck A/S; Sunovion Pharmaceuticals Inc.; Pfizer; Astra-Zeneca; Bial; Janssen-Cilag; Sanofi-Aventis; Servier; United BioSource Corporation; Netherlands Organization for Health Research and Development; European Union; Stanley Medical Research Institute; Wyeth FX Dr. Kupka has received research grants from AstraZeneca and honoraria from Eli Lilly, Janssen-Cilag, Bristol-Myers Squibb, and AstraZeneca.; Dr. Keck is employed by the University of Cincinnati College of Medicine and University of Cincinnati Physicians. Dr. Keck is a principal or coinvestigator on research studies sponsored by Alkermes, AstraZeneca, Cephalon, GlaxoSmithKline, Eli Lilly, Marriott Foundation, the National Institute of Mental Health, the National Institute of Drug Abuse, Orexigen, Pfizer Inc., and Shire, and has been reimbursed for consulting to, in the past 2 years, Bristol-Myers-Squibb, Teva, Otsuka, Forest, Merck, Sunovion, Alkermes, and Shire. Dr. Keck is also inventor on US Patent No. 6,387,956: Shapira NA, Goldsmith TD, Keck PE Jr (University of Cincinnati), Methods of Treating Obsessive-Compulsive Spectrum Disorder Comprises the Step of Administering an Effective Amount of Tramadol to an Individual; filed March 25, 1999; approved May 14, 2002.; Dr. McElroy is a consultant to or member of the scientific advisory boards of Eli Lilly and Schering-Plough and is a principal or coinvestigator on research studies sponsored by Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Jazz, the Marriott Foundation, the National Institute of Mental Health, Orexigen, Shire, and Takeda. Dr. McElroy is also inventor on US Patent No. 6,323,236, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and, along with the patent's assignee, the University of Cincinnati, has received payments from Johnson & Johnson Pharmaceutical Research & Development, which has exclusive rights under the patent.; Dr. Altshuler has received past funding from Sepracor (advisory board honoraria, January 2010), and Eli Lilly (consultant, September 2010) and past and potential future funding from Takeda Pharmaceuticals North America, Inc., and H. Lundbeck A/S (advisory board honoraria, October 2012) and Sunovion Pharmaceuticals Inc. (advisory board honoraria, January 2013).; Dr. Frye has received grant support from Pfizer (drug supply: varenicline), has been a consultant to Cephalon, Dainippon Sumitomo, Ortho McNeil/Janssen, Johnson & Johnson, Schering-Plough, and Pfizer, and has participated in supported CME activities for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Otsuka, Pfizer, and Schering-Plough.; Dr. Grunze has received grant/research support, consulting fees, and honoraria within the last 3 years from Astra-Zeneca, Bial, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Janssen-Cilag, Sanofi-Aventis, Servier, United BioSource Corporation.; Dr. Nolen has received grants from The Netherlands Organization for Health Research and Development, the European Union, The Stanley Medical Research Institute, AstraZeneca, Eli Lilly, GlaxoSmithKline, and Wyeth; has received honoraria or speaker's fees from AstraZeneca, Eli Lilly, Pfizer, Servier, and Wyeth; and has served on the advisory boards of AstraZeneca, Cyberonics, Pfizer, and Servier. NR 25 TC 19 Z9 19 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-690X EI 1600-0447 J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PD MAY PY 2014 VL 129 IS 5 SI SI BP 375 EP 382 DI 10.1111/acps.12208 PG 8 WC Psychiatry SC Psychiatry GA AE8AP UT WOS:000334221600006 PM 24138298 ER PT J AU Barranger, JA Brady, RO Grabowski, GA Mankin, H Mistry, PK Weinreb, NJ AF Barranger, John A. Brady, Roscoe O. Grabowski, Gregory A. Mankin, Henry Mistry, Pramod K. Weinreb, Neal J. TI Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014 SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Editorial Material ID ENZYME REPLACEMENT THERAPY; VELAGLUCERASE ALPHA; SKELETAL MANIFESTATIONS; TALIGLUCERASE ALPHA; DISEASE PATIENTS; TYPE-1; IMIGLUCERASE; EXPERIENCE; GLUCOCEREBROSIDASE; IMPROVEMENT C1 [Barranger, John A.] Lysosomal Storage Dis Clin Care Network, Pittsburgh, PA USA. [Brady, Roscoe O.] NIH, Bethesda, MD 20892 USA. [Grabowski, Gregory A.] Synageva BioPharma, Lexington, MA USA. [Mankin, Henry] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. [Mistry, Pramod K.] Yale Univ, Sch Med, New Haven, CT USA. [Weinreb, Neal J.] Univ Res Fdn Lysosomal Storage Dis, Coral Springs, FL USA. RP Weinreb, NJ (reprint author), 8170 Royal Palm Blvd, Coral Springs, FL 33065 USA. EM boneal@winning.com NR 31 TC 2 Z9 2 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2014 VL 89 IS 5 BP 457 EP 458 DI 10.1002/ajh.23687 PG 2 WC Hematology SC Hematology GA AE9MN UT WOS:000334332000002 PM 24488939 ER PT J AU Golub, MS Hogrefe, CE Malka, R Higgins, JM AF Golub, Mari S. Hogrefe, Casey E. Malka, Roy Higgins, John M. TI Developmental plasticity of red blood cell homeostasis SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID IRON-DEFICIENCY ANEMIA; GENOME-WIDE ASSOCIATION; JUVENILE RHESUS-MONKEYS; GESTATIONAL-AGE; MACACA-MULATTA; INFANTS; ERYTHROCYTES; CONSORTIUM; PHENOTYPES; PREGNANCY AB Most human physiologic set points like body temperature are tightly regulated and show little variation between healthy individuals. Red blood cell (RBC) characteristics such as hematocrit and mean cell volume are stable within individuals but can vary by 20% from one healthy person to the next. The mechanisms for the majority of this inter-individual variation are unknown and do not appear to involve common genetic variation. Here, we show that environmental conditions present during development, namely in utero iron availability, can exert long-term influence on a set point related to the RBC life cycle. In a controlled study of rhesus monkeys and a retrospective study of humans, we use a mathematical model of in vivo RBC population dynamics to show that in utero iron deficiency is associated with a lowered threshold for RBC clearance and turnover. This in utero effect is plastic, persisting at least 2 years after birth and after the cessation of iron deficiency. Our study reports a rare instance of developmental plasticity in the human hematologic system and also shows how mathematical modeling can be used to identify cellular mechanisms involved in the adaptive control of homeostatic set points. Am. J. Hematol. 89:459-466, 2014. (c) 2014 Wiley Periodicals, Inc. C1 [Golub, Mari S.] Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA. [Golub, Mari S.; Hogrefe, Casey E.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA. [Malka, Roy; Higgins, John M.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Malka, Roy; Higgins, John M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Malka, Roy; Higgins, John M.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA. RP Golub, MS (reprint author), Univ Calif Davis, Dept Environm Toxicol, One Shields Ave, Davis, CA 95616 USA. EM msgolub@ucdavis.edu; john_higgins@hms.harvard.edu FU NIH [HD39386, P51OD011107, 1-DP2-DK098087, NIH DK083242] FX Contract grant sponsor: NIH; Contract grant numbers: HD39386, P51OD011107 (M. S. G. and C. E. H.), 1-DP2-DK098087, and NIH DK083242 (J.M.H.). NR 36 TC 7 Z9 7 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2014 VL 89 IS 5 BP 459 EP 466 DI 10.1002/ajh.23666 PG 8 WC Hematology SC Hematology GA AE9MN UT WOS:000334332000003 PM 24415575 ER PT J AU Joseph, JM Farron, AM Renella, R Gapany, C AF Joseph, J. M. Farron, A. M. Renella, R. Gapany, C. TI Can Smaller-Scale Comprehensive Cancer Centers Provide Outstanding Care in Abdominal and Thoracic Pediatric Solid Tumor Surgery? Results of a 14-Year Retrospective Single-Center Analysis SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article ID WILMS-TUMOR; RISK NEUROBLASTOMA; QUALITY ASSESSMENT; COMPLICATIONS; CHEMOTHERAPY; EXPERIENCE; ONCOLOGY; STUDY-5; THERAPY AB Purpose. Quality of care and its measurement represent a considerable challenge for pediatric smaller- scale comprehensive cancer centers (pSSCC) providing surgical oncology services. It remains unclear whether center size and/or yearly case-flow numbers influence the quality of care, and therefore impact outcomes for this population of patients. Patients and Methods. We performed a 14-year, retrospective, single-center analysis, assessing adherence to treatment protocols and surgical adverse events as quality indicators in abdominal and thoracic pediatric solid tumor surgery. Results. Forty-eight patients, enrolled in a research-associated treatment protocol, underwent 51 cancer-oriented surgical procedures. All the protocols contain precise technical criteria, indications, and instructions for tumor surgery. Overall, compliance with such items was very high, with 997/1,035 items (95 %) meeting protocol requirements. There was no surgical mortality. Twenty-one patients (43 %) had one or more complications, for a total of 34 complications (66 % of procedures). Overall, 85 % of complications were grade 1 or 2 according to Clavien-Dindo classification requiring observation or minor medical treatment. Case-sample and outcome/effectiveness data were comparable to published series. Overall, our data suggest that even with the modest caseload of a pSSCC within a Swiss tertiary academic hospital, compliance with international standards can be very high, and the incidence of adverse events can be kept minimal. Conclusion. Open and objective data sharing, and discussion between pSSCCs, will ultimately benefit our patient populations. Our study is an initial step towards the enhancement of critical self-review and quality-of-care measurements in this setting. C1 [Joseph, J. M.; Farron, A. M.; Renella, R.] Univ Lausanne Hosp, Dept Pediat & Pediat Surg DMCP, Div Pediat Surg, Lausanne, Switzerland. [Renella, R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA. [Gapany, C.] Univ Hosp Geneva, Dept Pediat & Pediat Surg, Geneva, Switzerland. RP Joseph, JM (reprint author), Univ Lausanne Hosp, Dept Pediat & Pediat Surg DMCP, Div Pediat Surg, Lausanne, Switzerland. EM jean-marc.joseph@chuv.ch NR 20 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 EI 1534-4681 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD MAY PY 2014 VL 21 IS 5 BP 1726 EP 1731 DI 10.1245/s10434-013-3455-y PG 6 WC Oncology; Surgery SC Oncology; Surgery GA AE8BU UT WOS:000334224900052 PM 24407314 ER PT J AU LeClere, LE Shi, LL Lin, A Yannopoulos, P Higgins, LD Warner, JJP AF LeClere, Lance E. Shi, Lewis L. Lin, Albert Yannopoulos, Paul Higgins, Laurence D. Warner, Jon J. P. TI Complete Fatty Infiltration of Intact Rotator Cuffs Caused by Suprascapular Neuropathy SO ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY LA English DT Article ID NERVE ENTRAPMENT; TEARS; SUPRASPINATUS; MUSCLE; DENERVATION; REPAIR; NOTCH; RETRACTION; MANAGEMENT; DIAGNOSIS AB Suprascapular neuropathy is generally considered to be a diagnosis of exclusion, although it has been described in association with several activities and conditions. To our knowledge, this is the first description of suprascapular neuropathy with complete neurogenic fatty replacement in patients with intact rotator cuff tendons in the absence of traction or compression mechanisms. We present 4 cases of patients who presented with complete fatty infiltration of the supraspinatus (1 patient), infraspinatus (2 patients), and both (1 patient) resulting from suprascapular neuropathy. Each of these patients underwent arthroscopic suprascapular nerve decompression and subsequently had immediate improvement in pain and subjective shoulder value. C1 [LeClere, Lance E.] Naval Med Ctr San Diego, Dept Orthopaed Surg, San Diego, CA USA. [Shi, Lewis L.] Univ Chicago, Dept Orthopaed Surg & Rehabilitat Med, Chicago, IL 60637 USA. [Lin, Albert] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA. [Yannopoulos, Paul; Warner, Jon J. P.] Massachusetts Gen Hosp, Harvard Shoulder Serv, Dept Orthopaed Surg, Boston, MA 02114 USA. [Higgins, Laurence D.] Brigham & Womens Hosp, Dept Orthopaed Surg, Sports Med & Shoulder Serv, Boston, MA 02115 USA. RP Warner, JJP (reprint author), Massachusetts Gen Hosp, Harvard Shoulder Serv, Yawkey Ctr Outpatient Care, 55 Fruit St,Ste 3200,3G,Room 3-046, Boston, MA 02114 USA. EM jwarner@partners.org FU Tournier; Mitek FX The authors report the following potential conflict of interest or source of funding: J.J.P.W. receives support from Tournier and Mitek. NR 28 TC 1 Z9 1 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-8063 EI 1526-3231 J9 ARTHROSCOPY JI Arthroscopy PD MAY PY 2014 VL 30 IS 5 BP 639 EP 644 DI 10.1016/j.arthro.2014.01.010 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AE9OR UT WOS:000334337700020 PM 24630957 ER PT J AU Kirchmer, MN Franco, A Albasanz-Puig, A Murray, J Yagi, M Gao, L Dong, ZM Wijelath, ES AF Kirchmer, Mayumi Namekata Franco, Anais Albasanz-Puig, Adaia Murray, Jacqueline Yagi, Mayumi Gao, Lu Dong, Zhao Ming Wijelath, Errol S. TI Modulation of vascular smooth muscle cell phenotype by STAT-1 and STAT-3 SO ATHEROSCLEROSIS LA English DT Article DE STAT-1; STAT-3; Smooth muscle cell; Phenotype; Oncostatin-M ID COLONY-STIMULATING FACTOR; C-FOS PROMOTER; ONCOSTATIN-M; GENE-EXPRESSION; ACTIVATION; ATHEROSCLEROSIS; DIFFERENTIATION; INFLAMMATION; MYOCARDIN; PROLIFERATION AB Objective: Smooth muscle cell (SMC) de-differentiation is a key step that leads to pathological narrowing of blood vessels. De-differentiation involves a reduction in the expression of the SMC contractile genes that are the hallmark of quiescent SMCs. While there is considerable evidence linking inflammation to vascular diseases, very little is known about the mechanisms by which inflammatory signals lead to SMC de-differentiation. Given that the Signal Transducers and Activators of Transcription (STAT) transcriptional factors are the key signaling molecules activated by many inflammatory cytokines and growth factors, the aim of the present study was to determine if STAT transcriptional factors play a role SMC dedifferentiation. Methods and results: Using shRNA targeted to STAT-1 and STAT-3, we show by real time RT-PCR and Western immunoblots that STAT-1 significantly reduces SMC contractile gene expression. In contrast, STAT-3 promotes expression of SMC contractile genes. Over-expression studies of STAT-1 and STAT-3 confirmed our observation that STAT-1 down-regulates whereas STAT-3 promotes SMC contractile gene expression. Bioinformatics analysis shows that promoters of all SMC contractile genes contain STAT binding sites. Finally, using ChIP analysis, we show that both STAT-1 and STAT-3 associate with the calponin gene. Conclusion: These data indicate that the balance of STAT-1 and STAT-3 influences the differentiation status of SMCs. Increased levels of STAT-1 promote SMC de-differentiation, whereas high levels of STAT-3 drive SMC into a more mature phenotype. Thus, inhibition of STAT-1 may represent a novel target for therapeutic intervention in the control of vascular diseases such as atherosclerosis and restenosis. Published by Elsevier Ireland Ltd. C1 [Wijelath, Errol S.] VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA USA. RP Wijelath, ES (reprint author), Dept Vet Affairs Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM errolw@u.washington.edu FU U.S. Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program FX This work was funded by a grant from the U.S. Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program. NR 35 TC 8 Z9 9 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAY PY 2014 VL 234 IS 1 BP 169 EP 175 DI 10.1016/j.atherosclerosis.2014.02.029 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AE9ON UT WOS:000334337300028 PM 24657387 ER PT J AU Ravi, P Bianchi, M Hansen, J Trinh, QD Tian, Z Meskawi, M Abdollah, F Briganti, A Shariat, SF Perrotte, P Montorsi, F Karakiewicz, PI Sun, M AF Ravi, Praful Bianchi, Marco Hansen, Jens Quoc-Dien Trinh Tian, Zhe Meskawi, Malek Abdollah, Firas Briganti, Alberto Shariat, Shahrokh F. Perrotte, Paul Montorsi, Francesco Karakiewicz, Pierre I. Sun, Maxine TI Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis SO BJU INTERNATIONAL LA English DT Article DE muscle-invasive bladder cancer; radical cystectomy; regionalisation ID IN-HOSPITAL MORTALITY; HIGH-VOLUME HOSPITALS; OPERATIVE MORTALITY; SURGICAL-PROCEDURES; CANCER-SURGERY; UNITED-STATES; STATISTICS; TRENDS; DISPARITIES; NUMBER AB Objective To quantify in absolute terms the potential benefit of regionalisation of care from low- to high-volume hospitals. Patients and Methods Patients with a primary diagnosis of bladder cancer treated with radical cystectomy (RC) were identified within the Nationwide Inpatient Sample, a retrospective observational population-based cohort of the USA, between 1998 and 2009. Intraoperative and postoperative complications, blood transfusions, prolonged length of stay, and in-hospital mortality rates represented the outcomes of interest. Potentially avoidable outcomes were calculated by subtracting predicted rates (i.e. estimated outcomes if care was delivered at a high-volume hospital) from observed rates (i.e. actual observed outcomes after care delivered at a low-volume hospital). Multivariable logistic regression models and number needed to treat were generated. Results Patients treated at high-volume hospitals had lower odds of complications during hospitalisation than those treated in low-volume hospitals. Potentially avoidable intraoperative complications, postoperative complications, blood transfusions, prolonged hospitalisation, and in-hospital mortality rates were 0.6, 7.4, 2.8, 9.4, and 2.0%, respectively. This corresponds to a number needed to redirect from low- to high-volume hospitals in order to avoid one adverse event of 166, 14, 36, 11 and 50, respectively. Conclusion This is the first report to quantify the potential benefit of regionalisation of RC for muscle-invasive bladder cancer to high-volume hospitals. C1 [Ravi, Praful] West Middlesex Univ Hosp, London, England. [Bianchi, Marco; Hansen, Jens; Tian, Zhe; Meskawi, Malek; Karakiewicz, Pierre I.; Sun, Maxine] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ H2X 1P1, Canada. [Perrotte, Paul; Karakiewicz, Pierre I.] Univ Montreal, Ctr Hlth, Dept Urol, Montreal, PQ H2X 1P1, Canada. [Sun, Maxine] Univ Montreal, Fac Med, Dept Publ Hlth, Montreal, PQ H2X 1P1, Canada. [Bianchi, Marco; Abdollah, Firas; Briganti, Alberto; Montorsi, Francesco] Univ Vita Salute San Raffaele, Urol Res Inst, Dept Urol, Milan, Italy. [Hansen, Jens] Prostate Canc Ctr Hamburg Eppendorf, Martini Klin, Hamburg, Germany. [Shariat, Shahrokh F.] Cornell Univ, Weill Med Coll, Dept Urol, New York, NY 10021 USA. [Quoc-Dien Trinh] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Div Urol,Med Sch, Boston, MA 02115 USA. [Quoc-Dien Trinh] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Quoc-Dien Trinh] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Sun, M (reprint author), Univ Montreal, Ctr Hlth, 264 Blvd Rene Levesque East,Room 228, Montreal, PQ H2X 1P1, Canada. EM mcw.sun@umontreal.ca FU University of Montreal Health Centre Urology Specialists; Fonds de la Recherche en Sante du Quebec; University of Montreal Department of Surgery; University of Montreal Health Centre (CHUM) Foundation FX P.I.K. is partially supported by the University of Montreal Health Centre Urology Specialists, Fonds de la Recherche en Sante du Quebec, the University of Montreal Department of Surgery and the University of Montreal Health Centre (CHUM) Foundation. NR 28 TC 9 Z9 9 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-4096 EI 1464-410X J9 BJU INT JI BJU Int. PD MAY PY 2014 VL 113 IS 5 BP 733 EP 740 DI 10.1111/bju.12288 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AE4NX UT WOS:000333960500014 PM 24007240 ER PT J AU Aizer, AA Urun, Y McKay, RR Kibel, AS Nguyen, PL Choueiri, TK AF Aizer, Ayal A. Urun, Yuksel McKay, Rana R. Kibel, Adam S. Nguyen, Paul L. Choueiri, Toni K. TI Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC) SO BJU INTERNATIONAL LA English DT Article DE non-clear-cell; cytoreductive nephrectomy; mortality; renal cell carcinoma; survival; clear cell ID TARGETED THERAPY; COMPETING RISK; INTERFERON-ALPHA; KIDNEY CANCER; SURVIVAL; ERA; SORAFENIB; SUNITINIB; PAPILLARY; HISTOLOGY AB Objective To determine whether patients with metastatic non-clear-cell renal cell carcinoma (RCC) benefit from cytoreductive nephrectomy (CN). Patients and Methods We used the Surveillance, Epidemiology, and End Results (SEER) programme to identify a population-based sample of 4914 patients diagnosed with metastatic RCC between 2000 and 2009. Of the 4914 patients, 591 had non-clear-cell histology. The median follow-up was 20 months. The primary outcome measure was RCC-specific mortality. Results Approximately 64% of patients underwent CN. Patients with non-clear-cell histology who underwent CN had lower RCC-specific and all-cause mortality than those who did not (P < 0.001 in both cases). After adjustment for age, gender, race, marital status, year of diagnosis, geographical location and histology, the associations between CN and lower RCC-specific mortality (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.48-0.80, P < 0.001) and between CN and all-cause mortality (HR 0.45, 95% CI 0.37-0.55, P < 0.001) remained highly significant. Among patients diagnosed between 2006 and 2009 (targeted therapy era), the results remained unchanged (HR 0.50, 95% CI 0.34-0.72, P < 0.001 and HR 0.43, 95% CI 0.31-0.59, P < 0.001, respectively). An interaction model found lower all-cause mortality for all histologies after CN. Conclusions Patients from the SEER programme with metastatic non-clear-cell RCC, including those treated in the targeted therapy era, appear to derive a survival benefit from CN, an association which remained significant regardless of histological subtype. This observation suggests that CN should remain standard in patients with advanced RCC who are deemed to be surgical candidates. C1 [Aizer, Ayal A.] Brigham & Womens Hosp, Harvard Radiat Oncol Program, Boston, MA 02215 USA. [Urun, Yuksel; McKay, Rana R.; Kibel, Adam S.; Nguyen, Paul L.; Choueiri, Toni K.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02215 USA. RP Choueiri, TK (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Kidney Canc Ctr, 450 Brookline Ave,DANA1230, Boston, MA 02215 USA. EM Toni_Choueiri@dfci.harvard.edu FU Varian Consulting; Ferring Inc.; Astellas Pharma; Medivation FX There was no external financial support for this study. T. C. is a Consultant and/or on an Advisory Board for Pfizer Inc., Bayer AG, GlaxoSmithKline and Novartis. P.N. declares research funding from Varian Consulting, Ferring Inc., Astellas Pharma and Medivation. No other conflicts of interest declared. NR 29 TC 11 Z9 12 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-4096 EI 1464-410X J9 BJU INT JI BJU Int. PD MAY PY 2014 VL 113 IS 5B SI SI BP E67 EP E74 DI 10.1111/bju.12442 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AF4LA UT WOS:000334682300009 PM 24053727 ER PT J AU Carter, SC Lipsitz, S Shih, YCT Nguyen, PL Trinh, QD Hu, JC AF Carter, Stacey C. Lipsitz, Stuart Shih, Ya-Chen T. Nguyen, Paul L. Quoc-Dien Trinh Hu, Jim C. TI Population-based determinants of radical prostatectomy operative time SO BJU INTERNATIONAL LA English DT Article DE prostate cancer; operative time; robot-assisted radical prostatectomy; retropubic radical prostatectomy; prostatectomy ID LEARNING-CURVE; SURGEON VOLUME; OUTCOMES; DATABASE; OBESITY; HEALTH; COST AB Objectives To determine factors that influence radical prostatectomy (RP) operative times. Operative time assessment is inherent to defining surgeon learning curves and evaluating quality of care. Subjects/Patients and Methods Population-based observational cohort study using USA Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data of men diagnosed with prostate cancer during 2003-2007 who underwent robot-assisted radical prostatectomy (RARP, 3458 men) and retropubic RP (RRP, 6993) through to 2009. We obtained median operative time using anaesthesia administrative data for RP and used median regression to assess the contribution of patient, surgeon, and hospital factors to operative times. Results The median RARP operative time decreased from 315 to 247 min from 2003 to 2008-2009 (P < 0.001), while the median RRP operative time remained similar (195 vs 197 min, P = 0.90). In adjusted analysis, RARP vs RRP (parameter estimate [PE] 70.9; 95% confidence interval [CI] 58, 84; P < 0.001) and obesity (PE 15; 95% CI 7, 23; P < 0.001) were associated with longer operative times while higher surgeon volumes were associated with shorter operative times (P < 0.001). RPs performed by surgeons employed by group (parameter estimate [PE] -22.76; 95% CI -38, -7.49; P = 0.004) and non-government (PE -35.59; 95% CI -68.15, -3.03; P = 0.032) vs government facilities and non-profit vs government hospital ownership (PE -21.85; 95% CI -32.28, -11.42; P < 0.001) were associated with shorter operative times. Conclusions During our study period, RARP operative times decreased by 68 min while RRP operative times remained stagnant. Higher surgeon volume was associated with shorter operative times, and selective referral or improved efficiency to the level of high-volume surgeons would net almost $15 million (USA dollars) in annual savings. C1 [Carter, Stacey C.; Hu, Jim C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90024 USA. [Lipsitz, Stuart] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Shih, Ya-Chen T.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Nguyen, Paul L.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Quoc-Dien Trinh] Brigham & Womens Hosp, Dept Surg, Div Urol, Boston, MA 02115 USA. [Quoc-Dien Trinh] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Hu, JC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, 924 Westwood BLVD,STE 1000, Los Angeles, CA 90024 USA. EM jchu@mednet.ucla.edu FU Bayer; AHRQ [R01 (R01HS018535, R01 (HS020263)]; NCI [R21 (CA165092)] FX Y.-C.S. reports paid consultancy work for MRI Advisory Board sponsored by Bayer and received institution funding from AHRQ; R01 (R01HS018535, R01 HS020263), and NCI; R21 (CA165092), outside the submitted work. No other authors declare any conflicts of interest. NR 29 TC 8 Z9 8 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-4096 EI 1464-410X J9 BJU INT JI BJU Int. PD MAY PY 2014 VL 113 IS 5B SI SI BP E112 EP E118 DI 10.1111/bju.12451 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA AF4LA UT WOS:000334682300015 PM 24053198 ER PT J AU Kim, SP Karnes, RJ Nguyen, PL Ziegenfuss, JY Thompson, RH Han, LC Shah, ND Smaldone, MC Gross, CP Frank, I Weight, CJ Beebe, TJ Tilburt, JC AF Kim, Simon P. Karnes, R. Jeffrey Nguyen, Paul L. Ziegenfuss, Jeanette Y. Thompson, R. Houston Han, Leona C. Shah, Nilay D. Smaldone, Marc C. Gross, Cary P. Frank, Igor Weight, Christopher J. Beebe, Timothy J. Tilburt, Jon C. TI A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer SO BJU INTERNATIONAL LA English DT Article DE screening; prostate-specific antigen; outcomes; survey; prostate cancer ID SERVICES TASK-FORCE; FOLLOW-UP; RESPONSE RATES; MORTALITY; TRIAL; GUIDELINE; SOCIETY AB Objective To assess recommendations for prostate-specific antigen (PSA) screening in a national survey of radiation oncologists and urologists following the recent USA Preventive Services Task Force (USPSTF) grade D recommendation. Methods A random sample of 1366 radiation oncologists and urologists were identified from the American Medical Association Physician Masterfile. From November 2011 to April 2012, a mail survey was sent to query PSA screening recommendations for men at average risk of prostate cancer for the following age groups: 40-49, 50-59, 60-69, 70-74, 75-79 and >= 80 years. Multivariable logistic regression was used to test for differences in PSA-based screening recommendations by physician characteristics. Results Response rates were similar at 52% for radiation oncologists and urologists (P = 0.92). Overall, 51.5% of respondents recommended PSA-based screening for men aged 40-49 years, while nearly all endorsed it for those aged 50-74 years (96.1% for 50-59, 97.3% for 60-69, and 87.7% for 70-74 years). However, screening recommendations decreased to 43.9% and 12.8% for men aged 75-79 and >= 80 years, respectively. On multivariable analysis, urologists were more likely to recommend screening for men aged 40-49 (odds ratio [OR] 3.09; P < 0.001) and 50-59 years (OR 3.81; P = 0.01), but less likely for men aged 75-79 (OR 0.66; P = 0.01) and >= 80 years (OR 0.45; P = 0.002) compared with radiation oncologists. Conclusion While radiation oncologists and urologists recommended PSA screening for men aged 50-69 years, there was less agreement about screening for younger (40-49 years old) and older (>= 70 years) men at average risk for prostate cancer. C1 [Kim, Simon P.] Yale Univ, Dept Urol, Sch Med, New Haven, CT 06519 USA. [Karnes, R. Jeffrey; Thompson, R. Houston; Frank, Igor] Mayo Clin, Dept Urol, Rochester, MN USA. [Nguyen, Paul L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Ziegenfuss, Jeanette Y.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Han, Leona C.; Shah, Nilay D.; Beebe, Timothy J.] Mayo Clin, Div Hlth Care Policy & Res, Rochester, MN USA. [Smaldone, Marc C.] Fox Chase Canc Ctr, Dept Surg, Philadelphia, PA 19111 USA. [Gross, Cary P.] Yale Univ, Dept Internal Med, Sch Med, New Haven, CT 06519 USA. [Kim, Simon P.; Gross, Cary P.] Yale Univ, Canc Outcomes Publ Policy & Effectiveness Res Ctr, New Haven, CT 06519 USA. [Weight, Christopher J.] Univ Minnesota, Dept Urol, Minneapolis, MN USA. [Tilburt, Jon C.] Mayo Clin, Biomed Eth Res Unit, Rochester, MN USA. [Tilburt, Jon C.] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN USA. [Tilburt, Jon C.] Mayo Clin, Div Gen Internal Med, Rochester, MN USA. RP Kim, SP (reprint author), Yale Univ, Dept Urol, Sch Med, POB 208058, New Haven, CT 06519 USA. EM simkim@me.com OI Weight, Christopher/0000-0001-9381-959X FU NCATS NIH HHS [UL1 TR000135] NR 29 TC 6 Z9 6 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-4096 EI 1464-410X J9 BJU INT JI BJU Int. PD MAY PY 2014 VL 113 IS 5B SI SI BP E106 EP E111 DI 10.1111/bju.12422 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA AF4LA UT WOS:000334682300014 PM 24053213 ER PT J AU Pond, GR Agarwal, N Bellmunt, J Choueiri, TK Qu, A Fougeray, R Vaughn, D James, ND Salhi, Y Albers, P Niegisch, G Galsky, MD Wong, YN Ko, YJ Stadler, WM O'Donnell, PH Sridhar, SS Vogelzang, NJ Necchi, A Di Lorenzo, G Sternberg, CN Mehta, A Sonpavde, G AF Pond, Gregory R. Agarwal, Neeraj Bellmunt, Joaquim Choueiri, Toni K. Qu, Angela Fougeray, Ronan Vaughn, David James, Nicholas D. Salhi, Yacine Albers, Peter Niegisch, Guenter Galsky, Matthew D. Wong, Yu-Ning Ko, Yoo-Joung Stadler, Walter M. O'Donnell, Peter H. Sridhar, Srikala S. Vogelzang, Nicholas J. Necchi, Andrea Di Lorenzo, Giuseppe Sternberg, Cora N. Mehta, Amitkumar Sonpavde, Guru TI A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma SO BJU INTERNATIONAL LA English DT Article DE advanced urothelial cancer; response rate; progression-free survival at 6 months; second-line therapy; nomogram ID TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; PLATINUM-CONTAINING REGIMEN; ONCOLOGY-GROUP; SINGLE GROUP; CANCER; PACLITAXEL; CHEMOTHERAPY; TRACT; VINFLUNINE AB Objective To study the impact of the prognostic factors liver metastasis (LM), anaemia (haemoglobin [Hb] <10 g/dL), Eastern Cooperative Oncology Group performance status (ECOG-PS) >= 1 and time from previous chemotherapy (TFPC) on the activity of second-line therapy for advanced urothelial carcinoma (UC). Patients and Methods Twelve phase II trials evaluating second-line chemotherapy and/or biological characteristics (n = 748) in patients with progressive disease were pooled. Progression-free survival (PFS) was defined as tumour progression or death from any cause. The PFS rate at 6 months (PFS6) was defined from the date of registration and calculated using the Kaplan-Meier method. Response rate (RR) was defined using Response Evaluation Criteria in Solid Tumours (RECIST) 1.0. A nomogram predicting PFS6 was constructed using the rms software package in R (). Results Data regarding progression, anaemia, LM, ECOG-PS and TFPC were available from 570 patients in nine phase II trials. The overall median PFS was 2.7 months, PFS6 was 22.2% (95% confidence interval 18.8-25.9) and the RR was 17.5% (95% CI: 14.5-20.9%). For every unit increase in risk group, the hazard of progression in 6 months increased by 41% and the odds of response decreased by 48%. A nomogram was constructed to predict PFS6 on an individual patient level. The model was internally validated and was shown to have acceptable calibration performance. Conclusions The RR and PFS6 vary as a function of baseline prognostic factors in patients receiving second-line therapy for advanced UC. A nomogram incorporating prognostic factors facilitates the evaluation of outcomes across phase II trials enrolling heterogeneous populations and helps select suitable agents for phase III testing. C1 [Pond, Gregory R.] McMaster Univ, Ontario Clin Oncol Grp, Hamilton, ON, Canada. [Agarwal, Neeraj] Univ Utah, Dept Med, Sect Hematol Oncol, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Bellmunt, Joaquim] Univ Hosp del Mar IMIM, Barcelona, Spain. [Choueiri, Toni K.] Dana Farber Canc Inst, Dept Med, Sect Hematol Oncol, Boston, MA 02115 USA. [Choueiri, Toni K.] Harvard Univ, Sch Med, Boston, MA USA. [Qu, Angela; Fougeray, Ronan; Salhi, Yacine] Inst Rech Pierre Fabre, Boulogne, France. [Vaughn, David] Univ Penn, Dept Med, Sect Hematol Oncol, Philadelphia, PA 19104 USA. [James, Nicholas D.] Univ Birmingham, Birmingham, W Midlands, England. [Albers, Peter; Niegisch, Guenter] Univ Dusseldorf, Dusseldorf, Germany. [Galsky, Matthew D.] Mt Sinai Sch Med, Dept Med, Sect Hematol Oncol, Tisch Canc Ctr Inst, New York, NY USA. [Wong, Yu-Ning] Fox Chase Canc Ctr, Sect Hematol Oncol, Dept Med, Philadelphia, PA 19111 USA. [Ko, Yoo-Joung] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. [Stadler, Walter M.; O'Donnell, Peter H.] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA. [Sridhar, Srikala S.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Vogelzang, Nicholas J.] Comprehens Canc Ctr Nevada, Las Vegas, NV USA. [Necchi, Andrea] Fdn IRCCS Ist Nazl Tumori, Milan, Italy. [Di Lorenzo, Giuseppe] Univ Naples Federico II, Naples, Italy. [Sternberg, Cora N.] San Camillo Hosp, Rome, Italy. [Sternberg, Cora N.] Forlanini Hosp, Rome, Italy. [Mehta, Amitkumar; Sonpavde, Guru] Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Med, Sect Hematol Oncol UAB, Birmingham, AL 35294 USA. RP Sonpavde, G (reprint author), UAB Comprehens Canc Ctr, 1720 2nd Ave S NP2540B, Birmingham, AL 35294 USA. EM gsonpavde@uabmc.edu OI Niegisch, Gunter/0000-0001-6929-8691; Necchi, Andrea/0000-0002-3007-2756 FU Boehringer-Ingelheim; Celgene; Pierre-Fabre; Astrazeneca; BMS; GSK; Eli-Lilly FX G. S. received research support to institution from Boehringer-Ingelheim and Celgene. R. F is an employee of Pierre-Fabre. Y.S. is an employee of Pierre-Fabre. N.D.J. and D. V. received research support from Pierre-Fabre. T. K. C. and A. Q. received research support to institution from Astrazeneca. J.M.B. received research support to institution from Pierre-Fabre. Y.N.W. received research support from BMS. S. S. and Y.-J.K. received research support to institution from Celgene. A.N. received research support and is a consultant for GSK. W. M. S. and P.H.O'D. received research support from Boehringer-Ingelheim and GSK. M. D. G. received research support to institution from Eli-Lilly. N.J.V. received research support to institution from Boehringer-Ingelheim. G.N. and P. A. received research support to institution from Eli Lilly and BMS. N.A, G. R. P., C.N.S, G. D. L and M. A. have no conflicts to declare. NR 25 TC 13 Z9 13 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-4096 EI 1464-410X J9 BJU INT JI BJU Int. PD MAY PY 2014 VL 113 IS 5B SI SI BP E137 EP E143 DI 10.1111/bju.12564 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA AF4LA UT WOS:000334682300018 PM 24219029 ER PT J AU Merry, AF Avery, EG Nussmeier, NA Playford, HR Warman, GR Wang, YM Sladen, RN AF Merry, Alan F. Avery, Edwin G. Nussmeier, Nancy A. Playford, Hugh R. Warman, Guy R. Wang, Yamei Sladen, Robert N. TI Clevidipine compared with nitroglycerin for blood pressure control in coronary artery bypass grafting: a randomized double-blind study SO CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE LA English DT Article ID ACTING CALCIUM-ANTAGONIST; ACUTE POSTOPERATIVE HYPERTENSION; CARDIAC-SURGERY PATIENTS; SODIUM-NITROPRUSSIDE; HEALTHY-VOLUNTEERS; CONTROLLED-TRIAL; OUTCOMES; RISK; REVASCULARIZATION; PATIENT AB We tested the hypothesis that clevidipine, a rapidly acting dihydropyridine calcium channel blocker, is not inferior to nitroglycerin (NTG) in controlling blood pressure before cardiopulmonary bypass (CPB) during coronary artery bypass grafting (CABG). In this double-blind study from October 4, 2003 to April 26, 2004, 100 patients undergoing CABG with CPB were randomized at four centres to receive intravenous infusions of clevidipine (0.2-8 mu g center dot kg(-1)center dot min(-1)) or NTG (0.4 mu g center dot kg(-1)center dot min(-1) to a clinician-determined maximum dose rate) from induction of anesthesia through 12 hr postoperatively. The study drug was titrated in the pre-CPB period with the aim of maintaining mean arterial pressure (MAP) within +/- A 5 mmHg of a clinician-predetermined target. The primary endpoint was the area under the curve (AUC) for the total time each patient's MAP was outside the target range from drug initiation to the start of CPB, normalized per hour (AUC(MAP-D)). The predefined non-inferiority criterion for the primary endpoint was a 95% confidence interval (CI) upper limit no greater than 1.50 for the geometric means ratio between clevidipine and NTG. Total mean [standard deviation (SD)] dose pre-bypass was 4.5 (4.7) mg for clevidipine and 6.9 (5.4) mg for NTG (P < 0.05). The geometric mean AUC(MAP-D) for clevidipine was 283 mmHg center dot min center dot hr(-1) (n = 45) and for NTG was 292 mmHg center dot min center dot hr(-1) (n = 48); the geometric means ratio was 0.97 (95% CI 0.74 to 1.27). The geometric mean AUC(MAP-D) during aortic cannulation was 357.7 mmHg center dot min center dot hr(-1) for clevidipine compared with 190.5 mmHg center dot min center dot hr(-1) for NTG. Mean (SD) heart rate with clevidipine was 76.0 (13.8) beats center dot min(-1) compared with 81.5 (14.4) beats center dot min(-1) for NTG. There were no clinically important differences between groups in adverse events. During CABG, clevidipine was not inferior to NTG for blood pressure control pre-bypass. C1 [Merry, Alan F.; Warman, Guy R.] Univ Auckland, Sch Med, Fac Med & Hlth Sci, Auckland 1003, New Zealand. [Merry, Alan F.] Green Lane Hosp, Auckland 3, New Zealand. [Merry, Alan F.] Mercy Ascot Integrated Hosp, Auckland, New Zealand. [Avery, Edwin G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nussmeier, Nancy A.] Texas Heart Inst, Houston, TX 77025 USA. [Playford, Hugh R.; Sladen, Robert N.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Wang, Yamei] Medicines Co, Parsippany, NJ USA. RP Merry, AF (reprint author), Auckland City Hosp, Auckland, New Zealand. EM a.merry@auckland.ac.nz OI Warman, Guy/0000-0001-9064-3090; Merry, Alan/0000-0001-7100-009X FU Medicines Company, Parsippany, NJ USA FX This study was sponsored by The Medicines Company, Parsippany, NJ USA. NR 20 TC 4 Z9 4 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0832-610X EI 1496-8975 J9 CAN J ANESTH JI Can. J. Anesth. PD MAY PY 2014 VL 61 IS 5 BP 398 EP 406 DI 10.1007/s12630-014-0131-z PG 9 WC Anesthesiology SC Anesthesiology GA AF1ST UT WOS:000334494500003 PM 24700403 ER PT J AU Schlett, CL Pursnani, A Marcus, RP Truong, QA Hoffmann, U AF Schlett, Christopher L. Pursnani, Amit Marcus, Roy P. Truong, Quynh A. Hoffmann, Udo TI The Use of Coronary CT Angiography for the Evaluation of Chest Pain SO CARDIOLOGY IN REVIEW LA English DT Review DE acute chest pain syndrome; computed tomographic angiography; stable chest pain syndrome ID COMPUTED-TOMOGRAPHY-ANGIOGRAPHY; INTERNATIONAL MULTICENTER REGISTRY; INCREMENTAL PROGNOSTIC VALUE; ALL-CAUSE MORTALITY; MYOCARDIAL-PERFUSION SPECT; AMERICAN-HEART-ASSOCIATION; LEFT-VENTRICULAR FUNCTION; PITCH SPIRAL ACQUISITION; FRACTIONAL FLOW RESERVE; RULE-OUT CT AB Coronary computed tomography angiography (CCTA) may improve the diagnosis and management of acute and stable chest pain syndromes. The key for caregivers of patients presenting with acute chest pain is the early identification and management of life-threatening conditions, such as acute coronary syndromes, pulmonary embolism, and acute aortic dissection. The main goal in stable chest pain syndromes is to determine the extent and severity of coronary artery disease. This review article will critically evaluate the current literature supporting the evidence for the clinical use of CCTA in acute and stable chest pain syndromes, considering the latest innovations in CCTA technology and their potential impact on patient care. C1 [Schlett, Christopher L.; Pursnani, Amit; Marcus, Roy P.; Truong, Quynh A.; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Cardiac MR PET CT Program, Dept Radiol,Div Cardiol,Med Sch, Boston, MA 02114 USA. [Schlett, Christopher L.; Pursnani, Amit; Marcus, Roy P.; Truong, Quynh A.; Hoffmann, Udo] Univ Munich, Dept Clin Radiol, Klinikum Grosshadern, Munich, Germany. [Schlett, Christopher L.] Heidelberg Univ, Dept Diagnost & Intervent Radiol, Univ Heidelberg Hosp, Heidelberg, Germany. RP Hoffmann, U (reprint author), Harvard Univ, Massachusetts Gen Hosp, Cardiac MR PET CT Program, Dept Radiol,Med Sch, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM uhoffmann@partners.org NR 96 TC 2 Z9 2 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1061-5377 EI 1538-4683 J9 CARDIOL REV JI Cardiol. Rev. PD MAY-JUN PY 2014 VL 22 IS 3 BP 117 EP 127 DI 10.1097/CRD.0000000000000015 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AE9IH UT WOS:000334321000002 PM 24407046 ER PT J AU Voskuijl, T Hageman, M Ring, D AF Voskuijl, Timothy Hageman, Michiel Ring, David TI Higher Charlson Comorbidity Index Scores are Associated With Readmission After Orthopaedic Surgery SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article ID TOTAL KNEE ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; RISK-FACTORS; HOSPITAL READMISSIONS; PERIOPERATIVE MORTALITY; WOUND COMPLICATIONS; 30-DAY READMISSION; BLOOD-TRANSFUSION; FRACTURES; OUTCOMES AB The Charlson Comorbidity Index (CCI) originally was developed to predict mortality within 1 year of hospital admission in patients without trauma. As it includes factors associated with medical and surgical complexities, it also may be useful as a predictive tool for hospital readmission after orthopaedic surgery, but to our knowledge, this has not been studied. We asked whether an increased score on the CCI was associated with (1) readmission, (2) an increased risk of surgical site infection or other adverse events, (3) transfusion risk, or (4) mortality after orthopaedic surgery. A total of 30,129 orthopaedic surgeries performed between 2008 and 2011 without any orthopaedic surgery in the preceding 30 days were analyzed. International Classification of Diseases, 9(th) Revision codes were used to identify diagnoses, procedures, surgery-related adverse events, surgical site infection, and comorbidities as listed in the updated and reweighted CCI. A total of 913 patients (3.0%) were readmitted within 30 days after discharge; in 393 (1.4%) patients adverse events occurred; 417 patients (1.4%) had a surgical site infection develop; 211 (0.7%) needed transfusions, and 56 (0.2%) died within 30 days after surgery. Ordinary least squares regression analyses were used to determine whether the CCI was associated with these outcomes. The CCI accounted for 10% of the variation in readmissions. Every point increase in CCI score added an additional 0.45% risk in readmission for patients undergoing arthroplasty, 0.63% for patients undergoing trauma surgery, and 0.9% risk for patients undergoing spine surgery (all p < 0.01). The CCI was not associated with surgical site infection or other adverse events, but accounted for 8% of the variation in transfusion rate and 10% of the variation in mortality within 30 days of surgery. The CCI can be used to estimate the risk of readmission after arthroplasty, hand and upper extremity surgery, spine surgery, and trauma surgery. It also can be used to estimate the risk of transfusion after arthroplasty, spine, trauma, and oncologic orthopaedic surgery and the risk of mortality after shoulder, trauma, and oncologic orthopaedic surgery. Level IV, prognostic study. See the Instructions for Authors for a complete description of levels of evidence. C1 [Voskuijl, Timothy; Hageman, Michiel; Ring, David] Massachusetts Gen Hosp, Yawkey Ctr, Dept Orthopaed Surg, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Dept Orthopaed Surg, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 38 TC 29 Z9 30 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X EI 1528-1132 J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD MAY PY 2014 VL 472 IS 5 BP 1638 EP 1644 DI 10.1007/s11999-013-3394-8 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AE7LV UT WOS:000334180400043 PM 24276857 ER PT J AU Hinton, DE Jalal, B AF Hinton, Devon E. Jalal, Baland TI Parameters for Creating Culturally Sensitive CBT: Implementing CBI in Global Settings SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Editorial Material DE global health; CBT; culture; implementation; scale up; assessment; transdiagnostic treatment; culture; treatment adaptation; global health; PTSD ID TREATMENT-RESISTANT PTSD; CAMBODIAN REFUGEES; CONTROLLED-TRIAL; PANIC-ATTACKS; SYMPTOM AB The current article is a commentary on the article, "A Common Elements Approach for Adult Mental Health Problems in Low- and Middle-Income Countries," which describes a form of transdiagnostic CBT and its implementation among a highly traumatized Burmese and Iraqi group. Murray et al.'s (this issue) article is one of several new studies indicating the efficacy of CBT in global contexts. In this commentary, we suggest a set of parameters to create culturally sensitive CBT in global settings in a way to maximize efficacy and effectiveness. When applicable, we will discuss ways in which these parameters are illustrated by Murray et al. in this pilot study. These parameters can be used more generally to design culturally sensitive CBT studies in global contexts and to evaluate such studies. Some examples of these parameters are culturally appropriate framing of CBT techniques, assessing and addressing key local complaints (e.g., somatic symptoms) and local catastrophic cognitions, and incorporating key local sources of recovery and resilience. C1 [Hinton, Devon E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hinton, Devon E.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Hinton, Devon E.] Arbour Counseling Serv, Lowell, MA 01852 USA. [Jalal, Baland] Univ Calif San Diego, San Diego, CA USA. RP Hinton, DE (reprint author), Arbour Counseling Serv, 10 Bridge St,Simpson Block, Lowell, MA 01852 USA. EM devon_hinton@hms.harvard.edu NR 25 TC 3 Z9 3 U1 5 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 EI 1878-187X J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD MAY PY 2014 VL 21 IS 2 BP 139 EP 144 PG 6 WC Psychology, Clinical SC Psychology GA AE7AZ UT WOS:000334150400005 ER PT J AU Thurston, IB Bogart, LM Wachman, M Closson, EF Skeer, MR Mimiaga, MJ AF Thurston, Idia B. Bogart, Laura M. Wachman, Madeline Closson, Elizabeth F. Skeer, Margie R. Mimiaga, Matthew J. TI Adaptation of an HIV Medication Adherence Intervention for Adolescents and Young Adults SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Article DE Sexual minority youth; Adherence intervention; problem; solving; technology; case study ID ENHANCE ART ADHERENCE; LESS-THAN 95-PERCENT; ANTIRETROVIRAL THERAPY; PEDIATRIC-PATIENTS; CHILDREN; YOUTH; PILOT; AIDS; SUPPRESSION; HIV/AIDS AB Rising rates of human immunodeficiency virus (HIV) infection among adolescents and young adults underscore the importance of interventions for this population. While the morbidity and mortality of HIV has greatly decreased over the years, maintaining high rates of adherence is necessary to receive optimal medication effects. Few studies have developed interventions for adolescents and young adults and none have specifically been developed for sexual minority (lesbian, gay, and bisexual; LGB) youth. Guided by an evidence-based adult intervention and adolescent qualitative interviews, we developed a multicomponent, technology-enhanced, customizable adherence intervention for adolescents and young adults for use in a clinical setting. The two cases presented in this paper illustrate the use of the five-session positive strategies to enhance problem solving (Positive STEPS) intervention, based on cognitive-behavioral techniques and motivational interviewing. We present a perinatally infected heterosexual woman and a behaviorally infected gay man to demonstrate the unique challenges faced by these youth and showcase how the intervention can be customized. Future directions include varying the number of intervention sessions based on mode of HIV infection and incorporating booster sessions. C1 [Thurston, Idia B.] Univ Memphis, Memphis, TN 38152 USA. [Bogart, Laura M.] Harvard Univ, Sch Med, Boston Childrens Hosp, Cambridge, MA 02138 USA. [Wachman, Madeline] Boston Univ, Boston, MA 02215 USA. [Skeer, Margie R.] Tufts Univ, Sch Med, Medford, MA USA. [Mimiaga, Matthew J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Mimiaga, Matthew J.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. RP Thurston, IB (reprint author), Univ Memphis, Dept Psychol, 310 Psychol Bldg, Memphis, TN 38152 USA. EM bthrston@memphis.edu FU NIAID NIH HHS [P30 AI060354]; NICHD NIH HHS [RC4 HD066907]; NIMH NIH HHS [R34 MH090790] NR 39 TC 3 Z9 4 U1 1 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 EI 1878-187X J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD MAY PY 2014 VL 21 IS 2 BP 191 EP 205 PG 15 WC Psychology, Clinical SC Psychology GA AE7AZ UT WOS:000334150400010 PM 25452680 ER PT J AU Lovejoy, TI Heckman, TG AF Lovejoy, Travis I. Heckman, Timothy G. CA Project SAFER Intervention Team TI Telephone-Administered Motivational Interviewing and Behavioral Skills Training to Reduce Risky Sexual Behavior in HIV-Positive Late Middle-Age and Older Adults SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Article DE HIV/AIDS; older adults; risky sexual behavior; motivational; interviewing; behavioral skills training ID OUTCOMES; TRIAL AB By 2014, 50% of all persons living with HIV/AIDS in the U.S. will be 50 years of age or older. An estimated 13% to 30% of HIV-positive older adults continue to engage in risky sexual behaviors that risk HIV transmission. Project SAFER, a large pilot randomized controlled trial, evaluated telephone-administered motivational interviewing and behavioral skills training to reduce sexual risk behavior in HIV-positive, urban-dwelling late middle-age and older adults. The intervention consists of 4 weekly integrated motivational interviewing and behavioral skills training sessions delivered by a mental health clinician over the telephone. This paper highlights study procedures and intervention outcomes. The primary focus, however, is a detailed description of the 4-session intervention with sample counselor-client dialogue that is thematically emblematic of topics addressed in the intervention. We conclude with lessons learned conducting telephone-administered motivational interviewing and behavioral skills training with HIV-positive late middle-age and older adults. C1 [Lovejoy, Travis I.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Lovejoy, Travis I.] Portland VA Med Ctr, Portland, OR 97239 USA. [Heckman, Timothy G.] Univ Georgia, Athens, GA 30602 USA. [Project SAFER Intervention Team] Ohio Univ, Athens, OH 45701 USA. RP Lovejoy, TI (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM travis.lovejoy@va.gov NR 24 TC 4 Z9 4 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 EI 1878-187X J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD MAY PY 2014 VL 21 IS 2 BP 224 EP 236 PG 13 WC Psychology, Clinical SC Psychology GA AE7AZ UT WOS:000334150400012 ER PT J AU Letourneau, AR Issa, NC Baden, LR AF Letourneau, Alyssa R. Issa, Nicolas C. Baden, Lindsey R. TI Pneumonia in the immunocompromised SO CURRENT OPINION IN PULMONARY MEDICINE LA English DT Review DE biologic agents; bone marrow transplant; immunocompromised host; pneumonia; solid organ transplant ID RESPIRATORY SYNCYTIAL VIRUS; CELL TRANSPLANT RECIPIENTS; INVASIVE FUNGAL-INFECTIONS; PNEUMOCYSTIS-JIROVECII PNEUMONIA; ANTITUMOR NECROSIS FACTOR; BETA-D-GLUCAN; SOLID-ORGAN; ANTIFUNGAL THERAPY; GALACTOMANNAN ANTIGENEMIA; HEMATOLOGIC MALIGNANCIES AB Purpose of reviewNovel treatment modalities for previously fatal diseases, including newer chemotherapeutic and biologic agents and the expansion of the indications for solid organ and stem cell transplantation, have resulted in prolonged patient survival and a significant increase in the population of immunocompromised hosts (ICHs).Recent findingsThis review discusses the increasing spectrum of opportunistic infections in the ICH, the general approach for early diagnosis and treatment of pulmonary infections in this population, and the current and novel diagnostic modalities available to establish a rapid and specific microbiologic diagnosis, focusing on recent controversies and advances.SummaryEarly diagnosis and prompt initiation of effective therapy for infection help reduce morbidity in ICHs. Advances in diagnostic assays using nonculture-based methods, such as nucleic acid amplification, may allow for earlier targeted therapy. Invasive procedures including bronchoscopy and biopsy remain essential and should be vigorously pursued in ICHs given the broad differential diagnosis of possible pulmonary pathogens in this population, and the need to establish a specific diagnosis to allow accurate targeted therapy. C1 [Letourneau, Alyssa R.; Issa, Nicolas C.; Baden, Lindsey R.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Issa, Nicolas C.; Baden, Lindsey R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Issa, Nicolas C.; Baden, Lindsey R.] Harvard Univ, Sch Med, Boston, MA USA. RP Letourneau, AR (reprint author), Brigham & Womens Hosp, Div Infect Dis, PBB A4,75 Francis St, Boston, MA 02115 USA. EM aletourneau@partners.org NR 78 TC 2 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5287 EI 1531-6971 J9 CURR OPIN PULM MED JI Curr. Opin. Pulm. Med. PD MAY PY 2014 VL 20 IS 3 BP 272 EP 279 DI 10.1097/MCP.0000000000000051 PG 8 WC Respiratory System SC Respiratory System GA AE0EB UT WOS:000333635300009 PM 24626236 ER PT J AU Shamsi, MM Hassan, ZH Gharakhanlou, R Quinn, LS Azadmanesh, K Baghersad, L Isanejad, A Mahdavi, M AF Shamsi, M. Molanouri Hassan, Z. H. Gharakhanlou, R. Quinn, L. S. Azadmanesh, K. Baghersad, L. Isanejad, A. Mahdavi, M. TI Expression of interleukin-15 and inflammatory cytokines in skeletal muscles of STZ-induced diabetic rats: effect of resistance exercise training SO ENDOCRINE LA English DT Article DE Interleukin-15; Inflammatory cytokines; Resistance training; Type-1 diabetes ID RECEPTOR-ALPHA EXPRESSION; OXIDATIVE STRESS; GLUCOSE-UPTAKE; MESSENGER-RNA; GROWTH-FACTOR; IN-VITRO; HYPERTROPHY; ATROPHY; DAMAGE; RESPONSES AB Skeletal muscle atrophy is associated with type-1 diabetes. Skeletal muscle is the source of pro- and anti-inflammatory cytokines that can mediate muscle hypertrophy and atrophy, while resistance exercise can modulate both muscle mass and muscle cytokine expression. This study determined the effects of a 5-week resistance exercise training regimen on the expression of muscle cytokines in healthy and streptozotocin-induced diabetic rats, with special emphasis on interleukin-15 (IL-15), a muscle-derived cytokine proposed to be involved in muscle hypertrophy or responses to stress. Induction of diabetes reduced muscle weight in both the fast flexor hallucis longus (FHL) and slow soleus muscles, while resistance training preserved FHL muscle weight in diabetic rats. IL-15 protein content was increased by training in both FHL and soleus muscles, as well as serum, in normal and diabetic rats. With regard to proinflammatory cytokines, muscle IL-6 levels were increased in diabetic rats, while training decreased muscle IL-6 levels in diabetic rats; training had no effect on FHL muscle IL-6 levels in healthy rats. Also, tumor necrosis factor-alpha (TNF-alpha) and IL-1 beta levels were increased by diabetes, but not changed by training. In conclusion, we found that in diabetic rats, resistance training increased muscle and serum IL-15 levels, decreased muscle IL-6 levels, and preserved FHL muscle mass. C1 [Shamsi, M. Molanouri; Gharakhanlou, R.; Baghersad, L.] Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, Tehran 1411713116, Iran. [Hassan, Z. H.] Tarbiat Modares Univ, Sch Med Sci, Dept Immunol, Tehran 1411513116, Iran. [Quinn, L. S.] Univ Washington, Geriatr Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Quinn, L. S.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA. [Azadmanesh, K.; Mahdavi, M.] Pasteur Inst Iran, Dept Virol, Tehran, Iran. [Isanejad, A.] Shahed Univ, Fac Humanities, Phys Educ & Sport Sci Dept, Tehran, Iran. RP Shamsi, MM (reprint author), Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, Tehran 1411713116, Iran. EM Mahdieh_molanouri@yahoo.com; Hassan_zm@modares.ac.ir; ghara_re@modares.ac.ir; quinnL@uw.edu; azadmanesh@pasteur.ac.ir; l.baghersad@gmail.com; sa61es@yahoo.com; mahdavivac@gmail.com FU Research Center of Tarbiat Modares University (TMU), Tehran, Iran FX This work was supported by the Research Center of Tarbiat Modares University (TMU), Tehran, Iran. We wish to thank Professor Yaghob Fathoallahy and Dr Alireza Mani for their kind help and sincere cooperation. NR 59 TC 14 Z9 14 U1 0 U2 11 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD MAY PY 2014 VL 46 IS 1 BP 60 EP 69 DI 10.1007/s12020-013-0038-4 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AE7LP UT WOS:000334179700010 ER PT J AU Werth, VP AF Werth, V. P. TI Introduction of approach SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 3rd International Conference on Cutaneous Lupus Erythematosus CY MAY 06-08, 2013 CL Edinburgh, SCOTLAND C1 [Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Werth, V. P.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 IS 5 BP 1484 EP 1484 PG 1 WC Dermatology SC Dermatology GA AF2VJ UT WOS:000334570300048 ER PT J AU Szepietowski, JC Werth, V Furukawa, F Samotij, D Reich, A AF Szepietowski, J. C. Werth, V. Furukawa, F. Samotij, D. Reich, A. TI Current practice variations in cutaneous lupus therapy and thoughts about international guidelines SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 3rd International Conference on Cutaneous Lupus Erythematosus CY MAY 06-08, 2013 CL Edinburgh, SCOTLAND C1 [Szepietowski, J. C.; Samotij, D.; Reich, A.] Wroclaw Med Univ, Dept Dermatol Venereol & Allergol, Wroclaw, Poland. [Werth, V.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Werth, V.] Univ Penn, Philadelphia, PA 19104 USA. [Furukawa, F.] Wakayama Med Univ, Dept Dermatol, Wakayama, Japan. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 IS 5 BP 1485 EP 1485 PG 1 WC Dermatology SC Dermatology GA AF2VJ UT WOS:000334570300058 ER PT J AU Verma, SM Werth, VP AF Verma, S. M. Werth, V. P. TI Quality of Life in Lupus and Dermatomyositis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 3rd International Conference on Cutaneous Lupus Erythematosus CY MAY 06-08, 2013 CL Edinburgh, SCOTLAND C1 [Verma, S. M.] Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Verma, S. M.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 IS 5 BP 1485 EP 1485 PG 1 WC Dermatology SC Dermatology GA AF2VJ UT WOS:000334570300054 ER PT J AU Werth, VP AF Werth, V. P. TI New clinical treatments in CLE SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 3rd International Conference on Cutaneous Lupus Erythematosus CY MAY 06-08, 2013 CL Edinburgh, SCOTLAND C1 [Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Werth, V. P.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 IS 5 BP 1486 EP 1486 PG 1 WC Dermatology SC Dermatology GA AF2VJ UT WOS:000334570300064 ER PT J AU Chun, AC AF Chun, Ang Chia TI Lung diseases in dermatomyositis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 3rd International Conference on Cutaneous Lupus Erythematosus CY MAY 06-08, 2013 CL Edinburgh, SCOTLAND C1 [Chun, Ang Chia] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chun, Ang Chia] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Chun, Ang Chia] Changi Gen Hosp, Dept Dermatol, Singapore, Singapore. RI hui, li/L-5008-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 IS 5 BP 1488 EP 1488 PG 1 WC Dermatology SC Dermatology GA AF2VJ UT WOS:000334570300075 ER PT J AU Ang, CC Anyanwu, C Werth, VP AF Ang, C. C. Anyanwu, C. Werth, V. P. TI Dermatomyositis patients with mechanic's hands have a higher risk of both early and established interstitial lung disease SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 3rd International Conference on Cutaneous Lupus Erythematosus CY MAY 06-08, 2013 CL Edinburgh, SCOTLAND C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 IS 5 BP 1489 EP 1489 PG 1 WC Dermatology SC Dermatology GA AF2VJ UT WOS:000334570300079 ER PT J AU Anyanwu, C Propert, K Werth, VP AF Anyanwu, C. Propert, K. Werth, V. P. TI Determination of cutaneous dermatomyositis severity using the cutaneous dermatomyositis disease area and severity index SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 3rd International Conference on Cutaneous Lupus Erythematosus CY MAY 06-08, 2013 CL Edinburgh, SCOTLAND C1 [Anyanwu, C.; Werth, V. P.] Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Anyanwu, C.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Propert, K.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 IS 5 BP 1489 EP 1489 PG 1 WC Dermatology SC Dermatology GA AF2VJ UT WOS:000334570300081 ER PT J AU Azimi, E Reddy, VB Luo, T Elmariah, S Lerner, EA AF Azimi, E. Reddy, V. B. Luo, T. Elmariah, S. Lerner, E. A. TI The role of Mas-related G-protein coupled receptors in substance P signaling SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Azimi, E.; Reddy, V. B.; Luo, T.; Elmariah, S.; Lerner, E. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 3 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 111 BP S19 EP S19 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400112 ER PT J AU Azimi, E Lerner, EA Elmariah, S AF Azimi, E. Lerner, E. A. Elmariah, S. TI Altered manifestations of skin disease in patients with nerve damage SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Azimi, E.; Lerner, E. A.; Elmariah, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 109 BP S19 EP S19 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400110 ER PT J AU Azimi, E Reddy, VB Elmariah, S Luo, T Lerner, EA AF Azimi, E. Reddy, V. B. Elmariah, S. Luo, T. Lerner, E. A. TI Ficin, a plant protease, induces itch and edema by different mechanisms SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Azimi, E.; Reddy, V. B.; Elmariah, S.; Luo, T.; Lerner, E. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 110 BP S19 EP S19 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400111 ER PT J AU Boyers, LN Karimkhani, C Crane, L Asdigian, N Hollonds, A Dellavalle, R AF Boyers, L. N. Karimkhani, C. Crane, L. Asdigian, N. Hollonds, A. Dellavalle, R. TI Buying indoor UV tanning with university debit cards SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Boyers, L. N.] Georgetown Univ, Sch Med, Washington, DC USA. [Dellavalle, R.] Univ Colorado, Sch Med, Denver, CO USA. [Dellavalle, R.] Dept Vet Affairs Denver, Denver, CO USA. [Karimkhani, C.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Crane, L.; Asdigian, N.; Hollonds, A.] Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Denver, CO USA. [Dellavalle, R.] US Dept Vet Affairs, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 290 BP S50 EP S50 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400289 ER PT J AU Elmariah, S Luo, T Azimi, E Reddy, VB Lerner, EA AF Elmariah, S. Luo, T. Azimi, E. Reddy, V. B. Lerner, E. A. TI Neural recruitment and activation is required for the development of atopic dermatitis: Novel insights into disease pathogenesis revealed by in vivo imaging SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Elmariah, S.; Luo, T.; Azimi, E.; Reddy, V. B.; Lerner, E. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 090 BP S16 EP S16 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400091 ER PT J AU Fu, X Park, C Jiang, X Watanabe, R Clark, R Fuhlbrigge, RC Lin, C Kupper, TS AF Fu, X. Park, C. Jiang, X. Watanabe, R. Clark, R. Fuhlbrigge, R. C. Lin, C. Kupper, T. S. TI Characterization of cutaneous Th17 CD4+T-RM with heterogeneous migratory properties after candida infection of skin SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Fu, X.; Park, C.; Jiang, X.; Watanabe, R.; Clark, R.; Fuhlbrigge, R. C.; Kupper, T. S.] Brigham & Women, Dermatol, Boston, MA USA. [Lin, C.] Massachusetts Gen Hosp, Wellman Labs, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 036 BP S6 EP S6 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400037 ER PT J AU Jimenez, J Wikramanayake, TC Bergfeld, W Hordinsky, M Hickman, J Hamblin, M Schachner, L AF Jimenez, J. Wikramanayake, T. C. Bergfeld, W. Hordinsky, M. Hickman, J. Hamblin, M. Schachner, L. TI Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Jimenez, J.; Wikramanayake, T. C.; Schachner, L.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Bergfeld, W.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Hordinsky, M.] Univ Minnesota, Minneapolis, MN USA. [Hickman, J.] Educ & Res Fdn Inc, Lynchburg, VA USA. [Hamblin, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 578 BP S100 EP S100 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400577 ER PT J AU Katiyar, SK Singh, T Vaid, M AF Katiyar, S. K. Singh, T. Vaid, M. TI Dietary proanthocyanidins inhibit UV-induced immune suppression by decreasing the functional activation of suppressor T cells in mice SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Katiyar, S. K.; Singh, T.; Vaid, M.] Univ Alabama Birmingham, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 651 BP S114 EP S114 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400649 ER PT J AU Kim, GE Shlyankevich, J Kimball, AB AF Kim, G. E. Shlyankevich, J. Kimball, A. B. TI Positive predictive value of the diagnostic code for hidradenitis suppurativa in an electronic database improves as number of codes increases SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Kim, G. E.; Kimball, A. B.] Harvard Univ, Sch Med, Boston, MA USA. [Shlyankevich, J.; Kimball, A. B.] Massachusetts Gen Hosp, Clin Unit Res Trials & Outcomes Skin, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 287 BP S50 EP S50 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400286 ER PT J AU Kim, YH Krathen, MS Duvic, M Wong, H Porcu, P Tacastacas, J Korman, NJ Guitart, J Landau, SB Bradner, JE AF Kim, Y. H. Krathen, M. S. Duvic, M. Wong, H. Porcu, P. Tacastacas, J. Korman, N. J. Guitart, J. Landau, S. B. Bradner, J. E. TI Tolerability and encouraging clinical activity of SHP-141, a topical skin-restricted HDAC inhibitor, in a phase 1B study in cutaneous t-cell lymphoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Kim, Y. H.; Krathen, M. S.] Stanford U, Palo Alto, CA USA. [Duvic, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Wong, H.; Porcu, P.] Ohio State U, Columbus, OH USA. [Tacastacas, J.; Korman, N. J.] UH Case Med Ctr, Cleveland, OH USA. [Guitart, J.] Northwestern U, Chicago, IL USA. [Bradner, J. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Landau, S. B.] Shape Pharmaceut, Cambridge, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 531 BP S93 EP S93 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400530 ER PT J AU Kleffel, S Lee, N Lezcano, C Sobolewski, K Mueller, H DoRosario, A Wang, L Frank, MH Murphy, GF Schatton, T AF Kleffel, S. Lee, N. Lezcano, C. Sobolewski, K. Mueller, H. DoRosario, A. Wang, L. Frank, M. H. Murphy, G. F. Schatton, T. TI ABCB5 inhibition sensitizes Merkel cell carcinoma cells to chemotherapy-induced apoptosis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Kleffel, S.; Lee, N.; Sobolewski, K.; Mueller, H.; Frank, M. H.; Schatton, T.] Harvard Univ, Sch Med, Dept Dermatol, Brigham & Womens Hosp, Boston, MA 02115 USA. [Lezcano, C.; Murphy, G. F.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA. [DoRosario, A.; Wang, L.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Frank, M. H.; Schatton, T.] Harvard Univ, Sch Med, Childrens Hosp Boston, Transplantat Res Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 178 BP S31 EP S31 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400179 ER PT J AU Koo, EB Enamandram, M Kimball, AB AF Koo, E. B. Enamandram, M. Kimball, A. B. TI Relative to obesity, negative effect of hidradenitis suppurativa is enhanced on quality of life in super obese patients SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Koo, E. B.; Enamandram, M.; Kimball, A. B.] Harvard Univ, Sch Med, Boston, MA USA. [Koo, E. B.; Enamandram, M.; Kimball, A. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 602 BP S104 EP S104 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400600 ER PT J AU Landow, S Oh, DH Weinstock, MA AF Landow, S. Oh, D. H. Weinstock, M. A. TI Teledermatology programs in the veterans health administration SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Landow, S.; Weinstock, M. A.] Brown Univ, Providence, RI 02912 USA. [Oh, D. H.] UCSF, San Francisco, CA USA. [Landow, S.; Weinstock, M. A.] Providence VA Med Ctr, Dermatoepidemiol Unit, Providence, RI USA. [Oh, D. H.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 324 BP S56 EP S56 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400323 ER PT J AU Luo, Y Liu, S Kutty, LK Arcaroli, JJ Robinson, SE Robinson, WA Norris, DA Messersmith, WA Fujita, M AF Luo, Y. Liu, S. Kutty, L. K. Arcaroli, J. J. Robinson, S. E. Robinson, W. A. Norris, D. A. Messersmith, W. A. Fujita, M. TI Methods of generating single cell suspensions from tumor tissues influence the frequency of tumor-initiating cells SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Luo, Y.; Liu, S.; Kutty, L. K.; Arcaroli, J. J.; Robinson, S. E.; Robinson, W. A.; Norris, D. A.; Messersmith, W. A.; Fujita, M.] Univ Colorado Denver, Aurora, CO USA. [Norris, D. A.; Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 728 BP S127 EP S127 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400726 ER PT J AU Luo, Y Liu, S Lee, J Robinson, SE Robinson, WA Norris, DA Dinarello, CA Fujita, M AF Luo, Y. Liu, S. Lee, J. Robinson, S. E. Robinson, W. A. Norris, D. A. Dinarello, C. A. Fujita, M. TI IL-37, an inhibitor of innate inflammation and adaptive immunity, is elevated in the blood of melanoma patients and is related with poor prognosis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Luo, Y.; Liu, S.; Lee, J.; Robinson, S. E.; Robinson, W. A.; Norris, D. A.; Dinarello, C. A.; Fujita, M.] Univ Colorado Denver, Aurora, CO USA. [Norris, D. A.; Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 577 BP S100 EP S100 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400576 ER PT J AU Marneros, A AF Marneros, A. TI Genetic basis of congenital wound disorders: Aplasia culls congenita SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Marneros, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 451 BP S78 EP S78 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400450 ER PT J AU McEnery-Stonelake, M Mostaghimi, A Kroshinsky, D AF McEnery-Stonelake, M. Mostaghimi, A. Kroshinsky, D. TI Initial findings for the effectiveness of using IVIG to treat Stevens-Johnson syndrome and toxic epidermal necrolysis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [McEnery-Stonelake, M.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Mostaghimi, A.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Kroshinsky, D.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 346 BP S59 EP S59 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400345 ER PT J AU Miller, DM Taylor, M Kumar, R Flaherty, K Srinivasa, S Buch, S Tsao, H AF Miller, D. M. Taylor, M. Kumar, R. Flaherty, K. Srinivasa, S. Buch, S. Tsao, H. TI P1 446A-05: A potent cyclin-dependent kinase inhibitor with preclinical activity in melanoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Miller, D. M.] Columbia Univ, Med Ctr, New York, NY USA. [Taylor, M.; Kumar, R.; Tsao, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Flaherty, K.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Srinivasa, S.; Buch, S.] Piramal Enterprises Ltd, Bombay, Maharashtra, India. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 743 BP S130 EP S130 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400741 ER PT J AU Nambudiri, VE Watson, A Thakuria, M Vivero, M Fletcher, C Ng, A Russell, S Rabinowitz, G Leboeuf, N AF Nambudiri, V. E. Watson, A. Thakuria, M. Vivero, M. Fletcher, C. Ng, A. Russell, S. Rabinowitz, G. Leboeuf, N. TI Metastatic Merkel cell carcinoma presenting as a subcutaneous breast nodule: An uncommon presentation of a rare cutaneous malignancy SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Nambudiri, V. E.; Watson, A.; Thakuria, M.; Vivero, M.; Fletcher, C.; Leboeuf, N.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ng, A.; Russell, S.; Rabinowitz, G.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 BP S98 EP S98 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400565 ER PT J AU Okhovat, J Zhu, W Agak, GW Qin, M Park, AJ Garban, HJ Kim, J AF Okhovat, J. Zhu, W. Agak, G. W. Qin, M. Park, A. J. Garban, H. J. Kim, J. TI Differential inflammatory response of Propionibacterium acnes strains on sebocytes and keratinocytes SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Okhovat, J.; Zhu, W.; Agak, G. W.; Qin, M.; Park, A. J.; Garban, H. J.; Kim, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA. [Kim, J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 642 BP S112 EP S112 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400640 ER PT J AU Okon, LG Feng, R Werth, V AF Okon, L. G. Feng, R. Werth, V. TI Novel topical cream delivers safe and effective alternative to traditional psoriasis phototherapy SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Werth, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Okon, L. G.; Feng, R.; Werth, V.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 BP S97 EP S97 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400558 ER PT J AU Ortiz, AE Franco, W Taghados, SJ Gutierrez-Herrera, E Farinelli, W Jiang, B Doukas, A Anderson, R AF Ortiz, A. E. Franco, W. Taghados, S. J. Gutierrez-Herrera, E. Farinelli, W. Jiang, B. Doukas, A. Anderson, R. TI A novel camera device captures tryptophan autofluorescence in rapid epidermal proliferations SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Ortiz, A. E.; Jiang, B.] Univ Calif San Diego, Med Dermatol, San Diego, CA USA. [Ortiz, A. E.; Franco, W.; Taghados, S. J.; Gutierrez-Herrera, E.; Farinelli, W.; Doukas, A.; Anderson, R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 585 BP S102 EP S102 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400584 ER PT J AU Osborne, R Palli, MA Tamura, M Tiesman, J Toyama, K Soh, C Kimball, AB AF Osborne, R. Palli, M. Alora Tamura, M. Tiesman, J. Toyama, K. Soh, C. Kimball, A. B. TI Expression of oxidative stress, cellular senescence and skin structure-related genes affected by aging in vivo is reversed by galactomyces ferment filtrate in vitro SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Osborne, R.; Tamura, M.; Tiesman, J.] Procter & Gamble Co, P&G Beauty, Cincinnati, OH USA. [Palli, M. Alora; Kimball, A. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Palli, M. Alora; Kimball, A. B.] Harvard Univ, Sch Med, Boston, MA USA. [Toyama, K.; Soh, C.] SK2, Kobe, Hyogo, Japan. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 610 BP S106 EP S106 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400608 ER PT J AU Park, AJ Oin, M Garban, HJ Kim, J AF Park, A. J. Oin, M. Garban, H. J. Kim, J. TI Interleukin-37 is a potent inhibitor of inflammatory responses induced by Propionibacterium acnes and ultraviolet B radiation in human keratinocytes SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Park, A. J.; Oin, M.; Garban, H. J.; Kim, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA. [Kim, J.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Dermatol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 640 BP S112 EP S112 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400638 ER PT J AU Park, AJ Qin, M Hisaw, LD Pirouz, A Agak, GW Marinelli, L Garban, HJ Kim, J AF Park, A. J. Qin, M. Hisaw, L. D. Pirouz, A. Agak, G. W. Marinelli, L. Garban, H. J. Kim, J. TI G2A attenuates Propionibacterium acnes induction of inflammatory cytokines via regulation of MAPK signaling and is regulated by 13-cis-retinoic acid SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Park, A. J.; Qin, M.; Hisaw, L. D.; Pirouz, A.; Agak, G. W.; Marinelli, L.; Garban, H. J.; Kim, J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Dept Med, Los Angeles, CA 90095 USA. [Kim, J.] VA Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA. [Marinelli, L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 627 BP S109 EP S109 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400625 ER PT J AU Park, CO Fu, X Jiang, X Watanabe, R Clark, R Fuhlbrigge, RC Lin, C Kupper, TS AF Park, C. O. Fu, X. Jiang, X. Watanabe, R. Clark, R. Fuhlbrigge, R. C. Lin, C. Kupper, T. S. TI Identification of skin resident memory CD4+T cells (T-RM) producing IL-17A after cutaneous candida infection SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Park, C. O.; Jiang, X.; Watanabe, R.; Clark, R.; Fuhlbrigge, R. C.; Kupper, T. S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Fu, X.; Lin, C.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 044 BP S8 EP S8 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400045 ER PT J AU Petukhova, L Betz, RC Ripke, S Huang, H Menelaou, A Redler, S Becker, T Heilmann, S Duvic, M Hordinsky, M Norris, D Price, V Mackay-Wiggan, J DeStefano, GM Bohm, M Blume-Peytavi, U Wolff, H Lutz, G Kruse, R Blaumeiser, B Altshuler, D Nothen, M de Bakker, PIW Daly, M Christiano, AM AF Petukhova, L. Betz, R. C. Ripke, S. Huang, H. Menelaou, A. Redler, S. Becker, T. Heilmann, S. Duvic, M. Hordinsky, M. Norris, D. Price, V. Mackay-Wiggan, J. DeStefano, G. M. Bohm, M. Blume-Peytavi, U. Wolff, H. Lutz, G. Kruse, R. Blaumeiser, B. Altshuler, D. Nothen, M. de Bakker, P. I. W. Daly, M. Christiano, A. M. TI Meta-analysis of genome-wide association studies in alopecia areata reveals new susceptibility loci SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Petukhova, L.; Mackay-Wiggan, J.; DeStefano, G. M.; Nothen, M.; Christiano, A. M.] Columbia Univ, New York, NY USA. [Betz, R. C.; Redler, S.; Becker, T.; Heilmann, S.] U Bonn, Bonn, Germany. [Ripke, S.; Altshuler, D.; Daly, M.] Mass Gen Hosp, Boston, MA USA. [Ripke, S.; Huang, H.; Altshuler, D.; Daly, M.] Harvard U, Boston, MA USA. [Huang, H.] Broad Inst, Boston, MA USA. [Duvic, M.] MD Anderson, Houston, TX USA. [Hordinsky, M.] U Minnesota, Minneapolis, MN USA. [Norris, D.] U Colorado, Denver, CO USA. [Price, V.] UCSF, San Franciscon, CA USA. [Bohm, M.] U Munster, Munster, Germany. [Blume-Peytavi, U.] Charite, D-13353 Berlin, Germany. [Wolff, H.] U Dusseldorf, Dusseldorf, Germany. [Lutz, G.] Hair & Nail, Wesseling, Germany. [Blaumeiser, B.] U Antwerp, Antwerp, Belgium. [de Bakker, P. I. W.] U Med Ctr Utrecht, Utrecht, Netherlands. RI de Bakker, Paul/B-8730-2009 OI de Bakker, Paul/0000-0001-7735-7858 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 455 BP S79 EP S79 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400454 ER PT J AU Prasad, R Vaid, M Singh, T Katiyar, SK AF Prasad, R. Vaid, M. Singh, T. Katiyar, S. K. TI High-fat diet stimulates the growth of UV radiation-induced skin tumors by enhancing DNA hypermethylation and silencing of tumor suppressor genes in mouse skin and tumors SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Prasad, R.; Vaid, M.; Singh, T.; Katiyar, S. K.] Univ Alabama Birmingham, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 652 BP S114 EP S114 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400650 ER PT J AU Qin, M Park, AJ Agak, GW Garban, HJ Kim, J AF Qin, M. Park, A. J. Agak, G. W. Garban, H. J. Kim, J. TI Human keratinocytes display distinct NOD-like receptor expression signatures when exposed to Propionibacterium acnes and ultraviolet B radiation SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Qin, M.; Park, A. J.; Agak, G. W.; Garban, H. J.; Kim, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA. [Kim, J.] VA Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 644 BP S112 EP S112 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400642 ER PT J AU Ramsey, MR Cardoso, RF Rheinwald, JG Ellisen, LW AF Ramsey, M. R. Cardoso, R. F. Rheinwald, J. G. Ellisen, L. W. TI DBC1 modulates Delta Np63 alpha function in squamous cell carcinoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Ramsey, M. R.; Cardoso, R. F.; Rheinwald, J. G.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ellisen, L. W.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 176 BP S31 EP S31 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400177 ER PT J AU Richmond, J Essien, K Groom, J Luster, A Harris, J AF Richmond, J. Essien, K. Groom, J. Luster, A. Harris, J. TI Keratinocytes drive depigmentation in a mouse model of vitiligo via recruitment and activation of CD8+T cells in the skin SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Richmond, J.; Essien, K.; Harris, J.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Groom, J.] Univ Melbourne, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia. [Luster, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 065 BP S12 EP S12 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400066 ER PT J AU Sharma, M Werth, V AF Sharma, M. Werth, V. TI Role of UVB-induced neutrophils in collagenase induction, and collagen fragmentation SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Sharma, M.; Werth, V.] Univ Penn, Philadelphia, PA 19104 USA. [Sharma, M.; Werth, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 681 BP S119 EP S119 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400679 ER PT J AU Shlyankevich, J Chen, AJ Kim, GE Kimball, AB AF Shlyankevich, J. Chen, A. J. Kim, G. E. Kimball, A. B. TI Hidradenitis suppurativa is a disease of significant co-morbidity burden: Results from a case-control analysis of a large patient database SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Shlyankevich, J.; Kimball, A. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chen, A. J.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Kim, G. E.; Kimball, A. B.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 329 BP S57 EP S57 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400328 ER PT J AU Sproule, TJ Sundberg, JP Low, BE Adkins, EB Silva, KA Reyon, D Joung, JK Wiles, MV Roopenian, DC AF Sproule, T. J. Sundberg, J. P. Low, B. E. Adkins, E. B. Silva, K. A. Reyon, D. Joung, J. K. Wiles, M. V. Roopenian, D. C. TI Deletion of mouse Col17a1 exon 50 results in a remarkably normal phenotype alone but greatly accelerates Lamc2(jeb) induced junctional epidermolysis bullosa SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Sproule, T. J.; Sundberg, J. P.; Low, B. E.; Adkins, E. B.; Silva, K. A.; Wiles, M. V.; Roopenian, D. C.] Jackson Lab, Bar Harbor, ME 04609 USA. [Adkins, E. B.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA. [Reyon, D.; Joung, J. K.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA. [Reyon, D.; Joung, J. K.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA USA. [Reyon, D.; Joung, J. K.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 422 BP S74 EP S74 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400421 ER PT J AU Teague, J Robins, H Kirsch, L Williamson, D Watanabe, R Kupper, TS Clark, R AF Teague, J. Robins, H. Kirsch, L. Williamson, D. Watanabe, R. Kupper, T. S. Clark, R. TI High throughput TCR sequencing provides superior ability to diagnose, stage and follow patients with cutaneous T-cell lymphoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Teague, J.; Watanabe, R.; Kupper, T. S.; Clark, R.] Dana Farber Brigham & Womens Canc Ctr, Cutaneous Lymphoma Program, Boston, MA USA. [Robins, H.; Kirsch, L.; Williamson, D.] Adapt Biotechnol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 141 BP S24 EP S24 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400142 ER PT J AU Vandiver, A Irizzary, R Hansen, K Garza, L Runarsson, A Li, X Chien, AL Leung, SG Kang, S Feinberg, AP AF Vandiver, A. Irizzary, R. Hansen, K. Garza, L. Runarsson, A. Li, X. Chien, A. L. Leung, S. G. Kang, S. Feinberg, A. P. TI Widespread genomic blocks of hypomethylation in nonmalignant epidermis related to age and sun exposure SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Vandiver, A.; Runarsson, A.; Li, X.; Feinberg, A. P.] Johns Hopkins Sch Med, Ctr Epigenet, Baltimore, MD USA. [Irizzary, R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hansen, K.; Chien, A. L.; Leung, S. G.; Kang, S.; Feinberg, A. P.] Johns Hopkins Sch Med, Baltimore, MD USA. [Hansen, K.] Johns Hopkins Sch Med, Inst Med Genet, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 448 BP S78 EP S78 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400447 ER PT J AU Vedak, P Kroshinsky, D AF Vedak, P. Kroshinsky, D. TI Eczematous response to squaric acid sensitization not required for scalp treatment initiation in alopecia areata SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Vedak, P.; Kroshinsky, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kroshinsky, D.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 338 BP S58 EP S58 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400337 ER PT J AU Wan, MT Kakavand, H Mihm, MC Scolyer, RA Thompson, JT Murphy, GF Lin, JY AF Wan, M. T. Kakavand, H. Mihm, M. C. Scolyer, R. A. Thompson, J. T. Murphy, G. F. Lin, J. Y. TI Sox2 and sox10 expression patterning in melanoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Wan, M. T.; Mihm, M. C.; Murphy, G. F.; Lin, J. Y.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Lin, J. Y.] Dana Farber Canc Inst, Melanoma Program, Boston, MA 02115 USA. [Kakavand, H.; Scolyer, R. A.; Thompson, J. T.] Royal Prince Alfred Hosp, Melanoma Inst Australia, Sydney, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 742 BP S129 EP S129 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400740 ER PT J AU Yu, KK Crew, AB Messingham, K Fairley, JA Woodley, DT AF Yu, K. K. Crew, A. B. Messingham, K. Fairley, J. A. Woodley, D. T. TI Successful biologic therapy for bullous pemphigoid SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Yu, K. K.; Crew, A. B.; Woodley, D. T.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Messingham, K.; Fairley, J. A.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. [Fairley, J. A.] Iowa City VA Med Ctr, Iowa City, IA USA. [Woodley, D. T.] Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 154 BP S26 EP S26 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400155 ER PT J AU Zhai, Z Liu, W Kaur, M Luo, Y Norris, DA Dinarello, CA Spritz, RA Fujita, M AF Zhai, Z. Liu, W. Kaur, M. Luo, Y. Norris, D. A. Dinarello, C. A. Spritz, R. A. Fujita, M. TI NLRP1 is involved in melanoma tumorigenesis and temozolomide chemoresistance SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 07-10, 2014 CL Albuquerque, NM SP Soc Invest Dermatol C1 [Zhai, Z.; Liu, W.; Kaur, M.; Luo, Y.; Norris, D. A.; Dinarello, C. A.; Spritz, R. A.; Fujita, M.] Univ Colorado Denver SOM, Aurora, CO USA. [Norris, D. A.; Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2014 VL 134 SU 1 MA 727 BP S127 EP S127 PG 1 WC Dermatology SC Dermatology GA AF2RT UT WOS:000334560400725 ER PT J AU Fiorella, D Hirsch, JA Mocco, J AF Fiorella, D. Hirsch, J. A. Mocco, J. TI In search of the optimized stroke trial design SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Editorial Material DE Stroke ID ACUTE ISCHEMIC-STROKE; RANDOMIZED-TRIAL; THERAPY C1 [Fiorella, D.] SUNY Stony Brook, Dept Neurosurg, Stony Brook, NY 11794 USA. [Hirsch, J. A.] Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA. [Mocco, J.] Vanderbilt Univ, Dept Neurosurg, Nashville, TN 37235 USA. RP Fiorella, D (reprint author), SUNY Stony Brook, Dept Neurosurg, Stony Brook, NY 11794 USA. EM David.Fiorella@sbumed.org NR 12 TC 3 Z9 3 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD MAY PY 2014 VL 6 IS 4 BP 249 EP 251 DI 10.1136/neurintsurg-2014-011204 PG 3 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA AF0NX UT WOS:000334412400007 PM 24719480 ER PT J AU Guth, CA Sodroski, J AF Guth, Charles Alexander Sodroski, Joseph TI Contribution PDZD8 to Stabilization of the Human Immunodeficiency Virus Type 1 Capsid SO JOURNAL OF VIROLOGY LA English DT Article ID RETROVIRAL INFECTION; NUCLEAR IMPORT; HUMAN-CELLS; HIV-1 CORE; TRIM5-ALPHA; PROTEINS; CYCLOPHILIN; REPLICATION; RESTRICTION; BINDING AB Following human immunodeficiency virus type 1 (HIV-1) entry into the host cell, the viral capsid gradually disassembles in a process called uncoating. A proper rate of uncoating is important for reverse transcription of the HIV-1 genome. Host restriction factors such as TRIM5 alpha and TRIMCyp bind retroviral capsids and cause premature disassembly, leading to blocks in reverse transcription. Other host factors, such as cyclophilin A, stabilize the HIV-1 capsid and are required for efficient infection in some cell types. Here, we show that a heat-labile factor greater than 100 kDa in the cytoplasm of cells from multiple vertebrate species slows the spontaneous disassembly of HIV-1 capsid-nucleocapsid (CA-NC) complexes in vitro. We identified the PDZ domain-containing protein 8 (PDZD8) as a critical component of the capsid-stabilizing activity in the cytoplasmic extracts. PDZD8 has been previously reported to bind the HIV-1 Gag polyprotein and to make a positive contribution to the efficiency of HIV-1 infection (M. S. Henning, S. G. Morham, S. P. Goff, and M. H. Naghavi, J. Virol. 84: 8990-8995, 2010, doi: 1). PDZD8 knockdown accelerated the disassembly of HIV-1 capsids in infected cells, resulting in decreased reverse transcription. The PDZD8 coiled-coil domain is sufficient for HIV-1 capsid binding, but other parts of the protein, including the PDZ domain, are apparently required for stabilizing the capsid and supporting HIV-1 infection. In summary, PDZD8 interacts with and stabilizes the HIV-1 capsid and thus represents a potentially targetable host cofactor for HIV-1 infection. C1 [Guth, Charles Alexander; Sodroski, Joseph] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Sodroski, Joseph] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Sodroski, Joseph] Massachusetts Inst Technol & Harvard, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA. RP Sodroski, J (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM joseph_sodroski@dfci.harvard.edu FU National Institutes of Health [AI063987]; National Institutes of Health (Center for AIDS Research Award) [AI06354]; International AIDS Vaccine Initiative; late William F. McCarty-Cooper FX We acknowledge the support of the National Institutes of Health (AI063987 and a Center for AIDS Research Award [AI06354]), the International AIDS Vaccine Initiative, and the late William F. McCarty-Cooper. NR 50 TC 11 Z9 13 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD MAY PY 2014 VL 88 IS 9 BP 4612 EP 4623 DI 10.1128/JVI.02945-13 PG 12 WC Virology SC Virology GA AE9TT UT WOS:000334353900001 PM 24554657 ER PT J AU Yen, PJ Herschhorn, A Haim, H Salas, I Gu, C Sodroski, J Gabuzda, D AF Yen, Po-Jen Herschhorn, Alon Haim, Hillel Salas, Ignacio Gu, Christopher Sodroski, Joseph Gabuzda, Dana TI Loss of a Conserved N-Linked Glycosylation Site in the Simian Immunodeficiency Virus Envelope Glycoprotein V2 Region Enhances Macrophage Tropism by Increasing CD4-Independent Cell-to-Cell Transmission SO JOURNAL OF VIROLOGY LA English DT Article ID ANTIBODY-MEDIATED NEUTRALIZATION; HIV-1 VACCINE EFFICACY; RHESUS-MONKEYS; TYPE-1 ISOLATE; IN-VIVO; BIOLOGICAL CHARACTERIZATION; INTEGRIN ALPHA(4)BETA(7); MOLECULAR ARCHITECTURE; MONOCLONAL-ANTIBODIES; VIROLOGICAL SYNAPSES AB Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) strains differ in their capacity to replicate in macrophages, but mechanisms underlying these differences are not fully understood. Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype. Loss of the N173 glycosylation site in the non-macrophage-tropic SIVmac239 by introducing an N173Q mutation enhanced viral replication and multinucleated giant cell formation upon infection of rhesus macrophages, while the addition of N173 to SIVmac251 had the opposite effect. The removal of N173 in SIVmac239 enhanced CD4-independent cell-to-cell transmission to CCR5-expressing cells. SIVmac239 with N173Q mediated CD4-independent cell-cell fusion but could not infect CD4-negative cells in single-round infections. Thus, CD4-independent phenotypes were detected only in the context of cell-to-cell contact. Similar results were obtained in SIVmac251 with and without N173. N173 decreased the neutralization sensitivity of SIVmac251 but had no effect on the neutralization sensitivity of SIVmac239. The N173Q mutation had no effect on SIVmac239 binding to CD4 in Biacore assays, coimmunoprecipitation assays, and enzyme-linked immunosorbent assays (ELISAs). These findings suggest that the loss of the N173 N-linked glycosylation site increases SIVmac239 replication in macrophages by enhancing CD4-independent cell-to-cell virus transmission through CCR5-mediated fusion. This mechanism may facilitate the escape of macrophage-tropic viruses from neutralizing antibodies while promoting spreading infection by these viruses in vivo. C1 [Yen, Po-Jen; Herschhorn, Alon; Haim, Hillel; Salas, Ignacio; Gu, Christopher; Sodroski, Joseph; Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Yen, Po-Jen] Harvard Univ, Sch Med, Div Med Sci, Program Virol, Boston, MA USA. [Sodroski, Joseph] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA USA. [Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. RP Gabuzda, D (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. EM Dana_Gabuzda@dfci.harvard.edu RI sourisseau, marion/M-7542-2014 FU NIH [MH83588, MH97659]; Harvard Medical School Center for AIDS Research (CFAR); DFCI/Harvard Cancer Center; American Foundation for AIDS Research FX This work was supported by NIH grants MH83588 and MH97659 to D.G. Core facilities were supported by Harvard Medical School Center for AIDS Research (CFAR) and DFCI/Harvard Cancer Center grants. A.H. is the recipient of a Mathilde Krim fellowship in basic science from the American Foundation for AIDS Research. NR 101 TC 7 Z9 7 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD MAY PY 2014 VL 88 IS 9 BP 5014 EP 5028 DI 10.1128/JVI.02785-13 PG 15 WC Virology SC Virology GA AE9TT UT WOS:000334353900035 PM 24554659 ER PT J AU Jia, B Yu, ZJ Duan, ZF Lu, XQ Li, JJ Liu, XR Sun, R Gao, XJ Wang, YF Yan, JY Kan, QC AF Jia, Bin Yu, Zu-Jiang Duan, Zhen-Feng Lu, Xin-quan Li, Jing-Jing Liu, Xiao-Rui Sun, Ran Gao, Xiao-Juan Wang, Yan-Fang Yan, Jing-Ya Kan, Quan-Cheng TI Hyperammonaemia induces hepatic injury with alteration of gene expression profiles SO LIVER INTERNATIONAL LA English DT Article DE microarray; hepatic injury; hyperammonaemia ID INDUCED APOPTOSIS; CLINICAL PROFILE; LIVER-INJURY; CYCLIN D1; ENCEPHALOPATHY; CELLS; METABOLISM; AMMONIA; OSTEOPONTIN; CHECKPOINT AB Background Hyperammonaemia is a serious metabolic disorder commonly observed in patients with hepatic failure. However, it is unknown whether hyperammonaemia has a direct adverse effect on the hepatocytes and thereby serves as both a cause and effect of hepatic failure. Aims The purposes were to determine whether hepatic injury can be caused by hyperammonaemia, and if so, screen the key genes involved in hyperammonaemia. Methods Hyperammonaemic rats were established via intragastric administration of the ammonium chloride solution. The liver tissues were assessed via biochemistry, histology, immunohistochemistry and microarray analysis. Selected genes were confirmed by quantitative RT-PCR. Results Administration of the ammonium chloride caused the hyperammonaemia, accompanied with the changes of plasma markers indicating hepatic injury. A pathological assessment demonstrated increased apoptosis and higher level of cyclin D1 and cyclin A in hyperammonaemic rat liver. Microarray was performed on the liver samples and 198 differentially expressed genes were identified in hyperammonaemic rats and validated by quantitative RT-PCR. These genes were associated with many vital functional classes and belonged to different signal transduction pathways. Conclusions This study demonstrates that hyperammonaemia can directly induce hepatic injury via the hepatocyte apoptosis. Gene expression profile may provide the possible explanations and mechanisms for the hepatic injury induced by hyperammonaemia. C1 [Jia, Bin; Li, Jing-Jing; Wang, Yan-Fang; Kan, Quan-Cheng] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharmacol, Zhengzhou 450052, Peoples R China. [Yu, Zu-Jiang; Liu, Xiao-Rui; Sun, Ran; Gao, Xiao-Juan; Yan, Jing-Ya] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Peoples R China. [Duan, Zhen-Feng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA. [Duan, Zhen-Feng] Harvard Univ, Sch Med, Boston, MA USA. [Lu, Xin-quan] Zhengzhou Univ, Affiliated Hosp 1, Dept Pathol, Zhengzhou 450052, Peoples R China. RP Kan, QC (reprint author), Zhengzhou Univ, Affiliated Hosp 1, 40 Daxue Rd, Zhengzhou 450052, Peoples R China. EM kanqc@zzu.edu.cn NR 32 TC 6 Z9 8 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1478-3223 EI 1478-3231 J9 LIVER INT JI Liver Int. PD MAY PY 2014 VL 34 IS 5 BP 748 EP 758 DI 10.1111/liv.12365 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AE2UP UT WOS:000333828900014 PM 24134218 ER PT J AU Pellicelli, M Miller, JA Arabian, A Gauthier, C Akhouayri, O Wu, JY Kronenberg, HM St-Arnaud, R AF Pellicelli, Martin Miller, Julie A. Arabian, Alice Gauthier, Claude Akhouayri, Omar Wu, Joy Y. Kronenberg, Henry M. St-Arnaud, Rene TI The PTH-G alpha(s)-Protein Kinase A Cascade Controls alpha NAC Localization To Regulate Bone Mass SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID POLYPEPTIDE-ASSOCIATED COMPLEX; DEPENDENT PROTEIN-KINASE; PARATHYROID-HORMONE PTH; RAT OSTEOBLASTIC CELLS; MOUSE OSTEOCALCIN GENE; INTEGRIN-LINKED KINASE; C-JUN; CYCLIC-AMP; SUBSTRATE-SPECIFICITY; PTH/PTHRP RECEPTOR AB The binding of PTH to its receptor induces G alpha(s)-dependent cyclic AMP (cAMP) accumulation to turn on effector kinases, including protein kinase A (PKA). The phenotype of mice with osteoblasts specifically deficient for G alpha(s) is mimicked by a mutation leading to cytoplasmic retention of the transcriptional coregulator alpha NAC, suggesting that G alpha(s) and alpha NAC form part of a common genetic pathway. We show that treatment of osteoblasts with PTH(1-34) or the PKA-selective activator N-6-benzoyladenosine cAMP (6Bnz-cAMP) leads to translocation of alpha NAC to the nucleus. alpha NAC was phosphorylated by PKA at serine 99 in vitro. Phospho-S99-alpha NAC accumulated in osteoblasts exposed to PTH(1-34) or 6Bnz-cAMP but not in treated cells expressing dominant-negative PKA. Nuclear accumulation was abrogated by an S99A mutation but enhanced by a phosphomimetic residue (S99D). Chromatin immunoprecipitation (ChIP) analysis showed that PTH(1-34) or 6Bnz-cAMP treatment leads to accumulation of alpha NAC at the Osteocalcin (Ocn) promoter. Altered gene dosages for G alpha(s) and alpha NAC in compound heterozygous mice result in reduced bone mass, increased numbers of osteocytes, and enhanced expression of Sost. Our results show that alpha NAC is a substrate of PKA following PTH signaling. This enhances alpha NAC translocation to the nucleus and leads to its accumulation at target promoters to regulate transcription and affect bone mass. C1 [Pellicelli, Martin; Miller, Julie A.; Arabian, Alice; Gauthier, Claude; Akhouayri, Omar; St-Arnaud, Rene] Shriners Hosp Children Canada, Res Unit, Montreal, PQ, Canada. [Pellicelli, Martin; Miller, Julie A.; St-Arnaud, Rene] McGill Univ, Dept Human Genet, Montreal, PQ, Canada. [Wu, Joy Y.] Stanford Univ, Div Endocrinol, Sch Med, Stanford, CA USA. [Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP St-Arnaud, R (reprint author), Shriners Hosp Children Canada, Res Unit, Montreal, PQ, Canada. EM rst-arnaud@shriners.mcgill.ca FU Shriners Hospitals for Children; NIH [AR54741]; Canadian Institutes for Health Research [MOP-119306] FX M.P. holds a Shriners Hospitals for Children Postdoctoral Fellowship award. This work was supported by NIH grant AR54741 to J.Y.W. and by an operating grant from the Canadian Institutes for Health Research (MOP-119306) to R.S. A. NR 57 TC 1 Z9 1 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 EI 1098-5549 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAY PY 2014 VL 34 IS 9 BP 1622 EP 1633 DI 10.1128/MCB.01434-13 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA AE9HE UT WOS:000334316300007 PM 24550008 ER PT J AU Hamouda, AK Stewart, DS Chiara, DC Savechenkov, PY Bruzik, KS Cohen, JB AF Hamouda, Ayman K. Stewart, Deirdre S. Chiara, David C. Savechenkov, Pavel Y. Bruzik, Karol S. Cohen, Jonathan B. TI Identifying Barbiturate Binding Sites in a Nicotinic Acetylcholine Receptor with [H-3]Allyl m-Trifluoromethyldiazirine Mephobarbital, a Photoreactive Barbiturate SO MOLECULAR PHARMACOLOGY LA English DT Article ID GENERAL ANESTHETIC ACTIONS; NONCOMPETITIVE ANTAGONIST; AMINO-ACIDS; ION-CHANNEL; GABA(A) RECEPTOR; IDENTIFICATION; ETOMIDATE; INHIBITION; MECHANISMS; SUBUNIT AB At concentrations that produce anesthesia, many barbituric acid derivatives act as positive allosteric modulators of inhibitory GABA(A) receptors (GABA(A)Rs) and inhibitors of excitatory nicotinic acetylcholine receptors (nAChRs). Recent research on [H-3]R-mTFD-MPAB ([H-3]R-5-allyl-1-methyl-5-(m-trifluorome-thyldiazirinylphenyl) barbituric acid), a photoreactive barbiturate that is a potent and stereoselective anesthetic and GABA(A)R potentiator, has identified a second class of intersubunit binding sites for general anesthetics in the alpha 1 beta 3 gamma 2 GABA(A)R transmembrane domain. We now characterize mTFD-MPAB interactions with the Torpedo (muscle-type) nAChR. For nAChRs expressed in Xenopus oocytes, S-and R-mTFD-MPAB inhibited ACh-induced currents with IC50 values of 5 and 10 mu M, respectively. Racemic mTFD-MPAB enhanced the equilibrium binding of [H-3]ACh to nAChR-rich membranes (EC50 = 9 mu M) and inhibited binding of the ion channel blocker [H-3] tenocyclidine in the nAChR desensitized and resting states with IC50 values of 2 and 170 mu M, respectively. Photoaffinity labeling identified two binding sites for [H-3]R-mTFD-MPAB in the nAChR transmembrane domain: 1) a site within the ion channel, identified by photolabeling in the nAChR desensitized state of amino acids within the M2 helices of each nAChR subunit; and 2) a site at the gamma-alpha subunit interface, identified by photolabeling of gamma Met299 within the gamma M3 helix at similar efficiency in the resting and desensitized states. These results establish that mTFD-MPAB is a potent nAChR inhibitor that binds in the ion channel preferentially in the desensitized state and binds with lower affinity to a site at the gamma-alpha subunit interface where etomidate analogs bind that act as positive and negative nAChR modulators. C1 [Hamouda, Ayman K.; Chiara, David C.; Cohen, Jonathan B.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [Stewart, Deirdre S.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Savechenkov, Pavel Y.; Bruzik, Karol S.] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL USA. RP Cohen, JB (reprint author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA. EM jonathan_cohen@hms.harvard.edu OI Hamouda, Ayman/0000-0001-7819-3074 FU National Institutes of Health National Institute of General Medical Sciences [P01-GM58448] FX This work was supported, in part, by the National Institutes of Health National Institute of General Medical Sciences [Grant P01-GM58448 (to J.B.C.)]. NR 46 TC 10 Z9 10 U1 0 U2 7 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X EI 1521-0111 J9 MOL PHARMACOL JI Mol. Pharmacol. PD MAY PY 2014 VL 85 IS 5 BP 735 EP 746 DI 10.1124/mol.113.090985 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AE9VD UT WOS:000334358100009 PM 24563544 ER PT J AU Peterson, CL Riley, ZA Krepkovich, ET Murray, WM Perreault, EJ AF Peterson, Carrie L. Riley, Zachary A. Krepkovich, Eileen T. Murray, Wendy M. Perreault, Eric J. TI WITHDRAWAL REFLEXES IN THE UPPER LIMB ADAPT TO ARM POSTURE AND STIMULUS LOCATION SO MUSCLE & NERVE LA English DT Article DE endpoint force; fingertip stimulation; humans; motor control; nociceptive; spinal reflexes ID II MUSCLE AFFERENTS; FUNCTIONAL-ORGANIZATION; CUTANEOUS AFFERENTS; UPPER EXTREMITY; ELECTRICAL-STIMULATION; FINGERTIP STIMULATION; MODULAR ORGANIZATION; NOCICEPTIVE REFLEXES; RECEPTIVE-FIELDS; FOOT-SOLE AB Introduction: Withdrawal reflexes in the leg adapt in a context-appropriate manner to remove the limb from noxious stimuli, but the extent to which withdrawal reflexes adapt in the arm remains unknown. Methods: We examined the adaptability of withdrawal reflexes in response to nociceptive stimuli applied in different arm postures and to different digits. Reflexes were elicited at rest, and kinetic and electromyographic responses were recorded under isometric conditions, thereby allowing motorneuron pool excitability to be controlled. Results: Endpoint force changed from a posterior-lateral direction in a flexed posture to predominantly a posterior direction in a more extended posture [change in force angle (mean +/- standard deviation) 35.6 +/- 5.0 degrees], and the force direction changed similarly with digit I stimulation compared with digit V (change=22.9 +/- 2.9 degrees). Conclusions: The withdrawal reflex in the human upper limb adapts in a functionally relevant manner when elicited at rest. Muscle Nerve49: 716-723, 2014 C1 [Peterson, Carrie L.; Murray, Wendy M.; Perreault, Eric J.] Rehabil Inst Chicago, Sensory Motor Performance Program, Chicago, IL 60611 USA. [Peterson, Carrie L.; Murray, Wendy M.; Perreault, Eric J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Riley, Zachary A.] Indiana Univ Purdue Univ, Dept Kinesiol, Indianapolis, IN 46202 USA. [Krepkovich, Eileen T.] Barron Associates Inc, Charlottesville, VA USA. [Murray, Wendy M.; Perreault, Eric J.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA. [Murray, Wendy M.; Perreault, Eric J.] Northwestern Univ, Dept Phys Med & Rehabil, Evanston, IL USA. RP Peterson, CL (reprint author), Rehabil Inst Chicago, Sensory Motor Performance Program, 345 East Super St, Chicago, IL 60611 USA. EM cpeterson@ric.org RI Murray, Wendy/B-7629-2009; Perreault, Eric/B-7632-2009; Murray, Wendy/D-1520-2009; Peterson, Carrie/C-6007-2016 OI Murray, Wendy/0000-0002-7547-621X; Peterson, Carrie/0000-0002-7169-2089 FU Nielsen Foundation [84054] FX This work was funded by the Nielsen Foundation (84054). NR 38 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0148-639X EI 1097-4598 J9 MUSCLE NERVE JI Muscle Nerve PD MAY PY 2014 VL 49 IS 5 BP 716 EP 723 DI 10.1002/mus.23987 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AF0TK UT WOS:000334426800014 PM 23929755 ER PT J AU Heyworth, L Kleinman, K Oddleifson, S Bernstein, L Frampton, J Lehrer, M Salvato, K Weiss, TW Simon, SR Connelly, M AF Heyworth, L. Kleinman, K. Oddleifson, S. Bernstein, L. Frampton, J. Lehrer, M. Salvato, K. Weiss, T. W. Simon, S. R. Connelly, M. TI Comparison of interactive voice response, patient mailing, and mailed registry to encourage screening for osteoporosis: a randomized controlled trial SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Bonemineral density; Interactive voice response; Mailed registry; Osteoporosis screening; Patient mailing ID AUTOMATED TELEPHONE OUTREACH; PRIMARY-CARE; REMINDERS; INTERVENTION; EPIDEMIOLOGY; PREVENTION; MESSAGES; FRACTURE; VISITS; SYSTEM AB Guidelines recommend screening for osteoporosis with bone mineral density (BMD) testing in menopausal women, particularly those with additional risk factors for fracture. Many eligible women remain unscreened. This randomized study demonstrates that a single outreach interactive voice response phone call improves rates of BMD screening among high-risk women age 50-64. Osteoporotic fractures are a major cause of disability and mortality. Guidelines recommend screening with BMD for menopausal women, particularly those with additional risk factors for fracture. However, many women remain unscreened. We examined whether telephonic interactive voice response (IVR) or patient mailing could increase rates of BMD testing in high risk, menopausal women. We studied 4,685 women age 50-64 years within a not-for-profit health plan in the United States. All women had risk factors for developing osteoporosis and no prior BMD testing or treatment for osteoporosis. Patients were randomly allocated to usual care, usual care plus IVR, or usual care plus mailed educational materials. To avoid contamination, patients within a single primary care physician practice were randomized to receive the same intervention. The primary endpoint was BMD testing at 12 months. Secondary outcomes included BMD testing at 6 months and medication use at 12 months. Mean age was 57 years. Baseline demographic and clinical characteristics were similar across the three study groups. In adjusted analyses, the incidence of BMD screening was 24.6 % in the IVR group compared with 18.6 % in the usual care group (P < 0.001). There was no difference between the patient mailing group and the usual care group (P = 0.3). In this large community-based randomized trial of high risk, menopausal women age 50-64, IVR, but not patient mailing, improved rates of BMD screening. IVR remains a viable strategy to incorporate in population screening interventions. C1 [Heyworth, L.; Simon, S. R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Kleinman, K.; Connelly, M.] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Oddleifson, S.; Bernstein, L.; Frampton, J.; Lehrer, M.; Salvato, K.] Harvard Pilgrim Hlth Care Inst, Wellesley, MA USA. [Weiss, T. W.] Merck, West Point, PA USA. [Heyworth, L.; Simon, S. R.] Vet Affairs Boston Healthcare Syst, Boston, MA USA. [Kleinman, K.] Harvard Univ, Sch Med, Boston, MA USA. [Heyworth, L.] VA Boston Healthcare Syst, Sect General Internal Med, Jamaica Plain, MA 02130 USA. RP Heyworth, L (reprint author), VA Boston Healthcare Syst, Sect General Internal Med, 150 S Huntington Ave,Mailstop 152G, Jamaica Plain, MA 02130 USA. EM lheyworth@gmail.com FU Merck (West Point, PA) FX Merck (West Point, PA) funded this study. The funding source was involved in the study design and manuscript preparation, but had no role in study concept, analysis of the data, data interpretation, or decision to submit the manuscript for publication. NR 34 TC 4 Z9 4 U1 0 U2 4 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAY PY 2014 VL 25 IS 5 BP 1519 EP 1526 DI 10.1007/s00198-014-2629-1 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AF0OU UT WOS:000334414700011 PM 24566584 ER PT J AU Hermos, JA Quach, L Gagnon, DR Weber, HC Altincatal, A Cho, K Lawler, EV Grotzinger, KM AF Hermos, John A. Quach, Lien Gagnon, David R. Weber, H. Christian Altincatal, Arman Cho, Kelly Lawler, Elizabeth V. Grotzinger, Kelly M. TI Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE thrombocytopenia; hepatitis C; interferon; veterans; pharmacoepidemiology ID CHRONIC LIVER-DISEASE; VIRUS-INFECTION; GENOTYPE 1; PREVALENCE; ARTICLE; ASSOCIATION; UPDATE; RISK AB PurposeWe sought to determine the incidence and risks for severe thrombocytopenia (platelets<50000/L) in United States Veteran patients treated with pegylated interferon (PEG-IFN) plus ribavirin for hepatitis C virus-positive (HCV) chronic liver disease (CLD). MethodsUsing a retrospective, observational cohort study design to analyze databases from the New England Veterans Healthcare System, we identified 979 patients diagnosed with HCV-positive CLD treated solely with PEG-IFN plus ribavirin. The cohort was stratified by pre-treatment platelet counts of 50000-100000/L (N=90), >100000-150000/L (N=162), and >150000L (N=727). The cumulative incidence of severe thrombocytopenia and major bleeding events were determined for each baseline platelet group for 48weeks following treatment initiation. Multivariable Cox regression was used to identify risk factors for incident severe thrombocytopenia. ResultsOverall, severe thrombocytopenia occurred in 6.1% (N=60), but in 41.1% of patients with pre-treatment platelet counts 50000-100000/L compared with 11.7% (p<0.001) and 0.55% (p<0.001) in the two higher pre-treatment platelet groups. Most episodes occurred within the first 12weeks of treatment. Median nadir count for these 60 patients was 35000/L (inter-quartile range 28000, 44000). Baseline platelet counts of 50000-100000/L [adjusted hazard ratio (HR)=3.81; 95%CI=2.07-7.00] and hemoglobin <10g/dL (adjusted HR=3.39; 95%CI=1.45-7.960) associated with severe thrombocytopenia. Major bleeding events during the 48-week observation period were rare (N=5, 0.51%). ConclusionsThe incidence of severe thrombocytopenia in a large, observational cohort of veteran patients with HCV CLD treated with PEG-IFN plus ribavirin was 6.1%. Low pre-treatment platelet counts and hemoglobin levels associated with early, incident severe thrombocytopenia. Copyright (c) 2014 John Wiley & Sons, Ltd. C1 [Hermos, John A.; Quach, Lien; Gagnon, David R.; Altincatal, Arman; Cho, Kelly; Lawler, Elizabeth V.] VA Boston Healthcare Syst, VA Cooperat Studies Program, Massachusetts Vet Epidemiol Res & Informat Ctr MA, Boston, MA USA. [Hermos, John A.; Weber, H. Christian] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Gagnon, David R.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA. [Weber, H. Christian] VA Boston Healthcare Syst, Gastroenterol Sect, Boston, MA USA. [Cho, Kelly; Lawler, Elizabeth V.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Grotzinger, Kelly M.] GlaxoSmithKline, Collegeville, PA USA. RP Hermos, JA (reprint author), VA Boston Healthcare Syst 151MAV, 150S Huntington Ave, Boston, MA 02130 USA. EM jhermos@bu.edu FU VA Cooperative Studies Program; Massachusetts Veterans Epidemiology Research and Information Center; VA Boston Healthcare System, Boston, MA; GlaxoSmithKline, Philadelphia, PA FX The authors acknowledge the programming support of Mrs. Galina Solokovskaya. The study was supported by core funds of the VA Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA, and from GlaxoSmithKline, Philadelphia, PA. NR 28 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD MAY PY 2014 VL 23 IS 5 BP 480 EP 488 DI 10.1002/pds.3585 PG 9 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AE4JI UT WOS:000333948300004 PM 24677630 ER PT J AU Hall, SA Ranganathan, G Tinsley, LJ Lund, JL Kupelian, V Wittert, GA Kantoff, PW Morales, A Araujo, AB AF Hall, Susan A. Ranganathan, Gayatri Tinsley, Liane J. Lund, Jennifer L. Kupelian, Varant Wittert, Gary A. Kantoff, Philip W. Morales, Alvaro Araujo, Andre B. TI Population-based patterns of prescription androgen use, 1976-2008 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE androgens; testosterone; drug utilization; hypogonadism; pharmacoepidemiology ID UNITED-STATES; TESTOSTERONE; MEN; DEFICIENCY; MALES; HYPOGONADISM; AUSTRALIA; CAMPAIGN; THERAPY; SOCIETY AB PurposePrescription testosterone (T) has limited approved medical indications and is a controlled substance in Canada. Utilization studies in other Westernized countries have revealed sharp increases in T use in recent years. We examined medical use of androgens, including T, over a 30-year period among adult (18+) men in a population-based study set in a Canadian juridisdiction of universal health care. MethodsAnalyses were based on data from electronic records of dispensed prescriptions during 1976-2008 in Saskatchewan, Canada. All formulations of androgens listed in the provincial formulary (oral and injectable) were included. We examined demographics of users, androgen types used, switching patterns, and trends in the annual rate of use over time. ResultsThere were 11521 androgen users who were followed for an average of 11.8years. Overall, 11 types of androgens were used, and there were 86812 dispensing events. The mean age at first use was 56.4years (median: 58). Men had 7.5 prescription dispensing events on average (median: 2). The most commonly used formulations were methyl-T (36.2% of users) followed by T-enanthate (32.5%), T-cypionate (22.3%), and T-undecanoate (20.0%). Most users (82%) did not switch among androgen types. The annual rate of use varied substantially over time, with a marked increase observed from 1994 to 1999 and a decrease from 2000 to 2008. ConclusionsAndrogen users were largely middle aged and had relatively few dispensings. We hypothesize that observed secular trends in androgen use may align with drug treatment pattern changes for erectile dysfunction, including the advent of phosphodiesterase type 5 inhibitors. Copyright (c) 2014 John Wiley & Sons, Ltd. C1 [Hall, Susan A.; Ranganathan, Gayatri; Tinsley, Liane J.; Kupelian, Varant; Araujo, Andre B.] New England Res Inst, Dept Epidemiol, Watertown, MA 02472 USA. [Lund, Jennifer L.] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark. [Wittert, Gary A.] Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia. [Kantoff, Philip W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. [Morales, Alvaro] Queens Univ, Dept Urol, Kingston, ON K7L 3N6, Canada. RP Hall, SA (reprint author), New England Res Inst, Dept Epidemiol, 9 Galen St, Watertown, MA 02472 USA. EM shall@neriscience.com FU National Cancer Institute [R21CA143170] FX Supported by Grant Number R21CA143170 from the National Cancer Institute. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. This study is based in part on de-identified data provided by the Saskatchewan Ministry of Health. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Ministry of Health. NR 33 TC 9 Z9 9 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD MAY PY 2014 VL 23 IS 5 BP 498 EP 506 DI 10.1002/pds.3579 PG 9 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AE4JI UT WOS:000333948300006 PM 24510484 ER PT J AU Rauh-Hain, JA Clemmer, J Clark, RM Bradford, LS Growdon, WB Goodman, A Boruta, DM Dizon, DS Schorge, JO del Carmen, MG AF Rauh-Hain, J. A. Clemmer, J. Clark, R. M. Bradford, L. S. Growdon, W. B. Goodman, A. Boruta, D. M., II Dizon, D. S. Schorge, J. O. del Carmen, M. G. TI Management and outcomes for elderly women with vulvar cancer over time SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY LA English DT Article DE vulvar cancer; Elderly ID CERVICAL-CANCER; TREATMENT TRENDS; BREAST-CANCER; UNITED-STATES; CARCINOMA; PATTERNS; CARE; AGE; DECISIONS; SURVIVAL AB Objective To examine changes over time in survival and treatment for women diagnosed with vulvar squamous cell carcinoma included in the Surveillance, Epidemiology, and End Results (SEER) Program. Design Retrospective analysis. Setting USA, data obtained from the SEER Program for 1988-2009. Population Women with vulvar squamous cell carcinoma. Methods Women were stratified by age: <50, 50-64, 65-79, and >= 80years. Differences in survival and treatment patterns were analysed between age groups. Multivariate logistic regression models were constructed to examine treatment patterns. Kaplan-Meier and Cox proportional hazards survival methods were used to assess survival. Main outcome measures Vital status from the date of diagnosis until death, censoring or last follow-up. Results The final study group consisted of 8553 women, 1806 (21.12%) <50years, 2141 (25.03%) 50-64years, 2585 (30.22%) 65-79years, and 2021 (23.63%) >80years old. After adjusting for patient and tumour characteristics, older women were less likely to have surgery and more likely to receive radiotherapy. Compared with women under 50years, women 50-64 had a two-fold higher risk of death (HR 1.91, 95% CI 1.55-2.34); those 65-79years had a four-fold higher risk of death (HR 4.01, 95% CI 3.32-4.82), and those >= 80years had a seven-fold higher risk of death (HR 6.98, 95% CI 5.77-8.46). These trends stayed relatively constant over the time periods studied. Conclusions Women over 50years are at a higher risk of vulvar cancer-specific mortality, which increases with age. These trends stayed relatively constant over the time periods studied. C1 [Rauh-Hain, J. A.; Clemmer, J.; Clark, R. M.; Bradford, L. S.; Growdon, W. B.; Goodman, A.; Boruta, D. M., II; Schorge, J. O.; del Carmen, M. G.] Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA USA. [Dizon, D. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9, Boston, MA 02114 USA. EM mdelcarmen@partners.org FU Deborah Kelly Center for Outcomes Research, Massachusetts General Hospital FX This work was supported by The Deborah Kelly Center for Outcomes Research, Massachusetts General Hospital. NR 30 TC 8 Z9 8 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1470-0328 EI 1471-0528 J9 BJOG-INT J OBSTET GY JI BJOG PD MAY PY 2014 VL 121 IS 6 BP 719 EP 726 DI 10.1111/1471-0528.12580 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AE9UR UT WOS:000334356700011 PM 24621118 ER PT J AU Castillo, JJ Reagan, JL Bishop, KD Apor, E AF Castillo, Jorge J. Reagan, John L. Bishop, Kenneth D. Apor, Emmanuel TI Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Review DE human herpesvirus 8; Epstein-Barr virus; human T-lymphotrophic virus type 1; lymphomagenesis; lymphoma ID EPSTEIN-BARR-VIRUS; PRIMARY-EFFUSION LYMPHOMA; T-CELL LEUKEMIA; SARCOMA-ASSOCIATED HERPESVIRUS; NF-KAPPA-B; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; KILLER (NK)/T-CELL LYMPHOMA; NON-HODGKIN-LYMPHOMA; INTERNATIONAL PROGNOSTIC INDEX; ACTIVE ANTIRETROVIRAL THERAPY AB The association between viruses and lymphomas has long been recognized; however, the pathophysiological phenomena behind this relationship are unclear, and have been the object of intense research. Although our understanding of such mechanisms is slowly improving, much is still left to learn. With the recent advances in cancer biology, a diversity of biological pathways and novel targets and agents have been described in patients with haematological malignancies and successfully put into clinical practice. Clear examples are rituximab and brentuximab vedotin in patients with B cell lymphomas and Hodgkin lymphoma respectively. The main purpose of this review is not only to succinctly summarize what we know regarding the pathogenesis and pathophysiology of virally induced lymphomas and to describe the current practices in terms of diagnosis of treatment of such lymphomas, but also to provide a scientific rationale for the use of novel therapies that are likely to improve the outcomes of patients with these conditions. C1 [Castillo, Jorge J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02215 USA. [Reagan, John L.; Bishop, Kenneth D.] Rhode Isl Hosp, Div Hematol & Oncol, Providence, RI USA. [Apor, Emmanuel] Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA. RP Castillo, JJ (reprint author), Dana Farber Canc Inst, Div Hematol Malignancies, 450 Brookline Ave,M221, Boston, MA 02215 USA. EM jorgej_castillo@dfci.harvard.edu OI Castillo, Jorge/0000-0001-9490-7532 NR 153 TC 6 Z9 6 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD MAY PY 2014 VL 165 IS 3 BP 300 EP 315 DI 10.1111/bjh.12788 PG 16 WC Hematology SC Hematology GA AE5LR UT WOS:000334031000006 PM 24533596 ER PT J AU Siddesha, JM Valente, AJ Yoshida, T Sakamuri, SSVP Delafontaine, P Iba, H Noda, M Chandrasekar, B AF Siddesha, Jalahalli M. Valente, Anthony J. Yoshida, Tadashi Sakamuri, Siva S. V. P. Delafontaine, Patrice Iba, Hideo Noda, Makoto Chandrasekar, Bysani TI Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration SO CELLULAR SIGNALLING LA English DT Article DE Fibrosis; RECK; MicroRNA; omega-3 lipids; PTEN; SPRY1 ID POLYUNSATURATED FATTY-ACIDS; MYOCARDIAL-INFARCTION; CELL INVASION; METALLOPROTEINASE INHIBITORS; TARGETED DELETION; PRESSURE-OVERLOAD; HEART-FAILURE; EXPRESSION; MATRIX; MICRORNA-21 AB The omega-3 polyunsaturated fatty acids (omega-3 fatty adds) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been reported to inhibit or delay the progression of cardiovascular diseases, including myocardial fibrosis. Recently we reported that angiotensin II (Ang II) promotes cardiac fibroblast (CF) migration by suppressing the MMP regulator reversion-inducing-cysteine-rich protein with Kazal motifs (RECK), through a mechanism dependent on AT1, ERK, and Sp1. Here we investigated the role of miR-21 in Ang II-mediated RECK suppression, and determined whether the to 3 fatty adds reverse these effects. Ang II induced miR-21 expression in primary mouse cardiac fibroblasts (CFs) via ERK-dependent AP-1 and STAT3 activation, and while a miR-21 inhibitor reversed Ang II-induced RECK suppression, a miR-21 mimic inhibited both RECK expression and Ang II-induced CF migration. Moreover, Ang II suppressed the pro-apoptotic PTEN, and the ERK negative regulator Sprouty homologue 1 (SPRY1), but induced the metalloendopeptidase MMP2, all in a manner that was miR-21-dependent. Further, forced expression of PTEN inhibited Akt phosphorylation, Spl activation, and MMP2 induction. Notably, while both EPA and DHA reversed Ang II-mediated RECK suppression, DHA appeared to be more effective, and reversed Ang II-induced miR-21 expression, RECK suppression, MMP2 induction, and CF migration. These results indicate that Ang II-induced CF migration is differentially regulated by miR-21-mediated MMP induction and RECK suppression, and that DHA has the potential to upregulate RECK, and therefore may exert potential beneficial effects in cardiac fibrosis. (C) 2014 Elsevier Inc. All rights reserved. C1 [Siddesha, Jalahalli M.; Chandrasekar, Bysani] Southeast Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA. [Siddesha, Jalahalli M.; Yoshida, Tadashi; Sakamuri, Siva S. V. P.; Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA. [Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Valente, Anthony J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Iba, Hideo] Univ Tokyo, Dept Microbiol & Immunol, Tokyo 1088639, Japan. [Noda, Makoto] Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan. RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave,SL-48, New Orleans, LA 70112 USA. EM bchandra@tulane.edu OI Delafontaine, Patrice/0000-0003-3744-3617; Yoshida, Tadashi/0000-0002-4544-1497 FU Development Biomedical Laboratory Research and Development Service Award [1101BX000246]; NIH/NHLBI [HL-86787]; [HL-70241]; [HL-80682] FX BC is a recipient of the Department of Veterans Affairs Research Career Scientist award, and is supported by the VA Office of Research and Development Biomedical Laboratory Research and Development Service Award 1101BX000246 and the NIH/NHLBI grant HL-86787. PD is supported by HL-70241 and HL-80682. The contents of this report do not represent the views of the Department of Veterans Affairs or the United States Government. NR 40 TC 9 Z9 9 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 EI 1873-3913 J9 CELL SIGNAL JI Cell. Signal. PD MAY PY 2014 VL 26 IS 5 BP 933 EP 941 DI 10.1016/j.cellsig2014.01.005 PG 9 WC Cell Biology SC Cell Biology GA AE4IT UT WOS:000333946800011 PM 24447911 ER PT J AU Ly, M Canu, E Xu, GF Oh, J McLaren, DG Dowling, NM Alexander, AL Sager, MA Johnson, SC Bendlin, BB AF Ly, Martina Canu, Elisa Xu, Guofan Oh, Jennifer McLaren, Donald G. Dowling, N. Maritza Alexander, Andrew L. Sager, Mark A. Johnson, Sterling C. Bendlin, Barbara B. TI Midlife measurements of white matter microstructure predict subsequent regional white matter atrophy in healthy adults SO HUMAN BRAIN MAPPING LA English DT Article DE diffusion tensor imaging; longitudinal; aging; microstructure; atrophy; tensor-based morphometry; fractional anisotropy ID AGE-RELATED-CHANGES; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; HUMAN BRAIN; EXECUTIVE FUNCTION; IN-VIVO; CORTICAL DISCONNECTION; INDIVIDUAL-DIFFERENCES; STRUCTURAL INTEGRITY; CORPUS-CALLOSUM AB Objectives: Although age-related brain changes are becoming better understood, midlife patterns of change are still in need of characterization, and longitudinal studies are lacking. The aim of this study was to determine if baseline fractional anisotropy (FA), obtained from diffusion tensor imaging (DTI) predicts volume change over a 4-year interval. Experimental design: Forty-four cognitively healthy middle-age adults underwent baseline DTI and longitudinal T1-weighted magnetic resonance imaging. Tensor-based morphometry methods were used to evaluate volume change over time. FA values were extracted from regions of interest that included the cingulum, entorhinal white matter, and the genu and splenium of the corpus callosum. Baseline FA was used as a predictor variable, whereas gray and white matter atrophy rates as indexed by Tensor-based morphometry were the dependent variables. Principal observations: Over a 4-year period, participants showed significant contraction of white matter, especially in frontal, temporal, and cerebellar regions (P < 0.05, corrected for multiple comparisons). Baseline FA in entorhinal white matter, genu, and splenium was associated with longitudinal rates of atrophy in regions that included the superior longitudinal fasciculus, anterior corona radiata, temporal stem, and white matter of the inferior temporal gyrus (P < 0.001, uncorrected for multiple comparisons). Conclusions: Brain change with aging is characterized by extensive shrinkage of white matter. Baseline white matter microstructure as indexed by DTI was associated with some of the observed regional volume loss. The findings suggest that both white matter volume loss and microstructural alterations should be considered more prominently in models of aging and neurodegenerative diseases. Hum Brain Mapp 35:2044-2054, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Ly, Martina; Xu, Guofan; Oh, Jennifer; Dowling, N. Maritza; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Ly, Martina; Xu, Guofan; Oh, Jennifer; Dowling, N. Maritza; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53792 USA. [Ly, Martina] Univ Wisconsin, Neurosci Training Program, Madison, WI 53792 USA. [Canu, Elisa] Natl Ctr Res & Care Alzheimers & Mental Dis, IRCCS Ctr San Giovanni di Dio FBF, Lab Epidemiol Neuroimaging & Telemed, Brescia, Italy. [McLaren, Donald G.] Harvard Univ, Sch Med, Boston, MA USA. [McLaren, Donald G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [McLaren, Donald G.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA. [McLaren, Donald G.] Edith Nourse Rogers Mem Vet Adm Hosp, Geriatr Res Educ & Clin, Bedford, MA 01730 USA. [Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, J5-1 Mezzanine,600 Highland Ave, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu RI Canu, Elisa/K-1423-2016; OI Canu, Elisa/0000-0001-5804-3378; Bendlin, Barbara/0000-0002-0580-9875; McLaren, Donald/0000-0002-0566-4610 FU National Institutes of Health [NIH R01 AG037639, AG027161, AG021155, P50 AG033514]; Department of Veterans Affairs [I01CX000165] FX Contract grant sponsor: The National Institutes of Health; Contract grant number: NIH R01 AG037639, AG027161, AG021155, P50 AG033514; Contract grant sponsor: A Merit Review Grant from the Department of Veterans Affairs; Contract grant number: I01CX000165 NR 75 TC 11 Z9 11 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD MAY PY 2014 VL 35 IS 5 BP 2044 EP 2054 DI 10.1002/hbm.22311 PG 11 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA AE5FB UT WOS:000334012100019 PM 23861348 ER PT J AU Bianciardi, M van Gelderen, P Duyn, JH AF Bianciardi, Marta van Gelderen, Peter Duyn, Jeff H. TI Investigation of BOLD fMRI resonance frequency shifts and quantitative susceptibility changes at 7 T SO HUMAN BRAIN MAPPING LA English DT Article DE fractional oxygen saturation; BOLD fMRI resonance frequency shifts; BOLD fMRI quantitative susceptibility changes; BOLD fMRI phase signal changes ID IN-VIVO; OXYGEN-METABOLISM; BLOOD; PHASE; MRI; SIGNAL; FLUCTUATIONS; ACTIVATION; COMPLEX; NOISE AB Although blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) experiments of brain activity generally rely on the magnitude of the signal, they also provide frequency information that can be derived from the phase of the signal. However, because of confounding effects of instrumental and physiological origin, BOLD related frequency information is difficult to extract and therefore rarely used. Here, we explored the use of high field (7 T) and dedicated signal processing methods to extract frequency information and use it to quantify and interpret blood oxygenation and blood volume changes. We found that optimized preprocessing improves detection of task-evoked and spontaneous changes in phase signals and resonance frequency shifts over large areas of the cortex with sensitivity comparable to that of magnitude signals. Moreover, our results suggest the feasibility of mapping BOLD quantitative susceptibility changes in at least part of the activated area and its largest draining veins. Comparison with magnitude data suggests that the observed susceptibility changes originate from neuronal activity through induced blood volume and oxygenation changes in pial and intracortical veins. Further, from frequency shifts and susceptibility values, we estimated that, relative to baseline, the fractional oxygen saturation in large vessels increased by 0.02-0.05 during stimulation, which is consistent to previously published estimates. Together, these findings demonstrate that valuable information can be derived from fMRI imaging of BOLD frequency shifts and quantitative susceptibility changes. Hum Brain Mapp 35:2191-2205, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Bianciardi, Marta; van Gelderen, Peter; Duyn, Jeff H.] NINDS, Adv MRI Sect, Lab Funct & Mol Imaging, NIH, Bethesda, MD 20892 USA. [Bianciardi, Marta] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Bianciardi, Marta] Harvard Univ, Sch Med, Boston, MA USA. RP Bianciardi, M (reprint author), NINDS, AMRI, LFMI, NIH, Bldg 10,Rm B1D 723A MSC 1065, Bethesda, MD 20892 USA. EM bianciardim@mail.nih.gov FU National Institutes of Health; National Institute of Neurological Disorders and Stroke FX Contract grant sponsor: Intramural Research Program of the National Institutes of Health; Contract grant sponsor: National Institute of Neurological Disorders and Stroke. NR 34 TC 8 Z9 8 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD MAY PY 2014 VL 35 IS 5 BP 2191 EP 2205 DI 10.1002/hbm.22320 PG 15 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA AE5FB UT WOS:000334012100028 PM 23897623 ER PT J AU Safdar, N Anderson, DJ Braun, BI Carling, P Cohen, S Donskey, C Drees, M Harris, A Henderson, DK Huang, SS Juthani-Mehta, M Lautenbach, E Linkin, DR Meddings, J Miller, LG Milstone, A Morgan, D Sengupta, S Varman, M Yokoe, D Zerr, DM AF Safdar, Nasia Anderson, Deverick J. Braun, Barbara I. Carling, Philip Cohen, Stuart Donskey, Curtis Drees, Marci Harris, Anthony Henderson, David K. Huang, Susan S. Juthani-Mehta, Manisha Lautenbach, Ebbing Linkin, Darren R. Meddings, Jennifer Miller, Loren G. Milstone, Aaron Morgan, Daniel Sengupta, Sharmila Varman, Meera Yokoe, Deborah Zerr, Danielle M. CA Soc Healthcare Epidemiology Amer TI The Evolving Landscape of Healthcare-Associated Infections: Recent Advances in Prevention and a Road Map for Research SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID SURGICAL-SITE INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE; CATHETER-RELATED INFECTIONS; GENTAMICIN-COLLAGEN SPONGE; URINARY-TRACT-INFECTIONS; BLOOD-STREAM INFECTION; CRITICALLY-ILL ADULTS; INTENSIVE-CARE AB This white paper identifies knowledge gaps and new challenges in healthcare epidemiology research, assesses the progress made toward addressing research priorities, provides the Society for Healthcare Epidemiology of America (SHEA) Research Committee's recommendations for high-priority research topics, and proposes a road map for making progress toward these goals. It updates the 2010 SHEA Research Committee document, "Charting the Course for the Future of Science in Healthcare Epidemiology: Results of a Survey of the Membership of SHEA," which called for a national approach to healthcare-associated infections (HAIs) and a prioritized research agenda. This paper highlights recent studies that have advanced our understanding of HAIs, the establishment of the SHEA Research Network as a collaborative infrastructure to address research questions, prevention initiatives at state and national levels, changes in reporting and payment requirements, and new patterns in antimicrobial resistance. C1 [Safdar, Nasia] Univ Wisconsin, Div Infect Dis, William S Middleton Mem Vet Hosp, Madison, WI USA. [Anderson, Deverick J.] Duke Univ, Med Ctr, Dept Infect Dis, Durham, NC USA. [Braun, Barbara I.] Joint Commiss, Oak Brook Terrace, IL USA. [Carling, Philip] Boston Univ, Sch Med, Boston, MA 02118 USA. [Cohen, Stuart] Univ Calif Davis, Div Infect Dis, Sch Med Hosp Epidemiol & Infect Prevent, Sacramento, CA 95817 USA. [Donskey, Curtis] Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA. [Drees, Marci] Christiana Care Hlth Syst, Newark, DE USA. [Harris, Anthony] Univ Maryland, Sch Med, EPH Genom Epidemiol & Clin Outcomes, Baltimore, MD 21201 USA. [Henderson, David K.] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Huang, Susan S.] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA. [Juthani-Mehta, Manisha] Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT USA. [Lautenbach, Ebbing] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Linkin, Darren R.] Univ Penn, Philadelphia, PA 19104 USA. [Meddings, Jennifer] Univ Michigan, Ann Arbor, MI 48109 USA. [Miller, Loren G.] Harbor UCLA Med Ctr, Div Infect Dis, Torrance, CA 90509 USA. [Milstone, Aaron] Johns Hopkins Univ, Baltimore, MD USA. [Morgan, Daniel] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Morgan, Daniel] Vet Affairs Maryland Healthcare Syst, Baltimore, MD USA. [Sengupta, Sharmila] BLK Super Specialty Hosp, Dept Microbiol, Delhi, India. [Varman, Meera] Creighton Univ, Med Ctr, Omaha, NE USA. [Yokoe, Deborah] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Yokoe, Deborah] Harvard Univ, Sch Med, Boston, MA USA. [Zerr, Danielle M.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Zerr, Danielle M.] Seattle Childrens Res Inst, Seattle, WA USA. RP Safdar, N (reprint author), 600 Highland Ave,H4-574, Madison, WI 53792 USA. EM ns2@medicine.wisc.edu FU US Department of Veterans Affairs (VA); National Institutes of Health (NIH) [AG40669]; Centers for Disease Control and Prevention (CDC), Duke University/Duke Infection Control Outreach Network [U54CK000164]; NIH/National Institute of Allergy and Infectious Diseases (NIAID) Duke University [K23AI095357]; CDC/Duke University [U54CK000172-01]; The Joint Commission: Agency for Healthcare Research and Quality (AHRQ) [1R13HS022174-0112]; CDC National Institute for Occupational Safety and Health National Personal Protective Technology Laboratory; AHRQ; CDC; state of Pennsylvania; Doris Duke Charitable Foundation; University of Pennsylvania; Pennsylvania Department of Health; VA National Center for Patient Safety; NIH/National Institute of Nursing Research; CDC [1U54 CK000172-01]; NIH/NIAID; NIH/National Cancer Institute FX Potential conflicts of interest. N.S. reports research grants and/or contracts from the US Department of Veterans Affairs (VA) and the National Institutes of Health (NIH; AG40669). D.J.A. reports a financial relationship with UpToDate Online, a company involved in treatment of subjects, and having received research grants or contracts from the Centers for Disease Control and Prevention (CDC), Duke University/Duke Infection Control Outreach Network (U54CK000164), NIH/National Institute of Allergy and Infectious Diseases (NIAID) Duke University (K23AI095357), and CDC/Duke University (U54CK000172-01). B.I.B. reports having received research grants or contracts from The Joint Commission: Agency for Healthcare Research and Quality (AHRQ; 1R13HS022174-0112) and the CDC National Institute for Occupational Safety and Health National Personal Protective Technology Laboratory. P.C. reports being an advisor or consultant for Ecolab and holding patents, copyrights, or licenses from Steris. S.C. reports having received research grants or contracts from Viropharma, Merck, and Cubist for clinical trials in C. difficile infection. A.H. reports financial involvement with companies involved in the treatment of subjects and having served in an advisory or consultant role for Premier, Cubist, and UpToDate. S.S.H. reports leading a clinical trial in which participating hospitals receive contributed product from Sage. E.L. reports having received research grants or contracts from AHRQ, the CDC, and the state of Pennsylvania. D.R.L. reports having received research grants/contracts from Doris Duke Charitable Foundation, the University of Pennsylvania, and the Pennsylvania Department of Health. J.M. reports having received research grants or contracts from AHRQ, VA National Center for Patient Safety, and the NIH/National Institute of Nursing Research. L.G.M. reports having received research grant or contracts from Merck Harbor-UCLA and Cerexa and honoraria from Durata. A.M. reports a financial relationship with Sage Products, a company involved in the treatment of subjects, and past research support and research grants or contracts from the NIH. D.M. reports serving in an advisory or consultant role for Welch-Allyn. D.Y. reports having received research grants or contracts from the CDC (1U54 CK000172-01). D.M.Z. reports having received research grants or contracts from the NIH/NIAID and the NIH/National Cancer Institute. All other authors report no conflicts of interest relevant to this article. NR 77 TC 7 Z9 7 U1 1 U2 10 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY 1 PY 2014 VL 35 IS 5 BP 480 EP 493 DI 10.1086/675821 PG 14 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AE4EI UT WOS:000333933900004 PM 24709716 ER PT J AU Balbale, SN Johnson, S Burns, SP Kralovic, SM Goldstein, B Gerding, DN Evans, CT AF Balbale, Salva N. Johnson, Stuart Burns, Stephen P. Kralovic, Stephen M. Goldstein, Barry Gerding, Dale N. Evans, Charlesnika T. TI Community-Associated Clostridium difficile Infection among Veterans with Spinal Cord Injury and Disorder SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID EPIDEMIOLOGY AB The impact of community-associated Clostridium difficile infection (CA-CDI) on patients with spinal cord injuries and disorders (SCI/Ds) is not fully understood. We examined CA-CDI cases among veterans with SCI/D, comparing them with community-onset, healthcare facility-associated (CO-HCFA) cases. Generally, patients with CA-CDI had less comorbidity, less severe CDI, and lower likelihood of antibiotic exposure. C1 [Balbale, Salva N.; Evans, Charlesnika T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA. [Balbale, Salva N.; Evans, Charlesnika T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA. [Johnson, Stuart; Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Johnson, Stuart; Gerding, Dale N.] Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA. [Burns, Stephen P.; Goldstein, Barry] Vet Affairs Puget Sound Hlth Care Syst, Spinal Cord Injury Qual Enhancement Res Initiat, Seattle, WA USA. [Burns, Stephen P.; Goldstein, Barry] Univ Washington, Seattle, WA 98195 USA. [Kralovic, Stephen M.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA. [Kralovic, Stephen M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Evans, Charlesnika T.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Evans, Charlesnika T.] Northwestern Univ, Ctr Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. RP Balbale, SN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, 5000 South 5th Ave 151H,Room D304, Hines, IL 60141 USA. EM salva.balbale@va.gov FU Veterans Affairs Health Services Research and Development Service [IIR-10-148] FX Veterans Affairs Health Services Research and Development Service (IIR-10-148). NR 10 TC 1 Z9 1 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY 1 PY 2014 VL 35 IS 5 BP 577 EP 580 DI 10.1086/675830 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AE4EI UT WOS:000333933900017 PM 24709729 ER PT J AU Reisinger, HS Perencevich, EN Morgan, DJ Forrest, GN Shardell, M Schweizer, ML Graham, MM Franciscus, CL Vander Weg, MW AF Reisinger, Heather Schacht Perencevich, Eli N. Morgan, Daniel J. Forrest, Graeme N. Shardell, Michelle Schweizer, Marin L. Graham, Margaret M. Franciscus, Carrie L. Vander Weg, Mark W. TI Improving Hand Hygiene Compliance with Point-of-Use Reminder Signs Designed Using Theoretically Grounded Messages SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material ID BEHAVIOR C1 [Reisinger, Heather Schacht; Perencevich, Eli N.; Schweizer, Marin L.; Graham, Margaret M.; Franciscus, Carrie L.; Vander Weg, Mark W.] Iowa City Vet Affairs VA Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat CA, Iowa City, IA USA. [Reisinger, Heather Schacht; Perencevich, Eli N.; Schweizer, Marin L.; Vander Weg, Mark W.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. [Morgan, Daniel J.] Maryland VA Hlth Care Syst, Baltimore, MD USA. [Morgan, Daniel J.; Shardell, Michelle] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Forrest, Graeme N.] Portland VA Med Ctr, Portland, OR USA. RP Reisinger, HS (reprint author), 601 Highway 6 West, Iowa City, IA 52246 USA. EM heather.reisinger@va.gov NR 9 TC 1 Z9 2 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY 1 PY 2014 VL 35 IS 5 BP 593 EP 594 DI 10.1086/675827 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AE4EI UT WOS:000333933900022 PM 24709734 ER PT J AU Jeon, HJ Walker, RS Inamori, A Hong, JP Cho, MJ Baer, L Clain, A Fava, M Mischoulon, D AF Jeon, Hong Jin Walker, Rosemary S. Inamori, Aya Hong, Jin Pyo Cho, Maeng Je Baer, Lee Clain, Alisabet Fava, Maurizio Mischoulon, David TI Differences in depressive symptoms between Korean and American outpatients with major depressive disorder SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE major depressive disorder; Korean; Hamilton Depression Rating Scale; American ID COMORBIDITY SURVEY REPLICATION; STAR-ASTERISK-D; SUICIDE ATTEMPTS; MELANCHOLIC FEATURES; PREVALENCE; SHAME; TRIAL; SCALE AB Previous epidemiologic studies have revealed that East-Asian populations experience fewer depressive symptoms than American populations do. However, it is unclear whether this difference applies to clinical patients with major depressive disorder (MDD). This present study included 1592 Korean and 3744 American outpatients who were 18 years of age or older and met the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. criteria for single or recurrent episodes of nonpsychotic MDD, and evaluated their symptoms of depression using the Hamilton Depression Rating Scale and the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form. Korean patients scored significantly lower for guilt and depressed mood items, and higher for hypochondriasis and suicidality items than American patients did, after adjusting for total Hamilton Depression Rating Scale scores. Conversely, no significant differences were found in quality and function of daily life between groups. Multivariate logistic regression analyses revealed that Korean patients experienced less frequent depressed mood and guilt, including verbal and nonverbal expression of depressed mood [adjusted odds ratio (AOR)=0.14, 95% confidence interval (CI) 0.08-0.23] and feelings of punishment (AOR=0.036, 95% CI 0.025-0.054) when compared with Americans after adjusting for age and sex. Conversely, Korean patients experienced more frequent suicidality and hypochondriasis, including suicidal ideas or gestures (AOR=2.10, 95% CI 1.60-2.76) and self-absorption of hypochondriasis (AOR=1.94, 95% CI 1.70-2.20). In conclusion, decreased expression of depressed mood and guilt may cause underdiagnosis of MDD in Korean patients. Early diagnosis of and intervention for depression and suicide may be delayed because of this specific cross-cultural difference in depression symptoms. C1 [Jeon, Hong Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, Seoul, South Korea. [Hong, Jin Pyo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Psychiat, Seoul, South Korea. [Cho, Maeng Je] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul, South Korea. [Jeon, Hong Jin; Walker, Rosemary S.; Inamori, Aya; Baer, Lee; Clain, Alisabet; Fava, Maurizio; Mischoulon, David] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Mischoulon, D (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Depress Clin & Res Program, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM dmischoulon@partners.org FU National Institute of Mental Health (NIMH) [N01 MH-90003]; Pfizer Pharmaceuticals Korea Ltd; National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology [2011-0013064] FX The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was supported by federal funds from the National Institute of Mental Health (NIMH) under contract (N01 MH-90003) to the University of Texas Southwestern Medical Center at Dallas (A. J. Rush, MD, Principal Investigator). Korean study was supported by Pfizer Pharmaceuticals Korea Ltd and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology (No. 2011-0013064). NR 34 TC 13 Z9 13 U1 3 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-1315 EI 1473-5857 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD MAY PY 2014 VL 29 IS 3 BP 150 EP 156 DI 10.1097/YIC.0000000000000019 PG 7 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA AE6LG UT WOS:000334103600003 PM 24323201 ER PT J AU de Blacam, C Colakoglu, S Ogunleye, AA Nguyen, JT Ibrahim, AMS Lin, SJ Kim, PS Lee, BT AF de Blacam, Catherine Colakoglu, Salih Ogunleye, Adeyemi A. Nguyen, John T. Ibrahim, Ahmed M. S. Lin, Samuel J. Kim, Peter S. Lee, Bernard T. TI Risk factors associated with complications in lower-extremity reconstruction with the distally based sural flap: A systematic review and pooled analysis SO JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY LA English DT Review DE Lower-extremity reconstruction; Sural flap; Distally based sural flap ID SOFT-TISSUE DEFECTS; LOWER-LIMB RECONSTRUCTION; OPEN TIBIAL FRACTURES; LOWER 3RD LEG; ARTERY FLAP; FASCIOCUTANEOUS FLAP; FASCIOMUSCULOCUTANEOUS FLAP; CLINICAL-EXPERIENCE; FOOT RECONSTRUCTION; ANKLE RECONSTRUCTION AB The distally based sural fasciocutaneous flap is one of the few options available for local flap reconstruction of soft-tissue defects in the lower one-third of the leg. Few studies have assessed risk factors associated with poor outcomes in this flap. A literature search was performed of MEDLINE, EMBASE, CINAHL and the Cochrane Library for articles evaluating the use of sural artery fasciocutaneous flaps for soft-tissue reconstruction of the leg. Data were pooled and a univariate analysis was performed to identify characteristics associated with increased morbidity. A logistic regression model was created, and odds ratios and p values associated with the development of complications were calculated. Sixty-one papers were identified which included data on 907 patients. The majority of sural flaps were used to cover defects of the heel (28.2%), foot (14.4%) or ankle (25.8%). Trauma was the most common indication, followed by ulcers and open fractures. Flap complications were recorded in 26.4% of cases with a flap loss rate of 3.2%. With multivariate analysis, venous insufficiency and increasing age were independent risk factors for complications. Patients with venous insufficiency had nine times the risk of developing a complication compared to patients without venous insufficiency. (C) 2014 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved. C1 [de Blacam, Catherine] Royal Coll Surgeons Ireland, Dublin 2, Ireland. [Colakoglu, Salih] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02215 USA. [Ogunleye, Adeyemi A.] Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Dept Surg, New York, NY 10032 USA. [Nguyen, John T.; Ibrahim, Ahmed M. S.; Lin, Samuel J.; Kim, Peter S.; Lee, Bernard T.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Div Plast & Reconstruct Surg, Boston, MA 02215 USA. RP Lee, BT (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Div Plast & Reconstruct Surg, 110 Francis St,Suite 5A, Boston, MA 02215 USA. EM blee3@bidmc.harvard.edu RI Lee, Bernard/K-1106-2016; OI Lee, Bernard/0000-0002-5533-3166; Colakoglu, Salih/0000-0002-8747-0616 NR 105 TC 5 Z9 6 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1748-6815 EI 1878-0539 J9 J PLAST RECONSTR AES JI J. Plast. Reconstr. Aesthet. Surg. PD MAY PY 2014 VL 67 IS 5 BP 607 EP 616 DI 10.1016/j.bjps.2014.01.044 PG 10 WC Surgery SC Surgery GA AE2OE UT WOS:000333811800013 PM 24662152 ER PT J AU Fairbairn, NG Randolph, MA Redmond, RW AF Fairbairn, N. G. Randolph, M. A. Redmond, R. W. TI The clinical applications of human amnion in plastic surgery SO JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY LA English DT Review DE Human amnion; Plastic surgery; Biological dressing ID EPITHELIAL-CELLS; FETAL MEMBRANES; GRAFT MATERIAL; STROMAL CELLS; STEM-CELLS; LEG ULCERS; REPAIR; BURNS; MYELOMENINGOCELE; VESTIBULOPLASTY AB Since the early 1900s, human amnion has been applied to a wide variety of clinical scenarios including burns, chronic ulcers, dural defects, intra-abdominal adhesions, peritoneal reconstruction, genital reconstruction, hip arthroplasty, tendon repair, nerve repair, microvascular reconstruction, corneal repair, intra-oral reconstruction and reconstruction of the nasal lining and tympanic membrane. Amnion epithelial and mesenchymal cells have been shown to contain a variety of regulatory mediators that result in the promotion of cellular proliferation, differentiation and epithelialisation and the inhibition of fibrosis, immune rejection, inflammation and bacterial invasion. The full repertoire of biological factors that these cells synthesise, store and release and the mechanisms by which these factors exert their beneficial effects are only now being fully appreciated. Although many commercially available biological and synthetic alternatives to amnion exist, ethical, religious, and financial constraints may limit the widespread utilisation of these products. Amnion is widely available, economical and is easy to manipulate, process and store. Although many clinical applications are of historical interest only, amnion offers an alternative source of multi-potent or pluripotent stem cells and therefore may yet have a great deal to offer the plastic surgery and regenerative medicine community. It is the purpose of this article to review the clinical applications of human amnion relevant to plastic surgery. (C) 2014 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved. C1 [Fairbairn, N. G.; Randolph, M. A.; Redmond, R. W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Plast Surg, Boston, MA 02114 USA. RP Fairbairn, NG (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Plast Surg, 78 Winter St, Boston, MA 02141 USA. EM NGF174@hotmail.com NR 80 TC 15 Z9 16 U1 1 U2 17 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1748-6815 EI 1878-0539 J9 J PLAST RECONSTR AES JI J. Plast. Reconstr. Aesthet. Surg. PD MAY PY 2014 VL 67 IS 5 BP 662 EP 675 DI 10.1016/j.bjps.2014.01.031 PG 14 WC Surgery SC Surgery GA AE2OE UT WOS:000333811800022 PM 24560801 ER PT J AU Anderson, TA Kasser, JR Holzman, RS AF Anderson, Thomas Anthony Kasser, James R. Holzman, Robert S. TI Anesthetic considerations in Sheldon-Hall syndrome SO PEDIATRIC ANESTHESIA LA English DT Article DE congenital anomalies & syndromes; congenital; airway; arthrogryposis; orthopedics; anomalies AB Arthrogryposis is characterized by multiple, nonprogressive joint contractures which may be caused by maternal disorders such as oligohydramnios as well as fetal akinesia resulting from primary disorders of muscle, connective tissue, or neurologic tissue. Its prevalence is about 1:3000. Distal arthrogryposis (DA) is a heterogenous group of genetic disorders with a characteristic flexion of the joints of the hands and feet divided into different types with additional features. Sheldon-Hall Syndrome (SHS), also known as distal arthrogryposis type 2A (DA2A), has some nonorthopedic features of specific importance to anesthetic care. C1 [Anderson, Thomas Anthony] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Kasser, James R.] Childrens Hosp Boston, Dept Orthoped Surg, Boston, MA USA. [Holzman, Robert S.] Childrens Hosp Boston, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA. RP Anderson, TA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM tanderson9@partners.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1155-5645 EI 1460-9592 J9 PEDIATR ANESTH JI Pediatr. Anesth. PD MAY PY 2014 VL 24 IS 5 BP 538 EP 540 DI 10.1111/pan.12303 PG 3 WC Anesthesiology; Pediatrics SC Anesthesiology; Pediatrics GA AE4BH UT WOS:000333922700013 PM 24829975 ER PT J AU Welt, CK Duran, JM AF Welt, Corrine K. Duran, Jessica M. TI Genetics of Polycystic Ovary Syndrome SO SEMINARS IN REPRODUCTIVE MEDICINE LA English DT Article DE genome-wide association; hyperandrogenism; gonadotropins ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; CHROMOSOME 2P16.3; GONADOTROPIN-SECRETION; INSULIN-RESISTANCE; EUROPEAN ANCESTRY; CAUCASIAN WOMEN; FTO GENE; VARIANTS; COMMON AB The etiology of polycystic ovary syndrome (PCOS) has been difficult to determine because its features are heterogeneous, and its origin may also be heterogeneous. Twin studies suggest that its etiology is strongly heritable and genetic approaches are rapidly uncovering new regions of the genome that appear to confer risk for PCOS. Recent genome-wide association studies in Han Chinese women with PCOS demonstrate 11 genetic loci that are associated with PCOS. The variants identified are in regions that contain genes important for gonadotropin action, genes that are associated with risk for type 2 diabetes, and other genes in which the relationship to PCOS is not yet clear. Replication studies have demonstrated that variants at several of these loci also confer risk for PCOS in women of European ethnicity. The strongest loci in Europeans contain genes for DENND1A and THADA, with additional associations in loci containing the LHCGR and FSHR, YAP1 and RAB5/SUOX. The next steps in uncovering the pathophysiology borne out by these loci and variants will include mapping to determine the causal variant and gene, phenotype studies to determine whether these regions are associated with particular features of PCOS and functional studies of the causal variant to determine the direct cause of PCOS based on the underlying genetics. The next years will be very exciting times as groups from around the world come together to further elucidate the genetic origins of PCOS. C1 [Welt, Corrine K.; Duran, Jessica M.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Duran, Jessica M.] Harvard Univ, Sch Med, Boston, MA USA. RP Welt, CK (reprint author), Massachusetts Gen Hosp, BHX 511,55 Fruit St, Boston, MA 02114 USA. EM cwelt@partners.org OI Welt, Corrine/0000-0002-8219-5504 FU National Institutes of Health [U01 HD 4417]; Harvard Clinical and Translational Science Center [1R01HD065029, ADA 1-10-CT-57, 1 UL1 RR025758]; National Center for Research Resources [M01-RR-01066] FX This work was supported by the National Institutes of Health U01 HD 4417 (WFC), Harvard Clinical and Translational Science Center 1R01HD065029 (CKW), ADA 1-10-CT-57 (CKW), 1 UL1 RR025758, and the National Center for Research Resources M01-RR-01066. NR 52 TC 15 Z9 17 U1 1 U2 21 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1526-8004 EI 1526-4564 J9 SEMIN REPROD MED JI Semin. Reprod. Med. PD MAY PY 2014 VL 32 IS 3 BP 177 EP 182 DI 10.1055/s-0034-1371089 PG 6 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AE4TU UT WOS:000333977600006 PM 24715512 ER PT J AU Op Den Dries, S Westerkamp, A Karimian, N Gouw, ASH Markmann, J Lisman, T Yeh, H Uygun, K Martins, P Porte, RJ AF Op Den Dries, S. Westerkamp, A. Karimian, N. Gouw, A. S. H. Markmann, J. Lisman, T. Yeh, H. Uygun, K. Martins, P. Porte, R. J. TI INJURY OF PERIBILIARY GLANDS AND VASCULAR PLEXUS BEFORE LIVER TRANSPLANTATION PREDICTS FORMATION OF NON-ANASTOMOTIC BILIARY STRICTURES SO TRANSPLANT INTERNATIONAL LA English DT Meeting Abstract C1 [Westerkamp, A.; Karimian, N.; Gouw, A. S. H.; Lisman, T.; Porte, R. J.] Univ Med Ctr Groningen, Dept Surg, Sect Hepatopancreatobiliary Surg & Liver Transpla, NL-9713 AV Groningen, Netherlands. [Op Den Dries, S.; Markmann, J.; Yeh, H.; Uygun, K.; Martins, P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0934-0874 EI 1432-2277 J9 TRANSPL INT JI Transpl. Int. PD MAY PY 2014 VL 27 SU 1 SI SI BP 4 EP 4 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AE6YB UT WOS:000334142800013 ER PT J AU Yaghoobi, M Yuan, Y Hunt, RH AF Yaghoobi, M. Yuan, Y. Hunt, R. H. TI Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients - authors' reply SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Editorial Material C1 [Yaghoobi, M.] Med Univ S Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA. [Yaghoobi, M.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Yuan, Y.; Hunt, R. H.] McMaster Univ, Hlth Sci Ctr, Dept Med, Div Gastroenterol, Hamilton, ON, Canada. RP Yaghoobi, M (reprint author), Med Univ S Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA. EM huntr@mcmaster.ca NR 3 TC 1 Z9 1 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD MAY PY 2014 VL 39 IS 9 BP 993 EP 993 DI 10.1111/apt.12708 PG 1 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA AD8ZA UT WOS:000333553000012 PM 24689345 ER PT J AU Wilhelm, S Phillips, KA Didie, E Buhlmann, U Greenberg, JL Fama, JM Keshaviah, A Steketee, G AF Wilhelm, Sabine Phillips, Katharine A. Didie, Elizabeth Buhlmann, Ulrike Greenberg, Jennifer L. Fama, Jeanne M. Keshaviah, Aparna Steketee, Gail TI Modular Cognitive-Behavioral Therapy for Body Dysmorphic Disorder: A Randomized Controlled Trial SO BEHAVIOR THERAPY LA English DT Article DE body dysmorphic disorder; BDD; cognitive-behavioral therapy; body image; treatment ID OBSESSIVE-COMPULSIVE DISORDER; POPULATION-BASED SURVEY; CLINICAL-TRIALS; FOLLOW-UP; PREVALENCE; VALIDITY; SCALE; MAINTENANCE; RELIABILITY; PREDICTORS AB There are few effective treatments for body dysmorphic disorder (BDD) and a pressing need to develop such treatments. We examined the feasibility, acceptability, and efficacy of a manualized modular cognitive-behavioral therapy for BDD (CBT-BDD). CBT-BDD utilizes core elements relevant to all BDD patients (e.g., exposure, response prevention, perceptual retraining) and optional modules to address specific symptoms (e.g., surgery seeking). Thirty-six adults with BDD were randomized to 22 sessions of immediate individual CBT-BDD over 24 weeks (n = 17) or to a 12-week waitlist (n = 19). The Yale-Brown Obsessive-Compulsive Scale Modified for BDD (BDD-YBOCS), Brown Assessment of Beliefs Scale, and Beck Depression Inventory R were completed pretreatment, monthly, posttreatment, and at 3- and 6-month follow-up. The Sheehan Disability Scale and Client Satisfaction Inventory (CSI) were also administered. Response to treatment was defined as >= 30% reduction in BDD-YBOCS total from baseline. By week 12, 50% of participants receiving immediate CBT-BDD achieved response versus 12% of waitlisted participants (p = 0.026). By posttreatment, 81% of all participants (immediate CBT-BDD plus waitlisted patients subsequently treated with CBT-BDD) met responder criteria. While no significant group differences in BDD symptom reduction emerged by Week 12, by posttreatment CBT-BDD resulted in significant decreases in BDD-YBOCS total over time (d = 2.1, p < 0.0001), with gains maintained during follow-up. Depression, insight, and disability also significantly improved. Patient satisfaction was high, with a mean CSI score of 87.3% (SD = 12.8%) at posttreatment. CBT-BDD appears to be a feasible, acceptable, and efficacious treatment that warrants more rigorous investigation. C1 [Wilhelm, Sabine; Greenberg, Jennifer L.; Fama, Jeanne M.; Keshaviah, Aparna] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wilhelm, Sabine; Greenberg, Jennifer L.; Fama, Jeanne M.; Keshaviah, Aparna] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Phillips, Katharine A.; Didie, Elizabeth] Brown Univ, Rhode Isl Hosp, Providence, RI 02912 USA. [Phillips, Katharine A.; Didie, Elizabeth] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Buhlmann, Ulrike] Humboldt Univ, Berlin, Germany. [Steketee, Gail] Boston Univ, Boston, MA 02215 USA. RP Wilhelm, S (reprint author), Massachusetts Gen Hosp, Simches Res Bldg,185 Cambridge St,Suite 2282, Boston, MA 02114 USA. EM wilhelm@psy-ch.mgh.harvard.edu FU NIMH NIH HHS [R34 MH070490] NR 54 TC 33 Z9 33 U1 5 U2 33 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD MAY PY 2014 VL 45 IS 3 BP 314 EP 327 PG 14 WC Psychology, Clinical SC Psychology GA AE2GW UT WOS:000333792300003 PM 24680228 ER PT J AU Taylor, DJ Zimmerman, MR Gardner, CE Williams, JM Grieser, EA Tatum, JI Bramoweth, AD Francetich, JM Ruggero, C AF Taylor, Daniel J. Zimmerman, Marian R. Gardner, Christie E. Williams, Jacob M. Grieser, Emily A. Tatum, Jolyn I. Bramoweth, Adam D. Francetich, Jade M. Ruggero, Camilo TI A Pilot Randomized Controlled Trial of the Effects of Cognitive-Behavioral Therapy for Insomnia on Sleep and Daytime Functioning in College Students SO BEHAVIOR THERAPY LA English DT Article DE cognitive; behavioral; therapy; insomnia; college ID QUALITY-OF-LIFE; GENERAL MEDICAL-PRACTICE; MOTOR-VEHICLE ACCIDENTS; OLDER-ADULTS; YOUNG-ADULTS; CLINICAL EFFECTIVENESS; DYSFUNCTIONAL BELIEFS; PERSISTENT INSOMNIA; BREAST-CANCER; MENTAL-HEALTH AB The purpose of this study was to pilot test if cognitive behavioral therapy for insomnia (CBT-I) is an effective intervention for insomnia and daytime functioning in college students. College students' developmental stage and lifestyle are significantly different than the general adult population, yet there have been no studies of CBT-I in this age group. Thirty-four college students (ages 18-27; M = 19.71, SD = 2.10) were randomly assigned to and completed either six sessions of CBT-I or a 6-week wait list control (WLC). All participants completed 1-week sleep diaries and actigraphy, as well as sleep and daytime functioning questionnaires at baseline and posttreatment. The treatment group repeated all measures at 3-month follow-up. Students who received CBT-I showed greater baseline to posttreatment improvements in sleep efficiency, sleep onset latency, number of awakenings, time awake after sleep onset, sleep quality, insomnia severity, dysfunctional beliefs about sleep, general fatigue, and global sleep quality than the WLC group. These improvements were durable at 3-month follow-up. Ninety-four percent of participants in the CBT-I condition completed at least 4 sessions of treatment. Significantly more participants in the CBT-I group than the WLC group responded (68.8% vs 7.7%, respectively) and remitted (68.8% vs 15.4%, respectively). CBT-I is an effective treatment for insomnia in college students. This study found that treatment responses were similar to results from studies in the general population. The treatment appeared to be well tolerated based on very low attrition rates. C1 [Taylor, Daniel J.; Zimmerman, Marian R.] Univ N Texas, Denton, TX 76203 USA. [Gardner, Christie E.] Texas Tech Univ, Lubbock, TX 79409 USA. [Williams, Jacob M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Grieser, Emily A.] Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA. [Tatum, Jolyn I.] Wright Patterson Med Ctr, Dayton, OH USA. [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Taylor, Daniel J.; Francetich, Jade M.; Ruggero, Camilo] Univ N Texas, Dept Psychol, Denton, TX 76203 USA. RP Taylor, DJ (reprint author), Univ N Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA. EM djtaylor@unt.edu NR 89 TC 6 Z9 6 U1 9 U2 41 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD MAY PY 2014 VL 45 IS 3 BP 376 EP 389 PG 14 WC Psychology, Clinical SC Psychology GA AE2GW UT WOS:000333792300007 PM 24680232 ER PT J AU Cohen, S O'Leary, KD Foran, HM Kliem, S AF Cohen, Shiri O'Leary, K. Daniel Foran, Heather M. Kliem, Soeren TI Mechanisms of Change in Brief Couple Therapy for Depression SO BEHAVIOR THERAPY LA English DT Article DE couple therapy; depression; treatment mechanisms; psychoeducation; support ID RANDOMIZED CLINICAL-TRIAL; COGNITIVE THERAPY; MARITAL-THERAPY; TREATING DEPRESSION; EXPRESSED EMOTION; DYADIC ADJUSTMENT; COMMUNITY SAMPLE; DISORDER; DISCORD; QUALITY AB The goal of the present study was to investigate potential mechanisms of previously documented treatment effects for a brief, 5-session, problem-focused couple therapy for depression in a sample of 35 depressed women and their nondepressed husbands. The primary treatment effects were reducing women's depressive symptoms and their husbands' psychological distress and depression-specific burden. Secondarily, treatment resulted in increased relationship satisfaction for both partners. Given these significant treatment changes observed in 5 sessions, we sought to examine the mechanisms of change by testing the following three factors as potential mediators: (a) negative behaviors and attitudes toward depression, (b) support provision, and (c) empathic communication towards the depressed female partners. Women's depression and husbands' depression-specific burden were alleviated by positive changes in their illness-related attitudes and behaviors. Improvements in women's marital satisfaction were also mediated by positive change in their illness-related attitudes and behaviors, along with perceptions of increased positivity and support from their husbands. Findings highlight the importance of targeting specific treatment agents in a brief couple therapy for depression such as psychoeducation about depression and support-building to increase partners' understanding and acceptance of the illness, and teaching communication skills to reduce negative behaviors and criticism that are replaced by more empathic communication towards the depressed individual. C1 [Cohen, Shiri] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [O'Leary, K. Daniel] SUNY Stony Brook, Stony Brook, NY USA. [Foran, Heather M.; Kliem, Soeren] Tech Univ Carolo Wilhelmina Braunschweig, Braunschweig, Germany. RP Cohen, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, 101 Merrimac St,Suite 250, Boston, MA 02114 USA. EM scohen17@mgh.harvard.edu OI Kliem, Soren/0000-0003-1788-9574 NR 53 TC 2 Z9 2 U1 4 U2 13 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD MAY PY 2014 VL 45 IS 3 BP 402 EP 417 PG 16 WC Psychology, Clinical SC Psychology GA AE2GW UT WOS:000333792300009 PM 24680234 ER PT J AU Baker, AS Litwack, SD Clapp, JD Beck, JG Sloan, DM AF Baker, Aaron S. Litwack, Scott D. Clapp, Joshua D. Beck, J. Gayle Sloan, Denise M. TI The Driving Behavior Survey as a Measure of Behavioral Stress Responses to MVA-Related PTSD (vol 45, pg 263, 2014) SO BEHAVIOR THERAPY LA English DT Correction ID VEHICLE ACCIDENT SURVIVORS; POSTTRAUMATIC-STRESS; ANXIETY DISORDERS; TRAFFIC ACCIDENTS; DRIVER STRESS; THERAPY; VETERANS; TRAUMA; EPIDEMIOLOGY; PERFORMANCE C1 VA Boston Healthcare Syst, Boston, MA 02130 USA. Boston Univ, Sch Med, Boston, MA 02215 USA. Univ Wyoming, Laramie, WY 82071 USA. Univ Memphis, Memphis, TN 38152 USA. Univ LaVerne, La Verne, CA USA. RP Sloan, DM (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 2, 150 South Huntington Ave, Boston, MA 02130 USA. EM denise.sloan@va.gov NR 51 TC 1 Z9 1 U1 0 U2 3 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD MAY PY 2014 VL 45 IS 3 BP 443 EP 453 DI 10.1016/j.beth.2013.12.002 PG 11 WC Psychology, Clinical SC Psychology GA AE2GW UT WOS:000333792300012 ER PT J AU Bredella, MA Gerweck, AV Barber, LA Breggia, A Rosen, CJ Torriani, M Miller, KK AF Bredella, Miriam A. Gerweck, Anu V. Barber, Lauren A. Breggia, Anne Rosen, Clifford J. Torriani, Martin Miller, Karen K. TI Effects of growth hormone administration for 6 months on bone turnover and bone marrow fat in obese premenopausal women SO BONE LA English DT Article DE Obesity; MR spectroscopy; Bone; Bone marrow fat; Growth hormone; Bone turnover ID PLACEBO-CONTROLLED TRIAL; BODY-COMPOSITION; POSTMENOPAUSAL WOMEN; GH DEFICIENCY; RESONANCE SPECTROSCOPY; HEALTHY PREMENOPAUSAL; ENERGY-METABOLISM; ANOREXIA-NERVOSA; MINERAL DENSITY; VISCERAL FAT AB Purpose: Abdominal adiposity is associated with low BMD and decreased growth hormone (GH) secretion, an important regulator of bone homeostasis. The purpose of our study was to determine the effects of a short course of GH on markers of bone turnover and bone marrow fat in premenopausal women with abdominal adiposity. Materials and methods: In a 6-month, randomized, double-blind, placebo-controlled trial we studied 79 abdominally obese premenopausal women (21-45y) who underwent daily sc injections of GH vs. placebo. Main outcome measures were body composition by DXA and CT, bone marrow fat by proton MR spectroscopy, P1NP, CTX, 25(OH)D, hsCRP, undercarboxylated osteocalcin (ucOC), preadipocyte factor 1 (Pref 1), apolipoprotein B (ApoB), and IGF-1. Results: GH increased IGF-1, P1NP, 25(OH)D, ucOC, bone marrow fat and lean mass, and decreased abdominal fat, hsCRP, and ApoB compared with placebo (p < 0.05). There was a trend toward an increase in CTX and Pref-1. Among all participants, a 6-month increase in IGF-1 correlated with 6-month increase in P1NP (p = 0.0005), suggesting that subjects with the greatest increases in IGF-1 experienced the greatest increases in bone formation. A six-month decrease in abdominal fat, hsCRP, and ApoB inversely predicted 6-month change in P1NP, and 6-month increase in lean mass and 25(OH)D positively predicted 6-month change in P1NP (p <= 0.05), suggesting that subjects with greatest decreases in abdominal fat, inflammation and ApoB, and the greatest increases in lean mass and 25(OH)D experienced the greatest increases in bone formation. A six-month increase in bone marrow fat correlated with 6-month increase in P1NP (trend), suggesting that subjects with the greatest increases in bone formation experienced the greatest increases in bone marrow fat. Forward stepwise regression analysis indicated that increase in lean mass and decrease in abdominal fat were positive predictors of P1NP. When IGF-1 was added to the model, it became the only predictor of P1NP. Conclusion: GH replacement in abdominally obese premenopausal women for 6 months increased bone turnover and bone marrow fat. Reductions in abdominal fat,.and inflammation, and increases in IGF-1, lean mass and vitamin D were associated with increased bone formation. The increase in bone marrow fat may reflect changes in energy demand from increased bone turnover. (C) 2014 Elsevier Inc. All rights reserved. C1 [Bredella, Miriam A.; Barber, Lauren A.; Torriani, Martin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Gerweck, Anu V.; Miller, Karen K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Gerweck, Anu V.; Miller, Karen K.] Harvard Univ, Sch Med, Boston, MA USA. [Breggia, Anne; Rosen, Clifford J.] Maine Med Ctr, Res Inst, Scarborough, ME 04074 USA. RP Bredella, MA (reprint author), Massachusetts Gen Hosp, Yawkey 6E,55 Fruit St, Boston, MA 02114 USA. EM mbredella@partners.org OI Breggia, Anne/0000-0001-7545-0303 FU National Institutes of Health [R01 HL-077674, UL1 RR-025758, K24 HL092902-03, K23 RR-23090] FX This work was supported in part by National Institutes of Health Grants R01 HL-077674, UL1 RR-025758, K24 HL092902-03 and K23 RR-23090.The authors have no conflict of interest to declare.Study medication (GH and placebo) only was provided by Genentech, Inc., South San Francisco, CA.Clinical trials registration number: NCT00131378. NR 42 TC 8 Z9 8 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 EI 1873-2763 J9 BONE JI Bone PD MAY PY 2014 VL 62 BP 29 EP 35 DI 10.1016/j.bone.2014.01.022 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD6NU UT WOS:000333378300004 PM 24508386 ER PT J AU Wachowska, M Gabrysiak, M Muchowicz, A Bednarek, W Barankiewicz, J Rygiel, T Boon, L Mroz, P Hamblin, MR Golab, J AF Wachowska, Malgorzata Gabrysiak, Magdalena Muchowicz, Angelika Bednarek, Weronika Barankiewicz, Joanna Rygiel, Tomasz Boon, Louis Mroz, Pawel Hamblin, Michael R. Golab, Jakub TI 5-Aza-2 '-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy SO EUROPEAN JOURNAL OF CANCER LA English DT Article DE 5-Aza-2 '-deoxycitidine; Cancer; Photodynamic therapy; Specific antitumour immunity; Tumour associated antigens ID CANCER/TESTIS ANTIGEN; MURINE TUMOR; CANCER; IMMUNOTHERAPY; INDUCTION; MICE; CELLS; GENE; P1A AB Photodynamic therapy (PDT) of tumours is based on administration of a photosensitiser followed by irradiation of the tumour with visible light leading to production of reactive oxygen species that cause direct tumour cell death and vascular damage. PDT also initiates acute local inflammation, which facilitates the development of adaptive antitumour immunity. It has recently been reported that PDT can induce strong antitumour immunity towards tumours cells expressing P1A, tumour-associated antigen. Using four different tumour models, we show that antitumour immune response can be further improved when PDT is combined with a clinically approved epigenetic agent that induces expression of a silenced P1A antigen. Induction of P1A with 5-aza-2 '-deoxycytidine, a methyltransferase inhibitor, resulted in potentiated antitumour effects in mice with Lewis lung carcinoma and 4T1 mammary carcinoma when combined with PDT treatment. In CT26 colon carcinoma and EMT6 mammary carcinoma models the combination therapy resulted in complete responses and long-term survival. All long-term surviving mice were resistant to re-inoculation with the same tumour cells. Antitumour efficacy of the combination treatment was severely impaired by depletion of CD8(+) cytotoxic T cells, whereas adoptive transfer of CD8(+) T cells from long-term surviving mice allowed for significant tumour growth delay in tumour-bearing mice. Taken together, these findings show that PDT leads to strong specific antitumour immune responses, and that epigenetic modification of tumour antigens levels may be a novel approach to further enhance the effectiveness of PDT. The present results provide a strong rationale for clinical development of this therapeutic approach. (C) 2014 Elsevier Ltd All rights reserved. C1 [Wachowska, Malgorzata; Gabrysiak, Magdalena; Muchowicz, Angelika; Bednarek, Weronika; Barankiewicz, Joanna; Rygiel, Tomasz; Golab, Jakub] Med Univ Warsaw, Ctr Biostruct Res, Dept Immunol, PL-02097 Warsaw, Poland. [Boon, Louis] Bioceros, NL-3584 CM Utrecht, Netherlands. [Mroz, Pawel; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Mroz, Pawel; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Mroz, Pawel] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Golab, Jakub] Polish Acad Sci, Inst Phys Chem, Warsaw, Poland. RP Golab, J (reprint author), Med Univ Warsaw, Ctr Biostruct Res, Dept Immunol, 1A Banacha Str,F Bldg, PL-02097 Warsaw, Poland. EM jakub.golab@wum.edu.pl RI Golab, Jakub/K-6974-2013; OI Golab, Jakub/0000-0002-2830-5100; Hamblin, Michael/0000-0001-6431-4605 FU European Commission [FP7-REG-POT-2012-CT2012-316254-BASTION]; Foundation for Polish Science; EU European Regional Development Fund FX Research was supported by a grant from the European Commission Seventh Framework Programme: FP7-REG-POT-2012-CT2012-316254-BASTION (J.G.). J.G., M. W., M. G., J.B., A. M. were members of TEAM Programme co-financed by the Foundation for Polish Science and the EU European Regional Development Fund. NR 29 TC 21 Z9 21 U1 3 U2 20 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0959-8049 EI 1879-0852 J9 EUR J CANCER JI Eur. J. Cancer PD MAY PY 2014 VL 50 IS 7 BP 1370 EP 1381 DI 10.1016/j.ejca.2014.01.017 PG 12 WC Oncology SC Oncology GA AE2LW UT WOS:000333805500017 PM 24559534 ER PT J AU Peralta, CA Scherzer, R Grunfeld, C Abraham, A Tien, PC Devarajan, P Bennett, M Butch, AW Anastos, K Cohen, MH Nowicki, M Sharma, A Young, MA Sarnak, MJ Parikh, CR Shlipak, MG AF Peralta, C. A. Scherzer, R. Grunfeld, C. Abraham, A. Tien, P. C. Devarajan, P. Bennett, M. Butch, A. W. Anastos, K. Cohen, M. H. Nowicki, M. Sharma, A. Young, M. A. Sarnak, M. J. Parikh, C. R. Shlipak, M. G. TI Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women's Interagency HIV Study (WIHS) SO HIV MEDICINE LA English DT Article DE kidney injury molecule-1; neutrophil gelatinase-associated lipocalin; interleukin-18; HIV; urinary biomarkers; liver fatty acid binding protein ID ACID-BINDING PROTEIN; IMMUNODEFICIENCY-VIRUS-INFECTION; GELATINASE-ASSOCIATED LIPOCALIN; CYSTATIN-C; ANTIRETROVIRAL THERAPY; CARDIOVASCULAR EVENTS; FUNCTION DECLINE; CARDIAC-SURGERY; DISEASE; OUTCOMES AB Objectives Chronic kidney disease (CKD) is common in HIV-infected individuals, and is associated with mortality in both the HIV-infected and general populations. Urinary markers of tubular injury have been associated with future kidney disease risk, but associations with mortality are unknown. Methods We evaluated the associations of urinary interleukin-18 (IL-18), liver fatty acid binding protein (L-FABP), kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL) and the albumin-to-creatinine ratio (ACR) with 10-year, all-cause death in 908 HIV-infected women. Serum cystatin C was used to estimate the glomerular filtration rate (eGFRcys). Results There were 201 deaths during 9269 person-years of follow-up. After demographic adjustment, compared with the lowest tertile, the highest tertiles of IL-18 [hazard ratio (HR) 2.54; 95% confidence interval (CI) 1.75-3.68], KIM-1 (HR 2.04; 95% CI 1.44-2.89), NGAL (HR 1.50; 95% CI 1.05-2.14) and ACR (HR 1.63; 95% CI 1.13-2.36) were associated with higher mortality. After multivariable adjustment including adjustment for eGFRcys, only the highest tertiles of IL-18 (HR 1.88; 95% CI 1.29-2.74) and ACR (HR 1.46; 95% CI 1.01-2.12) remained independently associated with mortality. Findings for KIM-1 were borderline (HR 1.41; 95% CI 0.99-2.02). We found a J-shaped association between L-FABP and mortality. Compared with persons in the lowest tertile, the HR for the middle tertile of L-FABP was 0.67 (95% CI 0.46-0.98) after adjustment. Associations were stronger when IL-18, ACR and L-FABP were simultaneously included in models. Conclusions Among HIV-infected women, some urinary markers of tubular injury are associated with mortality risk, independently of eGFRcys and ACR. These markers represent potential tools with which to identify early kidney injury in persons with HIV infection. C1 [Peralta, C. A.; Scherzer, R.; Grunfeld, C.; Tien, P. C.; Shlipak, M. G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Peralta, C. A.; Scherzer, R.; Grunfeld, C.; Tien, P. C.; Shlipak, M. G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Abraham, A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Devarajan, P.; Bennett, M.] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA. [Butch, A. W.] Univ Calif Los Angeles, Clin Immunol Res Lab, Los Angeles, CA USA. [Anastos, K.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Anastos, K.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Cohen, M. H.] John H Stroger Jr Hosp, Dept Med, Chicago, IL USA. [Cohen, M. H.] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA. [Nowicki, M.] Univ So Calif, Los Angeles, CA USA. [Sharma, A.] Suny Downstate Med Ctr, Dept Med, Div Infect Dis, Brooklyn, NY 11203 USA. [Young, M. A.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA. [Sarnak, M. J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Parikh, C. R.] Yale Univ, Dept Med, Sect Nephrol, New Haven, CT 06520 USA. [Parikh, C. R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA. RP Peralta, CA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU National Institutes of Health [NIDDK 23]; Robert Wood Johnson Foundation Harold Amos Program; National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute, the National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI Grant) [UL1 RR024131]; [1R01AG034853-01A2] FX CAP has received funding from the National Institutes of Health (NIDDK 23) and the Robert Wood Johnson Foundation Harold Amos Program. CRP is a co-inventor on an IL-18 patent issued to the University of Colorado. PD is a co-inventor on patents related to the use of NGAL as a marker of acute and chronic kidney injury. The WIHS Kidney Aging Study is funded by grant 1R01AG034853-01A2 (awarded to P. I. Shlipak), which was administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, CA. Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centres (principal investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993 and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. NR 36 TC 14 Z9 14 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD MAY PY 2014 VL 15 IS 5 BP 291 EP 300 DI 10.1111/hiv.12113 PG 10 WC Infectious Diseases SC Infectious Diseases GA AE0TP UT WOS:000333679400005 PM 24313986 ER PT J AU Benmansour, S Privratsky, AA Adeniji, OS Frazer, A AF Benmansour, Saloua Privratsky, Anthony A. Adeniji, Opeyemi S. Frazer, Alan TI Signaling mechanisms involved in the acute effects of estradiol on 5-HT clearance SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Article DE ER agonist; estradiol; serotonin transporter; SSRI; signaling pathways ID GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; METABOTROPIC GLUTAMATE RECEPTORS; MEMBRANE ESTROGEN-RECEPTORS; NEUROTROPHIC FACTOR BDNF; LONG-TERM POTENTIATION; MAP KINASE; ANTIDEPRESSANT TREATMENT; SEROTONIN TRANSPORTERS; MOLECULAR-MECHANISMS AB Estradiol was found previously to have an antidepressant-like effect and to block the ability of selective serotonin reuptake inhibitors (SSRIs) to have an antidepressant-like effect. The antidepressant-like effect of estradiol was due to estrogen receptor beta (ER beta) and/or GPR30 activation, whereas estradiol's blockade of the effect of an SSRI was mediated by ER alpha. This study focuses on investigating signaling pathways as well as interacting receptors associated with these two effects of estradiol. In vivo chronoamperometry was used to measure serotonin transporter (SERT) function. The effect of local application of estradiol or selective agonists for ER alpha (PPT) or ER beta (DPN) into the CA(3) region of the hippocampus of ovariectomized (OVX) rats on 5-hydroxytryptamine (5-HT) clearance as well as on the ability of fluvoxamine to slow 5-HT clearance was examined after selective blockade of signaling pathways or that of interacting receptors. Estradiol- or DPN-induced slowing of 5-HT clearance mediated by ER beta was blocked after inhibition of MAPK/ERK1/2 but not of PI3K/Akt signaling pathways. This effect also involved interactions with TrkB, and IGF-1 receptors. Estradiol's or PPT's inhibition of the fluvoxamine-induced slowing of 5-HT clearance mediated by ER alpha, was blocked after inhibition of either MAPK/ERK1/2 or PI3K/Akt signaling pathways. This effect involved interactions with the IGF-1 receptor and with the metabotropic glutamate receptor 1, but not with TrkB. This study illustrates some of the signaling pathways required for the effects of estradiol on SERT function, and particularly shows that ER subtypes elicit different as well as common signaling pathways for their actions. C1 [Benmansour, Saloua; Privratsky, Anthony A.; Adeniji, Opeyemi S.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Frazer, Alan] South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Benmansour, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, MC 7764,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM benmansour@uthscsa.edu FU NARSAD; Department of Veterans Affairs; National Institute of Mental Health [MH090386] FX This research was supported by funds from NARSAD to SB, the Department of Veterans Affairs and the National Institute of Mental Health (MH090386) to AF. NR 78 TC 7 Z9 8 U1 0 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD MAY PY 2014 VL 17 IS 5 BP 765 EP 777 DI 10.1017/S146114571300165X PG 13 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AD9CM UT WOS:000333562300008 PM 24423185 ER PT J AU Maserejian, NN Shrader, P Brown, OA Trachtenberg, FL Soncini, J Hauser, R Shenker, BJ AF Maserejian, Nancy N. Shrader, Peter Brown, Olivia A. Trachtenberg, Felicia L. Soncini, Jennifer Hauser, Russ Shenker, Bruce J. TI Dental sealants and composite restorations and longitudinal changes in immune function markers in children SO INTERNATIONAL JOURNAL OF PAEDIATRIC DENTISTRY LA English DT Article ID URINARY BISPHENOL-A; RANDOMIZED CLINICAL-TRIAL; LYMPHOCYTE SUBSETS; MERCURIC COMPOUNDS; EXPOSURE; AMALGAM; RESIN; OBESITY; ASSOCIATION; CELLS AB Objective Resins used in dental composites, derived from bisphenol-A (BPA), have been shown to alter immune cells. The objective of this study was to explore children's immune function changes in relation to resin composite treatment. Design We conducted secondary data analysis of the New England Children's Amalgam Trial immune function substudy (N=59). Immune function was measured pre-treatment and up to five times post-treatment through 5-year follow-up. Multivariable generalized linear regression models were used to estimate the association between three classes of resin composites (bisphenol-A-diglycidyl-dimethacrylate [BisGMA]-based flowables used for preventive sealants; urethane dimethacrylate [UDMA]-based compomer restorations; bisGMA-based restorations) and changes in immune function markers measured annually. Results Total white blood cell counts and responsiveness of T cells or neutrophils were not appreciably altered by composite treatment levels. Changes in B cell responsiveness were greater throughout follow-up among children with more bisGMA-based composite restorations, which opposed findings for amalgam treatment levels. Monocyte responsiveness changes were decreased at 6months with greater treatment, but not over longer follow-up. Conclusions Results of this analysis showed no overt immune function alterations associated with resin composites. Additional research regarding lymphocyte activation may be warranted given the consistency of results within these analyses and with a prior study showing increased B cell activation. C1 [Maserejian, Nancy N.; Shrader, Peter; Brown, Olivia A.; Trachtenberg, Felicia L.] New England Res Inst, Dept Epidemiol, Watertown, MA 02172 USA. [Maserejian, Nancy N.] Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA. [Soncini, Jennifer] Boston Univ, Sch Dent Med, Boston, MA 02215 USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Hauser, Russ] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hauser, Russ] Harvard Univ, Sch Med, Boston, MA USA. [Shenker, Bruce J.] Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA. RP Maserejian, NN (reprint author), New England Res Inst Inc, 9 Galen St, Watertown, MA 02472 USA. EM nmaserejian@neriscience.com FU National Institute of Environmental Health Sciences (NIEHS) [R01ES019155]; USPHS from the National Institute of Dental and Craniofacial Research [N01-DE-72622] FX The analyses presented in this article were funded by Award Number R01ES019155 from the National Institute of Environmental Health Sciences (NIEHS). The data collection was supported by USPHS Grant N01-DE-72622 from the National Institute of Dental and Craniofacial Research. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Environmental Health Sciences, the National Institute of Dental and Craniofacial Research, or the National Institutes of Health. NR 48 TC 5 Z9 5 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0960-7439 EI 1365-263X J9 INT J PAEDIATR DENT JI Int. J. Paediatr. Dent. PD MAY PY 2014 VL 24 IS 3 BP 215 EP 225 DI 10.1111/ipd.12064 PG 11 WC Dentistry, Oral Surgery & Medicine; Pediatrics SC Dentistry, Oral Surgery & Medicine; Pediatrics GA AE2UO UT WOS:000333828800008 PM 24033362 ER PT J AU Perlis, RH Cusin, C Fava, M AF Perlis, R. H. Cusin, C. Fava, M. TI Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder SO PSYCHOLOGICAL MEDICINE LA English DT Article DE treatment-resistant depression; selective serotonin reuptake inhibitors; DSM-5; bipolar spectrum; major depressive disorder; mixed state; citalopram; Bipolar disorder ID STAR-ASTERISK-D; DIAGNOSTIC SCREENING QUESTIONNAIRE; SEQUENCED TREATMENT ALTERNATIVES; BIPOLAR DISORDER; MANIC SYMPTOMS; STEP-BD; OUTPATIENTS; SPECTRUM; SCALE; DEFINITION AB Background Draft DSM-5 criteria for a mixed major depressive episode have been proposed, but their predictive validity has not yet been established. We hypothesized that such symptoms would be associated with poorer antidepressant treatment outcomes. Method We examined outcomes among individuals with major depressive disorder participating in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, an effectiveness study conducted at primary and specialty care centers in the USA. Mixed features were derived from the six self-report items of the mania subscale of the Psychiatric Diagnosis Screening Questionnaire. Primary analyses examined the association between the presence of at least two of these in the 6 months before study entry, and remission across up to four sequential treatment trials, as well as adverse outcomes. Results Of the 2397 subjects with a major depressive episode of at least 6 months' duration, 449 (18.7%) reported at least two mixed symptoms. The presence of such symptoms was associated with a greater likelihood of remission across up to four sequential treatments, which persisted after adjustment for potential confounding clinical and demographic variables (adjusted hazard ratio 1.16, 95% confidence interval 1.03-1.28). Two individual items, expansive mood and cheerfulness, were strongly associated with a greater likelihood of remission. Conclusions Proposed DSM-5 mixed state features were associated with a greater rather than a lesser likelihood of remission. While unexpected, this result suggests the potential utility of further investigation of depressive mixed states in major depression. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Ctr Expt Drugs & Diagnost, 185 Cambridge St, Boston, MA 02114 USA. EM rperlis@partners.org FU National Institute of Mental Health (NIMH) [N01 MH-90003]; NIMH [MH086026] FX The STAR*D study is supported by federal funds from the National Institute of Mental Health (NIMH) under contract no. N01 MH-90003 to the University of Texas - SouthWestern Medical Center at Dallas (A. J. Rush, principal investigator). R. H. P. is supported by NIMH MH086026. NR 22 TC 5 Z9 5 U1 0 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD MAY PY 2014 VL 44 IS 7 BP 1361 EP 1367 DI 10.1017/S0033291712000281 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AD9BV UT WOS:000333560500003 PM 22417535 ER PT J AU Wolf, EJ Mitchell, KS Koenen, KC Miller, MW AF Wolf, E. J. Mitchell, K. S. Koenen, K. C. Miller, M. W. TI Combat exposure severity as a moderator of genetic and environmental liability to post-traumatic stress disorder SO PSYCHOLOGICAL MEDICINE LA English DT Article DE post-traumatic stress disorder; twins; Combat exposure; genetic; GxE ID ERA TWIN REGISTRY; TRAUMA EXPOSURE; CHILDHOOD ADVERSITY; LIFE EVENTS; SUBSEQUENT TRAUMA; MAJOR DEPRESSION; RISK; SYMPTOMS; ADULTS; PTSD AB Background Twin studies of veterans and adults suggest that approximately 30-46% of the variance in post-traumatic stress disorder (PTSD) is attributable to genetic factors. The remaining variance is attributable to the non-shared environment, which, by definition, includes combat exposure. This study used a gene by measured environment twin design to determine whether the effects of genetic and environmental factors that contribute to the etiology of PTSD are dependent on the level of combat exposure. Method The sample was drawn from the Vietnam Era Twin Registry (VETR) and included 620 male-male twin pairs who served in the US Military in South East Asia during the Vietnam War era. Analyses were based on data from a clinical diagnostic interview of lifetime PTSD symptoms and a self-report measure of combat exposure. Results Biometric modeling revealed that the effects of genetic and non-shared environment factors on PTSD varied as a function of level of combat exposure such that the association between these factors and PTSD was stronger at higher levels of combat exposure. Conclusions Combat exposure may act as a catalyst that augments the impact of hereditary and environmental contributions to PTSD. Individuals with the greatest exposure to combat trauma were at increased risk for PTSD as a function of both genetic and environmental factors. Additional work is needed to determine the biological and environmental mechanisms driving these associations. C1 [Wolf, E. J.; Mitchell, K. S.; Miller, M. W.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Wolf, E. J.; Mitchell, K. S.; Miller, M. W.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Koenen, K. C.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. RP Wolf, EJ (reprint author), VA Boston Healthcare Syst 116B 2, Natl Ctr PTSD, 150 South Huntington Ave, Boston, MA 02130 USA. EM Erika.Wolf@va.gov RI Koenen, Karestan/K-5402-2014; OI Koenen, Karestan/0000-0003-3293-4281; Wolf, Erika/0000-0003-2666-2435 FU VA CSR&D Career Development Award; National Institute on Mental Health [MH079806]; Department of Veterans Affairs Merit Award Program; Cooperative Studies Program of the Office of Research and Development of the United States Department of Veterans Affairs FX E. J. Wolf's contribution to this project was supported by a VA CSR&D Career Development Award. K. S. Mitchell's contribution was supported by K01MH093750. K. C. Koenen's contribution was supported by MH093612. M. Miller's effort was supported by National Institute on Mental Health award MH079806 and the Department of Veterans Affairs Merit Award Program. The Cooperative Studies Program of the Office of Research and Development of the United States Department of Veterans Affairs has provided financial support for the development and maintenance of the VETR. All statements, opinions or views are solely of the author(s) and do not necessarily reflect the position or policy of the VA or the US Government. Most importantly, we gratefully acknowledge the continued cooperation and participation of the members of the VETR and their families; without their contribution this research would not have been possible. NR 55 TC 3 Z9 3 U1 4 U2 15 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD MAY PY 2014 VL 44 IS 7 BP 1499 EP 1509 DI 10.1017/S0033291713002286 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AD9BV UT WOS:000333560500015 PM 24001428 ER PT J AU Lai, JS Zelko, F Krull, KR Cella, D Nowinski, C Manley, PE Goldman, S AF Lai, Jin-Shei Zelko, Frank Krull, Kevin R. Cella, David Nowinski, Cindy Manley, Peter E. Goldman, Stewart TI Parent-reported cognition of children with cancer and its potential clinical usefulness SO QUALITY OF LIFE RESEARCH LA English DT Article DE Perceived cognitive function; Item bank; Pediatric cancer; Brain tumor; Item response theory; Quality of life ID ORDINAL LOGISTIC-REGRESSION; TRAUMATIC BRAIN-INJURY; ITEM RESPONSE THEORY; ECOLOGICAL VALIDITY; CHILDHOOD-CANCER; NEUROPSYCHOLOGICAL ASSESSMENT; EXECUTIVE FUNCTION; SURVIVORS; TESTS; CHEMOTHERAPY AB Cognitive dysfunction is a common concern for children with brain tumors (BTs) or those receiving central nervous system (CNS) toxic cancer treatments. Perceived cognitive function (PCF) is an economical screening that may be used to trigger full, formal cognitive testing. We assessed the potential clinical utility of PCF by comparing parent-reported scores for children with cancer with scores from the general US population. Children (n = 515; mean age = 13.5 years; 57.0 % male) and one of their parents were recruited from pediatric oncology clinics. Most children (53.3 %) had a diagnosis of CNS tumor with an average time since diagnosis of 5.6 years. PCF was evaluated using the pediatric PCF item bank (pedsPCF), which was developed and normed on a sample drawn from the US general pediatric population. Children also completed computer-based neuropsychological tests. We tested relationships between PCF and clinical variables. Differential item functioning (DIF) was used to evaluate measurement bias between the samples. No item showed DIF, supporting the use of pedsPCF in the cancer sample. PedsPCF differentiated children with (vs. without) a BT, p < 0.01, and groups defined by years since diagnosis, p < 0.01. It significantly (p < 0.05) correlated with computerized neuropsychological tests in 40 of 60 comparisons. Children with BTs were rated as having worse pedsPCF scores than the norm, regardless of years since diagnosis. PCF significantly differentiated cancer survivors with various clinical characteristics. It is brief and easy to implement. PCF should be considered for routine care of pediatric cancer survivors. C1 [Lai, Jin-Shei; Cella, David; Nowinski, Cindy] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Zelko, Frank] Ann Robert H Lurie Childrens Hosp Chicago, Dept Child & Adolescent Psychiat, Pediat Neuropsychol Serv, Chicago, IL 60611 USA. [Krull, Kevin R.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Manley, Peter E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Manley, Peter E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goldman, Stewart] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. RP Lai, JS (reprint author), Northwestern Univ, Feinberg Sch Med, 633 N St Clair,19-039, Chicago, IL 60611 USA. EM js-lai@northwestern.edu; fzelko@luriechildrens.org; kevin.krull@stjude.org; d-cella@northwestern.edu; c-nowinski@northwestern.edu; Peter_Manley@dfci.harvard.edu; SGoldman@luriechildrens.org FU National Cancer Institute at the National Institutes of Health [R01CA174452] FX This study was supported by the National Cancer Institute at the National Institutes of Health (R01CA174452; Principle Investigator: Jin-Shei Lai). NR 42 TC 6 Z9 6 U1 2 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD MAY PY 2014 VL 23 IS 4 BP 1049 EP 1058 DI 10.1007/s11136-013-0548-9 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AD6SK UT WOS:000333391000003 PM 24197478 ER PT J AU Keenan, HA AF Keenan, Hillary A. TI Do Erectile Dysfunction and Cardiovascular Disease Have the Same Mechanism? SO EUROPEAN UROLOGY LA English DT Editorial Material ID PREDICTION C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Vasc Cell Biol, Boston, MA 02215 USA. RP Keenan, HA (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Vasc Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA. EM hillary.keenan@joslin.harvard.edu NR 10 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 EI 1873-7560 J9 EUR UROL JI Eur. Urol. PD MAY PY 2014 VL 65 IS 5 BP 979 EP 980 DI 10.1016/j.eururo.2013.11.013 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA AD2JE UT WOS:000333060200027 PM 24287318 ER PT J AU Sun, M Trinh, QD Perrotte, P Karakiewicz, PI AF Sun, Maxine Quoc-Dien Trinh Perrotte, Paul Karakiewicz, Pierre I. TI Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma SO EUROPEAN UROLOGY LA English DT Editorial Material ID INTERFERON-ALPHA C1 [Sun, Maxine; Perrotte, Paul; Karakiewicz, Pierre I.] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada. [Quoc-Dien Trinh] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Surg,Div Urol,Brigham & Womens Hosp, Boston, MA 02115 USA. [Perrotte, Paul; Karakiewicz, Pierre I.] Univ Montreal, Ctr Hlth, Dept Urol, Montreal, PQ, Canada. RP Sun, M (reprint author), Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, 264 Blvd Rene Levesque E,Suite 228, Montreal, PQ, Canada. EM mcw.sun@umontreal.ca NR 3 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 EI 1873-7560 J9 EUR UROL JI Eur. Urol. PD MAY PY 2014 VL 65 IS 5 BP 1014 EP 1015 DI 10.1016/j.eururo.2013.12.042 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA AD2JE UT WOS:000333060200036 PM 24646500 ER PT J AU Eyler, LT Vuoksimaa, E Panizzon, MS Fennema-Notestine, C Neale, MC Chen, CH Jak, A Franz, CE Lyons, MJ Thompson, WK Spoon, KM Fischl, B Dale, AM Kremen, WS AF Eyler, Lisa T. Vuoksimaa, Eero Panizzon, Matthew S. Fennema-Notestine, Christine Neale, Michael C. Chen, Chi-Hua Jak, Amy Franz, Carol E. Lyons, Michael J. Thompson, Wesley K. Spoon, Kelly M. Fischl, Bruce Dale, Anders M. Kremen, William S. TI Conceptual and Data-based Investigation of Genetic Influences and Brain Asymmetry: A Twin Study of Multiple Structural Phenotypes SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article ID CORTICAL SURFACE-AREA; HUMAN CEREBRAL-CORTEX; VIETNAM ERA TWIN; LIKELIHOOD RATIO TESTS; RESONANCE-IMAGING TWIN; ENVIRONMENTAL-INFLUENCES; MRI; THICKNESS; SEGMENTATION; METAANALYSES AB Right-left regional cerebral differences are a feature of the human brain linked to functional abilities, aging, and neurodevelopmental and mental disorders. The role of genetic factors in structural asymmetry has been incompletely studied. We analyzed data from 515 individuals (130 monozygotic twin pairs, 97 dizygotic pairs, and 61 unpaired twins) from the Vietnam Era Twin Study of Aging to answer three questions about genetic determinants of brain structural asymmetry: First, does the magnitude of heritability differ for homologous regions in each hemisphere? Despite adequate power to detect regional differences, heritability estimates were not significantly larger in one hemisphere versus the other, except left > right inferior lateral ventricle heritability. Second, do different genetic factors influence left and right hemisphere size in homologous regions? Interhemispheric genetic correlations were high and significant; in only two subcortical regions (pallidum and accumbens) did the estimate statistically differ from 1.0. Thus, there was little evidence for different genetic influences on left and right hemisphere regions. Third, to what extent do genetic factors influence variability in left-right size differences? There was no evidence that variation in asymmetry (i.e., the size difference) of left and right homologous regions was genetically determined, except in pallidum and accumbens. Our findings suggest that genetic factors do not play a significant role in determining individual variation in the degree of regional cortical size asymmetries measured with MRI, although they may do so for volume of some subcortical structures. Despite varying interpretations of existing data, we view the present results as consistent with previous findings. C1 [Eyler, Lisa T.; Vuoksimaa, Eero; Panizzon, Matthew S.; Fennema-Notestine, Christine; Chen, Chi-Hua; Jak, Amy; Franz, Carol E.; Thompson, Wesley K.; Spoon, Kelly M.; Dale, Anders M.; Kremen, William S.] Univ Calif San Diego, San Diego, CA 92103 USA. [Eyler, Lisa T.; Jak, Amy; Kremen, William S.] VA San Diego Healthcare Syst, San Diego, CA USA. [Vuoksimaa, Eero] Univ Helsinki, FIN-00014 Helsinki, Finland. [Neale, Michael C.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Lyons, Michael J.] Boston Univ, Boston, MA 02215 USA. [Spoon, Kelly M.] San Diego State Univ, Claremont Grad Univ, San Diego, CA 92182 USA. [Fischl, Bruce] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Fischl, Bruce] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Eyler, LT (reprint author), 9500 Gilman Dr,Mail Code 9151B, La Jolla, CA 92093 USA. EM lteyler@ucsd.edu OI Lyons, Michael/0000-0001-6516-9219; Fennema-Notestine, Christine/0000-0002-6527-6361 FU National Institutes of Health National Institute on Aging [U24 RR021382, R01 AG18386, R01 AG18384, R01 AG22381, R01 AG 22982]; National Institute for Mental Health [T32 MH20030]; National Institute for Drug Abuse [R01 DA18673]; VA Desert Pacific Mental Illness Research Education and Clinical Center; National Center for Research Resources [P41-RR14075]; National Center for Research Resources (NCRR BIRN Morphometric Project) [U24 RR021382, BIRN002]; National Institute for Biomedical Imaging and Bioengineering [R01 EB006758]; National Institute for Neurological Disorders and Stroke [R01 NS052585-01]; Ellison Medical Foundation; Sigrid Juselius Foundation; Academy of Finland [257075] FX This work was supported by the National Institutes of Health National Institute on Aging (grants U24 RR021382, R01 AG18386, R01 AG18384, R01 AG22381, and R01 AG 22982), National Institute for Mental Health (grant T32 MH20030), National Institute for Drug Abuse (grant R01 DA18673), and VA Desert Pacific Mental Illness Research Education and Clinical Center. Additional support was provided in part by the National Center for Research Resources (grants P41-RR14075 and the NCRR BIRN Morphometric Project BIRN002, U24 RR021382), the National Institute for Biomedical Imaging and Bioengineering (grant R01 EB006758), the National Institute for Neurological Disorders and Stroke (grant R01 NS052585-01), and the Autism and Dyslexia Project funded by the Ellison Medical Foundation. Support of Dr. Vuoksimaa was provided by the Sigrid Juselius Foundation and the Academy of Finland (grant 257075). The U.S. Department of Veterans Affairs and the VA Cooperative Studies Program have provided support for the development and maintenance of the VET Registry. Numerous other organizations have contributed to the VET Registry, including Department of Defense; National Personnel Records Center, National Archives and Records Administration; the Internal Revenue Service; National Institutes of Health; National Opinion Research Center; National Research Council, National Academy of Sciences; the Institute for Survey Research, Temple University; and Schulman, Ronca, and Bucuvalas, Inc. Most importantly, we gratefully acknowledge the cooperation and participation of the members of the VET Registry and their families. Without their contribution, this research would not have been possible. NR 60 TC 9 Z9 9 U1 1 U2 10 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X EI 1530-8898 J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD MAY PY 2014 VL 26 IS 5 BP 1100 EP 1117 DI 10.1162/jocn_a_00531 PG 18 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA AE0BF UT WOS:000333627800014 PM 24283492 ER PT J AU Bedard-Gilligan, M Cronce, JM Lehavot, K Blayney, JA Kaysen, D AF Bedard-Gilligan, Michele Cronce, Jessica M. Lehavot, Keren Blayney, Jessica A. Kaysen, Debra TI The Relationship Between Assault and Physical Health Complaints in a Sample of Female Drinkers Roles of Avoidant Coping and Alcohol Use SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE trauma exposure; physical health; PTSD; coping; college students; alcohol ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE BEHAVIORS; SEXUAL ASSAULT; COLLEGE-STUDENTS; RISK-FACTORS; SYMPTOM SEVERITY; DRINKING MOTIVES; PERCEIVED HEALTH; TRAUMA EXPOSURE; IMMUNE-SYSTEM AB Trauma exposure and PTSD are associated with poorer physical health. Psychological and behavioral mechanisms may help account for this relationship. In this study, we tested avoidant coping and alcohol use as mediators of the relationship between trauma exposure, PTSD, and self-reported physical health complaints in female drinkers. In 827 college women, we compared three groups: women with no trauma history, women with a sexual assault but no PTSD, and women with a sexual assault and PTSD, on avoidant coping, alcohol use, and physical health complaints. We found that PTSD was positively associated with alcohol use and that PTSD and trauma exposure were associated with increased avoidant coping. We also found that avoidant coping mediated the relationship between trauma, PTSD, and physical health complaints. Alcohol use did not predict physical health but was associated with PTSD. These results suggest that in female college students, coping may be more critical in the PTSD/physical health relationship than alcohol and have implications for targeting coping in young trauma-exposed women to improve physical health. C1 [Bedard-Gilligan, Michele; Cronce, Jessica M.; Kaysen, Debra] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lehavot, Keren; Blayney, Jessica A.] Univ Washington, Seattle, WA 98195 USA. [Kaysen, Debra] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Kaysen, Debra] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Lehavot, Keren] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. RP Bedard-Gilligan, M (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Box 354944, Seattle, WA 98195 USA. EM mab29@u.washington.edu FU NIAAA NIH HHS [R21 AA016211, F32 AA018609, F32 AA18609] NR 60 TC 3 Z9 3 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 EI 1552-6518 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD MAY PY 2014 VL 29 IS 8 BP 1359 EP 1379 DI 10.1177/0886260513507139 PG 21 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA AD6PD UT WOS:000333382400001 PM 24288191 ER PT J AU Gordon, RW Tirumani, H Kurra, V Shinagare, AB Jagannathan, JP Hornick, JL Ramaiya, NH AF Gordon, Robert W. Tirumani, Harsha Kurra, Vikram Shinagare, Atul B. Jagannathan, Jyothi P. Hornick, Jason L. Ramaiya, Nikhil H. TI MRI, MDCT features, and clinical outcome of extremity leiomyosarcomas: experience in 47 patients SO SKELETAL RADIOLOGY LA English DT Article DE Extremity leiomyosarcoma; Bone sarcoma; Soft-tissue sarcoma; MRI; Metastases ID SOFT-TISSUE SARCOMAS; SMOOTH-MUSCLE TUMORS; PROGNOSTIC-FACTORS; FRENCH-FEDERATION; IMAGING FEATURES; BONE AB Objective To describe MRI, MDCT features, and clinical outcome of extremity leiomyosarcomas (LMS). In this IRB-approved, HIPAA-compliant retrospective study, we included 47 patients (23 women, 24 men; mean age: 55.3 years, range: 17-85 years) with pathologically confirmed extremity LMS seen at our adult tertiary cancer center between 2000 and 2012. MRI/MDCT of primary tumors in 23 patients and follow-up in all patients were reviewed by two radiologists in consensus. Clinical data were extracted from electronic medical records. Primary tumors were distributed in bones (6 out of 47), deep soft tissues (24 out of 47), and superficial soft tissues (17 out of 47). On imaging (bone = 4, deep soft tissue = 11, superficial soft tissue = 8), compared with skeletal muscle, they were T1 iso-hypointense and T2 hyperintense. Bone LMS were metaphyseal tumors with cortical destruction (3 out of 4). Deep soft-tissue LMS were large with hemorrhage (7 out of 11) and necrosis (10 out of 11). Superficial soft-tissue LMS were relatively smaller, homogeneously enhancing (6 out of 8) tumors. Distant metastases developed in 32 out of 47 patients (bone LMS [6 out of 6], deep soft-tissue LMS [18 out of 24], superficial soft-tissue LMS [8 out of 17]), commonly to lung (29 out of 47) and bone (14 out of 47). At the time of writing, 22 out of 36 patients (bone LMS [4 out of 6], deep soft-tissue LMS [15 out of 24], superficial soft-tissue LMS [4 out of 17]) have died. There was no statistically significant correlation between metastatic disease and tumor size or grade. Extremity LMS arise in bones and in the deep and superficial soft tissues, frequently metastasize to the lungs, and have a poor prognosis. Superficial LMS tend to have a better prognosis than bone or deep soft-tissue LMS. C1 [Gordon, Robert W.; Tirumani, Harsha; Shinagare, Atul B.; Jagannathan, Jyothi P.; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Tirumani, Harsha; Kurra, Vikram; Jagannathan, Jyothi P.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA. [Hornick, Jason L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Tirumani, H (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA. EM Sreeharsha_Tirumani@DFCI.HARVARD.EDU NR 24 TC 4 Z9 4 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2348 EI 1432-2161 J9 SKELETAL RADIOL JI Skeletal Radiol. PD MAY PY 2014 VL 43 IS 5 BP 615 EP 622 DI 10.1007/s00256-014-1823-8 PG 8 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA AD4GM UT WOS:000333206200007 PM 24496586 ER PT J AU Glover, M Chebib, I Simeone, FJ AF Glover, McKinley Chebib, Ivan Simeone, F. Joseph TI Intra-articular fibroma of tendon sheath arising in the acromioclavicular joint SO SKELETAL RADIOLOGY LA English DT Article DE Acromioclavicular joint; Fibroma; Tendon sheath; Magnetic resonance imaging ID GIANT-CELL TUMOR; MR-IMAGING FEATURES; SOFT-TISSUE TUMORS; NODULAR FASCIITIS; RADIOLOGIC FINDINGS; KNEE-JOINT; TENOSYNOVITIS; ADULTS AB Fibroma of the tendon sheath, a rare benign soft tissue tumor that most often occurs in the distal upper extremities (hands and wrist), is exceedingly rare to present as an intraarticular mass. Presented here is the first case in the English literature, to our knowledge, of a fibroma of the tendon sheath arising in the acromioclavicular joint. The patient presented with recurrent shoulder pain with activity without antecedent trauma. Radiographs were essentially normal. MR images demonstrated a lobulated, heterogeneous mass with contrast enhancement arising from the acromioclavicular joint. Following surgical resection, histopathology revealed hypocellular collagen matrix with spindle-shaped fibroblasts, confirming the diagnosis of fibroma of tendon sheath. The imaging features of the fibroma of the tendon sheath and a brief review of the literature are presented. C1 [Glover, McKinley; Simeone, F. Joseph] Massachusetts Gen Hosp, Dept Musculoskeletal Imaging, Boston, MA 02114 USA. [Glover, McKinley; Chebib, Ivan; Simeone, F. Joseph] Harvard Univ, Sch Med, Boston, MA USA. [Chebib, Ivan] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA. RP Simeone, FJ (reprint author), Massachusetts Gen Hosp, Dept Musculoskeletal Imaging, Boston, MA 02114 USA. EM mglover2@partners.org; fsimeone@partners.org NR 34 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2348 EI 1432-2161 J9 SKELETAL RADIOL JI Skeletal Radiol. PD MAY PY 2014 VL 43 IS 5 BP 681 EP 686 DI 10.1007/s00256-013-1749-6 PG 6 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA AD4GM UT WOS:000333206200016 PM 24158770 ER PT J AU Ahmad, S Varagic, J Groban, L Dell'Italia, LJ Nagata, S Kon, ND Ferrario, CM AF Ahmad, Sarfaraz Varagic, Jasmina Groban, Leanne Dell'Italia, Louis J. Nagata, Sayaka Kon, Neal D. Ferrario, Carlos M. TI Angiotensin-(1-12): A Chymase-Mediated Cellular Angiotensin II Substrate SO CURRENT HYPERTENSION REPORTS LA English DT Article DE Angiotensin-(1-12); Angiotensin II; Angiotensin-(1-7); Cardiac chymase; Angiotensin-converting enzyme; Metabolism; Renin-angiotensin system; Angiotensinogen ID PLASMA-PROTEIN SUBSTRATE; CONVERTING ENZYME; BLOOD-PRESSURE; DOG HEART; PROANGIOTENSIN-12 PA12; INDEPENDENT MECHANISMS; CARDIOVASCULAR ACTIONS; DIASTOLIC DYSFUNCTION; MITRAL REGURGITATION; RECEPTOR BLOCKERS AB The classical view of biochemical pathways for the formation of biologically active angiotensins continues to undergo significant revision as new data uncovers the existence of important species differences between humans and rodents. The discovery of two novel substrates that, cleaved from angiotensinogen, can lead to direct tissue angiotensin II formation has the potential of radically altering our understanding of how tissues source angiotensin II production and explain the relative lack of efficacy that characterizes the use of angiotensin converting enzyme inhibitors in cardiovascular disease. This review addresses the discovery of angiotensin-(1-12) as an endogenous substrate for the production of biologically active angiotensin peptides by a non-renin dependent mechanism and the revealing role of cardiac chymase as the angiotensin II convertase in the human heart. This new information provides a renewed argument for exploring the role of chymase inhibitors in the correction of cardiac arrhythmias and left ventricular systolic and diastolic dysfunction. C1 [Ahmad, Sarfaraz; Varagic, Jasmina; Nagata, Sayaka; Ferrario, Carlos M.] Wake Forest Sch Med, Div Surg Sci, Winston Salem, NC 27157 USA. [Varagic, Jasmina; Groban, Leanne] Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC 27157 USA. [Varagic, Jasmina; Ferrario, Carlos M.] Wake Forest Sch Med, Dept Physiol Pharmacol, Winston Salem, NC 27157 USA. [Groban, Leanne] Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA. [Kon, Neal D.] Wake Forest Sch Med, Winston Salem, NC 27157 USA. [Ferrario, Carlos M.] Wake Forest Sch Med, Dept Internal Med Nephrol, Winston Salem, NC 27157 USA. [Dell'Italia, Louis J.] Univ Alabama Birmingham, Med Ctr, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Dell'Italia, Louis J.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Ferrario, CM (reprint author), Wake Forest Sch Med, Dept Internal Med Nephrol, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM cferrari@wakehealth.edu FU National Heart, Lung and Blood Institute [HL-051952]; National Institute on Aging of the NIH [AG042758, AG033727] FX Leanne Groban and Carlos M. Ferrario have declared that this work was supported by grants HL-051952 from the National Heart, Lung and Blood Institute and AG042758 (LG) and AG033727 (LG) from the National Institute on Aging of the NIH. NR 92 TC 9 Z9 9 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1522-6417 EI 1534-3111 J9 CURR HYPERTENS REP JI Curr. Hypertens. Rep. PD MAY PY 2014 VL 16 IS 5 AR 429 DI 10.1007/s11906-014-0429-9 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AD0XO UT WOS:000332957900004 PM 24633843 ER PT J AU Hasegawa, K Brenner, BE Clark, S Camargo, CA AF Hasegawa, Kohei Brenner, Barry E. Clark, Sunday Camargo, Carlos A., Jr. TI Emergency department visits for acute asthma by adults who ran out of their inhaled medications SO ALLERGY AND ASTHMA PROCEEDINGS LA English DT Article AB This study was designed to determine the percentage of asthma-related emergency department (ED) visits made by patients who recently ran out of their inhaled short-acting beta-agonists or inhaled corticosteroids and to characterize this understudied patient population. A secondary analysis was performed of data from four ED-based multicenter studies of acute asthma during 1996-1998 (n = 64 EDs). In each study, consecutive adult patients, aged 18-54 years, with acute asthma underwent a structured interview that assessed running out of inhaled medications. The analytic cohort comprised 1095 adults. Overall, 324 patients (30%; 95% confidence interval [CI], 27-32%) ran out of either of their inhaled beta-agonists or inhaled corticosteroids during the week before their index ED visit; 311 (28%; 95% CI, 26-31%) ran out of inhaled beta-agonists per se. Among a subset of 518 patients on inhaled corticosteroids, 55 patients (11%; 95% CI, 8-14%) ran out of inhaled corticosteroids. In the multivariable model, predictors of running out of an asthma medication were male sex, non-Hispanic black race, Hispanic ethnicity, no insurance, lower household income, and use of EDs as the preferred source of asthma prescriptions (all p < 0.05). Among patients who ran out of medications, 49% (95% CI, 43-55%) ran out of inhaled beta-agonists and 72% (95% CI, 58-84%) ran out of inhaled corticosteroids, before onset of their acute asthma symptoms. In 1095 adult ED patients with acute asthma, we found that 30% ran out of their inhaled asthma medications before the ED visit. Asthma patients who ran out of medications had sociodemographic characteristics that may help with identification of preventable ED visits. Multifaceted strategies needed to ensure optimal use of inhaled medications are warranted. C1 [Hasegawa, Kohei; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Brenner, Barry E.] Univ Hosp Case Med Ctr, Dept Emergency Med, Cleveland, OH USA. [Clark, Sunday] Weill Cornell Med Coll, Dept Emergency Med, New York, NY USA. RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM khasegawa1@partners.org FU National Institutes of Health (Bethesda, Maryland) [HL-63253]; Glaxo Wellcome, Inc. (Research Triangle Park, North Carolina); Monaghan Medical Corp. (Syracuse, New York); Teva (North Wales, Pennsylvania); Novartis FX Funded by grant HL-63253 from the National Institutes of Health (Bethesda, Maryland), and by unrestricted grants from Glaxo Wellcome, Inc. (Research Triangle Park, North Carolina) and Monaghan Medical Corp. (Syracuse, New York); the present analysis was funded by an unrestricted grant from Teva (North Wales, Pennsylvania); CA Camargo has provided asthma-related consultation for Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer, and received a research grant from Novartis to study emergency care of acute asthma. The remaining authors have no conflicts of interest to declare pertaining to this article NR 44 TC 3 Z9 3 U1 0 U2 0 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1088-5412 EI 1539-6304 J9 ALLERGY ASTHMA PROC JI Allergy Asthma Proc. PD MAY-JUN PY 2014 VL 35 IS 3 BP E42 EP E50 DI 10.2500/aap.2014.35.3747 PG 9 WC Allergy SC Allergy GA V43AW UT WOS:000209655300002 ER PT J AU D'Angelo, OM Simons, JC Gil, DD Gianatasio, C Rosow, C Pierce, E Eikermann, M AF D'Angelo, O. M. Simons, J. C. Gil, D. Diaz Gianatasio, C. Rosow, C. Pierce, E. Eikermann, M. TI ANESTHESIA AND INCREASED HYPERCARBIC DRIVE IMPAIR THE COORDINATION BETWEEN BREATHING AND SWALLOWING SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract CT Annual Meeting of the International-Anesthesia-Research-Society CY MAY 17-20, 2014 CL Montreal, CANADA SP Int Anesthesia Res Soc C1 [D'Angelo, O. M.; Simons, J. C.; Gil, D. Diaz; Gianatasio, C.; Rosow, C.; Pierce, E.; Eikermann, M.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-20 BP S20 EP S20 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600017 ER PT J AU Duarte, IM Haerter, F Simons, J Gill, DD Eikermann-Haerter, K Isaacs, L Matthias, E AF Duarte, I. Moreno Haerter, F. Simons, J. Gill, D. Diaz Eikermann-Haerter, K. Isaacs, L. Matthias, E. TI CALABADION II REVERSES STEROIDAL NEUROMUSCULAR BLOCKING AGENTS FASTER THAN SUGAMMADEX AND REVERSES THE EFFECTS OF BENZYLISOQUINOLINES, WITHOUT ALTERING THE EFFECTS OF SUCCINYLCHOLINE IN RATS SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract CT Annual Meeting of the International-Anesthesia-Research-Society CY MAY 17-20, 2014 CL Montreal, CANADA SP Int Anesthesia Res Soc C1 [Duarte, I. Moreno; Haerter, F.; Simons, J.; Gill, D. Diaz; Matthias, E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Eikermann-Haerter, K.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Isaacs, L.] Univ Maryland, Dept Chem & Biochem, Baltimore, MD 21201 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-50 BP S50 EP S50 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600043 ER PT J AU Feng, H Liu, K Jounaidi, Y Forman, SA AF Feng, H. Liu, K. Jounaidi, Y. Forman, S. A. TI DO DELTA SUBUNITS INTRODUCE ASYMMETRY IN GABA-A RECEPTOR ETOMIDATE SITES? SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract CT Annual Meeting of the International-Anesthesia-Research-Society CY MAY 17-20, 2014 CL Montreal, CANADA SP Int Anesthesia Res Soc C1 [Feng, H.; Liu, K.; Jounaidi, Y.; Forman, S. A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-35 BP S35 EP S35 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600030 ER PT J AU Hyder, JA Bohman, JK Kor, DJ Subramanian, A Bittner, EA Narr, BJ Montori, VM AF Hyder, J. A. Bohman, J. K. Kor, D. J. Subramanian, A. Bittner, E. A. Narr, B. J. Montori, V. M. TI TOO MANY COOKS IN THE KITCHEN? A COHORT STUDY OF ANESTHESIA PROVIDER VOLUME AND RISK OF POSTOPERATIVE COMPLICATIONS SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Hyder, J. A.; Bohman, J. K.; Kor, D. J.; Subramanian, A.; Narr, B. J.] Mayo Clin, Anesthesiol, Rochester, MN USA. [Bittner, E. A.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Montori, V. M.] Mayo Clin, Endocrinol, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-252 BP S252 EP S252 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600221 ER PT J AU Ishizawa, Y Patel, S Ahmed, OJ Sierra-Mercado, D Brown, EN AF Ishizawa, Y. Patel, S. Ahmed, O. J. Sierra-Mercado, D. Brown, E. N. TI DIFFERENTIAL NEURONAL DYNAMICS IN SOMATOSENSORY VERSUS HIGHER-ORDER CORTICES DURING RECOVERY FROM PROPOFOL ANESTHESIA IN PRIMATES SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Ishizawa, Y.; Brown, E. N.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Patel, S.; Sierra-Mercado, D.] Massachusetts Gen Hosp, Neurosurg, Boston, MA 02114 USA. [Ahmed, O. J.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-179 BP S179 EP S179 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600154 ER PT J AU Kenny, JD Ching, S Westovee, B Brown, EN Solt, K AF Kenny, J. D. Ching, S. Westovee, B. Brown, E. N. Solt, K. TI SEVOFLURANE AND PROPOFOL INDUCE DISTINCT EEG BURST-SUPPRESSION PATTERNS IN RATS SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Kenny, J. D.; Ching, S.; Brown, E. N.; Solt, K.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Westovee, B.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-158 BP S158 EP S158 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600135 ER PT J AU Ladha, KS Nanji, K Pierce, E Hyder, JA AF Ladha, K. S. Nanji, K. Pierce, E. Hyder, J. A. TI THE EFFECT OF PRE-DRAWN SYRINGES ON INTRAOPERATIVE MEDICATION USAGE SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Ladha, K. S.; Nanji, K.; Pierce, E.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Hyder, J. A.] Mayo Clin, Dept Anesthesiol, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-119 BP S119 EP S119 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600106 ER PT J AU Lee, S Yang, H Kim, Y Martyn, J AF Lee, S. Yang, H. Kim, Y. Martyn, J. TI PRE-BLOCK OF alpha 7ACHRS BY ITS SPECIFIC ANTAGONIST, METHYLLYCACONITINE (MLA) OBLITERATES THE IMMOBILIZATION-INDUCED RESISTANCE TO ROCURONIUM IN MICE SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Lee, S.] Inje Univ, Sanggye Paik Hosp, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea. [Yang, H.] Univ Ulsan, Dept Anesthesiol & Pain Med, Coll Med, Asan Med Ctr, Seoul, South Korea. [Kim, Y.] Gachon Univ Med & Sci, Dept Anesthesiol & Pain Med, Inchon, South Korea. [Martyn, J.] Mass Gen Hosp, Anesthesiol, Boston, MA USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-93 BP S93 EP S93 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600083 ER PT J AU McLean, DJ Igumenshcheva, AI Nimeh, T Ladha, KS Wanderer, JP Kurth, T Eikermann, M AF McLean, D. J. Igumenshcheva, A. I. Nimeh, T. Ladha, K. S. Wanderer, J. P. Kurth, T. Eikermann, M. TI LIBERAL INTRAOPERATIVE FLUID RESUSCITATION IS ASSOCIATED WITH REINTUBATION AND UNPLANNED MECHANICAL VENTILATION ON THE INTENSIVE CARE UNIT SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [McLean, D. J.; Igumenshcheva, A. I.; Nimeh, T.; Ladha, K. S.; Eikermann, M.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Wanderer, J. P.] Vanderbilt Univ, Anesthesia, Nashville, TN 37235 USA. [Kurth, T.] French Natl Inst Hlth & Med Res, INSERM, Bordeaux, France. NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-100 BP S100 EP S100 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600090 ER PT J AU Pavone, KJ Akeju, O Sampson, AL Ling, K Purdon, PL Brown, EN AF Pavone, K. J. Akeju, O. Sampson, A. L. Ling, K. Purdon, P. L. Brown, E. N. TI NITROUS OXIDE-INDUCED SLOW AND DELTA OSCILLATIONS SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Pavone, K. J.; Akeju, O.; Sampson, A. L.; Ling, K.; Purdon, P. L.; Brown, E. N.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-139 BP S139 EP S139 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600121 ER PT J AU Schumann, R George, E Gupta, A Ladd, D Bonney, I Ianchulev, S Pivalizza, EG AF Schumann, R. George, E. Gupta, A. Ladd, D. Bonney, I. Ianchulev, S. Pivalizza, E. G. TI OBJECTIVE POSTOPERATIVE VENTILATORY ASSESSMENT ALGORITHMS IN OBESE PATIENTS FOR PACU MONITORING SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Schumann, R.; Gupta, A.; Bonney, I.; Ianchulev, S.] Tufts Med Ctr, Anesthesiol, Boston, MA USA. [George, E.] Massachusetts Gen Hosp, Anesthesiol, Boston, MA 02114 USA. [Ladd, D.] West Virginia Univ, R&D, Morgantown, WV USA. [Pivalizza, E. G.] Univ Texas Houston, Sch Med, Anesthesiol, Houston, TX USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-234 BP S234 EP S234 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600203 ER PT J AU Shanechi, M Chemali, J Liberman, M Solt, K Brown, EN AF Shanechi, M. Chemali, J. Liberman, M. Solt, K. Brown, E. N. TI CONTROL OF BURST-SUPPRESSION IN A RODENT MODEL OF MEDICAL COMA USING A BRAIN-MACHINE INTERFACE SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Shanechi, M.] Cornell Univ, Elect & Comp Engn, Ithaca, NY USA. [Chemali, J.; Liberman, M.; Solt, K.; Brown, E. N.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-319 BP S319 EP S319 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600282 ER PT J AU Smith, MM Mauermann, WJ Cook, DJ Hyder, JA Barbara, DW AF Smith, M. M. Mauermann, W. J. Cook, D. J. Hyder, J. A. Barbara, D. W. TI SAME DAY CANCELLATION OF CARDAC SURGERY: A RETROSPECTIVE REVIEW AT A LARGE ACADEMIC TERTIARY REFERRAL CENTER SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Smith, M. M.; Mauermann, W. J.; Cook, D. J.; Barbara, D. W.] Mayo Clin, Anesthesiol, Rochester, MN USA. [Hyder, J. A.] Massachusetts Gen Hosp, Anesthesiol, Boston, MA 02114 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-66 BP S66 EP S66 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600057 ER PT J AU Vijjeswarapu, M Kuo, AS Philip, JH AF Vijjeswarapu, M. Kuo, A. S. Philip, J. H. TI INHALATIONAL INDUCTION FOR DIFFICULT AIRWAY, FACTORS AFFECTING SPONTANEOUS AIRWAY RECOVERY AFTER OBSTRUCTION: A COMPUTATIONAL SIMULATION SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Vijjeswarapu, M.; Philip, J. H.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA. [Kuo, A. S.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-310 BP S310 EP + PG 2 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600274 ER PT J AU Yarmush, L AF Yarmush, L. TI VALIDATING A VETERANS AFFAIRS PERIOPERATIVE SURGICAL HOME: OPTIMIZING PATIENTS WITH CORONARY ARTERY DISEASE IN THE PREOPERATIVE CLINIC SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Yarmush, L.] Houston VAMC, Anesthesiol, Houston, TX USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-127 BP S127 EP S127 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600113 ER PT J AU Zou, L Feng, Y Li, D Cai, J Chao, W AF Zou, L. Feng, Y. Li, D. Cai, J. Chao, W. TI COMPLEMENT FACTOR B ACTS DOWNSTREAM OF TLR3 SIGNALING IN THE HEART IN A MOUSE MODEL OF POLYMICROBIAL SEPSIS SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 [Zou, L.; Feng, Y.; Li, D.; Cai, J.; Chao, W.] Harvard Med Sc, Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2014 VL 118 SU 1 MA S-95 BP S95 EP S95 PG 1 WC Anesthesiology SC Anesthesiology GA V45PD UT WOS:000209827600085 ER PT J AU Xie, ZC Swain, CA Ward, SAP Zheng, H Dong, YL Sunder, N Burke, DW Escobar, D Zhang, YY Marcantonio, ER AF Xie, Zhongcong Swain, Celeste A. Ward, Sarah A. P. Zheng, Hui Dong, Yuanlin Sunder, Neelakantan Burke, Dennis W. Escobar, Diana Zhang, Yiying Marcantonio, Edward R. TI Preoperative cerebrospinal fluid beta-Amyloid/Tau ratio and postoperative delirium SO ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY LA English DT Article AB Objective: The neuropathogenesis of postoperative delirium remains unknown. Low cerebrospinal fluid (CSF) beta-amyloid protein (A beta) and high CSF Tau levels are associated with Alzheimer's disease. We, therefore, assessed whether lower preoperative CSF A beta/Tau ratio was associated with higher incidence and greater severity of postoperative delirium. Methods: One hundred and fifty-three participants (71 +/- 5 years, 53% men) who had total hip/knee replacement under spinal anesthesia were enrolled. CSF was obtained during initiation of spinal anesthesia. The incidence and severity of postoperative delirium were determined by Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS) on postoperative day 1 and 2. A beta 40, A beta 42, and Tau levels in the CSF were measured by enzyme-linked immunosorbent assay. The relationships among these variables were determined, adjusting for age and gender. Results: Participants in the lowest quartile of preoperative CSF A beta 40/Tau and A beta 42/Tau ratio had higher incidence (32% vs. 17%, P = 0.0482) and greater symptom severity of postoperative delirium (A beta 40/Tau ratio: 4 vs. 3, P = 0.034; A beta 42/Tau ratio: 4 vs. 3, P = 0.062, the median of the highest MDAS score) as compared to the combination of the rest of the quartiles. The preoperative CSF A beta 40/Tau or A beta 42/Tau ratio was inversely associated with MDAS score (A beta 40/Tau ratio: -.12 +/- 0.05, P = 0.014, adj. -0.12 +/- 0.05, P = 0.018; Ab42/Tau ratio: -0.65 +/- 0.26, P = 0.013, adj. -0.62 +/- 0.27, P = 0.022). Interpretation: Lower CSF A beta/Tau ratio could be associated with postoperative delirium, pending confirmation of our preliminary results in further studies. These findings suggest potential roles of A beta and/or Tau in postoperative delirium neuropathogenesis. C1 [Xie, Zhongcong; Swain, Celeste A.; Ward, Sarah A. P.; Dong, Yuanlin; Escobar, Diana; Zhang, Yiying] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, 149 13th St,Room 4310, Charlestown, MA 02129 USA. [Xie, Zhongcong; Swain, Celeste A.; Ward, Sarah A. P.; Dong, Yuanlin; Escobar, Diana; Zhang, Yiying] Harvard Med Sch, Charlestown, MA 02129 USA. [Zheng, Hui] Massachusetts Gen Hosp, MGH Biostat Ctr, Boston, MA 02114 USA. [Zheng, Hui; Sunder, Neelakantan; Burke, Dennis W.] Harvard Med Sch, Boston, MA 02114 USA. [Sunder, Neelakantan] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Burke, Dennis W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Marcantonio, Edward R.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med, Boston, MA 02215 USA. [Marcantonio, Edward R.] Beth Israel Deaconess Med Ctr, Dept Med, Div Primary Care & Gerontol, Boston, MA 02215 USA. [Marcantonio, Edward R.] Harvard Med Sch, Boston, MA 02215 USA. RP Xie, ZC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, 149 13th St,Room 4310, Charlestown, MA 02129 USA. EM zxie@mgh.harvard.edu FU NIA NIH HHS [R21 AG038994, K24 AG035075, P01 AG031720, R01 AG030618, R01 AG041274, R21 AG029856]; NIGMS NIH HHS [R01 GM088801] NR 50 TC 4 Z9 4 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2328-9503 J9 ANN CLIN TRANSL NEUR JI Ann. Clin. Transl. Neurol. PD MAY PY 2014 VL 1 IS 5 BP 319 EP 328 DI 10.1002/acn3.58 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V45KH UT WOS:000209815000002 PM 24860840 ER PT J AU Waubant, E Maghzi, AH Revirajan, N Spain, R Julian, L Mowry, EM Marcus, J Liu, S Jin, CS Green, A McCulloch, CE Pelletier, D AF Waubant, Emmanuelle Maghzi, Amir-Hadi Revirajan, Nisha Spain, Rebecca Julian, Laura Mowry, Ellen M. Marcus, Jacqueline Liu, Shuang Jin, Chengshi Green, Ari McCulloch, Charles E. Pelletier, Daniel TI A randomized controlled phase II trial of riluzole in early multiple sclerosis SO ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY LA English DT Article AB Objectives: We evaluated the effect of riluzole versus placebo added to weekly IM interferon beta-1a in early multiple sclerosis (MS). Methods: This is a randomized (1: 1), double-blind, placebo-controlled trial of riluzole 50 mg twice daily in subjects with MS onset less than 1 year prior. Trial participation was up to 3 years. The primary endpoint was change in percent brain volume change. Secondary endpoints included changes in normalized gray and normal-appearing white matter volumes, retinal nerve fiber layer thickness (RNFL), MS Functional Composite and Symbol Digit Modalities Test scores. Mixed model regression analysis was used to compare the changes over time between groups. Results: Forty-three subjects were randomized to study drug (22 riluzole, 21 placebo). Baseline characteristics were overall similar between groups except for older age (P = 0.042), higher normalized cerebrospinal fluid volume (P = 0.050), lower normalized gray matter volume (P = 0.14), and thinner RNFL (P = 0.043) in the riluzole group. In the primary analysis, percent brain volume change in the placebo group decreased at a rate of 0.49% per year whereas the riluzole group decreased by 0.86% per year (0.37% more per year; 95% CI - 0.78, 0.024; P = 0.065). Although age did not influence the rate of brain volume decline, the difference between groups was attenuated after adjustment for baseline normalized gray matter and lesion volume (0.26% more per year in riluzole group; 95% CI - 0.057, 0.014; P = 0.22). Analyses of secondary outcomes showed no differences between groups. Interpretation: This trial provides class 1 evidence that riluzole treatment does not meaningfully reduce brain atrophy progression in early MS. C1 [Waubant, Emmanuelle; Maghzi, Amir-Hadi; Revirajan, Nisha; Julian, Laura; Marcus, Jacqueline; Green, Ari] Univ Calif San Francisco, Dept Neurol, MS Ctr, San Francisco, CA USA. [Waubant, Emmanuelle] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Spain, Rebecca] Portland VA Med Ctr, Portland, OR USA. [Spain, Rebecca] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Mowry, Ellen M.] Hopkins MS Ctr, Dept Neurol, Baltimore, MD USA. [Liu, Shuang; Pelletier, Daniel] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. [Jin, Chengshi; McCulloch, Charles E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Green, Ari] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. RP Waubant, E (reprint author), Neurosci Bldg,675 Nelson Rising Lane,Room 215B, San Francisco, CA 94158 USA. EM Emmanuelle.waubant@ucsf.edu NR 29 TC 10 Z9 10 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2328-9503 J9 ANN CLIN TRANSL NEUR JI Ann. Clin. Transl. Neurol. PD MAY PY 2014 VL 1 IS 5 BP 340 EP 347 DI 10.1002/acn3.60 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V45KH UT WOS:000209815000004 PM 25356404 ER PT J AU Chamoto, K Imataki, O Guo, TX Saito, T Saito, A Elia, A Chiu, P Butler, M Hirano, N AF Chamoto, Kenji Imataki, Osamu Guo, Tingxi Saito, Toshiki Saito, Akiko Elia, Andrew Chiu, Priscilla Butler, Marcus Hirano, Naoto TI Human peripheral invariant natural killer T are adaptive lymphocytes, whose TCR CDR3 beta regulates their antigen specificity and reactivity to avoid harmful autoimmune responses SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Chamoto, Kenji; Guo, Tingxi; Elia, Andrew; Butler, Marcus] Margaret Canc Ctr, Ontario Canc Inst, Toronto, ON, Canada. [Imataki, Osamu] Dana Farber Canc Inst, Boston, MA 02115 USA. [Saito, Toshiki; Saito, Akiko] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan. [Chiu, Priscilla] Hosp Sick Children, Torontot, ON, Canada. [Chiu, Priscilla; Butler, Marcus; Hirano, Naoto] Univ Toronto, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA BA8P.124 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765005178 ER PT J AU Chiang, HS Zhao, Y Song, JH Liu, S Wang, NH Terhorst, C Sharpe, A Basavappa, M Jeffrey, K Reinecker, HC AF Chiang, Hao-Sen Zhao, Yun Song, Joo-Hye Liu, Song Wang, Ninghai Terhorst, Cox Sharpe, Arlene Basavappa, Megha Jeffrey, Kate Reinecker, Hans-Christian TI Control of microtubule-dependent activation of nucleic acid sensors for antiviral host defenses SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Chiang, Hao-Sen; Zhao, Yun; Song, Joo-Hye; Liu, Song; Basavappa, Megha; Jeffrey, Kate; Reinecker, Hans-Christian] Harvard Med Sch, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA USA. [Chiang, Hao-Sen; Zhao, Yun; Song, Joo-Hye; Liu, Song; Basavappa, Megha; Jeffrey, Kate; Reinecker, Hans-Christian] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA USA. [Wang, Ninghai; Terhorst, Cox] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Immunol, Boston, MA USA. [Wang, Ninghai; Terhorst, Cox] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Study Inflammatory Bowel Dis, Boston, MA USA. [Sharpe, Arlene] Harvard Med Sch, Dept Microbiol & Immunol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA INM6P.419 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002091 ER PT J AU Cunningham, M Wirth, J Eudaly, J Gilkeson, G AF Cunningham, Melissa Wirth, Jena Eudaly, Jackie Gilkeson, Gary TI Decreased inflammatory dendritic cells in lupus prone ER alpha KO mice correlate with increased survival SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Cunningham, Melissa; Wirth, Jena; Eudaly, Jackie; Gilkeson, Gary] Med Univ SC, Med Rheumatol & Immunol, Charleston, SC USA. [Gilkeson, Gary] Ralph H Johnson VA Hosp, Med Rheumatol & Immunol, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA BA4P.214 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002195 ER PT J AU Das, A Dwivedi, N Chatterjee, P Carroll, M AF Das, Abhishek Dwivedi, Nishant Chatterjee, Priyadarshini Carroll, Michael TI Regulation of lupus-antigen specific B cells by follicular dendritic cells SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Das, Abhishek; Dwivedi, Nishant; Carroll, Michael] Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA USA. [Chatterjee, Priyadarshini] Reg Ctr Biotechnol, Gurgaon, India. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA BA12P.113 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002138 ER PT J AU Fishman, J Moise, L LeBlanc, P Brauns, T Berg, E Richer, D Boyle, C De Groot, A Martin, B Baker, D Zeigler, B Mais, D Taylor, W Coleman, R Shaw, W Gelfand, J Poznansky, M AF Fishman, Jordan Moise, Leonard LeBlanc, Pierre Brauns, Timothy Berg, Eric Richer, Daniel Boyle, Christine De Groot, Anne Martin, Bill Baker, David Zeigler, Brandon Mais, Dale Taylor, William Coleman, Russell Shaw, Warren Gelfand, Jeffrey Poznansky, Mark TI VaxCelerate: the use of MTBhsp70-avidin as an adjuvant to rapidly generate self-assembling vaccines with biotinylated, antigen-specific peptides targeting emerging pathogens. SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Fishman, Jordan; Berg, Eric] 21st Century Biochem Inc, Marlborough, MA USA. [Moise, Leonard; Boyle, Christine; De Groot, Anne; Martin, Bill] EpiVax, Providence, RI USA. [LeBlanc, Pierre; Brauns, Timothy; Richer, Daniel; Gelfand, Jeffrey; Poznansky, Mark] Massachusetts Gen Hosp, Vaccine & Immunotherapy Ctr, Charlestown, MA USA. [Shaw, Warren] Massachusetts Gen Hosp, Pediat & Infect Dis, Boston, MA 02114 USA. [Baker, David] Univ Washington, Seattle, WA 98195 USA. [Zeigler, Brandon; Mais, Dale] MPI Res, Mattawan, MI USA. [Taylor, William; Coleman, Russell] Pfenex, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA VAC6P.941 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765000068 ER PT J AU Flynn, R Dubovsky, J Harrington, B Reichenbach, D Zhong, YM Yang, C Towns, W Lehman, A Johnson, A Muthusamy, N Devine, S Jaglowski, S Serody, J Murphy, W Munn, D Luznik, L Maillard, I Koreth, J Cutler, C Soiffer, R Anne, J Ritz, J Panoskaltsis-Mortari, A Byrd, J Blazar, B AF Flynn, Ryan Dubovsky, Jason Harrington, Bonnie Reichenbach, Dawn Zhong Yiming Yang, Carrie Towns, Will Lehman, Amy Johnson, Amy Muthusamy, Natarajan Devine, Steven Jaglowski, Samantha Serody, Jonathan Murphy, William Munn, David Luznik, Leo Maillard, Ivan Koreth, John Cutler, Corey Soiffer, Robert Anne, Joseph Ritz, Jerome Panoskaltsis-Mortari, Angela Byrd, John Blazar, Bruce TI Therapeutic treatment of multi-organ system, obstructive pulmonary and scleradermatous chronic graft-versus-host disease with the BTK and ITK inhibitor Ibrutinib SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Flynn, Ryan; Reichenbach, Dawn; Panoskaltsis-Mortari, Angela; Blazar, Bruce] Univ Minnesota, Minneapolis, MN USA. [Dubovsky, Jason; Harrington, Bonnie; Zhong Yiming; Yang, Carrie; Towns, Will; Lehman, Amy; Johnson, Amy; Muthusamy, Natarajan; Devine, Steven; Jaglowski, Samantha; Byrd, John] Ohio State Univ, Columbus, OH 43210 USA. [Serody, Jonathan] Univ N Carolina, Cahpel Hill, NC USA. [Murphy, William] Univ Calif Davis, Sacramento, CA 95817 USA. [Munn, David] Med Coll Georgia, Augusta, GA 30912 USA. [Luznik, Leo] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Maillard, Ivan] Univ Michigan, Ann Arbor, MI 48109 USA. [Koreth, John; Cutler, Corey; Soiffer, Robert; Anne, Joseph; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA TRAN3P.873 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765006179 ER PT J AU Gupta, N Pore, D Parameswaran, N Matsui, K Stone, M Saotome, I McClatchey, A Veatch, S AF Gupta, Neetu Pore, Debasis Parameswaran, Neetha Matsui, Ken Stone, Matthew Saotome, Ichiko McClatchey, Andrea Veatch, Sarah TI Ezrin tunes the magnitude of humoral immunity. SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Gupta, Neetu; Pore, Debasis; Parameswaran, Neetha; Matsui, Ken] Cleveland Clin, Cleveland, OH 44106 USA. [Stone, Matthew; Veatch, Sarah] Univ Michigan, Ann Arbor, MI 48109 USA. [Saotome, Ichiko; McClatchey, Andrea] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA IRM8P.709 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765003232 ER PT J AU Hamilton, J Li, J Wu, Q Yang, P Luo, B Bradley, J Taylor, J Randall, T Mountz, J Hsu, HC AF Hamilton, Jennie Li, Jun Wu, Qi Yang, PingAr Luo, Bao Bradley, John Taylor, Justin Randall, Troy Mountz, John Hsu, Hui-Chen TI Autoreactive B cell tetramer analysis reveals a type I interferon-mediated marginal zone precursor B cell defect in autoimmune BXD2 mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Hamilton, Jennie; Li, Jun; Wu, Qi; Yang, PingAr; Luo, Bao; Bradley, John; Randall, Troy; Mountz, John; Hsu, Hui-Chen] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Taylor, Justin] Univ Minnesota, Sch Med, Ctr Immunol, Dept Microbiol, Minneapolis, MN 55455 USA. [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA BA12P.102 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002136 ER PT J AU Hou, LF Cooley, J Remold-O'Donnell, E AF Hou, Lifei Cooley, Jessica Remold-O'Donnell, Eileen TI T cell intrinsic SerpinB1 and a cathepsin protease serve as yin and yang to control Th17 differentiation SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Hou, Lifei; Cooley, Jessica; Remold-O'Donnell, Eileen] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. [Remold-O'Donnell, Eileen] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Hou, Lifei; Remold-O'Donnell, Eileen] Harvard Med Sch, Dept Pediat, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA LYM3P.732 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765000132 ER PT J AU Jie, HB Schuler, P Lee, S Srivastava, R Argiris, A Ferrone, S Whiteside, T Ferris, R AF Jie, Hyun-Bae Schuler, Patrick Lee, Steve Srivastava, Raghvendra Argiris, Athanassios Ferrone, Soldano Whiteside, Theresa Ferris, Robert TI CTLA-4+regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Jie, Hyun-Bae; Lee, Steve; Srivastava, Raghvendra; Whiteside, Theresa; Ferris, Robert] Univ Pittsburgh, Otolaryngol, Pittsburgh, PA USA. [Schuler, Patrick] Univ Duisburg Essen, Otorhinolaryngol, Essen, Germany. [Argiris, Athanassios] UT Hlth Sci Ctr San Antonio, Med, San Antonio, TX USA. [Ferrone, Soldano] Massachusetts Gen Hosp, Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA TUM2P.916 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765001208 ER PT J AU Jones, J Brandmaier, A Umetsu, S Bu, X Umetsu, D DeKruyff, R Freeman, G AF Jones, Jennifer Brandmaier, Andrew Umetsu, Sarah Bu, Xia Umetsu, Dale DeKruyff, Rosemarie Freeman, Gordon TI Evolutionary origins and structural analysis of phosphatidylserine binding by the TIM gene family SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Jones, Jennifer; Brandmaier, Andrew] NCI, NIH, Bethesda, MD 20892 USA. [Bu, Xia; Freeman, Gordon] DFCI, Boston, MA USA. [Umetsu, Sarah] UCSF, San Francisco, CA USA. [Umetsu, Dale; DeKruyff, Rosemarie] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA CAM5P.244 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002110 ER PT J AU Kaplan, D Tanoue, S AF Kaplan, David Tanoue, Shiroh TI Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Kaplan, David] Philadelphia VA Med Ctr, Gastroenterol, Philadelphia, PA USA. [Kaplan, David; Tanoue, Shiroh] Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA HUM7P.290 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765000208 ER PT J AU King, K Patel, S Yarmush, M Weissleder, R AF King, Kevin Patel, Suraj Yarmush, Martin Weissleder, Ralph TI Cyclic dinucleotides mediate gap junction-dependent spread of DNA-induced IRF3 activation. SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [King, Kevin] Brigham & Womens Hosp, Cardiovasc Med, Waltham, MA USA. [King, Kevin; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Patel, Suraj; Yarmush, Martin] Shriners Hosp Children, Surg, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA IRM9P.729 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765004013 ER PT J AU Li, H Wu, Q Li, J Yang, PA Luo, B Edberg, J Hsu, HC Mountz, J AF Li, Hao Wu, Qi Li, Jun Yang, PingAr Luo, Bao Edberg, Jeffrey Hsu, Hui-Chen Mountz, John TI Anti-scavenger receptor immune complexes disrupted marginal zone macrophage integrity via bruton's tyrosine kinase SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Li, Hao; Mountz, John] Univ Alabama Birmingham, Microbiol, Birmingham, AL USA. [Li, Hao; Wu, Qi; Li, Jun; Yang, PingAr; Luo, Bao; Edberg, Jeffrey; Hsu, Hui-Chen; Mountz, John] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL USA. [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA BA4P.213 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002198 ER PT J AU Li, H Hsu, HC Wu, Q Yang, PA Li, J Luo, B Fu, YX Zhou, Y Mountz, J AF Li, Hao Hsu, Hui-Chen Wu, Qi Yang, PingAr Li, Jun Luo, Bao Fu, Yang-Xin Zhou, Yong Mountz, John TI Lymphotoxin-expressing marginal zone B cells support marginal zone integrity by maintaining the megakaryoblastic leukemia-1 expression SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Li, Hao; Mountz, John] Univ Alabama Birmingham, Microbiol, Birmingham, AL USA. [Li, Hao; Hsu, Hui-Chen; Wu, Qi; Yang, PingAr; Li, Jun; Luo, Bao; Mountz, John] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL USA. [Fu, Yang-Xin] Univ Chicago, Pathol, Chicago, IL 60637 USA. [Zhou, Yong] Univ Alabama Birmingham, Div Pulm, Birmingham, AL USA. [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA BA4P.221 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002200 ER PT J AU Li, J Hsu, HC Yang, PA Wu, Q Luo, B Mobley, J Bridges, S Mountz, J AF Li, Jun Hsu, Hui-Chen Yang, PingAr Wu, Qi Luo, Bao Mobley, James Bridges, S. Mountz, John TI Identification of a novel epigenetic code, histone H1 fucosylation, and its roles in macrophage plasticity in rheumatoid arthritis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Li, Jun; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Luo, Bao; Mobley, James; Bridges, S.; Mountz, John] UAB, Med, Birmingham, AL USA. [Hsu, Hui-Chen; Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA IRM7P.491 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765000111 ER PT J AU Marino, J Tocco, G Mordecai, S Benichou, G AF Marino, Jose Tocco, Georges Mordecai, Scott Benichou, Gilles TI Trafficking of intra-graft T cells to recipients' lymphoid organs after skin transplantation SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Marino, Jose; Tocco, Georges; Benichou, Gilles] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA. [Mordecai, Scott] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol Flow & Imaging Cytometry Core, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA TRAN3P.916 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765006163 ER PT J AU Moon, J Lim, JB Legoux, F AF Moon, James Lim, Jong-Baeck Legoux, Francois TI Tissue-specific tolerance of endogenous self antigen-specific CD4+T cells SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Moon, James; Lim, Jong-Baeck; Legoux, Francois] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA. [Moon, James; Legoux, Francois] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA IRC4P.484 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765005026 ER PT J AU Penaloza-MacMaster, P Barber, D Wherry, J Provine, N Teigler, J Blackmore, S Borducchi, E Bronson, R Barouch, D AF Penaloza-MacMaster, Pablo Barber, Daniel Wherry, John Provine, Nicholas Teigler, Jeffrey Blackmore, Steven Borducchi, Erica Bronson, Roderick Barouch, Dan TI Vaccine induced immunopathology mediated by memory CD4 T cells following chronic viral infection SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Penaloza-MacMaster, Pablo; Provine, Nicholas; Teigler, Jeffrey; Blackmore, Steven; Borducchi, Erica; Barouch, Dan] Harvard Univ, BIDMC, Boston, MA 02115 USA. [Barber, Daniel] NIAID, Lab Parasit Dis, Bethesda, MD 20892 USA. [Wherry, John] Univ Penn, Dept Microbiol 3, Philadelphia, PA 19104 USA. [Wherry, John] Univ Penn, Inst Immunol, Philadelphia, PA 19104 USA. [Bronson, Roderick] Harvard Med Sch, Mouse Histopathol Core, Boston, MA USA. [Barouch, Dan] Ragon Inst MGH MIT & Harvard, MGH MIT & Harvard, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA VIR7P.1054 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765000021 ER PT J AU Pepper, M Hondowicz, B Moon, J AF Pepper, Marion Hondowicz, Brian Moon, James TI Allergen-specific lung resident CD4+Th2 cells in asthma SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Pepper, Marion; Hondowicz, Brian] Univ Washington, Immunol, Seattle, WA 98195 USA. [Moon, James] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA HYP4P.417 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765003016 ER PT J AU Provine, N Larocca, R Penaloza-MacMaster, P Borducchi, E Haining, W Barouch, D AF Provine, Nicholas Larocca, Rafael Penaloza-MacMaster, Pablo Borducchi, Erica Haining, W. Barouch, Dan TI Aberrant differentiation and exhaustion of adenovirus vaccine-elicited CD8 T cells primed in the absence of CD4 T cells SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Provine, Nicholas; Larocca, Rafael; Penaloza-MacMaster, Pablo; Borducchi, Erica; Barouch, Dan] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA. [Haining, W.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. [Barouch, Dan] Ragon Inst MGH MIT & Harvard, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA VAC3P.940 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765004191 ER PT J AU Qin, M Park, A Agak, G Garban, H Kim, J AF Qin, Min Park, Andrew Agak, George Garban, Hermes Kim, Jenny TI Dual role of Interleukin-37 in the regulation of inflammation triggered by Propionibacterium acnes in human monocytes SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Qin, Min; Park, Andrew; Agak, George; Garban, Hermes; Kim, Jenny] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA. [Kim, Jenny] Greater Los Angeles Vet Affairs Healthcare Syst, Dermatol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA INM8P.450 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765004131 ER PT J AU Richard, ML Sato, S Suzuki, E Williams, S Nowling, T Zhaug, X AF Richard, Mara Lennard Sato, Shuzo Suzuki, Eiji Williams, Sarah Nowling, Tamara Zhaug, Xian TI Identification of Fli-1 as a novel regulator of the inflammatory chemokine CCL5/RANTES SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Richard, Mara Lennard; Sato, Shuzo; Suzuki, Eiji; Nowling, Tamara; Zhaug, Xian] Med Univ South Carolina, Med, Charleston, SC USA. [Richard, Mara Lennard; Sato, Shuzo; Suzuki, Eiji; Nowling, Tamara; Zhaug, Xian] Med Univ South Carolina, Div Rheumatol & Immunol, Charleston, SC USA. [Williams, Sarah; Nowling, Tamara] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA CCR5P.253 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765003187 ER PT J AU Robins, H Muraro, P Malhotra, S Howell, M Phippard, D Desmarais, C Sousa, ADA Griffith, L Lim, N Nash, R Turka, L AF Robins, Harlan Muraro, Paolo Malhotra, Sachin Howell, Michael Phippard, Deborah Desmarais, Cindy Sousa, Alessandra de Paula Alves Griffith, Linda Lim, Noha Nash, Richard Turka, Laurence TI T cell repertoire renewal following autologous stem cell transplantation for multiple sclerosis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Robins, Harlan] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Muraro, Paolo; Sousa, Alessandra de Paula Alves] Imperial Coll, Div Brain Sci, Dept Med, London, England. [Malhotra, Sachin; Howell, Michael; Phippard, Deborah; Lim, Noha; Turka, Laurence] Immune Tolerance Network, Bethesda, MD USA. [Griffith, Linda] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA. [Nash, Richard] PSL, Colorado Blood Ctr Inst, Denver, CO USA. [Turka, Laurence] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Turka, Laurence] Harvard Med Sch, Boston, MA USA. [Robins, Harlan; Desmarais, Cindy] Adapt Biotechnol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA THER3P.879 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765001242 ER PT J AU Stelekati, E Shin, H Doering, T Dolfi, D Ziegler, C Beiting, D Dawson, L Liboon, J Wolski, D Ali, MA Katsikis, P Shen, H Roos, D Haining, W Lauer, G Wherry, J AF Stelekati, Erietta Shin, Haina Doering, Travis Dolfi, Douglas Ziegler, Carly Beiting, Daniel Dawson, Lucas Liboon, Jennifer Wolski, David Ali, Mohammed-Alkhatim Katsikis, Peter Shen, Hao Roos, David Haining, W. Lauer, Georg Wherry, John TI Altered CD8 T cell memory development in the presence of bystander chronic infections and inflammation SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Stelekati, Erietta; Shin, Haina; Doering, Travis; Dolfi, Douglas; Ziegler, Carly; Dawson, Lucas; Liboon, Jennifer; Ali, Mohammed-Alkhatim; Shen, Hao; Wherry, John] Univ Penn, Microbiol, Philadelphia, PA 19104 USA. [Beiting, Daniel; Roos, David] Univ Penn, Biol, Philadelphia, PA 19104 USA. [Wolski, David; Lauer, Georg] Massachussetts Gen Hosp, Gastrointestinal Unit, Boston, MA USA. [Katsikis, Peter] Drexel Univ, Coll Med, Microbiol & Immunol, Philadelphi, PA USA. [Haining, W.] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA IRC9P.712 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765005153 ER PT J AU Watanabe, A Cain, D Hanson, M Kim, M Reinherz, E Irvine, D Kelsoe, G AF Watanabe, Akiko Cain, Derek Hanson, Melissa Kim, Mikyung Reinherz, Ellis Irvine, Darrell Kelsoe, Garnett TI Cellular mechanism for immunogenicity of PEGylated "stealth" liposomes SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Watanabe, Akiko; Cain, Derek; Kelsoe, Garnett] Duke Univ, Durham, NC USA. [Hanson, Melissa; Irvine, Darrell] MIT, Cambridge, MA 02139 USA. [Kim, Mikyung; Reinherz, Ellis] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA IRC3P.466 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765004174 ER PT J AU Weathington, N Snavely, C Zhao, J Chen, B Zhao, YT Mallampalli, R AF Weathington, Nathaniel Snavely, Courtney Zhao, Jing Chen, Bill Zhao, Yutong Mallampalli, Rama TI Interleukin 22 receptor abundance and signaling is regulated by the ubiquitin proteasome and glycogen synthase kinase 3 beta. SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Weathington, Nathaniel; Snavely, Courtney; Zhao, Jing; Chen, Bill; Zhao, Yutong; Mallampalli, Rama] Univ Pittsburgh, Pulm & Crit Care Med, Pittsburgh, PA USA. [Zhao, Yutong; Mallampalli, Rama] Univ Pittsburgh, Cell Biol, Pittsburgh, PA USA. [Mallampalli, Rama] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA INM2P.422 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765006126 ER PT J AU Xiao, YP Yu, SH Zhu, BG Bedoret, D Bu, X Francisco, L Hua, P Duke-Cohan, J Umetsu, D Sharpe, A DeKruyff, R Freeman, G AF Xiao, Yanping Yu, Sanhong Zhu, Baogong Bedoret, Denis Bu, Xia Francisco, Loise Hua, Ping Duke-Cohan, Jonathan Umetsu, Dale Sharpe, Arlene DeKruyff, Rosemarie Freeman, Gordon TI RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Xiao, Yanping; Zhu, Baogong; Bu, Xia; Hua, Ping; Duke-Cohan, Jonathan; Freeman, Gordon] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Yu, Sanhong; Bedoret, Denis; Umetsu, Dale; DeKruyff, Rosemarie] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA. [Yu, Sanhong; Bedoret, Denis; Umetsu, Dale; DeKruyff, Rosemarie] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Boston, MA USA. [Francisco, Loise; Sharpe, Arlene] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA USA. [Sharpe, Arlene] Harvard Med Sch, Brigham & VVomens Hosp, Dept Pathol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA IRC5P.465 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765004096 ER PT J AU Zhou, J Jin, JO Patel, ES Yu, Q AF Zhou, Jing Jin, Jun-O Patel, Ekta S. Yu, Qing TI Endogenous IL-6 protects exocrine gland integrity and restrains Thl immune responses in a mouse model of primary Sjogren's syndrome SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Zhou, Jing; Jin, Jun-O; Patel, Ekta S.; Yu, Qing] Forsyth Inst, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA HUM7P.309 PG 2 WC Immunology SC Immunology GA V44RB UT WOS:000209765000190 ER PT J AU Zhu, M DeFuria, J Carr, J Belkina, A Van Dyke, T Gyurko, R Nikolajczyk, B AF Zhu, Min DeFuria, Jason Carr, Jordan Belkina, Anna Van Dyke, Thomas Gyurko, Robert Nikolajczyk, Barbara TI B cells promote obesity-associated periodontitis and oral pathogen-associated inflammation SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Zhu, Min; DeFuria, Jason; Carr, Jordan; Belkina, Anna; Nikolajczyk, Barbara] Boston Univ, Microbiol, Boston, MA 02215 USA. [Gyurko, Robert] Boston Univ, Goldman Sch Dent Med, Periodontol, Boston, MA 02215 USA. [Van Dyke, Thomas] Forsyth Inst, Periodontol, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA IRC3P.461 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765004173 ER PT J AU Belov, V Levine, D Belova, E Mushti, C Bonab, A Fischman, A Papisov, M AF Belov, Vasily Levine, Dylan Belova, Elena Mushti, Chandra Bonab, Ali Fischman, Alan Papisov, Mikhail TI Pharmacological PET imaging performance with I-124 and Zr-89 SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Levine, Dylan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Belov, Vasily; Belova, Elena; Mushti, Chandra; Bonab, Ali; Fischman, Alan; Papisov, Mikhail] Shriners Hosp Children, Boston, MA USA. [Belov, Vasily; Belova, Elena; Mushti, Chandra; Bonab, Ali; Papisov, Mikhail] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 590 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101085 ER PT J AU Berenji, G Silverman, D AF Berenji, Gholam Silverman, Daniel TI Perception of sensory/perceptual deficits and cerebellar hypometabolism in recently deployed veterans with post traumatic stress disorder (PTSD) SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Silverman, Daniel] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA. [Berenji, Gholam] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1878 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438104039 ER PT J AU Berenji, G Silverman, D AF Berenji, Gholam Silverman, Daniel TI Perception of sensory/perceptual deficits and cerebellar hypometabolism in recently deployed veterans with post traumatic stress disorder (PTSD) SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Silverman, Daniel] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA. [Berenji, Gholam] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1878 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438103049 ER PT J AU Brand, C Abdel-Atti, D Zhang, YC Carlin, S Clardy, S Keliher, E Weber, W Lewis, J Reiner, T AF Brand, Christian Abdel-Atti, Dalya Zhang, Yachao Carlin, Sean Clardy, Susan Keliher, Edmund Weber, Wolfgang Lewis, Jason Reiner, Thomas TI Dual-modality imaging and quantification of GLP-1R positive insulinoma and pancreatic beta-cell mass using a bimodal PET/fluorescence exendin-4 peptide SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Brand, Christian; Abdel-Atti, Dalya; Zhang, Yachao; Carlin, Sean; Weber, Wolfgang; Lewis, Jason; Reiner, Thomas] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA. [Clardy, Susan; Keliher, Edmund] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1172 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101336 ER PT J AU Collier, T Akula, M Liang, S AF Collier, Thomas Akula, Murthy Liang, Steven TI Purification of radiotracers produced by both microfluidic and conventional modules SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Collier, Thomas] Advion Inc, Res & Dev, Ithaca, NY USA. [Akula, Murthy] Univ Tennessee, Dept Radiol, Knoxville, TN 37996 USA. [Akula, Murthy] Univ Tennessee, Dept Chem, Knoxville, TN 37996 USA. [Liang, Steven] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Liang, Steven] Massachusetts Gen Hosp NMMI, CAMIS, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1245 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101409 ER PT J AU Collier, T Yokell, D Rice, P Jackson, R Shoup, T Normandin, M Brady, T El Fakhri, G Liang, S Vasdev, N AF Collier, Thomas Yokell, Daniel Rice, Peter Jackson, Raul Shoup, Timothy Normandin, Marc Brady, Thomas El Fakhri, Georges Liang, Steven Vasdev, Neil TI First human use of the tau radiopharmaceutical [F-18]T807 by microfluidic flow chemistry SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Collier, Thomas] Advion Inc, Ithaca, NY USA. [Shoup, Timothy; Normandin, Marc; Brady, Thomas; El Fakhri, Georges; Liang, Steven; Vasdev, Neil] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Yokell, Daniel; Rice, Peter; Jackson, Raul; Shoup, Timothy; Normandin, Marc; Brady, Thomas; El Fakhri, Georges; Liang, Steven; Vasdev, Neil] Massachusetts Gen Hosp NMMI, CAMIS, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1246 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101410 ER PT J AU Dutta, J El Fakhri, G Shao, XF Lorsakul, A Guo, N Li, QZ AF Dutta, Joyita El Fakhri, Georges Shao, Xingfeng Lorsakul, Auranuch Guo, Ning Li, Quanzheng TI Feasibility of respiratory motion compensated reconstruction using 4D PET-derived deformation fields SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Dutta, Joyita; El Fakhri, Georges; Shao, Xingfeng; Lorsakul, Auranuch; Guo, Ning; Li, Quanzheng] Massachusetts Gen Hosp, Radiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 2106 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438104267 ER PT J AU Dutta, J El Fakhri, G Shao, XF Lorsakul, A Guo, N Li, QZ AF Dutta, Joyita El Fakhri, Georges Shao, Xingfeng Lorsakul, Auranuch Guo, Ning Li, Quanzheng TI Feasibility of respiratory motion compensated reconstruction using 4D PET-derived deformation fields SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Dutta, Joyita; El Fakhri, Georges; Shao, Xingfeng; Lorsakul, Auranuch; Guo, Ning; Li, Quanzheng] Massachusetts Gen Hosp, Radiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 2106 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438103277 ER PT J AU Dutta, J Li, QZ Johnson, K Zhu, XP El Fakhri, G AF Dutta, Joyita Li, Quanzheng Johnson, Keith Zhu, Xuping El Fakhri, Georges TI High resolution PET imaging of tau using an MR-based information theoretic anatomical prior SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Dutta, Joyita; Li, Quanzheng; Johnson, Keith; Zhu, Xuping; El Fakhri, Georges] Massachusetts Gen Hosp, Radiol, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 2 U2 2 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 642 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101137 ER PT J AU Dutta, J Li, QZ Grogg, K Zhu, XP Huang, C El Fakhri, G AF Dutta, Joyita Li, Quanzheng Grogg, Kira Zhu, Xuping Huang, Chuan El Fakhri, Georges TI PSF modeling and anatomical prior design for improved quantitative PET using a dedicated NeuroPET/CT SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Dutta, Joyita; Li, Quanzheng; Grogg, Kira; Zhu, Xuping; Huang, Chuan; El Fakhri, Georges] Massachusetts Gen Hosp, Radiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 369 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100370 ER PT J AU Elmaleh, D Shoup, T Bonab, A Takahashi, K Fischman, A AF Elmaleh, David Shoup, Timothy Bonab, Ali Takahashi, Kazue Fischman, Alan TI Evaluation of 1-deoxy-1-[F-18]fluoro-D-mannitol as a brain imaging tracer for measuring osmotic disruption following cancer therapy SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Elmaleh, David; Shoup, Timothy; Bonab, Ali] Massachusetts Gen Hosp, Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Takahashi, Kazue] Massachusetts Gen Hosp, Pediat Med Serv, Boston, MA 02114 USA. [Fischman, Alan] Shriners Hosp Children, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1123 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101287 ER PT J AU Esfahani, S Leahy, A Foote, A Hui, C Rainbow, R Zeng, L Mahmood, U AF Esfahani, Shadi Leahy, Averi Foote, Andrea Hui, Carrie Rainbow, Roshni Zeng, Li Mahmood, Umar TI Real-time assessment of cartilage matrix metabolic changes during progression of osteoarthritis SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Esfahani, Shadi; Leahy, Averi; Foote, Andrea; Hui, Carrie; Rainbow, Roshni; Zeng, Li; Mahmood, Umar] Massachusetts Gen Hosp, Nucl Med & Mol Imaging, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 386 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100387 ER PT J AU Evbuomwan, O Schroeder, F Lois, C Gee, M Hooker, J AF Evbuomwan, Osasere Schroeder, Frederick Lois, Cristina Gee, Michael Hooker, Jacob TI Synthesis and evaluation of a radiolabeled stapled peptide for monitoring the apoptotic state of tumors SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Evbuomwan, Osasere; Lois, Cristina] MIT, Madrid MIT M Vis Consortium, Cambridge, MA 02139 USA. [Schroeder, Frederick; Hooker, Jacob] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Cambridge, MA 02138 USA. [Gee, Michael] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1043 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101207 ER PT J AU Guo, N Yen, RF Yu, CJ Liao, WY El Fakhri, G Li, QZ AF Guo, Ning Yen, Ruoh-Fang Yu, Chong-Jen Liao, Wei-Yu El Fakhri, Georges Li, Quanzheng TI F-18-FLT PET/CT tumor heterogeneity is an effective biomarker in the diagnosis and staging of lung cancer SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Guo, Ning; El Fakhri, Georges; Li, Quanzheng] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Adv Med Imaging Sci,Radiol, Boston, MA USA. [Yen, Ruoh-Fang; Yu, Chong-Jen; Liao, Wei-Yu] Natl Taiwan Univ Hosp, Taipei, Taiwan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 123 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100124 ER PT J AU Hara, T Truelove, J Wojtkiewicz, G Kessinger, C Tawakol, A Brownell, AL Weissleder, R Jaffer, F AF Hara, Tetsuya Truelove, Jessica Wojtkiewicz, Gregory Kessinger, Chase Tawakol, Ahmed Brownell, Anna-Liisa Weissleder, Ralph Jaffer, Farouc TI FDG-PET/CT enables the detection of recurrent, same-site DVT by the identification of recently formed neutrophil-rich thrombus SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Hara, Tetsuya; Kessinger, Chase; Jaffer, Farouc] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Truelove, Jessica; Wojtkiewicz, Gregory; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Tawakol, Ahmed] Massachusetts Gen Hosp, Cardiol, Boston, MA 02114 USA. [Brownell, Anna-Liisa] Massachusetts Gen Hosp, Martinos Biomed Imaging Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 463 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100464 ER PT J AU Heidari, P Deng, F Esfahani, S Leece, A Shoup, T Vasdev, N Mahmood, U AF Heidari, Pedram Deng, Francis Esfahani, Shadi Leece, Alicia Shoup, Timothy Vasdev, Neil Mahmood, Umar TI 18F-Fluoroestradiol PET guides dosing of selective estrogen receptor degraders SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Heidari, Pedram; Deng, Francis; Esfahani, Shadi; Leece, Alicia; Shoup, Timothy; Vasdev, Neil; Mahmood, Umar] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 11 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100012 ER PT J AU Holland, J Carlin, S Sosnovik, D Vasdev, N Josephson, L AF Holland, Jason Carlin, Sean Sosnovik, David Vasdev, Neil Josephson, Lee TI PET/CT imaging of macrophage infiltration in myocardial infarct with 89Zr-Ferumoxytol SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Holland, Jason; Vasdev, Neil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nucl Med, Boston, MA USA. [Carlin, Sean] Mem Sloan Kettering Canc Ctr, Med Phys, New York, NY 10021 USA. [Sosnovik, David] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging & Cardiol, Charlestown, MA USA. [Josephson, Lee] Massachusetts Gen Hosp, Ctr Adv Mol Imaging Sci, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1702 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438102368 ER PT J AU Holland, J Sosnovik, D Vasdev, N Josephson, L AF Holland, Jason Sosnovik, David Vasdev, Neil Josephson, Lee TI Heat-induced, chelate-free radiolabeling of iron-oxide nanoparticles SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Holland, Jason; Vasdev, Neil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nucl Med,Radiol, Boston, MA 02114 USA. [Sosnovik, David] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Sosnovik, David] Massachusetts Gen Hosp, Div Cardiol, Charlestown, MA USA. [Josephson, Lee] Massachusetts Gen Hosp, Ctr Adv Mol Imaging Sci, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1191 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101355 ER PT J AU Horky, L Reardon, D Huang, R Kijewski, M Wen, P Gerbaudo, V Semer, J Sticka, W Strader, C Park, MA AF Horky, Laura Reardon, David Huang, Raymond Kijewski, Marie Wen, Patrick Gerbaudo, Victor Semer, James Sticka, William Strader, Christopher Park, Mi-Ae TI Baseline FET-PET kinetic pattern predicts outcome in recurrent GBM patients prior to bevacizumab therapy SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Horky, Laura; Huang, Raymond; Kijewski, Marie; Gerbaudo, Victor; Semer, James; Sticka, William; Strader, Christopher; Park, Mi-Ae] BWH, Radiol, Boston, MA USA. [Reardon, David; Wen, Patrick] DFCI, Neurooncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 529 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101024 ER PT J AU Kil, KE Zhang, ZD Zhu, AJ Kuruppu, D Choi, JK Kura, S Brownell, AL AF Kil, Kun-Eek Zhang, Zhaoda Zhu, Aijun Kuruppu, Darshini Choi, Ji-Kyung Kura, Sreekanth Brownell, Anna-Liisa TI Radiosyntheses and preclinical evaluation of two N-(3-[C-11]methylthiophenyl)-2-picolinamide ([C-11]ML128) derivatives as radiotracers for mGlu4 SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Kil, Kun-Eek; Zhang, Zhaoda; Zhu, Aijun; Choi, Ji-Kyung; Kura, Sreekanth; Brownell, Anna-Liisa] Massachusetts Gen Hosp, Imaging, Charlestown, MA USA. [Kuruppu, Darshini] Massachusetts Gen Hosp, Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1169 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101333 ER PT J AU Leece, A Rushford, L Stevens, M Heidari, P Collier, T Mahmood, U AF Leece, Alicia Rushford, Laura Stevens, Maria Heidari, Pedram Collier, Thomas Mahmood, Umar TI Design, construction, and testing of an inexpensive automated 68Ga-DOTATOC synthesis unit SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Leece, Alicia; Rushford, Laura; Stevens, Maria; Heidari, Pedram; Collier, Thomas; Mahmood, Umar] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1257 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101421 ER PT J AU Liang, S Rotstein, B Stephenson, N Vasdev, N AF Liang, Steven Rotstein, Benjamin Stephenson, Nickeisha Vasdev, Neil TI Spiro hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Liang, Steven; Rotstein, Benjamin; Stephenson, Nickeisha; Vasdev, Neil] Harvard Univ, Sch Med, Radiol, Boston, MA USA. [Liang, Steven; Rotstein, Benjamin; Stephenson, Nickeisha; Vasdev, Neil] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 3 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100004 ER PT J AU Moody, J Lee, B Sitek, A Di Carli, M Ficaro, E AF Moody, Jonathan Lee, Benjamin Sitek, Arkadiusz Di Carli, Marcelo Ficaro, Edward TI A generalized Renkin-Crone relation for Rb-82 GFADS analysis SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Moody, Jonathan; Lee, Benjamin] INVIA, Ann Arbor, MI USA. [Ficaro, Edward] Univ Michigan, Ann Arbor, MI 48109 USA. [Sitek, Arkadiusz] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Di Carli, Marcelo] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 2040 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438104201 ER PT J AU Moody, J Lee, B Sitek, A Di Carli, M Ficaro, E AF Moody, Jonathan Lee, Benjamin Sitek, Arkadiusz Di Carli, Marcelo Ficaro, Edward TI A generalized Renkin-Crone relation for Rb-82 GFADS analysis SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Moody, Jonathan; Lee, Benjamin] INVIA, Ann Arbor, MI USA. [Ficaro, Edward] Univ Michigan, Ann Arbor, MI 48109 USA. [Sitek, Arkadiusz] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Di Carli, Marcelo] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 2040 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438103211 ER PT J AU Normandin, M Collier, T Wooten, D Kolnick, A Yokell, D Shoup, T Brady, T Vasdev, N Johnson, K El Fakhri, G AF Normandin, Marc Collier, Thomas Wooten, Dustin Kolnick, Aleksandra Yokell, Daniel Shoup, Timothy Brady, Thomas Vasdev, Neil Johnson, Keith El Fakhri, Georges TI Pharmacokinetic evaluation of the tau radiotracer [F-18]T807 and cerebral binding in a subject with traumatic brain injury SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Normandin, Marc; Wooten, Dustin; Kolnick, Aleksandra; Yokell, Daniel; Shoup, Timothy; Brady, Thomas; Vasdev, Neil; Johnson, Keith; El Fakhri, Georges] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Adv Med Imaging Sci, Boston, MA USA. [Collier, Thomas] Advion Inc, Ithaca, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 139 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100140 ER PT J AU Ouyang, JS Toole, T Keeler, M Grogg, K Zhu, XP Li, QZ Petibon, Y Normandin, M Alpert, N El Fakhri, G AF Ouyang, Jinsong Toole, Terry Keeler, Matthew Grogg, Kira Zhu, Xuping Li, Quanzheng Petibon, Yoann Normandin, Marc Alpert, Nathaniel El Fakhri, Georges TI Performance comparison between NeuroPET-CT and Siemens ECAT HR plus : NEMA and patient studies SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Ouyang, Jinsong; Grogg, Kira; Zhu, Xuping; Li, Quanzheng; Petibon, Yoann; Normandin, Marc; Alpert, Nathaniel; El Fakhri, Georges] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA. [Toole, Terry; Keeler, Matthew] PhotoDiagnost Syst Inc, Boxboro, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 2162 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438104323 ER PT J AU Ouyang, JS Toole, T Keeler, M Grogg, K Zhu, XP Li, QZ Petibon, Y Normandin, M Alpert, N El Fakhri, G AF Ouyang, Jinsong Toole, Terry Keeler, Matthew Grogg, Kira Zhu, Xuping Li, Quanzheng Petibon, Yoann Normandin, Marc Alpert, Nathaniel El Fakhri, Georges TI Performance comparison between NeuroPET-CT and Siemens ECAT HR plus : NEMA and patient studies SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Ouyang, Jinsong; Grogg, Kira; Zhu, Xuping; Li, Quanzheng; Petibon, Yoann; Normandin, Marc; Alpert, Nathaniel; El Fakhri, Georges] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA. [Toole, Terry; Keeler, Matthew] PhotoDiagnost Syst Inc, Boxboro, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 2162 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438103333 ER PT J AU Petibon, Y Huang, C Ouyang, JS Reese, T Kolnick, A Chen, YL El Fakhri, G AF Petibon, Yoann Huang, Chuan Ouyang, Jinsong Reese, Timothy Kolnick, Aleksandra Chen, Yen-Lin El Fakhri, Georges TI Cardiac, respiratory motion and point spread function (PSF) compensation in simultaneous PET-MR: A cardiac sarcoma study SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Petibon, Yoann; Huang, Chuan; Ouyang, Jinsong; Kolnick, Aleksandra; Chen, Yen-Lin; El Fakhri, Georges] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Adv Med Imaging Sci,Radiol, Boston, MA USA. [Reese, Timothy] A Martinos Ctr, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 647 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101142 ER PT J AU Rakvongthai, Y Borvorntanajanya, K Fahey, F El Fakhri, G Ouyang, JS AF Rakvongthai, Yothin Borvorntanajanya, Korn Fahey, Frederic El Fakhri, Georges Ouyang, Jinsong TI Joint ictal/interictal SPECT reconstruction for improved epileptic foci localization SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Rakvongthai, Yothin; Borvorntanajanya, Korn; El Fakhri, Georges; Ouyang, Jinsong] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Radiol, Boston, MA 02114 USA. [Rakvongthai, Yothin; Borvorntanajanya, Korn; Fahey, Frederic; El Fakhri, Georges; Ouyang, Jinsong] Harvard Univ, Sch Med, Boston, MA USA. [Fahey, Frederic] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 309 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100310 ER PT J AU Rice, P Yokell, D AF Rice, Peter Yokell, Daniel TI Radiochemical purity and radiochemical identity determination of N-13 ammonia injection using thin layer chromatography SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Rice, Peter; Yokell, Daniel] Massachusetts Gen Hosp, Nucl Med & Mol Imaging, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1158 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101322 ER PT J AU Rotstein, B Liang, S Collier, T Woo, J Brady, T Hooker, J Vasdev, N AF Rotstein, Benjamin Liang, Steven Collier, Thomas Woo, Jiyeon Brady, Thomas Hooker, Jacob Vasdev, Neil TI Synthesis of [C-11]bexarotene by [C-11]CO2 fixation: Preliminary preclinical imaging in nonhuman primate SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Rotstein, Benjamin; Liang, Steven; Woo, Jiyeon; Brady, Thomas; Vasdev, Neil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nucl Med & Mol Imaging, Boston, MA USA. [Collier, Thomas] Advion Inc, Ithaca, NY USA. [Hooker, Jacob] Harvard Univ, Sch Med, Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1107 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101271 ER PT J AU Rotstein, B Wey, HY Shoup, T Wilson, A Liang, S Hooker, J Vasdev, N AF Rotstein, Benjamin Wey, Hsiao-Ying Shoup, Timothy Wilson, Alan Liang, Steven Hooker, Jacob Vasdev, Neil TI Evaluation of [F-18]DOPP in nonhuman primates for imaging FAAH SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Rotstein, Benjamin; Shoup, Timothy; Liang, Steven; Vasdev, Neil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nucl Med & Mol Imaging,Radiol, Boston, MA USA. [Wey, Hsiao-Ying; Hooker, Jacob] Harvard Univ, Massachusetts Gen Hosp, Sch Med, AA Martinos Ctr Biomed Imaging, Boston, MA USA. [Wilson, Alan] Ctr Addict & Mental Hlth, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 357 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100358 ER PT J AU Shoup, T Bonab, A Wilson, A Vasdev, N AF Shoup, Timothy Bonab, Ali Wilson, Alan Vasdev, Neil TI Synthesis and in vivo evaluation of [F-18]CHC for neuroimaging fatty acid amide hydrolase SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Shoup, Timothy; Bonab, Ali; Vasdev, Neil] Massachusetts Gen Hosp, Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Shoup, Timothy; Bonab, Ali; Vasdev, Neil] Harvard Univ, Sch Med, Boston, MA USA. [Wilson, Alan] CAMH, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 557 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101052 ER PT J AU Wehrenberg-Klee, E Redjal, N Leece, A Turker, NS Heidari, P Shah, K Mahmood, U AF Wehrenberg-Klee, Eric Redjal, Navid Leece, Alicia Turker, N. Selcan Heidari, Pedram Shah, Khalid Mahmood, Umar TI A F(ab)' 2-based EGFR targeted PET probe for glioma imaging SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Wehrenberg-Klee, Eric; Redjal, Navid; Leece, Alicia; Turker, N. Selcan; Heidari, Pedram; Shah, Khalid; Mahmood, Umar] Massachusetts Gen Hosp, Radiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 1793 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438102459 ER PT J AU Wehrenberg-Klee, E Turker, NS Chang, B Heidari, P Mahmood, U AF Wehrenberg-Klee, Eric Turker, N. Selcan Chang, Bryan Heidari, Pedram Mahmood, Umar TI Development of a HER3 PET probe for breast cancer imaging SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Wehrenberg-Klee, Eric; Turker, N. Selcan; Chang, Bryan; Heidari, Pedram; Mahmood, Umar] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 550 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438101045 ER PT J AU Zukotynski, K Kim, C Gerbaudo, V Hainer, J Van Den Abbeele, A Seltzer, S Sweeney, C AF Zukotynski, Katherine Kim, Chun Gerbaudo, Victor Hainer, Jon Van Den Abbeele, Annick Seltzer, Steven Sweeney, Christopher TI Prognostic value of baseline evaluation of FDG and NaF PET/CT in castrate-resistant prostate cancer (CRPC): Early results from a prospective phase 1 trial SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI) CY JUN 07-11, 2014 CL St Louis, MO SP Soc Nucl Med & Mol Imaging C1 [Zukotynski, Katherine] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Kim, Chun; Gerbaudo, Victor; Hainer, Jon; Seltzer, Steven] Brigham & Womens Hosp, Boston, MA 02115 USA. [Van Den Abbeele, Annick; Sweeney, Christopher] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2014 VL 55 SU 1 MA 402 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CR6FA UT WOS:000361438100403 ER PT J AU Bianchi, MG Neto, CF Duncan, L Sotto, M AF Bianchi, Mara Giavina Festa Neto, Cyro Duncan, Lyn Sotto, Miriam TI NY-ESO-1 expression is associated with primary cutaneous melanoma thickness SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Bianchi, Mara Giavina; Festa Neto, Cyro; Sotto, Miriam] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil. [Duncan, Lyn] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P7904 BP AB74 EP AB74 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900293 ER PT J AU Christman, MP Kroshinsky, D Song, P Divito, SJ AF Christman, Mitalee P. Kroshinsky, Daniela Song, Philip Divito, Sherrie J. TI Migratory indurated plaques: An atypical presentation of mycobacterial infection SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Christman, Mitalee P.; Song, Philip; Divito, Sherrie J.] Harvard Univ, Sch Med, Boston, MA USA. [Kroshinsky, Daniela] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8305 BP AB117 EP AB117 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900461 ER PT J AU Kimball, AB Crow, JA Ridley, K Shear, NH AF Kimball, Alexa B. Crow, J. A. Ridley, Kari Shear, Neil H. TI Pregnancy outcomes in women with moderate to severe psoriasis: The PSOLAR experience SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Kimball, Alexa B.] Harvard Univ, Sch Med, Boston, MA USA. [Kimball, Alexa B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Crow, J. A.; Ridley, Kari] Janssen Serv LLC, Spring House, PA USA. [Shear, Neil H.] Univ Toronto, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8576 BP AB179 EP AB179 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900706 ER PT J AU Kimball, AB Pariser, D Kricorian, G Gelfand, JM AF Kimball, Alexa B. Pariser, David Kricorian, Gregory Gelfand, Joel M. TI Final results from OBSERVE-5, a 5-year observational registry of patients with moderate to severe plaque psoriasis receiving etanercept SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Kimball, Alexa B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pariser, David] Virginia Clin Res Inc, Norfolk, VA USA. [Kricorian, Gregory] Amgen Inc, Thousand Oaks, CA 91320 USA. [Gelfand, Joel M.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P7552 BP AB170 EP AB170 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900669 ER PT J AU Kumar, N Konnikov, N AF Kumar, Neal Konnikov, Nellie TI Teledermatology, a year of experience at the VA Boston SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Kumar, Neal] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Konnikov, Nellie] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8734 BP AB76 EP AB76 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900301 ER PT J AU Lagana, F Tran, TN AF Lagana, Frances Thanh-Nga Tran TI Verrucous carcinoma of the foot: Case presentation and review of the literature SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Lagana, Frances] Univ Massachusetts, Worcester, MA 01605 USA. [Thanh-Nga Tran] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8167 BP AB141 EP AB141 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900554 ER PT J AU Sakamoto, FH Gilchrest, BA Yu, B Su, MS Ramadurai, N Anderson, RR Kang, SY AF Sakamoto, Fernanda H. Gilchrest, Barbara A. Yu, Betty Su, Mandy S. Ramadurai, Nithin Anderson, R. Rox Kang, Soo-Young TI A novel at-home procedure providing marked improvements for lower lid aesthetics utilizing a tensile, elastic, noninvasive polymer system with in situ cross-linking functionality SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Sakamoto, Fernanda H.; Anderson, R. Rox] Harvard Univ, Sch Med, Boston, MA USA. [Sakamoto, Fernanda H.; Anderson, R. Rox] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Gilchrest, Barbara A.] Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA. [Yu, Betty; Su, Mandy S.; Ramadurai, Nithin; Kang, Soo-Young] Living Proof, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8117 BP AB12 EP AB12 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900049 ER PT J AU Shlyankevich, J Kimball, A Chen, A AF Shlyankevich, Julia Kimball, Alexandra Chen, Allison TI Prevalence of actinic keratosis in patients with psoriasis compared to control SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Shlyankevich, Julia; Kimball, Alexandra; Chen, Allison] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8034 BP AB179 EP AB179 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900707 ER PT J AU Shlyankevich, J Kimball, A Corey, K Kardos, M AF Shlyankevich, Julia Kimball, Alexandra Corey, Kristen Kardos, Marisa TI Diagnostic accuracy of referring providers sending patients to dermatology urgent care clinic for suspected skin cancers SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Shlyankevich, Julia; Kimball, Alexandra; Corey, Kristen; Kardos, Marisa] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P7807 BP AB81 EP AB81 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900318 ER PT J AU Shlyankevich, J Lantz, D George, E Stetsenko, G Nghiem, P Knezevich, S AF Shlyankevich, Julia Lantz, Daniel George, Evan Stetsenko, Galina Nghiem, Paul Knezevich, Stevan TI Merkel cell carcinoma in association with benign follicular structures: Report of 2 cases SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Shlyankevich, Julia] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lantz, Daniel; Stetsenko, Galina; Nghiem, Paul] Univ Washington, Dept Med, Div Dermatol, Seattle, WA USA. [George, Evan] Univ Washington, Dept Clin Pathol, Seattle, WA 98195 USA. [Knezevich, Stevan] VA Med Ctr, Dept Anat & Clin Pathol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8578 BP AB74 EP AB74 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900292 ER PT J AU Strazzula, L Piris, A Kroshinsky, D Tsiaras, W AF Strazzula, Lauren Piris, Adriano Kroshinsky, Daniela Tsiaras, William TI Neonatal drug eruption: A diagnosis for all ages SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Strazzula, Lauren; Piris, Adriano; Kroshinsky, Daniela; Tsiaras, William] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8468 BP AB147 EP AB147 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900578 ER PT J AU Strazzula, L Kroshinsky, D Hoang, M Tsiaras, W AF Strazzula, Lauren Kroshinsky, Daniela Hoang, Mai Tsiaras, William TI Leukemia cutis in the setting of CMML: A predictor for leukemic transformation SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Strazzula, Lauren; Kroshinsky, Daniela; Hoang, Mai; Tsiaras, William] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8458 BP AB117 EP AB117 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900459 ER PT J AU Strazzula, L Kroshinsky, D Das, S Nambudiri, V AF Strazzula, Lauren Kroshinsky, Daniela Das, Shinjita Nambudiri, Vinod TI Methyl methacrylate-induced purpuric contact dermatitis SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Strazzula, Lauren; Kroshinsky, Daniela; Das, Shinjita; Nambudiri, Vinod] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8469 BP AB69 EP AB69 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900270 ER PT J AU Strazzula, L Kroshinsky, D Miloslavsky, E Duncan, L Baker, M Nazarian, R Tsiaras, W AF Strazzula, Lauren Kroshinsky, Daniela Miloslavsky, Eli Duncan, Lyn Baker, Matthew Nazarian, Rosalynn Tsiaras, William TI Dermatomyositis in the setting of myxoid chondrosarcoma SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Strazzula, Lauren; Kroshinsky, Daniela; Miloslavsky, Eli; Duncan, Lyn; Baker, Matthew; Nazarian, Rosalynn; Tsiaras, William] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8452 BP AB58 EP AB58 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900229 ER PT J AU Strazzula, L Kroshinsky, D Tsiaras, W AF Strazzula, Lauren Kroshinsky, Daniela Tsiaras, William TI Cutaneous Loxoscelism: A diagnosis to consider SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Strazzula, Lauren; Kroshinsky, Daniela; Tsiaras, William] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8465 BP AB41 EP AB41 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900159 ER PT J AU Tran, TN Mihm, M Hoang, M Anderson, RR Nelson, S Phung, T AF Thanh-Nga Tran Mihm, Martin Hoang, Minh Anderson, Richard Rox Nelson, Stuart Thuy Phung TI Chronic radiation dermatitis resulting from the use of radioactive phosphorus 32 in the treatment of childhood hemangiomas in Vietnam SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Thanh-Nga Tran] Massachusetts Gen Hosp, Charlestown, MA USA. [Mihm, Martin] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hoang, Minh] Univ Med & Pharm, Ho Chi Minh City, Vietnam. [Anderson, Richard Rox] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Stuart] Univ Calif Irvine, Irvine, CA USA. [Thuy Phung] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8682 BP AB39 EP AB39 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900155 ER PT J AU Vedak, P Kroshinsky, D Nazarian, RM AF Vedak, Priyanka Kroshinsky, Daniela Nazarian, Rosalynn M. TI A case of eczematid-like purpura of Doucas and Kapetanakis in a child SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Vedak, Priyanka; Kroshinsky, Daniela; Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8555 BP AB141 EP AB141 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900557 ER PT J AU Vedak, P Kroshinsky, D Song, PI Divito, SJ AF Vedak, Priyanka Kroshinsky, Daniela Song, Philip I. Divito, Sherrie J. TI Two cases of burn-related skin grafts demonstrating locus minoris resistentiae SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Vedak, Priyanka; Kroshinsky, Daniela; Song, Philip I.; Divito, Sherrie J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8553 BP AB57 EP AB57 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900222 ER PT J AU Yoo, J Minh, HV Mihm, MC Anderson, R Nelson, S Tran, TN Phung, T AF Yoo, Jane Hoang Van Minh Mihm, Martin C. Anderson, Rox Nelson, Stuart Thanh Nga Tran Thuy Phung TI The Vietnam Vascular Anomalies Clinic SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Academy-of-Dermatology CY MAR 21-25, 2014 CL Denver, CO SP Amer Acad Dermatol C1 [Yoo, Jane] Albert Einstein Coll Med, New York, NY USA. [Hoang Van Minh] HCMC Univ Med Ctr, Ho Chi Minh City, Vietnam. [Mihm, Martin C.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Anderson, Rox] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nelson, Stuart] UC Urvine, Irvine, CA USA. [Thanh Nga Tran] Massachusetts Gen Hosp, Arlington, MA USA. [Thuy Phung] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2014 VL 70 IS 5 SU 1 MA P8613 BP AB201 EP AB201 PG 1 WC Dermatology SC Dermatology GA CQ4OI UT WOS:000360583900793 ER PT J AU Ozok, AA Wu, HJ Garrido, M Pronovost, PJ Gurses, AP AF Ozok, A. Ant Wu, Huijuan Garrido, Melissa Pronovost, Peter J. Gurses, Ayse P. TI Usability and perceived usefulness of personal health records for preventive health care: A case study focusing on patients' and primary care providers' perspectives SO APPLIED ERGONOMICS LA English DT Article DE Personal health records; Usefulness; Usability ID INFORMATION-TECHNOLOGY; SCREENING COMPLIANCE; ACTIVATION MEASURE; COLORECTAL-CANCER; SELF-MANAGEMENT; USER ACCEPTANCE; UNITED-STATES; ADOPTION; SYSTEMS; DEFINITION AB Personal Health Records (PHR) are electronic applications for individuals to access, manage and share their health information in a secure environment. The goal of this study was to evaluate the usefulness and usability of a Web-based PHR technology aimed at improving preventive care, from both the patients' and primary care providers' perspectives. We conducted a multi-method descriptive study that included direct observations, concurrent think-aloud, surveys, interviews and focus groups in a suburban primary care clinic. Patients found the tailored health recommendations useful and the PHR easy to understand and use. They also reported asking useful health-related questions to their physicians because of using the system. Generally, care providers were interested in using the system due to its useful content and impact on patient activation. Future successful systems should be better integrated with hospital records; put more emphasis on system security; and offer more tailored health information based on comprehensive health databases. (C) 2013 Elsevier Ltd and The Ergonomics Society. All rights reserved. C1 [Ozok, A. Ant; Wu, Huijuan] Univ Maryland Baltimore Cty, Dept Informat Syst, Baltimore, MD 21250 USA. [Garrido, Melissa] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. [Pronovost, Peter J.; Gurses, Ayse P.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD 21202 USA. RP Ozok, AA (reprint author), Univ Maryland Baltimore Cty, Dept Informat Syst, 1000 Hilltop Circle, Baltimore, MD 21250 USA. EM ozok@umbc.edu; huijuan.wu@umbc.edu; melissa.garrido@mssm.edu; ppronovo@jhmi.edu; agurses1@jhmi.edu FU Medical Industry Leadership Institute of the University of Minnesota; Agency for Healthcare Research and Quality [HS018762]; Dept. of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [CDA 11-201/CDP 12-255] FX This study was funded by the Medical Industry Leadership Institute of the University of Minnesota. Dr. Ayse P. Gurses was supported in part by the Agency for Healthcare Research and Quality K01 grant #HS018762. We would like to thank Dr. David Moen and the participating primary care clinic care providers for their support of the study. Supported by Dept. of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (CDA 11-201/CDP 12-255). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 79 TC 15 Z9 15 U1 1 U2 25 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0003-6870 EI 1872-9126 J9 APPL ERGON JI Appl. Ergon. PD MAY PY 2014 VL 45 IS 3 BP 613 EP 628 DI 10.1016/j.apergo.2013.9.005 PG 16 WC Engineering, Industrial; Ergonomics; Psychology, Applied SC Engineering; Psychology GA AB0RZ UT WOS:000331501100034 ER PT J AU Wang, LJ Gala, M Yamamoto, M Pino, MS Kikuchi, H Shue, DS Shirasawa, S Austin, TR Lynch, MP Rueda, BR Zukerberg, LR Chung, DC AF Wang, Liangjing Gala, Manish Yamamoto, Masayoshi Pino, Maria S. Kikuchi, Hirotoshi Shue, Daniel S. Shirasawa, Senji Austin, Thomas R. Lynch, Maureen P. Rueda, Bo R. Zukerberg, Lawrence R. Chung, Daniel C. TI Adrenomedullin is a therapeutic target in colorectal cancer SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE K-ras; adrenomedullin; hypoxia; colorectal cancers ID ENDOTHELIAL GROWTH-FACTOR; POSSIBLE PROMOTION MECHANISM; PANCREATIC-CANCER; TUMOR-GROWTH; CELL-LINES; KI-RAS; C-MYC; HYPOXIA; ANGIOGENESIS; EXPRESSION AB The KRAS oncogene influences angiogenesis, metastasis and chemoresistance in colorectal cancers (CRCs), and these processes are all enhanced in hypoxic conditions. To define functional activities of mutant KRAS in a hypoxic microenvironment, we first performed cDNA microarray experiments in isogenic DKs5 and DKO3 colon cancer cell lines that differ only by their expression of mutant KRAS (K-ras(D13)). Adrenomedullin (ADM) was identified as one of the most significantly upregulated genes in DKs5 cells that express the KRAS oncogene in hypoxia (3.2-fold, p = 1.47 x 10(-5)). Ectopic expression of mutant KRAS (K-rasV12) in Caco-2 cells (K-ras(WT)) induced ADM, whereas selective knockdown of mutant KRAS alleles (K-ras(D13) or K-ras(V12)) in HCT116, DLD1 and SW480 colon cancer cells suppressed the expression of ADM in hypoxia. Knockdown of ADM in colon tumor xenografts blocked angiogenesis and stimulated apoptosis, resulting in tumor suppression. Furthermore, ADM also regulated colon cancer cell invasion in vitro. Among 56 patients with CRC, significantly higher expression levels of ADM were observed in samples harboring a KRAS mutation. Collectively, ADM is a new target of oncogenic KRAS in the setting of hypoxia. This observation suggests that therapeutic targets may differ depending upon the specific tumor microenvironment. C1 [Wang, Liangjing; Gala, Manish; Yamamoto, Masayoshi; Pino, Maria S.; Kikuchi, Hirotoshi; Shue, Daniel S.; Austin, Thomas R.; Chung, Daniel C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA. [Wang, Liangjing] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China. [Pino, Maria S.] Azienda Sanitaria Firenze, Dept Oncol, Med Oncol Unit, Florence, Italy. [Shirasawa, Senji] Fukuoka Univ, Ctr Adv Mol Med, Fukuoka 81401, Japan. [Shirasawa, Senji] Fukuoka Univ, Fac Med, Dept Cell Biol, Fukuoka 81401, Japan. [Lynch, Maureen P.; Rueda, Bo R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Ctr Reprod Biol,Dept Obstet & Gynecol, Boston, MA USA. [Zukerberg, Lawrence R.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Chung, Daniel C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. RP Chung, DC (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, 50 Blossom St, Boston, MA 02114 USA. EM dchung@partners.org FU National Institutes of Health (NIH) [CA92594]; National Natural Science Foundation of China [81272678]; National Basic Research Program of China (973 Program) [2012CB945004]; Kate J. and Dorothy L. Clapp Fund FX Grant sponsor: National Institutes of Health (NIH); Grant number: CA92594; Grant sponsor: National Natural Science Foundation of China; Grant number: 81272678; Grant sponsor: National Basic Research Program of China (973 Program); Grant number: 2012CB945004; Grant sponsor: Kate J. and Dorothy L. Clapp Fund NR 38 TC 5 Z9 7 U1 1 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 EI 1097-0215 J9 INT J CANCER JI Int. J. Cancer PD MAY 1 PY 2014 VL 134 IS 9 BP 2041 EP 2050 DI 10.1002/ijc.28542 PG 10 WC Oncology SC Oncology GA AA3QE UT WOS:000331006600022 PM 24519534 ER PT J AU Korkmaz, OT Aytan, N Carreras, I Choi, JK Kowall, NW Jenkins, BG Dedeoglu, A AF Korkmaz, Orhan Tansel Aytan, Nurgul Carreras, Isabel Choi, Ji-Kyung Kowall, Neil W. Jenkins, Bruce G. Dedeoglu, Alpaslan TI 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis SO NEUROSCIENCE LETTERS LA English DT Article DE Amyotrophic lateral sclerosis; 7,8-Dihydroxyflavone; Motor neurons; BDNF; TrkB ID TRKB RECEPTOR; NEUROTROPHIC FACTORS; SYNAPTIC PLASTICITY; BDNF; DISEASE; AGONIST; MEMORY; POTENTIATION; MOTONEURONS; SYNAPSES AB Amyotrophic lateral sclerosis (ALS) is an enigmatic neurodegenerative disorder without any effective treatment characterized by loss of motor neurons (MNs) that results in rapidly progressive motor weakness and early